

## **HIGH THROUGHPUT FUNCTIONAL GENOMIC SCREENING METHODS FOR OSTEOARTHRITIS**

### **FIELD OF THE INVENTION**

The present invention provides novel functional genomic screening methods for identifying genes and gene products that are involved in OA. Genes and gene products are also provided that have been identified in such screening assays and which are useful *inter alia* as drug targets for treating OA. Methods of treating and diagnosing OA and compositions therefor which use genes and/or gene products identified in these screening assays are also provided.

### **BACKGROUND**

Osteoarthritis (OA) is primarily a non-inflammatory disease characterized by pain and stiffness of the joints caused by the progressive loss of articular cartilage. OA is among the most common age associated disease and is estimated to affect about 56 million individuals worldwide or 80% of the population greater than 60 years old. Although OA is generally considered a degenerative disorder, the disease is associated with activation of chondrocyte cells, the major cell type present in normal articular cartilage. Hallmarks of this cell activation include hypertrophy, proliferation, dedifferentiation, degradation of the existing extracellular matrix, and finally apoptosis.

The molecular etiology of OA remains unknown. Current therapeutic methods for treating OA are therefore directed toward symptomatic relief such as reducing joint pain and secondary inflammatory changes rather than toward treating the disease's underlying causes. Pharmacological interventions that prevent disease progression are not currently available. Many patients thus progress to advanced stages of the disease where total joint replacement surgery is necessary. For reviews, see Pritzken, "Pathology of Osteoarthritis" in *Osteoarthritis* (Brandt *et al.*, Eds.) Oxford University Press 1998, pages 50-61. See also, Sandell & Aigner, *Arthritis and Rheumatism* 2001, 3:107-113.

- 2 -

Large scale sequencing of OA cDNA libraries has identified several putative gene products that are expressed by diseased chondrocyte cells. See, Stokes *et al.*, *Arth. Rheum.* 2002, 46:404-419; Hu *et al.*, *J. Biol. Chem.* 1998, 273:34406-34412; Aigner *et al.*, *Arth. Rheum.* 2001, 44:2777-2789. However, functional information is not presently available for these gene products and their role in OA, if any, remains unknown. The molecular basis of OA therefore remains unknown and only a very limited number of potential drug targets is known. There remains a need, therefore, for therapeutic compounds and methods to treat OA and related diseases. There is moreover a need for novel genes and gene products that may be useful, *e.g.*, as drug targets for such therapeutic methods to treat OA.

In order to identify genes associated with OA that can serve as suitable drug targets, Applicants disclose herein several high throughput screening methods that may be used successfully with chondrocytes. Identification of genes that are critical in mediating the diseased phenotype requires development of comprehensive highly sensitive cell-based assays compatible with high-throughput settings. The availability of methods to shuttle full length cDNA clones from one vector into another (Gateway system, Invitrogen, Carlsbad, CA) combined with the ability to express genes in high levels in disease relevant primary cells using viral vectors and the availability of methods for assay miniaturization and liquid handling have lead to the possibility of efficiently screening for inducers of OA phenotype on a genome wide scale.

Using said methods, Applicants have identified several genes (referred to herein as "candidate genes") in chondrocytes that are associated with OA. Thus, according to the present invention, it is now proposed that these genes and gene products have a role in OA pathogenesis and it is contemplated herein that any one or more of them are useful drug targets for the development of therapeutics for the prevention, treatment or amelioration of OA or related conditions associated with abnormal cartilage degradation.

The invention also provides a method for identifying modulators (*e.g.* inhibitors) of these newly identified OA related genes and the use of such modulators for the treatment,

prevention, or amelioration of this disease and related conditions, in human and veterinary patients. The invention also provides pharmaceutical compositions comprising said modulators.

### SUMMARY OF THE INVENTION

The present invention provides high throughput functional genomic screening (HTS) assays that may be used to identify genes and gene products associated with OA. In preferred embodiments, a HTS assay of the invention comprises steps of transfecting a cell (preferably a chondrocyte cell) with a nucleic acid to be tested in the screening assay (*i.e.*, a “test” nucleic acid) so that the test nucleic acid is expressed by the cell. The transfected cell is then assayed for one or more characteristics that are associated with OA. For example, in one preferred embodiment, a screening assay of the invention comprises steps of detecting expression by the cell of one or more genes or gene products whose expression is known to be associated with OA.

Similarly, screening assays of the invention can be used to identify polypeptides and other gene products that are associated with OA in cells. Such methods involve transfecting a cell (preferably a chondrocyte cell) with a nucleic acid that encodes a polypeptide or other gene product to be tested in the screening assay (*i.e.*, a “test” polypeptide) so that the test polypeptide is expressed by the cell. The transfected cell is then assayed for one or more characteristics that are associated with OA. For example, in one preferred embodiment a screening assay of the invention comprises steps of detecting expression by the cell of one or more genes or gene products whose expression is known to be associated with OA.

A variety of known genes and gene products associated with OA are provided in the application and can be used in the above-described assays. Preferred genes and gene products that are associated with OA (or an “OA phenotype” include, for example, an Aggrecanase-1 gene, an MMP-13 gene, genes of Collagen Types I, IIa and X, an iNOS gene, an Aggrecan gene or gene product, and a Decorin gene, as well as gene products encoded by

any of these genes. Still other genes or gene products that are associated with an OA phenotype and can be used in the methods described here include new marker genes C17, SMOC2, OSF-2, MARCKS, retinoic acid receptor beta, Zic1, BASP1 and DIM1 genes and their gene products which were identified by computational analysis of OA cDNA libraries.

In another aspect, the Applicants have discovered that genes and gene products for an OA phenotype may be rapidly screened by identifying gene and gene products that induce the proliferation of chondrocyte cells. Hence, the invention also provides, in another aspect, a method for identifying a nucleic acid that induces an OA phenotype by transfecting a chondrocyte cell with a candidate nucleic acid, and detecting proliferation of the chondrocyte cell (*e.g.*, by identifying clusters of clonally proliferating chondrocyte cells in cell culture). Similarly, the invention provides methods for identifying a polypeptide that induces an OA phenotype in cells, by transfecting a chondrocyte cell with a nucleic acid that encodes a candidate polypeptide, and detecting proliferation of the chondrocyte cell (*e.g.*, by identifying clusters of clonally proliferating chondrocyte cells in cell culture). In such methods, proliferation of the chondrocyte cells indicates that the candidate nucleic acid or polypeptide is a nucleic acid or polypeptide that induces an OA phenotype.

Genes and gene products that are identified by such screening methods are useful, *inter alia*, for the diagnosis and treatment, prevention and/or amelioration of OA. For example, candidate genes and gene products identified by these screening methods may be used in still other screening assays, to identify compounds that bind to and/or inhibit expression of these candidate genes and gene products. The compounds (*i.e.*, modulators) identified in these screening assays are useful, *e.g.*, in therapeutic methods for treating OA and as pharmaceutical compositions or medicaments that can be administered in such therapeutic methods. Thus the present invention also pertains to the use of these genes, gene products, compounds and modulators in the manufacture of a medicament and/or as a pharmaceutical for the treatment, prevention and/or amelioration of OA and other cartilage-related diseases.



- 5 -

In still other embodiments, the invention provides methods for treating, preventing and/or ameliorating OA in an individual, by administering an effective amount of a compound that can modulate (i.e. a “modulator”) a candidate gene identified by the assay and methods of the present invention. In a preferred embodiment, the modulator inhibits a candidate gene disclosed in Tables V or VI disclosed herein. The invention also provides pharmaceutical compositions that comprise an effective amount of a modulator to a candidate gene identified herein.

Thus, in another aspect, the invention relates to a method to treat, prevent or ameliorate OA, comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of a modulator of a candidate gene and/or ligand thereof (i.e a gene provided in Tables V or VI provided herein. In various preferred embodiments, said pharmaceutical composition comprises one or more modulators to any one or more of said candidate genes and/or ligands thereof.

In another aspect, the invention relates to a pharmaceutical composition comprising a modulator of a candidate gene and/or ligand thereof in an amount effective to treat, prevent or ameliorate OA in a subject in need thereof wherein said modulator, e.g., can inhibit the activity, expression of or ligand binding to, any one or more of the candidate genes disclosed herein e.g., a candidate gene provided in Tables V or VI herein. In one embodiment, said pharmaceutical composition comprises any one or more substances selected from the group consisting of antisense oligonucleotides, triple helix DNA, siRNA, ribozymes, RNA aptamers or double or single stranded RNA directed to a nucleic acid sequence of a candidate gene or ligand thereof wherein said substances are designed to inhibit gene expression of said family member or ligand. In a further embodiment, said pharmaceutical composition comprises antibodies to a candidate gene or ligand thereof, or fragments thereof, wherein said antibodies can, e.g., inhibit the activity of said member and/or ligand.

In yet another aspect of the present invention there are provided assay methods and kits comprising the components necessary to detect expression of polynucleotides encoding a candidate gene or ligand thereof, or polypeptide levels of said candidate genes or ligands

thereof, or fragments thereof, in biological samples derived from a patient, such kits comprising, e.g., antibodies that bind to said polypeptides, or to fragments thereof, or oligonucleotide probes that hybridize with said polynucleotides. In a preferred embodiment, such kits also comprise instructions detailing the procedures by which the kit components are to be used.

The present invention also provides methods for identifying individuals who have OA. Such diagnostic methods involve detecting a candidate gene or gene product (identified by one of the high throughput functional assays described, *supra*) in a biological sample (e.g., chondrocyte cell or cartilage tissue sample) from the individual. Elevated expression of the candidate gene or gene product in the chondrocyte cell or cartilage tissue indicates that the individual does have OA.

The invention also provides methods for identifying compounds that may be used to treat OA. In a first embodiments, these methods involve contacting a test compound to a candidate gene or gene product under conditions sufficient to allow the test compound to bind to a candidate gene or gene product of the invention, and detecting complexes of the test compound bound to that candidate gene or gene product. The detection of the test compound bound to the candidate gene or gene product identifies the test compound as a compound that can be used for treating OA.

In another embodiment, methods for identifying compounds that may be used to treat OA involve contacting a test compound to a cell that normally expresses a candidate gene or gene product of the invention, and detecting expression of that candidate gene or gene product by the cell once it has been contacted with the test compound. In such embodiments, a decreased expression of the candidate gene or gene product by the cell in the presence of the test compound indicates that the test compound is a compound that can be used to treat OA.

### DETAILED DESCRIPTION

As used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to the "antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

"Nucleic acid sequence", as used herein, refers to an oligonucleotide, nucleotide or polynucleotide, and fragments or portions thereof, and to DNA or RNA of genomic or synthetic origin that may be single or double stranded, and represent the sense or antisense strand.

As used herein, "high throughput" refers to an increase in screening capacity compared to conventional methods. It is contemplated herein that the high throughput method of the present invention is preferably carried out using microtiter plates (i.e. 96, 384 or 1536 well plates). Assays at a genomic level are also contemplated.

cDNA libraries for use with the high throughput screen disclosed herein are those wherein each cDNA is defined and arrayed in a specific order in high throughput format (multititer dishes). While the examples in the present invention describe results obtained with a proprietary cDNA collection, suitable cDNA libraries are commercially available, for example, from Invitrogen (Carlsbad, CA), Origene (Rockville, MD) as well as the NIH (i.e., the Mammalian Gene Collection).

The term "antisense" as used herein, refers to nucleotide sequences which are complementary to a specific DNA or RNA sequence. The term "antisense strand" is used in reference to a nucleic acid strand that is complementary to the "sense" strand. Antisense molecules may be produced by any method, including synthesis by ligating the gene(s) of interest in a reverse orientation to a viral promoter which permits the synthesis of a

complementary strand. Once introduced into a cell, this transcribed strand combines natural sequences produced by the cell to form duplexes. These duplexes then block either the further transcription or translation. The designation "negative " is sometimes used in reference to the antisense strand, and "positive" is sometimes used in reference to the sense strand.

"cDNA" refers to DNA that is complementary to a portion of messenger RNA (mRNA) sequence and is generally synthesized from an mRNA preparation using reverse transcriptase.

As contemplated herein, antisense oligonucleotides, triple helix DNA, RNA aptamers, ribozymes, siRNA and double stranded RNA are directed to a nucleic acid sequence such that the nucleotide sequence chosen will produce gene-specific inhibition of gene expression. For example, knowledge of a nucleotide sequence may be used to design an antisense molecule which gives strongest hybridization to the mRNA. Similarly, ribozymes can be synthesized to recognize specific nucleotide sequences of a gene and cleave it (Cech. J. Amer. Med Assn. 260:3030 (1988)). Techniques for the design of such molecules for use in targeted inhibition of gene expression is well known to one of skill in the art.

The individual candidate gene products, (i.e. proteins/polypeptides) referred to herein include any and all forms of these proteins including, but not limited to, partial forms, isoforms, variants, precursor forms, the full length protein, fusion proteins containing the sequence or fragments of any of the above, from human or any other species. Protein homologs which would be apparent to one of skill in the art are included in this definition. It is also contemplated that the term refers to proteins isolated from naturally occurring sources of any species such as genomic DNA libraries as well as genetically engineered host cells comprising expression systems, or produced by chemical synthesis using, for instance, automated peptide synthesizers or a combination of such methods. Means for isolating and preparing such polypeptides are well understood in the art.

- 9 -

The terms "sample" or "biological sample" as used herein, are used in their broadest sense. A biological sample from a subject may comprise blood, urine or other biological material with which protein activity or gene expression may be assayed. A biological sample may include, for example, cells, cartilage, blood, tumors or other specimens from which total RNA may be purified for gene expression profiling using, for example, conventional glass chip microarray technologies such as Affymetrix chips, RT-PCR or other conventional methods.

As used herein, the term "antibody" refers to intact molecules as well as fragments thereof, such as Fa, F(ab')<sub>2</sub>, and Fv, which are capable of binding the epitopic determinant. Antibodies that bind specific polypeptides can be prepared using intact polypeptides or fragments containing small peptides of interest as the immunizing antigen. The polypeptides or peptides used to immunize an animal can be derived from the translation of RNA or synthesized chemically, and can be conjugated to a carrier protein, if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin and thyroglobulin. The coupled peptide is then used to immunize an animal (e.g., a mouse, a rat or a rabbit).

The term "humanized antibody" as used herein, refers to antibody molecules in which amino acids have been replaced in the non-antigen binding regions in order to more closely resemble a human antibody, while still retaining the original binding ability.

A "therapeutically effective amount" is the amount of drug sufficient to treat, prevent or ameliorate pathological conditions associated with OA.

"Subject" or "individual" refer to any human or nonhuman organism.

The high throughput assay disclosed herein is preferably used or performed in an at least substantially automated setting. A multiwell format is suited for performing at least part of the methods of the present invention, but can be performed on many different scales, including screening cDNAs on a genomic scale. The term "automated" as used herein means

able to perform the predetermined steps of the method without, for the most part, requiring manual intervention during the process. In this regard, machines for use in the high throughput methods disclosed herein include, but are not limited to, machines for preparing DNA plasmid preparations, reading DNA concentration and yield, plating cells, automated pipeting stations and luminescence detectors. Such machines are commercially available and familiar to one of skill in the art, for example, the Quiagen 8000 for automated DNA production (Quiagen Inc, Valencia CA), the Beckman Coulter BiomekFX for automated pipetting and transfections (Beckman Coulter, Fullerton CA) and the Fluoroskan Ascent for fluorescent and luminescent assay readouts (Thermo Labsystems, Franklin, MA).

Nucleic acid transfer into cells (e.g. transfection) may be performed according to any conventional method familiar to one of skill in the art. As mentioned above, transfections are preferably implemented in an automated, multiwell, high throughput format, for example, using commercially available robotics such as a Beckman Coulter BiomekFX.

The present invention provides high throughput screening (HTS) assays that are useful, *inter alia* for identifying therapeutic agents to treat and/or diagnose disorders such as osteoarthritis (OA) that affect the growth and/or degradation of cartilage. In particular, the Examples *infra* describe particular, preferred embodiments of screening assays that identify genes and gene products associated with OA. The genes and gene products identified in such screening assays are therefore useful, e.g., as drug target candidates for the development of novel drug therapies to treat OA and other such cartilage disorders. For convenience therefore, the genes and gene products identified in screening assays of the present invention are generally referred to in this document as "candidate" genes and "candidate" gene products, respectively.

Generally speaking, the HTS assays of this invention allow a user to rapidly screen large numbers of genes, e.g., in a cDNA library, to identify ones that are involved in OA. Briefly, nucleic acids (preferably cDNA molecules) corresponding to the genes to be tested in a screening assay are first transferred to expression vectors that are capable of expressing those "test" genes or gene products in chondrocyte cells. Preferred expression vectors are

retroviral vectors (such as those described in the Examples, *infra*) or other vectors that are capable of expressing the candidate genes at high levels in chondrocyte cells.

Chondrocyte cells are then transformed with the expression vectors carrying these test genes and are assayed for one or more characteristics that are associated with OA. For convenience, such characteristics are generally referred to in this application as "OA phenotypes." However, it is understood that a characteristic assayed or tested for in these screening assays may be any feature that is associated with OA.

For instance, Example 1 describes one preferred embodiment of a HTS assay that uses RT-PCR to measure the expression of one or more genes whose expression in chondrocyte cells is associated with OA. Examples of such genes which are preferred in these methods include Aggrecanase-1 and MMP-13 (the expression of which is associated with cartilage degradation), Collagen Type I, Collagen Type IIa and Collagen Type X (the over expression of which is associated with aberrant chondrocyte cell differentiation such as hypertrophy and proliferation), genes and gene products that induce inflammation (for example, iNOS and Cox-2), and genes such as Aggrecan and Decorin that modulate synthesis or repair of the cartilage matrix.

Such genes, whose expression or, more particular, over expression is indicative of OA in chondrocyte cells, are generally referred to here as "marker genes." However, "marker genes" that may be used in screening assays of the invention are not limited to the particular genes described, *e.g.*, in the examples (see, for example, in Table I or Table II, *infra*). Any gene or gene product whose elevated expression in chondrocyte cells is associated with OA may be used as a marker gene in screening assays according to the present invention. For example, and as explained in further detail below, the screening assays of this invention identify other genes and gene products whose elevated expression is associated with OA. Hence, a candidate gene or gene product identified in such screening assays (for example, any of the candidate genes and gene products listed in Tables V and VI *infra*) may itself be used as a marker gene in another screening assay according to this invention.

Similarly, those who are skilled in the art will appreciate that marker genes which can be used in screening assays of this invention are not limited to gene whose over expression is associated with OA. In particular, a screening assay of the present invention can also use marker genes that are underexpressed (*i.e.*, their expression is reduced) in OA chondrocytes. In such embodiments, the HTS assays of this invention will identify candidate genes that, when expressed in chondrocyte cells, cause the reduced expression of one or more marker genes.

The HTS assays of this invention also are not limited to embodiments that measure the expression of marker genes or their gene products. Other characteristics or phenotypes associated with OA can also be measured or observed, and then used to identify candidate genes in a screening assay. For instance, Example 2 *infra* describes an alternative embodiment of the screening assay which identify cDNAs that induce a particular type of cell proliferation characteristic of OA chondrocytes. In particular, whereas normal chondrocyte cells have a low division rate when grown in a 3-dimensional matrix (*e.g.*, of agarose or alginate), OA chondrocyte cells (both in cell culture and in OA cartilage tissue) grow in clusters of rapidly proliferating chondrocyte cell clones. Accordingly, screening assays of the invention can also identify genes and gene products which, when expressed in chondrocyte cell cultures, cause the formation of such clusters of chondrocyte cell clones.

Genes and gene products that are tested in a screening assay of the invention may be from any source and obtained by any method known in the art. For example, cDNA libraries may be derived from a cell or cell line of interest, which is preferably a chondrocyte cell. Methods for obtaining such cDNA libraries are well known in the art. See, for example, Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York); Glover, D.M. 3ed., 1985, *DNA Cloning: A Practical Approach*, MRL Press, Ltd. Oxford U.K. Vols. I and II). See also, in the Examples, *infra*. Alternatively, however, the genes and Gene Products may be hand selected. For instance, Example 1 describes an embodiment where the genes in a cDNA library are first "datamined" to identify genes and gene products that are particularly useful as drug targets (*e.g.*, for therapeutic compounds to treat OA). Examples of such preferred test



- 13 -

genes are genes that are involved in signal transduction and/or proteolysis (such as receptors, kinases and proteases).

Candidate genes and gene products that are identified in screening assays of the present invention are useful, *inter alia*, as new marker genes for identifying osteoarthritic cells (*i.e.*, cells that are present in cartilage from patients having OA and/or which exhibit one or more characteristics associated with OA). Moreover, the genes and gene products identified in these screening assays can also be used in diagnostic and prognostic applications. Hence, the candidate genes and gene products that are identified in the screening assays provided here can be used to identify individuals who have a disorder, such as OA, that is associated with abnormal cartilage growth and/or repair.

The candidate genes and gene products identified in screening assays of this invention can also be used in prognostic applications to identify individuals who are either have OA or who are at an increased risk of developing OA. Hence, the invention also provides therapeutic methods for treating OA related disorders in individuals. Such methods involve administering a compound to an individual that inhibits the expression or activity of a candidate gene identified in a screening assay of the invention or, alternatively, a compound that inhibits the expression or activity of a candidate gene product identified in a screening assay of this invention.

Various applications and uses for candidate genes and gene products identified in the present invention are described, in detail, *infra*. In particular, the following sections first describe various homologs and analogs of both candidate genes and candidate genes products that can be used in such prognostic, diagnostic, and therapeutic assays. Particular utilities for these candidate genes and gene products (including the various homologs and analogs thereof) are then also described in detail. Finally, the Examples describe detailed, exemplary embodiments of screening assays that are considered part of the present invention. These examples also provide Tables identifying the nucleotide and amino acid sequence (by GenBank Accession number) of both genes and gene products that are identified in such

screening assays. These nucleotide and amino acid sequences are therefore considered examples of preferred embodiments of candidate genes and gene products of the invention.

The present invention may employ a variety of conventional techniques in the arts of molecular biology, microbiology and recombinant DNA technology. Such techniques are well known in the art and are explained fully in the literature. See, for example, Sambrook, Fritsch & Maniatis, *Molecular Cloning: A Laboratory Manual*, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (referred to herein as "Sambrook *et al.*, 1989); *DNA Cloning: A Practical Approach* Volumes I and II (D.N. Glover *et al.* 1985); *Oligonucleotide Synthesis* (M.J. Gait ed. 1984); *Nucleic Acid Hybridization* (B.D. Hames & S.J. Higgins, eds. 1984); *Animal Cell Culture* (R.I. Freshney, ed. 1986); *Immobilized Cells and Enzymes* (IRL Press, 1986); B.E. Perbal, *A Practical Guide to Molecular Cloning* (1984); F.M. Ausubel *et al.* (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc.

#### Candidate polypeptides:

It is understood that, as used in the description of this invention, the term "candidate polypeptide" refers to the polypeptide encoded by a candidate gene of the invention. For convenience, candidate genes and gene products of the present invention are frequently identified here by SEQ ID number and by the GenBank Accession Number(s) for preferred nucleotide or amino acid sequences. However, it is understood that the candidate genes and gene products of this invention are not limited to these particular sequences, but also include homologs and variants evident to one of ordinary skill in the art.

As an example, and not by way of limitation, candidate gene product polypeptides of the present invention include not only polypeptides having the exemplary full length amino acid sequences specified here, but also include polypeptides comprising an amino acid sequence for one or more epitopes or domains of a full length candidate gene product polypeptide. An epitope of a polypeptide represents a site on the polypeptide against which an antibody may be produced and to which the antibody binds. Therefore, polypeptides comprising the amino acid sequence of a candidate gene product epitope are

useful for making antibodies to the candidate polypeptide. Preferably, an epitope comprises a sequence of at least 5, more preferably at least 10, 15, 20, 25 or 50 amino acid residues in length. Thus, polypeptides of the invention that comprises epitopes of a candidate gene product preferably contain an amino acid sequence corresponding to at least 5, at least 10, at least 15, at least 20, at least 25 or at least 50 amino acid residues of a full length candidate gene product polypeptide sequence.

Candidate gene products of the invention also include analogs and derivatives of the exemplary full length candidate gene product sequences provided in the Examples, *infra*. Analogs and derivatives of the candidate gene products of this invention have the same or homologous characteristics of the exemplary candidate gene product sequences set forth in the Examples, *infra*. Chimeric or fusion polypeptides can also be prepared in which the candidate gene product portion of the fusion polypeptide has one or more characteristics of the candidate gene product. Such fusion polypeptides therefore represent embodiments of the candidate gene product polypeptides of this invention. Such fusion polypeptides may also comprise the amino acid sequence of a marker polypeptide; for example FLAG, a histidine tag, glutathione S-transferase (GST), or the Fc portion of an IgG to name a few. Additionally, fusion polypeptides of the invention may comprise amino acid sequences that increase solubility of the polypeptide, such as a thioreductase amino acid sequence or the sequence of one or more immunoglobulin proteins (*e.g.*, IgG1 or IgG2).

Analogs or variants of a candidate polypeptide can also be made by altering encoding nucleic acid molecules, for example by substitutions, additions or deletions. Preferred analogs or variants of a candidate polypeptide are "function conservative variants" of the particular candidate polypeptide sequence specified in the Examples, *infra*. "Function-conservative variants" of a polypeptide or polynucleotide are those in which a given amino acid residue in the polypeptide, or the amino acid residue encoded by a codon of the polynucleotide, has been changed or altered without altering the overall conformation and function of the polypeptide. Such changes are expected to have little or no effect on the apparent molecular weight or isoelectric point of the polypeptide. Hence, such altered nucleic acid molecules preferably encode functionally similar molecules (*i.e.*, molecules that

perform one or more functions of a candidate polypeptide and/or have one or more of the candidate polypeptide's bioactivities).

Amino acid residues, other than ones that are specifically identified herein as being conserved, may differ among variants of a protein or polypeptide. Accordingly, the percentage of protein or amino acid sequence similarity between any two variants or analogs of a candidate polypeptide may vary. Typically, the percentage of protein or amino acid sequence similarity between variant or analog candidate polypeptides may be from 70% to 99%, as determined according to an alignment scheme such as the Cluster Method and/or the MEGALIGN or GCG alignment algorithm. Preferred variants and analogs of a candidate polypeptide are at least about 75%, and more preferably at least about 80%, 85%, 90%, 95% or 99% sequence identity as determined by a sequence comparison algorithm such as BLAST, FASTA, DNA Strider, CLUSTAL, *etc.*

Function-conservative variants of the present invention, as defined above, include not only variants of the full length candidate polypeptides of this invention (*e.g.*, variants of polypeptides comprising the particular candidate polypeptide sequences specified in the Examples, *infra*), but also include function-conservative variants of modified candidate polypeptides (*e.g.*, truncations and deletions) and of fragments (*e.g.*, corresponding to domains or epitopes) of full length candidate polypeptides.

In yet other embodiments, an analog of a candidate polypeptide is an allelic variant or mutant of a candidate polypeptide sequence provided, *e.g.*, in the Examples, *infra*. The terms allelic variant and mutant, when used herein to describe a polypeptide, refer to a polypeptide encoded by an allelic variant or mutant gene. Thus, the allelic variant and mutant candidate polypeptides of this invention are polypeptides encoded by allelic variants or mutants of a candidate nucleic acid of the present invention.

In yet other embodiments, an analog of a candidate polypeptide is a substantially homologous polypeptide from the same species (*e.g.*, allelic variants) or from another species (*e.g.*, an orthologous polypeptide). The term "homologous," in all its

grammatical forms and spelling variations, refers to the relationship between two proteins or nucleic acids that possess a "common evolutionary origin", including proteins from superfamilies (*e.g.*, the immunoglobulin superfamily) in the same species of organism as well as homologous proteins from different species of organism (for example, myosin light chain polypeptide, *etc.*; see, Reeck *et al.*, *Cell* 1987, 50:667). Such proteins (and their encoding nucleic acids) having sequence homology, as reflected by their sequence similarity, whether in terms of percent identity or by the presence of specific residues or motifs and conserved positions. Preferred homologous polypeptides of the present invention have levels of sequence similarity or identity as specified, above, for other variant and analog candidate polypeptides of the invention. Homologs and orthologs of the specific candidate polypeptides may be obtained, *e.g.*, from mammals such as humans, mice, rats, hamsters, rabbit, guinea pig, dog, cat, sheep, goat, pig, horse and cow to name a few.

In other embodiments, variants of a candidate polypeptide (including analogs, homologs, *etc.*) are polypeptides encoded by nucleic acid molecules that hybridize to the complement of a nucleic acid molecule encoding one or more of the particular candidate polypeptide sequences specified in the Examples, *infra*. A nucleic acid molecule is "hybridizable" to another nucleic acid molecule (for example cDNA, genomic DNA, or RNA) when a single stranded form of the nucleic acid molecule can anneal to the other nucleic acid molecule under appropriate conditions of temperature and solution ionic strength (see, *e.g.*, Sambrook *et al.*, *supra*). The conditions of temperature and ionic strength determine the "stringency" of the hybridization. For preliminary screening for homologous nucleic acids, low stringency hybridization conditions corresponding to a melting temperature ( $T_m$ ) of about 55 °C can be used (for example, 5x SSC, 0.1% SDS, 0.25% milk and no formamide; or, alternatively, 30% formamide, 5x SSC, and 0.5% SDS). Moderate stringency hybridization conditions correspond to a higher  $T_m$ , *e.g.*, 40% formamide with 5x or 6x SSC. High stringency hybridization conditions correspond to the highest  $T_m$ , *e.g.*, 50% formamide, 5x or 6x SSC. A 1x SSC solution is understood to be a solution containing 0.15 M NaCl and 0.015 M Na-citrate.

Hybridization requires that the two nucleic acids contain complementary sequences, although depending on the stringency of the hybridization, mismatches between bases are possible. The appropriate stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of similarity or homology between two nucleotide sequences the greater the value of  $T_m$  for hybrids of nucleic acids having those sequences.

For hybrids of greater than 100 nucleotides in length, equations for calculating  $T_m$  have been derived (see, Sambrook *et al.*, *supra*, 9.50-9.51).

In a specific embodiment, the term "standard hybridization conditions" refers to a  $T_m$  of about 55 °C and utilizes conditions as set forth above. In a preferred embodiment, the  $T_m$  is 60 °C; in a more preferred embodiment, the  $T_m$  is 65 °C. In a specific embodiment, the term "high stringency" refers to hybridization and/or washing conditions at 68 °C in 0.2x SSC, at 42 °C in 50% formamide, 4x SSC, or under conditions that afford levels of hybridization equivalent to those observed under either of these two conditions.

In still other embodiments, variants (including analogs, homologs and orthologs) of a candidate polypeptide can be identified by isolating variants of a candidate gene, *e.g.*, using PCR with degenerate oligonucleotide primers designed on the basis of amino acid sequences of the candidate polypeptides and as described below.

Derivatives of a candidate polypeptide of the invention further include phosphorylated polypeptides, myristylated polypeptides, methylated polypeptides, and other candidate polypeptides that are chemically modified. Candidate polypeptides of the invention further include labeled variants; for example, radio-labeled with iodine or phosphorous (see, *e.g.*, EP 372707B) or other detectable molecules such as, but by no means limited to, biotin, fluorescent dyes (*e.g.*, Cy5 or Cy3), a chelating group complexed with a metal ion, a chromophore or fluorophore, a gold colloid, a particle such as a latex bead, or attached to a water soluble polymer such as poly(ethylene)-glycol (PEG). Chemical modifications of a candidate polypeptide may provide additional advantages under certain

circumstances. See, for example, U.S. Patent No. 4,179,337. For a review, see also Abuchowski *et al.*, in *Enzymes as Drugs* (J.S. Holcerberg & J. Roberts, eds. 1981) pages 367-383. A review article describing protein modification and fusion proteins is also found in Francis, *Focus on Growth Factors* 1992, 3:4-10, Mediscript: Mountview Court, Friern Barnet Lane, London N20, OLD, UK.

#### Candidate Nucleic Acids:

It is understood that, for purposes of describing the present invention, the term "candidate nucleic acid" refers to a nucleic acid comprising the nucleotide sequence of a candidate gene. For convenience, candidate nucleic acids of the present invention are frequently identified here by the SEQ ID number or GenBank Accession number for their preferred nucleotide sequences or for preferred amino acid sequences that they encode. However, it is understood that, as with the candidate polypeptides, the candidate nucleic acids of this invention are not limited to those particular sequences and include homologs and variants that are well within the ordinary skill of the art.

In general, candidate nucleic acid molecule of the present invention comprises a nucleic acid sequence that encodes a candidate polypeptide as defined, *supra*, the complement of a nucleic acid sequence that encodes a candidate polypeptide, and fragments thereof. Thus, the exemplary nucleic acid sequences provided in GenBank Accession numbers specified for particular candidate genes of the Examples, *infra*, represent preferred candidate nucleic acid sequences of the present invention.

In still other embodiments, the candidate nucleic acid molecules of the invention comprise nucleotide sequences that encode one or more domains of a candidate polypeptide.

The candidate nucleic acid molecules of the invention also include nucleic acids which comprise a sequence encoding one or more fragments of a candidate polypeptide sequence.

- 20 -

The candidate nucleic acid molecules of the invention also include nucleic acid molecules that comprise coding sequences for modified candidate polypeptides (*e.g.*, having amino acid substitutions, deletions or truncations) and for variants (including allelic variants, analogs and homologs from the same or different species) candidate polypeptides. In preferred embodiments, such nucleic acid molecules have at least 50%, preferably at least 75% and more preferably at least 90% sequence identity to candidate polypeptide coding sequence (*e.g.*, to the coding sequence set forth in the Examples, *infra*).

In addition, candidate nucleic acid molecules of the invention include ones that hybridize to another candidate nucleic acid molecule, *e.g.*, in a Southern blot assay under defined conditions. For example, in specific embodiments a candidate nucleic acid molecule of the invention comprises a nucleotide sequence which hybridizes to a complement of a particular nucleic acid sequence, such as the coding sequence set forth in the GenBank Accession numbers for exemplary candidate genes specified in the Examples, *infra*. Alternatively, a nucleic acid molecule of the invention may hybridize, under the same defined hybridization conditions, to the complement of a fragment of a nucleotide sequence encoding a full length candidate polypeptide. Examples of preferred hybridization include those set forth above.

In other embodiments, the nucleic acid molecules of the invention comprise fragments of a full length candidate nucleic acid sequence. Such candidate nucleic acid fragments comprise a nucleotide sequence that corresponds to a sequence of at least 10 nucleotides, preferably at least 15 nucleotides and more preferably at least 20 nucleotides of a nucleotide sequence encoding a full length candidate polypeptide. In preferred embodiments, the candidate nucleic acid fragments comprise sequences of at least 10, preferably at least 15, and more preferably at least 20 nucleotides that are complementary and/or hybridize to a full length candidate nucleic acid sequence or to a fragment thereof. For hybridization with shorter nucleic acids, *i.e.*, oligonucleotides, the position of mismatches becomes more important and the length of the oligonucleotide determines its specificity (see, Sambrook *et al.*, *supra*, at 11.7-11.8). A minimum length for a hybridizable nucleic acid is preferably at



least about 10 nucleotides, more preferably at least about 15 nucleotides, and still more preferably at least about 20 nucleotides.

Nucleic acid molecules comprising such fragments are useful, for example, as oligonucleotide probes and primers (*e.g.*, PCR primers) to detect and amplify other nucleic acid molecules encoding a candidate polypeptide, including genes that encode variant candidate polypeptides. Oligonucleotide fragments of the invention may also be used, *e.g.*, as antisense nucleic acids to modulate levels of a candidate gene's expression or transcription in cells.

The nucleic acid molecules of the invention also include "chimeric" nucleic acid molecules. Such chimeric nucleic acid molecules are polynucleotides which comprise at least one candidate nucleic acid sequence (which may be any of the full length or partial candidate nucleic acid sequences described above), and also at least one non-candidate nucleic acid sequence (*i.e.*, a nucleic acid sequence not normally associated with the particular candidate gene). For example, the non-candidate nucleic acid sequence may be a heterologous regulatory sequence (for example a promoter sequence) that is derived from another gene and is not normally associated with the naturally occurring candidate gene. The non-candidate nucleic acid sequence may also be a coding sequence of another polypeptide such as FLAG, a histidine tag, glutathione S-transferase (GST), hemagglutinin,  $\beta$ -galactosidase, thioreductase or an immunoglobulin domain or domains (for examples, an Fc region). In preferred embodiments, a chimeric nucleic acid molecule of the invention encodes a fusion polypeptide of the invention.

Nucleic acid molecules of the invention, whether genomic DNA, cDNA or otherwise, can be isolated from any source including, for example, cDNA or genomic libraries derived from a cell or cell line from an organism that has the desired candidate gene. In the case of cDNA libraries, such libraries are preferably derived from a cell or cell line that expresses the particular candidate gene. Methods for obtaining candidate genes are well known in the art (see, *e.g.*, Sambrook *et al.*, 1989, *supra*).

The DNA may be obtained by standard procedures known in the art from cloned DNA (for example, from a DNA "library"), and preferably is obtained from a cDNA library prepared from tissues with high level expression of the protein. In one preferred embodiment, the DNA is obtained from a "subtraction" library to enrich the library for cDNAs of genes specifically expressed by a particular cell type or under certain conditions. Use of such a subtraction library may increase the likelihood of isolating cDNA for a particular gene. In still other embodiments, a library may be prepared by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA or fragments thereof purified from the desired cell (See, for example, Sambrook *et al.*, 1989, *supra*; Glover, D.M. ed., 1985, *DNA Cloning: A Practical Approach*, MRL Press, Ltd. Oxford, U.K. Vols. I and II).

In one embodiment, a cDNA library may be screened for a desired candidate nucleic acid by identifying cDNA inserts that encode a polypeptide which is homologous or substantially similar to a candidate polypeptide of particular interest. Similarly, a cDNA library may be screened for a desired candidate nucleic acid by identifying cDNA inserts having a nucleic acid sequence that is homologous or substantially similar to a particular candidate nucleic acid sequence of interest.

Clones derived from genomic DNA may contain regulatory and intron DNA regions in addition to coding regions. Clones derived from cDNA generally will not contain intron sequences. Whatever the source, the gene is preferably molecularly cloned into a suitable vector for propagation of the gene. Identification of the specific DNA fragment containing the desired candidate gene may be accomplished in a number of ways. For example, a portion of a candidate gene can be purified and labeled to prepare a labeled probe (Benton & Davis, *Science* 1977, 196:180; Grunstein & Hogness, *Proc. Natl. Acad. Sci. U.S.A.* 1975, 72:3961). Those DNA fragments with substantial homology to the probe, such as an allelic variant from another individual, will hybridize. In a specific embodiment, highest stringency hybridization conditions are used to identify a homologous candidate gene.

The genes encoding derivatives and analogs of a candidate gene of this invention can be produced by various methods known in the art. The manipulations which

result in their production can occur at the gene or protein level. For example, the cloned sequence can be modified by any of numerous strategies known in the art (Sambrook *et al.*, 1989, *supra*). The sequence can be cleaved at appropriate sites with restriction endonuclease(s), followed by further enzymatic modification if desired, isolated, and ligated *in vitro*. In the production of the gene encoding a derivative or analog of a candidate gene, care should be taken to ensure that the modified gene remains within the same translational reading frame as the candidate gene from which it is derived, uninterrupted by translational stop signals, in the gene region where the desired activity is encoded.

Additionally, a candidate gene sequence can be mutated *in vitro* or *in vivo*, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions and/or form new restriction endonuclease sites or destroy preexisting ones, to facilitate further *in vitro* modification. Modifications can also be made to introduce restriction sites and facilitate cloning the candidate gene into an expression vector. Any technique for mutagenesis known in the art can be used, including but not limited to, *in vitro* site-directed mutagenesis (Hutchinson, C., *et al.*, J. Biol. Chem. 253:6551, 1978; Zoller and Smith, DNA 3:479-488, 1984; Oliphant *et al.*, Gene 44:177, 1986; Hutchinson *et al.*, Proc. Natl. Acad. Sci. U.S.A. 83:710, 1986), use of TAB<sup>®</sup> linkers (Pharmacia Corp., Peapack, NJ), *etc.* PCR techniques are preferred for site directed mutagenesis (see Higuchi, 1989, "Using PCR to Engineer DNA", in *PCR Technology: Principles and Applications for DNA Amplification*, H. Erlich, ed., Stockton Press, Chapter 6, pp. 61-70).

The identified and isolated gene can then be inserted into an appropriate cloning vector. A large number of vector-host systems known in the art may be used. Possible vectors include, but are not limited to, plasmids or modified viruses, but the vector system must be compatible with the host cell used. Examples of vectors include, but are not limited to, *E. coli*, bacteriophages such as lambda derivatives, or plasmids such as pBR322 derivatives or pUC plasmid derivatives, *e.g.*, pGEX vectors, pmal-c, pFLAG, pKK plasmids (Clontech, Palo Alto, CA), pET plasmids (Novagen, Inc., Madison, WI), pRSET or pREP plasmids, pcDNA (Invitrogen, Carlsbad, CA), or pMAL plasmids (New England Biolabs, Beverly, MA), *etc.* The insertion into a cloning vector can, for example, be accomplished by

- 24 -

ligating the DNA fragment into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini. These ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences.

Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc., so that many copies of the gene sequence are generated. Preferably, the cloned gene is contained on a shuttle vector plasmid, which provides for expansion in a cloning cell, *e.g.*, *E. coli*, and facile purification for subsequent insertion into an appropriate expression cell line, if such is desired. For example, a shuttle vector, which is a vector that can replicate in more than one type of organism, can be prepared for replication in both *E. coli* and *Saccharomyces cerevisiae* by linking sequences from an *E. coli* plasmid with sequences from the yeast 2 $\mu$  plasmid.

It is understood that candidate nucleic acids of the invention may be either DNA or RNA and may be single-, double- or even triple-stranded (*e.g.*, a triple-helix of candidate single-stranded candidate nucleic acids and/or their complement(s)). Candidate nucleic acids of the invention include genomic DNA, cDNA, RNA, mRNA, cRNA, *etc.*; as well as synthetic and genetically manipulated polynucleotides and both sense and antisense polynucleotides. Such synthetic polynucleotides include, for example, "protein nucleic acids" (PNA) formed by conjugating nucleotide bases to an amino acid backbone. Other exemplary synthetic nucleic acids include nucleic acids containing modified bases, such as thio-uracil, thio-guanine and fluoro-uracil. For convenience, the exemplary nucleotide sequences provided in this description are provided as sequences of DNA. However, it is understood that identical sequences of other types of nucleic acids (for example, RNA) may also be used and are equivalent. Thus, for example, where the particular nucleotide sequences in this description specify a thymine (T) at some position, it is understood that a uracil (U) may be substituted at that position and is a functional equivalent.

- 25 -

The polynucleotides of this invention may be flanked by natural regulatory sequences, or they may be associated with heterologous sequences such as promoters, enhancers, response elements, signal sequences, polyadenylation sequences, introns, 5' and 3'-non-coding regions and the like. The term "heterologous", in this context, refers to a combination of elements (*e.g.*, sequences) that are not naturally occurring. Hence, a candidate nucleic acid of this invention may have sequences, such as a promoter *etc.*, that are not normally associated with the candidate gene.

Nucleic acids of the invention may also be modified by any means known in the art. Non-limiting examples of such modifications include methylation, "caps", substitution of one or more of the naturally occurring nucleotides with an analog, and internucleotide modifications such as, for example, those with uncharged linkages (*e.g.*, methyl phosphonates, phosphotriesters, phosphoroamidates, carbamates, *etc.*) and with charged linkages (*e.g.*, phosphorothioates, phosphorodithioates, *etc.*). Nucleic acids of the invention may contain one or more additional covalently linked moieties such as proteins (*e.g.*, nucleases, toxins, antibodies, signal peptides, poly-L-lysine, *etc.*), intercalators (*e.g.*, acridine, psoralen, *etc.*), chelators (*e.g.*, metals, radioactive metals; iron, oxidative metals, *etc.*) and alkylators to name a few. The polynucleotides may be derivatized by formation of a methyl or ethyl phosphotriester or an alkyl phosphoramidite linkage. Furthermore, the polynucleotides herein may also be modified with a label capable of providing a detectable signal, either directly or indirectly. Exemplary labels include radioisotopes, fluorescent molecules, biotin and the like.

#### Expression of Candidate Polypeptides and Nucleic Acids:

A nucleotide sequence coding for candidate polypeptides, including chimeric proteins, antigenic fragments, derivatives or analogs thereof may be inserted into an appropriate expression vector, *i.e.*, a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence. Thus, a nucleic acid encoding a candidate polypeptide of the invention can be operationally associated with a promoter in an expression vector of the invention. Both cDNA and genomic sequences can

- 26 -

be cloned and expressed under control of such regulatory sequences. Such vectors can be used to express functional or functionally inactivated candidate polypeptides.

The necessary transcriptional and translational signals can be provided on a recombinant expression vector.

Potential host-vector systems include but are not limited to mammalian or other vertebrate cell systems transfected with expression plasmids or infected with virus (*e.g.*, vaccinia virus; adenovirus, adeno-associated virus, herpes virus, etc.); insect cell systems infected with virus (*e.g.*, baculovirus); microorganisms such as yeast containing yeast vectors; or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used.

Expression of a candidate protein may be controlled by any promoter/enhancer element known in the art, but these regulatory elements must be functional in the host selected for expression. Promoters which may be used to control MIP-3 $\alpha$  gene expression include, but are not limited to, cytomegalovirus (CMV) promoter (U.S. Patent Nos. 5,385,839 and 5,168,062), the SV40 early promoter region (Benoist and Chambon, *Nature* 1981, 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, *et al.*, *Cell* 1980, 22:787-797), the herpes thymidine kinase promoter (Wagner *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 1981, 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster *et al.*, *Nature* 1982, 296:39-42); prokaryotic expression vectors such as the b-lactamase promoter (Villa-Komaroff, *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 1978, 75:3727-3731), or the *tac* promoter (DeBoer, *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 1983, 80:21-25, 1983); see also "Useful proteins from recombinant bacteria" in *Scientific American* 1980, 242:74-94. Still other useful promoter elements which may be used include promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter; and transcriptional control regions that exhibit hematopoietic tissue

specificity, in particular: beta-globin gene control region which is active in myeloid cells (Mogram *et al.*, *Nature* 1985, 315:338-340; Kollias *et al.*, *Cell* 1986, 46:89-94), hematopoietic stem cell differentiation factor promoters, erythropoietin receptor promoter (Maouche *et al.*, *Blood* 1991, 15:2557), *etc.*

In another embodiment, the invention provides methods for expressing candidate polypeptides by using a non-endogenous promoter to control expression of endogenous candidate genes within a cell. An endogenous candidate gene within a cell is a candidate gene of the present invention which is ordinarily (*i.e.*, naturally) found in the genome of that cell. A non-endogenous promoter, however, is a promoter or other nucleotide sequence that may be used to control expression of a gene but is not ordinarily or naturally associated with the endogenous candidate gene. As an example, methods of homologous recombination may be employed (preferably using non-protein encoding nucleic acid sequences of the invention) to insert an amplifiable gene or other regulatory sequence in the proximity of an endogenous candidate gene. The inserted sequence may then be used, *e.g.*, to provide for higher levels of the candidate gene's expression than normally occurs in that cell, or to overcome one or more mutations in the endogenous candidate gene's regulatory sequences which prevent normal levels of gene expression. Such methods of homologous recombination are well known in the art. See, for example, International Patent Publication No. WO 91/06666, published May 16, 1991 by Skoultchi; International Patent Publication No. WO 91/099555, published July 11, 1991 by Chappel; and International Patent Publication No. WO 90/14092, published November 29, 1990 by Kucherlapati and Campbell.

Soluble forms of the protein can be obtained by collecting culture fluid, or solubilizing inclusion bodies, *e.g.*, by treatment with detergent, and if desired sonication or other mechanical processes, as described above. The solubilized or soluble protein can be isolated using various techniques, such as polyacrylamide gel electrophoresis (PAGE), isoelectric focusing, 2-dimensional gel electrophoresis, chromatography (*e.g.*, ion exchange, affinity, immunoaffinity, and sizing column chromatography), centrifugation, differential solubility, immunoprecipitation, or by any other standard technique for the purification of proteins.

Preferred vectors are viral vectors, such as lentiviruses, retroviruses, herpes viruses, adenoviruses, adeno-associated viruses, vaccinia virus, baculovirus, and other recombinant viruses with desirable cellular tropism. Thus, a gene encoding a functional or mutant candidate protein or polypeptide domain fragment thereof can be introduced *in vivo*, *ex vivo*, or *in vitro* using a viral vector or through direct introduction of DNA. Expression in targeted tissues can be effected by targeting the transgenic vector to specific cells, such as with a viral vector or a receptor ligand, or by using a tissue-specific promoter, or both.

#### Antibodies to Candidate Gene Products:

Antibodies to candidate gene products of the present invention are useful, *inter alia*, for diagnostic and therapeutic methods, as set forth below. According to the invention, candidate polypeptides produced, *e.g.*, recombinantly or by chemical synthesis, and fragments or other derivatives or analogs thereof, including fusion proteins, may be used as an immunogen to generate antibodies that recognize these polypeptides. Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library. Such an antibody is preferably specific for (*i.e.*, specifically binds to) a human candidate polypeptide of the present invention. However, the antibody may, alternatively, be specific for an ortholog from some other species of organism, preferably another species of mammal such as mouse, rat or hamster, to name a few. The antibody may recognize wild-type, mutant or both forms of the candidate polypeptide.

Various procedures known in the art may be used for the production of polyclonal antibodies. For the production of polyclonal antibodies, various host animals can be immunized by injection with the desired candidate polypeptide, or derivatives (*e.g.*, fragments or fusion proteins) thereof, including but not limited to rabbits, mice, rats, sheep, goats, etc. In one embodiment, the candidate polypeptide or fragment thereof can be conjugated to an immunogenic carrier, *e.g.*, bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH). Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as



- 29 -

lyssolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (*bacille Calmette-Guerin*) and *Corynebacterium parvum*.

For preparation of monoclonal antibodies directed toward the candidate polypeptides, or fragment, analogs, or derivatives thereof, any technique that provides for the production of antibody molecules by continuous cell lines in culture may be used. These include but are not limited to the hybridoma technique originally developed by Kohler and Milstein (*Nature* 1975, 256:495-497), as well as the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, *Immunology Today* 1983, 4:72; Cote *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 1983, 80:2026-2030), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole *et al.*, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., 1985, pp. 77-96). In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals (International Patent Publication No. WO 89/12690). In fact, according to the invention, techniques developed for the production of "chimeric antibodies" (Morrison *et al.*, *J. Bacteriol.* 1984, 159:870; Neuberger *et al.*, *Nature* 1984, 312:604-608; Takeda *et al.*, *Nature* 1985, 314:452-454) may also be used. Briefly, such techniques comprise splicing the genes from an antibody molecule from a first species of organism (*e.g.*, a mouse) that is specific for a candidate polypeptide together with genes from an antibody molecule of appropriate biological activity derived from a second species of organism (*e.g.*, from a human). Such chimeric antibodies are within the scope of this invention.

Antibody fragments which contain the idiotype of the antibody molecule can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')<sub>2</sub> fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab')<sub>2</sub> fragment, and the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent.

According to the invention, techniques described for the production of single chain antibodies (U.S. Patent Nos. 5,476,786, 5,132,405, and 4,946,778) can be adapted to produce specific single chain antibodies that specifically bind to a particular candidate polypeptide. An additional embodiment of the invention utilizes the techniques described for the construction of Fab expression libraries (Huse *et al.*, *Science* 1989, 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for a candidate polypeptide, or for its derivatives, or analogs.

In the production and use of antibodies, screening for or testing with the desired antibody can be accomplished by techniques known in the art, *e.g.*, radioimmunoassay, ELISA (enzyme-linked immunosorbant assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, *in situ* immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), Western blots, precipitation reactions, agglutination assays (*e.g.*, gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays; and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.

The foregoing antibodies can be used in methods known in the art relating to the localization and activity of a candidate polypeptide of interest, *e.g.*, for Western blotting, imaging candidate polypeptides *in situ*, measuring levels thereof in appropriate physiological samples, *etc.* using any of the detection techniques mentioned above or known in the art. Such antibodies can also be used in assays for ligand binding, *e.g.*, as described in US Patent No. 5,679,582. Antibody binding generally occurs most readily under physiological conditions, *e.g.*, pH of between about 7 and 8, and physiological ionic strength. The presence of a carrier protein in the buffer solutions stabilizes the assays. While there is some tolerance of perturbation of optimal conditions, *e.g.*, increasing or decreasing ionic strength,

temperature, or pH, or adding detergents or chaotropic salts, such perturbations generally decrease binding stability.

In still other embodiments, antibodies may also be used to isolate cells which express a candidate polypeptide of interest (for example, OA chondrocyte cells) by panning or related immunoadsorption techniques.

In a specific embodiment, antibodies that agonize or antagonize the activity of a candidate polypeptide can be generated. In particular, intracellular single chain Fv antibodies can be used to regulate (inhibit) MIP-3 $\alpha$  activity (Marasco *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 1993, 90:7884-7893; Chen, *Mol. Med. Today* 1997, 3:160-167; Spitz *et al.*, *Anticancer Res.* 1996, 16:3415-22; Indolfi *et al.*, *Nat. Med.* 1996, 2:634-635; Kijma *et al.*, *Pharmacol. Ther.* 1995, 68:247-267). Such antibodies can be tested using the assays described *infra* for identifying ligands.

#### Applications and Uses:

Described herein are various applications and uses for candidate genes and gene products that are identified in screening methods of the present invention. These include, *inter alia*, applications and uses for the candidate nucleic acids and polypeptides described above, including the particular candidate nucleic acids and polypeptides provided in the examples as well as fragments, analogs, homologs and other variants thereof.

The candidate genes and gene products that are identified in screening assays of this invention include ones that are expressed at elevated levels in cells from patients with OA compared to healthy subjects. Other candidate genes and gene products of the invention induce one or more features of an OA phenotype when they are expressed in cells. Hence, candidate genes and/or gene products may be used as tissue-specific markers to detect and/or identify OA cells or tissue, including OA chondrocyte cells and cartilage. Candidate nucleic acids and polypeptides of the invention can therefore be used in methods for detecting OA, *e.g.*, in diagnostic and prognostic applications, by using one or more candidate genes or gene

products to detect expression in a sample such as a cell or tissue sample from an individual (obtained, *e.g.*, from a biopsy).

In addition, candidate genes and gene products of the invention can serve as drug targets for the development of therapeutics to treat individuals suffering from OA. Methods are provided that use candidate nucleic acids and polypeptides of the invention to screen for compounds that can be used to treat or prevent cartilage degradation, as well as for the treatment or prevention of conditions such as OA. Such screening methods may, for example, identify compounds that modulate or interfere with binding of a candidate gene or gene product to its ligand or receptor. In other embodiments, drug screening methods of the invention may identify compounds that modulate downstream signaling events from a candidate or gene or gene product, or they may identify compounds that interfere with upstream signaling event that activate a candidate gene or gene product. In still other embodiments, drug screening assays of the invention may identify compounds that inhibit the expression and/or activity of either a candidate gene or its gene product.

*Drug screening assays.* Using screening assays such as those described below, it is possible to identify compounds that bind to or otherwise interact with candidate genes of the present invention and/or their gene products, including intracellular compounds (for example, proteins or portions of proteins), natural and synthetic ligands or receptors, compounds that interfere with the interaction of a candidate gene product (for example, compounds that interfere with specific binding of a candidate gene product to its receptor or ligand), and compounds that modulate the activity of a candidate gene (for example, by modulating the level of the candidate gene's expression) or the activity (for example, the bioactivity) of a candidate gene product.

The screening assays of this invention may therefore be used to identify compounds that specifically bind to a candidate gene or gene product to modulate its expression. For example, the screening assays described here may be used to identify compounds that bind to a promoter or other regulatory sequence of a candidate gene, and so may modulate the level of that candidate gene's expression (see, for example, Platt, *J. Biol.*

*Chem.* 1994, 269:28558-28562). The screening assays may also be used to identify compounds that bind to and thereby stabilize a candidate nucleic acid or polypeptide. In addition, these screening assays may be used to identify compounds that inhibit or modulate such binding interactions and which are therefore useful, *e.g.*, as agonists or antagonists for the candidate gene product's binding to a specific transcription factor or enhancer, or for the candidate gene product's binding to a stabilizer. Compounds identified in these or similar screening assays may therefore be used to treat diseases and disorders that are associated with the candidate gene's abnormal expression and/or activity, associated with , but not limited to, OA.

Classes of compounds that may be identified by such screening assays include, but are not limited to, small molecules (*e.g.*, organic or inorganic molecules which are less than about 2 kDa in molecular weight, are more preferably less than about 1 kDa in molecular weight, and/or are able to cross the blood-brain barrier or gain entry into an appropriate cell and affect expression of either a candidate gene or of some gene involved in the candidate gene's regulatory pathway) as well as macromolecules (*e.g.*, molecules greater than about 2 kDa in molecular weight). Compounds identified by these screening assays may also include nucleic acids, peptides and polypeptides. Examples of such compounds (including peptides) include but are not limited to: soluble peptides; fusion peptide members of combinatorial libraries (such as ones described by Lam *et al.*, *Nature* 1991, 354:82-84; and by Houghten *et al.*, *Nature* 1991, 354:84-86); members of libraries derived by combinatorial chemistry, such as molecular libraries of D- and/or L-configuration amino acids; phosphopeptides, such as members of random or partially degenerate, directed phosphopeptide libraries (see, *e.g.*, Songyang *et al.*, *Cell* 1993, 72:767-778); antibodies, including but not limited to polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies; antibody fragments, including but not limited to Fab, F(ab')<sub>2</sub>, Fab expression library fragments, and epitope-binding fragments thereof. Nucleic acids used in these screening assays may be DNA or RNA, or synthetic nucleic acids. Particular examples include, but are by no means limited to, antisense nucleic acids and ribozymes, as well as double-stranded and triple helix nucleic acid molecules.

*Assays for binding compounds.* *In vitro* systems can be readily designed to identify compounds capable of binding to a candidate gene product of the present invention. Such compounds can be useful, for example, in modulating the expression, stability or activity of a wild-type candidate gene product or, alternatively, to modulate the expression, stability or activity of a mutant or other variant candidate gene product.

Generally, such screening assays involve preparation of a reactive mixture comprising the candidate gene product of interest and a test compound under conditions and for a time sufficient to allow the two compounds to interact (*e.g.*, bind), thereby forming a complex that may be detected. The assays may be conducted in any of a variety of different ways. For example, one embodiment comprises anchoring a candidate polypeptide or a test compound onto a solid phase and detecting complexes of the candidate polypeptide and the test compound that are on the solid phase at the end of the reaction and after removing (*e.g.*, by washing) unbound compounds. For example, in one preferred embodiment of such a method, a candidate gene product may be anchored onto a solid surface and a labeled compound (*e.g.*, labeled according to any of the methods described *supra*) is contacted to the surface. After incubating the test compound for a sufficient time and under sufficient conditions that a complex may form between the candidate gene product and the test compound, unbound molecules of the test compound are removed from the surface (*e.g.*, by washing) and labeled molecules which remain are detected.

In another, alternative embodiment, molecules of one or more different test compounds are attached to the solid phase and molecules of a labeled candidate polypeptide may be contacted thereto. In such embodiments, the molecules of different test compounds are preferably attached to the solid phase at a particular location on the solid phase so that test compounds that bind to the candidate polypeptide may be identified by determining the location of the bound candidate polypeptides on the solid phase or surface.

*Assays for compounds that interact with a candidate gene or gene product.* Any of a variety of known methods for detecting protein-protein interactions may also be used to detect and/or identify proteins that interact with a candidate gene product of the

invention. For example, co-immunoprecipitation, cross-linking and co-purification through gradients or chromatographic columns as well as other techniques known in the art may be employed. Proteins which may be identified using such assays include, but are not limited to, extracellular proteins, such as receptors and ligands for candidate genes and/or their gene products, as well as intracellular proteins such as signal transducing proteins.

Compounds, including other cellular proteins and nucleic acids, that interact with a candidate gene or gene product may themselves be used in the methods of this invention, *e.g.*, to modulate activity of the candidate gene or gene product and to treat or prevent cartilage degradation. Alternatively, such interacting compounds may, themselves, be used in the screening assays of this invention to identify other compounds that could, in turn, be used to treat or prevent cartilage degradation.

As an example, and not by way of limitation, an expression cloning assay may be used to identify receptors and other proteins that specifically interact with a candidate gene product of interest. In such assays, a cDNA expression library may be generated from any cell line that expresses such a receptor. Clones from such an expression library may then be transfected or infected into cells that do not normally express a receptor for the candidate gene product. Cells that are transfected with a clone that encodes a receptor which specifically binds to the candidate gene product may then express this receptor, and can be identified and isolated using standard techniques such as FACS or using magnetic beads that have the candidate polypeptide (for example, an Fc-fusion of the candidate polypeptide) attached thereto.

Alternatively, receptors and/or ligands that specifically bind to a candidate gene product may be isolated from a cell line using immunoprecipitation techniques that are well known in the art.

Receptors and/or ligands for a candidate gene product may also be isolated using any of the screening assays discussed, *supra* for identifying binding compounds. For example, an Fc-fusion polypeptide of a candidate gene product may be bound or otherwise

- 36 -

attached to a solid surface, and a labeled compound (*e.g.*, a candidate receptor or ligand) may be contacted to the surface for a sufficient time and under conditions that permit formation of a complex between the fusion polypeptide and the test compound. Unbound molecules of the test compound can then be removed from the surface (*e.g.*, by washing), and labeled compounds that remain bound can be detected.

Once so isolated, standard techniques may be used to identify any protein detected in such assays. For example, at least a portion of the amino acid sequence of a protein that interacts with a candidate gene product can be ascertained using techniques well known in the art, such as the Edman degradation technique (see, *e.g.*, Creighton, 1983, *Proteins: Structures and Molecular Principles*, W.H. Freeman & Co., New York, pages 34-49).

Once such proteins have been identified, their amino acid sequence may be used as a guide for the generation of oligonucleotide mixtures to screen for gene sequences encoding such proteins; *e.g.*, using standard hybridization or PCR techniques described *supra*. See, for example, Ausubel *supra*; and PCR Protocols: A Guide to Methods and Applications, Innis *et al.*, eds., Academic Press, Inc., New York (1990) for descriptions of techniques for the generation of such oligonucleotide mixtures and their use in screening assays.

Other methods are known in the art which result in the simultaneous identification of genes that encode a protein that interacts with a candidate gene or gene product. For example, expression libraries may be probed with a labeled candidate polypeptide.

As another example and not by way of limitation, a two-hybrid system may be used to detect protein interactions with a candidate gene product *in vivo*. Briefly, utilizing such a system, plasmids may be constructed which encode two hybrid proteins, one of which preferably comprises of the DNA-binding domain of a transcription activator protein fused to a candidate gene product. The other hybrid protein preferably comprises an activation



- 37 -

domain of the transcription activator protein used in the first hybrid, fused to an unknown protein that is encoded by a cDNA recombined into the plasmid library as part of a cDNA library. Both the DNA-binding domain fusion plasmid and the cDNA library may be co-transformed into a strain of *Saccharomyces cerevisiae* or other suitable organism which contains a reporter gene (for example, HBS, lacZ, HIS3 or GFP). Preferably, the regulatory region of this reporter gene comprises a binding site for the transcription activator moiety of the two hybrid proteins. In such a two-hybrid system, the presence of either of the two hybrid proteins alone cannot activate transcription of the reporter gene. Specifically, the DNA-binding domain hybrid protein cannot activate transcription because it cannot localize to the necessary activation function. Likewise, the activation domain hybrid protein cannot activate transcription because it cannot localize to the DNA binding site on the reporter gene. However, interaction between the two hybrid proteins, reconstitutes that functional transcription activator protein and results in expression of the reporter gene. Thus, in a two-hybrid system such as the one described here in detail, an interaction between a candidate polypeptide (*i.e.*, the candidate polypeptide fused to the transcription activator's DNA binding domain) and a test polypeptide (*i.e.*, a protein fused to the transcription activator's DNA binding domain) may be detected by simply detecting expression of a gene product of the reporter gene.

cDNA libraries for screening in such two-hybrid and other assays may be made according to any suitable technique known in the art. As a particular and non-limiting example, cDNA fragments may be inserted into a vector so that they are translationally fused to the transcriptional activation domain of GAL4, and co-transformed along with a "bait" GAL4 fusion plasmid (encoding a GAL4-fusion of a candidate gene product) into a strain of *Saccharomyces cerevisiae* or other suitable organism that contains a HIS3 gene driven by a promoter that contains a GAL4 activation sequence. A protein from this cDNA library, fused to the GAL4 transcriptional activation domain, which interacts with the candidate polypeptide moiety of the GAL4-fusion will reconstitute and active GAL4 protein, and can thereby drive expression of the HIS3 gene. Colonies that express the HIS3 gene may be detected by their growth on petri dishes containing semi-solid agar based media lacking

histidine. The cDNA may then be purified from these strains, sequenced and used to identify the encoded protein which interacts with the candidate polypeptide.

Once compounds have been identified which bind to a candidate gene or gene product of the invention, the screening methods described in these methods may also be used to identify other compounds (*e.g.*, small molecules, peptides and proteins) which bind to these binding compounds. Such compounds may also be useful for modulating bioactivities associated with a candidate gene and its gene product, for example by binding to a natural receptor, ligand or other binding partner and preventing its interaction with the candidate gene product. For instance, these compounds could be tested for their ability to inhibit the binding of an Fc-fusion of the candidate gene product to cell lines which express a specific receptor for the candidate gene product.

*Assays for compounds that interfere with a candidate gene/protein ligand interaction.* As noted *supra*, a candidate gene product of the invention may interact with one or more molecules (*e.g.*, with a specific receptor or ligand) *in vivo* or *in vitro*. Compounds that disrupt or otherwise interfere with this binding interaction are therefore useful in modulating biological activity or activities that are associated with the candidate gene product, including for example, cartilage degradation. Such compounds may therefore be useful, *e.g.*, to treat disorders such as OA that are associated with abnormal levels of a candidate gene or gene product's expression and/or activity.

Such compounds include, but are not limit to, compounds identified according to the screening assays described *supra*, for identifying compounds that bind to a candidate gene product, including any of the numerous exemplary classes of compounds described therein.

In general, assays for identifying compounds that interfere with the interaction between a candidate gene product and a binding partner (*e.g.*, a receptor or ligand) involve preparing a test reaction mixture that contains the candidate gene product and its binding partner under conditions and for a time sufficient for the candidate gene product and its

binding partner to bind and form a complex. In order to test a compound for inhibitory activity (*i.e.*, for the ability to inhibit formation of the binding complex or to disrupt the binding complex once formed), the test compound preferably is also present in the test reaction mixture. In one exemplary embodiment, the test compound may be initially included in the test reaction mixture with the candidate gene product and its binding partner. Alternatively, however, the test compound may be added to the test reaction mixture at a later time, subsequent to the addition of the candidate gene product and its binding partner. In preferred embodiments, one or more control reaction mixtures, which do not contain the test compound, may also be prepared. Typically, a control reaction mixture will contain the same candidate gene product and binding partner that are in the test reaction mixture, but will not contain a test compound. A control reaction mixture may also contain a placebo, not present in the test reaction mixture, in place of the test compound. The formation of a complex between the candidate gene product and the binding partner may then be detected in the reaction mixture. The formation of such a complex in the absence of the test compound (*e.g.*, in a control reaction mixture) but not in the presence of the test compound, indicates that the test compound is one which interferes with or modulates the interaction of the candidate polypeptide and its binding partner.

Such assays for compounds that modulate the interaction of a candidate gene product and a binding partner may be conducted in a heterogeneous format or, alternatively, in a homogeneous format. Heterogeneous assays typically involve anchoring either a candidate gene product or a binding partner onto a solid phase and detecting compounds anchored to the solid phase at the end of the reaction. Thus, such assays are similar to the solid phase assays described *supra* for detecting and/or identifying candidate nucleic acids and gene products and for detecting or identifying binding partners. Indeed, those skilled in the art will recognize that many of the principles and techniques described above for those assays may be modified and applied without undue experimentation in the solid phase assays described here, for identifying compounds that modulate interaction(s) between a candidate gene product and a binding partner.

- 40 -

Regardless of the particular assay used, the order to which reactants are added to a reaction mixture may be varied; for example, to identify compounds that interfere with the interaction of a candidate gene product with a binding partner by competition, or to identify compounds that disrupt a preformed binding complex. Compounds that interfere with the interaction of a candidate gene product with a binding partner by competition may be identified by conducting the reaction in the presence of a test compound. Specifically, in such assays a test compound may be added to the reaction mixture prior to or simultaneously with the candidate gene product and the binding partner. Test compounds that disrupt preformed complexes of a candidate gene product and a binding partner may be tested by adding the test compound to a reaction mixture after complexes have been formed.

The screening assays described herein may also be practiced using peptides or polypeptides that correspond to portions of a full length candidate polypeptide or protein, or with fusion proteins comprising such peptide or polypeptide sequences. For example, screening assays for identifying compounds that modulate interactions of a candidate polypeptide with a binding partner may be practiced using peptides or polypeptides corresponding to particular regions or domains of a full length candidate polypeptide that bind to a binding partner (*e.g.*, receptor "binding sites").

A variety of methods are known in the art that may be used to identify specific binding sites of a candidate polypeptide. For example, binding sites may be identified by mutating a candidate gene and screening for disruptions of binding as described above. A gene encoding the binding partner may also be mutated in such assays to identify mutations that compensate for disruptions from the mutation to the candidate gene. Sequence analysis of these mutations can then reveal mutations that correspond to the binding region of the two proteins.

In an alternative embodiment, a protein (*e.g.*, a candidate protein or a protein binding partner to a candidate protein) may be anchored to a solid surface or support using the methods described hereinabove. Another labeled protein which binds to the protein anchored to the solid surface may be treated with a proteolytic enzyme, and its fragments

may be allowed to interact with the protein attached to the solid surface, according to the methods of the binding assays described *supra*. After washing, short, labeled peptide fragments of the treated protein may remain associated with the anchored protein. These peptides can be isolated and the region of the full length protein from which they are derived may be identified by the amino acid sequence.

In still other embodiments, compounds that interfere with interactions between a candidate polypeptide and a receptor or ligand may also be identified by screening for compounds that modulate binding of the candidate polypeptide (for example, an Fc-fusion construct of the candidate polypeptide) to cells that express a specific receptor thereto.

#### Diagnostic and Prognostic Applications:

A variety of methods can be employed for diagnostic and prognostic methods using reagents such as the candidate nucleic acids and polypeptides described *supra* as well as antibodies directed against such candidate nucleic acids and polypeptides. For example, using the methods described here it is possible to detect expression of a candidate nucleic acid or protein in a biological sample from an individual, such as in cells or tissues in a sample (e.g., from a biopsy) obtained or derived from an individual subject or patient. As explained above, candidate nucleic acids and polypeptides identified in screening assays of this invention induce one or more characteristics associated with OA when they are expressed in cells. Hence, the expression of such candidate nucleic acids and/or polypeptides at elevated levels in cells is an indication of OA or a related disorder.

Using the methods described here (as well as other methods known in the art) a skilled artisan may detect elevated levels of a candidate nucleic acid or polypeptide in a sample of cells or tissue from an individual, and may thereby detect and/or identify cells or tissue in that sample as being symptomatic of OA. In certain preferred embodiments the particular type of tissue identified in such methods is cartilage tissue. By using such methods to detect such cells or tissue in an individual, a skilled user may thereby diagnose the presence of OA in that individual.

In preferred embodiments the methods described herein are performed using pre-packaged diagnostic kits. Such kits may comprise at least one specific candidate nucleic acid or a candidate gene product specific antibody reagent. For example, said diagnostic kit may be used for detecting mRNA levels or protein levels of a candidate gene or gene product selected from the group consisting of those disclosed in Table V and Table VI, said kit comprising: (a) a polynucleotide of said candidate gene or a fragment thereof; (b) a nucleotide sequence complementary to that of (a); (c) an expression product of said candidate gene, or a fragment thereof; or (d) an antibody to said expression product and wherein components (a), (b), (c) or (d) may comprise a substantial component.

In preferred embodiments, a kit will also contain instructions for its use, *e.g.*, to detect diseased cells or tissues, or to diagnose a disorder (such as OA) associated with abnormal expression of a candidate gene or gene product. In preferred embodiments, such instructions may be packaged directly with the kit. In other embodiments, however, instructions may be provided separately. For example, the invention provides embodiments of kits where instructions for using the kit may be downloaded, *e.g.*, from the internet. A kit of the invention may also comprise, preferably in separate containers, suitable buffers and other solutions to use the reagents (*e.g.*, nucleic acid or antibody specific for a candidate gene or gene product) to detect the candidate gene or gene product. The kit and any reagent(s) contained therein may be used, for example, in a clinical setting, to diagnose patients exhibiting or suspected of having OA.

A sample comprising a cell of any cell type or tissue of any tissue type in which a candidate gene is expressed may also be used in such diagnostic methods, *e.g.*, for detection of candidate gene expression or of candidate gene products (such as candidate polypeptides), as well as for identifying cells, *e.g.* chondrocytes, that express a candidate gene or a candidate gene product. Thus, in one embodiment, the methods described herein may be performed *in situ*, *e.g.*, using cells or tissues obtained from an individual such as in a biopsy. Such methods may be useful, for example, in surgical procedures where it is desirable to identify arthritic tissue without removing benign, healthy tissue.

The methods described herein are not limited to diagnostic applications, but may also be used in prognostic applications, *e.g.*, to monitor the progression of a disease (such as OA) that is associated with abnormal expression of a candidate gene or gene product, or to monitor a therapy thereto. Accordingly, prognostic methods of the invention may comprise, in one exemplary embodiment, monitoring candidate nucleic acid or polypeptide levels in an individual during the course of a treatment or therapy (for example, a drug treatment or exercise regimen) for OA. Similarly, the methods of the invention may also be used to detect and identify diseased cells and tissue (*e.g.* cells overexpressing one or more candidate genes or gene products compared to non OA cells or tissue) during the course of a therapy. In such embodiments, decreasing numbers of diseased cells is generally indicative of an effective treatment. The methods of the invention may further be used, *e.g.*, to screen candidate drugs or compounds and identify ones that may be effective, *e.g.*, as anti-OA drugs. Such methods may be performed *in vivo* (*e.g.*, using an animal model) or *in vitro* (for example, in a cell culture assay). In one embodiment such methods may comprise contacting a candidate compound to a cell and identifying whether expression of a candidate gene or gene product by the cell has been inhibited. In another embodiment, a compound may be contacted to a cell or administered to an organism, and extracellular levels of candidate nucleic acid or polypeptide may be measured (for example, in cell culture media for cell culture assays, or in blood or other body fluid in an animal model assay).

*Detection of candidate nucleic acids.* The diagnostic and prognostic methods of the invention include methods for assaying the level of candidate gene expression. A variety of methods known in the art may be used to detect assay levels of one or more candidate nucleic acid sequences in a sample. For example, RNA from a cell type or tissue that is known or suspected to express one or more candidate genes of interest may be isolated and tested utilizing hybridization or PCR techniques known in the art. The isolated cells may be, for example, cells derived from a cell culture or from an individual. The analysis of cells taken from a cell culture may be useful, *e.g.*, to test the effect of compounds on the expression of one or more candidate genes, or alternatively, to verify that the cells are ones of a particular cell type that express one or more candidate genes of interest.

As an example, and not by way of limitation, diagnostic methods for the detection of candidate nucleic acids can involve contacting and incubating nucleic acids (including recombinant DNA molecules, cloned genes or degenerate variants thereof) obtained from a sample with one or more labeled nucleic acid reagents, such as recombinant candidate DNA molecules, cloned genes or degenerate variants thereof, under conditions favorable for specifically annealing or hybridizing these reagents to their complementary sequences in the sample nucleic acids. After incubation, all non-annealed or non-hybridized nucleic acids are removed. The presence of nucleic acids that have hybridized, if any such molecules exist, is then detected and the level of candidate nucleic acid sequences to which the nucleic acid reagents have annealed may be compared to the annealing pattern or level expected from a control sample (*e.g.*, from a sample of normal, non-OA cells or tissues) to determine whether candidate nucleic acid is expressed at an elevated level.

In a preferred embodiment of such a detection scheme, the nucleic acid from the cell type or tissue of interest may be immobilized, for example, to a solid support such as a membrane or a plastic surface (for example, on a nylon membrane, a microtiter plate or on polystyrene beads). After incubation, non-annealed, labeled candidate nucleic acid reagents may be easily removed and detection of the remaining, annealed, labeled candidate nucleic acid reagents may be accomplished using standard techniques that are well-known in the art.

Alternative diagnostic methods for the detection of candidate nucleic acids in patient samples or in other cell or tissue sources may involve their amplification, *e.g.*, by PCR (see, for example, the experimental embodiment taught in U.S. Patent No. 4,683,202) followed by detection of the amplified molecules using techniques that are well known to those of skilled in the art. The resulting level of amplified candidate nucleic acids may be compared to those levels that would be expected if the sample being amplified contained only normal levels of the candidate nucleic acid(s), as normal cells or tissues, to determine whether elevated levels of any candidate nucleic acid(s) are expressed.



In one preferred embodiment of such a detection scheme, a cDNA molecule is synthesized from an RNA molecule of interest (*e.g.*, by reverse transcription). A sequence within the cDNA may then be used as a template for a nucleic acid amplification reaction such as PCR. Nucleic acid reagents used as synthesis initiation reagents (*e.g.*, primers) in the reverse transcription and amplification steps of such an assay are preferably chosen from the candidate nucleic acid sequences described herein or are fragments thereof. Preferably, the nucleic acid reagents are at least about 9 to 30 nucleotides in length. The amplification may be performed using, *e.g.*, radioactively labeled or fluorescently labeled nucleotides, for detection. Alternatively, enough amplified product may be made such that the product can be visualized by standard ethidium bromide or other staining methods.

Candidate gene expression assays of the invention may also be performed *in situ* (*i.e.*, directly upon tissue sections of patient tissue, which may be fixed and/or frozen), thereby eliminating the need for nucleic acid purification. Candidate nucleic acid reagents may be used as probes or as primers for such *in situ* procedures (see, for example, Nuovo, PCR In Situ Hybridization: Protocols And Application, 1992, Raven Press, New York). Alternatively, if a sufficient quantity of the appropriate cells can be obtained, standard Northern analysis can be performed to determine the level of candidate gene expression by detecting levels of one or more candidate mRNAs.

*Detection of candidate gene products.* The diagnostic and prognostic methods of the invention also include ones that comprise detecting levels of a candidate polypeptide and including functionally conserved variants and fragments thereof. For example, antibodies directed against unimpaired, wild-type or mutant candidate gene products or against functionally conserved variants or peptide fragments of a candidate gene product may be used as diagnostic and prognostic reagents. Such reagents may be used, for example, to detect abnormalities in the level of candidate gene product synthesis or expression, or to detect abnormalities in the structure, temporal expression or physical location of a candidate gene product. Antibodies and immunoassay methods such as those described hereinbelow also have important *in vitro* applications for assessing the efficacy of treatments, *e.g.*, for OA. For example, antibodies, or fragments of antibodies, can be used in screens of potentially

therapeutic compounds *in vitro* to ascertain a compound's effects on candidate gene expression and candidate polypeptide production. Compounds that may have beneficial effects on a disorder associated with abnormal candidate gene expression can be identified and a therapeutically effective dose for such compounds may be determined using such assays.

As one example, antibodies or fragments of antibodies may be used to detect the presence of a candidate gene product, a variant of a candidate gene product or fragments thereof, for example, by immunofluorescence techniques employing a fluorescently labeled antibody coupled with light microscopic, flow cytometric or fluorimetric detection methods.

In particularly preferred embodiments, antibodies or fragments thereof may also be employed histologically, for example in immunofluorescence or immunoelectron microscopy techniques, for *in situ* detection of a candidate gene product. *In situ* detection may be accomplished by removing a histological specimen (*e.g.*, a tissue sample) from a patient and applying thereto a labeled antibody of the present invention or a fragment of such an antibody. The antibody or antibody fragment is preferably applied by overlaying the labeled antibody or antibody fragment onto a biological sample. Through the use of such a procedure, it is possible to detect, not only the presence of a candidate gene product, but also the gene product's distribution in the examined tissue. A wide variety of histological methods that are well known in the art (for example, staining procedures) can be readily modified by those skilled in the art without undue experimentation to achieve such *in situ* detection.

Immunoassays for candidate gene products will typically comprise incubating a biological sample (for example, a tissue extract) in the presence of a detectably labeled antibody that is capable of specifically binding a candidate gene product (including, for example, a functionally conserved variant or a peptide fragment thereof). The bound antibody may then be detected by any of a number of techniques well known in the art.

#### Therapeutic Methods and Pharmaceutical Compositions:

Candidate nucleic acids and polypeptides, and specific antibodies thereto may also be used in therapeutic methods and compositions, *e.g.*, to treat, prevent or ameliorate diseases and disorders associated with abnormal (preferably elevated) levels of the candidate gene's expression. In preferred embodiments such methods are used to treat OA. In one preferred embodiment the therapeutic methods of the invention comprise administering one or more compounds that modulate (*e.g.*, inhibit) the expression or activity of a candidate gene or its gene product; for example, compounds that bind to a candidate nucleic acid or polypeptide of the invention, compounds that modulate expression of a candidate gene, and/or compounds that interfere with or modulate binding of a candidate nucleic acid or polypeptide with a binding compound.

In another preferred embodiment, the therapeutic methods of the invention may comprise one or more cell-targeted therapies which target compounds (for example, drugs, pro-drugs, toxins or cytotoxins) to cells expressing a candidate nucleic acid or polypeptide.

*Inhibitory approaches.* In alternative embodiments, the present invention provides methods and compositions for treating a disease or disorder (for example, OA) associated with the abnormal expression or activity of a candidate gene or gene product by modulating (*e.g.*, increasing or decreasing) the expression or activity of the candidate gene or its gene product. Such methods may simply comprise administering one or more compounds that modulate expression of a candidate gene, synthesis of a candidate gene product or activity of a candidate gene product so the immune response is modulated (*e.g.*, enhanced or suppressed). Preferably, these one or more compounds are administered until one or more symptoms of the disorder are eliminated or at least ameliorated.

Among the compounds that may exhibit an ability to modulate the activity, expression or synthesis of a candidate nucleic acid are antisense molecules. Such molecules may be designed to reduce or inhibit wild-type nucleic acids and polypeptides or, alternatively, may target mutant candidate nucleic acids or polypeptides.

Antisense RNA and DNA molecules act to directly block the translation of mRNA by hybridizing to target mRNA molecules and preventing protein translation. Antisense approaches involve the design of oligonucleotides that are complementary to a target gene mRNA. The antisense oligonucleotides will bind to the complementary target gene mRNA transcripts and prevent translation. Absolute complementarity, although preferred, is not required. As used in this description, "antisense" broadly includes RNA-RNA interactions, triple helix interactions, ribozymes and RNase-H mediated arrest. Antisense nucleic acid molecules can be encoded by a recombinant gene for expression in a cell (see, *e.g.*, U.S. Patent Nos. 5,814,500; and 5,811,234) or, alternatively, they can be prepared synthetically (U.S. Patent No. 5,780,607).

A sequence that is "complementary" to a portion of a nucleic acid refers to a sequence having sufficient complementarity to be able to hybridize with the nucleic acid and form a stable duplex. The ability of nucleic acids to hybridize will depend both on the degree of sequence complementarity and the length of the antisense nucleic acid. Generally, however, the longer the hybridizing nucleic acid, the more base mismatches it may contain and still form a stable duplex (or triplex in triple helix methods). A tolerable degree of mismatch can be readily ascertained, *e.g.*, by using standard procedures to determine the melting temperature of a hybridized complex.

In one preferred embodiment, oligonucleotides complementary to non-coding regions of a candidate gene may be used in an antisense approach to inhibit translation of endogenous candidate mRNA molecules. Antisense nucleic acids are preferably at least six nucleotides in length, and more preferably range from between about six to about 50 nucleotides in length. In specific embodiments, the oligonucleotides may be at least 10, at least 15, at least 20, at least 25 or at least 50 nucleotides in length.

It is generally preferred that *in vitro* studies are first performed to quantitate the ability of an antisense oligonucleotide to inhibit gene expression. It is preferred that these studies utilize controls that distinguish between antisense gene inhibition and nonspecific biological effects of oligonucleotides. It is also preferred that these studies compare levels of

the target RNA or protein with that of an internal control RNA or protein. Additionally, it is envisioned that results obtained using the antisense oligonucleotide are compared with those obtained using a control oligonucleotide. It is preferred that the control oligonucleotide is of approximately the same length as the test oligonucleotide and that the nucleotide sequence of the oligonucleotide differs from the antisense sequence no more than is necessary to prevent specific hybridization to the target sequence.

While antisense nucleotides complementary to the target gene coding region sequence could be used, those complementary to the transcribed, untranslated region are most preferred.

Antisense molecules are preferably delivered to cells, such as chondrocytes, that express the target gene *in vivo*. A number of methods have been developed for delivering antisense DNA or RNA to cells. For example, antisense molecules can be injected directly into the tissue site (*e.g.*, directly into a tumor), or modified antisense molecules can be designed to target the desired cells (*e.g.*, antisense linked to peptides or antibodies that specifically bind receptors or antigens expressed on the target cell surface) can be administered systemically.

Preferred embodiments achieve intracellular concentrations of antisense nucleic acid molecules which are sufficient to suppress translation of endogenous mRNAs. For example, one preferred approach uses a recombinant DNA construct in which the antisense oligonucleotide is placed under the control of a strong pol III or pol II promoter. The use of such a construct to transfect target cells in the patient will result in the transcription of sufficient amounts of single stranded RNAs that will form complementary base pairs with the endogenous target gene transcripts and thereby prevent translation of the target gene mRNA. For example, a vector, as set forth above, can be introduced *e.g.*, such that it is taken up by a cell and directs the transcription of an antisense RNA. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the

art, used for replication and expression in mammalian cells. Expression of the sequence encoding the antisense RNA can be by any promoter known in the art to act in the particular cell type (for example in a hemopoietic cell). For example, any of the promoters discussed *supra* in connection with the expression of recombinant candidate nucleic acids can also be used to express a candidate antisense nucleic acid.

In addition to antisense technology, RNA aptamers (Good et al., 1997, *Gene Therapy* 4: 45-54), double stranded RNA (WO 99/32619), ribozymes (Cech. J., 1988, *Amer. Med Assn.* 260:3030; Cotten et al., 1989, *EMBO J.* 8:3861-3866; Grassi and Marini, 1996, *Annals of Medicine* 28: 499-510; Gibson, 1996, *Cancer and Metastasis Reviews* 15: 287-299) and/or triple helix DNA (Gee, J.E. et al. (1994) In: Huber, B.E. and B. I. Carr, *Molecular and Immunologic Approaches*, Futura Publishing Co., Mt. Kisco, N.Y.) may be used to modulate the activity, expression or synthesis of a target candidate nucleic acid according to methods familiar to one of skill in the art.

Alternatively, small interfering RNA (siRNA) molecules can also be used to inhibit the expression of nucleic acids for a candidate receptor or for a candidate ligand. RNA interference is a method in which exogenous, short RNA duplexes are administered where one strand corresponds to the coding region of the target mRNA (Elbashir *et al.*, *Nature* 2001, 411: 494-498). Upon entry into cells, siRNA molecules cause not only degradation of the exogenous RNA duplexes, but also of single-stranded RNAs having identical sequences, including endogenous messenger RNAs. Accordingly, siRNA may be more potent and effective than traditional antisense RNA methodologies since the technique is believed to act through a catalytic mechanism.

Preferred siRNA molecules are typically greater than about 19 nucleotides in length and comprise the sequence of a nucleic acid for a candidate receptor or its ligand. Effective strategies for delivering siRNA to target cells include any of the methods described, *supra*, for delivering antisense nucleic acids. For example, siRNA can be introduced to cells by transduction using physical or chemical transfection. Alternatively siRNAs may be expressed in cells using, *e.g.*, various PolIII promoter expression cassettes that allow

transcription of functional siRNA or precursors thereof. See, for example, Scherr *et al.*, *Curr. Med. Chem.* 2003, 10(3):245-256; Turki *et al.*, *Hum. Gene Ther.* 2002, 13(18):2197-2201; Cornell *et al.*, *Nat. Struct. Biol.* 2003, 10(2):91-92.

*Pharmaceutical preparations.* Compositions used in the therapeutic methods of this invention may be administered (*e.g.*, *in vitro* or *ex vivo* to cell cultures, or, more preferably, *in vivo* to an individual) at therapeutically effective doses to treat a disease or disorder such as OA that is associated with abnormal candidate gene expression and/or activity. For example, compounds, including compounds identified in such screening methods as described above, that bind to a candidate gene or gene product of the invention may be administered to the cells or individual so that expression and/or activity of the candidate gene or gene product is inhibited. The invention therefore also provides pharmaceutical preparations for use, *e.g.*, as therapeutic compounds to treat disorders, including OA, that are associated with abnormal candidate gene expression or activity.

The terms "therapeutically effective dose" and "effective amount" refer to the amount of the compound that is sufficient to result in a therapeutic response. In embodiments where a compound (*e.g.*, a drug or toxin) is administered in a complex (*e.g.*, with a specific antibody), the terms "therapeutically effective dose" and "effective amount" may refer to the amount of the complex that is sufficient to result in a therapeutic response. A therapeutic response may be any response that a user (*e.g.*, a clinician) will recognize as an effective response to the therapy. Thus, a therapeutic response will generally be an amelioration of one or more symptoms of a disease or disorder. In preferred embodiments, where the pharmaceutical preparations are used to treat OA, a therapeutic response may be a reduction in the amount of cartilage degradation observed, *e.g.*, in biopsies from a patient during treatment.

Toxicity and therapeutic efficacy of compounds can be determined by standard pharmaceutical procedures, for example in cell culture assays or using experimental animals to determine the LD<sub>50</sub> and the ED<sub>50</sub>. The parameters LD<sub>50</sub> and ED<sub>50</sub> are well known in the art, and refer to the doses of a compound that are lethal to 50% of a population and

therapeutically effective in 50% of a population, respectively. The dose ratio between toxic and therapeutic effects is referred to as the therapeutic index and may be expressed as the ratio:  $LD_{50}/ED_{50}$ . Compounds that exhibit large therapeutic indices are preferred.

While compounds that exhibit toxic side effects may be used, however, in such instances it is particularly preferable to use delivery systems that specifically target such compounds to the site of affected tissue so as to minimize potential damage to other cells, tissues or organs and to reduce side effects.

Data obtained from cell culture assay or animal studies may be used to formulate a range of dosages for use in humans. The dosage of compounds used in therapeutic methods of the present invention preferably lie within a range of circulating concentrations that includes the  $ED_{50}$  concentration but with little or no toxicity (*e.g.*, below the  $LD_{50}$  concentration). The particular dosage used in any application may vary within this range, depending upon factors such as the particular dosage form employed, the route of administration utilized, the conditions of the individual (*e.g.*, patient), and so forth.

A therapeutically effective dose may be initially estimated from cell culture assays and formulated in animal models to achieve a circulating concentration range that includes the  $IC_{50}$ . The  $IC_{50}$  concentration of a compound is the concentration that achieves a half-maximal inhibition of symptoms (*e.g.*, as determined from the cell culture assays). Appropriate dosages for use in a particular individual, for example in human patients, may then be more accurately determined using such information.

Measures of compounds in plasma may be routinely measured in an individual such as a patient by techniques such as high performance liquid chromatography (HPLC) or gas chromatography.

Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers or excipients.



Thus, the compounds and their physiologically acceptable salts and solvates may be formulated for administration by inhalation or insufflation (either through the mouth or the nose) or oral, buccal, parenteral or rectal administration.

For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (*e.g.*, pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (*e.g.*, lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (*e.g.*, magnesium stearate, talc or silica); disintegrants (*e.g.*, potato starch or sodium starch glycolate); or wetting agents (*e.g.*, sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (*e.g.*, sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (*e.g.*, lecithin or acacia); non-aqueous vehicles (*e.g.*, almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (*e.g.*, methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.

Preparations for oral administration may be suitably formulated to give controlled release of the active compound. For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner. For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, *e.g.*, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of *e.g.*, gelatin for use in an inhaler or insufflator may be formulated

containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The compounds may be formulated for parenteral administration by injection, *e.g.*, by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, *e.g.*, in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, *e.g.*, sterile pyrogen-free water, before use.

The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, *e.g.*, containing conventional suppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

The compositions may, if desired, be presented in a pack or dispenser device that may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration.

Numerous references, including patents, patent applications and various publications, are cited and discussed in the description of this invention. The citation and/or discussion of such references is provided merely to clarify the description of the present invention and is not an admission that any such reference is "prior art" to the invention

- 55 -

described herein. All references cited and discussed in this specification (including references to biological sequences deposited in GenBank or other public databases) are incorporated herein by reference in their entirety and to the same extent as if each reference was individually incorporated by reference.

### **EXAMPLES**

The present invention is also described by means of the following examples. However, the use of these or other examples anywhere in the specification is illustrative only and in no way limits the scope and meaning of the invention or of any exemplified term. Likewise, the invention is not limited to any particular preferred embodiments described herein. Indeed, many modifications and variations of the invention may be apparent to those skilled in the art upon reading this specification and can be made without departing from its spirit and scope. The invention is therefore to be limited only by the terms of the appended claims along with the full scope of equivalents to which the claims are entitled.

#### **EXAMPLE 1:**

#### **A High Throughput Screen to identify candidate genes related to OA employing RT:PCR analysis of OA “marker” genes**

This example describes experiments that use a real time polymerase chain reaction (RT-PCR) assay to identify candidate genes or gene products that may be related to the pathogenesis of OA. In particular, the experiments described in this example test individual full length cDNAs in a high throughput parallel mode for their ability to activate one or more marker genes the expression of which is associated with OA in human articular chondrocyte (HAC) cells.

#### **Materials and Methods:**

*Data mining OA cDNA libraries.* cDNA libraries are preferably generated “in house” from OA chondrocyte cells and used in screening assays of the present invention. Raw sequences of genes in the OA cDNA library are pre-processed and then annotated to

identify clones that are likely to be particularly useful as drug targets. In particular, the Phred/Phrap system (Gordon *et al.*, *Genome Res.* 2001, 11(4):614-625; Ewing *et al.*, *Genome Res.* 1998, 8:175-185; Ewing *et al.*, *Genome Res.* 1998, 8:186-194; Gordon *et al.*, *Genome Res.* 1998, 8:195-202) is used to trim raw sequences to high quality regions and to trim vector sequences. Mitochondrial DNA, ribosomal DNA, repeat regions, low complexity sequence and linker regions are removed. Then, the resulting processed sequences are compared to known and predicted genes in the GenBank database.

Next, the resulting sequence annotations are searched for keywords of interest to select specific clones for screening. The keywords are chosen to emphasize proteins in classes considered most likely to play a role in the disease process based on current biological knowledge. Thus, for example, terms indicative of signal transduction and proteolysis (*e.g.*, “kinase,” “receptor,” “factor” and “protease”) are included since these processes have been previously implicated in osteoarthritis. Individual full length clones for genes selected in this way are then retrieved.

*Preparation of plasmid DNA from full length cDNA clones.* Bacterial stocks of full-length clones from the OA cDNA libraries in pCMVSPORT6 vector (Invitrogen, Carlsbad CA) are grown in 96 deep-well blocks (Qiagen, Valencia CA), each well containing 1.0 mL of Terrific broth (Sigma, St. Louis MO) and ampicillin (40 µg/mL). The cultures are initially grown for 24 hours at 37 °C with shaking at 300 RPM, re-inoculated into a fresh block and further grown overnight to ensure uniform growth of bacteria in all wells. Plasmid DNA is isolated from the bacteria with a Biorobot 8000 (Qiagen, Valencia CA) following standard protocols described by the manufacturer.

*GATEWAY™ transfer of full-length cDNA clones.* In order to screen individual clones in an RT-PCR assay, cDNA clones in the OA libraries are transferred from the pCMVSPORT6 vector to a retroviral vector using the GATEWAY™ platform (Invitrogen, Carlsbad CA).

Gateway BP reactions are carried out in 96-well plates (Ashford, United Kingdom). Briefly, 1.0 µL (100-120 ng) plasmid DNA is added to each well containing 1 µL

- 57 -

(100-120 ng) pDONR 201 entry vector (Invitrogen, Carlsbad CA), 1  $\mu$ L BP reaction buffer (Invitrogen, Carlsbad CA), 1  $\mu$ L tris-EDTA and 1  $\mu$ L BP Clonase enzyme mix (Invitrogen, Carlsbad CA) on ice. The plates are incubated at 25 °C for three hours.

The Gateway LR reaction mix, consisting of 0.25  $\mu$ L of 0.75 M NaCl, 1.0  $\mu$ L (100-120 ng) linearized retroviral vector and 1.5  $\mu$ L LR Clonase enzyme mix (Invitrogen, Carlsbad CA) is added to each BP reaction.

The retroviral vector contains a hybrid cytomegalovirus (CMV)/Maloney murine leukemia virus (MoMuLV) 5' LTR, a MoMuLV 3' LTR and a retroviral packaging  $\Psi$  site and may be constructed according to conventional methods. The same vector is also commercially available (Clontech). Samples are mixed thoroughly and incubated for two additional hours at 25 °C. One-tenth volume (0.8  $\mu$ L; 2 mg/mL) of Proteinase K solution (Invitrogen, Carlsbad CA) is added and incubated at 37 °C for ten minutes.

40  $\mu$ L of Max efficiency DH5 $\alpha$  cells (Invitrogen, Carlsbad CA) are aliquoted into wells of a flat bottom 96-well block (Qiagen, Valencia CA) on ice. 1  $\mu$ L of the LR reaction mixture from each well is then added to the cells and incubated on ice for 30 minutes. Cells are heat shocked for 30 seconds at 42 °C, placed on ice for 1-2 minutes, and 65  $\mu$ L of S.O.C. medium (Invitrogen, Carlsbad CA) is added to each well. The 96-well block is incubated at 37 °C for one hour with shaking. 35  $\mu$ L of the final transformation mixture was added to each well of a 2x48 deep-well block containing LB agar with 40  $\mu$ g/mL zeocin (Invitrogen, Carlsbad CA), and was grown overnight at 37 °C. Single colonies are inoculated to 1 mL Terrific broth/zeocin (40  $\mu$ g/mL) in 96-well format and grown overnight at 37 °C/300 RPM. Plasmid DNA is isolated using a Biorobot 8000 (Qiagen, Valencia CA) following standard protocols described by the manufacturer.

*Production of Supernatants.* GP2-293 packaging cells (BD Biosciences Clontech, Palo Alto CA) are seeded ( $5 \times 10^4$  cells per well) in 96-well PDL plates (BD Biosciences Clontech, Palo Alto CA) 16-24 hours prior to transfection in antibiotic-free DMEM containing 10% FBS (Invitrogen, Carlsbad CA). GATEWAY™ constructs along

with envelope vector pVPack-VSV-G (Stratagene, La Jolla CA) are cotransfected into the packaging cells by combining 150 ng GATEWAY™ construct with 150 ng envelope plasmid in a total volume of 25  $\mu$ L OPTIMEM (Invitrogen, Calsbad CA) in a 96-well format. In a separate plate, 25  $\mu$ L of OPTIMEM™ is combined with 1  $\mu$ L of Lipofectamine 2000 reagent (Invitrogen, Carlsbad CA). This second solution is incubated for five minutes at room temperature, and the two solutions are then combined. The DNA-lipofectamine complex is allowed to form for 20 minutes before being added to the cells. The media is replaced with complete media containing antibiotics 16-24 hours after the transfection procedure. The media, containing viral supernatants; is collected at 24 and 48 hours post transfection.

*Transduction into Primary Chondrocytes.* Primary chondrocytes (isolated from cartilage tissue obtained from joint replacement surgery, Mullenberg Hospital, Plainfield, NJ) are seeded at  $1.1 \times 10^4$  cells per well in duplicate 96-well plates, twenty-four hours prior to transduction. At time of transduction, media are replaced with 100  $\mu$ L viral supernatant and 100  $\mu$ L complete media supplemented with 20 mM HEPES and 16  $\mu$ g/mL polybrene. Cells are centrifuged in a swinging bucket rotor at 32 °C, 1000 x g, for 1.5 hours. The media are replaced after 16-24 hours with fresh media, and cells are incubated for an additional 48 hours.

*RNA isolation and RT-PCR.* Total cellular RNA is isolated from pooled duplicate 96-well plates using a BioRobot 8000 (Qiagen, Valencia CA) and Qiagen RNeasy 96 Biorobot reagents according to the manufacturer's instructions. On-column DNase I digestion is employed, pursuant to standard protocols published by Qiagen (Valencia CA) to eliminate contaminating genomic DNA. First strand cDNA is synthesized using random primers with a High-Capacity cDNA Archive kit (PE Applied Biosystems, Foster City CA) in a 100  $\mu$ L reaction volume. Real time PCR (RT-PCR) was performed in a 384-well format on the ABI Prism 7900HT Sequence Detection System (Applied Biosystems, Foster City CA). The cDNA template and PCR mix are distributed using a Biomek FX liquid handling robot. The 20  $\mu$ L reaction contains 5  $\mu$ L cDNA, 200 nM forward and reverse primers, and SYBR Green PCR Master Mix (Applied Biosystems, Foster City CA). The default cycling program (95 °C – 10 minutes and 40 cycles of 95 °C – 15 second, 60 °C – 1 minute) is followed by a

dissociation stage whereby a melting curve is generated to confirm the specificity of the PCR product and the absence of primer dimers.

Amplification of the ubiquitously expressed gene GAPDH is used to normalize the amount of cDNA added to the reaction. ROX dye is used as a passive reference to normalize non-PCR related fluctuations in the fluorescence signal. Changes in gene expression are calculated according to the manufacturer's instructions using the comparative  $C_t$  method which makes use of a calibrator sample (*i.e.*, a sample to which all others are compared). The value of the calibrator sample is normalized as 1.0 so that expression levels for all other samples are defined as multiples of the expression level measured for the calibrator sample. For RT-PCR experiments described in this example, a retroviral vector containing no cDNA insert is used as the calibrator sample. Briefly, the amount of target relative to the calibrator is calculated according to the formula:  $2^{-\Delta\Delta C_t}$  where  $C_t$  = threshold cycle (cycle# at which the amount of amplified target reaches a fixed threshold).

*Cell treatment.* To optimize RT-PCR conditions and validate the markers chosen in these screens, human articular chondrocytes from knee joint cartilage obtained in joint replacement surgeries are plated in 96 well plates (11,000 cells per well) using DMEM medium containing 10% FBS (Invitrogen, Carlsbad CA). Two days later, the cells are treated with IL-1 (5 ng/mL) (Peprotech, UK, London) and OSM (50 ng/mL) or PDGF (50 ng/mL) or TGF- $\beta$  (50 ng/mL) overnight in serum free medium. . OSM, PDGF and TGF- $\beta$  are purchased from R&D systems, (Minneapolis, MN). RNA is isolated from these cells and evaluated by RT-PCR using the methods described above.

*Data mining for OA associated genes.* Early and late OA cDNA libraries are mined to identify the most abundant genes associated with OA cartilage. Among the most highly expressed genes in early OA libraries is C17. An exemplary nucleotide sequence for this gene is available from GenBank Accession No. NM\_018659. The C17 gene encodes a protein that has been described as "cytokine-like" and was previously believed to be expressed only in CD34+ hematopoietic cells. The number of ESTs for C17 is higher in

early OA than in late OA, suggesting that the expression level of this gene decreases during progression of the disease.

A second abundant gene, known as SMOC2 (available from GenBank Accession No. NM\_022138) is highly expressed in late OA cartilage, as evidenced by the higher number of ESTs in a late OA cDNA library than in an early OA cDNA library. Thus, expression of this gene presumably increases during progression of the disease.

OA associated genes are also identified by mining gene expression data generated using DNA microarrays. U95A GeneChips from Affymetrix (Santa Clara, CA) are used according to the manufacturer's recommended protocol to compare sets of expressed genes in knee cartilage from 12 OA and 9 healthy patients. The average difference in intensity is calculated for all genes, and the significance of the difference between diseased and healthy patients is evaluated using a statistical t-test. Visual inspection confirms that the computed differences represent differences between patient groups rather than variability in the data. Among the most significantly changed genes between normal and OA knees are the genes OSF-2 (also known as periostin), MARCKS (myristoylated alanine-rich protein kinase C substrate), retinoic acid receptor beta, zinc finger protein Zic1, BASP1 (brain abundant membrane attached signal protein 1), and DIM1.. All of these genes are upregulated in OA patients but have not previously been associated with that disease. GenBank Accession numbers for preferred nucleotide sequences of these genes are provided below, along with GenBank Accession numbers for amino acid sequences that are encoded by these nucleic acids.

**TABLE I NEWLY IDENTIFIED OA MARKER GENES**

Gene	GenBank Accession Nos.		
	Nucleotide	Protein	
OSF-2	NM_006475	NP_006466	SEQ ID NO 23
	SEQ ID NO 171		
MARCKS	NM_002356	NP_002347	SEQ ID NO 24



- 61 -

	SEQ ID NO 172		
Retinoic Acid Receptor $\beta$	NM_00965	NP_000956	SEQ ID NO 25
	SEQ ID NO 173;	NP_057236	SEQ ID NO 26
	NM_016152		
	SEQ ID NO 174		
BASP1	NM_006317	NP_006308	SEQ ID NO 27
	SEQ ID NO 175		
Zic1	NM_003412	NP_003403	SEQ ID NO 28
	SEQ ID NO 176		
DIM1	NM_006701	NP_006692	SEQ ID NO 29
	SEQ ID NO 177		

---

*Choosing OA markers.* To identify genes that are involved in osteoarthritis (OA) and/or may be useful for the diagnosis or treatment of that disease, a real time polymerase chain reaction (RT-PCR) based assay is used to screen cDNA clones in a high throughput parallel mode. In particular, the assays described in this example use RT-PCR to measure expression of certain genes that are considered “markers” or indicators of OA.

The marker genes are preferably selected to represent various biological pathways that are affected in OA (see Table II). The GenBank Accession Number for an exemplary nucleotide sequence is also provided for each marker gene. In addition, the gene GAPDH (GenBank Accession No. AJ\_005371) is selected as a ubiquitously expressed “housekeeping” gene to which all samples are normalized.

**TABLE II: MARKER GENES FOR OA PHENOTYPES**

<b>OA Pheotype/Characteristic</b>	<b>Marker Gene</b>	<b>Accession No.</b>
• Cartilage degradation	Aggrecanase-1	AF148213
	MMP-13	XM_006274
• Aberrant chondrocyte cell differentiation (hypertrophy and proliferation)	Collagen Type I	AF017178
	Collagen Type Iia	XM_012271
	Collagen Type X	NM_000493
• Inflammation	Inos	AB022318
	Cox-2	M90100
• Matrix synthesis	Aggrecan	X80278
	Decorin	AF91944

PCR primers for each of the marker genes is designed with Primer Express software (Applied Biosystems, Foster City CA) under default parameters and reaction conditions. The primer sequences used for marker genes in this example are provided in Table III, below.

**TABLE III: RT-PCR PRIMERS TO DETECT OA MARKER GENES**

Marker Gene	Primer	Sequence	
Aggrecanase-1	forward	5'-TTTCCCTGGCAAGGACTATGA-3'	(SEQ ID NO:1)
	reverse	5'-AATGGCGTGAGTCGGGC-3'	(SEQ ID NO:2)
MMP-13	forward	5'-TGATCTCTTTTGAATTAAGGAGCAT-3'	(SEQ ID NO:3)
	reverse	5'-ATGGGCATCTCCTCCATAATTTG-3	(SEQ ID NO:4)
COX-2	forward	5'-AAATTGCTGGCAGGGTTGC-3'	(SEQ ID NO:5)
	reverse	5'-TTTCTGTACTGCGGGTGAAC-3'	(SEQ ID NO:6)
iNOS	forward	5'-GCAAACCTTCAAGGCAGCC-3'	(SEQ ID NO:7)
	reverse	5'-TGCTGTTTGCCTCGGACAT-3'	(SEQ ID NO:8)
Collagen IIa	forward	5'-ACGCTGCTCGTCGCCG-3'	(SEQ ID NO:9)
	reverse	5'-GCCAGCCTCCTGGACATCCT-3'	(SEQ ID NO:10)
Collage X	forward	5'-ACCCAACACCAAGACACAGTTCT-3'	(SEQ ID NO:11)
	reverse	5'-TCTTACTGCTATACCTTTACTCTTTATGGTGTA-3'	(SEQ ID NO:12)
Collagen I	forward	5'-CAGCCGCTTCACCTACAGC-3'	(SEQ ID NO:13)
	reverse	5'-TTTTGTATTCAATCACTGTCTTGCC-3'	(SEQ ID NO:14)
Decorin	forward	5'-GCCAGCCTCCTGGACATCCT-3'	(SEQ ID NO:15)
	reverse	5'-AGTCCTTTCAGGCTAGCTGCATC-3'	(SEQ ID NO:16)
Aggrecan	forward	5'-TCGAGGACAGCGAGGCC-3'	(SEQ ID NO:17)

- 64 -

	reverse	5'-TCGAGGGTGTAGCGTGTAGAGA-3'	(SEQ ID NO:18)
GAPDH	forward	5'-ATGGGGAAGGTGAAGGTCG-3'	(SEQ ID NO:19)
	reverse	5'-TAAAAGCAGCCCTGGTGACC-3'	(SEQ ID NO:20)

*Expression changes of OA markers.* To validate the RT-PCR conditions and primers, human articular chondrocyte cells are treated with various compounds as described in the Materials and Methods section, above, for this example. These compounds are known to induce an OA phenotype in the chondrocyte cells. See, for example, Smith *et al.*, *Arthritis Rheum.* 1991, 34:697-706; Tardif *et al.*, *Arthritis Rheum.* 1999, 42:1147-1158.

RT-PCR is performed to determine whether there is any detectable change in expression of one or more marker genes. Table IV, below, summarizes exemplary changes in mRNA levels of each marker mediated by treatment of the chondrocyte cells with: (i) IL-1 and OSM; (ii) TGF- $\beta$ ; and (iii) PDGF. Expression levels are indicated as the multiples of normalized expression levels (*i.e.*, as the "fold changes" in Mrna levels) measured in untreated chondrocyte cells. The data in Table IV indicates that the various OA marker genes undergo the expected changes in their expression levels in response to known treatments that induce an OA phenotype. Moreover, the response of these OA marker genes is sensitive enough to validate this RT-PCR assay for running high throughput functional screens.

**TABLE IV: CHANGE OF MARKER GENE EXPRESSION  
IN TREATED CHONDROCYTE CELLS**

Marker Gene	Treatment			
	IL-1/OSM	TGF- $\beta$	PDGF	Untreated
Aggrecanase-1	50.21	3.81	2.46	1.00
MMP-13	125.37	6.92	4.20	1.00
Collagen Iia	-227.54	1.45	-2.04	1.00
Collagen X	-3.71	19.97	-1.79	1.00
Collagen I	-3.58	3.84	-1.89	1.00

To further validate the RT-PCR assay for use in functional screens, the constitutively active gene AKT/PKB (GenBank Accession No. NPL-001907) is overexpressed in chondrocyte cells by retroviral-mediated gene transfer. Activation of this gene's biochemical pathway induces Aggrecanase-1 and MMP-13 in chondrocyte cells. Cellular RNA is harvested 48 hours and 72 hours post transduction, and changes in the expression of MMP-13 and aggrecanase-1 Mrna are detected by RT-PCR. AKT over-expression results in a 12-fold induction of Aggrecanase-1 and a 9-fold induction of MMP-13.

These experiments validate RT-PCR as a valid and sensitive method that can be used in high throughput functional assays to identify novel mediators of an OA phenotype.

#### Results:

*Verified hits from an RT-PCR screen.* The high throughput screen disclosed in this example is performed by overexpressing a select set of about 1200 test genes mined from OA libraries in primary chondrocytes. Expression levels of the OA marker genes are measured by RT-PCR when these test genes are expressed in chondrocyte cells, and these expression levels are compared to the expression levels measured in untransformed cells. To the Applicant's knowledge, heretofore, high throughput screens of chondrocytes have not been reported.

Table V lists 63 candidate genes identified in such an RT-PCR screen, along with GenBank accession numbers for their preferred nucleotide sequences. Residues coding the predicted amino acid sequence (*i.e.*, the coding sequence or "CDS") are also specified.

**TABLE V: CANDIDATE GENES IDENTIFIED IN RT-PCR SCREEN**

Gene	SEQ ID NOS	Accession # (nucleotide)	CDS	Accession # (protein)
SFRS3	30/31	NM_003017	106-600	NP_003008
SFRS10	32/33	NM_004593	122-988	NP_004584
U2AF1	34/35	NM_006758	39-761	NP_006749
TGFBR2	36/37	NM_003242	336-2039	NP_003233
TSC22	38/39	NM_006022	192-626	NP_006013
MTIF3	40/41	NM_152912	237-1073	NP_690876
CAMK2G	42/43	XM_044349	5-1561	XP_044349

Gene	SEQ ID NOS	Accession # (nucleotide)	CDS	Accession # (protein)
PHKG1	44/45	NM_006213	120-1283	NP_006204
DTR	46/47	NM_001945	262-888	NP_001936
TGFA	48/49	NM_003236	32-514	NP_003227
SF3B1	50/51	NM_012433	1-3915	NP_036565
BCAT1	52/53	BC033864	424-1386	AAH33864
CSNK2A1	54/55	NM_001895	149-1324	NP_001886
FLJ14103	56/57	NM_024689	76-624	NP_078965
U5snRNP-AP	58/59	AF221842	106-2931	AAF66128
VTI2	60/61	NM_006370	341-1039	NP_006361
LOC51231	62/63	NM_016440	119-1543	NP_057524
TCEA3	64/65	XM_114075	136-1182	XP_114075
UBE2G1	66/67	NM_003342	167-679	NP_003333
SENP3	68/69	NM_015670	71-1795	NP_056485
SF3A3	70/71	NM_006802	9-1514	NP_006793
NRF1	72/73	NM_005011	79-1647	NM_005002
ARF6	74/75	NM_001663	518-1045	NP_001654
TNFSF12	76/77	NM_003809	97-846	NP_003800
RELA	78/79	NM_021975	39-1652	NP_068810
TNFRSF1A	80/81	NM_001065	282-1649	NP_001056
RPS6KB2	82/83	NM_003952	16-1503	NP_003943
GSK3A	84/85	NM_019884	115-1566	NP_063937
CLC	86/87	NM_013246	46-723	NP_037378
ZNF213	88/89	XM_036493	366-1745	XP_036493
CAMK1	90/91	NM_003656	179-1291	NP_003647
FGFR1	92/93	NM_023107	727-1635	NP_075595
CLK1	94/95	NM_004071	156-1610	NP_004062
MUS81	96/97	NM_025128	511-1941	NP_079404
VEGF	98/99	NM_003376	702-1277	NP_003367
FGF18	100/101	NM_033649	538-1161	NP_387498
HGS	102/103	NM_004712	78-2411	NP_004703
RIPK2	103/104	NM_003821	212-1834	NP_003812
TNFAIP1	105/106	NM_021137	212-1162	NP_066960
CLK3	107/108	NM_003992	57-1529	NP_003983
ADAMTS9	109/110	NM_020249	13-3231	NP_064634
CDKN2C	111/112	NM_001262	1217-1723	NP_001253
FYN	113/114	NM_002037	580-2193	NP_002028
FGF1	115/116	NM_000800	142-609	NP_000791
PTN	117/118	NM_002825	396-902	NP_002816
GLA	119/120	NM_000169	61-1350	NP_000160
LOC162542	121/122	XM_091624	12-287	XP_091624
EXT2	123/124	NM_000401	488-2644	NP_000392
METAP2	125/126	NM_006838	35-1471	NP_006829

Gene	SEQ ID NOS	Accession # (nucleotide)	CDS	Accession # (protein)
MLL3	127/128	NM_021230	364-12441	NP_067053
RARG	129/130	NM_000966	138-1502	NP_000957
Rho GEF p114	131/132	NM_015318	108-3155	NP_056133
CHKL	133/134	NM_005198	185-1372	NP_005189
ANXA2	135/136	NM_004039	50-1069	NP_004030
LOC143785	137/138	XM_084635	390-1025	XP_084635
TGFB3	139/140	NM_003239	254-1492	NP_003230
MAP3K11	141/142	NM_002419	494-3037	NP_002410
PHKG2	143/144	NM_000294	94-1314	NP_000285
NNMT	145/146	NM_006169	118-912	NP_006160
TPT1	147/148	NM_003295	95-613	NP_003286
IL17BR	149/150	NM_018725	45-1553	NP_061195
ECRG4	151/152	NM_032411	109-555	NP_115787

**EXAMPLE 2:****A High Throughput Screen to identify candidate genes related to OA employing analysis of clonal proliferation of chondrocyte clusters in vitro**

This example describes experiments using another high throughput screen to identify genes and gene products associated with OA. In particular, the experiments described in this example screen whole cDNA libraries and identify genes that induce clonal proliferation of chondrocyte clusters, a type of cell proliferation associated with osteoarthritic chondrocytes .

**Materials and Methods:**

*Construction of late-OA cDNA library.* 1 µg of polyA(+) RNA is isolated from 200 µg of total RNA (extracted from OA chondrocyte cells) using a Dynabeads mRNA Purification kit (Dyna, Lake Success NY) following the manufacturer's recommend protocol. The library is constructed using the Superscript Choice System for cDNA Synthesis (Invitrogen Life Technologies, Carlsbad CA). The procedure follows the manufacturer's recommended protocol, but with the modifications specifically noted here. A modified oligo d(T)-NotI primer is used to prime the first-strand synthesis reaction.

- 68 -

Following second-strand synthesis, adaptor ligation includes the use of EcoRI half-site adaptors and Not I restriction digest to allow for the directional cloning of the size fractionated double-stranded cDNA into the entry vector pENTR2B (Invitrogen Life Technologies, Carlsbad CA). This vector is constructed to contain GATEWAY™ site-specific recombination sites (attL1 and attL2) flanking the cloned cDNAs and allows the one-step transfer of cDNA inserts into retroviral vectors containing the attR1 and attR2 site-specific recombination sites via LR clonase.

*Transfer of Late-OA library.* 300 ng of amplified library DNA is used for the transfer of cDNAs into each of two linearized retroviral vectors using LR Clonase (Invitrogen, Carlsbad CA) according to the manufacturer's recommended protocol. Following a brief clean-up step, the LR reaction products are electroporated into STBL4 electrocompetent cells (Invitrogen Life Technologies, Carlsbad CA) and amplified on selective solid medium.

*Construction of Early-OA cDNA library.* cDNA libraries are constructed "in house" from chondrocytes isolated from early stage human OA cartilage, following the same procedure as for the late-OA cDNA library, above, but with the following exceptions. A modified oligo d(T)-SfiI(B) primer primes the first strand synthesis reaction. Following second-strand synthesis, adaptor ligation includes the use of Sfi I (A) half-site adaptors and Sfi I restriction digest to allow for the directional cloning of the size fractionated double-stranded cDNA into the vector pCMBSport6 (Invitrogen Life Technologies, Carlsbad CA). This vector has been constructed to contain the GATEWAY™ site-specific recombination sites attB1 and attB2 flanking the cloned cDNAs and requires a two-step transfer of cDNA inserts — first into an entry vector (BP reaction) and second into a retroviral vector containing the attR1 and attR2 site-specific recombination sites via LR cleanse (LR Reaction; Nitrogen, Carlsbad CA). The early-OA cDNA library is transferred into a retroviral vector using DH10B cells from Invitrogen (Carlsbad, CA) as the host *E. coli* strain.

*Transfection.* GP2-293 cells are plated the day before transfection at  $7 \times 10^5$  cells per well in 6-well Bio coat plates (BD Biosciences, Palo Alto CA) with 2 M DMEM



- 69 -

containing 10% FBS per well (Nitrogen, Carlsbad CA). The following day, for each well to be transfected, 1  $\mu$ g of OA cDNA library DNA and 1  $\mu$ g of pVpack-VSVG plasmids are diluted in OPTIMEM™ medium (Invitrogen, Carlsbad CA) to a final volume of 250  $\mu$ L.

Lipofectamine 2000 (Invitrogen, Carlsbad CA) (9  $\mu$ L/2  $\mu$ g DNA for each well) is diluted in OPTIMEM™ to 250  $\mu$ L final volume. The diluted Lipofectamine is added drop wise to the diluted DNA, gently mixed and incubated at room temperature for 20 minutes. The DNA-Lipofectamine complex (500  $\mu$ L per well) is then added directly into the 2 mL conditioned medium, and the plates are incubated overnight at 37 °C. The following day, the medium in each well is aspirated and replaced with 3 mL DMEM containing 10% FBS per well. Supernatants are collected 48 hours and 72 hours post transfection, filtered through a 0.22 micron filter and frozen at -80 °C.

*Spinfection of viral supernatants into chondrocytes.* Human chondrocyte cells (Cell Applications, San Diego CA) derived from fetal human cartilage are cryopreserved at the first passage and used at passage 2. The chondrocyte cells are cultured in six well plates at a cell density of  $2.5 \times 10^5$  cells per well. The complete growth media is replaced with spinnoculation medium containing DMEM, 10% FBS, 8  $\mu$ g/mL polybrene and 10  $\mu$ M HEPES). The viral supernatants are diluted 1:2 with this medium, filtered through a 0.22 micron filter and added to the wells (2 mL/well). The chondrocyte cells are centrifuged for 1.5 hours at 2700 rpm, 32 °C. The cells are then placed in a CO<sub>2</sub> incubator for six hours. At the end of the day, 2 mL fresh spinnoculation media is added and the cells are incubated overnight. The next day, the spinnoculation media is replaced with growth media (containing DMEM and 10% FBS), and the cells are cultured for three days.

*Chondrocyte cloning assay.* Three days post transduction, the chondrocyte cells are trypsinized and suspended in 0.4% low melt agarose (Life Technologies, Rockville MD) in complete DMEM (Invitrogen, Carlsbad CA) at a density of  $1 \times 10^4$  cells/mL. 8 mL of the chondrocyte cell suspension is pipetted into 10 cm tissue culture plates that have been previously coated with 8 mL of 0.7% low melt agarose in DMEM containing 10% FBS

- 70 -

(Invitrogen, Carlsbad CA). The agarose is allowed to solidify at room temperature, and then placed in a 37 °C humidified incubator for 3-4 weeks.

*Identification of chondrocyte cell clones.* Chondrocyte cell clones are identified using a microscope under 20X magnification, picked using a hand pipetor and the seeded directly into 6-well cluster plates (BD Biosciences Clontech, Palo Alto CA) at one clone per well. Clones are allowed to expand in monolayer culture (DMEM, 10% FBS) until confluent.

RNA is isolated using RNeasy 96 (Qiagen, Valencia CA). RT-PCR is performed using 96 well format Advantage RT-PCR kit (Clontech, Palo Alto CA) with Amplitaq Gold (Perkin Elmer, Palo Alto CA), with the following primers for the AttB sites flanking each cDNA:

AttB1	5'-CAAGTTTGTACAAAAAAGC-3'	(SEQ ID NO:21)
AttB2	5'-ACCACTTTGTACAAGAAAG-3'	(SEQ ID NO:22)

The cDNA sequences thus isolated are cloned using a TOPO TA cloning kit (Invitrogen, Carlsbad CA). The plasmid DNA is then sequenced by standard sequencing methods (Seqwright, Houston TX) for identification. Full length clones corresponding to the identified genes were obtained from a full length clone collection that is generated "in house" by routine methods.

*GATEWAY™ transfer of full-length clones.* Full length cDNA clones obtained from an in house collection and are transferred into a retroviral vector using the Gateway™ platform as described above, and the fidelity of all clones is verified by nucleotide sequencing (Seqwright, Houston TX).

*Image Analysis.* Validation of a cDNA's ability to promote clonal chondrocyte cell proliferation is measured in agarose cultures of single-gene transduced chondrocyte cells. Chondrocyte cell response is based on the number of clones formed that are greater than 50 microns in diameter. Chondrocyte cell clones are observed using an

- 71 -

Olympus IX70 inverted microscope with a 4X objective (Olympus America, Inc.; Melville NY) under brightfield illumination. Each culture dish is photographed at five different microscope fields on three replicate plates and digitally captured on an Olympus MagnaFire camera and software. Each image is then analyzed using Image-Pro Plus v.4.5 software (Media Cybernetics, Inc., (Silver Spring, MD). Each image is optimized for cell and clone recognition using enhancement filters before being counted. Counts are done automatically using the software, and mean diameter measurements of cells or clones were compiled on an Excel (Microsoft Corporation, Redmond WA) spreadsheet.

#### Results:

Normal chondrocyte cells quickly lose their phenotype and become fibroblastic when grown in monolayer cultures. However, when grown in a 3-dimensional matrix (e.g., of agarose or alginate) these cells remain chondrocytic in their appearance, gene expression profile and low cell division rate. See, Benya & Shaffer, *Cell* 1982, 30:215-224; Glowacki *et al.*, *Proc. Soc. Exp. Biol. and Med.* 1983, 172:93-98. Under these culturing conditions, certain growth factors have been shown to induce cell proliferation, as evidenced by the formation of cell clusters reminiscent of the clusters observed in OA cartilage. Kato *et al.*, *J. Cell Physiol.* 1987, 133:491-498; Iwamoto *et al.*, *Biochem. Biophys. Res. Comm.* 1989, 159:1006-1011.

To evaluate whether such growth characteristics could be used in a functional screening assay, the clone forming activity of transduced chondrocyte cells overexpressing bFGF is compared to clone forming activity in chondrocyte cells cultured with bFGF exogenously added to the culture medium. The results demonstrate that expression of a retrovirally transduced gene in chondrocyte cells can stimulate cell proliferation in a manner similar to that observed when the gene product is added exogenously (data not shown).

cDNA libraries are constructed from both early and late stage OA cartilage tissue and transferred to retroviral vectors. These libraries can be virally packed and transduced in early passage human chondrocyte cells. Following growth in suspension cultures for 3-4 weeks, cell clusters are isolated using a micropipet under magnification. The

transgenes are recovered from these cell clusters using PCR, and are identified by routine nucleotide sequencing. The recovered transgenes are preferably verified by determining whether they induce chondrocyte cluster formation when the full length genes are over expressed individually in chondrocyte cells.

Table VI, below, lists candidate genes that can be identified and verified by such a screening assay. GenBank accession numbers for the preferred nucleotide sequences of those genes are also specified, along with the residues coding the predicted amino acid sequence (*i.e.*, the "CDS") accession numbers for preferred amino acid sequences of their gene product(s).

**TABLE VI: CANDIDATE GENES IDENTIFIED IN CLONAL SCREENS**

Gene	SEQ ID NOs	Accession # (nucleotide)	CDS	Accession # (protein)
Clr	153/154	NM_001733	52-2169	NP_001724
NDUFV2	155/156	NM_021074	19-768	NP_066552
BPOZ	157/158	NM_032548	505-1515	NP_115937
IL17-RC	159/160	NM_032732	198-1814	NP_116121
COMP	161/162	NM_000095	26-2219	NP_000086
SLC16A3	167/168	NM_004207	1-465	NP_004198
FGF1	169/170	NM_000800	142-609	NP_000791

Candidate genes which may be identified in such clonal screening assays include the bFGF gene, further validating the screening assay.

### **EXAMPLE 3**

#### **Sequences for candidate genes and newly identified OA marker genes identified herein**

```
>gi|24025684|gb|NM_003017.2|SFRS3 1403bp mRNA Homo sapiens
splicing factor, arginine/serine-rich 3 (SFRS3), mRNA.
CCGGGTGAGTGAGAGAGTTGGTTGGTGTGGGCCGGAGGAAAGCGGGAAGACTCATCGGA
GCGTGTGGATTTGAGCCGCCGCATTTTTTAACCCTAGATCTCGAAATGCATCGTGATTCC
TGTCATTGGACTGTAAGGTTTATGTAGGCAATCTTGGAACAATGGCAACAAGACGGAA
TTGGAACGGGCTTTTGGCTACTATGGACCACTCCGAAGTGTGTGGGTTGCTAGAAACCCA
CCCGGCTTTGCTTTTGTGTAATTGAAGATCCCCGAGATGCAGCTGATGCAGTCCGAGAG
```

- 73 -

CTAGATGGAAGAACAACACTATGTGGCTGCCGTGTAAGAGTGGAACGTGTCGAATGGTGAAAAA  
AGAAGTAGAAATCGTGGCCACCTCCCTCTTGGGGTCGTCGCCCTCGAGATGATTATCGT  
AGGAGGAGTCCCTCCACCTCGTCGCAGATCTCCAAGAAGGAGAAGCTTCTCTCGCAGCCGG  
AGCAGGTCCCTTTCTAGAGATAGGAGAAGAGAGAGATCGCTGTCTCGGGAGAGAAATCAC  
AAGCCGTCCCGATCCTTCTCTAGGTCTCGTAGTCGATCTAGGTCAAATGAAAGGAAATAG  
AAGACAGTTTGCAAGAGAAGTGGTGTACAGGAAATTACTTCATTTGACAGGAGTATGTAC  
AGAAAATTCAAGTTTTGTTTGAGACTTCATAAGCTTGGTGCATTTTTTAAGATGTTTTAGC  
TGTTCAAATCTGTTTGTCTCTTGAAACAGTGACACAAAGGTGTAATTCTCTATGGTTTGA  
AATGGATCATACGAGGCATGTAATACCAAGAATTGTTACTTTACAATGTTCCCTTAAGCA  
AAATTGAATTTGCTTTGAACTTTTAGTTATGCACAGACTGATAATAAACCTCTAAACCTG  
CCCAGCGGAAGTGTGTTTTTTTTTAAATTTAAATACAGAAACAACCTGGCAAAAATTGAAC  
TAAGATTTACTTTTTTTTCCATAGCTGGGATATAGGCTGCAGCTATAGTTGAACAAGCAG  
TCTTTAAAAACTGCTGTGAAACACAGGCCATCAGGGAAAACGAAATGCTGCACTATTAA  
TTAGAGGTTTTTGAAAAATCCAACCTCTCATCCTGGGCAGAGGTTGCCTAGTTGGTATAGA  
ATGTTAAGTTTCAAGAAAGTTTACCTTTGCTTTAGGTCATAAGTTCTTATTTGATTGCT  
GTATATGGATACATGGCTGTTTCGTGACATTCTTTATGTGCAAATTTGTGATTTCAAAAAT  
GTCCTGCCAGTTTAAGGGTACATTGTAGAGCCGAACTTTGAGTTACTGTGCAAGATTTTT  
TTTTCATGCTGTCAATTTGTAATATGTTTTGTGAGAATCCTTGGGATTAAAGTTTTGGTTA  
CAAATTGTTAAAAA

>gi|4506901|gb|NP\_003008.1|SFRS3 164aa linear splicing factor,  
arginine/serine-rich 3; splicing factor, arginine//serine-  
rich, 20-kD [Homo sapiens].

MHRDSCPLDCKVYVGNLGNNGNKTELERAFFGYGPLRSVWVARNPPGFVFEFEDPRDAA  
DAVRELDGRTLGCGRVRVELSNGEKRSRNRGPPPSWGRPRDDYRRRSPPPRRRSPRRRS  
FSRSRSRSLSRDRRRERSLSRERNHKPSRSFSRSRSRERNK

>gi|4759097|gb|NM\_004593.1|SFRS10 1972bp mRNA Homo sapiens  
splicing factor, arginine/serine-rich 10 (transformer 2  
homolog, Drosophila) (SFRS10), mRNA.

GAATTCGGCACGAGGGCGACCGGCGCGTCGTGCGGGGCTGCGGCGGAGCCTCCTTAAGGA  
AGGTGCAAGAGGTTGGCAGCTTCGATTGAAGCACATCGACCGGCGACAGCAGCCAGGAGT  
CATGAGCGACAGCGGCGAGCAGAACTACGGCGAGCGGGAATCCCGTTCTGCTTCCAGAAG  
TGGAAGTGCTCACGGATCGGGGAAATCTGCAAGGCATACCCCTGCAAGGTCTCGCTCCAA  
GGAAGATTCCAGGCGTTCCAGATCAAAGTCCAGGTCCCGATCTGAATCTAGGTCTAGATC  
CAGAAGAAGCTCCCGAAGGCATTATACCCGGTCACGGTCTCGCTCCCGCTCCCATAGACG  
ATCACGTAGCAGGTCTTACAGTCGAGATTATCGTAGACGGCACAGCCACAGCCATTCTCC  
CATGTCTACTCGCAGGCGTCATGTTGGGAATCGGGCAAATCCTGATCCTAACTGTTGTCT  
TGGAGTATTTGGGCTGAGCTTGTACACCACAGAAAGAGATCTAAGAGAAGTGTTCTCTAA  
ATATGGTCCCATTTGCCGATGTGTCTATTGTATATGACCAGCAGTCTAGGCGTTCAAGAGG  
ATTTGCCTTTGTATATTTTGAATGTAGATGATGCCAAGGAAGCTAAAGAACGTGCCAA  
TGGAATGGAGCTTGATGGGCGTAGGATCAGAGTTGATTTCTCTATAACAAAAAGACCACA  
TACGCCAACACCAGGAATTTACATGGGGAGACCTACCTATGGCAGCTCTCGCCGTCGGGA  
TTACTATGACAGAGGATATGATCGGGGCTATGATGATCGGGACTACTATAGCAGATCATA  
CAGAGGAGGAGGTGGAGGAGGAGGAGGATGGAGAGCTGCCAAGACAGGGATCAGATTTA  
TAGAAGGCGGTCACCTTCTCCTTACTATAGTCGTGGAGGATACAGATCACGTTCCAGATC  
TCGATCATACTACCTCGTCGCTATTAAAGCATGAAGACTTTCTGAAACCTGCCCTAGAG  
CTGGGATATTGTTTGTGGGCAATATTTTTTATTTGTCTCTTGTTTAAAAAGTGAACAGTGC  
CTAGTGAAGTTAGGTGACTTTTACACCTTTTACGATGACTACTTTTGGTGGAGTTGAAAT

- 74 -

GCTGTTTTTCATTCTGCATTTGTGTAGTTTGGTGCTTTGTTCCAAGTTAAGTGTTTTTCAGA  
AAAGTATGTTTTGTCATGTATTTTTTTTACAGTCTAAATTTTGGCTGCTGAGAAGTTTCTAT  
TGTACAAAACCTTCATTTAAAAGGTTTTTCTACTGAATCCAGGGTATTCTGAAGATCGAAG  
CCTGTGTAAAATGCTACCAAATGGCAAAAAGCAACAATAAACAGTTTGATTTTTTACTTTT  
CTTTCTAACATATCAATGCTTAGCAGAACTATTTCAGATTGTCAGTAGTAAATTTAAAGAC  
AAATGCCCCGTTTTCTCCAGTCCATGAAACATACCATACTTATATACCTGCAACTAAGTG  
TTTAAAATTATGCTCTGTAACTCTGTACTGCTAGTATTAGAACTAAAAATCTTAAATAC  
AGCCAGTGCTTAATGCTTATATCAATGTGGATTGTGCGGCTTTTATGTAATCTGTAATAT  
GTATAGCAGGAAATACGAAGAGTTACACAGTGTATGCCTTAAAAGGCTGTTTTCTTAAAGG  
TGTTACAAGGGGATAATGGTATTTCAACTAGTTATCAGCAAGTGACAATACATTCCACCA  
CAAATACACTCTTGTTCTTCTAGCTTTTAGACTATATGAAAAAACCGGGTGCTTCAAAGT  
ACATGATAAGGGAACACTATACCTGTCTATGGATGAACTGAAGACTTTGCCTGTTCAATTT  
TTAAATATTATTTTTCAGGTCCTTTGCTTACCAAAGGAGGCCCAATTTCACTCAAATGTTT  
TGAGAACTGTGTTTAAATAAACGCAAATGAAAAGAAAAA

>gi|4759098|gb|NP\_004584.1|SFRS10 288aa linear splicing  
factor, arginine/serine-rich 10 (transformer 2 homolog,  
Drosophila); splicing factor, arginine/serine-rich  
(transformer 2 Drosophila homolog) 10 [Homo sapiens].

MSDSGEQNYGERESRSASRSGSAHGSGKSARHTPARSRSKEDSRRSRSKSRSRSESRSRS  
RRSSRRHYTRSRSRSRSHRRSRRSYSRDYRRRHSHSHSPMSTRRRHVGNRANPDNCL  
GVFGLSLYTTERDLREVFSKYGPIADVSIVYDQQSRRSRGFAFVYFENVDDAKEAKERAN  
GMELDGRRI RVDFSITKRPHPTPTPGIYMGRPTYGSSRRRDYDRGYDRGYDDRDIYSRSY  
RGGGGGGGGWRAAQDRDQIYRRRSPSPYYSRGGYRSRSRSRSPRY

>gi|5803206|gb|NM\_006758.1|U2AF1 904bp mRNA Homo sapiens  
U2 (RNU2) small nuclear RNA auxillary factor 1 (U2AF1), mRNA.  
GGAATTCCGTCGACGGCAGCGCGGCGGGTGGGAAATGGCGGAGTATCTGGCCTCCA  
TCTTCGGCACCGAGAAAGACAAAGTCAACTGTTCAATTTTATTTCAAATTTGGAGCATGTC  
GTCATGGAGACAGGTGCTCTCGGTTGCACAATAAACCGACGTTTAGCCAGACCATTGCCC  
TCTTGAACATTTACCGTAACCCTCAAACTCTTCCCAGTCTGCTGACGGTTTGCGCTGTG  
CCGTGAGCGATGTGGAGATGCAGGAACACTATGATGAGTTTTTTGAGGAGGTTTTTACAG  
AAATGGAGGAGAAGTATGGGGAAGTAGAGGAGATGAACGTCTGTGACAACCTGGGAGACC  
ACCTGGTGGGGAACGTGTACGTCAAGTTTCGCCGTGAGGAAGATGCGGAAAAGGCTGTGA  
TTGACTTGAATAACCGTTGGTTTAATGGACAGCCGATCCACGCCGAGCTGTCACCCGTGA  
CGGACTTCAGAGAAGCCTGCTGCCGTGAGTATGAGATGGGAGAATGCACACGAGGCGGCT  
TCTGCAACTTCATGCATTTGAAGCCATTTCCAGAGAGCTGCGGCGGGAGCTGTATGGCC  
GCCGTGCAAGAAGCATAGATCAAGATCCCGATCCCGGGAGCGTCGTTCTCGGTCTAGAG  
ACCGTGGTTCGTGGCGGTGGCGGTGGCGGTGGTGGAGGTGGCGGCGGACGGGAGCGTGACA  
GGAGGCGGTCGAGAGATCGTGAAAGATCTGGGCGATTCTGAGCCATGCCATTTTTTACCTT  
ATGTCTGCTAGAAAGTGTGTAGTTGATTGACCAAACAGTTCATAAGGGGAATTTTTTA  
AAAAACAACAAAAAACAACATACAAAGATGGGTTTCTGAATAAAAATTTGTAGTGATAA  
CAGT

>gi|5803207|gb|NP\_006749.1|U2AF1 240aa linear U2 small nuclear  
RNA auxillary factor 1; U2 snRNP auxiliary factor small  
subunit; splicing factor U2AF 35kDa subunit [Homo sapiens].  
MAEYLASIFGTEKDKVNCSFYFKIGACRHGDRCSRLHNKPTFSQTIALLNIRNPQNSSQ  
SADGLRCAVSDVEMQEHYDEFFEEVFTEEMEEKYGEVEEMNVCDNLGDHLVGNVYVKFRE  
EDA EKAVIDLNNRWFNGQPIHAELSPVTD FREACCRQYEMGECTRGGF CNFMHLKPI SRE

- 75 -

LRRELYGRRRKKHRSRSRSRERRSRSDRGRGGGGGGGGGGGGRRERDRRRSRDRERSGRF  
 >gi|23308726|gb|NM\_003242.3|TGFB2 2090bp mRNA Homo sapiens  
 transforming growth factor, beta receptor II (70/80kDa)  
 (TGFB2), mRNA.

GTTGGCGAGGAGTTTCTGTTTCCCCCGCAGCGCTGAGTTGAAGTTGAGTGAGTCACTCG  
 CGCGCACGGAGCGACGACACCCCCGCGCGTGCACCCGCTCGGGACAGGAGCCGGACTCCT  
 GTGCAGCTTCCCTCGGCCGCCGGGGGCTCCCCGCGCTCGCCGGCCTCCAGGCCCTCC  
 TGGCTGGCGAGCGGGCGCCACATCTGGCCCGCACATCTGCGCTGCCGGCCCGGCGCGGGG  
 TCCGGAGAGGGCGCGGCGCGGAGCGCAGCCAGGGGTCCGGGAAGGCGCCGTCCGTGCGCT  
 GGGGGCTCGGTCTATGACGAGCAGCGGGGTCTGCCATGGGTGCGGGGCTGCTCAGGGGCC  
 TGTGGCCGCTGCACATCGTCTGTGGACGCGTATCGCCAGCACGATCCCACCGCACGTTT  
 AGAAGTCGGTTAATAACGACATGATAGTCACTGACAACAACGGTGCAGTCAAGTTTCCAC  
 AACTGTGTAAATTTTGTGATGTGAGATTTTCCACCTGTGACAACCAGAAATCCTGCATGA  
 GCAACTGCAGCATCACCTCCATCTGTGAGAAGCCACAGGAAGTCTGTGTGGCTGTATGGA  
 GAAAGAATGACGAGAACATAACACTAGAGACAGTTTGCCATGACCCCAAGCTCCCTTACC  
 ATGACTTTATTCTGGAAGATGCTGCTTCTCCAAAGTGCAATTATGAAGGAAAAAAAAAAGC  
 CTGGTGAGACTTTCTTCATGTGTTCTGTAGCTCTGATGAGTGCAATGACAACATCATCT  
 TCTCAGAAGAAATATAACACCAGCAATCCTGACTTGTTGCTAGTCATATTTCAAGTGACAG  
 GCATCAGCCTCCTGCCACCACTGGGAGTTGCCATATCTGTCATCATCATCTTCTACTGCT  
 ACCGCGTTAACCAGCAGCAGAAGCTGAGTTCAACCTGGGAAACCGGCAAGACGCGGAAGC  
 TCATGGAGTTTACGCGAGCACTGTGCCATCATCCTGGAAGATGACCGCTCTGACATCAGCT  
 CCACGTGTGCCAACAACATCAACCAGAACACAGAGCTGCTGCCCATTTAGCTGGACACCC  
 TGGTGGGGAAAGGTCGCTTTGCTGAGGTCTATAAGGCCAAGCTGAAGCAGAACACTTCAG  
 AGCAGTTTGAGACAGTGGCAGTCAAGATCTTTCCCTATGAGGAGTATGCCTCTTGGAAGA  
 CAGAGAAGGACATCTTCTCAGACATCAATCTGAAGCATGAGAACATACTCCAGTTCCTGA  
 CGGCTGAGGAGCGGAAGACGGAGTTGGGGAAACAATACTGGCTGATCACCGCCTTCCACG  
 CCAAGGGCAACCTACAGGAGTACCTGACGCGGCATGTCATCAGCTGGGAGGACCTGCGCA  
 AGCTGGGCAGCTCCCTCGCCCGGGGGATTGCTCACCTCCACAGTGATCACACTCCATGTG  
 GGAGGCCCAAGATGCCCATCGTGCACAGGGACCTCAAGAGCTCCAATATCCTCGTGAAGA  
 ACGACCTAACCTGCTGCCTGTGTGACTTTGGGCTTTCCCTGCGTCTGGACCCTACTCTGT  
 CTGTGGATGACCTGGCTAACAGTGGGCAGGTGGGAAGTCAAGATACATGGCTCCAGAAG  
 TCCTAGAATCCAGGATGAATTTGGAGAATGCTGAGTCTTCAAGCAGACCGATGTCTACT  
 CCATGGCTCTGGTGCTCTGGGAAATGACATCTCGCTGTAATGCAGTGGGAGAAGTAAAG  
 ATTATGAGCCTCCATTTGGTTCCAAGGTGCGGGAGCACCCCTGTGTGCGAAAGCATGAAGG  
 ACAACGTGTTGAGAGATCGAGGGCGACCAGAAATTTCCAGCTTCTGGCTCAACCACCAGG  
 GCATCCAGATGGTGTGTGAGACGTTGACTGAGTGCTGGGACCACGACCCAGAGGCCCGTC

TCACAGCCCAGTGTGTGGCAGAACGCTTCAGTGAGCTGGAGCATCTGGACAGGCTCTCGG  
 GGAGGAGCTGCTCGGAGGAGAAGATTCCTGAAGACGGCTCCCTAAACACTACCAATAGC  
 TCTTATGGGGCAGGCTGGGCATGTCCAAAGAGGCTGCCCTCTCACCAA

>gi|23308727|gb|NP\_003233.3|TGFB2 567aa linear transforming  
 growth factor, beta receptor II (70/80kDa); transforming  
 growth factor, beta receptor II (70-80kD) [Homo sapiens].

MGRGLLRGLWPLHIVLWTRIASTIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDFRST  
 CDNQKSCMSNCSITSICEKPQEVCAVVRKNDENITLETVCHDPKLPYHDFILEDAAAPK  
 CIMKEKKKPGETFFMCSSDECNDNIIFSEEYNTSNPDLLLVIQVGTGISLLPPLGVAI  
 SVIIIFYCYRVNRQQLSSTWETGKTRKLMEFSEHCAIILEDSDISSTCANNINHNT

- 76 -

LLPIELDTLVGKGRFAEVYKAKLKQNTSEQFETVAVKIFPYEEYASWKTEKDIFSDINLK  
HENILQFLTAEERKTEL GKQYWLITAFHAKGNLQEYLTRHVISWEDLRKLGSSSLARGIAH  
LHSDHTPCGRPKMPIVHRDLKSSNILVKNDLTCCLCDFGLSLRLDPTLSVDDLANSGQVG  
TARYMAPEVLES RMNLENAESFKQTDVYSMALVLWEMTSRCNAVGEVKDYEPFPGSKVRE  
HPCVESMKDNVLRDRGRPEIPSFVLNHQGIQMV CETLTECWDHDPEARLTAQCVAERFSE  
LEHLDRLSGRSCSEEKIPEDGSLNNTTK

>gi|5174728|gb|NM\_006022.1|TSC22 1725bp mRNA Homo sapiens  
transforming growth factor beta-stimulated protein TSC-22  
(TSC22), mRNA.

CGCCTCTTCACGGCACTGGGATCCGCATCTGCCTGGGATCATCAAGCCCTAGAAGCTGGG  
TTTCTTTAAATTAGGGCTGCCGTTTTCTGTTTTCTCCCTGGGCTGCCGAAAGCCAGAAGAT  
TTTATCTAGCTTATACAAGGCTGCTGGTGTTCCTCTTTTTTTCCACGAGGGTGTTTTTTG  
GCTGCAATTGCATGAAATCCCAATGGTGTAGACCAGTGGCGATGGATCTAGGAGTTTACC  
AACTGAGACATTTTTCAATTTCTTTCTTGTCATCCTTGCTGGGGACTGAAAACGCTTCTG  
TGAGACTTGATAATAGCTCCTCTGGTGCAAGTGTGGTAGCTATTGACAACAAAATCGAGC  
AAGCTATGGATCTAGTGAAAAGCCATTTGATGTATGCGGTGAGAGAAGAAGTGGAGGTCC  
TCAAAGAGCAAATCAAAGAACTAATAGAGAAAAATTTCCAGCTGGAGCAGGAGAACAAATC  
TGCTGAAGACACTGGCCAGTCTTGAGCAGCTTGCCCAGTTTCAGGCCCAGCTGCAGACTG  
GCTCCCCCCTGCCACCACCCAGCCACAGGGCACACAGCCCCCGCCCAGCCAGCAT  
CGCAGGGGCTCAGGACCAACCGCATAGCTGCCTATGCCCCCGCAGAACTGGCTGCTGCGTG  
TGAAGTGAACAGACGGAGAAGATGTGCTAGGGAGAATCTGCCTCCACAGTCACCCATTTT  
ATTGCTCGCTGCGAAAGAGACGTGAGACTGACATATGCCATTATCTCTTTTCCAGTATTA  
AACACTCATATGCTTATGGCTTGAGAGAAATTTCTTAGTTGGGTGAATTAAAGGTTAATCC  
GAGAATTAGCATGGATATACCGGGACCTCATGCAGCTTGGCAGATATCTGAGAAATGGTT  
TAATTCATGCTCAGGAGCTGTGTGCCTTTCCATCCCTTCCGGCTCCCTACCCCTCACTTC  
CAAGGGTTCTCTCTCCTGCTTGCGCTTAGTGTCTTACATGGGGTTGTGAAGCGATGGAGC  
TCCTCACTGGACTCGCCTCTCTCCTCTCCTCCCCCAGGAGGAACTTGAAAGGAGGGGTAA  
AAAGACTAAAATGAGGGGGAACAGAGTTCACTGTACAAATTTGACAACTGTCACCAAAT  
TCATAAAAAACAATAGTACTGTGCCTCTTTCTTCTCAAACAATGGATGACACAAAATAT  
GAGAGTGACAAAATGGTGACAGGTAGCTGGGACCTAGGCTATCTTACCATGAAGGTTGTT  
TTGCTTATTGTATATTTGTGTATGTAGTGTAATTTTGTACAATAGAGGACTGTAAT  
ACTATTTAGGTTGTACAGATTGAAATTTAGTTGTTTCATTGGCTGTCTGAGGAGGTGTGG  
ACTTTTATATATAGATCTACATAAAAACTGCTACATGACAAAAACCACACCTAAACCCCT  
TTTAAGAATTTGGCACAGTTACTCACTTTGTGTAATCTGAAATCTAGCTGCTGAATACGC  
TGAAGTAAATCCTTGTTCACTGAAGTCTTTCAATTGAGCTGGTTGAATACTTTGAAAAAT  
GCTCAGTTCTAACTAATGAAATGGATTTCCAGTAGGGGTTTCTGCATATCACCTGTATA  
GTAGTTATATGCATATGTTTCTGTGCATGTTCTCTACACAATTGTAAGGTGTCAGTGTAT  
TTAACTGTTGCACTTGTCAACTTTCAATAAAGCATATAAATGTTG

>gi|5174729|gb|NP\_006013.1|TSC22 144aa linear transforming  
growth factor beta-stimulated protein TSC-22 [Homo sapiens].  
MKSQWCRPVAMDLGVYQLRHFSISFLSLLGTENASVRLDNSSSGASVVAIDNKIEQAMD  
LVKSHLMYAVREEVEVLKEQIKELIEKNSQLEQENLLKTLASPEQLAQFQAQLQTGSP  
ATTQPQGTTPPAQPASQSGPTA

>gi|24432096|gb|NM\_152912.2|MTIF3 1693bp mRNA Homo sapiens  
mitochondrial translational initiation factor 3 (MTIF3), mRNA.  
GCAGATCCGCTGTACTTGCGGGCGCTACAGTATGTCAATCGCTTGCCCCAGCACAGTGGG  
CTCCGTGGCTTAAGACTTGAACCAAGTAAACGAAGTTCTCTTACTGAGAAGTCTCAGTTT



- 77 -

CAAAAGAGCTTCTCCTCATCAACTGGGGATGATTACAGTTCTTCCTAAAAAAGCCTACTT  
GATGTGAAGACAATGAGGATGAAGACCTTTATGGTGATCCACTTCCACTTAATAGGATGG  
CTGCTCTTTTTCTAAAGAGGTAACTACTACAACTGTAAAGTCTGAAAATAGTTGCATTA  
GATGTTTTGGTAAACACATCCTGCAAAAGACAGCACCAGCACAGTTGTCCCCTATTGCTT  
CTGCCCCAAGACTCTCCTTCCTAATTCATGCAAAAGCCTTTAGTACCGCTGAAGACACCC  
AGAATGAAGGAAAAAGACAAAAAGAATAAAACAGCTTTTAGTAACGTTGGAAGAAAA  
TTAGTCAGCGAGTTATTCACCTATTTGATGAGAAGGGCAATGATTTGGGAAACATGCACC  
GAGCAAATGTGATTAGACTTATGGATGAGCGAGACCTGCGACTGGTTCAAAGGAACACCA  
GCACAGAACCTGCAGAGTATCAGCTCATGACAGGATTGCAGATCCTCCAGGAGCGGCAGA  
GGCTGAGGGAGATGGAGAAGGCGAACCCCAAACTGGACCAACCCTGAGAAAGGAACTGA  
TTTTGTCTTCAAATATTGGACAACATGATTTGGACACAAAGACTAAACAGATTTCAGCAGT  
GGATTAAGAAAAAACACCTAGTCCAGATTACCATAAAGAAAGGAAAAAATGTAGACGTGT  
CAGAAAATGAAATGGAGGAGATATTTTCATCAAATACTCCAGACTATGCCTGGAATAGCTA  
CATTCCTCATCTAGGCCACAAGCTGTTCAAGGAGGAAAAGCTTTAATGTGTGTTCTTCGTG  
CTTTGAGCAAAAATGAGGAGAAGGCATATAAAGAACTCAAGAGACCCAGGAAAGAGACA  
CTTTGAACAAAGATCATGGAAATGATAAGGAATCAAATGTTCTGCATCAGTAATTTTAAT  
AAAGAAAAGCATGCTCTGAGAGAAAAAAAAGCTCGCTCCTTGGTCTGCAGTCTTTAAAC  
AAAGCAGTGCAGTTCTTAGCCAAGGGTAAGTACTGCAACTGTGAGAGCATCTTGTCTTC  
CACACAGTTGGGTGACTCTCCGTTTTGACACAAAGATAAGCCTTGCCCTTGTTTCCTTTT  
GGGAGGGATATATCCACTGAGATGAGAGGCCAACTCCGTTTTTTCACGAGATTTTTTGAC  
TTTGAGCTTCATTTTCTTCTTGTGTCAGGATCATGTACAACAGCATGCCTAGTGAGACTTTG  
TTTCATTGCAAATGTTTTGCCACAGCCAGCATGTTACACACAAAAGGGCGGCTTTCCTC  
ATGGAAGGAGAGGATATGGCTTTGGAGATTAAACACAGTTGTATAGGTTCTTCACAGCC  
TTCTCTTGGACAGCGACATAATCCCTTCTGGGGCATGAGTTTATGTGTTGCTTAAGGAAC  
TTGCGTTAAAGTTTTCCGGCAACTTCACATGGATTCTTTTGAATGAGTTCAAATGTTCCC  
ATGCTAAGCTGAGTCTGTGCCATAGCAAACCATGATATAGCAAGTCTCCAGAATGTGTAC  
GAATCAATACTCC

>gi|23097266|gb|NP\_690876.1|MTIF3 278aa linear mitochondrial  
translational initiation factor 3 [Homo sapiens].

MAALFLKRLTLQTVKSENSCIRCFGKHILQKTAPAQLSPIASAPRLSFLIHAKAFSTAED  
TQNEGKKTKKNKTAFSNVGRKISQRVIHLEFDEKGNLGNMHRANVIRLMDERDLRLVQRN  
TSTEPAEYQLMTGLQILQERQRLREMEKANPKTGPTLRKELILSSNIGQHDLDTKTKQIQ  
QWIKKKHLVQITIKKGKNVDVSENEEMEEIFHQILQTMPGIATFSSRPQAVQGGKALMCVL  
RALSKNEEKAYKETQETQERDTLNKDHGNDKESNVLHQ

>gi|27499034|gb|XM\_044349.7|CAMK2G 1776bp mRNA Homo sapiens  
calcium/calmodulin-dependent protein kinase (CaM kinase) II  
gamma (CAMK2G), mRNA.

CAGCATGGCCACCACCGCCACCTGCACCCGTTTCACCGACGACTACCAGCTCTTCGAGGA  
GCTTGGCAAGGGTGCTTTCTCTGTGGTCCGCAGGTGTGTGAAGAAAACCTCCACGCAGGA  
GTACGCAGCAAAAATCATCAATACCAAGAAGTTGTCTGCCCGGGATCACCAGAACTAGA  
ACGTGAGGCTCGGATATGTGCACTTCTGAAACATCCAAACATCGTGCGCCTCCATGACAG  
TATTTCTGAAGAAGGGTTTCACTACCTCGTGTGTTGACCTTGTTACCGGCGGGGAGCTGTT  
TGAAGACATTGTGGCCAGAGAGTACTACAGTGAAGCAGATGCCAGCCACTGTATACATCA  
GATTCTGGAGAGTGTTAACCACATCCACCAGCATGACATCGTCCACAGGGACCTGAAGCC  
TGAGAACCTGCTGCTGGCGAGTAAATGCAAGGGTGCCGCCGTCAAGCTGGCTGATTTTGG  
CCTAGCCATCGAAGTACAGGGAGAGCAGCAGGCTTGTTTGGTTTTGCTGGCACCCAGG  
TTACTTGTCCCCTGAGGTCTTGAGGAAAGATCCCTATGGAAAACCTGTGGATATCTGGGC

- 78 -

CTGCGGGGTCATCCTGTATATCCTCCTGGTGGGCTATCCTCCCTTCTGGGATGAGGATCA  
GCACAAGCTGTATCAGCAGATCAAGGCTGGAGCCTATGATTTCCCATCACCAGAATGGGA  
CACGGTAACTCCTGAAGCCAAGAACTTGATCAACCAGATGCTGACCATAAACCCAGCAAA  
GCGCATCACGGCTGACCAGGCTCTCAAGCACCCGTGGGTCTGTCAACGATCCACGGTGGC  
ATCCATGATGCATCGTCAGGAGACTGTGGAGTGTGTTGCGCAAGTTCAATGCCCCGAGAAA  
ACTGAAGGGTGCCATCCTCACGACCATGCTTGTCTCCAGGAACCTTCTCAGCTGCCAAAAG  
CCTATTGAACAAGAAGTCGGATGGCGGTGTCAAGCCACAGAGCAACAACAAAAACAGTCT  
CGTAAGCCCAGCCCAAGAGCCCGCGCCCTTGACAGACGGCCATGGAGCCACAAACCACTGT  
GGTACACAACGCTACAGATGGGATCAAGGGCTCCACAGAGAGCTGCAACACCACCACAGA  
AGATGAGGACCTCAAAGTGCGAAAAACAGGAGATCATTAAAGATTACAGAACAGCTGATTGA  
AGCCATCAACAATGGGGACTTTGAGGCCTACACGAAGATTTGTGATCCAGGCCTCACTTC  
CTTTGAGCCTGAGGGCCCTTGCTAACCTCGTGGAGGGGATGGATTTCCATAAGTTTACTT  
TGAGAATCTCCTGTCCAAGAACAGCAAGCCTATCCATACCACCATCCTAAACCCACACGT  
CCACGTGATTGGGGAGGACGCAGCGTGCATCGCCTACATCCGCCTCACCAGTACATCGA  
CGGGCAGGGTCGGCCTCGCACCCAGCCAGTCAGAAGAGACCCGGGTCTGGCACCGTCGGGA  
TGGCAAGTGGCTCAATGTCCACTATCACTGCTCAGGGGCCCCCTGCCGCACCGCTGCAGTG  
AGCTCAGCCACAGGGGGCTTTAGGAGATTCCAGCCGGAGGTCCAACCTTCGCAGCCAGTGG  
CTCTGGAGGGCCTGAGTGACAGCGGCAGTCCTGTTTGTGTTGAGGTTTAAACAATTCAAT  
TACAAAAGCGGCAGCAGCCAATGCACGCCCCCTGCATGCAGCCCTCCCGCCCGCCCTTCGT  
GTCTGTCTCTGCTGTACCGAGGTGTTTTTTACATTT

>gi|27499035|gb|XP\_044349.7|CAMK2G 518aa linear similar to  
calcium/calmodulin -dependent protein kinase II gamma [Mus  
musculus] [Homo sapiens].

MATTATCTRFTDDYQLFEELGKGAFSVVRRVCVKKSTSTQEYAAKIINTKKLSARDHQKLER  
EARICRLLKHPNIVRLHDSISEEGFHYLVFDLVTGGELFEDIVAREYYSEADASHCIHQI  
LESVNIHQHDIVHRDLKPENLLLASKCKGA AVKLADFLAIEVQGEQQAWFGFAGTPGY  
LSPEVLRKDPYGKPVDIWACGVILYILLVGYPPFWDEDQHKLYQQIKAGAYDFPSPWD  
VTPEAKNLINQMLTINPAKRITADQALKHPWVCQRSTVASMMHRQETVECLRKFNARRKL  
KGAILTTMLVSRNFSAAKSLNKKSDGGVQKPSNNKNSLVSPAQEPAPLQTAMEPQTTVV  
HNATDGIKGSTESCNTTTEDEDLKVRKQEI IKITEQLIEAINNGDFEAYTKICDPGLTSF  
EPEALGNLVEGMDFHKFYFENLLSKNSKPIHTTILNPHVHVIGEDAACIAYIRLTQYIDG  
QGRPRTSQSEETRVWHRRDGKWLNVHYHCSGAPAAPLQ

>gi|5453881|gb|NM\_006213.1|PHKG1 1377bp mRNA Homo sapiens  
phosphorylase kinase, gamma 1 (muscle) (PHKG1), mRNA.

GGCCTTCAGCCCTCTGTGGTCCCCTCTCCCCGGGGGGCTTTGGGATTCTTGTC AAGCTCC  
TTCAAGAGCCTGCAAGCACTTAACCAGCCACCCAGAGTTCCTCACTGAAGATCTGAGCA  
TGACCCGGGACGAGGCACTGCCGGA CTCTCATTCTGCACAGGACTTCTATGAGAATTATG  
AGCCCAAAGAGATCCTGGGCAGGGGCGTTAGCAGTGTGGTCAGGCGATGCATCCACAAGC  
CCACGAGCCAGGAGTACGCCGTGAAGGTCATCGACGTCACCGGTGGAGGCAGCTTCAGCC  
CGGAGGAGGTGCGGGAGCTGCGAGAAGCCACGCTGAAGGAGGTGGACATCCTGCGCAAGG  
TCTCAGGGCACCCCAACATCATA CAGCTGAAGGACACTTATGAGACCAACACTTTCTTCT  
TCTTGGTGTGTTGACCTGATGAAGAGAGGGGAGCTCTTTGACTACCTCACTGAGAAGGTCA  
CCTTGAGTGAGAAGGAAACCAGAAAGATCATGCGAGCTCTGCTGGAGGTGATCTGCACCT  
TGCACAACTCAACATCGTGCACCGGGACCTGAAGCCCGAGAACATTCTCTTGGATGACA  
ACATGAACATCAAGCTCACAGACTTTGGCTTTTCTGCCAGCTGGAGCCGGGAGAGAGGC  
TGCGAGAGGTCTGCGGGACCCCCAGTTACCTGGCCCCTGAGATTATCGAGTGCTCCATGA  
ATGAGGACCACCCGGGCTACGGGAAAGAGGTGGACATGTGGAGCACTGGCGTCATCATGT

- 79 -

ACACGCTGCTGGCCGGCTCCCCGCCCTTCTGGCACCGGAAGCAGATGCTGATGCTGAGGA  
TGATCATGAGCGGCAACTACCAGTTTGGCTCGCCCGAGTGGGATGATTACTCGGACACCG  
TGAAGGACCTGGTCTCCCGATTCTGGTGGTGCACCCCAAGACCGCTACACAGCGGAAG  
AGGCCTTGGCACACCCCTTCTTCCAGCAGTACTTGGTGGAGGAAGTGCGGCACTTCAGCC  
CCCGGGGGAAGTTCAAGGTGATCGCTCTGACCGTGGTGGCTTCAGTGCAGTCTACTACC  
AGTACCGCCGGGTGAAGCCTGTGACCCGGGAGATCGTCATCCGAGACCCCTATGCCCTCC  
GGCCTCTGCGCCGGCTCATCGACGCCTACGCTTTCGAATCTATGGCCACTGGGTGAAGA  
AGGGGCAGCAGCAGAACCGGGCAGCCCTTTTCGAGAACACACCCAAGGCCGTGCTCCTCT  
CCCTGGCCGAGGAGGACTACTGAGGGGCTGGCCAGTCAGGGAGGGCTAGGGGGCAGGTGG  
GGAGGGGAAGCCATGGAAATACAAGTCAAAGGGGTAAAAAAAAAAAAAAAAAAAAA

>gi|5453882|gb|NP\_006204.1|PHKG1 387aa linear phosphorylase  
kinase, gamma 1 (muscle) [Homo sapiens].

MTRDEALPDShSAQDFYENYEPKEILGRGVSSVVRRCIHKPTSQEYAVKVIDVTGGGSFS  
PEEVRELREATLKEVDILRKVSGHPNIIQLKDTYETNTFFFLVFDLMKRGELFDYLTEKV  
TLSEKETRKIMRALLEVICTLHKLNIHVRDLKPENILLDDNMNIKLTDGFGSCQLEPGER  
LREVCCTPSYLAPEIIIECSMNEDHPGYGKEVDMWSTGVIMYTLLAGSPFFWHRKQMLMLR  
MIMSGNYQFGSPWDDYSDTVKDLVSRFLVQVQPNRYTAEALAHPPFQQYLVEEVRHFS  
PRGKFKVIALTVLASVRIYYQYRRVKPVTREIVIRDPYALRPLRLRIDAYAFRIYGHVWK  
KGQQQNRAALFENTPKAVLLSLAEEDY

>gi|4503412|gb|NM\_001945.1|DTR 2360bp mRNA Homo sapiens  
diphtheria toxin receptor (heparin-binding epidermal growth  
factor-like growth factor) (DTR), mRNA.

GCTACGCGGGCCACGCTGCTGGCTGGCCTGACCTAGGCGCGCGGGGTCGGGCGGCCCGCGC  
GGGCGGGCTGAGTGAGCAAGACAAGACACTCAAGAAGAGCGAGCTGCGCCTGGGTCCCGG  
CCAGGCTTGACGCAGAGGCGGGCGGCAGACGGTGCCCGGCGGAATCTCCTGAGCTCCGC  
CGCCAGCTCTGGTGCCAGCGCCCACTGGCCGCGGCTTCGAAAGTGACTGGTGCCTCGCC  
GCCTCCTCTCGGTGCGGGACCATGAAGCTGCTGCCGTCGGTGGTGTGAAGCTCTTTCTG  
GCTGCAGTTCTCTCGGCACTGGTGACTGGCGAGAGCCTGGAGCGGCTTCGGAGAGGGCTA  
GCTGCTGGAACCAGCAACCCGGAACCTCCCACTGTATCCACGGACCAGCTGCTACCCCTA  
GGAGGCGGCCGGGACCGGAAAGTCCGTGACTTGCAAGAGGCAGATCTGGACCTTTTGAGA  
GTCACCTTTATCCTCCAAGCCACAAGCACTGGCCACACCAAACAAGGAGGAGCACGGGAAA  
AGAAAGAAGAAAGGCAAGGGGCTAGGGAAGAAGAGGGACCCATGTCTTCGGAATACAAG  
GACTTCTGCATCCATGGAGAATGCAAATATGTGAAGGAGCTCCGGGCTCCCTCCTGCATC  
TGCCACCCGGGTTACCATGGAGAGAGGTGTATGGGCTGAGCCTCCAGTGGAATAATCGC  
TTATATACCTATGACCACACAACCATCCTGGCCGTGGTGGCTGTGGTGCTGTATCTGTC  
TGTCTGCTGGTCATCGTGGGGCTTCTCATGTTTAGGTACCATAGGAGAGGAGGTTATGAT  
GTGGAATAATGAAGAGAAAGTGAAGTTGGGCATGACTAATTCCCACTGAGAGAGACTTGTG  
CTCAAGGAATCGGCTGGGGACTGCTACCTCTGAGAAGACACAAGGTGATTTAGACTGCA  
GAGGGGAAAGACTTCCATCTAGTCACAAAGACTCCTTCGTCCCCAGTTGCCGTCTAGGAT  
TGGGCTCCCATTAATTGCTTTGCCAAAATACCAGAGCCTTCAAGTGCCAAACAGAGTATG  
TCCGATGGTATCTGGGTAAGAAGAAAGCAAAAGCAAGGGACCTTCATGCCCTTCTGATT  
CCCTCCACCAAACCCCACTTCCCCTCATAAGTTTGTTTAAACACTTATCTTCTGGATTAG  
AATGCCGGTTAAATTCATATGCTCCAGGATCTTTGACTGAAAAAAAAAAGAAGAAGAA  
GAAGGAGAGCAAGAAGGAAAGATTTGTGAAGTGAAGAAAGCAACAAAGATTGAGAAGCC  
ATGTACTCAAGTACCACCAAGGGATCTGCCATTGGGACCCTCCAGTGCTGGATTGATGA  
GTTAACTGTGAAATACCACAAGCCTGAGAAGTGAATTTTGGGACTTCTACCCAGATGGAA  
AATAACAACCTATTTTTGTTGTTGTTGTTTGTAAATGCCTCTTAAATTATATATTTATTT

- 80 -

TATTCTATGTATGTAAATTTATTTAGTTTTTAAACAATCTAACAATAATATTTCAAGTGCC  
TAGACTGTTACTTTGGCAATTTCTGGCCCTCCACTCCTCATCCCCACAATCTGGCTTAG  
TGCCACCCACCTTTGCCACAAAGCTAGGATGGTTCTGTGACCCATCTGTAGTAATTTATT  
GTCTGTCTACATTTCTGCAGATCTTCCGTGGTCAGAGTGCCACTGCGGGAGCTCTGTATG  
GTCAGGATGTAGGGGTTAACTTGGTCAGAGCCACTCTATGAGTTGGACTTCAGTCTTGCC  
TAGGCGATTTTGTCTACCATTGTGTTTTGAAAGCCCAAGGTGCTGATGTCAAAGTGTA  
CAGATATCAGTGTCTCCCCGTGTCCTCTCCCTGCCAAGTCTCAGAAGAGGTTGGGCTTCC  
ATGCCTGTAGCTTTCTGGTCCCTCACCCCATGGCCCCAGGCCACAGCGTGGGAACTCA  
CTTTCCCTTGTGTCAAGACATTTCTCTAACTCCTGCCATTCTTCTGGTGCTACTCCATGC  
AGGGGTCAGTGCAGCAGAGGACAGTCTGGAGAAGGTATTAGCAAAGCAAAAGGCTGAGAA  
GGAACAGGGAACATTGGAGCTGACTGTTCTTGGTAACTGATTACCTGCCAATTGCTACCG  
AGAAGGTTGGAGGTGGGGAAGGCTTTGTATAATCCCACCCACCTCACCAAACGATGAAG  
GTATGCTGTCATGGTCCTTTCTGGAAGTTTCTGGTGCCATTTCTGAACTGTTACAACCTG  
TATTTCCAAACCTGGTTCATATTTATACTTTGCAATCCAAATAAAGATAACCCTTATTCC  
ATAAAAAAAAAAAAAAAAAAAAA

>gi|4503413|gb|NP\_001936.1|DTR.208aa linear diphtheria toxin  
receptor (heparin-binding epidermal growth factor-like growth  
factor); Diphtheria toxin receptor (heparin-binding EGF-like  
growth factor) [Homo sapiens].

MKLLPSVVLKFLAAVLSALVTGESLERLRRLAAGTSNPDPTVSTDQLLPLGGGRDRK  
VRDLQEADLDLLRVTLSSKPQALATPNKEEHGKRKKKGKGLGKKRDPCLRKYKDFCIHGE  
CKYVKELRAPSCICHPGYHGERCHGLSLPVENRLYTYDHTTILAVVAVVLSSVCLLVIVG  
LLMFRYHRRGGYDVENEKVKLGMTNSH

>gi|4507460|gb|NM\_003236.1|TGFA 4119bp mRNA Homo sapiens  
transforming growth factor, alpha (TGFA), mRNA.

CTGGAGAGCCTGCTGCCCCGCCCGCCCGTAAATGGTCCCCCTCGGCTGGACAGCTCGCCCT  
GTTTCGCTCTGGGTATTGTGTTGGCTGCGTGCCAGGCCTTGGAGAACAGCACGTCCCCGCT  
GAGTGCAGACCCGCCCGTGGCTGCAGCAGTGGTGTCCCATTTTAATGACTGCCCAGATT  
CCACACTCAGTTCTGCTTCCATGGAACCTGCAGGTTTTTGGTGCAGGAGGACAAGCCAGC  
ATGTGTCTGCCATTCTGGGTACGTTGGTGCACGCTGTGAGCATGCGGACCTCCTGGCCGT  
GGTGGCTGCCAGCCAGAAGAAGCAGGCCATCACCGCCTTGGTGGTGGTCTCCATCGTGGC  
CCTGGCTGTCTTATCATCACATGTGTGCTGATACTGCTGCCAGGTCCGAAAACACTG  
TGAGTGGTGCCGGGCCCTCATCTGCCGGCACGAGAAGCCCAGCGCCCTCCTGAAGGGAAG  
AACCGCTTGCTGCCACTCAGAAACAGTGGTCTGAAGAGCCCAGAGGAGGAGTTTGCCAG  
GTGGACTGTGGCAGATCAATAAAGAAAGGCTTCTTCAGGACAGCACTGCCAGAGATGCCT  
GGGTGTGCCACAGACCTTCTACTTGGCCTGTAATCACCTGTGCAGCCTTTTGTGGGCCT  
TCAAACTCTGTCAAGAACTCCGTCTGCTTGGGGTTATTAGTGTGACCTAGAGAAGAAA  
TCAGCGGACCACGATTTCAAGACTTGTTAAAAAAGAACTGCAAAGAGACGGACTCCTGTT  
CACCTAGGTGAGGTGTGTGCAGCAGTTGGTGTCTGAGTCCACATGTGTGCAGTTGTCTTC  
TGCCAGCCATGGATTCCAGGCTATATATTTCTTTTAAATGGGCCACCTCCCCACAACAGA  
ATTCTGCCCAACACAGGAGATTTCTATAGTTATTGTTTTCTGTCATTTGCCTACTGGGGA  
AGAAAGTGAAGGAGGGGAACTGTTTAAATATCACATGAAGACCCTAGCTTTAAGAGAAGC  
TGTATCCTCTAACCACGAGACTCTCAACCAGCCCAACATCTTCCATGGACACATGACATT  
GAAGACCATCCCAAGCTATCGCCACCCCTTGGAGATGATGTCTTATTTATTAGATGGATAA  
TGTTTTTATTTTTTAACTCTCTTAAGTCAATGTAAAAAGTATAAAACCCCTTCAGACTTCTA  
CATTAAATGATGTATGTGTGCTGACTGAAAAGCTATACTGATTAGAAATGTCTGGCCTCT  
TCAAGACAGCTAAGGCTTGGGAAAAGTCTTCAGGGTGCGGAGATGGAACCAGAGGCTGG

- 81 -

GTTACTGGTAGGAATAAAGGTAGGGGTTTCAGAAATGGTGCCATTGAAGCCACAAAGCCGG  
TAAATGCCTCAATACGTTCTGGGAGAAAACCTTAGCAAATCCATCAGCAGGGATCTGTCCC  
CTCTGTTGGGGAGAGAGGAAGAGTGTGTGTGTCTACACAGGATAAACCCAATACATATTG  
TACTGCTCAGTGATTAAATGGGTTTCACTTCCTCGTGAGCCCTCGGTAAGTATGTTTAGAA  
ATAGAACATTAGCCACGAGCCATAGGCATTTTCAGGCCAAATCCATGAAAGGGGGACCAGT  
CATTTATTTTCCATTTTGTGTGCTTGGTTGGTTTGTGTGCTTTATTTTTTAAAAGGAGAAGTT  
TAACTTTGCTATTTATTTTCGAGCACTAGGAAAACCTATTCCAGTAATTTTTTTTTTCTCA  
TTTCCATTTCAGGATGCCGGCTTTATTAACAAAACCTCTAACAAGTCACCTCCACTATGTG  
GGTCTTCCTTTCCCCTCAAGAGAAGGAGCAATTGTTCCCTTGACATCTGGGTCCATCTGA  
CCCATGGGGCCTGCCTGTGAGAAACAGTGGGTCCCTTCAAATACATAGTGGATAGCTCAT  
CCCTAGGAATTTTCATTAAATTTGGAAACAGAGTAATGAAGAAATAATATATAAACTCC  
TTATGTGAGGAAATGCTACTAATATCTGAAAAGTGAAAGATTTCTATGTATTAACTCTTA  
AGTGCACCTAGCTTATTACATCGTGAAAGGTACATTTAAAATATGTTAAATTGGCTTGAA  
ATTTTCAGAGAATTTTGTCTTCCCCTAATTCTTCTTCTTGGTCTGGAAGAACAATTTCT  
ATGAATTTTCTCTTTATTTTTTTTTTATAATTCAGACAATTCTATGACCCGTGTCTTCAT  
TTTTGGCACTCTTATTTAACAATGCCACACCTGAAGCACTTGGATCTGTTTCAGAGCTGAC  
CCCCTAGCAACGTAGTTGACACAGCTCCAGGTTTTTAAATTACTAAAATAAGTTCAAGTT  
TACATCCCTTGGGCCAGATATGTGGGTGAGGCTTGACTGTAGCATCCTGCTTAGAGACC  
AATCAATGGACACTGGTTTTTAGACCTCTATCAATCAGTAGTTAGCATCCAAGAGACTTT  
GCAGAGGCGTAGGAATGAGGCTGGACAGATGGCGGAACGAGAGGTTCCCTGCGAAGACTT  
GAGATTTAGTGTCTGTGAATGTTCTAGTTCCTAGGTCCAGCAAGTCACACCTGCCAGTGC  
CCTCATCCTTATGCCTGTAACACACATGCAGTGAGAGGCCCTCACATATACGCCTCCCTAG  
AAGTGCCTTCCAAGTCAGTCCCTTGGAAACCAGCAGGTCTGAAAAGAGGGCTGCATCAAT  
GCAAGCCTGGTTGGACCATTTGTCCATGCCTCAGGATAGAACAGCCTGGCTTATTTGGGGA  
TTTTTCTTCTAGAAATCAAATGACTGATAAGCATTGGCTCCCTCTGCCATTTAATGGCAA  
TGGTAGTCTTTGGTTAGCTGCAAAAATACTCCATTTCAAGTTAAAAATGCATCTTCTAAT  
CCATCTCTGCAAGCTCCCTGTGTTTCTTGGCCCTTTAGAAAATGAATTGTTCACTACAAT  
TAGAGAATCATTTAACATCCTGACCTGGTAAGCTGCCACACACCTGGCAGTGGGGAGCAT  
CGCTGTTTCCAATGGCTCAGGAGACAATGAAAAGCCCCCATTTAAAAAATAACAAACAT  
TTTTTAAAAGGCCTCCAATACTCTTATGGAGCCTGGATTTTTTCCCACTGCTCTACAGGCT  
GTGACTTTTTTTAAGCATCCTGACAGGAAATGTTTTCTTCTACATGGAAAGATAGACAGC  
AGCCAACCCTGATCTGGAAGACAGGGCCCCGGCTGGACACACGTGGAACCAAGCCAGGGA  
TGGGCTGGCCATTGTGTCCCCGCAGGAGAGATGGGCAGAATGGCCCTAGAGTTCTTTTCC  
CTGAGAAAGGAGAAAAAGATGGGATTGCCACTACCCACCCACACTGGTAAGGGAGGAGA  
ATTTGTGCTTCTGGAGCTTCTCAAGGGATTGTGTTTTGCAGGTACAGAAAACCTGCCTGTT  
ATCTTCAAGCCAGGTTTTTCGAGGGCACATGGGTCAACAGTTGCTTTTTTCAGTCAATTTGG  
CCGGGATGGACTAATGAGGCTCTAACACTGCTCAGGAGACCCCTGCCCTCTAGTTGGTTC  
TGGGCTTTGATCTCTTCCAACCTGCCAGTCACAGAAGGAGGAATGACTCAAATGCCCAA  
AACCAAGAACACATTGCAGAAGTAAGACAAACATGTATATTTTTTAAATGTTCTAACATAA  
GACCTGTTCTCTTAGCCATTGATTTACCAGGCTTCTGAAAGATCTAGTGGTTTCACACA  
GAGAGAGAGAGAGTACTGAAAAAGCAACTCCTCTTCTTAGTCTTAATAATTTACTAAAAT  
GGTCAACTTTTCATTATCTTTATTATAATAAACCTGATGCTTTTTTTTTTAGAACTCCTTAC  
TCTGATGTCTGTATATGTTGCACTGAAAAGGTTAATATTTAATGTTTTTAATTTATTTTGT  
GTGGTAAGTTAATTTTGATTTCTGTAATGTGTTAATGTGATTAGCAGTTATTTTCCTTAA  
TATCTGAATTATACTTAAAGAGTAGTGAGCAATATAAGACGCAATTGTGTTTTTCAGTAA  
TGTGCATTGTTATTGAGTTGTACTGTACCTTATTTGGAAGGATGAAGGAATGAACCTTTT  
TTTCCTAAAAA

- 82 -

>gi|4507461|gb|NP\_003227.1|TGFA 160aa linear transforming growth factor, alpha [Homo sapiens].  
MVPSAGQLALFALGIVLAACQALENSTSPLSADPPVAAAVVSHFNDPCDSHTQFCFHGTC  
RFLVQEDKPACVCHSGYVGARCEHADLLAVVAASQKKQAITALVVVSIVALAVLIITCVL  
IHCCQVRKHCEWCRALICRHEKPSALLKGRTACCHSETVV

>gi|6912653|gb|NM\_012433.1|SF3B1 4259bp mRNA Homo sapiens  
splicing factor 3b, subunit 1, 155kDa (SF3B1), mRNA.  
ATGGCGAAGATCGCCAAGACTCACGAAGATATTGAAGCACAGATTCGAGAAATTC AAGGC  
AAGAAGGCAGCTCTTGATGAAGCTCAAGGAGTGGGCCTCGATTCTACAGGTTATTATGAC  
CAGGAAATTTATGGTGGAAGTGACAGCAGATTTGCTGGATACGTGACATCAATTGCTGCA  
ACTGAACTTGAAGATGATGACGATGACTATTTCATCATCTACGAGTTTGCTTGCTGAGAAG  
AAGCCAGGATATCATGCCCCCTGTGGCATTGCTTAATGATATAACCACAGTCAACAGAACAG  
TATGATCCATTTGCTGAGCACAGACCTCCAAAGATTGCAGACCGGGAAGATGAATACAAA  
AAGCATAGGCGGACCATGATAATTTCCCCAGAGCGTCTTGATCCTTTTGCAGATGGAGGG  
AAGACCCCTGATCCTAAATGAATGTTAGGACTTACATGGATGTAATGCGAGAACAACAC  
TTGACTAAAGAAGAACGAGAAATTAGGCAACAGCTAGCAGAAAAAGCTAAAGCTGGAGAA  
CTAAAGTCGTCAATGGAGCAGCAGCGTCCAGCCTCCATCAAAACGAAAACGGCGTTGG  
GATCAAAACAGCTGATCAGACTCCTGGTGCCACTCCCAAAAACTATCAAGTTGGGATCAG  
GCAGAGACCCCTGGGCATACTCCTTCCTTAAGATGGGATGAGACACCAGGTCTGTCAAAG  
GGAAGCGAGACTCCTGGAGCAACCCAGGCTCAAAAATATGGGATCCTACACCTAGCCAC  
ACACCAGCGGGAGCTGCTACTCCTGGACGAGGTGATACACCAGGCCATGCGACACCAGGC  
CATGGAGGCGCAACTTCCAGTGCTCGTAAAAACAGATGGGATGAAACCCCCAAAACAGAG  
AGAGATACTCCTGGGCATGGAAGTGGATGGGCTGAGACTCCTCGAACAGATCGAGGTGGA  
GATTCTATTGGTGAAACACCGACTCCTGGAGCCAGTAAAGAAAAATCACGGTGGGATGAA  
ACACCAGCTAGTCAGATGGGTGGAAGCACTCCAGTTCTGACCCCTGGAAAGACACCAATT  
GGCACACCAGCCATGAACATGGCTACCCCTACTCCAGGTCACATAATGAGTATGACTCCT  
GAACAGCTTCAGGCTTGGCGGTGGGAAAGAGAAATTGATGAGAGAAATCGCCCACTTTCT  
GATGAGGAATTAGATGCTATGTTCCAGAGGATATAAGGTAATTCCTCCTCCAGCTGGT  
TATGTTCTTATTCGAACTCCAGCTCGAAAGCTGACAGCTACTCCAACACCTTTGGGTGGT  
ATGACTGGTTTCCACATGCAAACTGAAGATCGAACTATGAAAAGTGTTAATGACCAGCCA  
TCTGGAAATCTTCCATTTTTTAAACCTGATGATATTCAATACTTTGATAAACTATTGGTT  
GATGTTGATGAATCAACACTTAGTCCAGAAGAGCAAAAAGAGAGAAAAATAATGAAGTTG  
CTTTTAAAAAATTAAGAATGGAACACCACCAATGAGAAAGGCTGCATTGCGTCAGATTACT  
GATAAAGCTCGTGAATTTGGAGCTGGTCCTTTGTTAATCAGATTCTTCCTCTGCTGATG  
TCTCCTACACTTGAGGATCAAGAGCGTCATTTACTTGTGAAAGTTATTGATAGGATACTG  
TACAACTTGATGACTTAGTTTCGTCCATATGTGCATAAGATCCTCGTGGTCATTGAACCG  
CTATTGATTGATGAAGATTACTATGCTAGAGTGGAAGGCCTAGAGATCATTTCTAATTTG  
GCAAAGGCTGCTGGTCTGGCTACTATGATCTCTACCATGAGACCTGATATAGATAACATG  
GATGAGTATGTCCGTAAACACAACAGCTAGAGCTTTTGCTGTTGTAGCCTCTGCCCTGGGC  
ATTCCTTCTTTATTGCCCTTCTTAAAGCTGTGTGCAAAAGCAAGAAGTCCTGGCAAGCG  
AGACACACTGGTATTAAGATTGTACAACAGATAGCTATTCTTATGGGCTGTGCCATCTTG  
CCACATCTTAGAAGTTTAGTTGAAATCATTGAACATGGTCTTGTGGATGAGCAGCAGAAA  
GTTCGGACCATCAGTGCTTTGGCCATTGCTGCCTTGGCTGAAGCAGCAACTCCTTATGGT  
ATCGAATCTTTTGATTCTGTGTTAAAGCCTTTATGGAAGGGTATCCGCCAACACAGAGGA  
AAGGGTTTGGCTGCTTTCTTGAAGGCTATTGGGTATCTTATTCCTCTTATGGATGCAGAA  
TATGCCAACTACTATACTAGAGAAGTGATGTTAATCCTTATTCGAGAATTCCAGTCTCCT  
GATGAGGAAATGAAAAAATTGTGCTGAAGGTGGTAAAACAGTGTTGTGGGACAGATGGT



- 83 -

GTAGAAGCAAACCTACATTAAAAACAGAGATTCTTCCTCCCTTTTTTAAACACTTCTGGCAG  
CACAGGATGGCTTTGGATAGAAGAAATTACCGACAGTTAGTTGATACTACTGTGGAGTTG  
GCAAACAAAGTAGGTGCAGCAGAAATTATATCCAGGATTGTGGATGATCTGAAAGATGAA  
GCCGAACAGTACAGAAAAATGGTGATGGAGACAATTGAGAAAAATTATGGGCAATTTGGGA  
GCAGCAGATATTGATCATAAACTTGAAGAACAACCTGATTGATGGTATTCTTTATGCTTTC  
CAAGAACAGACTACAGAGGACTCAGTAATGTTGAACGGCTTTGGCACAGTGGTTAATGCT  
CTTGGCAAACGAGTCAAACCATACTTGCCTCAGATCTGTGGTACAGTTTTGTGGCGTTTA  
AATAACAAATCTGCTAAAGTTAGGCAACAGGCAGCTGACTTGATTTCTCGAACTGCTGTT  
GTCATGAAGACTTGTCAAGAGGAAAAATTGATGGGACACTTGGGTGTTGTATTGTATGAG  
TATTTGGGTGAAGAGTACCCTGAAGTATTGGGCAGCATTCTTGAGCACTGAAGGCCATT  
GTAAATGTCATAGGTATGCATAAGATGACTCCACCAATTAAAGATCTGCTGCCTAGACTC  
ACCCCCATCTTAAAGAACAGACATGAAAAAGTACAAGAGAATTGTATTGATCTTGTGGT  
CGTATTGCTGACAGGGGAGCTGAATATGTATCTGCAAGAGAGTGGATGAGGATTTGCTTT  
GAGCTTTTAGAGCTCTTAAAGCCCAAAAAAGGCTATTTCGTAGAGCCACAGTCAACACA  
TTTGGTTATATTGCAAAGGCCATTGGCCCTCATGATGTATTGGCTACACTTCTGAACAAC  
CTCAAAGTTCAAGAAAGGCAGAACAGAGTTTGTACCACTGTAGCAATAGCTATTGTTGCA  
GAAACATGTTCCACCCTTTACAGTACTCCCTGCCTTAATGAATGAATACAGAGTTCCTGAA  
CTGAATGTTCAAAATGGAGTGTTAAATCGCTTTCTTCTTGTGTTGAATATATTGGTGAA  
ATGGGAAAAGACTACATTTATGCCGTAACACCGTTACTTGAAGATGCTTTAATGGATAGA  
GACCTTGTACACAGACAGACGGCTAGTGCAGTGGTACAGCACATGTCACCTTGGGGTTTAT  
GGATTTGGTTGTGAAGATTCGCTGAATCACTTGTGTAAGTATGTATGGCCCAATGTATTT  
GAGACATCTCCTCATGTAATTCAGGCAGTTATGGGAGCCCTAGAGGGCCTGAGAGTTGCT  
ATTGGACCATGTAGAATGTTGCAATATTGTTTACAGGGTCTGTTTACCCAGCCCGGAAA  
GTCAGAGATGTATATTGGAATAATTACAACCTCATCTACATTGGTTCCCAGGACGCTCTC  
ATAGCACATTACCCAAGAATCTACAACGATGATAAGAACACCTATATTGTTATGAACCTT  
GACTATATCTTATAATTTTATTGTTTATTTTGTGTTTAAATGCACAGCTACTTCACACCTT  
AACTTGCTTTGATTTGGTGATGTAACTTTTAAACATTGCAGTTCAGTGTAGAACTGGT  
CATAGAGGAAGAGCTAGAAATCCAGTAGCATGATTTTTTAAATAACCTGTCTTTGTTTTTG  
ATGTTAAACAGTAAATGCCAGTAGTGACCAAGAACACAGTGATTATATACACTATACTGG  
AGGGATTTTCAATTTTAAATTCATCTTTATGAAGATTTAGAACTCATTCTTGTGTTTAAAG  
GGAATGTTTAAATTGAGAAATAAACATTTGTGTACAAAATGCTAAAAAAAAAAAAAAAAAA  
>gi|6912654|gb|NP\_036565.1|SF3B1 1304aa linear splicing factor  
3b, subunit 1, 155kDa; spliceosome-associated factor 155;  
splicing factor 3b, subunit 1, 155kD [Homo sapiens].  
MAKIAKTHEDIEAQIREIQGKKAALDEAQGVGLDSTGYDQEIYGGSDSRFAGYVTSIAA  
TELEDDDDDDYSSSTSLLGQKKPGYHAPVALLNDIPQSTEQYDPFAEHRPPKIADREDEYK  
KHRRTMIIISPERLDPFADGGKTPDPKMNVRTYMDVMREQHLTKEEREIRQQLAEKAKAGE  
LKVVNGAAASQPPSKRRKRRWDQTADQTPGATPKKLSSWDQAETPGHTPSLRWDETPGRAK  
GSETPGATPGSKIWDPTPSHTPAGAATPGRGDTPGHATPGHGGATSSARKNRWDETPKTE  
RDTPGHGSWAETPRTRDRGDSIGETPTPGASKRKSRWDETPASQMGGSTPVLTPGKTPI  
GTPAMNMATPTPGHIMSMTPEQLQAWRWEREIDERNRPLSDEELDAMFPEGYKVLPPPAG  
YVPIRTPARKLTATPTPLGGMTGFHMQTEDRTMKSVNDQPSGNLPFLKPDIDQYFDKLLV  
DVDESTLSPEEQKERKIMKLLLKIKNGTPPMRKAALRQITDKAREFGAGPLFNQILPLLM  
SPTLEDQERHLLVKVIDRILYKLDDLVPRPYVHKILVIEPLLEDYDYARVEGLEIISNL  
AKAAGLATMISTMRPIDNMDEYVRNTTARAFVVASALGIPSLLPFLKAVCKSKKSWQA  
RHTGIKIVQQIAILMGCAILPHLRSLVEIIIEHGLVDEQQKVRTISALAIALAEAAATPYG  
IESFDSVLKPLWKGIHQHRGKGLAFLKAIGYLIPLMDAEYANYYTREVMLILIREFQSP

- 84 -

DEEMKKIVLKVVKQCCGTDGVEANYIKTEILPPFFKHFWQHRMALDRRNYRQLVDTTVEL  
ANKVGAAEIIISRIVDDLKDEAEQYRKVMVETIEKIMGNLGAADIDHKLEEQLIDGILYAF  
QEQTTEDSVMLNGFGTVVNALGKRVKPYLPQICGTVLWRLNNKSAKVRQQAADLISRTAV  
VMKTCQEEKLMGHLGVVLYEYLGEYYPEVLGSI LGALKAI VNVIGMHKMT PPIKDLLPRL  
TPILKNRHEKVQENCIDLVGRIADRGAEYVSAREWMRICFELLELLKAHKKAIRRATVNT  
FGYIAKAIGPHDVLATLLNNLKVQERQNRVCTTVAIAIVAETCSPFTVLPALMNEYRVPE  
LNVQNGVLKSLSLFLEYIGEMGKDYIYAVTPLLEDALMDRDLVHRQTASAVVQHMSLGVY  
GFGCEDSLNHLNLYVWPNVFETSPHVIQAVMGALEGLRVAIGPCRMLQYCLOGLFHPARK  
VRDVYWKIYNSIYIGSQDALIAHYPRIYNDKNTYIRYELDYIL

>gi|21707321|gb|BC033864.1|BC033864 2321bp mRNA Homo sapiens,  
Similar to branched chain aminotransferase 1, cytosolic, clone  
MGC:45234 IMAGE:5186262, mRNA, complete cds.

GGTGGATGCTGCGGCATCGGAGGACCCTGCTGGTGGAGGAAATGGTTCACGCCCGTCCCC  
GTTCCCTTTGCAGGCTTGCTATTGTGCGTCTGTGATTGACAAGACCACGAGGCTGAGCGC  
GCCCTGGAGATTTTCTATAAATGGCTTAACACCCAGTCTAGACTATTTGCTCGGATAT  
AAGGGAGACAATTGTTTTTTTGTCTTTGCGGCGAACCTGGCTCTGTAGGGCTGACCT  
GGAATTTAACCAGTCTTCCCTGAGCCGGCGGAGGAGGACAAAAACCGCCGCGACCCCGGC  
AGGGTGGGAAGTGCAGGGCAGCGCTCCCAAGACACGCTTGTTGGAGGTTCTGGGCTGGGT  
GCTTGTTGTCTGAGCCTCCTTTTTTGTGTTTGCTGGGTCTGGAGAGGAGCGCACGGT  
ATCATGGATTGCAGTAACGGATGCTCCGCAGAGTGTACCGGAGAAGGAGGATCAAAAGAG  
GTGGTGGGGACTTTTAAGGCTAAAGACCTAATAGTCACACCAGCTACCATTTTAAAGGAA  
AAACCAGACCCCAATAATCTGGTTTTTGGAACTGTGTTACGGATCATATGCTGACGGTG  
GAGTGGTCCTCAGAGTTTGGATGGGAGAAACCTCATATCAAGCCTCTTCAGAACCTGTCA  
TTGCACCCTGGCTCATCAGCTTTGCACTATGCAGTGGAAATTATTTGAAGGATTGAAGGCA  
TTTCGAGGAGTAGATAATAAAATTCGACTGTTTCAGCCAAACCTCAACATGGATAGAATG  
TATCGCTCTGCTGTGAGGGCAACTCTGCCGGTATTTGACAAAGAAGAGCTCTTAGAGTGT  
ATTCAACAGCTTGTGAAATTGGATCAAGAAATGGGTCCCATTATTCAACATCTGCTAGTCTG  
TATATTCTGCTTACATTCAATTGGAAGTGAAGCCTTCTCTTGGAGTCAAGAAGCCTACCAA  
GCCCTGCTCTTTGTACTCTTGAGCCAGTGGGACCTTATTTTTCAAGTGGAACTTTAAT  
CCAGTGTCCCTGTGGGCCAATCCCAAGTATGTAAGAGCCTGGAAAGGTGGAAGTGGGGAC  
TGCAAGATGGGAGGGAATTACGGCTCATCTCTTTTGGCCAATGTGAAGCAGTAGATAAT  
GGGTGTCAGCAGGTCCTGTGGCTCTATGGAGAGGACCATCAGATCACTGAAGTGGGAACT  
ATGAATCTTTTTCTTTACTGGATAAATGAAGATGGAGAAGAAGAACTGGCAACTCCTCCA  
CTAGATGGCATCATCTTCCAGGAGTGACAAGGCGGTGCATTCTGGACCTGGCACATCAG  
TGGGACACAGAAGTCAAGCTTGTTTTCAATTAATTTGCCTGATTTTCTGCAGTTTCAATTTAC  
TTTTGAACAACATAATTGCAATTGTAGACTGAGAGAAATTGAAACTTTCAAAGAGCCATA  
TTTCTATTGCAGATATATTTTCTGCTCTTCCAAATCTACTTACAGCATGAGTTCTTCTT  
TTAAATATTCAAATATTTTGAATATTGCCAAGAGCTTTGATTTCCATTTTATCTCTTGT  
GGGTTTATAAATTAAGAAAAATACTCATCTTATTTTTTTAAACCTCTCTATTTTATTG  
CCCTTTATTCAAATAACTTGTGACAACTTTGAACTTGAACCACTGAGGTAAAAGAACA  
AGAATTAAACAGATAGTTTAAACACATAGCTTAAAAGGATCTTTTTCCCATTTTCTATCC  
TTGAGCAAAGAATATATTCAAACACTTTGGCAGAAGTCAATGAGGTTATAACCACTAATTC  
CATGATGAAAATCAACTGAATGTGATACTGAAAGAGAAGGAAGAGAATTGTCACTGTAAA  
GTCAACTGTTAGTCATATTAGGAAAAAAATAACATACAATACAATTTCTCAAATAAAGTC  
CAAATATACATTCAATGTTTAAAAATAATGAGTATTTTCAAGATATTTGAACTCAGTCTGTT  
CTTTATTCCATAAAAGATATAGGTAAGCCGTGCACGGTGGCTCACAACATAAATCCAGC  
ACTTTGGCACTTTGGGAGGCTGAGGTGGGAGGATCACATGAGCCAGCCTGGGCAACATA



- 85 -

GGGAGACCGCTATCTTTACAAAATAAAATATAAAATATAAAACCTAGTTGGGCATGGCAG  
CATAACCTGTAGTCCCAGGTGCTCGGGAGACTGAGACAGGAGGATCGCTTGGGCCTGGG  
AGGTCGAGGCTGCAGTGAGCCAAGATTATGCCACTGCATTCCAGCCTGGGTGACAGGGCA  
AGACCTGTCTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

>gi|21707322|gb|AAH33864.1|AAH33864 320aa linear Similar to  
branched chain aminotransferase 1, cytosolic [Homo sapiens].  
MDCSNGCSAECTGEGGSKEVVGTFKAKDLIVTPATILKEKPDPNNLVFGTVFTDHMLTVE  
WSSEFGWEKPHIKPLQNLSLHPGSSALHYAVELFEGLKAFRGVDNKIRLFQPNLNMDRM  
RSAVRATLPVFDKEELLECIQQLVKLDQEWVPYSTSASLYIRPTFIGTEPSLGVKKPTKA  
LLFVLLSPVGPYFSSGTFNPVSLWANPKYVRAWKGGTGDCKMGGNYGSSLFAQCEAVDNG  
CQQVLWLYGEDHQITEVGTMNLFYWINEDGEEELATPPLDGIILPGVTRRCILDLAHQW  
DTELSLFSINLPDFLQFIYF

>gi|29570794|gb|NM\_001895.2|CSNK2A1 2323bp mRNA Homo sapiens  
casein kinase 2, alpha 1 polypeptide (CSNK2A1), transcript  
variant 2, mRNA.

CCCGCCTCCTGGTAGGAGGGGGTTTCCGCTTCCGGCAGCAGCGGCTGCAGCCTCGCTCTG  
GTCCCTGCGGCTGGCGGCCGAGCCGTGTGTCTCCTCCTCCATCGCCGCCATATTGTCTGT  
GTGAGCAGAGGGGAGAGCGGCCCGCCGCTGCCGCTTCCACCACAGTTTGAAGAAAACA  
GGTCTGAAACAAGGTCTTACCCCCAGCTGCTTCTGAACACAGTGACTGCCAGATCTCCAA  
ACATCAAGTCCAGCTTTGTCCGCCAACCTGTCTGACATGTCCGGACCCGTGCCAAGCAGG  
GCCAGAGTTTACACAGATGTTAATACACACAGACCTCGAGAATACTGGGATTACGAGTCA  
CATGTGGTGGAATGGGGAAATCAAGATGACTACCAGCTGGTTCGAAAATTAGGCCGAGGT  
AAATACAGTGAAGTATTTGAAGCCATCAACATCACAAATAATGAAAAAGTTGTTGTTAAA  
ATTCTCAAGCCAGTAAAAAAGAAGAAAATTAAGCGTGAAATAAAGATTTTGGAGAATTTG  
AGAGGAGGTCCCAACATCATCACTGGCAGACATTGTAAAAGACCCTGTGTCCACGAACC  
CCCGCCTTGGTTTTTGAACACGTAAACAACACAGACTTCAAGCAATTGTACCAGACGTTA  
ACAGACTATGATATTCGATTTTACATGTATGAGATTCTGAAGGCCCTGGATTATTGTCAC  
AGCATGGGAATTATGCACAGAGATGTCAAGCCCCATAATGTCATGATTGATCATGAGCAC  
AGAAAGCTACGACTAATAGACTGGGGTTTTGGCTGAGTTTTATCATCCTGGCCAAGAATAT  
AATGTCCGAGTTGCTTCCCGATACTTCAAAGGTCCTGAGCTACTTGTAGACTATCAGATG  
TACGATTATAGTTTGGATATGTGGAGTTTGGGTTGTATGCTGGCAAGTATGATCTTTCGG  
AAGGAGCCATTTTTCCATGGACATGACAATTATGATCAGTTGGTGAGGATAGCCAAGGTT  
CTGGGGACAGAAGATTTATATGACTATATTGACAAATACAACATTGAATTAGATCCACGT  
TTCAATGATATCTTGGGCAGACACTCTCGAAAGCGATGGGAACGCTTTGTCCACAGTGAA  
AATCAGCACCTTGTGAGCCCTGAGGCCCTTGGATTTCTGACAAACTGCTGCGATATGAC  
CACCAGTCACGGCTTACTGCAAGAGAGGCAATGGAGCACCCCTATTTCTACACTGTTGTG  
AAGGACCAGGCTCGAATGGGTTTATCTAGCATGCCAGGGGGCAGTACGCCCGTCAGCAGC  
GCCAATATGATGTCAGGGATTTCTTCAGTGCCAACCCCTTACCCCTTGGACCTCTGGCA  
GGCTCACCAGTGATTGCTGCTGCCAACCCCTTGGGATGCCTGTTCCAGCTGCCGCTGGC  
GCTCAGCAGTAACGGCCCTATCTGTCTCCTGATGCCTGAGCAGAGGTGGGGGAGTCCACC  
CTCTCCTTGATGCAGCTTGCGCCTGGCGGGGAGGGGTGAAACACTTCAGAAGCACCGTGT  
CTGAACCGTTGCTTGTGGATTTATAGTAGTTCAGTCATAAAAAAAAAAATTATAATAGGCT  
GATTTTCTTTTTTCTTTTTTTTTTAACTCGAACTTTTCATAACTCAGGGGATTCCCTGA  
AAAATTACCTGCAGGTGGAATATTTTCATGGACAAATTTTTTTTTTCTCCCTCCCAAATTT  
AGTTCCTCATCACAAAAGAACAAAGATAAACCAGCCTCAATCCCGGCTGCTGCATTTAGG  
TGGAGACTTCTTCCCATTTCCACCATTTGTTCTCCACCGTCCCACACTTTAGGGGGTTGG  
TATCTCGTGCTCTTCTCCAGAGATTACAAAATGTAGCTTCTCAGGGGAGGCAGGAAGAA

- 86 -

AGGAAGGAAGGAAAGAAGGAAGGGAGGACCCAATCTATAGGAGCAGTGGACTGCTTGCTG  
GTCGCTTACATCACTTTACTCCATAAGCGCTTCAGTGGGGTTATCCTAGTGGCTCTTGCTG  
GAAGTGTGTCTTAGTTACATCAAGATGTTGAAAATCTACCCAAAATGCAGACAGATACTA  
AAAACCTTCTGTTCAGTAAGAATCATGTCTTACTGATCTAACCTAAATCCAACCTCATTTA  
TACTTTTATTTTTAGTTTCAAGTTTAAATGTTGATACCTTCCCTCCCAGGCTCCTTACCTT  
GGTCTTTTCCCTGTTTATCTCTCCCAACATGCTGTGCTCCATAGCTGGTAGGAGAGGGAAGG  
CAAAATCTTTCTTAGTTTCTTTGTCTTGGCCATTTTGAATTC

>gi|4503095|gb|NP\_001886.1|CSNK2A1 391aa linear casein kinase  
II alpha 1 subunit isoform a; CK2 catalytic subunit alpha  
[Homo sapiens].

MSGPVPSPRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVF EAINIT  
NNEKVVVKILKPKVKKKIKREIKILENLRGGPNIIITLADIVKDPVSRTPALVFEHVNNTD  
FKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAE  
FYHPGQEYNVRVASRYFKGPPELLVDYQMYDYSLDMWSLGCMLASMI FRKEPFFHGHNDYD  
QLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDF  
LDKLLRYDHQSRLTAREAMEHPYFYTVVKDQARMGSSSMPGGSTPVSSANMMMSGISSVPT  
PSPPLGLAGSPVIAAANPLGMPVPAAGAQQ

>gi|13375963|gb|NM\_024689.1|FLJ14103 2502bp mRNA Homo sapiens  
hypothetical protein FLJ14103 (FLJ14103), mRNA.

CTCTTTGGCCAAGCCCTGCCTCTGTACAGCCTCGAGTGGACAGCCAGAGGCTGCAGCTGG  
AGCCCAGAGCCCAAGATGGAGCCCCAGCTGGGGCCTGAGGCTGCCGCCCTCCGCCCTGGC  
TGGCTGGCCCTGCTGCTGTGGGTCTCAGCCCTGAGCTGTTCTTTCTCCTTGCCAGCTTCT  
TCCCTTTCTTCTCTGGTGCCCCAAGTCAGAACAGCTACAATTTTGGAAGGACTTTCCTC  
GGTCTTGATAAATGCAATGCCTGCATCGGGACATCTATTTGCAAGAAGTTCTTTAAAGAA  
GAAATAAGATCTGACAACCTGGCTGGCTTCCCACCTTGGACTGCCTCCCGATTCTTGTCTT  
TCTTATCCTGCAAATTA CTAGATGATTCAAAATCTGGCGCCCTGTGGAGATCTTTAGA  
CTGGTCAGCAAATATCAAAACGAGATCTCAGACAGGAAAATCTGTGCCTCTGCATCAGCC  
CCAAAGACCTGCAGCATTGAGCGTGTCTGCGGAAAACAGAGAGGTTCCAGAAATGGCTG  
CAGGCCAAGCGCCTCACGCCGGACCTGGTGCAGGACTGTCACCAGGGCCAGAGAGAACTA  
AAGTTCTGTGTATGCTGAGATAACACCAGTGAAAAAGCCTGGCATGGAGCCCAGCACTG  
AGAACTTCCAGAAAGTGTTAGCCTTCTCCCAACTGTGTTATACCAACCACATTTTCAAAT  
AGTAATCATTAAAGAGGCTTCTGCATCAAACCTTCACATGCAGCTCCCATGCCACCCTCC  
AGAATTCACCAACACACAGGCCACCAGCAACAGGCTACCTTTGCACAATATTTCTCTGAT  
GACAACCTCAAAGCCCCGGCTCTTTCCACCACACTGTGGTCCCCTAGATGGGGCTGTTGC  
TGAGCCCACCCCAATCCAGATGTGATCCCCCTGTGATCTACTTCTGGCAAGATTCTCAGT  
CTGGACAGGTCTTCCCTATGAGATAGAACCTGATAAGGAGCTAGGGCAATTCTGACAACA  
TTACCAAAGGCCACATAACTTCTAAATTTTGGTCTGGTCTGAAGGAAAACCTGTTCTCG  
CCCTAGTGATGGATGAACTCTCTTATCTCTGGCTTCTAGAGGGGAAAAAAAAAGCATACCT  
CTTTTACTTTTAAAGTACCTCCATCAGAGTCATGAAATCACCTGTCAAGACTATCTATCT  
TTTATGTTTCCATTCTGGTAAGAACTCTTTAAATGAGGACACTGCTGATTGCTGGTGATG  
TTTTTTGAGCAAACACTCGGGGGTATGGATGAAAGCCAATCGCAGGTCAAATGACTCCTT  
GGGGAAGCTACTTCTCCTCTATTTCAGATTTTCACTAAAATCTTCCAAGATGAAAGCAAATC  
TAGATTTCCGGTCTTCATTGCTGTCCATTTTTGTAATGAACGAGTGTTTTTCTTTAGCTA  
GTGTATCAGGCAGGGTTCTACCAGAGAAACAGAACAGTAGGAGATACATATACATGTCC  
AGATTTATTTCAAAGAATTGATTTACATGATTGTGGGGATTGGCAAGTCCAAAATCCATA  
TGGTAGGCCTGCAATCTGTAAACCTTTGGGCAGGAGCTGATGCTGTAGTTTGCAGATAGA  
ATTCCTTGTTCTTAAAAAATCTGTTTTTGTCTTAAGGGCTTTGAATGATTGGATCAG

- 87 -

GCCCACCCAGATTACCTAGATAATCTCTTTTACTTAAAGTAAACTGATTGTAGGTGCTAA  
TCACATCTATGAAATGCCTTCACAGCAACACCTAGATTAGCATTCAATTGAATAACTGGG  
GAATACAGCCTAGCCAAGTTGACACATAAAATTAACCATCACAGCAACATGCCTGCTAAA  
TTTTATCGACCGTCTTCAGACTGTAAAGGATTGTGGTAGAGAACTGTGACAGCCACTCTC  
AGCATCACCCCTGAACCAAAGGCCCTATCAAGTAACAATATAGCCAAGCAAAATTCAGT  
CAATAGAGACATTGACTGGTTGGCTGGCTTCCCAAGGGATAGCACCAGACAAGAAATGCA  
AGGATGAGGAAACCAGGCACGGGAGAGGGAGGGGCAACAGAGGTCCAGGGTTTGGTTATC  
TTTTTATTTTCACTGGGAGGTGGTAAGTTAGCCCTGTTGCCCATGTATGCAGATGGGAG  
AAGTGATTTAGAAACTCCAAAGCAATTGGTAATCCCCAAAATGGGTGTATCTGGTTTGAA  
ATGAAACCTTATTTTATTGGAAATGGTTGGTTTCCCAATTCTGTTTGCCATTGGCCAATA  
TAATTGTGGGTTTGCACATGGCCAGCACATGCCAAACAGAAGTAGACAAAGGTCTCACTC  
TGTAAGTGGGACCTTGGGGAGGAGCTGCCTCCATCATAAAGGGAGGGGTTAGTAAAAATG  
GTCTCTTAAGCCTGTTCTGCTACAGTTATAGAGGTTGCTCAGAACCTTCTCAGCAAATA  
TAGCAGTTATCTATTGTTGTGTATTAAACCATTTCAACACAT

>gi|13375964|gb|NP\_078965.1|FLJ14103 182aa linear hypothetical  
protein FLJ14103 [Homo sapiens].

MEPQLGPEAAALRPGLALLLWVSALSCSFSPLPASSLSSLVPQVRTSYNFGRTFLGLDKC  
NACIGTSICKKFKEEIRSDNWLASHLGLPPDSLSSYPANYSDDSKIWRPVEIFRLVSKY  
QNEISDRKICASASAPKTCSIERVLRKTERFQKWLQAKRLTPDLVQDCHQGQRELKFLCM  
LR

>gi|7658290|gb|AF221842.1|AF221842 3057bp mRNA Homo sapiens U5  
snRNP-associated 102 kDa protein mRNA, complete cds.

ACTTTGCTACGGAGTGCATCGGACGTCGAAGCCTAGAGTCTCTGCGTCTTTCCTCTTCC  
GCTGCCTCATTCCTTTCCTTCTAGCCTTGGTCGTCGCCGCCACCATGAACAAGAAGAAG  
AAACCGTTCTAGGGATGCCCCGCGCCCTCGGCTACGTGCCGGGGCTGGGCCGGGGCGCC  
ACTGGCTTCACCACGCGGTGAGACATTGGGCCCCGCGCGTGATGCAAATGACCCTGTGGAT  
GATCGCCATGCACCCCCAGGCAAGAGAACCGTTGGGGACCAGATGAAGAAAAATCAGGCT  
GCTGACGATGACGACGAGGATCTAAATGACACCAATTACGATGAGTTTAATGGCTATGCT  
GGGAGCCTCTTCTCAAGTGGACCTACGAGAAAGATGATGAGGAAGCAGATGCTATCTAT  
GCAGCCCTGGATAAAAGGATGGATGAAAGAAGAAAGAAAGACGGGAGCAAAGGGAGAAA  
GAAGAAATAGAGAAATATCGTATGGAACGCCCCAAAATCCAACAGCAGTTCTCAGACCTC  
AAGAGGAAGTTGGCAGAAGTCACAGAAGAAGAGTGGCTGAGCATCCCCGAGGTTGGCGAT  
GCCAGAAATAAACGTCAGCGGAACCCACGCTATGAGAAGCTGACCCCTGTTCTGACAGT  
TTCTTTGCCAAACATTTACAGACCGGAGAGAACCATACTCAGTGGATCCCCGACAACT  
CAATTTGGAGGTCTTAACACACCCCTATCCAGGTGGACTAAACACTCCATACCCAGGTGGA  
ATGACGCCAGGACTGATGACACCTGGCACAGGTGAGCTGGACATGAGGAAGATTGGCCAA  
GCGAGGAACACTCTGATGGACATGAGGCTGAGCCAGGTGTCTGACTCCGTGAGTGGACAG  
ACCGTCGTTGACCCCAAAGGCTACCTGACGGATTTAAATTCCATGATCCCGACACACGGA  
GGAGACATCAATGATATCAAGAAGGCGCGACTGCTCCTCAAGTCTGTTCTGGGAGACGAAC  
CCTCATCACCCGCCAGCCTGGATTGCATCAGCCCGCCTGGAAGAAGTCACTGGGAAGCTA  
CAAGTAGCTCGGAACCTTATCATGAAGGGGACGGAGATGTGCCCAAGAGTGAAGATGTC  
TGGCTGGAAGCAGCCAGGTTGCAGCCTGGGGACACAGCCAAGGCCGTGGTAGCCCAAGCT  
GTCCGTCATCTCCACAGTCTGTGAGGATTTACATCAGAGCCGCAGAGCTGGAAACGGAC  
ATTCTGTCAAAGAAGCGGGTTCTTCGGAAGCCCTCGAGCATGTTCCAAACTCGGTTTCGC  
TTGTGGAAAGCAGCCGTTGAGCTGGAAGAACCTGAAGATGCTAGAATCATGCTGAGCCGA  
GCTGTGGAGTGCTGCCCCACCAGCGTGGAGCTCTGGCTTGCTCTGGCAAGGCTGGAGACC  
TATGAAAATGCCCGCAAGGTCTTGAACAAGGCGCGGGAGAACATTCCTACAGACCGACAT

- 88 -

ATCTGGATCACGGCTGCTAAGCTGGAGGAAGCCAATGGGAACACGCAGATGGTGGAGAAG  
ATCATCGACCGAGCCATCACCTCGCTGCGGGCCAACGGTGTGGAGATCAACCGTGAGCAG  
TGGATCCAGGATGCCGAGGAATGTGACAGGGCTGGGAGTGTGGCCACCTGCCAGGCCGTC  
ATGCGTGCCGTGATTGGGATTGGGATTGAGGAGGAAGATCGGAAGCATACCTGGATGGAG  
GATGCTGACAGTTGTGTAGCCCACAATGCCCTGGAGTGTGCACGAGCCATCTACGCCTAC  
GCCCTGCAGGTGTTCCCCAGCAAGAAGAGTGTGTGGCTGCGCGCCGCGTACTTCGAGAAG  
AACCATGGCACTCGGGAGTCCCTGGAAGCACTCCTGCAGAGGGCTGTGGCCCACTGCCCC  
AAAGCAGAGGTGCTGTGGCTCATGGGCGCCAAGTCCAAGTGGCTGGCAGGGGATGTGCCT  
GCAGCAAGGAGCATCCTGGCCCTGGCCTTCCAGGCCAACCCCAACAGTGAGGAGATCTGG  
CTGGCAGCCGTGAAGCTGGAGTCCGAGAATGATGAGTACGAGCGGGCCCCGAGGCTGCTG  
GCCAAGGCGCGGAGCAGTGCCCCCACC GCCCGGGTGTTCATGAAGTCTGTGAAGCTGGAG  
TGGGTGCAAGACAACATCAGGGCAGCCCAAGATCTGTGCGAGGAGGCCCTGCGGCACTAT  
GAGGACTTCCCCAAGCTGTGGATGATGAAGGGGCAGATCGAGGAGCAGAAGGAGATGATG  
GAGAAGGCGCGGGAAGCCTATAACCAGGGGTTGAAGAAGTGTCCCACTCCACACCCTG  
TGGCTTTTGTCTCTCGGCTGGAGGAGAAGATTGGGCAGCTTACTCGAGCACGGGCCATT  
TTGGAAAAGTCTCGTCTGAAGAACC CAAGAACCTGGGCTGTGGTTGGAGTCCGTGCGG  
CTGGAGTACCGTGCGGGGCTGAAGAACATCGAAATACACTCATGGCCAAGGCGCTGCAG  
GAGTGCCCCAACTCCGGTATCCTGTGGTCTGAGGCCATCTTCCTCGAGGCAAGGCCCCAG  
AGGAGGACCAAGAGCGTGGATGCCCTGAAGAAGTGTGAGCATGACCCCCATGTGCTCCTG  
GCCGTGGCCAAGCTGTTTTGGAGTCAGCGGAAGATCACCAAGGCCAGGGAGTGGTTCCAC  
CGCACTGTGAAGATTGACTCGGACCTGGGGGATGCCTGGGCCTTCTTCTACAAGTTTGAG  
CTGCAGCATGGCACTGAGGAGCAGCAGGAGGAGGTGAGGAAGCGCTGTGAGAGTGCAGAG  
CCTCGGCATGGGGAGCTGTGGTGCGCCGTGTCCAAGGACATCGCCAACCTGGCAGAAGAAG  
ATCGGGGACATCCTTAGGCTGGTGGCCGGCCGCATCAAGAACACCTTCTGATTGAGCGGT  
TGCCATGGCCGGTCTCCGTGGGGCAGGGTTGGGCCGCATGTGGAAGGGCTCTGAGCTGTG  
TCCTCCTTCATTAAAAGTTTTTATGTCTCGTGTGAGAAAAAAAAAAAAAAAAAAAAA

>gi|7658291|gb|AAF66128.1|AAF66128 941aa linear U5 snRNP-  
associated 102 kDa protein [Homo sapiens].

MNKKKKPFLGMPAPLGYVPGLGRGATGFTTTRSDIGPARDANDPVDDRHAPPGKRTVGDQM  
KKNQAADDDDEDLNDTNDEFNGYAGSLFSSGPYEKDEEADAIYAALDKRMDERRKERR  
EQREKEEIEKYRMERPKIQQQFSDLKRKLAEVTEEWLSIPEVGDARNKRQRNPRYEKLT  
PVPDSFFAKHLQTGENHTSVDPRQTQFGGLNTPYPGGLNTPYPGGMTPGLMTPGTGELDM  
RKIGQARNTLMDMRLSQVSDSVSGQTVVDPKGYLTDLNSMIPTHGGDINDIKKARLLLKS  
VRETNPHHPPAWIASARLEEV TGKLQVARNLIMKGTEMCPKSEDVWLEAARLQPGDTAKA  
VVAQAVRHLPQSVRIYIRAAELETDIRAKKRVLRKALEHVPNSVRLWKAAVELEEPEDAR  
IMLSRAVECCPTSVELWLALARLETYENARKVLNKARENIPTDRHIWITAACLEANGNT  
QMVEKIIDRAITSLRANGVEINREQWIQDAEECDRAGSVATCQAVMRAVIGIGIEEEDRK  
HTWMEDADSCVAHNALECARAIYAYALQVFPSKKS VWLRAAYFEKNHGTRESLEALLQRA  
VAHCPKAEVLWLMGAKSKWLAGDVPAARSILALAFQANPNSEEIWLA AVKLESENDEYER  
ARRLLAKARSSAPTARVFMKSVKLEWVQDNIRAAQDLCEEALRHYEDFPKLWMMKGQIEE  
QKEMMEKAREAYNQGLKKCPHSTPLWLLLSRLEEKIGQLTRARAILEKSRLKNPKNPGLW  
LESVRLEYRAGLKNIAN TLMAKALQECPNSGILWSEAFLEARPQRRTKSVDALKKCEHD  
PHVLLAVAKLFW SQRKITKAREWFHRTVKIDSDLGDAWAFFYKFELQHGTEEQQEEVRKR  
CESAEPRHGE LWCAVSKDIANWQKKIGDILRLVAGRIKNTF

>gi|5454165|gb|NM\_006370.1|VTI1B 1287bp mRNA Homo sapiens  
vesicle transport through interaction with t-SNAREs homolog 1B  
(yeast) (VTI1B), mRNA.

CCCTTTTCGCTGCGGCCTTTCCCAACCCGGACCCGGCACTTCTCGGGTTCCGCGACTGCC  
GATCGCCCCGGCGCGGCACCGCTCCCTCAGGAGTCGCCTAGGCCGCGCAGTCTCCCGACT  
TCTCGTCAGGCTTTTCGCGCCGGCGCTCCAGCAATCACTGGCTGGAGAAGGTGGGCGTTCC  
GGCTCGAGAGGACCCTGCCGCGGCTCCGGAAGAGCCTCGTCCTGGGCGGCGGTGGTGCGG  
CGGTGCGCCGTTATGGCCACTGGGCTGGGCGGCTGACCGCGGGCTAGGAAAGGGCCCCAGGG  
CCCGAATCTCGGTGGCCGCTGCTCCAGCGCGGCCTGCGCCATGGCCTCCTCCGCCGCCTC  
CTCGGAGCATTTTCGAGAAGCTGCACGAGATCTTCCGCGGCCTCCATGAAGACCTACAAGG  
GGTGCCCCGAGCGGCTGCTGGGGACGGCGGGGACCGAAGAAAAGAAGAAATTGATCAGGGA  
TTTTGATGAAAAGCAACAGGAAGCAAATGAAACGCTGGCAGAGATGGAGGAGGAGCTACG  
TTATGCACCCCTGTCTTTCCGAAACCCCATGATGTCTAAGCTTCGAAACTACCGGAAGGA  
CCTTGCTAAACTCCATCGGGAGGTGAGAAGCACACCTTTGACAGCCACACCTGGAGGCCG  
AGGAGACATGAAATATGGCATATATGCTGTAGAGAATGAGCATATGAATCGGCTACAGTC  
TCAAAGGGCAATGCTTCTGCAGGGCACTGAAAGCCTGAACCGGGCCACCCAAAGTATTGA  
ACGTTCTCATCGGATTGCCACAGAGACTGACCAGATTGGCTCAGAAATCATAGAAGAGCT  
GGGGGAACAACGAGACCAGTTAGAACGTACCAAGAGTAGACTGGTAAACACAAGTGAAAA  
CTTGAGCAAAAGTCGGAAGATTCTCCGTTCAATGTCCAGAAAAGTGACAACCAACAAGCT  
GCTGCTTTCCATTATCATCTTACTGGAGCTCGCCATCCTGGGAGGCCTGGTTTACTACAA  
ATTCTTTTCGAGCCATTGAACTTCTATAGGGAAGGGTTTGTGGAACAGAACTTTGACCTT  
GTGAATGCATGATGTTAGGGATGTGGATAGAATAAGCATATTGCTGCTGTGGGCTGACAG  
TTCAAGGATGCACTGTATAGCCAGGCTGTGGGAGGAGGGAGGAAAGATGAAAAACCACTT  
AAATGTGAAGGAACAACAGCAACAAGACCAGTATGATATACCAAGGTAATAAATGCTGTT  
TATGACTTCTTTAAAAA

>gi|5454166|gb|NP\_006361.1|VTI1B 232aa linear vesicle-  
associated soluble NSF attachment protein receptor (v-SN;  
vesicle-associated soluble NSF attachment protein receptor (v-  
SNARE; homolog of *S. cerevisiae* VTI1) [*Homo sapiens*].

MASSAASSEHFEKLHEIFRGLHEDLQGVPERLLGTAGTEEEKKLIRDFDEKQQEANETLA  
EMEEELRYAPLSFRNPMMSKLRNYRKDLAKLHREVRSTPLTATPGGRGDMKYGIYAVENE  
HMNRLQSQRAMLLQGTESLNRATQSIERSHRIATETDQIGSEIIEELGEQRDQLERTKSR  
LVNTSENLSKSRKILRSMRKVTTNKLILLSIIILLELAILGGLVYYKFFRSH

>gi|7705992|gb|NM\_016440.1|LOC51231 1869bp mRNA *Homo sapiens*  
VRK3 for vaccinia related kinase 3 (LOC51231), mRNA.

CCGAGGGTCAGGCTGCAGAAGCCAGAAATCCACCCAGTCCCCAAGTACAGAGGTCGCT  
GTCAAGATGGAGTTTCCAACCCAGTAAATCCAAGGGCCAGACCGTGACCTCATAAAGCAT  
GATCTCCTTCTGTCCAGACTGTGGCAAAGTATCCAAGCGGCATTCAAATTCTGCCCCCTA  
CTGTGGAAATTCTTTGCCTGTAGAGGAGCATGTAGGGTCCCAGACCTTTGTCAATCCACA  
TGTGTCATCCTTCCAAGGCTCAAAGAGAGGGCTGAACTCCAGTTTGAACCTCTCCTAA  
GAAAGTGAAATGGTCCAGCACCGTCACCTCTCCCCGATTATCCCTCTTCTCAGATGGTGA  
CAGTTCTGAGTCTGAAGATACTCTGAGTTCCTCTGAGAGATCCAAAGGCTCCGGGAGCAG  
ACCCCCAACCCCAAAAGCAGCCCTCAGAAGACCAGGAAGAGCCCTCAGGTGACCAGGGG  
TAGCCCTCAGAAGACCAGCTGTAGCCCTCAGAAGACCAGGCAGAGCCCTCAGACGCTGAA  
GCGGAGCCGAGTGACCACCTCACTTGAAGCTTTGCCACAGGGACAGTGCTGACAGACAA  
GAGTGGGCGACAGTGGAAGCTGAAGTCCTTCCAGACCAGGGACAACCAGGGCATTCTCTA  
TGAAGCTGCACCCACCTCCACCCTCACCTGTGACTCAGGACCACAGAAGCAAAAGTTCTC  
ACTCAAACCTGGATGCCAAGGATGGGCGCTTGTTCAATGAGCAGAACTTCTTCCAGCGGGC  
CGCCAAGCCTCTGCAAGTCAACAAGTGGAAGAAGCTGTACTCGACCCCACTGCTGGCCAT  
CCCTACCTGCATGGGTTTCGGTGTTCACCAGGACAAATACAGGTTCTTGGTGTTACCCAG

- 90 -

CCTGGGGAGGAGCCTTCAGTCGGCCCTGGATGTCAGCCCAAAGCATGTGCTGTCAGAGAG  
GTCTGTGCTGCAGGTGGCCTGCCGGCTGCTGGATGCCCTGGAGTTCCTCCATGAGAATGA  
GTATGTTTCATGGAAATGTGACAGCTGAAAATATCTTTGTGGATCCAGAGGACCAGAGTCA  
GGTGACTTTGGCAGGCTATGGCTTCGCCTTCCGCTATTGCCCAAGTGGCAAACACGTGGC  
CTACGTGGAAGGCAGCAGGAGCCCTCACGAGGGGGACCTTGAGTTCATTAGCATGGACCT  
GCACAAGGGATGCGGGCCCTCCCGCCGCAGCGACCTCCAGAGCCTGGGCTACTGCATGCT  
GAAGTGGCTCTACGGGTTTCTGCCATGGACAAATTGCCTTCCCAACACTGAGGACATCAT  
GAAGCAAAAACAGAAGTTTGTGATAAGCCGGGGCCCTTCGTGGGACCCTGCGGTCACCTG  
GATCAGGCCCTCAGAGACCCTGCAGAAGTACCTGAAGGTGGTGATGGCCCTCACGTATGA  
GGAGAAGCCGCCCTACGCCATGCTGAGGAACAACCTAGAAGCTTTGCTGCAGGATCTGCG  
TGTGTCTCCATATGACCCCATTTGGCCTCCCGATGGTGCCCTAGGTGGAATCCAGAACTTT  
CCATTTGCAGTGTGCAACAGAAAAAATGAAGCAATGTGACTCAAGGCCTGCTGTTTA  
ATCACAGATAAGCTTCTAGAACAAAGCCCTGGAATGTGCATTCTGCCACTGGTTTCAGGA  
TACTCATCAGTCCTGATTAGCCTCCGGAGGGCCCCAGTTTCCCTCCCGTGAATGTGAAGT  
TCCCCATCTTGGTGGCCTGCCCTTCAGCCAGTGTCTAGCAAAGCTGGATGGGGTTGGGC  
CGGCCACAGGGGGGACCCCTCCTACCCTTGACTCCTCTGTGCTTTGGTAATAAATTGTT  
TTACCAGAG

>gi|7705993|gb|NP\_057524.1|LOC51231 474aa linear VRK3 for  
vaccinia related kinase 3 [Homo sapiens].

MISFCPCGKSIQAAFKFCPYCGNSLPVEEHVGSQTFVNPHVSSFQGSKRGLNSSFETSP  
KKVKWSSTVTSPLSLFSDGDSSESEDTLSSSERSKSGSRPPTPKSSPQKTRKSPQVTR  
GSPQKTSCSPQKTRQSPQTLKRSRVTTSLALPTGTVLTDKSGRQWKLKSFQTRDNQIL  
YEAAPTSTLTCDSPQKQKFSCLKDAKDGRLEFNEQNFFQRAAKPLQVNKWKLYSTPLLA  
IPTCMGFGVHQDKYRFLVLP SLGRSLQ SALDVSPKHVLSERSVLQVACRLLDALFLHEN  
EYVHGNVTAENIFVDPEDQSQVTLAGYGFAFRYCPSGKHVAYVEGSRSPHEGDLEFISMD  
LHKGCGPSRRSDLQSLGYCMLKWLYGFLPWTNCLPNTEDIMKQKQKFVDKPGPFVGPCH  
WIRPSETLQKYLKVVMALTYEEKPPYAMLRRNNLEALLQDLRVSPYDPIGLPMVP

>gi|27479296|gb|XM\_114075.2|TCEA3 1543bp mRNA Homo sapiens  
transcription elongation factor A (SII), 3 (TCEA3), mRNA.  
CGCCCCCGCCGGCGTGTGTGTGCTGTGTGTTTGGGGCCCGCGCGGGTTGCGCGCCCTCC  
GCCTTCGCGCCTCCTGCCCCGAGGCCCTACTGCTGCCCTGTGCCCTCGCCCCGCCGG  
GCGTCGCGGGCCAACATGGGCCAGGAAGAGGAGCTGCTGAGGATCGCCAAAAGCTGGAG  
AAGATGGTGGCCAGGAAGAACACGGAAGGGGCCCTGGACCTTCTGAAGAAGCTGCACAGC  
TGCCAGATGTCCATCCAGCTACTACAGACAACCAGGATTGGAGTTGCTGTTAATGGGGTC  
CGCAAGCACTGCTCAGACAAGGAGGTGGTGTCTTGGCCAAGTCTTATCAAAAAGCTGG  
AAGCGGCTGCTAGACTCCCCTGGACCCCCAAAAGGAGAAAAAGGAGAGGAAAGAGAAAAG  
GCAAAGAAGAAGGAAAAAGGGCTTGAGTGTTCAGACTGGAAGCCAGAAGCAGGCCTTTCT  
CCACCAAGGAAAAACGAGAAGACCCCAAACAGGAGAGACTCTGTGGACTCCAAGTCT  
TCTGCCCTCCTCCTCTCAAAAAGACCATCGGTGGAAAGATCAAACAGCAGCAAATCAAAA  
GCGGAGAGCCCCAAAACACCTAGCAGCCCCCTTGACCCCCACGTTTGCCTCTTCCATGTGT  
CTCCTGGCCCCCTGCTATCTCACAGGGGACTCTGTCCGGGACAAGTGTGTGGAGATGCTG  
TCAGCAGCCCTGAAGGCGGACGATGATTACAAGGACTATGGAGTCAACTGTGACAAGATG  
GCATCAGAAATCGAAGATCATATCTACCAAGAGCTCAAGAGCACGGACATGAAGTACCGG  
AACCGCGTGCGCAGCCGCATAAGCAACCTCAAGGACCCAGGAACCCCGGCCTGCGGCGG  
AACGTGCTCAGTGGGGCCATCTCCGCAGGGCTTATAGCCAAGATGACGGCAGAGGAAATG  
GCCAGTGATGAACTGAGGGAGTTGAGGAATGCCATGACCCAGGAGGCCATCCGTGAGCAC  
CAGATGGCCAAGACTGGCGGCACCACCACTGACCTCTTCCAGTGCAGCAAATGCAAGAAG



- 91 -

AAGAACTGCACCTATAACCAGGTGCAGACACGCAGTGCTGATGAGCCCATGACTACCTTT  
GTCTTATGCAATGAATGTGGCAATCGCTGGAAGTTCTGCTGATGGAACAGCCAGCCATGA  
ACAAGGTGAGGAAGAAGAAAGAGGAAGCGCTGAATTATCTGAACTGGAGAAGCAATAAAA  
ATTAAAGTGAAGGAAAATACTGAACTCTGTCTGAGTGGGATGGTATGAGTTAGAGGAAGA  
ATTCTCTTGCAAATTAATAATCGGTCATTAGAAACAATTGGTTAATGGGGGAGCCTAATT  
GGAGAATGATGCTGAGAATTTGTATTGATGAACCTCTTTTAGAACTGCAGAGGGCTGGG  
CACGGTGGTTTATGGCTGTAATCTGCAAACCTCTGGGAGGCTGAGGTGGGAGAATCGCTTA  
ACCCGAGAAGTTTGAGTCCAGCCAGGCAACACAGCAAGACCC

>gi|20473950|gb|XP\_114075.1|TCEA3 348aa linear similar to  
Transcription elongation factor A protein 3 (Transcription  
elongation factor S-II protein 3) (Transcription elongation  
factor TFIIS.h) [Homo sapiens].

MGQEEELLRIAKKLEKMVARKNTEGALDLLKKLHSCQMSIQLLQTRIGVAVNGVRKHCS  
DKEVVSIAKVLIKNWKRLLDSPGPPKGEKGEEREKAKKKEKGLECSDWKPEAGLSPPRKK  
REDPKTRRDSVDSKSSASSSPKRPSVERNSSSSKSAESPKTPSSPLTPTFFASSMCLLAPC  
YLTGDSVRDKCVEMLSAALKADDDYKDYGVNCDKMASEIEDHIYQELKSTDMKYRNRVRS  
RISNLKDPNPNGLRRNVLSGAISAGLIAKMTAEEMASDELRELNRNMTQEAIREHQMAKT  
GGTTTDLFQCSKCKKNCTYNQVQTRSADEPMTTFVLCNECGNRWKFC

>gi|21314607|gb|NM\_003342.2|UBE2G1 2430bp mRNA Homo sapiens  
ubiquitin-conjugating enzyme E2G 1 (UBC7 homolog, C. elegans)  
(UBE2G1); mRNA.

ACCGGCAGCGAGGCGCCGCTCCCGCCGCCTCAGCCCGGCCTTCCTCGGCTCCGGCGCTCC  
GGTCGCGGGGGCCCGGGTTCTCCTCGGCACACCCCGCTCCAGCCGCCCCCAGAGCCTGTCCCC  
AGCCCTTCGGAAGCCCCGGCGCCAGCCCGGGCCCTCGGCAGGGAGGATGACGGAGCTGCA  
GTCGGCACTGCTACTGCGAAGACAGCTGGCAGAACTCAACAAAAATCCAGTGGAAGGCTT  
TTCTGCAGGTTTAATAGATGACAATGATCTCTACCGATGGGAAGTCCTTATTATTGGCCC  
TCCAGATACACTTTATGAAGGTGGTGTGTTTTTAAGGCTCATCTTACTTTCCCAAAGATTA  
TCCCCTCCGACCTCCTAAAATGAAATTCATTACAGAAATCTGGCACCCAAATGTTGATAA  
AAATGGTGATGTGTGCATTTCTATTCTTCATGAGCCTGGGGAAGATAAGTATGGTTATGA  
AAAGCCAGAGGAACGCTGGCTCCCTATCCACACTGTGGAACCATCATGATTAGTGTGAT  
TTCTATGCTGGCAGACCCTAATGGAGACTCACCTGCTAATGTTGATGCTGCGAAAGAATG  
GAGGGAAGATAGAAATGGAGAATTTAAAAGAAAAGTTGCCCGCTGTGTAAGAAAAGCCA  
AGAGACTGCTTTTGAGTGACATTTATTTAGCAGCTAGTAACTTCACTTATTTTCAGGGTCT  
CCAATTGAGAAACATGGCACTGTTTTTCTGCACTCTACCCACCTATTGCTGGACTTCTG  
TTGTACAAGTTGGCAAACACTGGCTGGAAGTGGGCTGCAATAAAACATGCCAGTTATCAA  
TGCTGACAAGAGCCTAACAAGTGCCAATTACAGATGATTACGCATTTTGAATTCTAATG  
AACTGTTTTTAACCTTCAGGAAGAATTGTAAAGACCTGTACATAGCACAACATGATCCGGA  
TAATATATATACTGTTTCATGTACATCCACAAATACACCTTGTAACCAATAATGCTTTCTT  
GTAGTAGAATAAGAATCGTGTAATTTCTAAGAGATTTTAGCAGGTTTTCTTTCTTATTC  
TTGTTTTCTTATCAGTTTAAAAGGATTCTTTTAAAGCATGTCAGATGAAAAGCAATTAGGAT  
TAAAAGTTTCCATTTAATTTCCCTTAAACCCTTGAGGCTTCATTAAACTCTTTTCACTTA  
CTAAACTTTTTGTATCTTCTTTGTTTTGACACACTCCCCTTTGCTTTTATCTCTTACCTGC  
CAGAATGTTCTCAAATGATTTAGTTCAAATACTGAAATACTTAATGAGCAATTACTTGAT  
TTTTAATGATGACTTCGAAGGAGTCATCACTAGGTGCTTTGTCTTTTTTGTATTCTAGTT  
GCACCCACCTCTTGGAATTGGATATAGCAATAACATTTATTGGCCGTTGTGAGCTCTTGAT  
CCCAGTCATTACCCCTGAGAACTAAAAATAGATGGTTCTTAATTCAACTTACTGAAAATT  
TCCCCAAACAATAGCAAATCTGACTTTTCCCTCTTCAGTTGCCTGGTATTAAGGTTGGAT

- 92 -

AAATGAAGCATGCACAGCTACAGGCTTTCTACTTAACTTCTGGGTTTGCTATTACAAATC  
CTATTTACTCTCATACCCTTCTCCTTAGTCCTTCATATTTCTCTGCCTCTATTCTTCTAT  
ACTGCAGATTTTTCTCACCTATTGTACAAAGAAATTGCGATGTATATTTTCATGTAATTT  
GATTTTGGAATTCTGTACCTTATGTAGTGAGTTCTTCCAAAATATAATTTTTTTTCAAT  
AATTGTCAAGTTGTTGGCTTTTATTGTATTGAATGAAGGCTATAAATACTGAGTGCCAGAG  
AAGTGGTTTAGGAAAATCTCAGGTTGATTCTTATGCAAATGAACTTTTAATACTTGAAA  
ATCACATGGCCATGGCAGTATATGTATTTGGTTCTATCTAGATTCTTCTGTGAATCTAAA  
AGCATTACAGGGGTAAATGCTTTGCTATTTGACGTATAGATCCCGTCACTAACAAATAGTA  
CACTTGGAATGTGATTAATGTTTGAGCTTCAATATATTTTCATATCATACAGTTTTCTAAAA  
CAACTTCAGCAAATGGTAAATGAACATGTGCAGTGTTAAAGGCAGGCCTTAGGCTCCTT  
CATGTTTGTGTGAGGTTGTGTGTGGGAAGTAGTCTTTGGCTTATAAGGGATAGAACTTG  
AGACAGTAGCAGATGGGACATGGTGTGTTGATTGTGAGAATCAGTGAGAATTCGTGCATCT  
CTGCTCTGTGGGGTTTGGAGAAATGCTTTGGCAGAAGAGTGAAAGAACTCCTGCCAAGAG  
CCCAGACCTCTACAAACGTTGTATGTCCTTTTTTAAGCAGAAATAAAATGGTTGAGGACG  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAA

>gi|13489085|gb|NP\_003333.1|UBE2G1 170aa linear ubiquitin-  
conjugating enzyme E2G 1 (UBC7 homolog, *C. elegans*);  
Ubiquitin-conjugating enzyme E2G (UBC7, *C. elegans*, human  
homolog of); ubiquitin-conjugating enzyme E2G (homologous to  
*C. elegans* UBC7); ubiquitin-conjugating enzyme E2G 1  
(homologous to *C. elegans* UBC7) [*Homo sapiens*].

MTELQSALLRRQLAELNKNPVEGFSAGLIDDNDLYRWEVLIIGPPDTLYEGGVFKAHLT  
FPKDYPLRPPKMKFITEIWHPNVDKNGDVCISILHEPGEDKYGYEKPEERWLPIHTVETI  
MISVISMLADPNGDSPANVDAAKEWREDRNGEFKRKVARCVRKSSQETAFA

>gi|21361498|gb|NM\_015670.2|SEN3 2258bp mRNA *Homo sapiens*  
sen3/SUMO-specific protease 3 (SEN3), mRNA.

GAAGCTTGAGGCCGAGACGCCCCGCTTCGGGCCCCGTCCGCCCCGGCTTCCCCGCTCCCCG  
GTACTGGAAGATGAAAGAGACTATACAAGGGACCGGGTCTGCGGGGCTGAGCCTCCTGG  
ACCCGGCATACCCCGAGCTTACTCAAGTCCAGGCGGGAGCGTCTTCGTTGGCCCCCACC  
TCCCAAACCCCGACTCAAGTCAGGTGGAGGGTTTGGGCCAGATCCTGGGTGAGGACAC  
AGTGCCAGCCAGACGCCTCCCTGTCCCCCGACCTCTTTTGATGCCTCAGCAAGTGAAGA  
GGAGGAAGAAGAGGAGGAGGAGGAGGATGAAGATGAAGAGGAGGAAGTGGCAGCTTGAG  
GCTGCCCCCAAGATGGAGTCAGCTGGGAACCTCCAGCGGCCCGCCCTTCCCGCCCCAC  
TCATCGAAAAACCTGCTCACAGCGCCGCGCCGAGCCATGAGAGCCTTCCGGATGCTGCT  
CTACTCAAAAAGCACCTCGCTGACATTCCACTGGAAGCTTTGGGGGCGCCACCGGGGCCG  
GCGGCGGGGCTCGCACACCCCAAGAACCATCTTTACCCCGCAAGGGGGTGCGACGCC  
ACAGGTGCCATCCCCCTGTTGTCTTTTGAATCCCCCGGGGGCCACCTCCACCCCGGCT  
GGGTCTGCTAGGTGCTCTCATGGCTGAGGATGGGGTGAGAGGGTCTCCACCAAGTGCCCTC  
TGGGCCCCCATGGAGGAAGATGGACTCAGGTGGACTCCAAAGTCTCCTCTGGACCCTGA  
CTCGGGCCTCCTTTTCATGTACTCTGCCAACGGTTTTTGGGGGACAATCTGGGCCAGAAGG  
GGAGCGCAGCTTGGCACCCTGATGCCAGCATCCTCATCAGCAATGTGTGCAGCATCGG  
GGACCATGTGGCCAGGAGCTTTTTTCAGGGCTCAGATTTGGGCATGGCAGAAGAGGCAGA  
GAGGCCTGGGGAGAAAGCCGGCCAGCACAGCCCCCTGCGAGAGGAGCATGTGACCTGCGT  
ACAGAGCATCTTGGACGAATTCCTTCAAACGTATGGCAGCCTCATACCCCTCAGCACTGA  
TGAGGTAGTAGAGAAGCTGGAGGACATTTTCCAGCAGGAGTTTTCCACCCCTTCCAGGAA  
GGCCTGTTGTTGCAGCTGATCCAGTCTTACCAGCGGATGCCAGGCAATGCCATGGTGAG  
GGGCTTCCGAGTGGCTTATAAGCGGCACGTGCTGACCATGGATGACTTGGGGACCTTGTA



- 93 -

TGGACAGAACTGGCTCAATGACCAGGTGATGAACATGTATGGAGACCTGGTCATGGACAC  
AGTCCCTGAAAAGGTGCATTTCTTCAATAGTTTCTTCTATGATAAACTCCGTACCAAGGG  
TTATGATGGGGTGAAGAAGGTGGACCAAAAACGTGGACATCTTCAATAAGGAGCTACTGCT  
AATCCCCATCCACCTGGAGGTGCATTGGTCCCTCATCTCTGTTGATGTGAGGCGACGCAC  
CATCACCTATTTTGACTCGCAGCGTACCCTAAACCGCCGCTGCCCTAAGCATATTGCCAA  
GTATCTACAGGCAGAGGCGGTAAAGAAAGACCGACTGGATTTCCACCAGGGGCTGGAAAGG  
TTACTTCAAAATGAATGTGGCCAGGCAGAATAATGACAGTGAAGTGTGGTGTCTTTGTGT  
GCAGTACTGCAAGCATCTGGCCCTGTCTCAGCCATTGAGCTTCACCCAGCAGGACATGCC  
CAAACCTTCGTCGGCAGATCTACAAGGAGCTGTGTCACTGCAAACCTCACTGTGTGAGCCTC  
GTACCCAGACCCCAAGCCCATAAATGGGAAGGGAGACATGGGAGTCCCTTCCCAAGAAA  
CTCCAGTTCCTTTTCTCTCTTGCCTCTTCCCACTCACTTCCCTTTGGTTTTTTCATATTTA  
AATGTTTCAATTTCTGTATTTTTTTTTTCTTTGAGAGAATACTTGTGATTTCTGATGTGC  
AGGGGGTGGCTACAGAAAAGCCCTTTCTTCTCTGTTTGCAGGGGAGTGTGGCCCTGTG  
GCCTGGGTGGAGCAGTCATCCTCCCCCTTCCCCGTGCAGGGAGCAGGAAATCAGTGCTGG  
GGGTGGTGGGCGACAATAGGATCACTGCCTGCCAGATCTTCAAACCTTTTATATATATAT  
ATATATATATATATATATATATAAAAAATATATAAATGCCACGGTCCTGCTCTGGTCAATA  
AAGGATCCTTTGTTGATACGTAAAAA

>gi|21361499|gb|NP\_056485.2|SEN3 574aa linear sentrin/SUMO-  
specific protease 3 [Homo sapiens].

MKETIQGTGSWGPEPPGPGIPPAYSSPRRERLRWPPPKPRLKSGGGFGPDGSGTTPVA  
RRLPVPRPSFDASASEEEEEEEEEDEDEEEVAAWRLPPRWSQLGTSQRPRPSRPTHK  
TCSQRRRRAMRAFRMLLYSKSTSLTFHWKLWGRHRGRRRGLAHPKNHLSPOQGGATPQVP  
SPCCRFDSPRGPPPPRLGLLGALMAEDGVRGSPVPSPGPPMEEDGLRWTPKSPLDPDGSL  
LSCTLPNGFGGQSGPEGERSLAPPDASILISNVCSIGDHVAQELFQGSDLGMAEEAERPG  
EKAGQHSPLREEHVTCVQSILDEFLOQTYGSLIPLSTDEVVEKLEDIFQQEFSTPSRKGLV  
LQLIQSYQRMPPGNAMVRGFRVAYKRHVLTMDDLGTLYGQNLNDQVMNMYGDLVMDTVPE  
KVHFFNSFFYDKLRITKGYDGVKRWTKNVDIFNKELLLIPIHLEVHWSLISVDVRRRTITY  
FDSQRTLNRRCPKHIAKYLAQAEAVKKDRLDHFQGWKGYFKMNVARQNNDSDCGAFVLQYC  
KHLALSQPFSTQODMPKLRRQIYKELCHCKLTV

>gi|5803166|gb|NM\_006802.1|SF3A3 2733bp mRNA Homo sapiens  
splicing factor 3a, subunit 3, 60kDa (SF3A3), mRNA.

AAGGGAAGATGGAGACAATACTGGAGCAGCAGCGCGCTATCATGAGGAGAAGGAACGGC  
TCATGGACGTCATGGCTAAAGAGATGCTCACCAAGAAGTCCACGCTCCGGGACCAGATCA  
ATTCTGATCACCGCACTCGGGCCATGCAAGATAGGTATATGGAGGTCAGTGGGAACCTGA  
GGGATTTGTATGATGATAAGGATGGATTACGAAAGGAGGAGCTCAATGCCATTTACAGAC  
CCAATGAGTTTGCTGAATTCTATAATAGACTCAAGCAAATAAAGGAATTCACCCGAAGC  
ACCAAATGAGATCTGTGTGCCAATGTCAGTGGAATTTGAGGAACTCCTGAAGGCTCGAG  
AGAATCCAAGTGAAGAGGCACAAAACCTTGGTGGAGTTCACAGATGAGGAGGGATATGGTC  
GTTATCTCGATCTCCATGACTGTTACCTCAAGTACATTAACCTGAAGGCATCTGAGAAGC  
TGGATTATATCACATACCTGTCCATCTTTGACCAATTATTTGACATTCCTAAAGAAAGGA  
AGAATGCAGAGTATAAGAGATACCTAGAGATGCTGCTTGAGTACCTTCAGGATTACACAG  
ATAGAGTGAAGCCTCTCCAAGATCAGAATGAACTTTTTGGGAAGATTACAGGCTGAGTTTG  
AGAAGAAATGGGAGAATGGGACCTTTCTTGATGGCCGAAAGAGACAAGCAGTGCCCTGA  
CCCATGCTGGAGCCCATCTTGACCTCTCTGCATTCTCCTCCTGGGAGGAGTTGGCTTCTC  
TGGGTTTGGACAGATTGAAATCTGCTCTCTTAGCTTTAGGCTTGAAATGTGGCGGGACCC  
TAGAAGAGCGAGCCAGAGACTATTCAGTACCAAAGGAAAGTCCCTGGAGTCACTTGATA  
CCTCTTTGTTTGCCAAAATCCCAAGTCAAAGGGCACCAAGCGAGACACTGAAAGGAACA

- 94 -

AAGACATTGCTTTTCTAGAAGCCCAGATCTATGAATATGTAGAGATTCTCGGGGAACAGC  
GACATCTCACTCATGAAAATGTACAGCGCAAGCAAGCCAGGACAGGAGAAGAGCGAGAAG  
AAGAGGAAGAAGAGCAGATCAGTGAGAGTGAGAGTGAAGATGAAGAGAACGAGATCATT  
ACAACCCCAAAAACCTGCCACTTGGCTGGGATGGCAAACCTATTCCCTACTGGCTGTATA  
AGCTTCATGGCCTAAATATCAACTACAACCTGTGAGATTGTGGAACTACACCTACCGAG  
GGCCCAAAGCCTTCCAGCGACACTTTGCTGAATGGCGTCATGCTCATGGCATGAGGTGTT  
TGGGCATCCCAAATACTGCTCACTTTGCTAATGTGACACAGATTGAAGATGCTGTCTCCT  
TGTGGGCCAAACTGAAATTGCAGAAGGCTTCAGAACGATGGCAGCCTGACACTGAGGAAG  
AATATGAAGACTCAAGTGGGAATGTTGTGAATAAGAAGACATACGAGGATCTGAAAAGAC  
AAGGACTGCTCTAGTGTTGAGGGATGTAGCTCAGCTTTTGGGCTAGCCCAGGCTTCCCTA  
AGATCTGCTTTTTTCTATTTCTCCCAACCAAATCCTCTTAAAGACCCTTTGCTATGTAGTC  
TCATGGTCTAGCATGCATCTTGTAGAAACAAGGCATGCTGGCAGATTGCAGGGTTGAGAT  
GTGTTTTATCTGTTTTATATTTTAAAGATTCTGCCAGAAAATAAAACCAGACCTTGTTT  
TAAAGCCCAGGGTTATGGACCAACTCAGTGCTTCAGGTCTTAATGCCTCCATACCTCTTC  
CTCACCAACTTTACTAGTAGCTGAGATTTAATGGGCACCTATTATGCTACATATCATGTT  
AGGTAAATCTGACCTGACCTCTTTCCCCACCCTCCTTTGTTGCTGCTTCCCTGAATGAGT  
ATTACCCAGGATGAGGTCTGCCATCAGCTTAGTTAGCCATTGATGCAAATACTAGGGAA  
AGACTAGGAGGATGAGCCAGGGTTGCTACTAAGGACTAAGTGTGCGACCAAGGTTTGCCT  
TTTGTATTTGCATAAAGAAAGGAGTTGGAGCTGGGTGCAGTGGCTTGTGCCTGTAGTCCC  
AGCTACTTGGGAGGCTGAGGCAGGAGGGTTGCTTGAGACTAGCCTAGGTAACATAGTGAG  
ACCCTGTCTCATTAAAAAAGGCATGGTGGCACGCACTGTAGTCCCAGCTA  
CTCAGGAGACTGAGGCTAGAAGATCCTTTGAACCTAGGAGTTTGAGACCAGCCTGGGCGA  
TATAGTGAGGCCCATCTCAAAAAAAGCGGGGGGGGAGTTGGGCTGTGTTG  
GAATGGGCCTGCAGCCCAACAAACAAGGGAAGTAGGACCGACAGTGACTTCACCAGCTTG  
CTAGGTCAGAATGAGAGACTGGTGGGTCTGCTACCTGTTTCTTCTACAAGATCCCTATT  
TGACTGTAAAGTAGCTAATACTCACATGTTCTCCAATCCCAGGTAGCCATGGTAGAGTT  
GGGTAGAGTTGAGCAGCCGCCCCAGGATCCAAATGTGGTGTCTGAAATGGAAAGAACTAA  
GGCAACCAGGAAGGCACTGATCTGCCTTATAAGCACAGTCATCTGAAAGTCAGGCCTGCT  
GCAGGACAGGATCCCCCAGAGACCCCATTTGCCTCTCAACACTCAGACCTTCAACTGTTT  
TTTAATAAATCTACTTTTTTAAAAAATA

>gi|5803167|gb|NP\_006793.1|SF3A3 501aa linear splicing factor  
3a, subunit 3, 60kDa; pre-mRNA splicing factor SF3a (60kD)  
[Homo sapiens].

METILEQQRRYHEEKERLMDVMAKEMLTKKSTLRDQINS DHRTRAMQDRYMEVSGNLRDL  
YDDKDGLRKEELNAISGPNEFAEFYNRLKQIKEFHRKHPNEICVPMSVEFEELLKAREN  
SEEAQNLVEFTDEEGYGRYLDLHDCYLKYINLKASEKLDYITYLSIFDQLFDIPKERKNA  
EYKRYLEMLLEYLQDYTDVRVKPLQDQNELFGKIQAEFEKKWENGTFPGWPKETSSALTHA  
GAHLDL S AFS SWEELASLGLDRLKSALLALGLKCGGTLEERAQRLFSTKGKSLES LDTSL  
FAKNPKSKGTRKRDTERNKDIAFLEAQIYEYVEILGEQRHLTHENVQRKQARTGEEREEEE  
EEQISESESEDEENEIIYNPKNLPLGWDGKPIPYWLYKLHGLNINYNCEICGNYTYRGP  
AFQRHFAEWRHAHGMRLGIPNTAHFANVTQIEDAVSLWAKLKLQKASERWQPDTEEEYE  
DSSGNV VNK KTYEDLKRQGLL

>gi|28882054|gb|NM\_005011.2|NRF1 2514bp mRNA Homo sapiens  
nuclear respiratory factor 1 (NRF1), mRNA.

GAGGCTGCGAGGAGCCGGCGCGGTGCGAGTCTCCACGGCGCAGGCCACGGTAGCGCAGC  
CGCTCTGAGTAGAACTTCATGGAGGAACACGGAGTGACCCAAACCGAACATATGGCTACC  
ATAGAAGCACATGCAGTGGCCCAGCAAGTGCAGCAGGTCCATGTGGCTACTTACACCGAG

- 95 -

CATAGTATGCTGAGTGCTGATGAAGACTCGCCTTCTTCTCCCGAGGACACCTCTTACGAT  
GACTCAGATATACTCAACTCCACAGCAGCTGATGAGGTGACAGCTCATCTGGCAGCTGCA  
GGTCCTGTGGGAATGGCCGCTGCTGCTGCTGTGGCAACAGGAAAGAAACGGAAACGGCCT  
CATGTATTTGAGTCTAATCCATCTATCCGGAAGAGGCAACAAACACGTTTGCTTCGGAAA  
CTTCGAGCCACGTTAGATGAATATACTACTCGTGTGGGACAGCAAGCTATTGTCCTCTGT  
ATCTCACCCCTCCAAACCTAACCCCTGTCTTTAAAGTGTTTGGTGCAGCACCTTTGGAGAAT  
GTGGTGCGTAAGTACAAGAGCATGATCCTGGAAGACCTGGAGTCTGCTCTGGCAGAACAC  
GCCCCCTGCGCCACAGGAGGTTAACTCAGAACTGCCGCTCTCACCATCGACGGAATTCCA  
GTCTCTGTGGACAAAATGACCCAGGCCAGCTTCGGGCATTTATCCCAGAGATGCTCAAG  
TACTCTACAGGTCTGGGGAAAACCAGGCTGGGGGAAAGAAAGCTGCAAGCCCATCTGGTGG  
CCTGAAGATATCCCCTGGGCAAATGTCCGGAGTGATGTCCGCACAGAAGAGCAAAAAGCAG  
AGGGTTTCATGGACCCAGGCACTACGGACCATAGTTAAAACTGTTATAAACAGCATGGG  
CGGGAAGACCTTTTGTATGCCTTTGAAGATCAGCAAACGCAAACACAGGCCACAGCCACA  
CATAGTATAGCTCATCTTGTACCATCACAGACTGTAGTCCAGACTTTTAGTAACCCTGAT  
GGCACTGTCTCACTTATCCAGGTTGGTACGGGGGCAACAGTAGCCACATTGGCTGATGCT  
TCAGAAATTGCCAACCACGGTCAACCGTTGCCCAAGTGAATTATTCTGCCGTGGCTGATGGA  
GAGGTGGAACAAAATTGGGCCACGTTACAGGGAGGTGAGATGACCATCCAGACGACGCAA  
GCATCAGAGGCCACCCAGGCGGTGGCATCGTTGGCAGAGGCCGAGTGGCAGCTTCTCAG  
GAGATGCAGCAGGGAGCTACAGTCACTATGGCGCTTAACAGCGAAGCTGCCGCCCATGCT  
GTCGCCACCCTGGCTGAGGCCACCTTACAAGGTGGGGGACAGATCGTCTTGTCTGGGGAA  
ACCGCAGCAGCCGTCGGAGCACTTACTGGAGTCCAAGATGCTAATGGCCTCTTTATGGCA  
GATCGTGCAGGTCTGCAAGTGGATCCTGACTGACAAAGCCACAGGCCTGGTCCAGATCCCT  
GTGAGCATGTACCAGACTGTGGTGACCAGCCTCGCCAGGGCAACCGGACCAGTGCAGGTG  
GCCATGGCCCCCTGTGACCACCAGGATATCAGACAGCGCAGTCACCATGGACGGCCAAGCT  
GTGGAGGTGGTGACATTGGAACAGTGACATACAGCCATATTATGGCATCGTTTTTCTAGTC  
TACTTCAAATTTTTTACACGTTTGCAGAGGTGCAATCAAATGGAATTAAGTCTCTCGAC  
TTTGGAAGGAAAGTTTTGTTAACCTTTTTTTTTTTTAAAAGGAAGAAAGCGGATTTTGGA  
TTGCATTTTTTAAAGCACCACTCTTGATTTTCTGGGATTGGTGAAGAACTGCATTGTCA  
ATTTCACTGTCCCAAAAAGCCAAATTTGTGGCAGGACTTCTTTCTGCGGAAATGTGTGTG  
TATACTTATGTGTGTGTATGTGTGAGTGTGAATATATGTATATGTGTACATATGGACATA  
CACATTTACATATATATAAAGTATATATATACATATATATATATATATATGTATGAAACCCG  
CATGGAATTATCTGTATGAAATCAAGGTGCGCTGTGGAAACAATAATTACCCAGTTTAG  
TGGGTGGTAGGGTACGTGGCCAGACACAGTCACCCAGTTTTTTGTTTCATACCAGGGTCATG  
CGTTGAGCTACTGACAACTCAGGCGGAGGTGACCATGCCCTTCACCAAAGCTGCCTCCC  
AGTGGCCACACAGAACTCTCCCTGCTGGACTCACCTGAGGAAAGAGGCTCCAGCATGGGG  
TGGGTGAGAGATGTGCTTGCAAGGTCCAGGGACTGCGTGGTCTGCCAGCTGAGATGCTCC  
TCGGGCTGGCCCAGGTGCTGACCTTGCCACAGGCAGATGAATGTCTTGAAAGCTCCCGGG  
CCTCAGCCTCCCATCTCCTCTCCTTCCCAGGAATCCTTGATCTCATGACTATTAAAATGT  
TGCTCTGGTTTTTAAGGTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

>gi|28882055|gb|NP\_005002.2|NRF1 522aa linear nuclear  
respiratory factor 1 [Homo sapiens].

MEEHGVQTQTEHMAIEAHAVAQQVQVHVATYTEHSMLSADEDSPPSPEDTSYDDSDILN  
STAADEVTAHLAAAGPVGMAAAAVATGKKRKRPHVFESNPSIRKRQQTRLLRKLRLATLD  
EYTRVGQQAIVLCISPSKPNPVFKVFGAAPLENVVRKYKSMILEDLESALAEHAPAPQE  
VNSELPPLTIDGIPVSVDKMTQAQLRAFIPEMLKYSTGRGKPGWGKESCKPIWWPEDIPW  
ANVRSDVRTEEQKQRVSWTQALRTIVKNCYKQHGREDLLYAFEDQQTQTQATATHSIAHL  
VPSQTVVQTFSPNDGTVSLIQVGTGATVATLADASELP TTVTVAQVNYSAVADGEVEQNW

- 96 -

ATLQGGEMTIQTTQASEATQAVASLAEAAVAASQEMQQGATVTMALNSEAAAHAVATLAE  
ATLQGGGQIVLSGETAAAVGALTGVQDANGLFMADRAGRKWILTDKATGLVQIPVSMYQT  
VVTSLAQGNPQVQVAMAPVTTTRISDSAVTMDGQAVEVVTLEQ

>gi|6996000|gb|NM\_001663.2|ARF6 1806bp mRNA Homo sapiens ADP-  
ribosylation factor 6 (ARF6), mRNA.

GGCCGGAGGGAGCCCGCGCTCGGGGCGGCGGCTGGAGGCAGCGCACCGAGTTCCCGCGAG  
GATCCATGACCTGACGGGGCCCCGGAGCCGCGCTGCCTCTCGGGTGTCTTGGGTGCGGTGG  
GGAGCCCACTGCTCGCAGGCCGCGGGCGGGCCGGAGGGCTGCAGTCTCCCTCGCGGTGA  
GAGGAAGGCGGAGGAGCGGGAACCGCGGCGGCGCTCGCGCGGCGCCTGCGGGGGGAAGGG  
CAGTTCCGGGCCGGGCCGCGCCTCAGCAGGGCGGCGGCTCCCAGCGCAGTCTCAGGGCCC  
GGGTGGCGGCGGCGACTGGAGAAATCAAGTTGTGCGGTGCGGTGATGCCCGAGTGAGCGGG  
GGGCTTGGGCTCTGCCCTTAGGAGGCAACTCCACGCGAGGCCGCAAGGGCTCTCGCGG  
CCGAGAGGCTTCGTTTTCGGTTTCGCGGCGGCGGCGGCGGCGTTGTTGGCTGAGGGGACCCGGG  
ACACCTGAATGCCCCCGGCCCGGCTCCTCCGACGCGATGGGGAAGGTGCTATCCAAAAT  
CTTCGGGAACAAGGAAATGCGGATCCTCATGTTGGGCTTGACGCGGCCGGCAAGACAAC  
AATCCTGTACAAGTTGAAGCTGGGCCAGTCGGTGACCACCATTTCCACTGTGGGTTTCAA  
CGTGAGACGGTGACTTACAAAATGTCAAGTTCAACGTATGGGATGTGGGCGGCCAGGA  
CAAGATCCGGCCGCTCTGGCGGCATTACTACACTGGGACCCAAGTCTCATCTTCGTAGT  
GGACTGCGCCGACCGCGACCGCATCGATGAGGCTCGCCAGGAGCTGCACCGCATTATCAA  
TGACCGGGAGATGAGGGACGCCATAATCCTCATCTTCGCCAACAAGCAGGACCTGCCCGA  
TGCCATGAAACCCACGAGATCCAGGAGAACTGGGCTGACCCGGATTCCGGGACAGGAA  
CTGGTATGTGCAGCCCTCCTGTGCCACCTCAGGGGACGGAATCTATGAGGGGCTCACATG  
GTTAACCTCTAACTACAAATCTTAATGAGCATTCTCCACCCATCCCCTGGAAGGAGAGAA  
ATCAAAAACCCATTTCATAGGATTATCGCCACCATCACCTCTTTCAATTGCCACTTTCTCT  
TCTTTTGAATTTGAACTCTGGAGTTACTGTTCTACAGTTTGGCGGGGACGGGGCTTGGGG  
GTTTTCTCTTTTGTGTTTCCCTTTCTTTTCTTTTTTTTTTTTTTTTTTTTTTGTGCT  
TTGCGTTAGGATGGCTCTGATCTGACATTTGACATGAACACAAAGTTGCCAAGATGCTCC  
TTGTTGACTTCCAGCAGAATGGGAATGGGGGAAACACAGCAGTTCTTGGGTAAAAGTCCC  
TTTGTAATAATAGGTTTGGGATTTTTTTTATTTTCGAGAGAATCTTTCATTTTCTATGTAT  
GCTTTTTTCTTTTTTGGCCAGTTTCTTATCACTTGCTGTAGATGGCTTATTTTGCATT  
CATGCAGACTATGTTGCAAGTCTGTTTCATCTAGTAACTGAAAATTATTGCTTAATCAA  
ACTGCCGTTTGTCTTTTATATTTAAGGCCTTCCCCCCCCCTTCTTATGAGTTCTAACTTA  
GTAATTTCAAATGTGACCTTTTATATCTAAGACCAGTATAGTAACTTAGCCACAGTGG  
CAAATAATGAGTAATATTGTAATATGTTCCAGTTGCACCTCAGTATGTTAAACAGGTAAT  
GTAAGAAGTTCTCTGAAATGTCAGCAAGTAAGTTCTGAAACACATCATGCATGAGTAGGA  
ATAAAC

>gi|4502211|gb|NP\_001654.1|ARF6 175aa linear ADP-ribosylation  
factor 6 [Homo sapiens].

MGKVLISKIFGNKEMRILMLGLDAAGKTTILYKLKLGQSVTTIPTVGFNVETVITYKNVKFN  
VWDVGGQDKIRPLWRHYTGTQGLIFVVDCAHDRDRIDEARQELHRIINDREMRDAIILIF  
ANKQDLDPAMKPHEIQEKLGLTRIRDNRWYVQPSCATSGDGLYEGLTWLTSNYKS

>gi|23510442|gb|NM\_003809.2|TNFSF12 1407bp mRNA Homo sapiens  
tumor necrosis factor (ligand) superfamily, member 12  
(TNFSF12), transcript variant 1, mRNA.

CTCTCCCCGGCCCGATCCGCCCGCGGCTCCCCCTCCCCCGATCCCTCGGGTCCCGGGAT  
GGGGGGGCGGTGAGGCAGGCACAGCCCCCGCCCCCATGGCCGCCCGTCGGAGCCAGAGG  
CGGAGGGGGCGCCGGGGGGAGCCGGGCACCGCCCTGCTGGTCCCGCTCGCGCTGGGCTG

- 97 -

GGCCTGGCGCTGGCCTGCCTCGGCCTCCTGCTGGCCGTGGTCAGTTTGGGGAGCCGGGCA  
TCGCTGTCCGCCAGGAGCCTGCCAGGAGGAGCTGGTGGCAGAGGAGGACCAGGACCCG  
TCGGAACCTGAATCCCCAGACAGAAGAAAGCCAGGATCCTGCGCCTTTCTGAACCGACTA  
GTTCCGGCCTCGCAGAAGTGCACCTAAAGGCCGGAACACGGGCTCGAAGAGCGATCGCA  
GCCATTATGAAGTTCATCCACGACCTGGACAGGACGGAGCGCAGGCAGGTGTGGACGGG  
ACAGTGAGTGGCTGGGAGGAAGCCAGAATCAACAGCTCCAGCCCTCTGCGCTACAACCGC  
CAGATCGGGGAGTTTATAGTCACCCGGGCTGGGCTCTACTACCTGTACTGTGAGGTGCAC  
TTTGATGAGGGGAAGGCTGTCTACCTGAAGCTGGACTTGCTGGTGGATGGTGTGCTGGCC  
CTGCGCTGCCTGGAGGAATTCTCAGCCACTGCGGCGAGTTCCCTCGGGCCCCAGCTCCGC  
CTCTGCCAGGTGTCTGGGCTGTTGGCCCTGCGGCCAGGGTCTCCCTGCGGATCCGCACC  
CTCCCCTGGGCCCATCTCAAGGCTGCCCCCTTCCTCACCTACTTCGGACTCTTCCAGGTT  
CACTGAGGGGGCCCTGGTCTCCCCGCGAGTCGTCCAGGCTGCCGGCTCCCCTCGACAGCTC  
TCTGGGCACCCGGTCCCCTCTGCCCCACCCTCAGCCGCTCTTTGCTCCAGACCTGCCCCCT  
CCCTCTAGAGGCTGCCTGGGCCTGTTACGTGTTTTCCATCCCACATAAATACAGTATTC  
CCACTCTTATCTTACAACCTCCCCACCGCCCACTCTCCACCTCACTAGCTCCCCAATCCC  
TGACCCTTTGAGGCCCCCAGTGATCTCGACTCCCCCTGGCCACAGACCCCCAGGGCATT  
GTGTTCACTGTACTCTGTGGGCAAGGATGGGTCCAGAAGACCCCCACTTCAGGCACCTAAGA  
GGGGCTGGACCTGGCGGCAGGAAGCCAAAGAGACTGGGCCTAGGCCAGGAGTTCCCAAAT  
GTGAGGGGCGAGAAACAAGACAAGCTCCTCCCTTGAGAATTCCCTGTGGATTTTTAAAC  
AGATATTATTTTATTATTATTGTGACAAAATGTTGATAAATGGATATTAAATAGAATAA  
GTCATAAAAAAAAAAAAAAAAAAAAAA

>gi|4507597|gb|NP\_003800.1|TNFSF12 249aa linear tumor necrosis  
factor (ligand) superfamily, member 12 isoform 1 precursor;  
APO3/DR3 ligand; TNF-related WEAK inducer of apoptosis [Homo  
sapiens].

MAARRSQRRRGRRGEPGTALLVPLALGLGLALACLGLLLAVVSLGSRASLSAQEPAQEEL  
VAEEDQDPSELNPQTEESQDPAPFLNRLVPRRSAPKGRKTRARRAIAAHYEVHPRPGQD  
GAQAGVDGTVSGWEEARINSSPLRYNRQIGEFIVTRAGLYYLYCQVHFDEGKAVYLLKL  
LLVDGVLALRCLEEFSAATAASSLGPQLRLCQVSGLLALRPGSSLRIRTLPAHLKAAPFL  
TYFGLFQVH

>gi|11496238|gb|NM\_021975.1|RELA 2444bp mRNA Homo sapiens v-  
rel reticuloendotheliosis viral oncogene homolog A, nuclear  
factor of kappa light polypeptide gene enhancer in B-cells 3,  
p65 (avian) (RELA), mRNA.

GGCACGAGGCGGGCCGGGTGCGAGCTGGGCCCCGCGGCATGGACGAACTGTTCCCCCTCA  
TCTTCCCGGCAGAGCAGCCCAAGCAGCGGGGCATGCGCTTCCGCTACAAGTGCAGGGGGC  
GCTCCGCGGGCAGCATCCAGGCGAGAGGAGCACAGATACCACCAAGACCCACCCACCA  
TCAAGATCAATGGCTACACAGGACCAGGGACAGTGCGCATCTCCCTGGTCACCAAGGACC  
CTCCTCACCGGCCTCACCCCCACGAGCTTGTTAGGAAAGGACTGCCGGGATGGCTTCTATG  
AGGCTGAGCTCTGCCCCGACCGCTGCATCCACAGTTTCCAGAACCTGGGAATCCAGTGTG  
TGAAGAAGCGGGACCTGGAGCAGGCTATCAGTCAGCGCATCCAGACCAACAACAACCCCT  
TCCAAGTTCCTATAGAAGAGCAGCGTGGGGACTACGACCTGAATGCTGTGCGGCTCTGCT  
TCCAGGTGACAGTGCGGGACCCATCAGGCAGGCCCTCCGCTGCGGCTGTCTTTCTC  
ATCCCATCTTTGACAATCGTGCCCCCAACACTGCCGAGCTCAAGATCTGCCGAGTGAACC  
GAAACTCTGGCAGCTGCCTCGGTGGGGATGAGATCTTCTACTGTGTGACAAGGTGCAGA  
AAGAGGACATTGAGGTGTATTTACGGGACCAGGCTGGGAGGCCCCGAGGCTCCTTTTCGC  
AAGCTGATGTGCACCGACAAGTGGCCATTGTGTTCCGGACCCCTCCCTACGCAGACCCCA

- 98 -

GCCTGCAGGCTCCTGTGCGTGTCTCCATGCAGCTGCGGCGGCCTTCCGACCGGGAGCTCA  
GTGAGCCCATGGAATTCCAGTACCTGCCAGATACAGACGATCGTCACCGGATTGAGGAGA  
AACGTAAAAGGACATATGAGACCTTCAAGAGCATCATGAAGAAGAGTCCTTTTCAGCGGAC  
CCACCGACCCCCGGCCTCCACCTCGACGCATTGCTGTGCCTTCCCGCAGCTCAGCTTCTG  
TCCCCAAGCCAGCACCCCAGCCCTATCCCTTTACGTCATCCCTGAGCACCATCAACTATG  
ATGAGTTTCCCACCATGGTGTTCCTTCTGGGCAGATCAGCCAGGCCTCGGCCTTGGCCC  
CGGCCCCCTCCCCAAGTCCTGCCCCAGGCTCCAGCCCCCTGCCCCCTGCTCCAGCCATGGTAT  
CAGCTCTGGCCCAGGCCCCAGCCCCCTGTCCAGTCCTAGCCCCAGGCCCTCCTCAGGCTG  
TGGCCCCACCTGCCCCCAAGCCCACCCAGGCTGGGGAAGGAACGCTGTCAGAGGCCCTGC  
TGCAGCTGCAGTTTGTATGATGAAGACCTGGGGGCTTGGCTTGGCAACAGCACAGACCCAG  
CTGTGTTTACAGACCTGGCATCCGTCGACAACTCCGAGTTTCAGCAGCTGCTGAACCAGG  
GCATACCTGTGGCCCCCACAACTGAGCCCATGCTGATGGAGTACCCTGAGGCTATAA  
CTCGCCTAGTGACAGCCAGAGGCCCCCGACCCAGCTCCTGCTCCACTGGGGGCCCCGG  
GGCTCCCCAATGGCCTCCTTTTCAGGAGATGAAGACTTCTCCTCCATTGCGGACATGGACT  
TCTCAGCCCTGCTGAGTCAGATCAGCTCCTAAGGGGTGACGCCTGCCCTCCCCAGAGCA  
CTGGTTGCAGGGGATTGAAGCCCTCCAAAAGCACTTACGGATTCTGGTGGGGTGTGTTCC  
AACTGCCCCCAACTTTGTGGATGTCTTCCTTGGAGGGGGAGCCATATTTTATTCTTTTA  
TTGTCAGTATCTGTATCTCTCTCTCTTTTGGAGGTGCTTAAGCAGAAGCATTAACTTCT  
CTGGAAGGGGGGAGCTGGGGAACTCAAACCTTTTCCCCTGTCTCTGATGGTCAGCTCCCT  
TCTCTGTAGGGAAGTGTGGGGTCCCCCATCCCCATCCTCCAGCTTCTGGTACTCTCCTAG  
AGACAGAAGCAGGCTGGAGGTAAGGCCTTTGAGCCCAAAAGCCTTATCAAGTGTCTTCC  
ATCATGGATTCAATTACAGCTTAATCAAAATAACGCCCCAGATACCAGCCCCCTGTATGGCA  
CTGGCATTGTCCCTGTGCCTAACACCAGCGTTTGAGGGGCTGCCTTCCTGCCCTACAGAG  
GTCTCTGCCGGCTCTTTCCTTGCTCAACCATGGCTGAAGGAAACAGTGCAACAGCACTGG  
CTCTCTCCAGGATCCAGAAGGGGTTTGGTCTGGACTTCCTTGCTCTCCCCTCTTCTCAAG  
TGCCTTAATAGTAGGGTAAGTTGTTAAGAGTGGGGGAGAGCAGGCTGGCAGCTCTCCAGT  
CAGGAGGCATAGTTTTTAGTGAACAATCAAAGCACTTGGACTCTTGCTCTTTCTACTCTG  
AACTAATAAAGCTGTTGCCAAGCTGGACGGCAGAGCTCGTGCC

>gi|11496239|gb|NP\_068810.1|RELA 537aa linear v-rel  
reticuloendotheliosis viral oncogene homolog A, nuclear factor  
of kappa light polypeptide gene enhancer in B-cells 3, p65; v-  
rel avian reticuloendotheliosis viral oncogene homolog A  
(nuclear factor of kappa light polypeptide gene enhancer in B-  
cells 3 (p65)) [Homo sapiens].

MDELFPFLIFPAEQPKQRGMRFRYKCEGRSAGSIPGERSTDTKTHPTIKINGYTGPGETVR  
ISLVTKDPPHRPHPHHELVGKDCRDGFYEALCPDRCIHSFQNLGIQCVKKRDLEQAISQR  
IQTNNNPFQVPIEEQRGDYDLNAVRLCFQVTVRDPGRPLRLPPVLSHPIFDNRAPNTAE  
LKICRVNRNSGSLGGDEIFLLCDKVQKEDIEVYFTGPGWEARGSFSSQADVHRQVAIVFR  
TPPYADPSLQAPVRVSMQLRRPSDRELSEPMFQYLPDTRHRIEEKRKRTYETFKSIM  
KKSPFSGPTDPRPPPRRIAVPSRSSASVPKPAPQPYPTSSLSTINYDEFPTMVFPSGQI  
SQASALAPAPPQVLPQAPAPAPAPAMVSALAQAPAPVPVLAPGPPQAVAPPAPKPTQAGE  
GTLSEALLQLQFDDLDLGNSTDPVFTDLASVDNSEFQQLLNQGI PVAPHTTEPML  
MEYPEAITRLVTAQRPPDPAPAPLGPGLPNGLLSGDEDFSSIADMDFSALLSQISS

>gi|23312372|gb|NM\_001065.2|TNFRSF1A 2236bp mRNA Homo sapiens  
tumor necrosis factor receptor superfamily, member 1A  
(TNFRSF1A), mRNA.

GCTGTTGCAACACTGCCTCACTCTTCCCCTCCCACCTTCTCTCCCCTCCTCTCTGCTTTA

- 99 -

ATTTTCTCAGAATTCTCTGGACTGAGGCTCCAGTTCTGGCCTTTGGGGTTCAAGATCACT  
GGGACCAGGCCGTGATCTCTATGCCCCGAGTCTCAACCCTCAACTGTCACCCCAAGGCACT  
TGGGACGTCCTGGACAGACCGAGTCCCAGGGAAGCCCCAGCACTGCCGCTGCCACACTGCC  
CTGAGCCCCAAATGGGGGAGTGAGAGGCCATAGCTGTCTGGCATGGGCCTCTCCACCGTGC  
CTGACCTGCTGCTGCCACTGGTGCTCCTGGAGCTGTTGGTGGGAATATACCCCTCAGGGG  
TTATTGGACTGGTCCCTCACCTAGGGGACAGGGAGAAGAGAGATAGTGTGTGTCCCCAAG  
GAAAATATATCCACCTCAAAATAATTGATTGCTGTACCAAGTGCCACAAAGGAACCT  
ACTTGTACAATGACTGTCCAGGCCCGGGGACAGGATACGGACTGCAGGGAGTGTGAGAGCG  
GCTCCTTCACCGCTTCAGAAAACACCTCAGACACTGCCTCAGCTGCTCCAAATGCCGAA  
AGGAAATGGGTCAGGTGGAGATCTCTTCTTGACAGTGGACCGGGACACCGTGTGTGGCT  
GCAGGAAGAACCAGTACCGGCATTATTGGAGTGAACCTTTTCCAGTGCTTCAATTGCA  
GCCTCTGCCTCAATGGGACCGTGCACCTCTCCTGCCAGGAGAAACAGAACACCGTGTGCA  
CCTGCCATGCAGGTTTCTTTCTAAGAGAAAACGAGTGTGTCTCCTGTAGTAACTGTAAGA  
AAAGCCTGGAGTGCACGAAGTTGTGCCTACCCAGATTGAGAATGTTAAGGGCACTGAGG  
ACTCAGGCACCACAGTGCTGTTGCCCTGGTCATTTTCTTTGGTCTTTGCCTTTTATCCC  
TCCTCTTCATTGGTTTAAATGTATCGCTACCAACGGTGGAAGTCCAAGCTCTACTCCATTG  
TTTGTGGGAAATCGACACCTGAAAAAGAGGGGGAGCTTGAAGGAACTACTACTAAGCCCC  
TGGCCCCAAACCCAAGCTTCAGTCCCACTCCAGGCTTCACCCCCACCTGGGCTTCAGTC  
CCGTGCCCAGTTCACCTTCACCTCCAGCTCCACCTATACCCCCGGTGACTGTCCCAACT  
TTGCGGCTCCCCGCAGAGAGGTGGCACCACCTATCAGGGGGCTGACCCCATCCTTGCGA  
CAGCCCTCGCTCCGACCCCATCCCCAACCCCTTCAGAAAGTGGGAGGACAGCGCCACA  
AGCCACAGAGCCTAGACACTGATGACCCCGCGACGCTGTACGCCGTGGTGGAGAACGTGC  
CCCCGTTGCGCTGGAAGGAATTCGTGCGGCGCCTAGGGCTGAGCGACCACGAGATCGATC  
GGCTGGAGCTGCAGAACGGGCGCTGCCTGCGCGAGGCGCAATACAGCATGCTGGCGACCT  
GGAGGCGGCGCACGCGCGCGCGAGGCCACGCTGGAGCTGCTGGGACGCGTGTCCGCG  
ACATGGACCTGCTGGGCTGCCTGGAGGACATCGAGGAGGCGCTTTCGCGCCCCGCGCCC  
TCCCGCCCCGCGCCAGTCTTCTCAGATGAGGCTGCGCCCCCTGCGGGCAGCTCTAAGGACC  
GTCCTGCGAGATCGCCTTCCAACCCCACTTTTTTCTGGAAAGGAGGGGTCCTGCAGGGGC  
AAGCAGGAGCTAGCAGCCGCCTACTTGGTGCTAACCCCTCGATGTACATAGCTTTTCTCA  
GCTGCCTGCGCGCCGCGACAGTCAGCGCTGTGCGCGCGGAGAGAGGTGCGCCGTGGGCT  
CAAGAGCCTGAGTGGGTGGTTTTCGAGGATGAGGGACGCTATGCCTCATGCCCGTTTTTG  
GTGTCTCACCAGCAAGGCTGCTCGGGGGCCCCCTGGTTTCGTCCCTGAGCCTTTTTTCACAG  
TGCATAAGCAGTTTTTTTTTTGTTTTTGTTTTTGTTTTGTTTTTAAATCAATCATGTT  
ACACTAATAGAACTTGGCACTCCTGTGCCCTCTGCCTGGACAAGCACATAGCAAGCTGA  
ACTGTCCTAAGGCAGGGGCGAGCACGGAACAATGGGGCCTTCAGCTGGAGCTGTGGACTT  
TTGTACATACATAAAATTCTGAAGTTAAAGCTCTGCTCTTGGAIAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAAAAAAA

>gi|4507575|gb|NP\_001056.1|TNFRSF1A 455aa linear tumor  
necrosis factor receptor 1 precursor; tumor necrosis factor  
receptor type 1; tumor necrosis factor-alpha receptor; tumor  
necrosis factor binding protein 1 [Homo sapiens].

MGLSTVPDLLLPLVLELLLVGIYPSGVIGLVPHLGDREKRDSVCPQGYIHPQNNISICT  
KCHKGTLYLNDPCPGQDTCRECESGSFTASENHLRHCLSCSKCRKEMQVEISSCTVD  
RDTVCGCRKNQYRHYWSENLFQCFNCSLCLNGTVHLSCQEKQNTVCTCHAGFFLRENECV  
SCSNCKKSLECTKLCLPQIENVKGTEDSGTTVLLPLVIFFLCLLSLLFIGLMYRYQRWK  
SKLYSIVCGKSTPEKEGELEGTTTKPLAPNPSFSPTPGFTPTLGFSPVPSSTFTSSSTYT  
PGDCPNFAAPRREVAPPYQGADPILATALASDPIPNPLQKWEDSAHKPQSLDTPATLY



- 100 -

AVVENVPPLRWKEFVRRRLGLSDHEIDRLLELQNGRCLREAQYSMLATWRRRTTPRREATLEL  
LGRVLRDMDLLGCLEDIEEALCGPAALPPAPSLLR

>gi|4506738|gb|NM\_003952.1|RPS6KB2 1735bp mRNA Homo sapiens  
ribosomal protein S6 kinase, 70kDa, polypeptide 2 (RPS6KB2),  
mRNA.

AGAGACTCGTGCCGAATGGCACGAGGCCGACGGGCCCCGCGGGGCCGCGCCGCGCCATGGCG  
GCCGTGTTTGATTGATTTGGATTTGGAGACGGAGGAAGGCAGCGAGGGCGAGGGCGAGCCAGAG  
CTCAGCCCCCGCGGACGCATGTCCCTTGCCGAGTTGAGGGCAGCTGGCCTAGAGCCTGTG  
GGACACTATGAAGAGGTGGAGCTGACTGAGACCAGCGTGAACGTTGGCCCAGAGCGCATC  
GGGCCCCACTGCTTTGAGCTGCTGCGTGTGCTGGGCAAGGGGGGCTATGGCAAGGTGTTT  
CAGGTGCGAAAGGTGCAAGGCACCAACTTGGGCAAAATATATGCCATGAAAGTCCTAAGG  
AAGGCCAAAATTGTGCGCAATGCCAAGGACACAGCACACACACGGGCTGAGCGGAACATT  
CTAGAGTCAGTGAAGCACCCCTTTATTGTGGAAGTGGCCTATGCCTTCCAGACTGGTGGC  
AACTCTACCTCATCCTTGAGTGCCTCAGTGGTGGCGAGCTCTTCACGCATCTGGAGCGA  
GAGGGCATCTTCTTGGAAGATACGGCCTGCTTCTACCTGGCTGAGATCACGCTGGCCCTG  
GGCCATCTCCACTCCCAGGGCATCATCTACCGGGACCTCAAGCCCGAGAACATCATGCTC  
AGCAGCCAGGGCCACATCAAAGTGAACGACTTTGGACTCTGCAAGGAGTCTATCCATGAG  
GGCGCCGTCACCTCACACCTTCTGCGGCACCATTTAGTACATGGCCCCTGAGATTCTGGTG  
CGCAGTGGCCACAACCGGGCTGTGGACTGGTGGAGCCTGGGGGGCCCTGATGTACGACATG  
CTCACTGGATCGCCGCCCTTTACCGCAGAGAACCGGAAGAAAACCATGGATAAGATCATC  
AGGGGCAAGCTGGCACTGCCCCCTACCTCACCCAGATGCCCCGGGACCTTGTCAAAAAG  
TTTCTGAAACGGAATCCCAGCCAGCGGATTGGGGGTGGCCCAGGGGATGCTGCTGATGTG  
CAGAGACATCCCTTTTTTCCGGCACATGAATTGGGACGACCTTCTGGCCTGGCGTGTGGAC  
CCCCCTTTTCCAGGCCCTGTCTGCAGTCAGAGGAGGACGTGAGCCAGTTTGATACCCGCTTC  
ACACGGCAGACGCCGGTGGACAGTCTTGATGACACAGCCCTCAGCGAGAGTGCCAACCAG  
GCCTTCTTGGGCTTCACATACGTGGCGCCGTCTGTCTCTGGACAGCATCAAGGAGGGCTTC  
TCCTTCCAGCCCAAGCTGCGCTCACCCAGGCGCCTCAACAGTAGCCCCCGGGTCCCCGTC  
AGCCCCCTCAAGTTCTCCCTTTTGGAGGGGTTTCGGCCCAGCCCCAGCCTGCCGGAGCCC  
ACGGAGCTACCTCTACCTCCACTCCTGCCACCGCCGCCCTCGACCACCGCCCCCTCTC  
CCCATCCGTCCCCCTCAGGGACCAAGAAGTCCAAGAGGGGGCCGTGGGCGTCCAGGGCGC  
TAGGAAGCCGGGTGGGGGTGAGGGTAGCCCTTGAGCCCTGTCCCTGCGGCTGTGAGAGCA  
GCAGGACCCTGGGCCAGTTCCAGAGACCTGGGGGTGTGTCTGGGGGTGGGGTGTGAGTGC  
GTATGAAAGTGTGTGTCTGCTGGGGCAGCTGTGCCCTGAATCATGGGCACGGAGGGCCG  
CCCGCCACACCCCGCGCTCAACTGCTCCCGTGGGAAGATTAAAGGGCTGAATCATG

>gi|4506739|gb|NP\_003943.1|RPS6KB2 495aa linear ribosomal  
protein S6 kinase, 70kDa, polypeptide 2; ribosomal protein S6  
kinase, 70kD, polypeptide 2; p70 ribosomal S6 kinase beta  
[Homo sapiens].

MARGRRARGAGAAMA AVFDLDLETEEGSEGEPELSPADACPLAELRAAGLEPVGHYEE  
VELTETSVNVGPERIGPHCFELLRLVLGKGGYGKVFQVRKVQGTNLGKIYAMKVLKAKIV  
RNAKDTAHTRAERNILESVKHPFIVELAYAFQTGGKLYLILECLSGGELFTHLEREGIFL  
EDTACFYLAIEITLALGHLHSQGI IYRDLKPENIMLSSQGHIKLTDFGLCKESIHEGAVTH  
TFCGTIEYMAPEILVRS GHNRAVDWWSLGALMYDMLTGSPFFTAENRKKTMDKIIRGKLA  
LPPLYLTPDARDLVKKFLKRNPSQRIGGGPGDAADVQRHPFFRHMNWDDLAWRVDPPFRP  
CLQSEEDVSQFDTRFTRQTPVDSPPDTALSESANQAF LGFTYVAPSVLDSIKEGFSFQPK  
LRSPRRLNSSPRVPVSP LKFS PFEGFRPSPSLPEPTELPLPPLLPPPPSTTAPLPIRPP  
SGTKKSKRGRGRPGR



- 101 -

>gi|11995473|gb|NM\_019884.1|GSK3A 2169bp mRNA Homo sapiens  
glycogen synthase kinase 3 alpha (GSK3A), mRNA.  
GCCAGAGCGGCGCGGCCTGGAAGAGGCCAGGGCCCCGGGGGAGGCGACGGCAGCGGC GGCG  
GCTGGGGCAGCCCCGGGCAGCCCCGAGCCCCGAGCCTGGGCCTGTGCTCGGCGCCATGAGC  
GGCGGCGGGCCCTTCGGGAGGCGGCCCTGGGGGCTCGGGCAGGGCGCGGACTAGCTCGTTC  
GCGGAGCCCCGGCGGCGGAGGCGGAGGAGGCGGCGGCGGCCCCGGAGGCTCGGCCTCCGGC  
CCAGGCGGCACCGGCGGCGGAAAGGCATCTGTGCGGGCCATGGGTGGGGGCGTGGGGGCC  
TCGAGCTCCGGGGGTGGACCCGGCGGCAGCGGCGGAGGAGGCAGCGGAGGCCCGGCGCA  
GGCACTAGCTTCCCGCCGCCCGGGGTGAAGCTGGGGCCGTGACAGCGGGAAGGTGACCACA  
GTCGTAGCCACTCTAGGCCAAGGCCCAGAGCGCTCCCAAGAAGTGGCTTACACGGACATC  
AAAGTGATTGGCAATGGCTCATTTGGGGTTCGTGTACCAGGCACGGCTGGCAGAGACCAGG  
GAACTAGTCGCCATCAAGAAGGTTCTCCAGGACAAGAGGTTCAAGAACCAGAGAGCTGCAG  
ATCATGCGTAAGCTGGACCACTGCAATATTGTGAGGCTGAGATACTTTTTCTACTCCAGT  
GGCGAGAAGAAAGACGAGCTTTACCTAAATCTGGTGCTGGAATATGTGCCCCGAGACAGTG  
TACCGGGTGGCCCCGCCACTTCACCAAGGCCAAGTTGACCATCCCTATCCTCTATGTCAAG  
GTGTACATGTACCAGCTCTTCCGCAGCTTGGCCTACATCCACTCCCAGGGCGTGTGTACAC  
CGCGACATCAAGCCCCAGAACCTGCTGGTGGACCCTGACACTGCTGTCCTCAAGCTCTGC  
GATTTTGGCAGTGCAAAGCAGTTGGTCCGAGGGGAGCCCAATGTCTCCTACATCTGTTCT  
CGCTACTACCGGGCCCCAGAGCTCATCTTTGGAGCCACTGATTACACCTCATCCATCGAT  
GTTTGGTCAGCTGGCTGTGTACTGGCAGAGCTCCTCTTGGGCCAGCCCATCTTCCCTGGG  
GACAGTGGGGTGGACCAGCTGGTGGAGATCATCAAGGTGCTGGGAACACCAACCCGGGAA  
CAAATCCGAGAGATGAACCCCAACTACACGGAGTTCAAGTTCCTCAGATTAAAGCTCAC  
CCCTGGACAAAGGTGTTCAAATCTCGAACGCCGCCAGAGGCCATCGCGCTCTGCTCTAGC  
CTGCTGGAGTACACCCCATCCTCAAGGCTCTCCCCACTAGAGGCCTGTGCGCACAGCTTC  
TTTGATGAACTGCGATGTCTGGGAACCCAGCTGCCTAACAACCGCCCACTTCCCCCTCTC  
TTCAACTTCAGTGCTGGTGAACCTCTCCATCCAACCGTCTCTCAACGCCATTCTCATCCCT  
CCTCACTTGAGGTCCCCCAGCGCACTACCACCCTCACCCCGTCTCACAAGCTTTAACT  
GAGACTCCGACCAGCTCAGACTGGCAGTCGACCGATGCCACACCTACCCTCACTAACTCC  
TCCTGAGGGCCCCACCAAGCACCTTCCACTTCCATCTGGGAGCCCCAAGAGGGCGTGGG  
AAGGGGGGCCATAGCCCATCAAGCTCCTGCCCTGGCTGGGCCCCCTAGACTAGAGGGCAGA  
GGTAAATGAGTCCCTGTCCCCACCTCCAGTCCCTCCCTCACCAGCCTCACCCCTGTGGTG  
GGCTTTTTTAAGAGGATTTTAACTGGTTGTGGGGAGGGAAGAGAAGGACAGGGTGTGGGG  
GGATGAGGACCTCCTACCCCTTGGCCCCCTCCCTCCCCCAGACCTCACCTCCTCCAG  
ACCCCTCCCCCTCCTGTGTCCCTTGTAATAGAACCAGCCAGCCCGTCTCCTCTTCCCT  
TCCCTGGCCCCCGGGTGTAAATAGATTGTTATAATTTTTTTCTTAAAGAAAACGTCGATT  
CGCACCGTCCAACCTGCCCGCCCCCTCCTACAGCTGTAACCTCCCTCCTGTCTCTGCCC  
CCAAGGTCTACTCCCTCCTCACCCACCTGGAGGGCCAGGGGAGTGGAGAGAGCTCCTG  
ATGTCTTAGTTTCCACAGTAAGGTTTGCCTGTGTACAGACCTCCGTTCAATAAATTATTG  
GCATGAAAA

>gi|11995474|gb|NP\_063937.1|GSK3A 483aa linear glycogen  
synthase kinase 3 alpha [Homo sapiens].  
MSGGGPSGGGPGGSGRARTSSFAEPGGGGGGGGGGPGGGSASGPGGTGGGKASVGAMGGGV  
GASSSGGGPGGSGGGGSGGPGAGTSFPPPGVKLRD SGKVTTVVATLGQGPERSQEVAYT  
DIKVI GN SFGV VYQARLAETRELVAIKKVLQDKRFKNRELQIMRKL DHCNIVRLRYFFY  
SSGEKKDELYLNLVLEYVPETVYRVARHFTKAKLTIPILYVKVYMYQLFRSLAYIHSQGV  
CHRD IKPQNLLVDPDTAVLKLCDFGSAKQLVRGEPNVS YICSRYYRAPELIFGATDYTSS  
IDVWSAGCVLAELLLGQPIFPGDSGVDQLVEI IKVLGTPTREQIREMNP NYTEFKFPQIK

- 102 -

AHPWTKVFKSRTTPPEAIALCSSLLEYTPSSRLSPLEACAHSFFDELRLCLGTQLPNNRPLP  
PLFNFSAGELSIQPSLNAILIPPHLRSPSGTTTLTPSSQALTETPTSSDWQSTDATPTLT  
NSS

>gi|7019350|gb|NM\_013246.1|CLC 1689bp mRNA Homo sapiens  
cardiotrophin-like cytokine (CLC), mRNA.

GCCTCCGGGAGAGGAGCCGCACCCGGCCGGCCCGGCCCCAGCCCCATGGACCTCCGAGCA  
GGGGA CTCTCGTGGGGGATGTTAGCGTGCCTGTGCACGGTGCTCTGGCACCTCCCTGCAGTG  
CCAGCTCTCAATCGCACAGGGGACCCAGGGCCTGGCCCCCTCCATCCAGAAAACCTATGAC  
CTCACCCGCTACCTGGAGCACCAACTCCGCAGCTTGCTGGGACCTATCTGAACTACCTG  
GGCCCCCCTTTCAACGAGCCAGACTTCAACCCCTCCCCGCTGGGGGCAGAGACTCTGCCC  
AGGGCCACTGTTGACTTGAGGTGTGGCGAAGCCTCAATGACAAACTGCGGCTGACCCAG  
AACTACGAGGCCTACAGCCACCTTCTGTGTTACTTGCGTGGCCTCAACCGTCAGGCTGCC  
ACTGCTGAGCTGCGCCGCAGCCTGGCCCACTTCTGCACCAGCCTCCAGGGCCTGCTGGGC  
AGCATTGCGGGCGTCATGGCAGCTCTGGGCTACCCACTGCCCCAGCCGCTGCCTGGGACT  
GAACCCACTTGGA CTCTGGCCCTGCCACAGTGACTTCTCCAGAAGATGGACGACTTC  
TGGCTGCTGAAGGAGCTGCAGACCTGGCTGTGGCGCTCGGCCAAGGACTTCAACCGGCTC  
AAGAAGAAGATGCAGCCTCCAGCAGCTGCAGTCACCCTGCACCTGGGGGCTCATGGCTTC  
TGACTTCTGACCTTCTCCTCTTCGCTCCCCCTTCAAACCTGCTCCCACTTTGTGAGAGC  
CAGCCCTGTATGCCAACACCTGTTGAGCCAGGAGACAGAAGCTGTGAGCCTCTGGCCCTT  
TCCTGGACCGGCTGGGCGTGTGATGCGATCAGCCCTGTCTCCTCCCCACCTCCCAAAGGT  
CTACCGAGCTGGGGAGGAGGTACAGTAGGCCCTGTCTCTGCTCTTCTACAGGAAGTCA  
TGCTCGAGGGAGTGTGAAGTGGTTTCAAGTTGGTGCAGAGGCGCTCATGGCCTCCTGCTTC  
TTGCCTACCACTTGGCCAGTGCCCAACCCAGCCCCCTCAGGTGGCACATCTGGAGGGCAGGG  
GTTGAGGGGGCCACCACCACACATGCCTTTCTGGGGTGAAGCCCTTTGGCTGCCCCACTCT  
CCTTGATGGGTGTTGCTCCCTTATCCCCAAATCACTCTATACATCCAATTCAGGAAACA  
AACATGGTGGCAATTCTACACAAAAAGAGATGAGATTAACAGTGCAGGGTTGGGGTCTGC  
ATTGGAGGTGCCCTATAAACCAGAAGAGAAAAATACTGAAAGCACAGGGGCAGGGACAGAC  
CAGACCAGACCCAGGAGTCTCAAAGCACAGAGTGGCAAACAAAACCCGAGCTGAGCATC  
AGGACCTTGCCCTCGAATTGTCTTCCAGTATTACGGTGCCTCTTCTCTGCCCCCTTTCCCA  
GGGTATCTGTGGGTTGCCAGGCTGGGGAGGGCAACCATAGCCACACCACAGGATTTCTTG  
AAAGTTTACAATGCAGTAGCATTTTGGGGTGTAGGGTGGCAGCTCCCCAAGGCCCTGCCC  
CCCAGCCCCACCCACTCATGACTCTAAGTGTGTTGTATTAATATTTATTTATTTGGAGAT  
GTTATTTATTAGATGATATTTATTGCAGAATTTCTATTCTTGTATTAACAAATAAAATGC  
TTGCCCCAG

>gi|7019351|gb|NP\_037378.1|CLC 225aa linear cardiotrophin-like  
cytokine; neurotrophin-1/B-cell stimulating factor-3 [Homo  
sapiens].

MDLRAGDSWGM LACLCTVLWHLPAVPALNRTGDPGPGPSIQKTYDLTRYLEHQLRSLAGT  
YLN YLGPPFNEP DFNPPRLGAETLPRATVDLEVWRS LNDKLR L TQNYEAYSHLLCYLRGL  
NRQAATAELRRSLAHFCTSLQGLLGSIAGVMAALGYPLPQPLPGTEPTWTPGPAHSDFLQ  
KMDDFWLLKELQTWLWRS AKDFNRLKKKMOPPA AVTLHLGAHGF

>gi|22068574|gb|XM\_036493.3|ZNF213 3073bp mRNA Homo sapiens  
zinc finger protein 213 (ZNF213), mRNA.

GGCCTCTGGCCGCTGGCTCCAACATCAAGCACCGGGCTCCGAGTGGCCGGGATCAGCGC  
CCCGAGGCAGAGGCCGGAGGGCGCGCGCACTGCTAGGAAGTGTGGTCCCCCGCGCCGCT  
CTGCCAGCTTGGTCCCCCGGCAGACGCCCTGTACGATCGCCGCTCGCCCCGCGGGCGAG  
GCTGCGGTGGACAGCGCGGGGCTCCGGCTGGCTCGCCTTCCCGCTGCCGTGTCTGCTG

- 103 -

AGCGACCCTGGAGTACACATCCAGATGCCAGCCAGCTACCAACAGGGGATCCCTCTGGGA  
GACTGAAAGTACAGGTTCTGGGGCCAGGTTGAAGCCGACCAACCCTGAGCCTCAGGCCA  
GGGGAATGGCAGCCCCCTTGAGGCCCAGGACCAGGCCCTGGGGAGGGAGAAGGGCTTC  
TGATTGTGAAAGTGGAAGATTCCTCCTGGGAACAGGAATCTGCCCAGCATGAGGATGGCA  
GGGATTCCGAAGCCTGCCGCCAGCGCTTCCGGCAATTCTGCTACGGGGATGTGCATGGGC  
CTCATGAGGCCTTCAGCCAGCTCTGGGAGCTCTGCTGCCGCTGGCTGCGGCCCGAGCTGC  
GTACCAAGGAGCAGATCCTGGAGCTGCTGGTGCTGGAGCAGTTCTTGACAGTGCTGCCAG  
GGGAGATCCAGGGCTGGGTGCGTGAGCAGCACCCGGGAAGCGGTGAGGAGGCTGTGCGCT  
TGGTGGAGGACCTACAGAAGCAGCCAGTGAAAGCCTGGCGACAGGATGTGCCCTCGGAGG  
AGGCGGAACCCGAGGCTGCAGGCCGGGGATCCAGGCCACGGGGCCTCCCCGACGGTGG  
GGGCACGGAGGCGGCCGTCTGTTCCCCAGGAGCAGCACAGCCATAGCGCCCAGCCTCCTG  
CTCTTCTTAAAGAGGGTCGTCCCGGAGAGACGACGGACACCTGCTTTGTCTCTGGGGTCC  
ATGGACCTGTGGCATTGGGAGACATCCCAATTCTATTTCTCCCGGGAAGAATGGGGCACCC  
TGGACCCTGCTCAGCGGGATCTCTTCTGGGACATAAAGCGGGAGAAGTCCCGGAACACCA  
CCCTGGGTTTGGGCTCAAAGGCCAAAGTGAGAAGTCCCTGCTGCAGGAGATGGTGCCGG  
TGGTGCCAGGCCAGACAGGCAGCGACGTGACTGTGTCTTGAGCCCCGAGGAGGCTGAGG  
CCTGGGAGAGCGAGAACC GGCCGAGGGCGGCCCTGGGCCAGTGGTGGGCGCGCGACGGG  
GGCGGCCACCCACTCGCCGGCGCCAGTTCCGGGACCTGGCAGCCGAGAAGCCGCACAGCT  
GCGGGCAGTGTGAAAGCGCTTCCGCTGGGGCTCGGACCTGGCGCGGCACCAGCGCACGC  
ACACGGGCGAGAAGCCACACAAGTGCCCTGAGTGCGACAAGAGCTTCCGCAGCTCCTCGG  
ACCTGGTGCGCCACCAAGGCGTGACACAGGGCGAGAAGCCCTTCTCCTGTTCCGAGTGCG  
GCAAGAGCTTCAGCCGCAGCGCCTACCTGGCCGACCACCAGCGCATACACACGGGCGAGA  
AGCCTTTTCGGCTGCAGCGACTGCGGCAAGAGCTTCTCGCTGCGCTCCTACCTGCTGGACC  
ATCGGCGTGTGCACACCGGTGAGCGGCCCTTTCGGCTGCGGAGAGTGCGACAAGAGCTTCA  
AGCAGCGCGCGCACCTCATCGCGCATCAGAGCCTGCACGCCAAGATGGCCCAGCCCGTGG  
GGTGAGCAGCTGGCTTGGCCGGAACCCGGGGGAGGCCAGCCACGGCACATCCTGCTTT  
GTTCAACCACTGGGACTCTCCTTCCATCTGTGGCCACCTCCCGGGCTGTCCGAGGGACCCC  
AGGGTACCTCACACTCGGAGCTCGCCTGCCCTGCTTGGCTCTGAGGACCTGCCCAGCGCT  
CAAAGGGAACGGAAGCCTTCCCCCTCCCGCCCCGATCTTGTCCTCTTTCCCCCTTCTGCG  
CCTAGCGTTCTCTTCCCCCTCTAGTTTCTTGAGCCCCAACACATTCTTGCGAGGGACAG  
CAGGGTGGCAAGGACTCAGGTCTAGGTCCCTTCCAGAAAGCCCCGAGCCTCATTTGACT  
GTGTGGCTCTTTGGCCCCCACCCTGTGGGGTGGGTCCATGGGTGAGGCTCTGCCCTACC  
AACCTGTGCCTTTAGTGGGCGTGAGGACTGGCCTTGGCCCCCAGGGGGCTGTGGAC  
TTTGGGAGAGACAGCCACACCTGTGGGACCGCGGGTCTTAGTCACGGCGGCAGGGGCTT  
TCTGGCCCCCTCCCACTCCCGTTTCCAGGCCATGACCACTCTGCCCTGTCTGGCCATAC  
GGACTCGGCCTGCCTTTGCCCTCGGCCTACTTGCCCTAGCATGAGGCTCTGAGAGCCACC  
TGCCCAACCAATCTGGTGAGGATAATGGTGGCTCCAGCGACAGGAGGCCAACCCCTGGAGAC  
CAAGAACAGGGCGCCTGGCTGCCATCTTTTCTCCTCAGAGGTGGGGCTGCACCAGACTCAG  
CACTAGCACTCCATCAGCACTAGCACCTCACTCCATCAGCACTAGCACCTCACTCCATCG  
GCCCCGGCACCCCTGCTCCATCGGCCTGGCGCCCTGCTCCATCGGCACTAATGCTCCACT  
CGGCGCCCCACTCCATCGGCCCCGCTCCATCGGCACTAATGCCCCACTCGGCGCCCCACT  
CCATCAGCACTAATGCTCCACTCCATTGGCACTAACGCCCCAACTCCAGCGGCCTAATG  
ACCCGCTCCTTTGACATTGGTGCCCCACTCCATCAGCACTAACGCCCCGCTCCATCGGCA  
CTGGTGTCCCACTCCATTGTCACTAACGTCCGGCTCCATCGGCACTACCACCCCGCTCCA  
TCATCACTATGTCCAGCTCCGTCCGCACTACCACCCTGCTCCATCATCACTACGTCCAGC  
TCCAACGGCACTGGTGCCCCATTCATCGGCACTAACGCCCCGCTCCACCGGCACCAGTG  
CCTCGCTCCATTGGCACCAACGCCAGCTCCACCGGTACTGGCTCCCTGCTCCATCGGCA

- 104 -

CTAACGCCCTGCT

>gi|14777854|gb|XP\_036493.1|ZNF213 459aa linear similar to  
Zinc finger protein 213 (Putative transcription factor CR53)  
[Homo sapiens].

MAAPLEAQDQAPGEGEGLLIVKVEDSSWEQESAQHEDGRDSEACRQRFRQFCYGDVHGP  
EAFSQLWELCCRWLRPELRTKEQILELLVLEQFLTVPGEIQGWVREQHPGSGEEAVALV  
EDLQKQPVKAWRQDVPSEEAPEEAAGRGSQATGPPPTVGARRRPSVPQEQHSHSAQPPAL  
LKEGRPGETTTDTCFVSGVHGPVALGDI PFYFSREEWGTLDPAQORDLFWDIKRENSRNTTL  
GFGLKGQSEKSLLOEMVPVVPVPGQTGSDVTVSWSPEEAEAWESNRPRALGPVVGARRGR  
PPTRRRQFRDLAAEKPHSCGQCGRFRWGSDLARHQRTHTGEKPHKCPEC DKSFSSDL  
VRHQGVHTGEKPFSCSECGKSFSRSAYLADHQRIHTGEKPFGCSDCGKSFSLSYLLDHR  
RVHTGERPFGCGECDKSFQRAHLIAHQSLHAKMAQPVG

>gi|21536281|gb|NM\_003656.3|CAMK1 1501bp mRNA Homo sapiens  
calcium/calmodulin-dependent protein kinase I (CAMK1), mRNA.  
GGAGAGAGCCGCGAGCCGAGCCGAGCCCCAGCTCCAGCAAGAGCGCGGGCGGGTGGCCC  
AGGCACGCAGCGGTGAGGACCGCGGCCACAGCTCGGCGCCAACCACCGCGGGCCTCCCAG  
CCAGCCCCGCGCGGGGCAGCCGAGGAGCCCTGGCTGTGGTTCGGGGGCGAGTGGGCCAT  
GCTGGGGGCGAGTGAAGGCCCCAGGTGGAAGCAGGCGGAGGACATTAGAGACATCTACGA  
CTTCCGAGATGTTCTGGGCACGGGGGCCTTCTCGGAGGTGATCCTGGCAGAAGATAAGAG  
GACGCAGAAGCTGGTGGCCATCAAATGCATTGCCAAGGAGGCCCTGGAGGGCAAGGAAGG  
CAGCATGGAGAATGAGATTGCTGTCTTGCAAGATCAAGCACCCCAACATTGTAGCCCT  
GGATGACATCTATGAGAGTGGGGGCCACCTCTACCTCATCATGCAGCTGGTGTGGGTGG  
GGAGCTCTTTGACCGTATTGTGGA AAAAGGCTTCTACACGGAGCGGGACGCCAGCCGCCT  
CATCTTCCAGGTGCTGGATGCTGTGAAATACCTGCATGACCTGGGCATTGTACACCGGGA  
TCTCAAGCCAGAGAATCTGCTGTACTACAGCCTGGATGAAGACTCCAAAATCATGATCTC  
CGACTTTGGCCTCTCCAAGATGGAGGACCCGGGCAGTGTGCTCTCCACCGCCTGTGGAAC  
TCCGGGATACGTGGCCCCTGAAGTCCTGGCCCAGAAGCCCTACAGCAAGGCTGTGGATTG  
CTGGTCCATAGGTGTCATCGCCTACATCTTGCTCTGCGGTTACCTCCCTTCTATGACGA  
GAATGATGCCAAACTCTTTGAACAGATTTTGAAGGCCGAGTACGAGTTTGACTCTCCTTA  
CTGGGACGACATCTCTGACTCTGCCAAAGATTTTCATCCGGCACTTGATGGAGAAGGACCC  
AGAGAAAAGATTACCTGTGAGCAGGCCTTGCAGCACCCATGGATTGCAGGAGATACAGC  
TCTAGATAAGAATATCCACCAGTCGGTGAGTGAGCAGATCAAGAAGAACTTTGCCAAGAG  
CAAGTGGAAGCAAGCCTTCAATGCCACGGCTGTGGTGCGGCACATGAGGAACTGCAGCT  
GGGCACCAGCCAGGAGGGGCAGGGGCAGACGGCGAGCCATGGGGAGCTGCTGACACCACT  
GGCTGGGGGGCCGGCAGCTGGCTGTTGCTGTGAGACTGCTGCGTGGAGCCGGGCACAGA  
ACTGTCCCCCACACTGCCCCACCAGCTCTAGGGCCCTGGACCTCGGGTCATGATCCTCTG  
CGTGGGAGGGCTTGGGGGCAGCCTGCTCCCCTTCCCTCCCTGAACCGGGAGTTTCTCTGC  
CCTGTCCCCTCCTCACCTGCTTCCCTACCACTCCTCACTGCATTTTCCATACAAATGTTT  
CTATTTTATTGTTCTTCTTGTAAATAAAGGGAAGATAAAACCAAAAAAAAAAAAAAAAAA  
A

>gi|4502553|gb|NP\_003647.1|CAMK1 370aa linear  
calcium/calmodulin-dependent protein kinase I [Homo sapiens].  
MLGAVEGPRWKQAEIRDIDYDFRDVLGTGAFSEVILAEDKRTQKLVAIKCIAKEALEGKE  
GSMENEIAVLHKIKHPNIVALDDIYESGGHLYLIMQLVSGGELFDRIIVEKGFYTERDASR  
LIFQVLDAVKYLHDLGIVHRDLKPENLLYSLDEDSKIMISDFGLSKMEDPGSVLSTACG  
TPGYVAPEVLAQKPYSKAVDCWSIGVIAIYILLCGYPFFYDENDAKLFEQILKAIEYFDSP  
YWDDISDSAKDFIRHLMKDPKRFTEQALQHPWIAGDTALDKNIHQSVSEQIKKNFAK

- 105 -

SKWKQAFNATAVVRHMRKLQLGTSQEGQGQTASHGELLTPVAGGPAAGCCCRDCCVEPGT  
ELSPTLPHQL

>gi|13186237|gb|NM\_023107.1|FGFR1 2590bp mRNA Homo sapiens  
fibroblast growth factor receptor 1 (fms-related tyrosine  
kinase 2, Pfeiffer syndrome) (FGFR1); transcript variant 5,  
mRNA.

CCTCTTGCGGCCACAGGCGCGGCGTCCTCGGCGGCGGGCGGCAGCTAGCGGGAGCCGGGA  
CGCCGGTGCAGCCGCAGCGCGCGGAGGAACCCGGGTGTGCCGGGAGCTGGGCGGCCACGT  
CCGGACGGGACCGAGACCCCTCGTAGCGCATTGCGGCGACCTCGCCTTCCCCGGCCGCGA  
GCGCGCCGCTGCTTGAAAAGCCGCGGAACCCAAGGACTTTTCTCCGGTCCGAGCTCGGGG  
CGCCCCGCAGGCGCACGGTACCCGTGCTGCAGTCGGGCACGCCGCGGCGCCGGGGGCTC  
CGCAGGGCGATGGAGCCGGTCTGCAAGGAAAGTGAGGCGCCGCGCTGCGTTCTGGAGGA  
GGGGGGCACAAGGTCTGGAGACCCCGGGTGGCGGACGGGAGCCCTCCCCCGCCCCGCCT  
CCGGGGCACCAGCTCCGGCTCCATTGTTCCCGCCCGGGCTGGAGGCGCCGAGCACCAGAC  
GCCGCGGGGAGTCGAGCGCCGGCCGCGGAGCTCTTGCGACCCCGCCAGGACCCGAACAGA  
GCCCGGGGGCGGCGGGCCGGAGCCGGGGACGCGGGCACACGCCCGCTCGCACAAAGCCACG  
GCGGACTCTCCCGAGGCGGAACCTCCACGCCGAGCGAGGGTCAGTTTGAAAAGGAGGATC  
GAGCTCACTGTGGAGTATCCATGGAGATGTGGAGCCTTGTCACCAACCTCTAACTGCAGA  
ACTGGGATGTGGAGCTGGAAGTGCCTCCTCTTCTGGGCTGTGCTGGTCACAGCCACACTC  
TGCACCGCTAGGCCGTCCCCGACCTTGCTGAACAAGATGCTCTCCCTCCTCGGAGGAT  
GATGATGATGATGATGACTCCTCTTCAGAGGAGAAAGAAACAGATAACACCAAACCAAAC  
CGTATGCCCGTAGCTCCATATTGGACATCCCCAGAAAAGATGGAAAAGAAAATTGCATGCA  
GTGCCGGCTGCCAAGACAGTGAAGTTCAAATGCCCTTCCAGTGGGACCCCAAACCCACAC  
CTGCGCTGGTTGAAAAATGGCAAAGAATTCAAACCTGACCACAGAATTGGAGGCTACAAG  
GTCCGTTATGCCACCTGGAGCATCATAATGGACTCTGTGGTGCCCTCTGACAAGGGCAAC  
TACACCTGCATTGTGGAGAATGAGTACGGCAGCATCAACCACACATACCAGCTGGATGTC  
GTGGAGCGGTCCCCTCACCGGCCCATCCTGCAAGCAGGGTTGCCCGCCAACAAAACAGTG  
GCCCTGGGTAGCAACGTGGAGTTCATGTGTAAGGTGTACAGTGACCCGCAGCCGCACATC  
CAGTGGCTAAAGCACATCGAGGTGAATGGGAGCAAGATTGGCCCAGACAACCTGCC'TTAT  
GTCCAGATCTTGAAGGTAATCATGGCACCAGTCTTCGTGGGCCAGTCTACTGGGAAGGAG  
ACCACTGTCTCGGGGGCTCAAGTTCTGTGGGCAGGCTCAGTTGCCCCCGAATGGGATCA  
TTCCTCACGCTTCAGGCACACACACTCCATCTCAGTAGGGATCTAGCCACATCCCCCAGG  
ACTAGTAACAGAGGTCACAAAGTGGAGGTGAGCTGGGAACAGAGGGCTGCAGGGATGGGT  
GGTGCTGGTCTGTAATAAGCTTTGAGAGCAACGTCAGTGGGGCTTTGGGGTCAGCTACAC  
AAGGAAGGCATTTGGACCCCTGCCTTTTCATTGCCCGAAACCAGAGCCTTTCCACCAAGC  
GTTTCCAGTCTTAGCCCTGTGTTCTGAGTTACGTACGATCTTTCTGGCAAATGGGGTGC  
ATGATAAGAGCATCTCTTACGAAGAGTTGGAAAAACAAATGCCATATATAAATTCTAAGC  
CATATGAGGACGAGGAGTAATGGCATTCTTCTCCTTTTTCTCTCACTCCCAGACATTCA  
TTGTCCCTGAATGCTCCATTAATCCAGGGAAGGTAATTGCCTAAATCTCCAGTGGATCTC  
GCAACAGGAAGGAACCAGAAGCTGGGAAAGTTGTTTACCTCTTTGTCCAGAGTTAGACC  
TCATCCTCCCCTAGCTTAGCTGTCTCAGAGATATACTGGCCCTCCCTTCTCTTCTTTG  
CTGCTGGTGCTAAAACTGCTCTGTAGGTCATTGGCCACTGTCTCCACTCACAACCCCTGC  
TCCAGTCTTGAGGGAGTGGGTAAACACAAATAGAACATTCCATTTGAAGCAGTGATTCT  
TTTTTTTTTTTTTTTTTTTTTAAATCAAATGCTTTGGACTTTTGAAGTCCACTTGTTCTGT  
ACTTGTAAGGGAAGGAAGGCGGGCGCAGTCGTCACGCCTGTAATCCCAGCACTTTAG  
ATCACTTGAGGTCAGGAGTTTGAGACCAGCCCGGCCAACATGGTGAAACCCCATCTCTAC  
TAAAAATACAAAAATTAGCTGTGCATAGTGGTTGGCACCTGTAGTCCCAGCTACTCAGGA

- 106 -

GGCTGAGGCAAGCTAACTGCTTGAACCCAGAAGGCAGAGGTTGCAGTGAGCTGAGATCAC  
GCCACTGCACTCCAGCCTGGGTGACAGAGTGAGTGAGACTCTGCGTTAAAAAAAAAAAAA  
AAAAAAAAAA

>gi|13186238|gb|NP\_075595.1|FGFR1 302aa linear fibroblast  
growth factor receptor 1 isoform 5 precursor; fms-related  
tyrosine kinase-2; heparin-binding growth factor receptor;  
FMS-like tyrosine kinase 2; basic fibroblast growth factor  
receptor 1; N-sam tyrosine kinase; FLG protein; protein-  
tyrosine kinase; tyrosylprotein kinase; hydroxyaryl-protein  
kinase [Homo sapiens].

MWSWKCLLFWAVLVTATLCTARPSPTLPEQDALPSSSEDDDDDDSSSEEKETDNTKPNRM  
PVAPYWTSPEKMEKKLHAVPAAKTVKFKCPSSGTPNPRTLRLKNGKEFKPDHRIGGYKVR  
YATWSIIMDSVVP SDKGN YTCIVENEYGSINHTYQLDVVERSPHRPILQAGLPANKTVAL  
GSNVEFMCKVYS DPQPHIQWLKHIEVNGSKIGPDNLPYVQILKVIMAPV FVGQSTGKETT  
VSGAQVPVGR LSCPRMGSFLTLQAHTLHL SRDLATSPRTSNRGHKVEVSWEQRAAGMGA  
GL

>gi|4758007|gb|NM\_004071.1|CLK1 1834bp mRNA Homo sapiens CDC-  
like kinase 1 (CLK1), mRNA.

ATTTT TAGATAATCATTAAAGACCACAGAAAATGTAACAGATCCTACTCTTCAAAATAAT  
TGCTATT CAGTATTA AACGAGCAGTCAGCTGCGTGATTCCCGTGATTGCGTTACAAGCT  
TTGTCTCCTTCGACTTGGAGTCTTTGTCCAGGACGATGAGACACTCAAAGAGAACTTACT  
GTCCTGATTGGGATGACAAGGATTGGGATTATGGAAAATGGAGGAGCAGCAGCAGTCATA  
AAAGAAGGAAGAGATCACATAGCAGTGCCCAGGAGAACAGCGCTGCAAATACAATCACT  
CTAAATGTGTGATAGCCATTATTTGGAAAGCAGGTCTATAAATGAGAAAGATTATCATA  
GTCGACGCTACATTGATGAGTACAGAAATGACTACACTCAAGGATGTGAACCTGGACATC  
GCCAAAGAGACCATGAAAGCCGGTATCAGAACCATAGTAGCAAGTCTTCTGGTAGAAGTG  
GAAGAAGTAGTTATAAAAGCAAACACAGGATTCACCACAGTACTTCACATCGTCGTTTAC  
ATGGGAAGAGTCACCGAAGGAAAAGAACAGGAGTGTAGAGGATGATGAGGAGGGTCACC  
TGATCTGT CAGAGTGGAGACGTACTAAGTGCAAGATATGAAATTGTTGATACTTTAGGTG  
AAGGAGCTTTTGGAAAAGTTGTGGAGTGCATCGATCATAAAGCGGGAGGTAGACATGTAG  
CAGTAAAAATAGTTAAAAATGTGGATAGATACTGTGAAGCTGCTCGCTCAGAAATACAAG  
TTCTGGAACATCTGAATACAACAGACCCCAACAGTACTTTCCGCTGTGTCCAGATGTTGG  
AATGGTTTGAGCATCATGGTCACATTTGCATTTGTTTTTGAAGTATTGGGACTTAGTACTT  
ACGACTTCATTAAAGAAAATGGTTTTCTACCATTTGCGACTGGATCATATCAGAAAGATGG  
CATATCAGATATGCAAGTCTGTGAATTTTTTGCACAGTAATAAGTTGACTCACACAGACT  
TAAAGCCTGAAAACATCTTATTTGTGCAGTCTGACTACACAGAGGCGTATAATCCCAAAA  
TAAACGTGATGAACGCACCTTAATAAATCCAGATATTAAAGTTGTAGACTTTGGTAGTG  
CAACATATGATGACGAACATCACAGTACATTGGTATCTACAAGACATTATAGAGCACCTG  
AAGTTATTTTAGCCCTAGGGTGGTCCCAACCATGTGATGTCTGGAGCATAGGATGCATTC  
TTATTGAATACTATCTTGGGTTTACCGTATTTCCAACACACGATAGTAAGGAGCATTTAG  
CAATGATGGAAAGGATTCTTGGACCTTACCAAAACATATGATACAGAAAACCAGGAAAC  
GTAAATATTTTCACCACGATCGATTAGACTGGGATGAACACAGTTCTGCCGGCAGATATG  
TTTCAAGAGCCTGTAAACCTCTGAAGGAATTTATGCTTTCTCAAGATGTTGAACATGAGC  
GTCTCTTTGACCTCATTCAGAAAATGTTGGAGTATGATCCAGCCAAAAGAATTACTCTCA  
GAGAAGCCTTAAAGCATCCTTTCTTTGACCTTCTGAAGAAAAGTATATAGATCTGTAATT  
GGACAGCTCTCTCGAAGAGATCTTACAGACTGTATCAGTCTAATTTTTTAATTTTAAGTT  
ATTTTGTACAGCTTTGTAAATTCTTAACATTTTTTATATTGCCATGTTTATTTTGTGGG

- 107 -

TAATTTGGTTCATTAAGTACATAGCTAAGGTAATGAACATCTTTTTTCAGTAATTGTAAAG  
TGATTTATTTCAGAATAAATTTTTTTGTGCTTATGA

>gi|4758008|gb|NP\_004062.1|CLK1 484aa linear CDC-like kinase  
1; protein tyrosine kinase STY [Homo sapiens].

MRHSKRTYCPDWDDKDWDYGKWRSSSSHKRRKRSHSSAQENKRCKYNHSMCDSHYLESR  
SINEKDYHSRRYIDEYRNDYTQGCEPGRHQRDHESTRYQNHSSKSSGRSGRSSYKSKHRIH  
HSTSHRRSHGKSHRRKRTRSVEDDEEGHLICQSGDVLRSARYEIVDTLGEGAFGKVVECID  
HKAGGRHVAVKIVKNVDRYCEAARSEIQVLEHLNNTTDPNSTFRVCVQMLEWFEHHGHIÇIV  
FELLGLSTYDFIKENGFLPFRDLHIRKMAYQICKSVNFLHSNKLTHTDLPENILFVQSD  
YTEAYNPKIKRDERTLINPDIKVDFGSATYDDEHHSTLVSTRHYRAPEVILALGWSQPC  
DVWSIGCILIEYYLGFTVFPTHDSKEHLAMMERILGPLPKHMIQKTRKRKYFHHDRLDWD  
EHSSAGRYVSRACKPLKEFMLSQDVEHERLFDLIQKMLEYDPAKRITLREALKHPFFDLL  
KKSI

>gi|20127640|gb|NM\_025128.2|MUS81 2352bp mRNA Homo sapiens  
MUS81 endonuclease (MUS81), mRNA.

GGCACGAGGGTCTCAAAGGCTGGCTGGAGTGGAGCCAAAGGAAAAGATCGTTAGAGACAG  
CGCCCTGACCAACCACTTAGAGCAGCGCAGGGGTGGGAGGGCGGCCGACGGCTCTCCTC  
TCGTTAGTGCCCCCTGTGTTTGGGGCCCCGTGATCTCAACGGTCTTGCCCTCGGTCTCCC  
TCTTCCCCCGCCCCGCCCTGGGCCAGGTGTTTGAATCCCGACTCCAGAACTGGCGGGCGTC  
CCAGTCCCGCGGGCGTGGAGCGCCGGAGGACCCGCCCTCGGGCTCATGGCGGGCCCCGGTC  
CGCCTGGGCGCGGAAGCGCCCGCTGCCTGCCTGTCCCAACCCGCTCTTCGTTCTGCTGGCTG  
ACCGAGTGGCGGGACGAGGCGACCCGACGAGGACCCGACGCGCTTCGTATTTTCAGAAG  
GCGCTGCGTTCCCTCCGACGGTACCCACTGCCGCTGCGCAGCGGGAAGGAAGCTAAGATC  
CTACAGCACTTTCGAGACGGGCTCTGCCGGATGCTGGACGAGCGGCTGCAGCGGCACCGA  
ACATCGGGCGGTGACCATGCCCCGGACTCACCATCTGGAGAGAACAGTCCAGCCCCGCAG  
GGGCGACTTGCGGAAGTCCAGGACTCTTCCATGCCAGTTCCTGCCAGCCCCAAAGCGGGA  
GGCTCTGGCAGCTACTGGCCAGCTCGGCACTCAGGAGCCCGAGTGATACTGCTGGTGCTC  
TACCGGGAGCACCTGAATCCTAATGGTCACTTCTTAACCAAGGAGGAGCTGCTGCAG  
AGGTGTGCTCAGAAGTCCCCCAGGGTAGCCCCCTGGGAGTGCCCCACCCTGGCCAGCCCTC  
CGCTCCCTCCTTCACAGGAACCTGGTCCTCAGGACACACCAGCCAGCCAGGTACTCATTTG  
ACCCAGAGGGCCTGGAGCTGGCCCAGAAGTTGGCCGAGTCAGAAGGCCTGAGCTTGCTG  
AATGTGGGCATCGGGCCCAAGGAGCCCCCTGGGGAGGAGACAGCAGTGCCAGGAGCAGCT  
TCAGCAGAGCTTGCCAGTGAAGCAGGGGTCCAGCAGCAGCCACTGGAGCTGAGGCCTGGA  
GAGTACAGGGTGCTGTTGTGTGTGGACATTGGCGAGACCCGGGGGGGCGGGCACAGGCCG  
GAGCTGCTCCGAGAGCTACAGCGGCTGCACGTGACCCACACGGTGCGCAAGCTGCACGTT  
GGAGATTTTGTGTGGGTGGCTCAGGAGACCAATCCTAGAGACCCAGCAAACCCTGGGGAG  
TTGGTACTGGATCACATTGTGGAGCGCAAGCGACTGGATGACCTTTGCAGCAGCATCATC  
GACGGCCGCTTCCGGGAGCAGAAGTTCGACTGAAGCGCTGTGGTCTGGAGCGCCGGGTA  
TACCTGGTGGAAGAGCATGGTTCCGTCCACAACCTCAGCCTTCCTGAGAGCACACTGCTG  
CAGGCTGTCACCAACACTCAGGTCATTGATGGCTTTTTTGTGAAGCGCACAGCAGACATT  
AAGGAGTCAGCCGCCTACCTGGCCCTCTTGACTCGGGGCCTGCAGAGACTCTACCAGGGC  
CACACCCTACGCAGCCGCCCTGGGGAACCCCTGGGAACCCTGAATCAGGGGCCATGACC  
TCTCCAAACCCTCTCTGCTCACTCCTCACCTTCAGTGACTTCAACGCAGGAGCCATCAAG  
AATAAGGCCCAGTCGGTGCGAGAAGTGTTTGGCCGGCAGCTGATGCAGGTGCGCGGAGTG  
AGTGGGGAGAAGGCAGCAGCCCTGGTGGATCGATACAGCACCCCTGCCAGCCTCCTGGCC  
GCCTATGATGCCTGTGCCACCCCCAAGGAACAAGAGACACTGCTGAGCACCATTAAAGTGT  
GGGCGTCTACAGAGGAATCTGGGGCCTGCTCTGAGCAGGACCTTATCCCAGCTCTACTGC



- 108 -

AGCTACGGCCCCCTTGACCTGAGCTTATGCCGTGAAACAGCCCCCAGCCCCCGTCTGTCCC  
CCAACCCAGGCTAGCCAGCCTTTTAACAACATCTTTTGGGGTACAATTAGAATCTAAGTG  
TTTGCAGCCATATGTGTCATGTAGAAGATGCCTAGCCCTGGGGACCTTGTGAAATACGCA  
GGAACCAGGGATACCATCTGGTCCAGTGGTTTTTAAACAAAGCTGCTTAGCACCTGGAAT  
TCCCTGGTCAGGGAGATGGAGTCAGTGGGGCATTGCAGCTTGAATCTATTTTATGTCAC  
CAGTTGGTCCTCATCAAATAAAATTTCTTAGGAGTGCAGAGGGCTCATTTGGGAAAAATAA  
AAATAATAAAAAATAAAACTTCCTAAAAGAAAAGATTGAAACCCAAAAAATAAAAAA  
AAAAAATAAAAAA

>gi|13376707|gb|NP\_079404.1|MUS81 476aa linear MUS81  
endonuclease [Homo sapiens].

MLDERLQRHRTSGGDHAPDSPSGENSPAPQGRLAEVQDSSMPVPAQPKAGGSGSYWPARH  
SGARVILLVLYREHLNPNNGHHFLTKEELLQRCQKSPRVAPGSAPPWPALRSLLHRNLVL  
RTHQPARYSLTPEGLELAQKLAESEGLSLLNVGIGPKEPPGEETA VPGAASAELASEAGV  
QQQPLELRPGEYRVLLCVDIGETRGGGHRPELLRELQRLHVHTHTVRKLHVGDFVWVAQET  
NPRDPANPGELVLDHIVERKRLDDLCSSIIDGRFREQKFRLLKRCGLERRVYLVVEEHGSVH  
NLSLPSTLLQAVTNTQVIDGFFVKRTADIKESAAYLALLTRGLQRLYQGHTLRSRPWGT  
PGNPESGAMTSPNPLCSLLTFSDFNAGAIKNKAQSVREVFARQLMQVRGVSGEKAALVD  
RYSTPASLLAAYDACATPKQEETLLSTIKCGRQLQRLNLPALSRTLSQLYCSYGPLT

>gi|19923239|gb|NM\_003376.2|VEGF 3166bp mRNA Homo sapiens  
vascular endothelial growth factor (VEGF), mRNA.

AAGAGCTCCAGAGAGAAGTCGAGGAAGAGAGAGACGGGGTCAGAGAGAGCGCGCGGGCGT  
GCGAGCAGCGAAAGCGACAGGGGCAAAGTGAGTGACCTGCTTTTGGGGGTGACCGCCGGA  
GCGCGGCGTGAGCCCTCCCCCTTGGGATCCCGCAGCTGACCAGTCGCGCTGACGGACAGA  
CAGACAGACACCGCCCCCAGCCCCAGTTACCACCTCCTCCCCGGCCGGCGGGCGGACAGTG  
GACGCGGGCGGCGAGCCGCGGGCAGGGGCCGAGCCCGCCCCCGGAGGCGGGGTGGAGGGG  
GTCGGAGCTCGCGGCGTCGCACTGAAACTTTTCGTCCAACCTTCTGGGCTGTTCTCGCTTC  
GGAGGAGCCGTGGTCCGCGCGGGGGAAGCCGAGCCGAGCGGAGCCGCGAGAAGTGCTAGC  
TCGGGCGGGGAGGAGCCGCGAGCCGAGGAGGGGGAGGAGGAAGAAGAGAAGGAAGAGGAG  
AGGGGGCCGCGAGTGGCGACTCGGCGCTCGGAAGCCGGGCTCATGGACGGGTGAGGCGGCG  
GTGTGCGCAGACAGTGCTCCAGCGCGCGCTCCCCAGCCCTGGCCCCGGCCTCGGGCCGG  
GAGGAAGAGTAGCTCGCCGAGGCGCCGAGGAGAGCGGGCCGCCCCACAGCCCGAGCCGGA  
GAGGGACGCGAGCCGCGCGCCCCGGTCCGGCCCTCCGAAACCATGAACCTTCTGCTGTCTT  
GGGTGCATTGGAGCCTTGCTTGCTGCTCTACCTCCACCATGCCAAGTGGTCCCAGGCTG  
CACCCATGGCAGAAGGAGGAGGGCAGAAATCATCAGCAAGTGGTGAAGTTCATGGATGTCT  
ATCAGCGCAGCTACTGCCATCCAATCGAGACCCTGGTGGACATCTTCCAGGAGTACCTTG  
ATGAGATCGAGTACATCTTCAAGCCATCCTGTGTGCCCTGATGCGATGCGGGGGCTGCT  
CCAATGACGAGGGCCTGGAGTGTGTGCCCACTGAGGAGTCCAACATCACCATGCAGATTA  
TGCGGATCAAACCTCACCAAGGCCAGCACATAGGAGAGATGAGCTTCTACAGCACACA  
AATGTGAATGCAGACCAAAGAAAGATAGAGCAAGACAAGAAAATCCCTGTGGGCCTTGCT  
CAGAGCGGAGAAAGCATTTTGTGTTGTACAAGATCCGCGAGACGTGTAAATGTTCTGCAAAA  
ACACACACTCGCGTTGCAAGGCGAGGCAGCTTGAGTTAAACGAACGTACTTGAGATGTG  
ACAAGCCGAGGCGGTGAGCCGGGCGAGGAGGAAGGAGCCTCCCTCAGGGTTTCGGGAACCA  
GATCTCTCTCCAGGAAAGACTGATACAGAACGATCGATACAGAAACACGCTGCCGCCAC  
CACACCATCACCATCGACAGAACAGTCCTTAATCCAGAAACCTGAAATGAAGGAAGAGGA  
GACTCTGCGCAGAGCACTTTGGGTCCGGAGGGCGAGACTCCGGCGGAAGCATTTCCGGGGC  
GGGTGACCCAGCACGGTCCCTCTTGGAATTGGATTCCGCCATTTTATTTTCTTGCTGCTA  
AATCACCGAGCCCGGAAGATTAGAGAGTTTTATTTCTGGGATTCCTGTAGACACACCCAC



- 109 -

CCACATACATACATTTATATATATATATATTATATATATATAAAAAATAAATATCTCTATT  
TTATATATATAAAATATATATATTCTTTTTTTTAAATTAACAGTGCTAATGTTATTGGTGT  
CTTCACTGGATGTATTTGACTGCTGTGGACTTGAGTTGGGAGGGGAATGTTCCCACTCAG  
ATCCTGACAGGGAAGAGGAGGAGATGAGAGACTCTGGCATGATCTTTTTTTTGTCCCACT  
TGGTGGGGCCAGGGTCCTCTCCCTGCCCAAGAATGTGCAAGGCCAGGGCATGGGGGCAA  
ATATGACCCAGTTTTTGGGAACACCGACAAACCCAGCCCTGGCGCTGAGCCTCTCTACCCC  
AGGTCAGACGGACAGAAAGACAAATCACAGGTTCCGGGATGAGGACACCGGCTCTGACCA  
GGAGTTTGGGGAGCTTCAGGACATTGCTGTGCTTTGGGGATTCCCTCCACATGCTGCACG  
CGCATCTCGCCCCCAGGGGCACTGCCTGGAAGATTGAGGAGCCTGGGCGGCCTTCGCTTA  
CTCTCACCTGCTTCTGAGTTGCCCAGGAGGCCACTGGCAGATGTCCCGGCGAAGAGAAGA  
GACACATTGTTGGAAGAAGCAGCCCATGACAGCGCCCCCTTCTGGGACTCGCCCTCATCC  
TCTTCCTGCTCCCCCTTCTGGGGTGCAGCCTAAAAGGACCTATGTCTCACACCATTGAA  
ACCACTAGTTCTGTCCCCCAGGAAACCTGGTTGTGTGTGTGTGAGTGGTTGACCTTCCT  
CCATCCCCTGGTCTTCCCTTCCCTTCCCGAGGCACAGAGAGACAGGGCAGGATCCACGT  
GCCCATTGTGGAGGCAGAGAAAAGAGAAAGTGTTTTATATACGGTACTTATTTAATATCC  
CTTTTTTAATTAGAAATTAGAACAGTTAATTTAATTAAAGAGTAGGGTTTTTTTTTTCAGTAT  
TCTTGTTAATATTTAATTTCAACTATTTATGAGATGTATCTTTTGCTCTCTCTTGCTCT  
CTTATTTGTACCGTTTTTTGTATATAAAATTCATGTTTCCAATCTCTCTCTCCCTGATCG  
GTGACAGTCACTAGCTTATCTTGAACAGATATTTAATTTTGCTAACACTCAGCTCTGCCC  
TCCCCGATCCCCTGGCTCCCCCAGCACACATTCCTTTGAAAGAGGGTTTCAATATACATCT  
ACATACTATATATATATTGGGCAACTTGTATTTGTGTGTATATATATATATATATGTTTA  
TGTATATATGTGATCCTGAAAAATAAACATCGCTATTCTGTTTTTTATATGTTCAAACC  
AAACAAGAAAAAATAGAGAATTCTACATACTAAATCTCTCTCCTTTTTTAATTTAATAT  
TTGTTATCATTTATTTATTTGGTGCTACTGTTTATCCGTAATAATTGTGGGGAAAAGATAT  
TAACATCACGTCTTTGTCTCTAGTGCAGTTTTTTCGAGATATTCCGTAGTACATATTTATT  
TTTAAACAACGACAAAGAAATACAGATATATCTTAAAAA

>gi|19923240|gb|NP\_003367.2|VEGF 191aa linear vascular  
endothelial growth factor [Homo sapiens].

MNFLLSWVHWSLALLLYLHHAKWSQAAPMAEGGGQNHHEVVKFMDVYQRSYCHPIETLVD  
IFQEYPDEIEYIFKPSCVPLMRCGGCSNDEGLECVPTESNITMQIMRIKPHQGQHIGEM  
SFLQHNKCECRPKKDRARQENPCGPCSERRKHLFVQDPQTCKCSCKNTHSRCKARQLELN  
ERTCRCDKPRR

>gi|16306545|gb|NM\_033649.1|FGF18 1466bp mRNA Homo sapiens  
fibroblast growth factor 18 (FGF18), transcript variant 2,  
mRNA.

CACGGCCGGAGAGACGCGGAGGAGGAGACATGAGCCGGCGGGCGCCAGACGGAGCGGCC  
GTGACGCTTTCGCGCTGCAGCCGCGCGCCCCGACCCCGGAGCGCTGACCCCTGGCCCCAC  
GCAGCTCCGCGCCCGGGCCGGAGAGCGCAACTCGGCTTCAGACCCGCGCGCATGCTGT  
CCCCGGACTGAGCCGGGCAGCCAGCCTCCACGGACGCCCCGGACGGCCGGCCGGCCAGCA  
GTGAGCGAGCTTCCCCGCACCGGCCAGGCGCCTCCTGCACAGCGGCTGCCGCCCCGCAGC  
CCCTGCGCCAGCCCGGAGGGCGCAGCGCTCGGGAGGAGCCGCGCGGGGCGCTGATGCCGC  
AGGGCGCGCCGCGGAGCGCCCCGGAGCAGCAGAGTCTGCAGCAGCAGCAGCCGGCGAGGA  
GGGAGCAGCAGCAGCGGCGGCGGCGGCGGCGGCGGCGGCGGAGGCGCCCGGTCCCGGCCG  
CGCGGAGCGGACATGTGCAGGCTGGGCTAGGAGCCGCGCCTCCCTCCCGCCAGCGATG  
TATTCAGCGCCCTCCGCTGCACTTGCTGTGTTTACACTTCCTGCTGCTGTGCTTCCAG  
GTACAGGTGCTGGTTGCCGAGGAGAACGTGGACTTCCGCATCCACGTGGAGAACCAGACG  
CGGGCTCGGGACGATGTGAGCCGTAAGCAGCTGCGGCTGTACCAGCTCTACAGCCGGACC

- 110 -

AGTGGGAAACACATCCAGGTCCTGGGCCGCGAGGATCAGTGCCCGCGGCGAGGATGGGGAC  
AAGTATGCCCAGCTCCTAGTGGAGACAGACACCTTCGGTAGTCAAGTCCGGATCAAGGGC  
AAGGAGACGGAATTCTACCTGTGCATGAACCGCAAAGGCAAGCTCGTGGGGAAGCCCGAT  
GGCACCAGCAAGGAGTGTGTGTTTCATCGAGAAGGTTCTGGAGAACAACCTACACGGCCCTG  
ATGTCGGCTAAGTACTCCGGCTGGTACGTGGGCTTCACCAAGAAGGGGCGGCCGCGGAAG  
GGCCCAAGACCCGGGAGAACCAGCAGGACGTGCATTTCATGAAGCGCTACCCCAAGGGG  
CAGCCGGAGCTTCAGAAGCCCTTCAAGTACACGACGGTGACCAAGAGGTCCCGTCGGATC  
CGGCCACACACCCTGCCTAGGCCACCCCGCCGCGGCCCTCAGGTCGCCCTGGCCCACT  
CACTCCAGAAAACCTGCATCAGAGGAATATTTTACATGAAAAATAAGGATTTTATTG  
TTGACTTGAAACCCCGATGACAAAAGACTCACGCAAAGGGACTGTAGTCAACCCACAGG  
TGCTTGCTCTCTCTAGGAACAGACAACCTCTAACTCGTCCCCAGAGGAGGACTTGAATG  
AGGAAACCAACACTTTGAGAAACCAAAGTCCTTTTCCCAAAGGTTCTGAAAGGAAAAA  
AAAAAAAAACAAAAA

>gi|16306546|gb|NP\_387498.1|FGF18 207aa linear fibroblast  
growth factor 18 precursor [Homo sapiens].  
MYSAPSACTCLCLHFLLLCFQVQVLVAEENVDFRIHVENQTRARDDVSRKQLRLYQLYSR  
TSGKHIQVLGRRISARGEDGDKYAQLLVETDTFGSQVRIKGKETEFYLCMNRKGKLVGKP  
DGTSKECVFIEKVLNNYTALMSAKYSGWYVGFTKKGRPRKGPKTRENQQDVHFMKRYPK  
GQPELQKPFKYTTVTKRSRRI RPTHPA

>gi|24496766|gb|NM\_004712.3|HGS 2926bp mRNA Homo sapiens  
hepatocyte growth factor-regulated tyrosine kinase substrate  
(HGS), mRNA.

CGGAAGCGGAAGTCGGGGGGCGCGCCAGCTCGTAGCAGGGGAGCGCCCGCGGCGTCGGGT  
TTGGGCTGGAGGTCGCCATGGGGCGAGGCAGCGGCACCTTCGAGCGTCTCCTAGACAAGG  
CGACCAGCCAGCTCCTGTTGGAGACAGATTGGGAGTCCATTTTGCAGATCTGCGACCTGA  
TCCGCCAAGGGGACACACAAGCAAAATATGCTGTGAATTCCATCAAGAAGAAAGTCAACG  
ACAAGAACCCACACGTCGCCTTGTATGCCCTGGAGGTCATGGAATCTGTGGTAAAGAACT  
GTGGCCAGACAGTTTCATGATGAGGTGGCCAACAAGCAGACCATGGAGGAGCTGAAGGACC  
TGCTGAAGAGACAAGTGGAGGTAAACGTCCGTAACAAGATCCTGTACCTGATCCAGGCCT  
GGGCGCATGCCTTCCGGAACGAGCCCAAGTACAAGGTGGTCCAGGACACCTACCAGATCA  
TGAAGGTGGAGGGGCACGTCTTTCCAGAATTCAAAGAGAGCGATGCCATGTTTGCTGCCG  
AGAGAGCCCCAGACTGGGTGGACGCTGAGGAATGCCACCGCTGCAGGGTGCAGTTCCGGG  
TGATGACCCGTAAGCACCCTGCCGGGCGTGTGGGCAGATATTCTGTGGAAAGTGTTCTT  
CCAAGTACTCCACCATCCCCAAGTTTGGCATCGAGAAGGAGGTGCGCGTGTGTGAGCCCT  
GCTACGAGCAGCTGAACAGGAAAGCGGAGGGAAAGGCCACTTCCACCACTGAGCTGCCCC  
CCGAGTACCTGACCAGCCCCCTGTCTCAGCAGTCCAGCTGCCCCCAAGAGGGACGAGA  
CGGCCCTGCAGGAGGAGGAGCTGCAGCTGGCCCTGGCGCTGTCACAGTCAGAGGCGG  
AGGAGAAGGAGAGGCTGAGACAGAAGTCCACGTACACTTCGTACCCCAAGGCGGAGCCCA  
TGCCCTCGGCCTCCTCAGCGCCCCCGCCAGCAGCCTGTACTCTTACCTGTGAACTCGT  
CGGCGCCTCTGGCTGAGGACATCGACCCTGAGCTCGCACGGTATCTCAACCGGAACTACT  
GGGAGAAGAAGCAGGAGGAGGCTCGCAAGAGCCCCACGCCATCTGCGCCCGTGCCCTGA  
CGGAGCCGGCTGCACAGCCTGGGGAAGGGCACGCAGCCCCACCAACGTGGTGGAGAACC  
CCCTCCCGGAGACAGACTCTCAGCCCATTCCTCCCTCTGGTGGCCCCCTTTAGTGAGCCAC  
AGTTCACAAATGGCGAGTCTGAGGAGAGCCACGAGCAGTTCCTGAAGGCGCTGCAGAACG  
CCGTCAACACCTTCGTGAACCGCATGAAGAGTAACCACATGCGGGGCGCAGCATCACCA  
ATGACTCGGCCGTGCTCTCACTCTTCCAGTCCATCAACGGCATGCACCCGAGCTGCTGG  
AGCTGCTCAACCAGCTGGACGAGCGCAGGCTGTACTATGAGGGGCTGCAGGACAAGCTGG

- 111 -

CACAGATCCGCGATGCCCCGGGGGGCGCTGAGTGCCCTGCGCGAAGAGCACCGGGAGAAGC  
TTCGCCGGGGCAGCCGAGGAGGCAGAGCGCCAGCGCCAGATCCAGCTGGCCCAGAAGCTGG  
AGATAATGCGGCAGAAGAAGCAGGAGTACCTGGAGGTGCAGAGGCAGCTGGCCATCCAGC  
GCCTGCAGGAGCAGGAGAAGGAGCGGCAGATGCGGCTGGAGCAGCAGAAGCAGACGGTCC  
AGATGCGCGCGCAGATGCCCCGCTTCCCCCTGCCCTACGCCAGCTCCAGGCCATGCCCCG  
CAGCCGGAGGTGTGCTCTACCAGCCCTCGGGACCAGCCAGCTTCCCCAGCACCTTCAGCC  
CTGCCGGCTCGGTGGAGGGCTCCCCAATGCACGGCGTGTACATGAGCCAGCCGGCCCCCTG  
CCGCTGGCCCCCTACCCCAGCATGCCCAGCACTGCGGCTGATCCCAGCATGGTGAGTGCCCT  
ACATGTACCCAGCAGGGGGCCACTGGGGCGCAGGCGGCCCCCCCCAGGCCCAGGCCGGACCCA  
CCGCCAGCCCCGCTTACTCATCCTACCAGCCTACTCCCACAGCGGGCTACCAGAACGTGG  
CCTCCCAGGCCCCACAGAGCCTCCCGGCCATCTCTCAGCCTCCGCAGTCCAGCACCATGG  
GCTACATGGGGAGCCAGTCAGTCTCCATGGGCTACCAGCCTTACAACATGCAGAATCTCA  
TGACCACCTTCCCAAGCCAGGATGCGTCTCTGCCACCCCAGCAGCCCTACATCGCGGGGC  
AGCAGCCCATGTACCAGCAGATGGCACCCTCTGGCGGTCCCCCCCCAGCAGCAGCCCCCG  
TGGCCCAGCAACCGCAGGCACAGGGGCCCGCGGCACAGGGCAGCGAGGCCAGCTCATTT  
CATTGACTGACCCAGGCCATGCTCACGTCCGGAGTAACACTACATACAGTTTACCTGAA  
ACGCCTCGTCTCTAACTGCCGTGCTCCTGCCTCCCTGTCCTCTACTGCCGGTAGTGTCCC  
TTCTCTGCGAGTGAGGGGGGGCCTTCACCCCAAGCCACCTCCCTTGTCTCAGCCTACT  
GCAGTCCCTGAGTTAGTCTCTGCTTCTTTCCCCAGGGCTGGGCCATGGGGAGGGAAGGA  
CTTTCTCCCAGGGGAAGCCCCCAGCCCTGTGGGTCTGGTCTGTGAGAGGTGGCAGGAAT  
GGGGACCTCACCCCCCAAGCAGCCTGTGCCCTCTGGCCGCACTGTGAGCTGGCTGTGGT  
GTCTGGGTGTGGCTGGGGCTCCCTCTGCAGGGGCCTCTCTCGGCAGCCACAGCCAAGGG  
TGGAGGCTTCAGGTCTCCAGCTTCTCTGCTTCTCAGCTGCCATCTCCAGTGCCCCAGAAT  
GGTACAGCGATAATAAAATGTATTTTCAAAAAAAAAAAAAAAAAAAAAA

>gi|4758528|gb|NP\_004703.1|HGS 777aa linear hepatocyte growth  
factor-regulated tyrosine kinase substrate; human growth  
factor-regulated tyrosine kinase substrate [Homo sapiens].

MGRGSGTFRLLDKATSQLLLETDWESILQICDLIRQDGTQAKYAVNSIKKKVNDKNPHV  
ALYALEVMESVVKNCQTVHDEVANKQTMEECLKDLLKRQVEVNVRNKILYLIQAWAHAFR  
NEPKYKVVDQTYQIMKVEGHVFPFESDAMFAAERAPDWVDAEECHRCRVQFGVMTRKH  
HCRACGQIFCGKCSSKYSTIPKFGIEKEVRVCEPCYEQLNLRKAEGKATSTTELPPEYLTS  
PLSQQSQQLPPKRDETALQEEEEELQALALSQSEAEKERLRQKSTYTSYPKAEPMPSSASS  
APPASSLYSSPVNSSAPLAEDIDPELARYLNRNYWEKKQEEARKSPTPSAPVPLTEPAAQ  
PGEGHAAPTNNVENPLPETDSQPIPPSGGPFSEPQFHNGESEESHEQFLKALQNAVTTFV  
NRMKSNHMRGRSITNDSAVLSLFSINGMHPQLLELLNQLDERRLYEGLQDKLAQIRDA  
RGALSALREEHREKLRRAAEEAERQRQIQLAQKLEIMRQKKQEYLEVQRQLAIQRLQEQE  
KERQMRLEQQKQTVQMRQMPAFPLPYAQLQAMPAAGGVLYQPSGPASFPSTFSPAGSVE  
GSPMHGVYMSQPAPAAGPYPSMPSTAADPSMVSAYMYPAGATGAQAAPQAQAGPTASPAY  
SSYQPTPTAGYQNVASQAPQSLPAISQPPQSSTMGYMGSSQSVSMGYQPYNMQNLMTTLPS  
QDASLPPQQPYIAGQQPMYQQMAPSGGPPQQQPPVAQQPQAQGPQAQSEAQLISFD

>gi|20127435|gb|NM\_003821.2|RIPK2 1898bp mRNA Homo sapiens  
receptor-interacting serine-threonine kinase 2 (RIPK2), mRNA.  
GGCACGAGGGTCAGCTCTGGTTCGGAGAAGCAGCGGCTGGCGTGGGCCATCCGGGGAATG  
GGCGCCCTCGTGACCTAGTGTTCGGGGGCAAAAAGGGTCTTGCCGGCCTCGCTCGTGCGAG  
GGGCGTATCTGGGCGCCTGAGCGCGGCGTGGGAGCCTTGGGAGCCGCCGCAGCAGGGGGC  
ACACCCGGAACCGGCCTGAGCGCCCGGGACCATGAACGGGGAGGCCATCTGCAGCGCCCT  
GCCACCATTCCTACCACAACTCGCCGACCTGCGCTACCTGAGCCGCGGCGCCTCTGG

- 112 -

CACTGTGTCGTCCGCCCGCCACGCAGACTGGCGCGTCCAGGTGGCCGTGAAGCACCTGCA  
CATCCACACTCCGCTGCTCGACAGTGAAAGAAAGGATGTCTTAAGAGAAGCTGAAATTTT  
ACACAAAGCTAGATTTAGTTACATTCTTCCAATTTTGGGAATTTGCAATGAGCCTGAATT  
TTTGGGAATAGTTACTGAATACATGCCAAATGGATCATTAAATGAACTCCTACATAGGAA  
AACTGAATATCCTGATGTTGCTTGGCCATTGAGATTTTCGCATCCTGCATGAAATTGCCCT  
TGGTGTAATACCTGCACAATATGACTCCTCCTTTACTTCATCATGACTTGAAGACTCA  
GAATATCTTATTGGACAATGAATTTTCATGTTAAGATTGCAGATTTTGGTTTATCAAAGTG  
GCGCATGATGTCCCTCTCACAGTCACGAAGTAGCAAATCTGCACCAGAAGGAGGGACAAT  
TATCTATATGCCACCTGAAAACCTATGAACCTGGACAAAAATCAAGGGCCAGTATCAAGCA  
CGATATATATAGCTATGCAGTTATCACATGGGAAGTGTTATCCAGAAAACAGCCTTTTGA  
AGATGTCACCAATCCTTTGCAGATAATGTATAGTGTGTGACAAGGACATCGACCTGTTAT  
TAATGAAGAAAGTTTGGCATATGATATACCTCACCGAGCACGTATGATCTCTCTAATAGA  
AAGTGGATGGGCACAAAATCCAGATGAAAGACCATCTTCTTAAATGTTTAAATAGAACT  
TGAACCAAGTTTGGAGAACATTTGAAGAGATAACTTTTCTTGAAGCTGTTATTCAGCTAAA  
GAAAACAAAGTTACAGAGTGTTCAGGTGCCATTACCTATGTGACAAGAAGAAAATGGA  
ATTATCTCTGAACATACCTGTAAATCATGGTCCACAAGAGGAATCATGTGGATCCTCTCA  
GCTCCATGAAAATAGTGGTTCTCCTGAACTTCAAGGTCCCTGCCAGCTCCTCAAGACAA  
TGATTTTTTTATCTAGAAAAGCTCAAGACTGTTATTTTATGAAGCTGCATCACTGTCCTGG  
AAATCACAGTTGGGATAGCACCATTCTGGATCTCAAAGGGCTGCATTCTGTGATCACAA  
GACCACTCCATGCTCTTCAGCAATAATAAATCCACTCTCAACTGCAGGAACTCAGAACG  
TCTGCAGCCTGGTATAGCCAGCAGTGGATCCAGAGCAAAAGGGAAGACATTGTGAACCA  
AATGACAGAAGCCTGCCTTAACCAGTCGCTAGATGCCCTTCTGTCCAGGGACTTGATCAT  
GAAAGAGGACTATGAACTTGTTAGTACCAAGCCTACAAGGACCTCAAAGTCAGACAATT  
ACTAGACACTACTGACATCCAAGGAGAAGAATTTGCCAAAGTTATAGTACAAAATTTGAA  
AGATAACAAACAAATGGGTCTTCAGCCTTACCCGGAAATACTTGTGGTTTCTAGATCACC  
ATCTTTAAATTTACTTCAAAATAAAAGCATGTAAGTGACTGTTTTTCAAGAAGAAATGTG  
TTTCATAAAAGGATATTTATAAAAAAAAAAAAAAAAAAAAA

>gi|4506537|gb|NP\_003812.1|RIPK2 540aa linear receptor-  
interacting serine-threonine kinase 2; receptor interacting  
protein 2 [Homo sapiens].

MNGEAI CSALPTIPYHKLADLRYLSRGASGTVSSARHADWRVQVAVKHLHIHTPLLDSE  
KDVLR AEAILHKARFSYILPILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYPDVAWPL  
RFRILHEIALGVNYLHNMTPELLHHD LKTONILLDNEFHVKIADFGLSKWRMMSLSQSRS  
SKSAPEGGTIIYMPPE NYEPGQKSRASIKHDIYSYAVITWEVLSRKQPFEDVTNPLQIMY  
SVSQGHRPVINEESLPYDIPHRARMISLIESGWAQNPDERPSFLKCLIELEPVLRTFEEI  
TFLEAVIQLKKTKLQSVSSAIHLCDKKKMELSLNIPVNHGPQEESCGSSQLHENS GSPET  
SRSLPAPQDNDFLSRKAQDCYFMKLHHC PGNHSWDSTISGSQRAAFCDHKTTPCSSAIIN  
PLSTAGNSERLQPGIAQQW IQSKREDIVNQMT EACLNQSLDALLSRDLIMKEDYELVSTK  
PTRTSKVRQLLDTTDIQGE EFAKVIVQKLKDNKQMG LQPYPEILVVSRSPSLNLLQNKSM

>gi|26051238|gb|NM\_021137.3|TNFAIP1 3571bp mRNA Homo sapiens  
tumor necrosis factor, alpha-induced protein 1 (endothelial)  
(TNFAIP1), mRNA.

CACAGCTTGGGACTGCTGAGGGGCAGGCGGCTGCAGGCTAGGGGCGGCTCGGAGTCCGCT  
GGCCACCCAGCTGAGAGGAGAGGCGCCCCCGGGGACGCACTGAGATTATGAGGCTCTGGC  
CTCCACTGGCCACTCACTCGTGACCCTTTCCACCACGGCGGAGCCTTCCAAGCCTACCTC  
CTGCCGTGTGGTGATCTACCTGCAGCGGGAGATGTGCGGGGACACCTGCCTGTGCCACG  
CTCAGGGGGCCAAGCCCAAGCTCAGTGGCTTCAAGGGAGGAGGGTTGGGCAACAAGTATGT

- 113 -

CCAGCTCAACGTGGGCGGCTCTCTGTACTACACCACTGTGCGGGCCCTGACCCGCCACGA  
CACCATGCTCAAGGCCATGTTTCAGTGGGCGCATGGAGGTGCTGACCGACAAAGAAGGCTG  
GATCCTCATAGACCGTTGTGGAAAGCACTTTGGCACCATTTTGAATTACCTCCGAGATGA  
CACCATCACCTTCCCTCAGAACCGGCAAGAAATCAAGGAATTGATGGCTGAAGCAAAGTA  
TTACCTCATCCAGGGGCTGGTGAATATGTGCCAGAGTGCCCTGCAGGACAAGAAGGACTC  
CTACCAGCCTGTGTGCAACATCCCCATCATCACATCCCTAAAGGAGGAGGAGCGGCTCAT  
CGAATCCTCCACCAAGCCCGTGGTGAAGCTGCTGTACAACAGAAGCAACAACAAGTATTC  
CTACACCAGCAACTCTGACGACCACCTGCTGAAAAACATCGAGCTGTTTGACAAGCTCTC  
CCTGCGCTTCAACGGCCGCGTGCTCTTCATCAAGGATGTCATTGGTGACGAGATCTGCTG  
CTGGTGCTTTTATGGCCAGGGCCGTAAGCTGGCAGAGGTGTGCTGTACCTCCATCGTGTA  
TGCCACGGAGAAGAAGCAGACCAAGGTGGAATTCCCAGAGGCCCGAATCTATGAGGAGAC  
ACTCAACGTCTTACTCTATGAGACTCCCCGCGTCCCCGACAACTCCTTGTTGGAGGCCAC  
AAGCCGTAGCCGCAGCCAGGCTTCCCCCAGTGAAGATGAGGAGACCTTTGAACTGCGGGA  
CCGTGTCCGCCGCATCCACGTCAAGCGCTACAGCACTTACGATGACCGGCAGCTCGGCCA  
CCAGTCTACCCATCGCGACTGACCAGACCCTCAGGGAGTCAGGGCACGGGAGGCCCTATC  
TCCCATCCTGTGGAACCCGCCCCATTGGCCACCCCATGCTGCTGCTGCCTGGGTCTCTGC  
TCTAGCACCCAGAGGCATGACAGGCCCTGCTCAGAGGTGAGAGGTCTGGGCAGAGGAGG  
GACCACATTCCCCTGCCTTGCCCCTGAGCACTTCTGGAGACTGCGTCCTGTCTATCTGC  
TCACCATCACCTTCCTGCCCCGACGGAGCTGCTTCTGCTCCCTGGGGCATATGGACTGAC  
CCACCTCCTGCTGAGAACCTTCCCCTAGGCCCTGTGCAGAAAGGGCTACTGCCCCCTTAGGC  
CTCAGCTGGGGGAAAGGCAGTTCTGGTGCTGTAGAGGCCCTGGTGCAAGAGTGGGACGT  
CTTTTTTCTAAGGTGTTTAAGCACAGGCTTGATAAGTTTGGTTTTTAAAAATAATCTA  
GGAAATGAATAATTCTAAATCTAGTAATGAGGAACTGAGCATTCTTTTGCCCTCAGG  
GTGCCAAGACCCTACATATGACAGAACCCTTGGCCCTTCTCCATGCCTGTGGGATCTGTT  
TCTTTAAAGCACTTTGTACTGTTATTTCAGGAGGTTGATAATCTCCTTGACCCATGTCTTT  
CTACCCTAATCCCCACTTCCCTGCAGAATCAATCTGAGGGAGGGGATAAAGAGGAAGCAA  
TAAAAAATAACATCCGACAGAGCAGCTCTGGCTTTGCCAGCCTGGCCAGCAGCTCAGAG  
TGCACCGAGGAGGGAAGGATGGCTAAGCTGGGACCGGCAGTCCTCACAGGGTGCCTGTGA  
GAAAGGACATTTTACCCCCACATCATAGTCACATCACTGACTCCTAGGTCTAGCACGACT  
GCTCTTTGTGATTCTCTTGAGTACCCTTGGCTTCCAGCCATGCTGTCTCTACATACGGTA  
AAGCCAAAGAGCTGTCACATGGGCCAGAAACATGAGCCACGGCAGGAAGACCGTGGAGCC  
CGTGGGCACTGCATGGTGTGGCTGGCATGCCATCAGCTGAGGACAGCAAACTCCCAGC  
AGCCCCCTACAGAGGTGGCACATGCTTGGCCACACATCTACTCCCTGCCACACCATCTAT  
GCTCTTGTTGGTGCTGGCTGGGATGGCGGTTCTGCCAGTGGTGTCTCTGAGCGCGGGA  
TGACAGGAGCAACCGAAGCACCTGAAGGCCTTCACTCCTTGTGGGTAACTCAGCCATG  
GAGATGCCAAGCACTAGCCAGGAGGTGAGTTCCTCTTTAGGGCTTTGGTTTTTCATTCTT  
TTTGTGTTGGCTTGGCCAAACCAGAATTCAGCTTATCTGAATTATTTTCCAAAGGAATGCT  
GTCAGGGAGGGACTGTTCTGCCAGCCTAACAAAGCAACGTAGCCACGTATAGTACCCACT  
TTCTGCTCTTTGGAGAGAACACAGGTTATCAAGTTTCATCTCTCTTGACTACTCTTATGAT  
AGCTGATGCCACAGAGCCTATGGGCCAAATGCCAGACCCAGGGTTAGACACAAGGACCTGA  
AGTGACATGACGGCGGGACAGGGGAAATGTGACTTTCTAATTAGGCATTTTATGTTAGTC  
ACAGTCTTGAATGTATAAACAGCACTAAGACTCTCAGGTGAGGTACCTTGGTGATCAGCT  
ACTAGTTCTTCCAGCCCTCATTTGAGGTAACAAGATAAAGACAAATCCACTTCTTTGGCCA  
AATTCAGGCTTTGGCTTTATGACTTTCCACAGAGACTGGAATGCGTCAGCCTGAGACCA  
CTGGCCTATTTTCTCAGCTGCCCTCTTGAGGTCTTTAACACTCAAATCCCAGCTCCCC  
ACTGAGGTGTTGTGATGCTTGCCTTTTGACCTCCCCATCCCCCTTTAGTCCCTGCTTACTA  
CTTTGACATTACATCCTCAGTGTCTCAGTCTTTTTTTGCCGAGAAAGCACAGTAGTCTGG

- 114 -

GACTGGGCATTTATCTTCTCTGACTGAAAATCTCTCCTTGGTCTTAAGGAAAATACTAAC  
ATTGAACTCACTGACATGATCTTAGCTTCTTTAATCAGACTTTGTGACTTAAAAGTTTGG  
GGGTTTTCTTTGAAAGTTTCCAGCCCTATTCAGAAAGCAACTCTTGGCTGTGTGCATTTT  
TCAACTCCAAGCAGCCCAGGGGTAAAGTAAACAAAGTATGGATGAAGGTGAGATTTTCTTG  
TCAGTTTCTGAGAAACCTGGCAGCCTGCTGTTAACAACACAGGCCAGTATTGGGTTTTAT  
TGAATTTGGTATGTGACCAAGGTCGGCCTAAAGGATGGCGCAGGTCCTGGGCAGGAAAGA  
ATTTTTCCTTTATCACATAACTGTAATATTTGGTTGCTCAGCATAAGTGATGGAAGCAAA  
CACTAATTTCTAATAAAATTGTGTTAACTC

>gi|10863937|gb|NP\_066960.1|TNFAIP1 316aa linear tumor  
necrosis factor, alpha-induced protein 1 [Homo sapiens].  
MSGDTCLCPASGAKPKLSGFKGGGLGNKYVQLNVGGSLYYTTVRALTRHDTMLKAMFSGR  
MEVLTDKEGWILIDRCGKHFGTILNLYLRDDTITLPPQNRQEIKELMAEAKYYLIQGLVNMC  
QSALQDKKDSYQPVNIPITSLKEERLIESSTKPVVKLLYNRSNNKYSYTSNSDDHLL  
KNIELFDKLSLRFNGRVLFIKDVGDEICWSFYGQGRKLAEVCCTSIVYATEKKQTKVE  
FPEARIEETLNVLLYETPRVPDNLLEATSRSRSQASPEDEETFELRDRVRRIHVKRY  
STYDDRQLGHQSTHRD

>gi|27597077|gb|NM\_006293.2|TYRO3 3949bp mRNA Homo sapiens  
TYRO3 protein tyrosine kinase (TYRO3), mRNA.  
GCGGTGGCGCGGGAGCGGCCCGGGGACCCCGCGCTGCTGACGGCGGCGACCGCGGCCGG  
AGGCGGGCGCGGGTCTCGGAGGCGGTGCGCTCAGCACCGCCCCACGGGCGGCCCCAGCCC  
CTCCCGCAGCCCTCCTCCCTCCCGCTCCCTTCCCGCCGCTCCTCCCCGCCCTCCTCCCT  
CCTCGCTCGCGGGCCGGGCCCCGGCATGGTGCGGCGTCCCGCCGATGGCGCTGAGGCGGA  
GCATGGGGCGGCCGGGGCTCCCGCCGCTGCCGCTGCCGCCGCCACCGCGGCTCGGGCTGC  
TGCTGGCGGCTCTGGCTTCTCTGCTGCTCCCGGAGTCCGCCGCCGAGGTCTGAAGCTCA  
TGGGAGCCCCGGTGAAGCTGACAGTGTCTCAGGGGCAGCCGGTGAAGCTCAACTGCAGTG  
TGGAGGGGATGGAGGAGCCTGACATCCAGTGGGTGAAGGATGGGGCTGTGGTCCAGAACT  
TGGACCAGTTGTACATCCCAGTCAGCGAGCAGCACTGGATCGGCTTCCTCAGCCTGAAGT  
CAGTGGAGCGCTCTGACGCCGGCCGGTACTGGTGCCAGGTGGAGGATGGGGGTGAAACCG  
AGATCTCCAGCCAGTGTGGCTCACGGTAGAAGGTGTGCCATTTTTTCACAGTGGAGCCAA  
AAGATCTGGCAGTGCCACCCAATGCCCTTTTCCAAGTGTCTTGTGAGGCTGTGGGTCCCC  
CTGAACCTGTTACCATTGTCTGGTGGAGAGGAACTACGAAGATCGGGGGACCCGCTCCCT  
CTCCATCTGTTTTTAAATGTAACAGGGGTGACCCAGAGCACCATGTTTTCTGTGAAGCTC  
ACAACCTAAAAGGCCTGGCCTCTTCTCGCACAGCCACTGTTACCTTCAAGCACTGCCTG  
CAGCCCCCTTCAACATCACCGTGACAAAGCTTTCCAGCAGCAACGCTAGTGTGGCCTGGA  
TGCCAGGTGCTGATGGCCGAGCTCTGCTACAGTCTGTACAGTTTCAAGTGACACAGGCCC  
CAGGAGGCTGGGAAGTCTTGGCTGTGTGGTCCCTGTGCCCCCTTTACCTGCCTGCTCC  
GGGACCTGGTGCCTGCCACCAACTACAGCCTCAGGGTGCCTGTGCCAATGCCTTGGGGC  
CCTCTCCCTATGCTGACTGGGTGCCCTTTTCAAGCAAGGGTCTAGCCCCAGCCAGCGCTC  
CCCAAAACCTCCATGCCATCCGCACAGATTCAGGCCTCATCTTGGAGTGGGAAGAAGTGA  
TCCCCGAGGCCCTTTTGAAGGCCCTTGGGACCCCTACAACTGTCCTGGGTTCAAGACA  
ATGGAACCCAGGATGAGCTGACAGTGGAGGGGACCAGGGCCAATTTGACAGGCTGGGATC  
CCCAAAAGGACCTGATCGTACGTGTGTGCGTCTCCAATGCAGTTGGCTGTGGACCCTGGA  
GTCAGCCACTGGTGGTCTCTTCTCATGACCGTGCAGGCCAGCAGGGCCCTCCTCACAGCC  
GCACATCCTGGGTACCTGTGGTCCTTGGTGTGCTAACGGCCCTGGTGACGGCTGCTGCCC  
TGGCCCTCATCCTGCTTCGAAAGAGACGGAAAGAGACGCGGTTTGGGCAAGCCTTTGACA  
GTGTCATGGCCCGGGGAGAGCCAGCCGTTCACTTCCGGGCAGCCCGGTCTTCAATCGAG  
AAAGGCCCGAGCGCATCGAGGCCACATTGGACAGCTTGGGCATCAGCGATGAACTAAAG



- 115 -

AAAAAQTGGAGGATGTGCTCATCCCAGAGCAGCAGTTCACCCTGGGCCGGATGTTGGGCA  
AAGGAGAGTTTGGTTTCAGTGCGGGAGGCCAGCTGAAGCAAGAGGATGGCTCCTTTGTGA  
AAGTGGCTGTGAAGATGCTGAAAGCTGACATCATTGCCTCAAGCGACATTGAAGAGTTCC  
TCAGGGAAGCAGCTTGTCATGAAGGAGTTTGACCATCCACACGTGGCCAAACTTGTGGGG  
TAAGCCTCCGGAGCAGGGCTAAAGGCCGTCTCCCCATCCCCATGGTCATCTTGCCCTTCA  
TGAAGCATGGGGACCTGCATGCCTTCTGCTCGCCTCCCGGATTGGGGAGAACCCCTTTA  
ACCTACCCCTCCAGACCCTGATCCGGTTTCATGGTGGACATTGCCTGCGGCATGGAGTACC  
TGAGCTCTCGGAACCTTCATCCACCGAGACCTGGCTGCTCGGAATTGCATGCTGGCAGAGG  
ACATGACAGTGTGTGTGGCTGACTTCGGACTCTCCCGGAAGATCTACAGTGGGGACTACT  
ATCGTCAAGGCTGTGCCTCCAACTGCCTGTCAAGTGGCTGGCCCTGGAGAGCCTGGCCG  
ACAACCTGTATACTGTGCAGAGTGACGTGTGGGCGTTCGGGGTGACCATGTGGGAGATCA  
TGACACGTGGGCAGACGCCATATGCTGGCATCGAAAACGCTGAGATTTACAACTACCTCA  
TTGGCGGGAACCGCCTGAAACAGCCTCCGGAGTGTATGGAGGACGTGTATGATCTCATGT  
ACCAGTGCTGGAGTGCTGACCCCAAGCAGCGCCCGAGCTTTACTTGTCTGCGAATGGAAC  
TGGAGAACATCTTGGGCCAGCTGTCTGTGCTATCTGCCAGCCAGGACCCCTTATACATCA  
ACATCGAGAGAGCTGAGGAGCCCACTGCGGGAGGCAGCCTGGAGCTACCTGGCAGGGATC  
AGCCCTACAGTGGGGCTGGGGATGGCAGTGGCATGGGGGCAGTGGGTGGCACTCCCAGTG  
ACTGTCGGTACATACTACCCCCGGAGGGCTGGCTGAGCAGCCAGGGCAGGCAGAGCACC  
AGCCAGAGAGTCCCCTCAATGAGACACAGAGGCTTTTGCTGCTGCAGCAAGGGCTACTGC  
CACACAGTAGCTGTTAGCCACAGGCAGAGGGCATCGGGGCCATTTGGCCGGCTCTGGTG  
GCCACTGAGCTGGCTGACTAAGCCCCGTCTGACCCAGCCAGACAGCAAGGTGTGGAGG  
CTCCTGTGGTAGTCCTCCCAAGCTGTGCTGGGAAGCCCGGACTGACCAAATCACCCAATC  
CCAGTTCTTCTGCAACCACTCTGTGGCCAGCCTGGCATCAGTTTAGGCCTTGGCTTGAT  
GGAAGTGGGCCAGTCTGTGTTGTCTGAACCCAGGCAGCTGGCAGGAGTGGGGTGGTTATG  
TTTCCATGGTTACCATGGGTGTGGATGGCAGTGTGGGGAGGGCAGGTCCAGCTCTGTGGG  
CCCTACCCCTCCTGCTGAGCTGCCCCCTGCTGCTTAAGTGCATGCATTGAGCTGCCTCCAGC  
CTGGTGGCCAGCTATTACCACACTTGGGGTTTAAATATCCAGGTGTGCCCTCCAAGTC  
ACAAAGAGATGTCTTGTAAATATTCCTTTTAGGTGAGGGTTGGTAAGGGGTGGTATCT  
CAGGTCTGAATCTTCACCATCTTTCTGATTCCGCACCCTGCCTACGCCAGGAGAAGTTGA  
GGGGAGCATGCTTCCCTGCAGCTGACCGGGTCACACAAAGGCATGCTGGAGTACCCAGCC  
TATCAGGTGCCCTCTTCCAAGGCAGCGTGCCGAGCCAGCAAGAGGAAGGGGTGCTGTG  
AGGCTTGCCAGGAGCAAGTGAGGCCGGAGAGGAGTTTCAAGAACCTTCTCCATACCCAC  
AATCTGAGCACGCTACCAAATCTCAAAATATCCTAAGACTAACAAAGGCAGCTGTGTCTG  
AGCCCAACCCTTCTAAACGGTGACCTTTAGTGCCAACTTCCCCTCTAACTGGACAGCCTC  
TTCTGTCCCAAGTCTCCAGAGAGAAATCAGGCCTGATGAGGGGGAATTCCTGGAACCTGG  
ACCCAGCCTTGGTGGGGGAGCCTCTGGAATGCATGGGGCGGGTCCTAGCTGTTAGGGAC  
ATTTCCAAGCTGTTAGTTGCTGTTTAAAATAGAAATAAAATTGAAGACT

>gi|27597078|gb|NP\_006284.2|TYRO3 890aa linear TYRO3 protein  
tyrosine kinase; Brt; Dtk; Sky; Tif; Tyro3 protein tyrosine  
kinase (sea-related receptor tyrosine kinase); tyrosine-  
protein kinase receptor TYRO3 precursor [Homo sapiens].  
MALRRSMGRPGLPPLPLPPPPRLGLLLAALASLLLPESAAAGLKLKMGAPVKLTVSQGQPV  
KLNCSEVGMEEPDIQWVKDGAVVQNLDQLYIPVSEQHWIGFLSLKSVERS DAGRYWCQVE  
DGGETEISQPVWLTVEGVVFFFTVEPKDLAVPPNAPFQLSCEAVGPPEPVTVVWRGTTKI  
GGPAPSPSVLNVTVGTQSTMFSCAHNLKGLASSRTATVHLQALPAAPFNIITVKLSSSN  
ASVAMWPGADGRALLQSCVTQVTQAPGGWEVLAVVVPVPPFTCLLRDLVPATNYSRLVRVRC  
ANALGPSPYADWVPFQTKGLAPASAPQNLHAIRTD SGLILEWEEVIPEAPLEGPLGPYKL

- 116 -

SWVQDNGTQDELTVEGTRANLTGWDPQKDLIVRVCVSNVCGPWSQPLVVSSHDRAGQO  
 GPPHSRTSWVPVVLGVLTALVTAAALALILLRKRKRKETRFGQAFDSVMARGEPAVHFRAA  
 RSFNRERPERIEATLDSLGI SDELKEKLEDVLIPEQQFTLGRMLGKGFEFGSVREAQLKQE  
 DGSFVKVAVKMLKADIIASSDIEEFLREAACMKEFDHPHVAKLVGVSLRSRAKGRLPIM  
 VILPFMKHGDHLHAFLLASRIGENPFNLPLQTLIRFMVDIACGMEYLLSRNFIHRDLAARN  
 CMLAEDMTVCVADFGLSRKIYSGDYRQGCASKLPVKWLALESADNLYTVQSDVWAFGV  
 TMWEIMTRGQTPYAGIENAEIYNYLIGGNRLKQPPECMEDVYDLMYQCWSADPKQRPSFT  
 CLRMELLENILGQLSVLSASQDPLYINIERAE EPTAGGSLELPGRDQPYSGAGDGS GMGAV  
 GGTPSDCRYILTTPGGLAEQPGQAEHQPE SPLNETQRLLLLQQLLPHSSC

>gi|4502884|gb|NM\_003992.1|CLK3 1762bp mRNA Homo sapiens CDC-  
 like kinase 3 (CLK3), transcript variant phclk3, mRNA.

TGGGGCACTGGTACCTCCAGGACCTGGAGTGTACTGGAAGAAATGGTGCAGTCCAGATGC  
 ATCACTGTAAGCGATACCGCTCCCCTGAACCAGACCCGTACCTGAGCTACCGATGGAAGA  
 GGAGGAGGTCTCTACAGTCGGGAACATGAAGGGAGACTGCGATACCCGTCCCGAAGGGAGC  
 CTCCCCCACAAGATCTCGGTCCAGAAGCCATGACCGCCTGCCCTACCAGAGGAGGTACC  
 GGGAGCGCCGTGACAGCGATACATACCGGTGTGAAGAGCGGAGCCCATCCTTTTGAGAGAGG  
 ACTACTATGGACCTTCACGTTCTCGTCATCGTCGGCGATCGCGGGAGAGGGGGCCATACC  
 GGACCCGCAAGCATGCCCACTGCCCACAAACGCCGCACCAGGTCTTG TAGCAGCGCCT  
 CCTCGAGAAGCCAACAGAGCAGTAAGCGCACAGGCCGGAGTGTGGAAGATGACAAGGAGG  
 GTCACCTGGTGTGCCGGATCGGCGATTGGCTCCAAGAGCGATATGAGATTGTGGGGAACC  
 TGGGTGAAGGCACCTTTGGCAAGGTGGTGGAGTGCTTGGACCATGCCAGAGGGAAGTCTC  
 AGGTTGCCCTGAAGATCATCCGCAACGTGGGCAAGTACCGGGAGGCTGCCCGGCTAGAAA  
 TCAACGTGCTCAAAAAAATCAAGGAGAAGGACAAAGAAAACAAGTTCCTGTGTGTCTTGA  
 TGTCTGACTGGTTCACTTCCACGGTCACATGTGCATCGCCTTTGAGCTCCTGGGCAAGA  
 ACACCTTTGAGTTCTTGAAGGAGAATAACTTCCAGCCTTACCCCTACCACATGTCCGGC  
 ACATGGCCTACCAGCTCTGCCACGCCCTTAGATTTCTGCATGAGAATCAGCTGACCCATA  
 CAGACTTGAAACCTGAGAACATCCTGTTTGTGAATTCTGAGTTTGAAACCCTCTACAATG  
 AGCACAAGAGCTGTGAGGAGAAGTCAGTGAAGAACACCAGCATCCGAGTGGCTGACTTTG  
 GCAGTGCCACATTTGACCATGAGCACCAACCACCATTTGTGGCCACCCGTCACTATCGCC  
 CGCCTGAGGTGATCCTTGAGCTGGGCTGGGCACAGCCCTGTGACGTCTGGAGCATTGGCT  
 GCATTCTCTTTGAGTACTACCGGGGCTTCACACTCTTCCAGACCCACGAAAACCGAGAGC  
 ACCTGGTGATGATGGAGAAGATCCTAGGGCCCATCCCATCACACATGATCCACCGTACCA  
 GGAAGCAGAAATATTTCTACAAAGGGGGCCTAGTTTGGGATGAGAACAGCTCTGACGGCC  
 GGTATGTGAAGGAGAACTGCAAACCTCTGAAGAGTTACATGCTCCAAGACTCCCTGGAGC  
 ACGTGACGCTGTTTGACCTGATGAGGAGGATGTTAGAATTTGACCCTGCCCAGCGCATCA  
 CACTGGCCGAGGCCCTGCTGCACCCCTTCTTTGCTGGCCTGACCCCTGAGGAGCGGTCTCT  
 TCCACACCAGCCGCAACCCAAGCAGATGACAGGCACAGGCCACCGCATGAGGAGATGGAG  
 GGCGGGACTGGGCCGCCAGCCCTTGACTCCAGCCTCGACCGCCAGCCCCAGGCCAGAG  
 CCACCCAATGAACAGTGCAATGTGAAGGAAGGCAGGAGCCTGCAGGGGAGCAGACTTGGT  
 GCCCAGCTGCCAGAAAGCACAGATTTGACCCAAGCTATTTATATGTTATAAAGTTATAAT  
 AAAGTGTTTCTTACTGTTTGTA

>gi|4502885|gb|NP\_003983.1|CLK3 490aa linear CDC-like kinase 3  
 isoform hclk3 [Homo sapiens].

MHHCKRYRSPEPDYLSYRWKR RRSYSREHEGRLRYPSRREPPRRSRSRSHDRLPYQRR  
 YRERRDSDTYRCEERSPSFGEDYYGPSRSRHRRRSRERGPYRTRKHAHHCHKRRTRSCSS  
 ASSRSQSSKRTGRSVEDDKEGHLVCRI GDWLQERYEIVGNLGEFTFGKVVECLDHARGK  
 SQVALKIIRNVGKYREARLEINV LKKIKEKDKENKFLCVLMSDWFNFHGHMCIAFELLG



- 117 -

KNTFEFLKENNFQPYPLPHVRHMAYQLCHALRFLHENQLTHTDLKPENILFVNSEFETLY  
NEHKSCEEKSVKNTSIRVADFGSATFDHEHHTTIVATRHYRPPEVILELGWAQPCDVWSI  
GCILFEYYRGFTLFLQTHENREHLVMMEKILGPIPSHMIHRTRKQKYFYKGGVLWDENSSD  
GRYVKENCKPLKSYMLQDSLEHVQLFDLMRRMLEFDPAQRITLAEALLHPFFAGLTPEER  
SFHTSRNPSR

>gi|9910121|gb|NM\_020249.1|ADAMTS9 3674bp mRNA Homo sapiens a  
disintegrin-like and metalloprotease (reprolysin type) with  
thrombospondin type 1 motif, 9 (ADAMTS9), mRNA.

GCGGGAAGCACCATGCAGTTTGTATCCTGGGCCACACTGCTAACGCTCCTGGTGCGGGAC  
CTGGCCGAGATGGGGAGCCCAGACGCCGCGGCGGCCGTACGCAAGGACAGGCTGCACCCG  
AGGCAAGTGAAATTATTAGAGACCCTGGGCGAATACGAAATCGTGTCTCCCATCCGAGTG  
AACGCTCTCGGAGAACCCTTTCCACGAACGTCCACTTCAAAGAACGCGACGGAGCATT  
AACTCTGCCACTGACCCCTGGCCTGCCTTCGCCTCCTCCTCTTCTCCTCTACCTCCTCC  
CAGGCGCATTACCGCCTCTCTGCCTTCGGCCAGCAGTTTCTATTTAATCTCACCGCCAAT  
GCCGGATTTATCGCTCCACTGTTCACTGTCACCCTCCTCGGGACGCCCGGGGTGAATCAG  
ACCAAGTTTTATTCCGAAGAGGAAGCGGAACTCAAGCACTGTTTCTACAAAGGCTATGTC  
AATACCAACTCCGAGCACACGGCCGTCAATCAGCCTCTGCTCAGGAATGCTGGGCACATTC  
CGGTCTCATGATGGGGATTATTTTATTGAACCACTACAGTCTATGGATGAACAAGAAGAT  
GAAGAGGAACAAAACAAACCCACATCATTATAGGCGCAGCGCCCCCAGAGAGAGCCC  
TCAACAGGAAGGCATGCATGTGACACCTCAGAACACAAAATAGGCACAGTAAAGACAAG  
AAGAAAACCAGAGCAAGAAAATGGGGAGAAAGGATTAACTGGCTGGTGACGTAGCAGCA  
TTAAACAGCGGCTTAGCAACAGAGGCATTTTCTGCTTATGGTAATAAGACGGACAACACA  
AGAGAAAAGAGGACCCACAGAAGGACAAAACGTTTTTTTATCCTATCCACGGTTTGTAGAA  
GTCTTGGTGGTGGCAGACAACAGAATGGTTTCATACCATGGAGAAAACCTTCAACACTAT  
ATTTTAACCTTTAATGTCAATTGTAGCCTCTATCTATAAAGACCCAAGTATTGGAAATTTA  
ATTAATATTGTTATTGTGAACCTTAATTGTGATTCTAATGAACAGGATGGGCCTTCCATA  
TCTTTTAATGCTCAGACAACATTAATAAACCTTTGCCAGTGGCAGCATTCTGAAGAACAGT  
CCAGGTGGAATCCATCATGATACTGCTGTTCTCTTAACAAGACAGGATATCTGCAGAGCT  
CACGACAAATGTGATACCTTAGGCCTGGCTGAACTGGGAACCATTTGTGATCCCTATAGA  
AGCTGTTCTATTAGTGAAGATAGTGGATTGAGTACAGCTTTTACGATCGCCCATGAGCTG  
GGCCATGTGTTTAACATGCCTCATGATGACAACAACAAATGTAAAGAAGAAGGAGTTAAG  
AGTCCCAGCATGTGATGGCTCCAACACTGAACTTCTACACCAACCCCTGGATGTGGTCA  
AAGTGTAGTCGAAAATATATCACTGAGTTTTTTAGACACTGGTTATGGCGAGTGTGTTGCTT  
AACGAACCTGAATCCAGACCCTACCCTTTGCCTGTCCAACCTGCCAGGCATCCTTTACAAC  
GTGAATAAACAATGTGAATTGATTTTTTGGACCAGGTTCTCAGGTGTGCCCATATATGATG  
CAGTGCAGACGGCTCTGGTGCAATAACGTCAATGGAGTACACAAAGGCTGCCGGACTCAG  
CACACACCTGGGCCGATGGGACGGAGTGCAGCCTGGAAAGCACTGCAAGTATGGATTT  
TGTGTTCCCAAAGAAATGGATGTCCCGTGACAGATGGATCCTGGGGAAGTTGGAGTCCC  
TTTGGAACCTGCTCCAGAACATGTGGAGGGGGCATCAAAACAGCCATTTCGAGAGTGCAAC  
AGACCAGAACCACAAAATGGTGGAAAATACTGTGTAGGACGTAGAATGAAATTTAAGTCC  
TGCAACACGGAGCCATGTCTCAAGCAGAAGCGAGACTTCCGAGATGAACAGTGTGCTCAC  
TTTGACGGGAAGCATTTTAACATCAACGGTCTGCTTCCCAATGTGCGCTGGGTCCCTAAA  
TACAGTGGAATTCTGATGAAGGACCGGTGCAAGTTGTTCTGCAGAGTGGCAGGGAACACA  
GCCTACTATCAGCTTCGAGACAGAGTGATAGATGGAACCTCTTGTGGCCAGGACACAAAT  
GATATCTGTGTCCAGGGCCTTTGCCGGCAAGCTGGATGCGATCATGTTTTAACTCAAAA  
GCCCCGAGAGATAAATGTGGGGTTTGTGGTGGCGATAATTCTTCATGCAAAACAGTGGCA  
GGAACATTTAATACAGTACATTATGGTTACAATACTGTGGTCCGAATTCAGCTGGTGCT

- 118 -

ACCAATATTGATGTGCGGCAGCACAGTTTCTCAGGGGAAACAGACGATGACAACTACTTA  
GCTTTATCAAGCAGTAAAGGTGAATTCTTGCTAAATGGAACTTTGTTGTCACAATGGCC  
AAAAGGGAAATTTCGATTGGGAATGCTGTGGTAGAGTACAGTGGGTCCGAGACTGCCGTA  
GAAAGAATTAACCTCAACAGATCGCATTGAGCAAGAACCTTTTGCTTCAGGTTTTGTCTGGTG  
GGAAAGTTGTACAACCCCGATGTACGCTATTCTTTCAATATTCCAATTGAAGATAAACCT  
CAGCAGTTTTACTGGAACAGTCATGGGCCATGGCAAGCATGCAGTAAACCCTGCCAAGGG  
GAACGGAAACGAAAACCTTGTTCGACCAGGGAATCTGATCAGCTTACTGTTTTCTGATCAA  
AGATGCGATCGGCTGCCCCAGCCTGGACACATTACTGAACCCTGTGGTACAGACTGTGAC  
CTGAGGTGGCATGTTGCCAGCAGGAGTGAATGTAGTGCCAGTGTGGCTTGGGTTACCGC  
ACATTGGACATCTACTGTGCCAAATATAGCAGGCTGGATGGGAAGACTGAGAAGGTTGAT  
GATGGTTTTTTCAGCAGCCATCCCAAACCAAGCAACCGTGAAAAATGCTCAGGGGAATGT  
AACACGGGTGGCTGGCGCTATTCTGCCTGGACTGAATGTTCAAAAAGCTGTGACGGTGGG  
ACCCAGAGGAGAAGGGCTATTTGTGTCAATACCCGAAATGATGTACTGGATGACAGCAAA  
TGCACACATCAAGAGAAAGTTACCATTACAGAGGTGCAGTGAGTTCCTTGTCCACAGTGG  
AAATCTGGAGACTGGTCAGAGGTAAGATGGGAGGGCTGTTATTTCCCCTAGGTCATCTCT  
TACATTCTAGTTCTGGTGCTCTCTATCTGTTTAAAGACAAACCCTTGTGCACCTTTCTCCC  
ACCTCTCCCTTTCTCCCTTGTCTCCCTTGAGAAAACAACCTCCAGTTCTCTGCCTGCACCA  
TGACTGTCGTACTGGATGTAAGTAGTCTACCAGTGACCTCAGGGCACTTTGGGCTTGGCT  
AGATCACTCACTGTTGTAGCTTCTGTTGTGATTTTGAAGTTGCAGTCCATCACCTTCCCT  
CCTCTTTGAGCCCTAGCTAAGTCACTGAAAGGAAATCATGGATTTATTAATCATAAAGCT  
ATACTAGCTCACATCTGAAGTCAACATGAAGTTTCTACTTCTTGTCTTTGAAATAAGA  
GAATTAGACCCAGGGAGTGACCTCTCTGACTTACCCATCCAACCTGCCCAAAAAAAAAA  
AAAAAAAAAAAAAAAA

>gi|9910122|gb|NP\_064634.1|ADAMTS9 1072aa linear a disintegrin  
and metalloproteinase with thrombospondin motifs-9  
preproprotein [Homo sapiens].

MQFVSWATLLTLLVRDLAEMGSPDAAA AVRKDR LHPRQVKLLET LGEYEIVSPIRVNALG  
EPFPTNVHFKRTRRSINSATDPWPAFASSSSSSSTSSQAHYRLSAFGQQFLFNL TANAGFI  
APLFTVTLLGTPGVNQTKFYSEEEAELKHCFYKGYVNTNSEHTAVISLCSGMLGTFRSHD  
GDYFIEPLQSMDEQEDEEEQNKPHIIYRRSAPQREPSTGRHACDTSEHKNRHSDKKKKTR  
ARKWGERINLAGDVAALNSGLATEAFSAYGNKTDNTREKRTHRRTKRFLSYPRFVEVLVV  
ADNRMVSYHGENLQHYILTLMSIVASIYKDPSIGNLINIVIVNLIVIHNEQDGPSISFNA  
QTTLKNLCQWQH SKNSPGGIHHD TAVLLTRQDICRAHDKCDTLGLAELGTICDPYRSCSI  
SEDSGLSTAFTIAHELGHVFNMPHDDNNKCKEEGVKSPQHVMAPTLNFYTNPWMWSKCSR  
KYITEFLDTGYGECLLNEPESRPYPLPVQLPGILYNV NKQCELI FGPGSQVCPYMMQCR  
LWCNNVNGVHKGCRTOHTPWADGTECEPGKHCKYGF CVPKEMDVPVTDGSGWSWSPFGTC  
SRTC GGGIKTAIRECNRPEPKNGGKYCVGRMKFKSCNTEPCLKQKRDFRDEQCAHFDGK  
HFNINGLLPNVRWVPKYSGILMKDRCKLFCRVAGNTAYYQLRDRVIDGT PCGQDNDICV  
QGLCRQAGCDHVLNSKARRDKCGVCGDNNSSCKTVAGTFNTVHYGYNTVVRI PAGATNID  
VRQHSFSGETDDDN YLALSSSKGEFLLNGNFVVTMAKREIRIGNAVVEYSGETAVERIN  
STDRIEQELL LQVLSVGKLYNPVRYSFNIP IEDKPQQFYWNSHGPWQACSKPCQGERKR  
KLVTCTRES DQLTVSDQRCDRLPQPGHITEPCGTDCLRW HVASRSECSAQCGLG YRTLDI  
YCAKYSRLDGKTEKVDDGFCSSHPKPSNREKCSGECNTGGWRYSAWTECSKSCDGGTQRR  
RAICVNTRNDVLDDSKCTHQEKVTIQRCEFP CPQWKSGDWSEVRWEGCYFP

>gi|17981697|gb|NM\_001262.2|CDKN2C 2104bp mRNA Homo sapiens  
cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)  
(CDKN2C), transcript variant 1, mRNA.

- 119 -

CTCTGCCGAGCCTCCTTAAAACTCTGCCGTTAAATGGGGGCGGGTTTTTCAACTCAAAA  
AGCGCTCAATTTTTTTCTTTTCAAAAAAAGCTGATGAGGTCGGAAAAAAGGGAGAAGAAA  
CCGGCACCCCTCTCTGAGAGGCAACAGAAGCAGCAATTGTTTCAGCGAAAAAAGCAGCAAG  
GGAGGGAGTGAAGGAAAAAAGCAAAAAAGGGGGCGACACGCAAGTGCCTGTAGGGGTGAA  
AGGAGCAGGGACCGGCGATCTAGGGGGGGATCAGCTACAAAAGAACTGTCACTGGGAGC  
GGTGCGGCCAAGGAGGAAGCAGTGCTGCCAGGCTCTGCTCCAGGGCACAGCTGGCTGGCG  
GCTGCCCTGTCCGCAGCAAAGGGGGCACAGGCCGGGGACCGCGAGAGGTGGCAAAGTGGCA  
CCGGGGCGCCGAGGCTGCTGAGCGCTCGCCGAGACGGCGACCGGACTGGCTGCCCCGGAAC  
TGCGGGCGACTCTCCCTACTCAGAACTTGGCCTACGTTTCCCAGGACTCTCCCCATCTCCA  
GAGGCCCCCACAAAACCGGGAAAGGAAGGAAGGACAGCGGCGGCAGCAGCTCAATGAGT  
GCCTACAGCAGAAAGCCTGAACGAGCTCGGTCTGAGGCGGGAAGTTCCCGGGGGGGCTGC  
CCAGTGACGCCGAATGCTGCCGCGAGCTGCCCCAGCAGTCCGGGCTCCGTAGACGCTTT  
CCGCATCACTCTCCTTCTCGGGCTGCCGGGAGTCCCGGGACCTGGCGGGGGCCGGCATGA  
CGGGCTTCTCGGGGGCCCCGCCGACGCCCGGCAGCCTCCGGAGACGCGCGCCGAGCCCGG  
CTCCACGGCCTCTGAGGCTCGGCGGGGCTGCGGCTGCCTGGCGGGCGGGCTCCGGAGCT  
TTCCTGAGCGGCATTAGCCACGGCTTGGCCCGGACGCGACCAAAGGCTCTTCTGGAGAA  
GCCCAGAGCACTGGGCAATCGTTACGACCTGTAACCTGAGGGCCACCGAACTGCTACTCC  
CGTTTCGCCTTTGGCGATCATCTTTTAACCTCCGGAGCACGTCAGCATCCAGCCACCGCG  
GCGCTCTCCAGCAGCGGAGGACCCAGGACTATCCCTTCGGCGAGACGGATGGAAACCGA  
GCCCCCTGGAGGACCTGCCCCCTGCAGTTCTGCCTCACACGGCTCAAGTCACCACCGTGAA  
CAAGGGACCTAAAGAATGGCCGAGCCTTGGGGGAACGAGTTGGCGTCCGCAGCTGCCAG  
GGGGGACCTAGAGCAACTTACTAGTTTGTGCAAAATAATGTAAACGTCAATGCACAAAA  
TGGATTGGAAGGACTGCGCTGCAGGTTATGAACTTGGAAATCCCGAGATTGCCAGGAG  
ACTGCTACTTAGAGGTGCTAATCCCGATTTGAAAGACCGAACTGGTTTCGCTGTCATTCA  
TGATGCGGCCAGAGCAGGTTTTCCTGGACACTTTACAGACTTTGCTGGAGTTTCAAGCTGA  
TGTTAACATCGAGGATAATGAAGGGAACCTGCCCTTGCACTTGGCTGCCAAAGAAGGCCA  
CCTCCGGGTGTTGGAGTTCTTGGTGAAGCACACGGCCAGCAATGTGGGGCATCGGAACCA  
TAAGGGGGACACCGCCTGTGATTTGGCCAGGCTCTATGGGAGGAATGAGGTTGTTAGCCT  
GATGCAGGCAAACGGGGCTGGGGGAGCCACAAATCTTCAATAAACGTGGGGAGGGCTCCC  
CCACGTTGCCTCTACTTTATCAATTAAGTGTGAGTCTCTCTGACTTTTAAATGTCAATTTG  
TTAAATAACAGTTCTGTCAATATGTTAAGCAGCTAAATTTTCTGAAACTGCATAAGTGAAA  
ATCTTACAACAGGCTTATGAATATATTTAAGCAACATCTTTTAAACCTGCAAAATCTGTT  
CTAACATGTAATTGCAGATAACTTTGACTTTCTTCTGAATATTTTATCTTTCTTGGCTT  
TTCCCTTGCTTCCCCTTTTGCCAATCTCAACACCCAAGTTGAAGACTTTGTTTTTAAAT  
GGTTTGTCTGATGCTTTTGTCTAATTAAACACTTTCAAAACAGGAAAAAAAAAAAAAA  
AAAA

>gi|4502751|gb|NP\_001253.1|CDKN2C 168aa linear cyclin-  
dependent kinase inhibitor 2C; cyclin-dependent kinase 6  
inhibitor p18; cyclin-dependent kinase 4 inhibitor C; cyclin-  
dependent inhibitor; CDK6 inhibitor p18 [Homo sapiens].

MAEPWGNELASAAARGDLEQLTSLQNNVNVNAQNGFGR TALQVMKLG NPEIARRLLLRG  
ANPDLKDRTGFAVIHDAARAGFLDTLQTLLEFQADVNIEDNEGNLPLHLAAKEGHLRVVE  
FLVKHTASNVGHRNHKGD TACDLARLYGRNEVVSLMQANGAGGATNLQ

>gi|23510344|gb|NM\_002037.3|FYN 2650bp mRNA Homo sapiens FYN  
oncogene related to SRC, FGR, YES (FYN), transcript variant 1,  
mRNA.

GCCGCGCTGGTGGCGGCGGCGCGTCTGTCAGGAGCGGAGCCGG

- 120 -

CGAGGAGGGGGCTGCCGCGGGCGAGGAGGAGGGGTCGCCGCGAGCCGAAGGCCTTCGAGA  
CCCCGCCCGCCCGCGCGGCGAGAGTAGAGGCGAGGTTGTTGTGCGAGCGGCGCGTCCCTC  
TCCCGCCCCGGGCGCGCCGCGCTTCTCCAGCGCACCGAGGACCGCCCGGGCGCACACAAA  
GCCGCCGCCCCGCGCCGCACCGCCCCGGCGGCGCGCCCGCCCGCGCCAGGGAGGGATTTCGGCCG  
CCGGGCCGGGGACACCCCGCGCGCCGCCCCCTCGGTGCTCTCGGAAGGCCACCGGCTCCC  
GGGCCCGCCGGGGACCCCCCGAGCCGCTCGGCCGCGCCGGAGGAGGGCGGGGAGAGGA  
CCATGTGAGTGGGCTCCGGAGCCTCAGCGCCGCGCAGTTTTTTTTGAAGAAGCAGGATGCT  
GATCTAAACGTGGAAAAAGACCAGTCTCTGCCTCTGTTGTAGAAGACATGTGGTGTATATA  
AAGTTTGTGATCGTTGGCGGACATTTTGGAAATTTAGATAATGGGCTGTGTGCAATGTAAG  
GATAAGAAGCAACAAAACCTGACGGAGGAGAGGGACGGCAGCCTGAACCAGAGCTCTGGG  
TACCGCTATGGCACAGACCCCAACCCCTCAGCACTACCCAGCTTCGGTGTGACCTCCATC  
CCCAACTACAACAACTTCCACGCAGCCGGGGGCCAAGGACTCACCGTCTTTGGAGGTGTG  
AACTCTTCGTCTCATACGGGGACCTTGCGTACGAGAGGAGGAACAGGAGTGACACTCTTT  
GTGGCCCTTTATGACTATGAAGCACGGACAGAAGATGACCTGAGTTTTTCACAAAGGAGAA  
AAATTTCAAATATTGAACAGCTCGGAAGGAGATTGGTGGGAAGCCCGCTCCTTGACAACT  
GGAGAGACAGGTTACATTCCCAGCAATTATGTGGCTCCAGTTGACTCTATCCAGGCAGAA  
GAGTGGTACTTTGGA AAACTTGCCCGAAAAGATGCTGAGCGACAGCTATTGTCCTTTGGA  
AACCCAAGAGGTACCTTTCTTATCCGCGAGAGTGAAACCACCAAAGGTGCCTATTCACTT  
TCTATCCGTGATTGGGATGATATGAAAGGAGACCATGTCAAACATTATAAAATTCGCAAA  
CTTGACAATGGTGGATACTACATTACCACCCGGGCCCAGTTTGAAACACTTCAGCAGCTT  
GTACAACATTACTCAGAGAGAGCTGCAGGTCTCTGCTGCCGCCTAGTAGTTCCCTGTAC  
AAAGGGATGCCAAGGCTTACCGATCTGTCTGTCAAAACCAAAGATGTCTGGGAAATCCCT  
CGAGAATCCCTGCAGTTGATCAAGAGACTGGGAAATGGGCAGTTTGGGGAAGTATGGATG  
GGTACCTGGAATGGAAACACAAAAGTAGCCATAAAGACTCTTAAACCAGGCACAATGTCC  
CCCGAATCATTCCTTGAGGAAGCGCAGATCATGAAGAAGCTGAAGCACGACAAGCTGGTC  
CAGCTCTATGCAGTGGTGTCTGAGGAGCCCATCTACATCGTCACCGAGTATATGAACAAA  
GGAAGTTTACTGGATTTCCTTAAAGATGGAGAAGGAAGAGCTCTGAAATTACCAAATCTT  
GTGGACATGGCAGCACAGGTGGCTGCAGGAATGGCTTACATCGAGCGCATGAATTATATC  
CATAGAGATCTGCGATCAGCAAACATTCTAGTGGGGAATGGACTCATATGCAAGATTGCT  
GACTTTCGATTGGCCCCGATTGATAGAAGACAATGAGTACACAGCAAGACAAGGTGCAAAG  
TTCCCCATCAAGTGGACGGCCCCCGAGGCAGCCCTGTACGGGAGGTTTACAATCAAGTCT  
GACGTGTGGTCTTTTGGAACTTACTCACAGAGCTGGTCAACAAAGGAAGAGTGCCATAC  
CCAGGCATGAACAACCGGGAGGTGCTGGAGCAGGTGGAGCGAGGCTACAGGATGCCCTGC  
CCGCAGGACTGCCCCATCTCTCTGCATGAGCTCATGATCCACTGCTGGAAAAGGACCCT  
GAAGAACGCCCCACTTTTGAGTACTTGCAGAGCTTCCTGGAAGACTACTTTACCGCGACA  
GAGCCCCAGTACCAACCTGGTGAAAACCTGTAAGGCCCGGGTCTGCGGAGAGAGGCCTTG  
TCCCAGAGGCTGCCCCACCCCTCCCCATTAGCTTTCAATTCCGTAGCCAGCTGCTCCCCA  
GCAGCGGAACCGCCCAGGATCAGATTGCATGTGACTCTGAAGCTGACGAACTTCCATGGC  
CCTCATTAATGACACTTGTCCCCAAATCCGAACCTCCTCTGTGAAGCATTCGAGACAGAA  
CCTTGTTATTTCTCAGACTTTGGAAAATGCATTGTATCGATGTTATGTAAAAGGCCAAAC  
CTCTGTTTCAGTGTAATAAGTTACTCCAGTGCCAACAATCCTAGTGCTTTCCTTTTTTTAA  
AATGCAAATCCTATGTGATTTTAACTCTGTCTTCACCTGATTCAACTAAAAA AAG  
TATTATTTTCCAAAAGTGGCCTCTTTGTCTAAACAATAAAATTTTTTTTCATGTTTTAA  
CAAAAACCAA

>gi|4503823|gb|NP\_002028.1|FYN 537aa linear protein-tyrosine  
kinase fyn isoform a; proto-oncogene tyrosine-protein kinase  
fyn; src/yes-related novel gene; src-like kinase; c-syn

- 121 -

protooncogene; tyrosine kinase p59fyn(T); OKT3-induced calcium influx regulator [Homo sapiens].

MGCVQCKDKEATKLTEERDGS LNQSSGYRYGTDPTPOHYPSFGVTSIPNYNNFHAAGGQG  
LTVFGGVNSSSHTGTLRTRGGTGVTLFVALYDYEARTEDDLSFHKGEKFQILNSSEGDDW  
EARS LTTGETGYIPSNYVAPVDSIQAEWYFGKLGRKDAERQLLSFGNPRGTFLIRESET  
TKGAYSLSIRDWDDMKGDHVKHYKIRKLDNGGYIITTRAQFETLQQLVQHYSERAAAGLCC  
RLVVPCHKGMPRLTDLSVKT KDVWEIPRESLQLIKRLGNGQFGEVWMGTWNGNTKVAIKT  
LKPGTMSPE SFLEEAQIMKKLKHDKLVQLYAVVSEEP IYIVTEYMNKGSLLDFLKDGEGR  
ALKLPNLVDMAAQVAAGMAYIERMNYIHRDLRSANILVGNGLICKIADFG LARLIEDNEY  
TARQGA KFPIKWTAP EAALYGRFTIKSDVWSFGILLTELVT KGRVPYPGMNNREVLEQVE  
RGYRMPCPQDCPISLHELMIH CWKKDPEERPTFEYLQSFLEDYFTATEPQYQPGENL  
>gi|15055546|gb|NM\_000800.2|FGF1 2357bp mRNA Homo sapiens  
fibroblast growth factor 1 (acidic) (FGF1), transcript variant  
1, mRNA.

GAGCCGGGCTACTCTGAGAAGAAGACACCAAGTGGATTCTGCTTCCCCTGGGACAGCACT  
GAGCGAGTGTGGAGAGAGGTACAGCCCTCGGCCTACAAGCTCTTTAGTCTTGAAAGCGCC  
ACAAGCAGCAGCTGCTGAGCCATGGCTGAAGGGGAAATCACCACCTTCACAGCCCTGACC  
GAGAAGTTTAATCTGCCTCCAGGGAATTACAAGAAGCCCAAACCTCCTCTACTGTAGCAAC  
GGGGGCCACTTCTGAGGATCCTTCCGGATGGCACAGTGGATGGGACAAGGGACAGGAGC  
GACCAGCACATTCAGCTGCAGCTCAGTGC GGAAAGCGTGGGGGAGGTGTATATAAAGAGT  
ACCGAGACTGGCCAGTACTTGGCCATGGACACCGACGGGCTTTTATACGGCTCACAGACA  
CCAAATGAGGAATGTTTGTTCCTGGAAAGGCTGGAGGAGAACCATTACAACACCTATATA  
TCCAAGAAGCATGCAGAGAAGAATTGGTTTGTGTCCTCAAGAAGAATGGGAGCTGCAAA  
CGCGGTCCTCGGACTCACTATGGCCAGAAAGCAATCTTGTTTCTCCCCCTGCCAGTCTCT  
TCTGATTAAAGAGATCTGTTCTGGGTGTTGACCACTCCAGAGAAGTTTCGAGGGGTCCTC  
ACCTGGTTGACCCAAAAATGTTCCCTTGACCATTGGCTGCGCTAACCCCCAGCCACAGA  
GCCTGAATTTGTAAGCAACTTGCTTCTAAATGCCAGTTCACTTCTTGCAGAGCCTTTT  
ACCCCTGCACAGTTTAGAACAGAGGGACCAAATTGCTTCTAGGAGTCAACTGGCTGGCCA  
GTCTGGGTCTGGGTTTGGATCTCCAATTGCCTCTTGCAGGCTGAGTCCCTCCATGCAAAA  
GTGGGGCTAAATGAAGTGTGTTAAGGGGTGCGCTAAGTGGGACATTAGTAACTGCACACT  
ATTTCCCTCTACTGAGTAAACCTATCTGTGATTCCCCCAAACATCTGGCATGGCTCCCT  
TTTGTCTTCTGTGCCCTGCAAATATTAGCAAAGAAGCTTCATGCCAGGTTAGGAAGGC  
AGCATTCCATGACCAGAAACAGGGACAAAGAAATCCCCCTTCAGAACAGAGGCATTTAA  
AATGGAAAAGAGAGATTGGATTTTGGTGGGTAACTTAGAAGGATGGCATCTCCATGTAGA  
ATAAATGAAGAAAGGGAGGCCAGCCGAGGAAGGCAGAATAAATCCTTGGGAGTCATTA  
CCACGCCTTGACCTTCCCAAGGTTACTCAGCAGCAGAGAGCCCTGGGTGACTTCAGGTGG  
AGAGCACTAGAAGTGGTTTCTGATAACAAGCAAGGATATCAGAGCTGGGAAATTCATGT  
GGATCTGGGGACTGAGTGTGGGAGTGCAGAGAAAGAAAGGGAAACTGGCTGAGGGGATAC  
CATAAAAAGAGGATGATTT CAGAAGGAGAAGGAAAAAGAAAGTAATGCCACACATTGTGC  
TTGGCCCCCTGGTAAGCAGAGGCTTTGGGGTCTTAGCCAGTGCTTCTCCAACACTGAAGT  
GCTTGCAGATCATCTGGGGACCTGGTTTGAATGGAGATTCTGATT CAGTGGGTGGGGGC  
AGAGTTTCTGCAGTTCCATCAGGTCCCCCCCCAGGTGCAGGTGCTGACAATACTGCTGCCT  
TACCCGCCATACATTAAGGAGCAGGGTCTTGGTCTTAAAGAGTTATTCAAATGAAGGTGG  
TTCGACGCCCCGAACCTCACCTGACCTCAACTAACCTTAAAAATGCACACCTCATGAGT  
CTACCTGAGCATT CAGGCAGCACTGACAATAGTTATGCCTGTACTAAGGAGCATGATTTT  
AAGAGGCTTTGGCCAATGCCTATAAAATGCCCATTTTGAAGATATACAAAAACATACTTC  
AAAAATGTTAAACCTTACCAACAGCTTTTCCCAGGAGACCATTGTATTACCATTACTT

- 122 -

GTATAAATACACTTCCTGCTTAACTTGACCCAGGTGGCTAGCAAATTAGAAACACCATT  
CATCTCTAACATATGATACTGATGCCATGTAAAGGCCTTTAATAAGTCATTGAAATTTAC  
TGTGAGACTGTATGTTTTAATTGCATTTAAAAATATATAGCTTGAAAGCAGTTAACTGA  
TTAGTATTTCAGGCACTGAGAATGATAGTAATAGGATACAATGTATAAGCTACTCATTAT  
CTGATACTTATTTACCTATAAAATGAGATTTTTGTTTTTCCACTGTGCTATTACAAATTTT  
CTTTTGAAAGTAGGAACCTTAAGCAATGGTAATTGTGAATAAAAATTGATGAGAGTGTT  
AAAAAAAAAAAAAAAAAAAA

>gi|4503697|gb|NP\_000791.1|FGF1 155aa linear fibroblast growth  
factor 1 (acidic) isoform 1 precursor; heparin-binding growth  
factor 1 precursor; endothelial cell growth factor, alpha;  
endothelial cell growth factor, beta [Homo sapiens].

MAEGEITTTFTALTEKFNLPNGYKKPKLLYCSNGGHFLRILPDGTVDGTRDRSDQHIQLQ  
LSAESVGEVYIKSTETGQYLAMDTDGLLYGSQTPNEECLFLERLEENHYNTYISKKHAEK  
NWFVGLKKNKSGCKRGPRTHYGQKAILFLPLPVSSD

>gi|27552761|gb|NM\_002825.3|PTN 1029bp mRNA Homo sapiens  
pleiotrophin (heparin binding growth factor 8, neurite growth-  
promoting factor 1) (PTN), mRNA.

TCTGCTTTTAATAAGCTTCCCAATCAGCTCTCGAGTGCAAAGCGCTCTCCCTCCCTCGCC  
CAGCCTTCGTCCTCCTGGCCCGCTCCTCTCATCCCTCCCATTTCTCCATTTCCCTTCCGTT  
CCCTCCCTGTCAGGGCGTAATTGAGTCAAAGGCAGGATCAGGTTCCCCGCCTTCCAGTCC  
AAAAATCCCGCCAAGAGAGCCCCAGAGCAGAGGAAATCCAAAGTGGAGAGAGGGGAAGA  
AAGAGACCAGTGAGTCATCCGTCCAGAAGGCGGGGAGAGCAGCAGCGGCCCAAGCAGGAG  
CTGCAGCGAGCCGGGTACCTGGACTCAGCGGTAGCAACCTCGCCCCCTTGCAACAAAGGCA  
GACTGAGCGCCAGAGAGGACGTTTCCAACCTCAAAAATGCAGGCTCAACAGTACCAGCAGC  
AGCGTCGAAAATTTGCAGCTGCCTTCTTGGCATTTCATTTTCATACTGGCAGCTGTGGATA  
CTGCTGAAGCAGGGAAGAAAGAGAAACCAGAAAAAAAGTGAAGAAGTCTGACTGTGGAG  
AATGGCAGTGAGTGTGTGTGTGCCCCACAGTGGAGACTGTGGGCTGGGCACACGGGAGG  
GCACTCGGACTGGAGCTGAGTGCAAGCAAACCATGAAGACCCAGAGATGTAAGATCCCCCT  
GCAACTGGAAGAAGCAATTTGGCGCGGAGTGCAAATACCAGTTCCAGGCCTGGGGAGAAT  
GTGACCTGAACACAGCCCTGAAGACCAGAAGTGAAGTCTGAAGCGAGCCCTGCACAATG  
CCGAATGCCAGAAGACTGTCACCATCTCCAAGCCCTGTGGCAAACCTGACCAAGCCCAAAC  
CTCAAGCAGAATCTAAGAAGAAGAAAAAGGAAGGCAAGAAACAGGAGAAGATGCTGGATT  
AAAAGATGTCACCTGTGGAACATAAAAAGGACATCAGCAAACAGGATCAGTTAACTATTG  
CATTTATATGTACCGTAGGCTTTGTATTCAAAAATTATCTATAGCTAAGTACACAATAAG  
CAAAAACAA

>gi|4506281|gb|NP\_002816.1|PTN 168aa linear pleiotrophin  
(heparin binding growth factor 8, neurite growth-promoting  
factor 1); heparin affin regulatory protein; heparin-binding  
growth-associated molecule [Homo sapiens].

MQAQYQYQRRKFAAAFLAFIFILAAVDTAEGKKKEKPEKKVKKSDCGEWQWSVCVPTSG  
DCGLGTREGTRTGAECKQTMKTQRCKIPCNWKKQFGAECKYQFQAWGECDLNTALKTRTG  
SLKRALHNAECQKTVTISKPCGKLTKPKPQAESKKKKKEGKKQEKMLD

>gi|4504008|gb|NM\_000169.1|GLA 1350bp mRNA Homo sapiens  
galactosidase, alpha (GLA), mRNA.

AGGTTAATCTTAAAAGCCCAGGTTACCCGCGGAAATTTATGCTGTCCGGTCACCGTGACA  
ATGCAGCTGAGGAACCCAGAACTACATCTGGGCTGCGCGCTTGCGCTTCGCTTCCTGGCC  
CTCGTTTCCTGGGACATCCCTGGGGCTAGAGCACTGGACAATGGATTGGCAAGGACGCCT

- 123 -

ACCATGGGCTGGCTGCACTGGGAGCGCTTCATGTGCAACCTTGACTGCCAGGAAGAGCCA  
GATTCCTGCATCAGTGAGAAGCTCTTCATGGAGATGGCAGAGCTCATGGTCTCAGAAGGC  
TGGAAGGATGCAGGTTATGAGTACCTCTGCATTGATGACTGTTGGATGGCTCCCCAAAGA  
GATTCAGAAGGCAGACTTCAGGCAGACCCTCAGCGCTTTCCTCATGGGATTCGCCAGCTA  
GCTAATTATGTTACAGCAAAGGACTGAAGCTAGGGATTTATGCAGATGTTGGAAAATAAA  
ACCTGCGCAGGCTTCCCTGGGAGTTTTGGATACTACGACATTGATGCCAGACCTTTGCT  
GACTGGGGAGTAGATCTGCTAAAATTTGATGGTTGTTACTGTGACAGTTTGGAAAATTTG  
GCAGATGGTTATAAGCACATGTCCTTGGCCCTGAATAGGACTGGCAGAAGCATTGTGTAC  
TCCTGTGAGTGGCCTCTTTATATGTGGCCCTTTCAAAGCCCAATTATACAGAAATCCGA  
CAGTACTGCAATCACTGGCGAAATTTTGCTGACATTGATGATTCCTGGAAAAGTATAAAG  
AGTATCTTGGACTGGACATCTTTTAACCAGGAGAGAATTGTTGATGTTGCTGGACCAGGG  
GGTTGGAATGACCCAGATATGTTAGTGATTGGCAACTTTGGCCTCAGCTGGAATCAGCAA  
GTAATCAGATGGCCCTCTGGGCTATCATGGCTGCTCCTTTATTCATGTCTAATGACCTC  
CGACACATCAGCCCTCAAGCCAAAGCTCTCCTTCAGGATAAGGACGTAATTGCCATCAAT  
CAGGACCCCTTGGGCAAGCAAGGGTACCAGCTTAGACAGGGAGACAACCTTTGAAGTGTGG  
GAACGACCTCTCTCAGGCTTAGCCTGGGCTGTAGCTATGATAAACCGGCAGGAGATTGGT  
GGACCTCGCTCTTATACCATCGCAGTTGCTTCCCTGGGTAAAGGAGTGGCCTGTAATCCT  
GCCTGCTTCATCACACAGCTCCTCCCTGTGAAAAGGAAGCTAGGGTTCTATGAATGGACT  
TCAAGGTTAAGAAGTCACATAAATCCACAGGCACTGTTTTGCTTCAGCTAGAAAATACA  
ATGCAGATGTCATTAAAAGACTTACTTTAA

>gi|4504009|gb|NP\_000160.1|GLA 429aa linear galactosidase,  
alpha [Homo sapiens].

MQLRNPELHLGCALALRFLALVSWDIPGARALDNGLARTPTMGWLHWERFMCNLDCQEEP  
DSCISEKLFMEMAELMVSEGWKADAGYEYLCIDDCWMA PQRDSEGR LQADPQRFPHGIRQL  
ANYVHSGKGLKLG IYADVGNKTCAGFPGSFGYYDIDAQTFADWGV DLLKFDG CYCDSL ENL  
ADGYKHMSLALNRTGRSIVYSCEWPLYMWPFQKPNYTEIRQYCNHWRNFADIDDSWKS IK  
SILDWTSFNQERIVDVAGPGGWNDPDM LVIGNFGLSWNQV TQMALWAIMAAPLFMSNDL  
RHISPQAKALLQDKDVIAINQDPLGKQGYQLRQGDNF EVWERPLSGLAWAVAMINRQEIG  
GPRSYTIAVASLGKVACNPACFITQLLPVKRKLGFYEWTSRLRSHINPTGTVLLQLENT  
MQMSLKDLL

>gi|18587778|gb|XM\_091624.1|LOC162542 287bp mRNA Homo sapiens  
similar to ADP-ribosylation factor 1 (LOC162542), mRNA.

GTCTGATTTTTTATGGTTGACAGTAATGACAGAGAGCAGATTGATGAGGCCTGGGAAGTGC  
TAACTTACTTTGTTAGAGGACGATGAGCTCAGAAATGCAGTTTTTATTGGTATTTGCCAATA  
AACAAAGATCTCCCTAATACTATGAACGCGGCAGAGATAACGGACAAGCTCGGCCTCCATT  
CCCTCCGCTACAGAAACTGGCACATT CAGGCTACTTGTGCCACTACTGGACATGGGCTTT  
ACGAAGGCCTGAACTGGCTCGCCAACCAGTTCCAGAACCAGAACTGA

>gi|18587779|gb|XP\_091624.1|LOC162542 91aa linear similar to  
ADP-ribosylation factor 1 [Homo sapiens].

MVDSNDREQIDEAWEVLTYLLEDDEL RNAVLLVFANKQDLPNTMNAAEITDKLGLHSLRY  
RNWHIQATCATTGHGLYEGLNWL ANQFQNQN

>gi|4557572|gb|NM\_000401.1|EXT2 3781bp mRNA Homo sapiens  
exostoses (multiple) 2 (EXT2), mRNA.

CTGTCTGAGCATTTCACTGCGGAGCCTGAGCGCGCCTGCCTGGGAAAACACTGCAGCGGT  
GCTCGGACTCCTCCTGTCCAGCAGGAGGCGCGGCCCGGCAGCTCCCGCATGCGCAGTGCG  
CTCGGTGTCAGACGGCCCGGATCCCGGTTACCGGCCCTCGCTCGCTGCTCGCCAGCCCA  
GACTCGGCCCTGGCAGTGGCGGCTGGCGATTCCGACCGATCCGACCTGGGCGGAGGTGGC



- 124 -

CCGCGCCCCGCGGCATGAGCCGGTGACCAAGCTCGGGGCCGAGCGGGAGGCAGCCGTGGC  
CGAGCCACAGGGATCTGATTCCCTCCAGGGGGATGTCTTGCGCCTCAGGGTCCGGTGGTG  
GCCTGCGGCATCCCTTGCGGTGCCAGAAGCCGTGGGACGAGTGTCTTTAATGTTATAGAG  
CTACTCAGAGTTGCTGTTTCTCCTTGAGATGCTTTTGAGTGTGAGGAAGAGGCTGTCTG  
TGTCATTATGTGTGCGTGGTCAAGTATAATATCCGGGGTCTTGCCCTCATCCCAAGAAT  
GAAGACCAAGCACCGAATCTACTATATCACCTCTTCTCCATTGTCTCTGGGCCTCAT  
TGCCACTGGCATGTTTCAGTTTTGGCCCCATTCTATCGAGTCTCAAATGACTGGAATGT  
AGAGAAGCGCAGCATCCGTGATGTGCCGGTTGTTAGGCTGCCAGCCGACAGTCCCATCCC  
AGAGCGGGGGGATCTCAGTTGCAGAAATGCACACGTGTTTTGATGTCTATCGCTGTGGCTT  
CAACCCAAAGAACAAAATCAAGGTGTATATCTATGCTCTGAAAAAGTACGTGGATGACTT  
TGGCGTCTCTGTGTCAGCAACACCATCTCCCGGGAGTATAATGAACTGCTCATGGCCATCTC  
AGACAGTGACTIONACTGATGACATCAACCGGGCCTGTCTGTTTGTTCCTCCATCGA  
TGTGCTTAACCAGAACACACTGCGCATCAAGGAGACAGCACAAGCGATGGCCCAGCTCTC  
TAGGTGGGATCGAGGTACGAATCACCTGTTGTTCAACATGTTGCCTGGAGGTCCCCCAGA  
TTATAACACAGCCCTGGATGTCCCCAGAGACAGGGCCCTGTTGGCTGGTGGCGGCTTTTC  
TACGTGGACTTACCGGCAAGGCTACGATGTCAGCATTCTGTCTATAGTCCACTGTCAGC  
TGAGGTGGATCTTCCAGAGAAAGGACCAGGTCCACGGCAATACTTCTCTCTGTATCTCA  
GGTGGGTCTCCATCCTGAGTACAGAGAGGACCTAGAAGCCCTCCAGGTCAAACATGGAGA  
GTCAGTGTTAGTACTCGATAAATGCACCAACCTCTCAGAGGGTGTCTTTCTGTCCGTAA  
GCGCTGCCACAAGCACCGGTCTTCGATTACCCACAGGTGCTACAGGAGGCTACTTTCTG  
TGTGGTTCTTCGTGGAGCTCGGCTGGGCCAGGCAGTATTGAGCGATGTGTTACAAGCTGG  
CTGTGTCCCGTTGTCAATTGCAGACTCCTATATTTTGCCTTTCTCTGAAGTTCTTGACTG  
GAAGAGAGCATCTGTGGTTGTACCAGAAGAAAAGATGTCAGATGTGTACAGTATTTTGCA  
GAGCATCCCCCAAAGACAGATTGAAGAAATGCAGAGACAGGCCCGGTGGTTCTGGGAAGC  
GTACTTCCAGTCAATTAAAGCCATTGCCCTGGCCACCCTGCAGATTATCAATGACCGGAT  
CTATCCATATGCTGCCATCTCCTATGAAGAATGGAATGACCCTCCTGCTGTGAAGTGGGG  
CAGCGTGAGCAATCCACTCTTCTCCTCCCGCTGATCCCACCACAGTCTCAAGGGTTACCGC  
CATAGTCTCTACCTACGACCGAGTAGAGAGCCTCTTCCGGGTCACTGAAGTGTCCAA  
GGTGCCCACTCTATCCAACTACTTGTGCTCTGGAATAATCAGAATAAAAACCTCCAGA  
AGATTCTCTCTGGCCCCAAAATCCGGGTTCATTAAAGTTGTGAGGACTGCTGAAAACAA  
GTTAAGTAACCGTTTCTTCCCTTATGATGAAATCGAGACAGAAGCTGTTCTGGCCATTGA  
TGATGATATCATTATGCTGACCTCTGACGAGCTGCAATTTGGTTATGAGGTCTGGCGGGA  
ATTTCTGACCGGTTGGTGGGTTACCCGGGTCTGCTGCATCTCTGGGACCATGAGATGAA  
TAAGTGGAAGTATGAGTCTGAGTGGACGAATGAAGTGTCCATGGTGCTCACTGGGGCAGC  
TTTTTATCACAGTATTTTAATTACCTGTATACCTACAAAATGCCTGGGGATATCAAGAA  
CTGGGTAGATGCTCATATGAACTGTGAAGATATTGCCATGAACTTCTGGTGGCCAACGT  
CACGGGAAAAGCAGTTATCAAGGTAACCCACGAAAGAAATTCAAGTGTCTGAGTGCAC  
AGCCATAGATGGGCTTTCACTAGACCAAACACACATGGTGGAGAGGTGAGAGTGCATCAA  
CAAGTTTGCTTCAGTCTTCCGGGACCATGCCTCTCAAGGTGGTGGAAACACCGAGCTGACCC  
TGTCCTGTACAAAGATGACTTTCTGAGAAGCTGAAGAGCTTCCCCAACATTGGCAGCTT  
ATGAAACGTGTCAATTGGTGGAGGTCTGAATGTGAGGCTGGGACAGAGGGAGAGAAACAAGG  
CCTCCCAGCACTCTGATGTGAGAGTAGTAGGTTAAGGGTGGAAAGTTGACCTACTTGGAT  
CTTGGCATGCACCCACCTAACCCACTTTCTCAAGAACAAGAACCTAGAATGAATATCCAA  
GCACCTCGAGCTATGCAACCTCTGTTCTTGTATTTCTTATGATCTCTGATGGGTTCTTCT  
CGAAAATGCCAAGTGGAAGACTTTGTGGCATGCTCCAGATTTAAATCCAGCTGAGGCTCC  
CTTTGTTTTTCAGTTCCATGTAACAATCTGGAAGGAACTTCACGGACAGGAAGACTGCTG  
GAGAAGAGAAGCGTGTTAGCCCATTTGAGGTCTGGGGAATCATGTAAAGGGTACCCAGAC



- 125 -

CTCACTTTTAGTTATTTACATCAATGAGTTCTTTCAGGGAACCAAACCCAGAATTCGGTG  
CAAAAGCCAAACATCTTGGTGGGATTTGATAAATGCCTTGGGACCTGGAGTGCTGGGCTT  
GTGCACAGGAAGAGCACCAGCCGCTGAGTCAGGATCCTGTCAGTTCCATGAGCTATTCCT  
CTTTGGTTTGGCTTTTTTGATATGATTAAAATTATTTTTTATTCTTTTTCTACTGTGTCT  
TAAACACCAATTCCTGATAGTCCAAGGAACCACCTTCTCCCTTGATATATTTAACTCCG  
TCTTTGGCCTGACAACAGTCTTCTGCCCATGTCTGGGAACACACGCCAGGAGGAATGTCT  
GATACCCTCTGCATCAAGCGTAAGAAGGTCCCAAATCATAACCATTTTAAGAACAGATGA  
CTCAGAAACCTCCAGAGGAATCTGTTTGCTTCCTGATTAGATCCAGTCAATGTTTTAAAG  
GTATTGTCAGAGAAAAACAGAGGGTCTGTACTAGCCATGCAAGGAGTCGCTCTAGCTGGT  
ACCCGTAAAAGTTGTGGGATTTGTGACCCCCCATCCCAAGGGGATGCCAAAATTTCTCTCA  
TTCTTTTGGTATAAACTTAACATTAGCCAGGGAGGTTCTGGCTAACGTTAAATGCTGCTA  
TACAACTGCTTTGCAACAGTTGCTGGTATATTTAAATCATTAATTTTCAGCATTTACTAA  
T

>gi|4557573|gb|NP\_000392.1|EXT2 718aa linear exostoses  
(multiple) 2 [Homo sapiens].

MCASVKYNIRGPALIPRMKTKHRIYYITLFSIVLLGLIATGMFQFWPHSIESSNDWNVEK  
RSIRDVPVRLPADSPIPERGDLSCRMHTCFDVYRCGFNPKNKIKVYIYALKKYVDDFGV  
SVSNTISREYNELLMAISDSYYTDDINRACLFVPSIDVLNQNTLRKETQAQAMAQLSRW  
DRGTNHLLEFNMLPGGPPDYNTALDVPDRALLAGGGFSTWTYRQGYDVSIPVYSPLSAEV  
DLPEKGPGRQYFLLSSQVGLHPEYREDLEALQVKHGESVLVLDKCTNLSEGVLSVRKRC  
HKHQVFDYPQVLQEATFCVVLRGARLGQAVLSDVLQAGCVPVVIADSYILPFSEVLDWKR  
ASVVVPEEKMSDVYSILQSIQQRQIEEMQROARWFWEAYFQSIKAIALATLQIINDRIYP  
YAAISYEEWNDPPAVKWGSVSNPLFLPLIPPQSOGFTAIVLTYDRVESLFRVITEVSKVP  
SLSKLLVWNNQNKNPPEDSLWPKIRVPLKVVRTAENKLSNRFFPYDEIETEAVLAIDDD  
IIMLTSDDELQFGYEVWREFPDRLVGYPGRHLHLDHEMNKWKYSEWTNEVSMVLTGAIFY  
HKYFNYLYTYKMPGDIKNWVDAHMNCEDIAMNFLVANVTGKAVIKVTPRKKFKCPECTAI  
DGLSLDQTHMVERSEKINKFASVFGTMPLKVVEHRADPVLYKDDFPEKLKSFNIGSL  
>gi|27597083|gb|NM\_006838.2|METAP2 1908bp mRNA Homo sapiens  
methionyl aminopeptidase 2 (METAP2), mRNA.

CTCTGTCTCATTCCCTCGCGCTCTCTCGGGCAACATGGCGGGTGTGGAGGAGGTAGCGGC  
CTCCGGGAGCCACCTGAATGGCGACCTGGATCCAGACGACAGGGAAGAAGGAGCTGCCTC  
TACGGCTGAGGAAGCAGCCAAGAAAAAAGACGAAAGAAGAAGAAGAGCAAAGGGCCTTC  
TGCAGCAGGGGAACAGGAACCTGATAAAGAATCAGGAGCCTCAGTGGATGAAGTAGCAAG  
ACAGTTGGAAAGATCAGCATTGGAAGATAAAGAAAGAGATGAAGATGATGAAGATGGAGA  
TGGCGATGGAGATGGAGCAACTGGAAAGAAGAAGAAAAAGAAGAAGAAGAGAGGACC  
AAAAGTTCAAACAGACCCTCCCTCAGTTCCAATATGTGACCTGTATCCTAATGGTGTATT  
TCCCAAAGGACAAGAATGCGAATACCCACCCACACAAGATGGGCGAACAGCTGCTTGGAG  
AACTACAAGTGAAGAAAAGAAAGCATTAGATCAGGCAAGTGAAGAGATTTGGAATGATTT  
TCGAGAAGCTGCAGAAGCACATCGACAAGTTAGAAAATACGTAATGAGCTGGATCAAGCC  
TGGGATGACAATGATAGAAATCTGTGAAAAGTTGGAAGACTGTTACGCAAGTTAATAAA  
AGAGAATGGATTAAATGCAGGCCTGGCATTTCCTACTGGATGTTCTCTCAATAATTGTGC  
TGCCCATTTATACTCCCAATGCCGGTGACACAACAGTATTACAGTATGATGACATCTGTAA  
AATAGACTTTTGAACACATATAAGTGGTAGGATTATTGACTGTGCTTTTACTGTCACTTT  
TAATCCCAAATATGATACGTTATTTAAAGCTGTAAAAGATGCTACTAACACTGGAATAAA  
GTGTGCTGGAATTGATGTTCTGTGTGATGTTGGTGAGGCCATCCAAGAAGTTATGGA  
GTCCTATGAAGTTGAAATAGATGGGAAGACATATCAAGTGAAACCAATCCGTAATCTAAA  
TGGACATTCAATTGGGCAATATAGAATACATGCTGGAAAAACAGTGCCGATTGTGAAAGG

- 126 -

AGGGGAGGCAACAAGAATGGAGGAAGGAGAAGTATATGCAATTGAAACCTTTGGTAGTAC  
AGGAAAAGGTGTTGTTTCATGATGATATGGAATGTTTACATTACATGAAAAATTTTGATGT  
TGGACATGTGCCAATAAGGCTTCCAAGAACAAAACACTTGTTAAATGTCATCAATGAAAA  
CTTTGGAACCCCTTGCCTTCTGCCGCAGATGGCTGGATCGCTTGGGAGAAAGTAAATACTT  
GATGGCTCTGAAGAATCTGTGTGACTTGGGCATTGTAGATCCATATCCACCATTATGTGA  
CATTAAAGGATCATATACAGCGCAATTTGAACATACCATCCTGTTGCGTCCAACATGTAA  
AGAAGTTGTCAGCAGAGGAGATGACTATTAACTTAGTCCAAAGCCACCTCAACACCTTT  
ATTTTCTGAGCTTTGTTGGAAAACATGATACCAGAATTAATTTGCCACATGTTGTCTGTT  
TTAACAGTGGACCCATGTAATACTTTTATCCATGTTTAAAAAGAAGGAATTTGGACAAAG  
GCAAACCGTCTAATGTAATTAACCAACGAAAAAGCTTTCCGGACTTTTAAATGCTAACTG  
TTTTTCCCCTTCTGTCTAGGAAAATGCTATAAAGCTCAAATTAGTTAGGAATGACTTAT  
ACGTTTTGTTTTGAATACCTAAGAGATACTTTTTTGGATATTTATATTGCCATATTCTTAC  
TTGAATGCTTTGAATGACTACATCCAGTTCTGCACCTATACCCTCTGGTGTGCTTTTTTA  
ACCTTCCTGGAATCCATTTCTAAAAAATAAAGACATTTTTCAGATCTGA

>gi|5803092|gb|NP\_006829.1|METAP2 478aa linear methionyl  
aminopeptidase 2; methionine aminopeptidase; eIF-2-associated  
p67 [Homo sapiens].

MAGVEEVAASGSHLNGDLDPDDREEGAASTAEAAKKRRKKKKSKGPSAAGEQEPDKES  
GASVDEVARQLERSALEDKERDEDEDGDDGDGDGATGKKKKKKKKKRGPKVQTDPPSVPI  
CDLYPNGVFPKGQCECEYPPTQDGRТААWRTTSEEKKALDQASEEIWNDFREAAEAHRQVR  
KYVMSWIKPGMTMIEICEKLEDCSRKLIKENGLNAGLAFPTGCSLNNCAAHYTPNAGDIT  
VLQYDDICKIDFGTHISGRIIDCAFTVTFNPKYDTLLKAVKDATNTGIKCAGIDVRLCDV  
GEAIQEVMESEYEVEIDGKTYQVKPIRNLNGHSIGQYRIHAGKTVPIVKGGEATRMEEGEV  
YAIETFGSTGKGVVHDDMECSHYMKNFDVGHVPIRLPRTKHLNINENFGTLAFCCRRL  
DRLGESKYLKMLKNCGLGIVDPYPPLCDIKGSYTAQFEHTILLRPTCKEVVSRGDDY

>gi|10864040|gb|NM\_021230.1|MLL3 12689bp mRNA Homo sapiens  
myeloid/lymphoid or mixed-lineage leukemia3 (MLL3), mRNA.  
AAAATTCCTTAGTTGCTGGCTTTGACCTTTTATGTTGCTGAGTTTTACACATCTATTTTC  
TCAACTGCCATATCCTAGGGGGCTTGGAGTACCCATAATACAGTGAGCCCACCTTCCTGG  
TCCCAGACATTTTCAAGAGTCCGGGAAATTTTAAACCCAGGCAGCTTCCTGGCAGTGCC  
ATTTGGAGCATCAAAGTGGGCCGTGGGTCTGGATTTCAGGAAAGCGGAGACCTCGAGGT  
GCAGGACTGTCCGGGCGAGGTGGCCGAGGCAGGTCAAAGCTGAAAAGTGGAATCGGAGCT  
GTTGTATTACCTGGGGTGTCTACTGCAGATATTTTATCAAATAAGGATGATGAAGAAAAC  
TCTATGCACAATACAGTTGTGTTGTTTTCTAGCAGTGACAAGTTCACTTTGAATCAGGAT  
ATGTGTGTAGTTTGTGGCAGTTTTGGCCAAGGAGCAGAAGGAAGATTACTTGCCTGTTCT  
CAGTGTGGTCAGTGTACCATCCATACTGTGTGAGTATTAAGATCACTAAAGTGGTTCTT  
AGCAAAGGTTGGAGGTGTCTTGAGTGCAGTGTGTGTGAGGCCTGTGGGAAGGCAACTGAC  
CCAGGAAGACTCCTGCTGTGTGATGACTGTGACATAAGTTATCACACCTACTGCCTAGAC  
CCTCCATTGCAGACAGTTCCCAAAGGAGGCTGGAAGTGCAAATGGTGTGTTTGGTGCAGA  
CACTGTGGAGCAACATCTGCAGGTCTAAGATGTGAATGGCAGAACAAATTACACACAGTGC  
GCTCCTTGTGCAAGCTTATCTTCTGTCCAGTCTGCTATCGAACTATAGAGAAGAAGAT  
CTTATTCTGCAATGTAGACAATGTGATAGATGGATGCATGCAGTTTGTGAGAACTTAAAT  
ACTGAGGAAGAAGTGGAAGATGTAGCAGACATTGGTTTTGATTGTAGCATGTGCAGACCC  
TATATGCCTGCGTCTAATGTGCCTTCCTCAGACTGCTGTGAATCTTCACTTGTAGCACAA  
ATTGTCACAAAAGTAAAAGAGCTAGACCCACCAAGACTTATACCCAGGATGGTGTGTGT  
TTGACTGAATCAGGGATGACTCAGTTACAGAGCCTCACAGTTACAGTTCCAAGAAGAAAA  
CGGTCAAACCAAAATTGAAATTGAAGATTATAAATCAGAATAGCGTGGCCGTCCTTCAG

- 127 -

ACCCCTCCAGACATCCAATCAGAGCATTCAAGGGATGGTGAAATGGATGATAGTCGAGAA  
GGAGAACTTATGGATTGTGATGGAAAATCAGAATCTAGTCCTGAGCGGGAAGCTGTGGAT  
GATGAAACTAAGGGAGTGGAAGGAACAGATGGTGTCAAAAAGAGAAAAAGGAAACCATAC  
AGACCAGGTATTGGTGGATTTATGGTGCGGCAAAGAAGTCGAACTGGGCAAGGGAAAACC  
AAAAGATCTGTGATCAGAAAAGATTCCCTCAGGCTCTATTTCCGAGCAGTTACCTTGCAGA  
GATGATGGCTGGAGTGAGCAGTTACCAGATACTTTAGTTGATGAATCTGTTTTCTGTTACT  
GAAAGCACTGAAAAAATAAAGAAGAGATACCGAAAAAGGAAAAATAAGCTTGAAGAACT  
TTCCCTGCCTATTTACAAGAAGCTTTCTTTGGAAAAGATCTTCTAGATACAAGTAGACAA  
AGCAAGATAAGTTTAGATAATCTGTCAGAAGATGGAGCTCAGCTTTTATATAAAACAAAC  
ATGAACACAGGTTTCTTGGATCCTTCCCTTAGATCCACTACTTAGTTTCATCCTCGGCTCCA  
ACAAAATCTGGAACCTCACGGTCCCTGCTGATGACCCATTAGCTGATATTTCTGAAGTTTAA  
AACACAGATGATGACATTCTTGGATAATTTTCAGATGATCTAGCAAAATCAGTTGATCAT  
TCAGATATTGGTCCTGTCACTGATGATCCTTCCCTCTTTGCCTCAGCCAAATGTCAATCAG  
AGTTCACGACCATTAAAGTGAAGAACAGCTAGATGGGATCCTCAGTCCTGAACTAGACAAA  
ATGGTTCACAGATGGAGCAATTCTTGGAAAATTATATAAAATTCAGAGCTTGGCGGAAAA  
GATGTTGAAGACTTATTTACAGCTGTACTTAGTCCTGCGAACTCAGCCAACTCCATTG  
CCACAGCCTCCCCACCAACACAGCTGTTGCCAATACACAATCAGGATGCTTTTTTCACGG  
ATGCCTCTCATGAATGGCCTTATTGGATCCAGTCCTCATCTCCACATAATTCTTTGCCA  
CCTGGAAGCGGACTGGGAACTTTCTCTGCAATTGCACAATCCTCTTATCCTGATGCCAGG  
GATAAAAATTCAGCCTTTAATCCAATGGCAAGTGATCCTAACAACTCTTGACATCATCA  
GCTCCCACTGTGGAAGGAGAAAATGACACAATGTCGAATGCCAGAGAAGCACGCTTAAG  
TGGGAGAAAGAGGAGGCTCTGGGTGAAATGGCAACTGTTGCCCCAGTTCTCTACACCAAT  
ATTAATTTCCCCAACTTAAAGGAAGAATCCCTGATTGGACTACTAGAGTGAAGCAAATT  
GCCAAATTGTGGAGAAAAGCAAGCTCACAGAAAGAGCACCATATGTGCAAAAAGCCAGA  
GATAACAGAGCTGCTTTACGCATTAATAAAGTACAGATGTCAAATGATTCCATGAAAAGG  
CAGCAACAGCAAGATAGCATTGATCCCAGCTCTCGTATTGATTCCGAGCTTTTTTAAAGAT  
CCTTTAAAGCAAAGAGAATCAGAACATGAACAGGAATGGAAATTTAGACAGCAAATGCGT  
CAGAAAAGTAAGCAGCAAGCTAAAATTGAAGCCACACAGAACTTGAACAGGTGAAAAAT  
GAGCAGCAGCAGCAGCAACAACAGCAATTTGGTTCTCAGCATCTTCTGGTGCAGTCTGGT  
TCAGATACACCAAGTAGTGGGATACAGAGTCCCTTGACACCTCAGCCTGGCAATGGAAAT  
ATGTCTCCTGCACAGTCATTCCATAAAGAACTGTTTACAAAACAGCCACCCAGTACCCCT  
ACGTCTACATCTTCAGATGATGTGTTTGTAAAGCCACAAGCTCCACCTCCTCCTCCAGCC  
CCATCCCGGATTCCCATCCAGGATAGTCTTTCTCAGGCTCAGACTTCTCAGCCACCCCTCA  
CCGCAAGTGTTTTCACCTGGGTCTCTAACTCACGACCACCATCTCCAATGGATCCATAT  
GCAAAAATGGTTGGTACCCCTCGACCACCTCCTGTGGGCCATAGTTTTTCCAGAAGAAAT  
TCTGCTGCACCAGTGGAAGAACTGTACACCTTTATCATCGGTATCTAGGCCCCCTCAAATG  
AATGAGACAACAGCAAATAGGCCATCCCTGTGAGAGATTTATGTTCTTCTTCCACGACA  
AATAATGACCCCTATGCAAAACCTCCAGACACACCTAGGCCTGTGATGACAGATCAATTT  
CCCAAATCCTTGGGCCTATCCCGGTCTCCTGTAGTTTCAGAACAACTGCAAAAGGCCCT  
ATAGCAGCTGGAACCAGTGATCACTTTACTAAACCATCTCCTAGGGCAGATGTGTTTCAA  
AGACAAAGGATACCTGACTCATATGCACGACCCCTTGTTGACACCTGCACCTCTTGATAGT  
GGTCTTGACCTTTTAAAGACTCCAATGCAACCTCCTCCATCCTCTCAGGATCCTTATGGA  
TCAGTGTACAGGCATCAAGGCGATTGTCTGTTGACCCCTTATGAAAGGCCTGCTTTGACA  
CCAAGACCTATAGATAATTTTTCTCATAATCAGTCAAATGATCCATATAGTCAGCCTCCC  
CTTACCCACATCCAGCAGTGAATGAATCTTTTGCCCATCCTTCAAGGGCTTTTTCCAG  
CCTGGAACCATATCAAGGCCAACATCTCAGGACCCATACTCCCAACCCCCAGGAACTCCA  
CGACCTGTTGTAGATTCTTATTCCCAATCTTCAGGAACAGCTAGGTCCAATACAGACCT

- 128 -

TACTCTCAACCTCCTGGAACCTCCCCGGCCTACTACTGTTGACCCATATAGTCAGCAGCCC  
CAAACCCCAAGACCATCTACACAACTGACTTGTTTGTACACCTGTAACAAATCAGAGG  
CATTCTGATCCATATGCTCATCCTCCTGGAACACCAAGACCTGGAATTTCTGTCCCTTAC  
TCTCAGCCACCAGCAACACCAAGGCCAAGGATTTTCAGAGGGTTTTACTAGGTCCTCAATG  
ACAAGACCAGTCCTCATGCCAAATCAGGATCCTTTTCTGCAAGCAGCACAAAACCGAGGA  
CCAGCTTTACCTGGCCCGTTGGTAAGGCCACCTGATACATGTTCCCAGACACCTAGGCCC  
CCTGGACCTGGTCTTTTCAGACACATTTAGCCGTGTTTCCCCATCTGCTGCCCCGTGATCCC  
TATGATCAGTCTCCAATGACTCCAAGATCTCAGTCTGACTCTTTTGGAAACAAGTCAAACCT  
GCCCATGATGTTGCTGATCAGCCAAGGCCTGGATCAGAGGGGAGCTTCTGTGCATCTTCA  
AACTCTCCAATGCACTCCCAAGGCCAGCAGTTCTCTGGTGTCTCCCAACTTCCTGGACCT  
GTGCCAACTTCAGGAGTAACTGATACACAGAATACTGTAAATATGGCCCAAGCAGATACA  
GAGAAATTGAGACAGCGGCAGAAGTTACGTGAAATCATTCTCCAGCAGCAACAGCAGAAG  
AAGATTGCAGGTCGACAGGAGAAGGGGTCACAGGACTCACCCGCAGTGCCTCATCCAGGG  
CCTCTTCAACACTGGCAACCAGAGAATGTTAACCAGGCTTTCACCAGACCCCCACCTCCC  
TATCCTGGGAACATTAGGTCTCCTGTTGCCCTCCTTTAGGACCTAGATATGCTGTTTTTC  
CCAAAAGATCAGCGTGGACCCCTATCCTCCTGATGTTGCTAGTATGGGGATGAGACCTCAT  
GGATTTAGATTTGGATTTCCAGGAGGTAGTCATGGTACCATGCCGAGTCAAGAGCGCTTC  
CTTGTGCCTCCTCAGCAAATACAGGGATCTGGAGTTTCTCCACAGCTAAGAAGATCAGTA  
TCTGTAGATATGCCTAGGCCTTTAAATAACTCACAAATGAATAATCCAGTTGGACTTCCT  
CAGCATTTTTTCACCACAGAGCTTGCCAGTTTCAGCAGCACAACTACTGGGCCAAGCATAT  
ATTGAACTGAGACATAGGGCTCCTGACGGAAGGCAACGGCTGCCTTTTCAGTGCTCCACCT  
GGCAGCGTTGTAGAGGCATCTTCTAATCTGAGACATGGAACTTCATTCCCCGGCCAGAC  
TTTCCGGGCCCTAGACACACAGACCCCATGCGACGACCTCCCCAGGGTCTACCTAATCAG  
CTACCTGTGCACCCAGATTTGGAACAAGTGCCACCATCTCAACAAGAGCAAGGTCATTCT  
GTCCATTCTCTTCTATGGTCTGAGGACTCTGAACCATCCACTAGGTGGTGAATTTTCA  
GAAGCTCCTTTGTCAACATCTGTACCGTCTGAAACAACGTCTGATAATTTACAGATAACC  
ACCCAGCCTTCTGATGGTCTAGAGGAAAACTTGATTCTGATGACCTTCTGTGAAGGAA  
CTGGATGTTAAAGACCTTGAGGGGGTTGAAGTCAAAGACTTAGATGATGAAGATCTTGAA  
AACTTAAATTTAGATACAGAGGATGGCAAGGTAGTTGAATTGGATACTTTAGATAATTTG  
GAACTAATGATCCCAACCTGGATGACCTCTTAAGGTCAGGAGAGTTTGATATCATTTGCA  
TATACAGATCCAGAACTTGACATGGGAGATAAGAAAAGCATGTTTAATGAGGAACTAGAC  
CTTCCAATTGATGATAAGTTAGATAATCAGTGTGTATCTGTTGAACCAAAAAAAAAAGGAA  
CAAGAAAACAAAACCTCTGGTTCTCTCTGATAAACATTCAACACAGAAAAAATCCACTGTT  
ACCAATGAGGTAAAAACGGAAGTACTGTCTCAAATTCTAAGGTGGAATCCAAATGTGAA  
ACTGAAAAAATGATGAGAATAAAGATAATGTTGACACTCCTTGCTCACAGGCTTCTGCT  
CACTCAGACCTAAATGATGGAGAAAAGACTTCTTTGCATCCTTGTGATCCAGATCTATTT  
GAGAAAAGAACCAATCGAGAACTGCTGGCCCCAGTGCAAATGTCATTTCAGGCATCCACT  
CAACTACCTGCTCAAGATGTAATAAACTCTTGTGGCATAACTGGATCAACTCCAGTTCTC  
TCAAGTTTACTTGCTAATGAGAAATCTGATAATTCAGACATTAGGCCATCGGGGTCTCCA  
CCACCACCAACTCTGCCGGCCTCCCCATCCAATCATGTGTCAAGTTTGCCTCCTTTTCATA  
GCACCGCCTGGCCGTGTTTTGGATAATGCCATGAATTCTAATGTGACAGTAGTCTCTAGG  
GTAAACCATGTTTTTTCTCAGGGTGTGCAGGTAAACCCAGGGCTCATTCCAGGTCAATCA  
ACAGTTAACCACAGTCTGGGGACAGGAAAACCTGCAACTCAAACCTGGGCCTCAAACAAGT  
CAGTCTGGTACCAGTAGCATGTCTGGACCCCAACAGCTAATGATTCTTCAAACATTAGCA  
CAGCAGAATAGAGAGAGGCCCCCTTCTTCTAGAAGAACAGCCTCTACTTCTACAGGATCTT  
TTGGATCAAGAAAGGCAAGAACAGCAGCAGCAAAGACAGATGCAAGCCATGATTTCGTGAG  
CGATCAGAACCGTTCTTCCCTAATATTGATTTTGATGCAATTACAGATCCTATAATGAAA

GCCAAAATGGTGGCCCTTAAAGGTATAAATAAAGTGATGGCACAACCAATCTGGGCATG  
CCACCAATGGTGATGAGCAGGTTCCCTTTTATGGGCCAGGTGGTAACTGGAACACAGAAC  
AGTGAAGGACAGAACCTTGGACCACAGGCCATTCTCAGGATGGCAGTATAACACATCAG  
ATTTCTAGGCCTAATCCTCCAAATTTTGGTCCAGGCTTTGTCAATGATTCACAGCGTAAG  
CAGTATGAAGAGTGGCTCCAGGAGACCCAACAGCTGCTTCAAATGCAGCAGAAAGTATCTT  
GAAGAACAAATTGGTGCTCACAGAAAATCTAAGAAGGCCCTTTCAGCTAAACAACGTACT  
GCCAAGAAAGCTGGGCGTGAATTTCCAGAGGAAGATGCAGAACAACTCAAGCATGTTACT  
GAACAGCAAAGCATGGTTTCAGAAACAGCTAGAACAGATTTCGTAAACAACAGAAAGAACAT  
GCTGAATTGATTGAAGATTATCGGATCAAACAGCAGCAGCAATGTGCAATGGCCCCACCT  
ACCATGATGCCCAGTGTCAGCCCCAGCCACCCCTAATTCAGGTGCCACTCCACCCACC  
ATGAGCCAACCCACCTTTCCCATGGTGCCACAGCAGCTTCAGCACCAGCAGCACACAACA  
GTTATTTCTGGCCATACTAGCCCTGTTAGAATGCCCAGTTTACCTGGATGGCAACCCAAC  
AGTGCTCCTGCCACCTGCCCTCAATCCTCCTAGAATTCAGCCCCCAATTGCCCAGTTA  
CCAATAAAAACTTGTACACCAGCCCCAGGGACAGTCTCAAATGCAAATCCACAGAGTGGA  
CCACCACCTCGGGTAGAATTTGATGACAACAATCCCTTTAGTGAAAGTTTTCAAGAACGG  
GAACGTAAGGAACGTTTACGAGAACAGCAAGAGAGACAACGGATCCAACATCATGCAGGAG  
GTAGATAGACAAAGAGCTTTGCAGCAGAGGATGGAAATGGAGCAGCATGGTATGGTGGGC  
TCTGAGATAAGTAGTAGTAGGACATCTGTGTCCAGATTCCCTTCTACAGTTCCGACTTA  
CCTTGTGATTTTATGCAACCTCTAGGACCCCTTCAGCAGTCTCCACAACACCAACAGCAA  
ATGGGGCAGGTTTTACAGCAGCAGAATATACAACAAGGATCAATTAATTCACCTCCACC  
CAAACCTTTCATGCAGACTAATGAGCGAAGGCAGGTAGGCCCTCCTTCATTTGTTCTTGAT  
TCACCATCAATCCCTGTTGGAAGCCCAAATTTTTCTTCTGTGAAGCAGGGACATGGAAAT  
CTTTCTGGGACCAGCTTCCAGCAGTCCCCAGTGAGGCCCTTCTTTTACACCTGCTTTACCA  
GCAGCACCTCCAGTAGCTAATAGCAGTCTCCCATGTGGCCAAGATTCTACTATAACCCAT  
GGACACAGTTATCCGGGATCAACCCAATCGCTCATTGAGTTGTATTCTGATATAATCCCA  
GAGGAAAAAGGGAAAAAGAAAAGAACAAAGAAAGAAAGAGATGATGATGCAGAATCC  
ACCAAGGCTCCATCAACTCCCCATTGAGATATAACTGCCCCACCGACTCCAGGCATCTCA  
GAACTACCTCTACTCCTGCAGTGAGCACACCCAGTGAGCTTCTCAACAAGCCGACCAA  
GAGTCGGTGGAACCAAGTCGGCCCATCCACTCCCAATATGGCAGCAGGCCAGCTATGTACA  
GAATTAGAGAACAACTGCCCAATAGTGATTTCTCACAAGCAACTCCAAATCAACAGACG  
TATGCAAATTCAGAAGTAGACAAGCTCTCCATGGAAACCCCTGCCAAAACAGAAGAGATA  
AACTGGAAAAGGCTGAGACAGAGTCCTGCCCAGGCCAAGAGGAGCCTAAATTGGAGGAA  
CAGAATGGTAGTAAGGTAGAAGGAAACGCTGTAGCCTGTCTGTCTCCTCAGCACAGAGT  
CCTCCCCATTCTGCTGGGGCCCCCTGCTGCCAAGGAGACTCAGGGAATGAACTTCTGAAA  
CACTTGTTGAAAAATAAAAAGTCATCTTCTCTTTTGAATCAAAAACCTGAGGGCAGTATT  
TGTTCAGAAGATGACTGTACAAAGGATAATAAACTAGTTGAGAAGCAGAACCCAGCTGAA  
GGACTGCAAACCTTTGGGGGCTCAAATGCAAGGTGGTTTTGGATGTGGCAACCAGTTGCCA  
AAAACAGATGGAGGAAGTGAAACCAAGAAACAGCGAAGCAAACGGACTCAGAGGACGGGT  
GAGAAAGCAGCACCTCGCTCAAAGAAAAGGAAAAAGGACGAAGAGGAGAAACAAGCTATG  
TACTCTAGCACTGACACGTTTACCCACTTGAAACAGGTGAGGCAGCTCTCTCTGCTCCCT  
CTAATGGAACCAATCATTGGAGTGAACCTTTCGCGACTTCTTCTCCTTATGGCAGTGCCAA  
TTTAATAGTGGGAATCGACTTCTAGGAACCTTTTGGCAGTGCTACCCTGGAAGGGGTTTCG  
GACTACTATTCTCAGTTGATCTACAAGCAGAATAATTTAAGTAATCCTCCAACACCCCT  
GCCTCTCTTCTCCTACACCACCTCCTATGGCTTGTGAGAAGATGGCCAATGGTTTTGCA  
ACAACTGAAGAACTTGCTGGAAAAGCCGGAGTGTTAGTGAGCCATGAAGTTACCAAACT  
CTAGGACCTAAACCATTTCAGCTGCCCTTCAGACCCACAGGACGACTTGTTGGCCCGAGCT  
CTTGCTCAGGGCCCCAAGACAGTTGATGTGCCAGCCTCCCTCCCAACACCACCTCATAAC

- 130 -

AATCAGGAAGAATTAAGGATACAGGATCACTGTGGTGATCGAGATACTCCTGACAGTTTT  
GTTCCCTCATCCTCTCCTGAGAGTGTGGTTGGGGTAGAAGTGAGCAGGTATCCAGATCTG  
TCATTGGTCAAGGAGGAGCCTCCAGAACC GG TGCCGTCCCCCATCATTCCAATTCTTCTCT  
AGCACTGCTGGGAAAAGTTCAGAATCAAGAAGGAATGACATCAAAACTGAGCCAGGCACT  
TTATATTTTGCCTCACCTTTTGGTCCTTCCCCAAATGGTCCCAGATCAGGTCTTATATCT  
GTAGCAATTACTCTGCATCCTACAGCTGCTGAGAACATTAGCAGTGTTGTGGCTGCATTT  
TCCGACCTTCTTCACGTCCGAATCCCTAACAGCTATGAGGTTAGCAGTGCTCCAGATGTC  
CCATCCATGGGTTTGGTCAGTAGCCACAGAATCAACCCGGGTTTGGAGTATCGACAGCAT  
TTACTTCTCCGTGGGCCTCCGCCAGGATCTGCAAACCCTCCCAGATTAGTGAGCTCTTAC  
CGGCTGAAGCAGCCTAATGTACCATTTCTCTCCAACAAGCAATGGTCTTTCTGGATATAAG  
GATTTCTAGTCATGGTATTGCAGAAAGCGCAGCACTCAGACCACAGTGGTGTGTCAATTGT  
AAAGTGGTTATTCTTGGAAAGTGGTGTGCGGAAATCTTTCAAAGATCTGACCCTTTTGAAC  
AAGGATTTCCGAGAAAGCACCAAGAGGGTAGAGAAGGACATTGTCTTCTGTAGTAATAAC  
TGCTTTTATTCTTTATTCATCAACTGCACAAGCGAAAACTCAGAAAACAAGGAATCCATT  
CCTTCATTGCCACAATCACCTATGAGAGAAACGCCTTCCAAGCATTTCATCAGTACAGC  
AACACATCTCCACTTTGGATGTGCACTGTCTCCCCAGCTCCCAGAGAAAGCTTCTCCC  
CCTGCCTCACCAACCATCGCCTTCCCTCCTGCTTTTGAAGCAGCCCAAGTCGAGGCCAAG  
CCAGATGAGCTGAAGGTGACAGTCAAGCTGAAGCCTCGGCTAAGAGCTGTCCATGGTGGG  
TTTGAAGATTGCAGGCCGCTCAATAAAAAATGGAGAGGAATGAAATGGAAGAAGTGGAGC  
ATTCATATTGTAATCCCTAAGGGGACATTTAAACCACCTTGTGAGGATGAAATAGATGAA  
TTTCTAAAGAAATTGGGCACTTCCCTTAAACCTGATCCTGTGCCCCAAAGACTATCGGAAA  
TGTTGCTTTTGTTCATGAAGAAGGTGATGGATTGACAGATGGACCAGCAAGGCTACTCAAC  
CTTGACTTGATCTGTGGGTCCACTTGAAGTGCCTCTGTGGTCCACGGAGGTCTATGAG  
ACTCAGGCTGGTGCCTTAATAAATGTGGAGCTAGCTCTGAGGAGAGGCCTACAAATGAAA  
TGTGTCTTCTGTCAACAAGACGGGTGCCACTAGTGGATGCCACAGATTTTCATGCACCAAC  
ATTTATCACTTCACTTGCGCCATTAAAGCACAATGCATGTTTTTTAAGGACAAAACCTATG  
CTTTGCCCCATGCACAAACCAAAGGGAATTCATGAGCAAGAATTAAGTTACTTTGCAGTC  
TTCAGGAGGGTCTATGTTTCAGCGTGATGAGGTGCGACAGATTGCTAGCATCGTGCAACGA  
GGAGAACGGGACCATACTTTTCGCGTGGGTAGCCTCATCTTCCACACAATTGGTCAGCTG  
CTTCCACAGCAGATGCAAGCATTCCATTCTCCTAAAGCACTCTTCCCTGTGGGCTATGAA  
GCCAGCCGGCTGTACTGGAGCACTCGCTATGCCAATAGGCGCTGCCGCTACCTGTGCTCC  
ATTGAGGAGAAGGATGGGCGCCAGTGTGTGTTCATCAGGATTGTGGAACAAGGCCATGAA  
GACCTGGTTCTAAGTGACATCTCACCTAAAGGTGTCTGGGATAAGATTTTGGAGCCTGTG  
GCATGTGTGAGAAAAAAGTCTGAAATGCTCCAGCTTTTCCCAGCGTATTTAAAAGGAGAG  
GATCTGTTTGGCCTGACCGTCTCTGCAGTGGCAGCATAGCGGAATCACTTCTGGGGTT  
GAGGCATGTGAAAATTATACCTTCCGATACGGCCGAAATCCTCTCATGGAACTTCTCTT  
GCCGTTAACCCACAGGTTGTGCCCGTTCTGAACCTAAATGAGTGCCCATGTCAAGAGG  
CCTCACACCTTAAACAGCACCTCAAAGTCATTTTCAGAGCACAGTCACTGGAGAA  
CTGAACGCACCTTATAGTAAACAGTTTGTTCCTCCAAGTCATCGCAGTACCGGAAGATG  
AAAACCTGAATGGAAATCCAATGTGTATCTGGCACGGTCTCGGATTACAGGGGCTGGGCCTG  
TATGCTGCTCGAGACATTGAGAAACACACCATGGTTCATTGAGTACATCGGGACTATCATT  
CGAAACGAAGTAGCCAACAGGAAAGAGAAGCTTTATGAGTCTCAGAACCGTGGTGTGTAC  
ATGTTCCGCATGGATAACGACCATGTGATTGACGCGACGCTCACAGGAGGGCCCGCAAGG  
TATATCAACCATTTCGTGTGCACCTAATTGTGTGGCTGAAGTGGTGACTTTTGGAGAGAGGA  
CACAAAATTATCATCAGCTCCAGTCGGAGAATCCAGAAAGGAGAAGAGCTCTGCTATGAC  
TATAAGTTTGAAGTGTGACCAAGATTCAGTGTGAGCTGTGAACTGCGGGAAGTGGATGAACTGAAATGCATTCCTTGCTAGCTCAGCGGGCGGCTTGTCCCTA



- 131 -

GGAAGAGGCGATTCAACACACCATTGGAATTTTGCAGACAGAAAGAGATTTTTGTTTTCT  
GTTTTATGACTTTTTGAAAAAGCTTCTGGGAGTTCTGATTTCTCAGTCCTTTAGGTAA  
AGCAGCGCCAGGAGGAAGCTGACAGAAGCAGCGTTCCTGAAGTGGCCGAGGTAAACGGA  
ATCACAGAATGGTCCAGCACTTTTGCTTT

>gi|10864041|gb|NP\_067053.1|MLL3 4025aa linear

myeloid/lymphoid or mixed-lineage leukemia 3; ALR-like protein  
[Homo sapiens].

MHNTVVLFSSSDKFTLNQDMCVVCGSFGQGAEGRLILACSQCGQCYHPYCVSIKITKVVL  
KGWRCLECTVCEACGKATDPGRLLLCDDCDISYHTYCLDPPLQTVPKGGWKCKWCVWCRH  
CGATSAGLRCEWQNNYTQCAPCASLSSCPVCYRNYREEDLILQCRQCDRWMHAVCQNLNT  
EEVENVADIGFDCSMCRPYMPASNPSSDCESSLVAQIVTKVKELDPKTYTQDGVCL  
TESGMTQLQSLTVTVPRRKRKRKPKLKLKIINQNSVAVLQTPPDIQSEHSRDGEMDD  
SREGELMDCDGKSESSPEREAVDDETKGVEGTDGVKKRKRKPYRPGIGGFMVRQSR  
RTGQGKTKRSVIRKDSGSGISEQLPCRDDGWSEQLPDTLVDESVSVTESTEKIKR  
YRKRKNKLEETFPAYLQEAFFGKDLLDTSRQSKISLDNLSEDGAQLLYKTNMNTGFL  
DPSLDPLSSSSAPT KSGTHGPADDPLADISEVLNTDDDILGIISDDLAKSV  
DHSIDIGPVTD DPSSLPQPNVNQS SRPLSEEQLDGILSPELDKMVTDGAILGKLY  
KIPELGGKDVEDLFTAVLSPANTQPTPLP QPPPPTQLLP  
IHNQDAFSRMPLMNGLIGSSPHLPHNSLPPGSGLGTFSAIAQSSYPDARD  
KNSAFNPMA SDPNNSWTSSAPTVEGENDTMSNAQRSTLKEKEEALGEMATVAPV  
LYTNI NFPNLKEEFPDWTTTRVKQIAKLWRKASSQERAPYVQKARDNRAALRINK  
VQMSNDSMKRQ QQQDSIDPSSRIDSELFKDPLKQRESEHEQE  
WKFRQQMRQKSKQQAKIEATQKLEQVKNE QQQQQQQQFGSQHLLVQSGSD  
TPSSGIQSPLTPQPGNGNMSPAQSFHKELFTKQPPSTPT STSSDDV  
FVKPQAPPPPPAPSRIPIQDSLQAQTSQPPSPQVFS  
PGSSNSRPPSPMDPYA KMGVTPRPPVGHFS  
SRNSAAPVENCTPLSSVSRPLQMNETTANRPS  
PVRDLCSSSTTN NDPYAKPPDTPRPVMTDQ  
FPKSLGLSRSPVSEQTAKGPIAAGTSDHFTKPS  
PRADVFOR QRIPDSYARPLLT  
PAPLDSGPGPFKTPMQPPSSQDPYGSVSQAS  
RRLSVDPYERPALTP RPIDNFSHNQSN  
DPYSQPPLTPHPAVNESFAHPSRAFSQPGTISR  
PTSQDPYSQPPGTPR PVVDSYSQSSGTARSNT  
DPYSQPPGTPRPTTVDPYSQQPQTPRPSTQTD  
LFTVTPVTNQRH SDPYAHPPGTPRPGISV  
PYSQPPATPRPRISEGFTRSSMTRPVLMPNQD  
PFLQAAQNRGP ALPGPLVRPPDTC  
SQTPRPPGGLSDTFSRVSPSAARDPYDQSPMT  
PRSQSDSFGTSQTA HDVADQPRPGSEGS  
FCASSNSPMHSQGGQFSGVSQLPGPVPTSGV  
TDTQNTVNMAQADTE KLRQRQKLREIILQ  
QQQQQKKIAGRQEKGSQDSPAVPHPGPLQHWQ  
PENVNQAFTRPPPPY PGNIRSPVAPPLGPRY  
AVFPKDQRGYPYPPDVASMGMRPHGFRFGF  
PGGSHGTMP SQERFL VPPQQIQSGSVSPQ  
LRRSVSDMPRPLNNSQMNNPVGLPQHFSPQSL  
FPVQQHNILGQAYI ELRHRAPDGRQRLPFS  
APPGSVVEASSNLRHGNFI PRPDFPGPRHTD  
PMRRPPQGLPNQL PVHPDLEQVPPSQEQGHS  
VHSSSMVMTLNLHPLGGEFSEAPLSTSVPS  
ETTSDNLQITTT QPSDGLEEKLDSDDP  
SVKELDVKDLEGVEVKDLDDLENLNLDTE  
DGKVVELDTLDNLE TNDPNLDDLLRS  
GEFDIIAYTDPELDMGDKKSMFNEELDLPI  
DDKLDNQCVSVEPKKKEQ ENKTLVLSDKHS  
PQKKSTVTNEVKTEVLSPNSKVESKCE  
TEKNDENKDNVDTPCSQASAH SDLNDGEKTS  
LHPCDPLFEKRTNRETAGPSANVIASTQLPAQ  
DVINSCGITGSTPVL SLLANEKSDNSDIRPSG  
SPPPPTLPASPSNHVSSLPPFIAPPGRVLDNA  
MNSNVTVVSRV NHVFSQGVQVNPG  
LIPGQSTVNHSLGTGKPATQTGPQTSQSGTSS  
MSGPQQLMIPQTLAQ QNRERPLLLLEE  
QPLLLQDLLDQERQEQQQQRQMAMIRQRSE  
PFFPNIDFDAITDPI MKA KMVALKGINKVMA  
QNNLGMPPMVMSRFPFMGQVVTGTQNSEGQ  
NLGPQAIPODGSITHQISRPNPPNFGPGFV  
NDSQRKQYEEWLQETQQLLQMQQKYLEEQI  
GAHRKSKKALSAKQRTAKKAGREFPEEDAEQ  
LKHVTEQQSMVQKQLEQIRKQQKEHAELI  
EDYRIKQQQQCAMA PPT MMPSVQPQPPLI  
PGATPPTMSQPTFPMVPQQLQHQHHTTVIS  
GHTSPVRMPSLPGWQPN S

- 132 -

APAHLP LNPPRIQPPIAQLPIKTCTPAPGTVSNANPQSGPPPRVEFDDNNPFSESFQERE  
RKERLREQQERQRIQLMQEVDQRALQORMEMEQHGMVGSEISSRSTSVSQIPFYSSDLP  
CDFMQPLGPLQQSPQHQQQMGQVLQQQNIQQGSINSPSTQTFMQTNERRQVGPPSFVPS  
PSIPVGSPNFSVVKQHGHNLSGTSFQQSPVRPSFTPALPAAPPVANSSSLPCGQDSTITHG  
HSYPGSTQSLIQLYSDIIPEEKGKKRTRKKRDDD AESTKAPSTPHSDITAPPTPGISE  
TTSTPAVSTPSELPPQADQESVEPVGSTPNMAAGQLCTELENKLPSNDFSQATPNQOTY  
ANSEVDKLSMETPAKTEEIKLEKAETESCPGQEEP KLEEQNGSKVEGNAVACPVSSAQSP  
PHSAGAPAAKGD SGNELLKHL LKNKKSSSLN QKPEGSICSEDDCTKDNKLVEKQNP AEG  
LQTLGAQMGGFGCGNQLPKTDGGSETKKQRSKRTQRTGEKAAPRSKKRKKDEEEKQAMY  
SSTDTFTHLKQVRQLSLLPLMEPIIGVNFAHFLPYGSGQFN SGNRL LGTFGSATLEGVSD  
YYSQLIYKQNNLSNPPTPPASLPPTPPMACQKMANGFATTEELAGKAGVLVSHEVTKTL  
GPKPFQLPFRPQDDLLARALAQGPKTVDPASLPPTPHNNQEELRIQDHCGDRDTPDSFV  
PSSSPESVVGVEVSRYPDL SLVKEEPPEPVPSPIIPILPSTAGKSSESRRNDIKTEPGTL  
YFASPFGPSPNGPRSLISVAITLHPTAAENISSVVAAFSDLLHVRI PNSYEVSSAPDVP  
SMGLVSSHRI NPGLEYRQHLLLRGPPPGSANPPRLVSSYRLKQPNVPFPPTS NGLSGYKD  
SSHGIAESAALRPQWCCHKVVLGSGVRKSFKDLTLLNKDSRESTKRVEKDIVFCSNNC  
FILYSSTAQAKNSENKESIPSLPQSPMRETPSKAFHQYSNNISTLDVHCLPQLPEKASPP  
ASPPIAFPPAFEA AQVEAKPDELKVTVKLKPRLRAVHGGFEDCRPLNKKWRGMKWKWSI  
HIVI PKGTFKPPCEDEIDEFLKKLGTSLKPDVPKDYRKCCFCHEEGDGLTDGPARLLNL  
DLDLWVHLN CALWSTEVEYETQAGALINVELALRRGLQMKCVFCHKTGATSGCHRFRCTNI  
YHFTCAIKAQCMFFKDKTMLCPMHKPKGIHEQELSYFAVFRRVYVQRDEVRQIASIVQRG  
ERDHTFRVGS LI FHTIGQLLPQQMQAFHSPKALFPVGYEASRLYWSTRYANRRCRYLCSI  
EEKDGRPVFVIRIVEQGHEDLVLSDISPKGVWDKILEPVACVRKKSEMLQLFPAYLKGED  
LFGLTVSAVARIAESLP GVEACENYTFRYGRNPLMELPLAVNPTGCARSEP KMSAHVKRP  
HTLNSTSTSKSFQSTVTGELNAPYSKQFVHSSQYRKMKTEWKS NVYLARSRIQGLGLY  
AARDIEKHTMVIEYIGTIIRNEVANRKEKLYESQNRGVYMFMDNDHVIDATLTGGPARY  
INHSCAPNCVAEVVTFERGHKIISSSRRIQKGEELCYDYKDFEDDQHKI PCHCGAVNC  
RKWMN

>gi|21359851|gb|NM\_000966.2|RARG 2663bp mRNA Homo sapiens  
retinoic acid receptor, gamma (RARG), mRNA.  
GGCACGAGGCAGTGGGCAGGCCAGGCAGGGCGGGTACGGAGCCTCCCAGGCTGGGGCAGT  
GGGCATGGGCAGGGGCTGTGGCTGAAGACCTCGCCCGCCACTGCAGACTCCAGGGGACT  
CTCACACCGCAGCTGCCATGGCCACCAATAAGGAGCGACTCTTTGCGGCTGGTGCCCTGG  
GGCCTGGATCTGGCTACCCAGGGGCAGGTTTCCCCTTCGCCTTCCAGGGGCACTCAGGG  
GGTCTCCGCCTTTTCGAGATGCTGAGCCCTAGCTTCCGGGGCCTGGGCCAGCCTGACCTCC  
CCAAGGAGATGGCCTCTCTGTCTGGTGGAGACACAGAGCACCAGCTCAGAGGAGATGGTGC  
CCAGCTCGCCCTCGCCCCCTCCGCCTCCTCGGGTCTACAAGCCATGCTTCGTGTGCAATG  
ACAAGTCCTCTGGCTACCACTATGGGGTCAGCTCTTGTAAGGCTGCAAGGGCTTCTTTC  
GCCGAAGCATCCAGAAGAACATGGTGTACACGTGTACCCGCGACAAAACTGTATCATCA  
ACAAGGTGACCAGGAATCGCTGCCAGTACTGCCGGCTACAGAAGTGCTTTCGAAGTGGGCA  
TGTCCAAGGAAGCTGTGCGAAATGACCGGAACAAGAAGAAGAGGTGAAGGAAGAAG  
GGTCACCTGACAGCTATGAGCTGAGCCCTCAGTTAGAAGAGCTCATCACCAGGTGAGCA  
AAGCCCATCAGGAGACTTTCCCCTCGCTCTGCCAGCTGGGCAAGTATACCACGAACTCCA  
GTGCAGACCACCGCGTGCAGCTGGATCTGGGGCTGTGGGACAAGTTCAGTGAGCTGGCTA  
CCAAGTGCATCATCAAGATCGTGGAGTTTGCCAAGCGGTTGCCTGGCTTTACAGGGCTCA  
GCATTGCTGACCAGATCACTCTGCTCAAAGCTGCCTGCCTAGATATCCTGATGCTGCGTA  
TCTGCACAAGGTACACCCAGAGCAGGACACCATGACCTTCTCCGACGGGCTGACCCTGA



- 133 -

ACCGGACCCAGATGCACAAATGCCGGCTTCGGGCCCCCTCACAGACCTTGTCTTTGCCTTTG  
CTGGGCAGCTCCTGCCCCCTGGAGATGGATGACACCGAGACAGGGCTGCTCAGCGCCATCT  
GCCTCATCTGCGGAGACCGCATGGACCTGGAGGAGCCCGAAAAAGTGGACAAGCTGCAGG  
AGCCACTGCTGGAAGCCCTGAGGCTGTACGCCCCGGCGCCGGCGGCCAGCCAGCCCTACA  
TGTTCCCAAGGATGCTAATGAAATCACCGACCTCCGGGGCATCAGCACTAAGGGAGCTG  
AAAGGGCCATTACTCTGAAGATGGAGATTCCAGGCCCGATGCCTCCCTTAATCCGAGAGA  
TGCTGGAGAACCCTGAAATGTTTGAGGATGACTCCTCGCAGCCTGGTCCCCACCCCAATG  
CCTCTAGCGAGGATGAGGTTCCCTGGGGGCCAGGGCAAAGGGGGCCTGAAGTCCCCAGCCT  
GACCAGGGCCCCCTGACCTCCCCGCTGTGGGGGTGGGGCTTCAGGCAGCAGACTGACCAT  
CTCCAGACCGCCAGTGAAGTGGGGGAGGACCTGCTCTGCCCTCTCCCCACCCCTTCCAAT  
GAGCTCCTTGTTTTTGGCAAAGTTTCTAGGGGTGCCTCTGTGTTTCATCCCCCTTCCTGATC  
TAACCGGCTCCCTCGCCAGTCCCGGGGGCCTGCCCTGCTCCCACCAGGAGAGAGGGCAAA  
GGGATGAGCCTGGGTTTGGACTCTAAAATCTCAGCACTGCCCCATGGGTCTTAGACTTCC  
CAGGGCAAGAGGAAGACCCTGCCATTCCACAGCCCCCTTCCTCTGCCAGGTGCTTGGCTCT  
CTGAGAGCAAACAGGAACACTAGAGACCAAAAAGGGGACAAAGGAGAAGGGCTGAGCCCA  
CCTTCTTGCTCCTACCCTTGGTGCCTAATGCTGTGTGATGCACCTGCAGGGTGTGTGCTA  
GCCTCTGTGCCCCGTCCTTGTGCCAGGTCAAGGTGGGGGCAGGCTGGGCCCTGCATTTCT  
GGGGCAGGAACAGAGGGTGAAGGGACAGATAGATGCAGGTCCATTCTGCACCTCTTGGC  
TCGGGTGCAGAGTTACACCCTGTGCCCTCCGTTATAAGTCCCTCCCCCAGCCCTGTCATGT  
GCCTTGGGCTCCTCCTGCCCTCCATCTCAGCCATTGGGGCAGGGACCCTCCTACACTACA  
GAGGGGCCAGGGGATCCCTCTCTCCCTAGTGCCTTCCACCCTTTACTCCCCAGAGCAGCT  
TGGCCCAGGGAGGGGGGATGCTGCTTAGCTGATCCCGCCCTGACCCAGAGGAAGCCTCTA  
TTTATTTATTAGCTTTTGTTTACACCGTGGAATTGACCCCTTCCTCCAGGGGTCTTGGGT  
GGGGGAGCCCAGGGCCCCCTGTGACCCCTCCTTTCTTCTTCCAATCCCCAGTTTGTATTTA  
GCTGCCAAATAAGATTCCCATTTGGCTCCCTGTGTTCTCTTGGGGGGTTCAGGGTGTGTCC  
CCTCCCCCTCTGTTTACATCTCCCTCTACCCCGCTGTATCGCATATTGCTGAGTTTTCTA  
TTTTTGCAAAATAAAGTGATGGAACTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAAAAAAAAAAAAAAA

>gi|4506423|gb|NP\_000957.1|RARG 454aa linear retinoic acid  
receptor, gamma; Retinoic acid receptor, gamma polypeptide  
[Homo sapiens].

MATNKERLFAAGALGPGSGYPGAGFPFAFPGALRGSPPFEMLSPSFRGLGQPDLPKEMAS  
LSVETQSTSSEEMVPSSPSPPPPPRVYKPCFVCNDKSSGYHYGVSSCEGCKGFFRRSIQK  
NMVYTCHRDKNCIINKVTRNRCQYCRLQKCFEVGMSKEAVRNDRNKKKKEVKEEGSPDSY  
ELSPQLEELITKVSKAHQETFPSLCQLGKYTTNSSADHRVQLDLGLWDKFSELATKCIK  
IVEFAKRLPGFTGLSIADQITLLKAACLDILMLRICTRYTPEQDTMTFSDGLTLNRTQMH  
NAGFGPLTDLVFAFAGQLLPLEMDDTETGLLSAICLICGDRMDLEEPEKVDKLOEPLLEA  
LRLYARRRRPSQPYMFPRLMKITDLRGISTKGAERAITLKMEIPGPMPLIREMLENPE  
MFEDDSSQPGPHPNASSEDEVPGGQKGGLKSPA

>gi|14670376|gb|NM\_015318.1|P114-RHO-GEF 5113bp mRNA Homo  
sapiens Rho-specific guanine nucleotide exchange factor p114  
(P114-RHO-GEF), mRNA.

GCTGGCGGAGAGCGGCCTGCGGGCGATCGGGCCGAGCCTCGCTCAAGGAGCACCCCCGGG  
GCACCCTCCTGTCCGATGGCAGCCCCGGCCCTGTCCAGGAATGTCGGTATGACGGTCTCTC  
AGAAAGGGGGTCCCCAGCCAACACCGAGCCCGGCTGGCCCTGGGACGCAACTCGGACCAA  
TCACAGGAGAGATGGATGAAGCCGATTCTGCGTTTTTAAATTTAAGCAGACAGCTGATG  
ACTCTCTGTCCCTTACATCTCCAAACACCGAGTCCATTTTTGTAGAAGATCCCTACACCG

- 134 -

CCTCGCTGAGGAGTGAGATTGAGTCAGACGGCCACGAGTTTGAAGCTGAGTCCTGGAGCC  
TCGCCGTGGATGCAGCCTACGCCAAGAAGCAAAAGAGGGAGGTGGTGAAAAGACAAGATG  
TCCTTTATGAGCTGATGCAGACAGAGGTGCACCACGTGCGGACGCTCAAGATCATGCTGA  
AGGTGTACTCCAGGGCCCTGCAGGAGGAGCTGCAGTTCAGCAGCAAGGCCATTGGCCGCC  
TCTTCCCATGCGCTGACGACCTGCTGGAGACGCACAGCCACTTCCTCGCTCGGCTCAAGG  
AGCGCCGCCAGGAGTCCCTGGAGGAGGGCAGTGACCGGAATTATGTCATCCAGAAAATCG  
GCGACCTCCTGGTTCAGCAGTTTTTCAGGTGAAAATGGGGAGAGAATGAAAGAAAAGTACG  
GTGTGTTTTGTAGTGGCCACAATGAAGCTGTTAGTCATTACAAGTTGCTGCTTCAGCAAA  
ACAAGAAAATTTCAAAACTTGATCAAGAAAATTGGCAACTTCTCCATCGTGCGGCGGCTTG  
GCGTGACAGGAGTGCAATTCCTGGTTACACAACGCATAACCAAATACCCAGTGCTGGTGG  
AGCGCATCATCCAGAACACGGAAGCTGGCACTGAGGACTATGAAGACCTGACCCAGGCCT  
TGAACCTCATCAAAGATATCATCTCACAAGTGGACGCCAAGGTGAGTGAGTGTGAGAAGG  
GCCAGCGCCTCAGGGAGATCGCAGGGAAGATGGACCTGAAGTCTTCAGCAAACTCAAGA  
ACGGGCTCACCTTCGCAAGGAAGACATGCTTCAGCGGCAGCTCCACCTGGAGGGCATGC  
TATGCTGGAAGACCACATCAGGGCGCTTGAAAGATATCCTGGCTATCCTGCTGACCGACG  
TACTTTTGCTGCTACAAGAAAAAGATCAGAAATACGTCTTTGCTTCTGTGGACTCAAAGC  
CACCCGTCATCTCGTTACAAAAGCTCATCGTGAGGGAAGTGGCCAACGAGGAGAAAGCGA  
TGTTTCTGATCAGCGCCTCCTTGCAAGGGCCGGAGATGTATGAAATCTACACGAGCTCCA  
AAGAGGACAGGAACGCCTGGATGGCCCATCCAAAGGGCTGTGGAGAGCTGCCCTGACG  
AGGAGGAGGGGCCCTTCAGCCTGCCCGAAGAGGAAAGGAAGGTGGTCGAGGCCCCGCGCCA  
CGAGACTCCGGGACTTTCAAGAGCGGTTGAGCATGAAAGACCAGCTGATCGCACAGAGCC  
TCCTAGAGAAACAGCAGATCTACCTGGAGATGGCCGAGATGGGCGGCCTCGAAGACCTGC  
CCCAGCCCCGAGGCCTATTCCGTGGAGGGGACCCATCCGAGACCTGCAGGGGGAGCTAA  
TTCTCAAGTCGGCCATGAGCGAGATCGAGGGCATCCAGAGCCTGATCTGCAGGCGGCTGG  
GCAGCGCCAACGGCCAGGCGGAAGACGGAGGCAGCTCCACAGGCCCCGCCAGGAGGGCTG  
AGACCTTCGCGGGCTACGACTGCACAAACAGCCCCACCAAGAATGGCAGTTTCAAGAAGA  
AAGTCAGCAGCACTGACCCAGGCCCCGAGACTGGCGAGGCCCCCAAACAGCCCGGACT  
TGAAGCTCAGTGACAGTGACATTCTGGGAGCTCTGAGGAATCGCCGAGGTGGTGGAGG  
CGCCAGGCACGGAATCCGATCCCCGTCTGCCACCGTCTGAGTCGGAGCTTGTCCAGC  
GGATCCAGACACTGTCCAGCTGCTCCTGAACCTTCAGGCGGTAATCGCCCACCAGGACA  
GCTATGTGGAGACGCAGCGGGCTGCCATCCAGGAGCGGGAGAAGCAGTTCCGGCTGCAGT  
CGACGCGTGGGAACCTGCTGCTGGAGCAGGAGCGGCAACGCAACTTCGAGAAGCAGCGGG  
AGGAGCGCGCGGCCCTGGAGAAGCTGCAGAGCCAGCTGCGGCACGAGCAGCAGCGCTGGG  
AGCGCGAGCGCCAGTGGCAGCACAGGAGCTGGAGCGTGCGGGCGCGCGCTGCAGGAGC  
GCGAGGGCGAGGCGCGGCAGCTACGCGAGCGGCTGGAGCAGGAGCGGGCCGAGCTGGAGC  
GCCAGCGCCAGGCCTACCAGCACGACCTGGAGCGGCTGCGCGAGGCCCAGCGTGCCGTGG  
AGCGCGAGCGGGAGCGCCTGGAGCTGCTGCGCCGCTCAAGAAGCAGAACACCGCGCCAG  
GCGCGCTGCCGCCCGACACACTGGCCGAGGCCCAGCCCCCAAGCCACCTCCAGCTTCA  
ACGGGGAAGGGCTGGAGGGCCCTCGGGTGAGCATGCTGCCATCCGGCGTGGGGCCAGAGT  
ACGCAGAGCGCCCCGAGGTGGCTCGCCGGGACAGCGCCCCCACCGAGAGCCGGCTGGCCA  
AGAGCGATGTGCCCATCCAGCTGCTCAGCGCCACCAACAGTTCCAGAGGCAGGCGGCCG  
TGCAGCAGCAGATCCCCACCAAGCTGGCGGCCTCCACCAAGGGTGGCAAGGACAAGGGCG  
GCAAGAGCAGGGGCTCTCAGCGCTGGGAGAGCTCAGCGTCCTTCGACCTGAAGCAGCAGC  
TGCTGCTCAACAAGCTCATGGGGAAGATGAGAGCACCTCACGGAACCGCCGCTCGCTGA  
GCCCTATCCTGCCCGGCAGACACAGTCTGCGCCCCCACCAGACCTGGCTTCCCCGCC  
CGAGCCCACCGCCAGCTGACAGCCCCTCCGAGGGCTTCTCTCTCAAGGCCGGGGGCACAG  
CCCTCCTGCCCGGCCCCCCAGCTCCCTCGCCACTGCCGGCCACACCACTCAGCGCCAAGG

- 135 -

AGGACGCCAGCAAAGAAGACGTCATCTTCTTCTAAAAGGGCCGTGACTCAAGGAAAGTTT  
TTAATGGAAAGTTGAGCCAGAACTAAACCAGGGAGCTGTCTGAAATCATAGCACCCCATC  
CGGGTGGCGGGGAGATCAACTCCGAGCTGTTTTTCCGAGGCAGTGAGGAACGGTGCCGGC  
TCTGCACGGAGCTGAGGACAGGACAGACCTTGCTTTGAGAAGGAGCTGCCGGCCGGGGCC  
ACGCTCCACAGCCGCCGCGCAGTGGAGCCAAGGGTTAGGGCACCAGGAGGGGCCAGG  
TGGCGTCGGCAGCATCTGTCCCCAGAATCAGGCAGAATCCACTTCCCAAACAGAGCCCCA  
CGCAGGTTTACCATGAACCTCAGGGTCAGGGAATGAGCCAGGCACGGGGGCATGGGCAGA  
GAGGGCCACGGGGCAGGGCCCCACTGAGGGAACATCAGTGGCCCTCCAGTCAGGTTCTGTG  
GGTTTGGAAGCCCATCGTGAAAGGGGCTGACCTTTGCCCTTTTTACTTGGCATTGGTTT  
TGAAACCAGCTGTTTCCCAAACCTCTGCTTCCAAAGGGCAACCGTTGCTGTTTACACGCTC  
AGCCTGTCTGGGGGAGCGGGCCTCTAGCTTCAGCCAGGGCGGGTACACACCCTGGGCACA  
GGGTCTTCAGCCCCCGGGAATGAGCTCCCAGGGCTGGCGTCCCACCTTCCAGGTGGGGG  
CTGGCACATCACAGACTGTGAGAGCGCCATGTCCCAGGGCATGCAGAGGTTGCACCTAG  
AGACGTTGCAGCAAGTGGACAAGTGGCCGCTGTGCGGGCCCCCTCGCTTGAGTGAGCTGT  
TGCAGCTTACGGTCCGTTCCTTGGAGGGGTGGAGGAAGGAGGTGTTGGGCAGCATCAAAG  
GTGCTGGGACATCCCAGGGTGGTGAGATCCATCCACGATCCAGCTCCGGTGGAGAAAGG  
CCCATGTCAAGCCTTGTTCTGCACCCCAAGCATTGGTGGTAGGACTGGGTCCTGGCTGAT  
CGTCCTTGTTCCAGTGGGGTACATGTGAGCCCCTGCCAGGGCCAAGTCCTTCTCCCGAA  
CCCAGGGTCTGGGAACTGCAGATCCCGGGGGGATTGAGCCCTTCTCCCACTGTGCTGGC  
AGAGGCACTCCTGTGACGCTGAATACAGTGAACAGGGACATTCCCGCCACTCGGGGACAG  
ATGGGCACAAGGGAGGGGAACTCCATCAGGAAGTGCTCCCCTGGGCAGAGGCGCCCACT  
GGGTGCTGTGGGCTCAGGAGGGGGCGGGCAGGAGCTGGTGCCAACCGGGAACCAGAGCC  
CCACAGCCATACAGCCCATTTGGTGACAAGGTCTGAGAACACAGTGGCCAGGTGTCCCA  
GGCTCCTGGCCCCCTCCGACGACCTCAACTCTGCCAGCCCGGTCCCTGGCCATCAGCGAC  
GCTGTCCGCCCCCGTCAGATCCCATGTGTGCCATGTTTATCATCAGTGTTTTGTATTTT  
TGTA CTGAGTATCGGAGCACTTTACAGAAGCTGACTGTACATTCTGTCTGTGTAAG  
AGAACATTCCCAGACCCTGGCACCCCTCCTGAGCCGGCGTGTGCCGGTCCAGCCCTCCGAG  
ATGCCACAATTCTTGGATGGGGGAGAAGTTCAAGGAATTTCTGCTCGGCCACGCGGTGG  
GAACCCCGCGTCCCCGCCATGTGGCAGAGGGGTCTCAGTCGTGCTAGGCATCGGGCGGCA  
GCGCCGACAGCCCTTCCCTCGCCAGTGCCCTCGGCCACTCCTGGGTTGGAGCCCGATTT  
TATTTGTAAAGTTGACAGTCGAGCAAATGTTCTTATTTTCGTGGGATCTGCACACGTCTT  
TGTCAGTTGTGGTCATGATCTTAGTCACCTGCTAATTATTTTACAATGATTACAACATT  
TCCTCACTGCGGGATATTTCTGACCCGCTTTAGAACTTAAGACCTGATTCTAGCAATAAA  
CGTGTCCGAGATG

>gi|14670377|gb|NP\_056133.1|P114-RHO-GEF 1015aa linear Rho-  
specific guanine nucleotide exchange factor p114 [Homo  
sapiens].

MTVSQKGGPQPTPSPAGPGTQLGPITGEMDEADSAFLKFKQTADDSLSLTSPNTESIFVE  
DPYTASLRSEIESDGHEFEAESWSLAVDAAYAKKQKREVVKRQDVLIELMQTEVHHVRTL  
KIMLKVYSRALQEELQFSSKAIGRLFPCADDLLETHSHFLARLKERQESLEEGSDRNYV  
IQKIGDLLVQQFSGENGERMKEKYGVFCSGHNEAVSHYKLLQONKKFQNLIKKIGNFSI  
VRRLGVQECILLVTQRITKYPVLVERIIQNTAGTEDYEDLTQALNLIKDIISQVDAKVS  
ECEKGQRLREIAGKMDLKSSSKLKNGLTFRKEDMLQRQLHLEGMLCWKTTSGRLKDILAI  
LLTDVLLLLQEKDQKYVFASVDSKPPVISLQKLIVREVANEEKAMFLISASLQGPMEYEI  
YTSSKEDRNAWMAHIQRAVESCPDEEEGPFSLPEEERKVVEARATRLRDFQERLSMKDQL  
IAQSLLEKQQIYLEMAEMGGLEDLPQPRGLFRGGDPSETLQGELILKSAMSEIEGIQSLI  
CRRLGSANGQAEDGGSSTGPPRAETFAGYDCTNSPTKNGSFKKKVSSTDPRPRDWRGPP

- 136 -

NSPDLKLSDS DIPGSSEES PQVVEAPGTESDPRLPTVLESELVQRIQTLSQLLNLQAVI  
AHQDSYVETQRAAIQEREKQFRLQSTRGNLLLEQERQRNFEKQREERAALKLSQLRHE  
QQRWERERQWQHQLERAGARLQEREGEARQLRERLEQERAELERQRQAYQHDLERLREA  
QRAVERERERLELLRLRLKKQNTAPGALPPD TLAEAQPPSHPPSFNGEGLEGPRVSMPLPSG  
VGPEYAERPEVARRDSAPTESRLAKSDVPIQLLSATNQFQRQA AVQQQIPTKLAASTKGG  
KDKGGKSRGSQRWESSASFDLKQQLLLNKL MGKDESTSRNRRSLSPILPGRHSPAPPDP  
GFPAPSPPPADSPSEGFSLKAGGTALLPGPPAPSPLPATPLSAKEDASKEDVIFF

>gi|23238259|gb|NM\_005198.3|CHKL 1595bp mRNA Homo sapiens  
choline kinase-like (CHKL), transcript variant 1, mRNA.

CCCGGGCCGGGACCGAGAGAGCCGAGCGCCGAGCCGTGAGCCGAATAGAGCCGGAGA  
GACCCGAGTATGACCGGAGAAGCCAGGCCGGCCGGAAGAGGAGCCGAGCGCGCCGGAA  
GGAACCGAGCCCGTCCGAAGGGAGCGGAGCGCAGCCTGGCCTGGGGCCCGGTCGAGCCCG  
CGCCATGGCGGCCGAGGCGACAGCTGTGGCCGGAAGCGGGCTGTTGGCGGCTGCCTGGC  
CAAAGACGGCTTGCAGCAGTCTAAGTGCCCGGACACTACCCCAAACGGCGGCGCGCCTC  
GTCGCTGTGCGGTGACGCCGAGCGCCGAGCCTACCAATGGTGCCGGGAGTACTTGGGCGG  
GGCCTGGCGCCGAGTGCAGCCCGAGGAGCTGAGGGTTTACCCCGTGAGCGGAGGCCTCAG  
CAACCTGCTCTTCCGCTGCTCGCTCCCGGACCACCTGCCAGCGTTGGCGAGGAGCCCCG  
GGAGGTGCTTCTGCGGCTGTACGGAGCCATCTTGACGGGCGTGACTCCCTGCTGCTAGA  
AAGCGTGATGTTTCGCCATACTTGCGGAGCGGTGCTGGGGCCCCAGCTGTACGGAGTCTT  
CCCAGAGGGCCGGCTGGAACAGTACATCCCAAGTCGGCCATTGAAAACCAAGAGCTTCG  
AGAGCCAGTGTGTCAGCAGCCATTGCCACGAAGATGGCGCAATTTTCATGGCATGGAGAT  
GCCTTTACCAAGGAGCCCCACTGGCTGTTTGGGACCATGGAGCGGTACCTAAACAGAT  
CCAGGACCTGCCCCCAACTGGCCTCCCTGAGATGAACCTGCTGGAGATGTACAGCCTGAA  
GGATGAGATGGGCAACCTCAGGAAGTTACTAGAGTCTACCCCATCGCCAGTCGTCTTCTG  
CCACAATGACATCCAGGAAGGGAACATCTTGCTGCTCTCAGAGCCAGAAAATGCTGACAG  
CCTCATGCTGGTGGACTTCGAGTACAGCAGTTATAACTATAGGGGCTTTGACATTGGGAA  
CCATTTTTGTGAGTGGGTTTATGATTATACTCACGAGGAATGGCCTTTCTACAAAGCAAG  
GCCACAGACTACCCCACTCAAGAACAGCAGTTGCATTTTATTCGTCATTACCTGGCAGA  
GGCAAAGAAAGGTGAGACCCTCTCCCAAGAGGAGCAGAGAAAACCTGGAAGAAGATTTGCT  
GGTAGAAGTCAGTCGGTATGCTCTGGCATCCCATTTCTTCTGGGGTCTGTGGTCCATCCT  
CCAGGCATCCATGTCCACCATAGAATTTGGTTACTTGGACTATGCCAGTCTCGGTTCCA  
GTTCTACTTCCAGCAGAAGGGGCAGCTGACCAGTGTCCACTCCTCATCCTGACTCCACCC  
TCCCACTCCTTGATTCTCTCTGGAGCCTCCAGGGCAGGACCTTGAGGGGAGGAACAACG  
AGCAGAAGGCCCTGGCGACTGGGCTGAGCCCCCAAGTGAACTGAGGTTTCAGGAGACCGG  
CCTGTTCTGAGTTTGAGTAGGTCCCATGGCTGGCAGGCCAGAGCCCCGTGCTGTGTAT  
GTAACACAATAAACAAGCTTCTTCTTCCACCTG

>gi|6978649|gb|NP\_005189.2|CHKL 395aa linear  
choline/ethanolamine kinase isoform a [Homo sapiens].

MAAEATAVAGSGAVGGCLAKDGLQQSKCPDTPKRRRASSLSRDAERRAYQWCREYLGGA  
WRRVQPEELRVYPVSGGLSNLLFRCSLPDHLPSVGEEPREVLLRLYGAILQGVDSLVL  
VMFAILAERSLGPQLYGVFPEGRLEQYIPSRPLKTQELREPVL SAAIATKMAQFHGMEMP  
FTKEPHWLFGT MERYLKQIQDLPTGLPEMNLLEMYS LKDEMGNLRKLLLESTPSPVVFCH  
NDIQEGNILLSEPENADSLMLVDFEYSSYNR GFDIGNHFCEWVYDYTHEEWP FYKARP  
TDYPTQEQQLHFIRHYLA EAKKGETLSQEEQRKLEEDLLVEVSR YALASHFFWGLWSILQ  
ASMSTIEFGYLDYAQSRFQFYFQKQQLTSVHSSS

- 137 -

>gi|4757755|gb|NM\_004039.1|ANXA2 1362bp mRNA Homo sapiens annexin A2 (ANXA2), mRNA.

CATTTGGGGACGCTCTCAGCTCTCGGCGCACGGCCCAGCTTCCTTCAAAATGTCTACTGT  
TCACGAAATCCTGTGCAAGCTCAGCTTGGAGGGTGATCACTCTACACCCCCAAGTGCATA  
TGGGTCTGTCAAAGCCTATACTAACTTTGATGCTGAGCGGGATGCTTTGAACATTGAAAC  
AGCCATCAAGACCAAAGGTGTGGATGAGGTCAACATTGTCAACATTTTGACCAACCGCAG  
CAATGCACAGAGACAGGATATTGCCTTCGCCTACCAGAGAAGGACCAAAAAGGAACTTGC  
ATCAGCACTGAAGTCAGCCTTATCTGGCCACCTGGAGACGGTGATTTTGGGCCTATTGAA  
GACACCTGCTCAGTATGACGCTTCTGAGCTAAAAGCTTCCATGAAGGGGCTGGGAACCGA  
CGAGGACTCTCTCATTGAGATCATCTGCTCCAGAACCAACCAGGAGCTGCAGGAAATTAA  
CAGAGTCTACAAGGAAATGTACAAGACTGATCTGGAGAAGGACATTATTTCCGACACATC  
TGGTGACTTCCGCAAGCTGATGGTTGCCCTGGCAAAGGGTAGAAGAGCAGAGGATGGCTC  
TGTCATTGATTATGAACTGATTGACCAAGATGCTCGGGATCTCTATGACGCTGGAGTGAA  
GAGGAAAGGAACTGATGTTCCCAAGTGGATCAGCATCATGACCGAGCGGAGCGTGCCCCA  
CCTCCAGAAAGTATTTGATAGGTACAAGAGTTACAGCCCTTATGACATGTTGGAAAGCAT  
CAGGAAAGAGGTTAAAGGAGACCTGGAAAATGCTTTCCTGAACCTGGTTCAGTGCATTCA  
GAACAAGCCCCCTGTATTTTGCTGATCGGCTGTATGACTCCATGAAGGGCAAGGGGACGCG  
AGATAAGGTCCTGATCAGAATCATGGTCTCCCGCAGTGAAGTGGACATGTTGAAAATTAG  
GTCTGAATTCAAGAGAAAGTACGGCAAGTCCCTGTACTATTATATCCAGCAAGACACTAA  
GGGCGACTACCAGAAAGCGCTGCTGTACCTGTGTGGTGGAGATGACTGAAGCCCGACACG  
GCCTGAGCGTCCAGAAATGGTGCTCACCATGCTTCCAGCTAACAGGTCTAGAAAACCAGC  
TTGCGAATAACAGTCCCCGTGGCCATCCCTGTGAGGGTGACGTTAGCATTACCCCCAACC  
TCATTTTGTAGTTGCCTAAGCATTGCCTGGCCTTCCTGTCTAGTCTCTCCTGTAAAGCCAAAG  
AAATGAACATTCCAAGGAGTTGGAAGTGAAGTCTATGATGTGAAACACTTTGCCTCCTGT  
GTACTGTGTCATAAACAGATGAATAAACTGAATTTGTACTTT

>gi|4757756|gb|NP\_004030.1|ANXA2 339aa linear annexin A2;  
annexin II; annexin II (lipocortin II); calpactin I, heavy  
polypeptide (p36); lipocortin II; Annexin II (lipocortin I);  
annexin II (lipocortin II; calpactin I, heavy polypeptide)  
[Homo sapiens].

MSTVHEILCKLSLEGDHSTPPSAYGSVKAYTNFDAERDALNIETAIKTKGVDEVTIVNIL  
TNRSNAQRQDIAFAYQRRTKKELASALKSALSGLHETVILGLLKTTPAQYDASELKASMKG  
LGTDEDSLIEIICSRTNQELQEIINRVYKEMYKTDLEKDIISDTSGDFRKLMLVALAKGRRRA  
EDGSVIDYELIDQDARDLYDAGVKRKGTDPKWKISIMTERSVPFLQKVFDKYSPYDM  
LESIRKEVKGDLENFLNLVQCIQNKPLYFADRLYDSMKGKGTDRDKVLIRIMVSRSEVDM  
LKIRSEFKRKYGKSLYYYIQQDTKGDYQKALLYLCGGDD

>gi|27484939|gb|XM\_084635.3|LOC143785 1982bp mRNA Homo sapiens  
similar to hypothetical protein XP\_084635 [Homo sapiens]  
(LOC143785), mRNA.

TACTATCAGGGGGCAAGAGCCTTTCTCTCCAGCTACACACTCCATCTCCCGGGAGCAAGG  
GGAAACTCCGAGAGGAGGGCAACAGAGCCAGCATCTTGCCAGGGCCCCGGAGGAGGGGTT  
CCCCGCTACGCCTGTGCCGGAGGAGTTCAGTCAACGAGCGAGGGGCGCAAGGGTGGGTG  
CATCCTGCGCTGCGGCGGGCGCGCTACCCAGACGCTGGTGTGCAGAGCCACATGAAGCCT  
GCTGGGGACTGGGGGCCAGGGAGCAGCAAGCCAGCTGGGACTGAGGCGGACGCTGTCTCA  
GGGAGACGCTGACTCGCAAAGACACTCCCTTCCTTGTGCCTGGGTAAAAAGTCTCCTCCT  
GGGGTCCCTGGCCATCCTGAATATCCAGAATGGTGTCTTCTGAAGTTCTTCTGCATGAGTT  
TCTTCTGCCACCTGTGTCAAGGCTACTTCGATGGCCCCCTCTACCCAGAGATGTCCAATG

- 138 -

GGACTCTGCACCACTACTTCGTGCCCCGATGGGGACTATGAGGAGAACGATGACCCCCGAGA  
AGTGCCAGCTGCTCTTCAGGGTGAGTGACCACAGGCGCTGCTCCCAGGGGGAGGGGAGCC  
AGGTTGGCAGCCTGCTGAGCCTCACCTGCGGGAGGAGTTACCGTGCTGGGCCGCCAGG  
TGGAGGATGCTGGGCGCGTGCTGGAGGGCATCAGCAAAAGCATCTCCTACGACCTAGACG  
GGGAAGAGAGCTATGGCAAGTACCTGCGGCGGGAGTCCCACCAGATCGGGGATGCCTACT  
CCAACCTCGGACAAATCCCTCACTGAGCTGGAGAGCAAGTTCAAGCAGGGGCCAGGAACAGG  
ACAGCCGGCAGGAGAGCAGGCTCAACGAGGACTTTCTGGGAATGCTGGTCCACACCAGGT  
CCCTGCTGAAGGAGACACTGGACATCTCTGTGGGGCTCAGGGACAAATACGAGCTGCTGG  
CCCTCACCATTAGGAGCCATGGGACCCGACTAGGTGCGCTGAAAAATGATTATCTTAAAG  
TATAGGTGGAAGGATACAAATGCTAGAAAGAGGGAATCAAATCAGCCCCGTTTTGGAGGG  
TGGGGGACAGAAGATGGGGCTACATTTCCCCCATACTACTATTTTTTTTATATCCCGATT  
TGCACTTTGAGAATACATCTAAGGTCATCTTTCAAAGAGAAAAATTGGACACTTGAGTG  
ACTTTGTTTTTAGTTTTGTTTTTGTACATTATTTATGTGATTGTTATGGAATTGTCACCT  
GGAAAGAACAATTTTAAGCAATGTCATTTCTAGATGGGTTTCTAATTCTGCAGAGACACC  
CGTTTCAGCCACATCTAAAAGAGCACAGTTTATGTGGTGCGGAATTAACTTCCCCATCC  
TGCAGATTATGTGGAATAACCAAGATAATAGTGCATAGCTCCTTTCAGCCTCTAGCCT  
TCACTCCTGGGCTCCAAAAGCTATCCCAGTTGCCTGTTTTTCAAATGAGGTTCAAGGTGC  
TGCTTTGCATGCCTGCCAACCCATGGAAGTTGTTTCTTACTTCTTTTCTCTTATTTAT  
TAACCATGGTCTGAGAGTTGTTTTTGTCTATGTAACAGTATTGCCACAAAACCTATAGGC  
AAATCGTGTTTGCAGGGAGATTTCTGATGCCTCTGTGGGTGTGTGTAAGTTAAAGTGGCC  
ACATTTAAGAAGGCCAAGCTTTGTAGTGGTTGCACAGTCACACTGATATGCTGATTTGCT  
CTTTCTCATTGTATGTCTATGCTTTGTCTATCAGTGCTATAGTAAATTACAAAGAAATAGG  
TAGATTGTATGAACATACCCAAAATGCCTATGATTTAGGTTACCAATGTATTCTTTCTC  
ATTTGGGGTTTTGCTTCTGTCTGTCTGTTTATTGGAACTTGTAAGTTCAAGTAGGGGGAA  
TCCTAATTCTAATAACTCCTTAGCTAAGTTTTATTATTTCAGGCAATAAACATGTTTTTCAT  
GT

>gi|18578340|gb|XP\_084635.1|LOC143785 211aa linear similar to  
hypothetical protein XP\_084635 [Homo sapiens].

MVFLKFFCMSFFCHLCQGYFDGPLYPEMSNGTLHHYFVPDGDYEENDDPEKCQLLFRVSD  
HRRCSQGEQSQVGSLLSLTLREEFTVLGRQVEDAGRVLEGISKSISYDLDEESYGKYLR  
RESHQIGDAYSNSDKSLTELESKFQKGQEQDSRQESRLNEDFLGMLVHTRSLLKETLDIS  
VGLRDKEYELLALTIRSHGTRLGRLKNDYLKV

>gi|4507464|gb|NM\_003239.1|TGFB3 2574bp mRNA Homo sapiens  
transforming growth factor, beta 3 (TGFB3), mRNA.

CCTGTTTAGACACATGGACAACAATCCCAGCGCTACAAGGCACACAGTCCGCTTCTTCGT  
CCTCAGGGTTGCCAGCGCTTCCTGGAAGTCCTGAAGCTCTCGCAGTGCAGTGAGTTCATG  
CACCTTCTTGCCAAGCCTCAGTCTTTGGGATCTGGGGAGGCCCGCTGGTTTTCTCCCTC  
CTTCTGCACGTCTGCTGGGGTCTCTTCTCTCCAGGCCTTGCCGTCCCCCTGGCCTCTCT  
TCCCAGCTCACACATGAAGATGCACTTGCAAAGGGCTCTGGTGGTCTTGCCCTGCTGAA  
CTTTGCCACGGTCAGCCTCTCTGTCCACTTGCAACACCTTGGAATTCGGCCACATCAA  
GAAGAAGAGGGTGGAAGCCATTAGGGGACAGATCTTGAGCAAGCTCAGGCTCACCAGCCC  
CCCTGAGCCAACGGTGATGACCCACGTCCCCTATCAGGTCTTGCCCTTTTACAACAGCAC  
CCGGGAGCTGCTGGAGGAGATGCATGGGGAGAGGGAGGAAGGCTGCACCCAGGAAAACAC  
CGAGTCGGAATACTATGCCAAAGAAATCCATAAATTCGACATGATCCAGGGGCTGGCGGA  
GCACAACGAAGTGGCTGTCTGCCCTAAAGGAATTACCTCCAAGGTTTTCCGCTTCAATGT  
GTCTCAGTGGAGAAAAATAGAACCAACCTATTCCGAGCAGAATTCCGGGTCTTGCGGGT  
GCCCAACCCAGCTCTAAGCGGAATGAGCAGAGGATCGAGCTCTTCAGATCCTTCGGCC

- 139 -

AGATGAGCACATTGCCAAACAGCGCTATATCGGTGGCAAGAATCTGCCACACGGGGGCAC  
TGCCGAGTGGCTGTCCTTTGATGTCACTGACACTGTGCGTGAGTGGCTGTTGAGAAGAGA  
GTCCAACCTTAGGTCTAGAAATCAGCATTCACTGTCCATGTCACACCTTTCAGCCCAATGG  
AGATATCCTGGAAAACATTACGAGGTGATGGAAATCAAATTCAAAGGCGTGAGACAATGA  
GGATGACCATGGCCGTGGAGATCTGGGGCGCCTCAAGAAGCAGAAGGATCACCACAACCC  
TCATCTAATCCTCATGATGATTCCCCCACACCGGCTCGACAACCCGGGCCAGGGGGGTCA  
GAGGAAGAAGCGGGCTTTGGACACCAATTACTGCTTCCGCAACTTGGAGGAGAACTGCTG  
TGTGCGCCCCCTCTACATTGACTTCCGACAGGATCTGGGCTGGAAGTGGGTCCATGAACC  
TAAGGGCTACTATGCCAACTTCTGCTCAGGCCCTTGCCCATACCTCCGCAGTGCAGACAC  
AACCCACAGCACGGTGCTGGGACTGTACAACACTCTGAACCCTGAAGCATCTGCCTCGCC  
TTGCTGCGTGCCCCAGGACCTGGAGCCCCTGACCATCCTGTACTATGTTGGGAGGACCCC  
CAAAGTGGAGCAGCTCTCCAACATGGTGGTGAAGTCTTGTAATGTAGCTGAGACCCAC  
GTGCGACAGAGAGAGGGGAGAGAGAACCACCCTGCCTGACTGCCCGCTCCTCGGGAAAC  
ACACAAGCAACAAACCTCACTGAGAGGCCTGGAGCCCACAACCTTCGGCTCCGGGCAAAT  
GGCTGAGATGGAGGTTTCCTTTTGGAAACATTTCTTTCTTGCTGGCTCTGAGAATCACGGT  
GGTAAAGAAAGTGTGGGTTTGGTTAGAGGAAGGCTGAACTCTTCAGAACACACAGACTTT  
CTGTGACGCAGACAGAGGGGATGGGGATAGAGGAAGGGATGGTAAGTTGAGATGTTGTG  
TGGCAATGGGATTTGGGCTACCCTAAAGGGAGAAGGAAGGGCAGAGAATGGCTGGGTGAG  
GGCCAGACTGGAAGACACTTCAGATCTGAGGTTGGATTTGCTCATTGCTGTACCACATCT  
GCTCTAGGGAATCTGGATTATGTTATACAAGGCAAGCATTTTTTTTTTTTAAAGACAGGTT  
ACGAAGACAAAGTCCCAGAATTGTATCTCATACTGTCTGGGATTAAGGGCAAATCTATTA  
CTTTTGCAAACGTCTCTACATCAATTAACATCGTGGGTCACTACAGGGAGAAAATCCA  
GGTCATGCAGTTCCTGGCCCATCAACTGTATTGGGCCCTTTTGGATATGCTGAACGCAGAA  
GAAAGGGTGGAAATCAACCCTCTCCTGTCTGCCCTCTGGGTCCCTCCTCTCACCTCTCCC  
TCGATCATATTTCCCTTGGACACTTGGTTAGACGCCTTCCAGGTCAGGATGCACATTTCT  
TGGATTGTGGTTCCATGCAGCCTTGGGGCATTATGGGTCTTCCCCCACTTCCCCCTCCAAG  
ACCCTGTGTTTCAATTTGGTGTTCCTGGAAGCAGGTGCTACAACATGTGAGGCATTCGGGGA  
AGCTGCACATGTGCCACACAGTGACTTGGCCCCAGACGCATAGACTGAGGTATAAAGACA  
AGTATGAATATTACTCTCAAATCTTTGTATAAATAAATATTTTTTGGGGCATCCTGGATG  
ATTTCACTTCTGGAATATTGTTTCTAGAACAGTAAAAGCCTTATTCTAAGGTG

>gi|4507465|gb|NP\_003230.1|TGFB3 412aa linear transforming  
growth factor, beta 3 [Homo sapiens].

MKMHLQRALVVLALLNFATVLSLSLSTCTTLDLFGHIKKRVEAIRGQILSKLRLTSPPEPT  
VMTHVPYQVLALYNSTRELLEEMHGEREEGCTQENTESEYYAKEIHKFDMIQGLAEHNEL  
AVCPKGITSKVFRFNVSSVEKNRTNLFRAEFRVLRVPNPSSKRNEQRIELFQILRPDEHI  
AKQRYIGGKNLPTRGTAEWLSFDVTDTVREWLLRRESNLGLEISIHCPCHTFQPNGDILE  
NIHEVMEIKFKGVDNEDDHGRGDLGRLKKQKDHNPPLILMMIPPHRLDNPQGQGGQRKKR  
ALDTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKGYANFCSGPCPYLRSADTTTST  
VLGLYNTLNPEASASPCCVPQDLEPLTILYYVGRTPKVEQLSNMVVKCKCS

>gi|21735553|gb|NM\_002419.2|MAP3K11 3603bp mRNA Homo sapiens  
mitogen-activated protein kinase kinase kinase 11 (MAP3K11),  
mRNA.

ACAAAGGGAGGAGGAAGAAGGGAGCGGGGTGCGAGCCGTCGGGGCCAAAGGAGACGGGGC  
CAGGAACAGGCAGTCTCGGCCCAACTGCGGACGCTCCCTCCACCCCCTGCGCAAAAAGAC  
CCAACCGGAGTTGAGGCGCTGCCCCCTGAAGGCCCCACCTTACACTTGGCGGGGGCCGGAG  
CCAGGCTCCCAGGACTGCTCCAGAACCGAGGGAAGCTCGGGTCCCTCCAAGCTAGCCATG  
GTGAGGCGCCGGAGGCCCCGGGGCCCCACCCCCCGGCCTGACCACACTGCCCTGGGTGC



- 140 -

CCTCCTCCAGAAGCCCGAGATGCGGGGGGCGGGAGACAACACTCCTGGCTCCCCAGAGA  
GGCGTGGGTCTGGGGCTGAGGGCCAGGGCCCGGATGCCAGGTTCCGGGACTAGGGCCTT  
GGCAGCCAGCGGGGGTGGGGACCACGGGCACCCAGAGAAGGTCCTCCACACATCCCAGCG  
CCGGCTCCCGGCCATGGAGCCCTTGAAGAGCCTCTTCTCAAGAGCCCTCTAGGGTCATG  
GAATGGCAGTGGCAGCGGGGGTGGTGGGGGCGGTGGAGGAGGCCGGCCTGAGGGGTCTCC  
AAAGGCAGCGGGTTATGCCAACCCGGTGTGGACAGCCCTGTTGACTACGAGCCCAAGTGG  
GCAGGATGAGCTGGCCCTGAGGAAGGGTGACCGTGTGGAGGTGCTGTCCCGGGACGCAGC  
CATCTCAGGAGACGAGGGCTGGTGGGCGGGCCAGGTGGGTGGCCAGGTGGGCATCTTCCC  
GTCCAACATATGTGTCTCGGGGTGGTGGCCCCGCCCCCTGCGAGGTGGCCAGCTTCCAGGA  
GCTGCGGCTGGAGGAGGTGATCGGCATTGGAGGCTTTGGCAAGGTGTACAGGGGCAGCTG  
GCGAGGTGAGCTGGTGGCTGTGAAGGCAGCTCGCCAGGACCCCGATGAGGACATCAGTGT  
GACAGCCGAGAGCGTTTCGCCAGGAGGCCCGGCTCTTCGCCATGCTGGCACACCCCAACAT  
CATTGCCCTCAAGGCTGTGTGCCTGGAGGAGCCCAACCTGTGCCTGGTGTGAGTATGC  
AGCCGGTGGGCCCCCTCAGCCGAGCTCTGGCCGGGCGGCGCGTGCCTCCCATGTGCTGGT  
CAACTGGGCTGTGCAGATTGCCCGTGGGATGCACTACCTGCACTGCGAGGCCCTGGTGGC  
CGTCATCCACCGTGATCTCAAGTCCAACAACATTTTGCTGCTGCAGCCCATTGAGAGTGA  
CGACATGGAGCACAAGACCCTGAAGATCACCGACTTTGGCCTGGCCCGAGAGTGGCACAA  
AACCACACAAATGAGTGCCGCGGGCACCTACGCCTGGATGGCTCCTGAGGTTATCAAGGC  
CTCCACCTTCTCTAAGGGCAGTGACGTCTGGAGTTTGGGGTGCTGCTGTGGGAACGTCT  
GACCGGGGAGGTGCCATACCGTGGCATTGACTGCCTTGCTGTGGCCTATGGCGTAGCTGT  
TAACAAGCTCACACTGCCCATCCCATCCACCTGCCCCGAGCCCTTCGCACAGCTTATGGC  
CGACTGCTGGGCGCAGGACCCCCACCGCAGGCCCGACTTCGCCTCCATCCTGCAGCAGTT  
GGAGGCGCTGGAGGCACAGGTCCTACGGGAAATGCCGCGGGACTCCTTCCATTCCATGCA  
GGAAGGCTGGAAGCGCGAGATCCAGGGTCTCTTCGACGAGCTGCGAGCCAAGGAAAAGGA  
ACTACTGAGCCGCGAGGAGGAGCTGACGCGAGCGGCGCGCGAGCAGCGGTACAGGCGGA  
GCAGCTGCGGCGGCGCGAGCACCTGCTGGCCAGTGGGAGCTAGAGGTGTTTCGAGCGCGA  
GCTGACGCTGCTGCTGCAGCAGGTGGACCGCGAGCGACCGCACGTGCGCCGCCCGCGCGG  
GACATTCAAGCGCAGCAAGCTCCGGGCGCGCGACGGCGGCGAGCGTATCAGCATGCCACT  
CGACTTCAAGCACCGCATCACCGTGCAGGCCTCACCCGGCCTTGACCGGAGGAGAAACGT  
CTTCGAGGTGCGGCCTGGGGATTGCCCCACCTTTCCCCGGTTCCGAGCCATCCAGTTGGA  
GCCTGCAGAGCCAGGCCAGGCATGGGGCCGCCAGTCCCCCGACGTCTGGAGGACTCAAG  
CAATGGAGAGCGGCGAGCATGCTGGGCTTGGGGTCCAGTTCCCCCAAGCCTGGGGGAAGC  
CCAGAATGGGAGGAGAAGGTCCCGCATGGACGAAGCCACATGGTACCTGGATTACAGATGA  
CTCATCCCCCTTAGGATCTCCTTCCACACCCCCAGCACTCAATGGTAACCCCCCGCGGCC  
TAGCCTGGAGCCCGAGGAGCCCAAGAGGCCTGTCCCCGAGAGCGCGGTAGCAGCTCTGG  
GACGCCCAAGCTGATCCAGCGGGCGCTGCTGCGCGGCACCGCCCTGCTCGCCTCGCTGGG  
CCTTGGCCGCGACCTGCAGCCGCCGGGAGGCCCAGGACGCGAGCGCGGGGAGTCCCCGAC  
AACACCCCCACGCCAACGCCCGCGCCCTGCCCGACCGAGCCGCCCCCTTCCCCGCTCAT  
CTGCTTCTCGCTCAAGACGCCCGACTCCCCGCCACTCCTGCACCCCTGTTGCTGGACCT  
GGGTATCCCTGTGGGCCAGCGGTGAGCCAAGAGCCCCCGACGTGAGGAGGAGCCCCGCGG  
AGGCACTGTCTCACCCCCACCGGGGACATCACGCTCTGCTCCTGGCACCCCCAGGCACCCC  
ACGTTACACACCCCTGGGCCTCATCAGCCGACCTCGGCCCTCGCCCCCTTCGAGCCGCAT  
TGATCCCTGGAGCTTTGTGTGCTGAGCTGGGCCACGGCCTTCTCCCCTGCCATCACCACAGCC  
TGACCCCCGCGAGCACCTTGACCTTGTTCGCGACTCAGACCCCTTCTGGGACTCCCC  
ACCTGCCAACCCCTTCCAGGGGGGCCCCCAGGACTGCAGGGCACAGACCAAAGACATGGG  
TGCCAGGCCCGTGGGTGCCGGAAGCGGGCCTTGAGTGGGCCAGGCCACTCCCCCGAG  
CTCCAGCTGCCTTAGGAGGAGTCACAGCATACACTGGAACAGGAGCTGGGTGAGCCTCTG



- 141 -

CAGCTGCCTCAGTTTCCCCAGGGACCCACCCCCCTTTGGGGGTCAGGAACACTACACTG  
CACAGGAAGCCTTCACACTGGAAGGGGGACCTGCGCCCCACATCTGAAACCTGTAGGTC  
CCCCAGCTCACCTGCCCTACTGGGGCCCAACACTGTACCCAGCTGGTTGGGAGGACCAG  
AGCCTGTCTCAGGGAATTGCCTGCTGGGGTGATGCAGGGAGGAGGGGAGGTGCAGGGAAG  
AGGGGCCCGCCTCAGCTGTCACCAGCACTTTTGACCAAGTCCTGCTACTGCGCCCCCTGC  
CCTAGGGCTTAGAGCATGGACCTCCTGCCCTGGGGGTCATCTGGGGCCAGGGCTCTCTGG  
ATGCCTTCCTGCTGCCCCAGCCAGGGTTGGAGTCTTAGCCTCGGGATCCAGTGAAGCCAG  
AAGCCAAATAAACTCAAAAGCTGTCTCCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAA

>gi|4505195|gb|NP\_002410.1|MAP3K11 847aa linear mitogen-  
activated protein kinase kinase kinase 11; mixed lineage  
kinase 3; SH3 domain-containing proline-rich kinase; protein-  
tyrosine kinase PTK1 [Homo sapiens].

MEPLKSLFLKSPLGSWNGSGSGGGGGGGGRPEGSPKAAGYANPVWTALFDYEPSGQDEL  
ALRKGDREVLRSDAISGDEGWAGQVGGQVGIFPSNYVSRGGGPPCEVASFQELRLE  
EVIGIGGFVKYRGSWRGELVAVKAARQDPDEDISVTAESVRQEARLFAMLAHPNI IALK  
AVCLEEPNLCLVMEYAAGGPLSRALAGRRVPPHVLVNWAVQIARGMHYHLHCEALVPVIHR  
DLKSNNI LLLQPIESDDMEHKTLLKITDFGLAREWHKTQMSAAGTYAWMAPEVIKASTFS  
KGSVDVWSFGVLLWELLTGEVPYRGIDCLAVAYGVAVNKLTLPI PSTCPEPFAQLMADCWA  
QDPHRRPDFASILQQLEALEAQVLRMPRDSFHSMQEGWKREIQGLFDELRAKEKELLSR  
EEELTRAAREQRSQAEQLRRREHLLAQWELEVFERELTLLLQQVDRERPHVRRRRGTFR  
SKLRARDGGERISMPDLDFKHRI TVQASPLDRRRNVFEVGPDSPTFPRFRAIQLEPAEP  
GQAWGRQSPRRLEDSSNGERRACWAWGPSSPKPGEAQNGRRRSRMDEATWYLDSDSSPL  
GSPSTPPALNGNPPRPSLEPEEPKRPVPAERGSSSGTPKLIQRALLRG TALLASLGLGRD  
LQPPGGPGRERGESPTTPPTPTPAPCPTPPPSPLICFSLKTPDSPPTPAPLLLDLGI PV  
GQSAKSPRREEPRGGTVSPPPGTSRSAPGTGTPRSPPLGLISRPRPSPLRSRIDPWS  
FVSAGPRPSPLPSPQPAPRRAPWTLFPDSDPFWDSPPANPFQGGPQDCRAQTKDMGAQAP  
WVPEAGP

>gi|4505784|gb|NM\_000294.1|PHKG2 1571bp mRNA Homo sapiens  
phosphorylase kinase, gamma 2 (testis) (PHKG2), mRNA.

AAGGTGAGCGACTGCAGGCAAACCCGGCGACAGCGCAGCTCGCGTCGACCCTGGCTCCTC  
TGCTTGGCCCCCTCAGGCCCCCGCCTCCTTCAGGATGACGCTGGACGTGGGGCCGGAGGAT  
GAGCTGCCCCGACTGGGCGCGCCGCAAGAGTTTTACCAGAAGTACGACCCTAAGGACGTC  
ATCGGCAGAGGAGTGAGCTCTGTGGTCCGCCGTTGTGTTTCATCGAGCTACTGGCCACGAG  
TTTGCGGTGAAGATTATGGAAGTGACAGCTGAGCGGCTGAGTCCTGAGCAGCTGGAGGAG  
GTGCGGGAAGCCACACGGCGAGAGACACACATCCTTCGCCAGGTCGCCGGCCACCCCCAC  
ATCATCACCTTCATCGATTCTTACGAGTCTTCTAGCTTCATGTTCTTGGTGTTTGACCTG  
ATGCGGAAGGGAGAGCTGTTTGACTATCTCACAGAGAAGGTGGCCCTCTCTGAAAAGGAA  
ACCAGGTCCATCATGCGGTCTCTGCTGGAAGCAGTGAGCTTTCTCCATGCCAACACATT  
GTGCATCGAGATCTGAAGCCCGAGAATATTCTCCTAGATGACAATATGCAGATCCGACTT  
TCAGATTTTCGGGTTCTCCTGCCACTTGGAACCTGGCGAGAAGCTTCGAGAGTTGTGTGGG  
ACCCAGGGTATCTAGCGCCAGAGATCCTTAAATGCTCCATGGATGAAACCCACCCAGGC  
TATGGCAAGGAGGTCGACCTCTGGGCCTGTGGGGTGATCTTGTTTCACTCCTGGCTGGC  
TCGCCACCTTTCTGGCACCGGCGGCGAGATCCTGATGTTACGCATGATCATGGAGGGCCAG  
TACCAGTTCAGTTCCTCCGAGTGGGATGACCGTTCCAGCACTGTCAAAGACCTGATCTCC  
AGGCTGCTGCAGGTGGATCCTGAGGCACGCCTGACAGCTGAGCAGGCCCTACAGCACCCC  
TTCTTTGAGCGTTGTGAAGGCAGCCAACCTGGAACCTCACCCCCCGCCAGCGGTTCCGG

- 142 -

GTGGCAGTGTGGACAGTGCTGGCTGCTGGACGAGTGGCCCTAAGCACCCATCGTGTACGG  
CCACTGACCAAGAATGCACTGTTGAGGGACCCCTTATGCGCTGCGGTCACTGCGGCACCTC  
ATCGACAACCTGTGCCTTCCGGCTCTACGGGCACTGGGTAAAGAAAGGGGAGCAGCAGAAC  
CGGGCGGCTCTCTTTCAGCACCGGCCCTGGGCCTTTTCCCATCATGGGCCCTGAAGAG  
GAGGGAGACTCTGCTGCTATAACTGAGGATGAGGCCGTGCTTGTGCTGGGCTAGGACCTC  
AACCCAGGGATTCCCAGGAAGCAGAACTCTCCAGAAGAAGGGTTTTGATCATTCCAGCT  
CCTCTGGGCTCTGGCCTCAGGCCCACTAATGATCCTGCTACCCTCTTGAAGACCAGCCCG  
GTACCTCTCTCCCACTGGCCAGGACTCTGAGATCAGAGCTGGGGTGGAAGGGAGCCATT  
CTGAACGCCACGCCTGGCCCGGTCAGTGCTGCATGCACTGCATATGAAATAAAATCTGCT  
ACACGCCAGGG

>gi|4505785|gb|NP\_000285.1|PHKG2 406aa linear phosphorylase  
kinase, gamma 2 (testis); Phosphorylase kinase, gamma 2  
(testis/liver) [Homo sapiens].

MTLDVGPEDLPDWAAAKEFYQKYDPKDVIGRGVSSVVRRCVHRATGHEFAVKIMEVTAE  
RLSPEQLEEVREATRRETHILRQVAGHPHIITLIDSYESSFSMFLVFDLMRKGELFDYLT  
EKVALSEKETRSIMRSLLEAVSFLHANNIVHRDLKPENILLDDNMQIRLSDFGFSCHLEP  
GEKLRELCGTPGYLAPEILKCSMDETHPGYGKEVDLWACGVILFTLLAGSPFFWHRROIL  
MLRMIMEGQYQFSSPEWDDRSSTVKDLISRLQVDPEARLTAEQALQHPFFERCEGSQPW  
NLTPRQRFRAVAVWTVLAAGRVALSTHRVRPLTKNALLRDPYALRSVRHLIDNCAFRLYGH  
WVKKGEQQNRAALFQHRPPGPFPIMGPEEEGDSAAITEDEAVLVLG

>gi|5453789|gb|NM\_006169.1|NNMT 952bp mRNA Homo sapiens  
nicotinamide N-methyltransferase (NNMT), mRNA.

TGAACCTCTGGATGCTGTTAGCCTGAGACTCAGGAAGACAACCTTCTGCAGGGTCACTCCCT  
GGCTTCTGGAGGAAAGAGAAGGAGGGCAGTGCTCCAGTGGTACAGAAGTGAGACATAATG  
GAATCAGGCTTCACCTCCAAGGACACCTATCTAAGCCATTTTAACCCCTCGGGATTACCTA  
GAAAAATATTACAAGTTTGGTTCTAGGCACTCTGCAGAAAGCCAGATTCTTAAGCACCTT  
CTGAAAAATCTTTTCAAGATATTCTGCCTAGACGGTGTGAAGGGAGACCTGCTGATTGAC  
ATCGGCTCTGGCCCCACTATCTATCAGCTCCTCTCTGCTTGTGAATCCTTTAAGGAGATC  
GTCGTCACCTGACTACTCAGACCAGAACCTGCAGGAGCTGGAGAAGTGGCTGAAGAAAGAG  
CCAGAGGCCTTTGACTGGTCCCCAGTGGTGACCTATGTGTGTGATCTTGAAGGGAACAGA  
GTCAAGGGTCCAGAGAAGGAGGAGAAGTTGAGACAGGCGGTCAAGCAGGTGCTGAAGTGT  
GATGTGACTCAGAGCCAGCCACTGGGGGCCCTCCCCTTACCCCGGCTGACTGCGTGCTC  
AGCACACTGTGTCTGGATGCCGCTGCCAGACCTCCCCACCTACTGCAGGGCGCTCAGG  
AACCTCGGCAGCCTACTGAAGCCAGGGGGCTTCTGCTGATCATGGATGCGCTCAAGAGC  
AGCTACTACATGATTGGTGAGCAGAAGTTCTCCAGCCTCCCCCTGGGCCGGGAGGCAGTA  
GAGGCTGCTGTGAAAGAGGCTGGCTACACAATCGAATGGTTTGAGGTGATCTCGCAAAGT  
TATTCTTCCACCATGGCCAACAACGAAGGACTTTTCTCCCTGGTGGCGAGGAAGCTGAGC  
AGACCCCTGTGATGCCTGTGACCTCAATTAAAGCAATTCCTTTGACCTGTCA

>gi|5453790|gb|NP\_006160.1|NNMT 264aa linear nicotinamide N-  
methyltransferase [Homo sapiens].

MESGFTSKDITYLSHFNPRDYLEKYYKFGSRHSAESQILKHLLKNLFKIFCLDGVKGDLLI  
DIGSGPTIYQLLSACESFKEIVVTDYSDQNLQELEKWLKKEPEAFDWSPVVTVYVCDLEG  
RVKGPEKEEKLQAVKQVLKCDVTQSQPLGAVPLPPADCVLSTLCLDAACPDLPITYCRAL  
RNLGSLKPGGFLVIMDALKSSYYMIGEQQKFSSPLGREAVEAAVKEAGYTIWFEVISQ  
SYSSTMANNEGLFSLVARKLSRPL

>gi|4507668|gb|NM\_003295.1|TPT1 830bp mRNA Homo sapiens tumor  
protein, translationally-controlled 1 (TPT1), mRNA.

- 143 -

CCCCCCCCGAGCGCCGCTCCGGCTGCACCGCGCTCGCTCCGAGTTTCAGGCTCGTGCTAAG  
CTAGCGCCGTCGTCGTCTCCCTTCAGTCGCCATCATGATTATCTACCGGGACCTCATCAG  
CCACGATGAGATGTTCTCCGACATCTACAAGATCCGGGAGATCGCGGACGGGTGTGTCCT  
GGAGGTGGAGGGGAAGATGGTTCAGTAGGACAGAAGGTAACATTGATGACTCGCTCATTGG  
TGGAAATGCCTCCGCTGAAGGCCCCGAGGGGCGAAGGTACCGAAAGCACAGTAATCACTGG  
TGTCGATATTGTCATGAACCATCACCTGCAGGAAACAAGTTTCACAAAAGAAGCCTACAA  
GAAGTACATCAAAGATTACATGAAATCAATCAAAGGGAAACTTGAAGAACAGAGACCAGA  
AAGAGTAAAACCTTTTATGACAGGGGCTGCAGAACAAATCAAGCACATCCTTGCTAATTT  
CAAAAACCTACCAGTTCCTTTATTGGTGAAAACATGAATCCAGATGGCATGGTTGCTCTATT  
GGACTACCGTGAGGATGGTGTGACCCCATATATGATTTTCTTTAAGGATGGTTTAGAAAT  
GGAAAAATGTTAACAAATGTGGCAATTATTTTGGATCTATCACCTGTCATCATAACTGGC  
TTCTGCTTGTTCATCCACACAACACCAGGACTTAAGACAAATGGGACTGATGTCATCTTGA  
GCTCTTCATTTATTTTGACTGTGATTTATTTGGAGTGGAGGCATTGTTTTTAAGAAAAAC  
ATGTCATGTAGGTTGTCTAAAAATAAAATGCATTTAAACTCATTGAGAG

>gi|4507669|gb|NP\_003286.1|TPT1 172aa linear tumor protein,  
translationally-controlled 1; fortilin; histamine-releasing  
factor [Homo sapiens].

MIIYRDLISHDEMFSDIYKIREIADGLCLEVEGKMVSRTEGNIDDSLIGGNASAEGPEGE  
GTESTVITGVDIVMNHHLQETSFTKEAYKKYIKDYMKSIGKLEEQRPERVKPFMTGAAE  
QIKHILANFKNYQFFIGENMNPDMVALLDYREDGVTPYMIFFKDGLEMEKC

>gi|27477073|gb|NM\_018725.2|IL17BR 2077bp mRNA Homo sapiens  
interleukin 17B receptor (IL17BR), transcript variant 1, mRNA.  
AGCGCAGCGTGCGGGTGGCCTGGATCCCGCGCAGTGGCCCGCGGATGTCGCTCGTGCTGC  
TAAGCCTGGCCGCGCTGTGCAGGAGCGCCGTACCCCGAGAGCCGACCGTTCAATGTGGCT  
CTGAAACTGGGCCATCTCCAGAGTGGATGCTACAACATGATCTAATCCCCGGAGACTTGA  
GGGACCTCCGAGTAGAACCTGTTACAACCTAGTGTGCAACAGGGGACTATTCAATTTTGA  
TGAATGTAAGCTGGGTACTCCGGGCAGATGCCAGCATCCGCTTGTTGAAGGCCACCAAGA  
TTTGTGTGACGGGCAAAAGCAACTTCCAGTCTTACAGCTGTGTGAGGTGCAATTACACAG  
AGGCCTTCCAGACTCAGACCAGACCCTCTGGTGGTAAATGGACATTTTCTTACATCGGCT  
TCCCTGTAGAGCTGAACACAGTCTATTTTCATTGGGGCCCATATATTCCTAATGCAAATA  
TGAATGAAGATGGCCCTTCCATGTCTGTGAATTTACCTCACCAGGCTGCCTAGACCACA  
TAATGAAATATAAAAAAAGTGTGTCAAGGCCGGAAGCCTGTGGGATCCGAACATCACTG  
CTTGTAAGAAGAATGAGGAGACAGTAGAAGTGAACCTCACAACCACTCCCCTGGGAAACA  
GATACATGGCTCTTATCCAACACAGCACTATCATCGGGTTTTCTCAGGTGTTTGAGCCAC  
ACCAGAAGAAACAAACGCGAGCTTCAGTGGTGATTCCAGTGACTGGGGATAGTGAAGGTG  
CTACGGTGCAGCTGACTCCATATTTTCTTACTTGTGGCAGCGACTGCATCCGACATAAAG  
GAACAGTTGTGCTCTGCCCACAAACAGGCGTCCCTTTCCCTCTGGATAACAACAAAAGCA  
AGCCGGGAGGCTGGCTGCCTCTCCTCCTGCTGTCTCTGCTGGTGGCCACATGGGTGCTGG  
TGGCAGGGATCTATCTAATGTGGAGGCACGAAAGGATCAAGAAGACTTCCTTTTCTACCA  
CCACACTACTGCCCCCATTAAGGTTCTTGTGGTTTACCCATCTGAAATATGTTTCCATC  
ACACAATTTGTTACTTCACTGAATTTCTTCAAACCAATTGCAGAAGTGAGGTCATCCTTG  
AAAAGTGGCAGAAAAAGAAAATAGCAGAGATGGGTCCAGTGCAGTGGCTTGCCACTCAA  
AGAAGGCAGCAGACAAAGTCGTCTTCTTCTTCCAATGACGTCAACAGTGTGTGCGATG  
GTACCTGTGGCAAGAGCGAGGGCAGTCCCAGTGAGAACTCTCAAGACCTCTTCCCCCTTG  
CCTTTAACCTTTTCTGCAGTGATCTAAGAAGCCAGATTCATCTGCACAAATACGTGGTGG  
TCTACTTTAGAGAGATTGATACAAAAGACGATTACAATGCTCTCAGTGTCTGCCCCAAGT  
ACCACCTCATGAAGGATGCCACTGCTTTCTGTGCAGAACTTCTCCATGTCAAGCAGCAGG

- 144 -

TGTCAGCAGGAAAAAGATCACAAGCCTGCCACGATGGCTGCTGCTCCTTG TAGCCCACCC  
ATGAGAAGCAAGAGACCTTAAAGGCTTCCTATCCCACCAATTACAGGGAAAAAACGTGTG  
ATGATCCTGAAGCTTACTATGCAGCCTACAAACAGCCTTAGTAATTAAAACATTTTATAC  
CAATAAAATTTTCAAATATTGCTAACTAATGTAGCATTAACTAACGATTGGAACTACAT  
TTACAACTTCAAAGCTGTTTTATACATAGAAATCAATTACAGTTTTTAATTGAAAAC TATA  
ACCATTTTGATAATGCAACAATAAAGCATCTTCAGCCAAACATCTAGTCTTCCATAGACC  
ATGCATTGCAGTGTACCCAGA ACTGTTTAGCTAATATTCTATGTTTAATTAATGAATACT  
AACTCTAAGAACCCCTCACTGATTCACTCAATAGCATCTTAAGTGAAAAACCTTCTATTA  
CATGCAAAAAATCATTTGTTTTTAAGATAACAAAAGTAGGGAATAACAAGCTGAACCCAC  
TTTTAAAAA

>gi|27477074|gb|NP\_061195.2|IL17BR 502aa linear IL-17B  
receptor isoform 1 precursor; IL-17B receptor; interleukin 17  
receptor homolog 1; interleukin 17 receptor homolog; cytokine  
receptor CRL4 [Homo sapiens].

MSLVLLSLAALCRSAVPREPTVQCGSETGPSPEWMLQHDLPDGLRDLRVEPVTT SVATG  
DYSILMNVSWVLRADASIRLLKATKICVTGKSNFQSYSCVRCNYTEAFQTQTRPSGGKWT  
FSYIGFPVELNTVYFIGAHNIPNANMNEDGPSMSVNFTSPGCLDHIMKYKKKCVKAGSLW  
DPNITACKKNEETVEVNFTTTPLGNRYMALIQHSTIIGFSQVFEPHQKKQTRASVVIPVT  
GDSEGATVQLTPYFPTCGSDCIRHKGTVVLC PQTGVFPPLDNNKSKPGGWLPLLLLSLLV  
ATWVLVAGIYLMWRHERIKKTSFSTTTLLPPIKVLVVYPSEICFHHTICYFTEFLQNHCR  
SEVILEKWQKKKIAEMGPVQWLATQKKAADKVVFLLSNDVNSVCDGTCGKSEGSPSENSQ  
DLFPLAFNLFCSDLRSQIHLHKYVVVYFREIDTKDDYNALSVCPKYHLMKDATAFCAELL  
HVKQQVSAGKRSQACHDGCCSL

>gi|14165275|gb|NM\_032411.1|ECRG4 772bp mRNA Homo sapiens  
esophageal cancer related gene 4 protein (ECRG4), mRNA.  
GGATAACCCGCGGCCGCGCCTGCCCGCTCGCACCCCTCTCCCGCGCCCGGTTCTCCCTCG  
CAGCACCTCGAAGTGCGCCCTCGCCCTCCTGCTCGCGCCCCGCGCCCATGGCTGCCTCC  
CCCGCGCGCCTGCTGTCTGGCCCTGACCGGGCTGGCGCTGCTCCTGCTCCTGTGCTGG  
GGCCCAGGTGGCATAAGTGGAATAAACTCAAGCTGATGCTTCAAAAACGAGAAGCACCT  
GTTCCAAC TAAGACTAAAGTGGCCGTTGATGAGAATAAAGCCAAAGAATTCTTGGCAGC  
CTGAAGCGCCAGAAGCGGCAGCTGTGGGACCGGACTCGGCCCCGAGGTGCAGCAGTGGTAC  
CAGCAGTTTCTCTACATGGGCTTTGACGAAGCGAAATTTGAAGATGACATCACCTATTGG  
CTTAACAGAGATCGAAATGGACATGAATACTATGGCGATTACTACCAACGTC ACTATGAT  
GAAGACTCTGCAATTGGTCCCCGAGCCCCTACGGCTTTAGGCATGGAGCCAGCGTCAAC  
TACGATGACTACTAACCATGACTTGCCACACGCTGTACAAGAAGCAAATAGCGATTCTCT  
TCATGTATCTCCTAATGCCTTACACTACTTGGTTTCTGATTTGCTCTATTTTCAGCAGATC  
TTTCTACCTACTTTGGTGATCAAAAAGAAGAGTTAAAACAACACATGTAAATGCCTTTT  
GATATTTTCATGGGAATGTTTAAAAATAGAAATAAAGCATTTTGTTAAAACGA

>gi|14165276|gb|NP\_115787.1|ECRG4 148aa linear esophageal  
cancer related gene 4 protein [Homo sapiens].  
MAASPARPAVLALTGLALLLLLCWGPGGISGNKLKLMLOKREAPVPTKTKVAVDENKAKE  
FLGSLKRQKRQLWDRTRPEVQQWYQQFLYMGFDEAKFEDDITYWLNDRDRNGHEY YGDYYQ  
RHYDEDSAIGPRSPYGF RHGASVNYDDY

- 145 -

>gi|24025684|gb|NM\_003017.2|SFRS3 1403bp mRNA Homo sapiens  
splicing factor, arginine/serine-rich 3 (SFRS3), mRNA.

CCGGGTGAGTGAGAGAGTTGGTTGGTGTGGGCCGAGGAAAGCGGGAAGACTCATCGGA  
GCGTGTGGATTTGAGCCGCCGCATTTTTTAACCCTAGATCTCGAAATGCATCGTGATTCC  
TGTCATTGGACTGTAAGGTTTATGTAGGCAATCTTGGAAACAATGGCAACAAGACGGAA  
TTGGAACGGGCTTTTGGCTACTATGGACCACTCCGAAGTGTGTGGGTTGCTAGAAACCA  
CCCGGCTTTGCTTTTGTGTAATTTGAAGATCCCCGAGATGCAGCTGATGCAGTCCGAGAG  
CTAGATGGAAGAACACTATGTGGCTGCCGTGTAAGAGTGGAAGTGTGCAATGGTGAAAAA  
AGAAGTAGAAATCGTGGCCACCTCCCTCTTGGGGTCGTCGCCCTCGAGATGATTATCGT  
AGGAGGAGTCTCCACCTCGTCGCAGATCTCCAAGAAGGAGAAGCTTCTCTCGCAGCCGG  
AGCAGGTCCCTTTCTAGAGATAGGAGAAGAGAGAGATCGCTGTCTCGGGAGAGAAATCAC  
AAGCCGTCCCGATCCTTCTCTAGGTCTCGTAGTCGATCTAGGTCAAATGAAAGGAAATAG  
AAGACAGTTTGCAAGAGAAGTGGTGTACAGGAAATTACTTCATTTGACAGGAGTATGTAC  
AGAAAATTCAAGTTTTGTTTGAGACTTCATAAGCTTGGTGCATTTTTTAAGATGTTTTAGC  
TGTTCAAATCTGTTTGTCTCTTGAAACAGTGACACAAAGGTGTAATTCTCTATGGTTTGA  
AATGGATCATACGAGGCATGTAATACCAAGAATTGTTACTTTACAATGTTCCCTTAAGCA  
AAATTGAATTTGCTTTGAACTTTTAGTTATGCACAGACTGATAATAAACCTCTAAACCTG  
CCCAGCGGAAGTGTGTTTTTTTTTAAATTTAAATACAGAAACAACTGGCAAAAATTGAAC  
TAAGATTTACTTTTTTTTCCATAGCTGGGATATAGGCTGCAGCTATAGTTGAACAAGCAG  
TCTTTAAAACTGCTGTGAAACACAGGCCATCAGGGAAAACGAAATGCTGCACTATTAAA  
TTAGAGGTTTTTGAAAAATCCAACCTCTCATCCTGGGCAGAGGTTGCCTAGTTGGTATAGA  
ATGTTAAGTTTCAAGAAAGTTTACCTTTGCTTTAGGTCATAAGTTCCTTATTTGATTGCT  
GTATATGGATACATGGCTGTTTCGTGACATTCTTTATGTGCAAATTTGTGATTTCAAAAAT  
GTCCTGCCAGTTTAAGGGTACATTGTAGAGCCGAACTTTGAGTTACTGTGCAAGATTTTT  
TTTTCATGCTGTCATTTGTAATATGTTTTGTGAGAATCCTTGGGATTAAAGTTTTGGTTA  
CAAATTGTTAAAAA

>gi|4506901|gb|NP\_003008.1|SFRS3 164aa linear splicing factor,  
arginine/serine-rich 3; splicing factor, arginine//serine-  
rich, 20-kD [Homo sapiens].

MHRDSCPLDCKVYVGNLGNNGNKTELERAFGYYGPLRSVWVARNPPGFAFVEFEDPRDAA  
DAVRELDGRTLCCGRVVRVELSNGEKRSRNRGPPPSWGRRPRDDYRRRSPPPRRRSPRRRS  
FSRSRSRSLSRDRRRERSLSRERNHKPSRSFSRSRSRSRNERK

>gi|4759097|gb|NM\_004593.1|SFRS10 1972bp mRNA Homo sapiens  
splicing factor, arginine/serine-rich 10 (transformer 2  
homolog, Drosophila) (SFRS10), mRNA.

GAATTCGGCACGAGGGCGACCGGCGCGTCGTGCGGGGCTGCGGCGGAGCCTCCTTAAGGA  
AGGTGCAAGAGGTTGGCAGCTTCGATTGAAGCACATCGACCGGCGACAGCAGCCAGGAGT  
CATGAGCGACAGCGGCGAGCAGAACTACGGCGAGCGGGAATCCCGTTCTGCTTCCAGAAG  
TGGAAGTGCTCACGGATCGGGGAAATCTGCAAGGCATACCCCTGCAAGGTCTCGCTCCAA  
GGAAGATTCCAGGCGTTCCAGATCAAAGTCCAGGTCCCGATCTGAATCTAGGTCTAGATC  
CAGAAGAAGCTCCCGAAGGCATTATACCCGGTCACGGTCTCGCTCCCGCTCCCATAGACG  
ATCACGTAGCAGGTCTTACAGTCGAGATTATCGTAGACGGCACAGCCACAGCCATTCTCC  
CATGTCTACTCGCAGGCGTCATGTTGGGAATCGGGCAAATCCTGATCCTAACTGTTGTCT  
TGGAGTATTTGGGCTGAGCTTGTACACCACAGAAAGAGATCTAAGAGAAGTGTTCTCTAA  
ATATGGTCCCATTGCCGATGTGTCTATTGTATATGACCAGCAGTCTAGGCGTTCAAGAGG  
ATTTGCCTTTGTATATTTTGAATGTAGATGATGCCAAGGAAGCTAAAGAACGTGCCAA  
TGGAATGGAGCTTGATGGGCGTAGGATCAGAGTTGATTTCTCTATAACAAAAGACCACA

- 146 -

TACGCCAACACCAGGAATTTACATGGGGAGACCTACCTATGGCAGCTCTCGCCGTCGGGA  
TTACTATGACAGAGGATATGATCGGGGCTATGATGATCGGGACTACTATAGCAGATCATA  
CAGAGGAGGAGGTGGAGGAGGAGGAGGATGGAGAGCTGCCCAAGACAGGGATCAGATTTA  
TAGAAGGCGGTCACCTTCTCCTTACTATAGTCGTGGAGGATACAGATCACGTTCCAGATC  
TCGATCATACTCACCTCGTCGCTATTTAAAGCATGAAGACTTTCTGAAACCTGCCCTAGAG  
CTGGGATATTGTTTGTGGGCAATATTTTTTATTGTCTCTTGTTTAAAAAGTGAACAGTGC  
CTAGTGAAGTTAGGTGACTTTTACACCTTTTACGATGACTACTTTTGGTGGAGTTGAAAT  
GCTGTTTTTCATTCTGCATTTGTGTAGTTTGGTGCTTTGTTCCAAGTTAAGTGTTTTCAGA  
AAAGTATGTTTTGCATGTATTTTTTTTACAGTCTAAATTTTGAAGTCTGAGAAGTTTCTAT  
TGTACAAAACCTTCATTTAAAAGGTTTTTCTACTGAATCCAGGGTATTCTGAAGATCGAAG  
CCTGTGTAAAATGCTACCAAATGGCAAAAAGCAACAATAAACAGTTTGATTTTTACTTTT  
CTTTCTAACATATCAATGCTTAGCAGAACTATTTCAGATTGTCAGTAGTAAATTTAAAGAC  
AAATGCCCCGTTTTCTCCAGTCCATGAAACATACTACTTATATACCTGCAACTAAGTG  
TTTAAAATTATGCTCTGTAACCTCTGTACTGCTAGTATTAGAACTAAAAATCTTAAATAC  
AGCCAGTGCTTAATGCTTATATCAATGTGGATTTGTCTGGCTTTTATGTAATCTGTAATAT  
GTATAGCAGGAAATACGAAGAGTTACACAGTGTATGCCTTAAAAGGCTGTTTCTTAAAGG  
TGTTACAAGGGGATAATGGTATTTCAACTAGTTATCAGCAAGTGACAATACATTCCACCA  
CAAATACACTCTTGTTCTTCTAGCTTTTAGACTATATGAAAAAACCGGGTGCTTCAAAGT  
ACATGATAAGGGAACACTATACCTGTCATGGATGAACTGAAGACTTTGCCTGTTCAATTT  
TTAAATATTATTTTTCAGGTCCTTTGCTTACCAAAGGAGGCCCAATTTCACTCAAATGTTT  
TGAGAACTGTGTTTAAATAAACGCAATGAAAAGAAAAA

>gi|4759098|gb|NP\_004584.1|SFRS10 288aa linear splicing  
factor, arginine/serine-rich 10 (transformer 2 homolog,  
Drosophila); splicing factor, arginine/serine-rich  
(transformer 2 Drosophila homolog) 10 [Homo sapiens].

MSDSGEQNYGERESRSASRSGSAHSGKSARHTPARSRSKEDSRRSRSKSRSRSESRSRS  
RRSSRRHYTRSRSRSRSHRRSRSRSYSRDYRRRHSHSHSPMSTRRRHVGNRANPDPNCCL  
GVFGLSLYTTERDLREVFASKYGPIADVSIYVDQQSRRSRGFAFVYFENVDDAKEAKERAN  
GMELDGRRIRVDFSITKRPHPTPTPGIYMGRPTYGSSRRRDYDRGYDRGYDDRDYYSRSY  
RGGGGGGGGWRAAQDRDQIYRRRSPSPYYSRGGYRSRSRSRSYSPRRY

>gi|5803206|gb|NM\_006758.1|U2AF1 904bp mRNA Homo sapiens  
U2 (RNU2) small nuclear RNA auxillary factor 1 (U2AF1), mRNA.  
GGAATTCCGTCGACGGCAGCGCGCGCGGGTGGGAAATGGCGGAGTATCTGGCCTCCA  
TCTTCGGCACCGAGAAAGACAAAGTCAACTGTTCAATTTATTTCAAATTTGGAGCATGTC  
GTCATGGAGACAGGTGCTCTCGGTTGCACAATAAACCGACGTTTAGCCAGACCATTGCC  
TCTTGAACATTTACCGTAACCTCAAACTCTTCCCAGTCTGCTGACGGTTTGCGCTGTG  
CCGTGAGCGATGTGGAGATGCAGGAACACTATGATGAGTTTTTTTGAGGAGGTTTTTACAG  
AAATGGAGGAGAAAGTATGGGGAAGTAGAGGAGATGAACGTCTGTGACAACCTGGGAGACC  
ACCTGGTGGGGAACGTGTACGTCAAGTTTCGCCGTGAGGAAGATGCGGAAAAGGCTGTGA  
TTGACTTGAATAACCGTTGGTTTAATGGACAGCCGATCCACGCCGAGCTGTCACCCGTGA  
CGGACTTCAGAGAAGCCTGCTGCCGTCAGTATGAGATGGGAGAATGCACACGAGGCGGCT  
TCTGCAACTTCATGCATTTGAAGCCATTTCCAGAGAGCTGCGGCGGGAGCTGTATGGCC  
GCCGTCGCAAGAAGCATAGATCAAGATCCCGATCCCGGGAGCGTCGTTCTCGGTCTAGAG  
ACCGTGGTTCGTGGCGGTGGCGGTGGCGGTGGAGGTGGCGGCGGACGGGAGCGTGACA  
GGAGGCGGTGAGAGATCGTGAAAGATCTGGGCGATTCTGAGCCATGCCATTTTTTACCTT  
ATGTCTGCTAGAAAGTGTTGTAGTTGATTGACCAAACAGTTCATAAGGGGAATTTTTTA  
AAAAACAACAAAAAACAACATACAAAGATGGGTTTCTGAATAAAAATTTGTAGTGATAA

- 147 -

CAGT

>gi|5803207|gb|NP\_006749.1|U2AF1 240aa linear U2 small nuclear RNA auxillary factor 1; U2 snRNP auxiliary factor small subunit; splicing factor U2AF 35kDa subunit [Homo sapiens].

MAEYLASIFGTEKDKVNCSFYFKIGACRHGDRCSRLHNKPTFSQTIALLLNIYRNPQNSSQ  
SADGLRCAVSDVEMQEHYDEFEEVFTEEMEEKYGEVEEMNVCDNLGDHLVGNVYVKFRRE  
EDAEKAVIDLNNRWFNGQPIHAELSPVTDFREACCRQYEMGECTRGGFCNFMHLKPISRE  
LRRELYGRRRKKHRSRSRSRERRSRSDRGRGGGGGGGGGGGGGRERDRRRSRDRERSGRF

>gi|23308726|gb|NM\_003242.3|TGFB2 2090bp mRNA Homo sapiens transforming growth factor, beta receptor II (70/80kDa) (TGFB2), mRNA.

GTTGGCGAGGAGTTTCCTGTTTCCCCCGCAGCGCTGAGTTGAAGTTGAGTGAGTCACTCG  
CGCGCACGGAGCGACGACACCCCCGCGCGTGCACCCGCTCGGGACAGGAGCCGGACTCCT  
GTGCAGCTTCCCTCGGCCGCCGGGGGCTCCCCGCGCCTCGCCGGCCTCCAGGCCCCCTCC  
TGGCTGGCGAGCGGGCGCCACATCTGGCCCCGACATCTGCGCTGCCGGCCCCGGCGCGGGG  
TCCGGAGAGGGCGCGGCGCGGAGCGCAGCCAGGGGTCCGGGAAGGCGCCGTCCGTGCGCT  
GGGGGCTCGGTCTATGACGAGCAGCGGGGTCTGCCATGGGTCCGGGGCTGCTCAGGGGCC  
TGTGGCCGCTGCACATCGTCCTGTGGACGCGTATCGCCAGCACGATCCCACCGCACGTTT  
AGAAGTCCGTTAATAACGACATGATAGTCACTGACAACAACGGTGCAGTCAAGTTTCCAC  
AACTGTGTAAATTTTGTGATGTGAGATTTTCCACCTGTGACAACCAGAAATCCTGCATGA  
GCAACTGCAGCATCACCTCCATCTGTGAGAAGCCACAGGAAGTCTGTGTGGCTGTATGGA  
GAAAGAATGACGAGAACATAACACTAGAGACAGTTTGCCATGACCCCAAGCTCCCCTACC  
ATGACTTTATTCTGGAAGATGCTGCTTCTCAAAGTGCATTATGAAGGAAAAAAAAAAGC  
CTGGTGAGACTTTCTTCATGTGTTCTGTAGCTCTGATGAGTGCAATGACAACATCATCT  
TCTCAGAAAGAATATAACACCAGCAATCCTGACTTGTGCTAGTCATATTTCAAGTGACAG  
GCATCAGCCTCCTGCCACCACTGGGAGTTGCCATATCTGTCATCATCATCTTCTACTGCT  
ACCGCGTTAACCGGCAGCAGAAGCTGAGTTCAACCTGGGAAACCGGCAAGACGCGGAAGC  
TCATGGAGTTTCAGCGAGCACTGTGCCATCATCCTGGAAGATGACCGCTCTGACATCAGCT  
CCACGTGTGCCAACACATCAACCACAACACAGAGCTGCTGCCCATTTGAGCTGGACACCC  
TGGTGGGGAAAGGTCGCTTTGCTGAGGTCTATAAGGCCAAGCTGAAGCAGAACACTTCAG  
AGCAGTTTGAGACAGTGGCAGTCAAGATCTTCCCTATGAGGAGTATGCCTCTTGGAAGA  
CAGAGAAGGACATCTTCTCAGACATCAATCTGAAGCATGAGAACATACTCCAGTTCTCTGA  
CGGCTGAGGAGCGGAAGACGGAGTTGGGGAAACAATACTGGCTGATCACCGCCTTCCACG  
CCAAGGGCAACCTACAGGAGTACCTGACGCGGCATGTCATCAGCTGGGAGGACCTGCGCA  
AGCTGGGCAGCTCCCTCGCCCGGGGGATTGCTCACCTCCACAGTGATCACACTCCATGTG  
GGAGGCCCAAGATGCCCATCGTGCACAGGGACCTCAAGAGCTCCAATATCCTCGTGAAGA  
ACGACCTAACCTGCTGCCTGTGTGACTTTGGGCTTTCCCTGCGTCTGGACCCTACTCTGT  
CTGTGGATGACCTGGCTAACAGTGGGCAGGTGGGAAC TGCAAGATACATGGCTCCAGAAG  
TCCTAGAATCCAGGATGAATTTGGAGAATGCTGAGTCCTTCAAGCAGACCGATGTCTACT  
CCATGGCTCTGGTGCTCTGGGAAATGACATCTCGCTGTAATGCAGTGGGAGAAGTAAAAG  
ATTATGAGCCTCCATTTGGTTCCAAGGTGCGGGAGCACCCCTGTGTGCGAAAGCATGAAGG  
ACAACGTGTTGAGAGATCGAGGGCGACCAGAAATTCCAGCTTCTGGCTCAACCACCAGG  
GCATCCAGATGGTGTGTGAGACGTTGACTGAGTGCTGGGACCACGACCCAGAGGCCCGTC

TCACAGCCCAGTGTGTGGCAGAACGCTTCAGTGAGCTGGAGCATCTGGACAGGCTCTCGG  
GGAGGAGCTGCTCGGAGGAGAAGATTCTGAAGACGGCTCCCTAAACACTACCAAATAGC  
TCTTATGGGGCAGGCTGGGCATGTCCAAAGAGGCTGCCCTCTCACCAA



- 148 -

>gi|23308727|gb|NP\_003233.3|TGFR2 567aa linear transforming growth factor, beta receptor II (70/80kDa); transforming growth factor, beta receptor II (70-80kD) [Homo sapiens].

MGRGLLRGLWPLHIVLWTRIASTIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDFVRFST  
CDNQKSCMSNCSITSICEKPQEVCAVVRKNDENITLETVCHDPKLPYHDFILEDAAAPK  
CIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLLIVIFQVTGISLLPPLGVAI  
SVIIIFYCYRVNRQOKLSSTWETGKTRKLMFSEHCAIILEDSDISSTCANNINHNT  
LLPIELDTLVGKGRFAEVYKAKLKQNTSEQFETVAVKIFPYEYASWKTEKDIFSDINLK  
HENILQFLTAEERKTELKQYWLITAFHAKGNLQEYLTRHVISWEDLRKLGSSLARGIAH  
LHSDHTPCGRPKMPIVHRDLKSSNILVKNDLTCCLCDFGLSLRLDPTLSVDDLANSGQVG  
TARYMAPEVLESRMNLENAESFKQTDVYSMALVLWEMTSRCNAVGEVKDYEPFGSKVRE  
HPCVESMKDNVLRDRGRPEIPSFVLNHQGIQMVCELTTECWDHDPPEARLTAQCVAERFSE  
LEHLDRLSGRSCSEEKIPEDGSLNNTTK

>gi|5174728|gb|NM\_006022.1|TSC22 1725bp mRNA Homo sapiens transforming growth factor beta-stimulated protein TSC-22 (TSC22), mRNA.

CGCCTCTTCACGGCACTGGGATCCGCATCTGCCTGGGATCATCAAGCCCTAGAAGCTGGG  
TTTCTTTTAAATTAGGGCTGCCGTTTTCTGTTTCTCCCTGGGCTGCGGAAAGCCAGAAGAT  
TTTATCTAGCTTATACAAGGCTGCTGGTGTTCCTCTTTTTTTCCACGAGGGTGTTTTTG  
GCTGCAATTGCATGAAATCCCAATGGTGTAGACCAGTGGCGATGGATCTAGGAGTTTACC  
AACTGAGACATTTTTCAATTTCTTTCTTGTCTCCTTGCTGGGGACTGAAAACGCTTCTG  
TGAGACTTGATAATAGCTCCTCTGGTGCAGGTGTGGTAGCTATTGACAACAAATCGAGC  
AAGCTATGGATCTAGTGAAAAGCCATTTGATGTATGCGGTGAGAGAAGAAGTGGAGGTCC  
TCAAAGAGCAAATCAAAGAACTAATAGAGAAAAATTTCCAGCTGGAGCAGGAGAACAATC  
TGCTGAAGACACTGGCCAGTCTTGAGCAGCTTGCCAGTTTCAGGCCAGCTGCAGACTG  
GCTCCCCCTGACCACCCAGCCACAGGGCACCACACAGCCCCCGCCAGCCAGCAT  
CGCAGGGCTCAGGACCAACCGCATAGCTGCCTATGCCCCGCAGAACTGGCTGCTGCGTG  
TGAAGTGAACAGACGGAGAAGATGTGCTAGGGAGAATCTGCCTCCACAGTCACCCATTTT  
ATTGCTCGCTGCGAAAGAGACGTGAGACTGACATATGCCATTATCTCTTTTCCAGTATTA  
AACACTCATATGCTTATGGCTTGGAGAAATTTCTTAGTTGGGTGAATTAAAGGTTAATCC  
GAGAATTAGCATGGATATACCGGGACCTCATGCAGCTTGGCAGATATCTGAGAAATGGTT  
TAATTCATGCTCAGGAGCTGTGTGCCTTTCCATCCCTTCCGGCTCCCTACCCCTCACTTC  
CAAGGGTTCTCTCTCCTGCTTGCGCTTAGTGTCCTACATGGGGTTGTGAAGCGATGGAGC  
TCCTCACTGGACTCGCCTCTCTCCTCTCCTCCCCCAGGAGGAAGTTGAAAGGAGGGTAA  
AAAGACTAAAATGAGGGGGAACAGAGTTCAGTGTACAAATTTGACAAGTGTACCAAAT  
TCATAAAAAACAATAGTACTGTGCCTCTTTCTTCTCAAACAATGGATGACACAAAATAT  
GAGAGTGACAAAATGGTGACAGGTAGCTGGGACCTAGGCTATCTTACCATGAAGGTTGTT  
TTGCTTATTGTATATTTGTGTATGTAGTGTAATTTTGTACAATAGAGGACTGTAAT  
ACTATTTAGGTTGTACAGATTGAAATTTAGTTGTTTCATTGGCTGTCTGAGGAGGTGTGG  
ACTTTTATATATAGATCTACATAAAAACTGCTACATGACAAAAACACACCTAAACCCCT  
TTTAAGAATTTGGCACAGTTACTCACTTTGTGTAATCTGAAATCTAGCTGCTGAATACGC  
TGAAGTAAATCCTTGTTCACTGAAGTCTTTCAATTGAGCTGGTTGAATACTTTGAAAAAT  
GCTCAGTTCTAACTAATGAAATGGATTTCCAGTAGGGGTTTCTGCATATCACCTGTATA  
GTAGTTATATGCATATGTTTCTGTGCATGTTCTCTACACAATTGTAAGGTGTCACTGTAT  
TTAACTGTTGCACTTGTCAACTTTCAATAAAGCATATAAATGTTG

>gi|5174729|gb|NP\_006013.1|TSC22 144aa linear transforming growth factor beta-stimulated protein TSC-22 [Homo sapiens].



- 149 -

MKSQWCRPVAMDLGVYQLRHFSISFLSSLLGTENASVRLDNSSSGASVVAIDNKIEQAMD  
LVKSHLMYAVREEVEVLKEQIKELIEKNSQLEQENLLKTLASPEQLAQFQAQLQTGSPP  
ATTQPQGTTPPPAQPASQSGPTA

>gi|24432096|gb|NM\_152912.2|MTIF3 1693bp mRNA Homo sapiens  
mitochondrial translational initiation factor 3 (MTIF3), mRNA.

GCAGATCCGCTGTACTTGCGGGCGCTACAGTATGTCAATCGCTTGCCCCAGCACAGTGGG  
CTCCGTGGCTTAAGACTTGAACCAAGTAAACGAAGTTCTCTTACTGAGAAGTCTCAGTTT  
CAAAAGAGCTTCTCCTCATCAACTGGGGATGATTACAGTTCTTCTAAAAAAGCCTACTT  
GATGTGAAGACAATGAGGATGAAGACCTTTATGGTGATCCACTTCCACTTAATAGGATGG  
CTGCTCTTTTCTAAAGAGGTTAACTACTACAACTGTAAAGTCTGAAAATAGTTGCATTA  
GATGTTTTGGTAAACACATCCTGCAAAAGACAGCACCAGCACAGTTGTCCCCCTATTGCTT  
CTGCCCCAAGACTCTCCTTCCTAATTCATGCAAAAGCCTTTAGTACCGCTGAAGACACCC  
AGAATGAAGGAAAAAAGACAAAAAGAATAAAACAGCTTTTAGTAACGTTGGAAGAAAAA  
TTAGTCAGCGAGTTATTTCACTTATTTGATGAGAAGGGCAATGATTTGGGAAACATGCACC  
GAGCAAATGTGATTAGACTTATGGATGAGCGAGACCTGCGACTGGTTCAAAGGAACACCA  
GCACAGAACCTGCAGAGTATCAGCTCATGACAGGATTGCAGATCCTCCAGGAGCGGCAGA  
GGCTGAGGGAGATGGAGAAGGCGAACCCCAAACTGGACCAACCCTGAGAAAGGAACTGA  
TTTTGTCTTCAAATATTGGACAACATGATTTGGACACAAAGACTAAACAGATTCAGCAGT  
GGATTAAGAAAAAACCTAGTCCAGATTACCATAAAGAAAGGAAAAAATGTAGACGTGT  
CAGAAAATGAAATGGAGGAGATATTTTCATCAAATACTCCAGACTATGCCTGGAATAGCTA  
CATTCTCATCTAGGCCACAAGCTGTTCAAGGAGGAAAAGCTTTAATGTGTGTTCTTCGTG  
CTTTGAGCAAAAATGAGGAGAAGGCATATAAAGAACTCAAGAGACCCAGGAAAGAGACA  
CTTTGAACAAAGATCATGAAATGATAAGGAATCAAATGTTCTGCATCAGTAATTTTAAT  
AAAGAAAAGCATGCTCTGAGAGAAAAAAAAGCTCGCTCCTTGGTCTGCAGTCCTTTAAAC  
AAAGCAGTGCAGTCTTAGCCAAGGGTAAGTACTGCAACTGTCGAGAGCATCTTGTCTTC  
CACACAGTTGGGTGACTCTCCGTTTTGACACAAAGATAAGCCTTGCCCTTGTTTCCTTTT  
GGGAGGGATATATCCACTGAGATGAGAGGCCAACTCCGTTTTTCACGAGATTTTTTGAC  
TTTGAGCTTCATTTTCTTCTTGTGTCAGGATCATGTACAACAGCATGCCTAGTGAGACTTTG  
TTTCATTGCAAATGTTTTGCCACAGCCAGCATGTTACACACAAAAGGGCGGCTTTCCTC  
ATGGAAGGAGAGGATATGGCTTTGGAGATTAAACACAGTTGTATAGGTTCTTCACAGCC  
TTCTCTTGACAGCGACATAATCCCTTCTGGGGCATGAGTTTATGTGTTGCTTAAGGAAC  
TTGCGTTAAAGTTTTCCGGCAACTTCACATGGATTCTTTGAATGAGTTCAAATGTTCCC  
ATGCTAAGCTGAGTCTGTGCCATAGCAAACCATGATATAGCAAGTCTCCAGAATGTGTAC  
GAATCAATACTCC

>gi|23097266|gb|NP\_690876.1|MTIF3 278aa linear mitochondrial  
translational initiation factor 3 [Homo sapiens].

MAALFLKRLTLQTVKSENSCIRCFGKHILQKTAPAQLSPIASAPRLSFLIHAKAFSTAED  
TQNEGKTKKNKTAFSNVGRKISQRVIHLEFDEKGNDLGNMHRANVIRLMDERDLRLVQRN  
TSTEPAEYQLMTGLQILQERQRLREMEKANPKTGPTLRKELILSSNIGQHDLDTKTKQIQ  
QWIKKKHLVQITIKKGKNVDVSENEEMEIFHQILQTMPGIATFSSRPQAVQGGKALMCVL  
RALSKNEEKAYKETQETQERDTLNDHGNDKESNVLHQ

>gi|27499034|gb|XM\_044349.7|CAMK2G 1776bp mRNA Homo sapiens  
calcium/calmodulin-dependent protein kinase (CaM kinase) II  
gamma (CAMK2G), mRNA.

CAGCATGGCCACCACCGCCACCTGCACCCGTTTCACCGACGACTACCAGCTCTTCGAGGA  
GCTTGGCAAGGGTGCTTTCTCTGTGGTCCGCAGGTGTGTGAAGAAAACCTCCACGCAGGA  
GTACGCAGCAAAAATCATCAATACCAAGAAGTTGTCTGCCCCGGGATCACCAGAACTAGA

- 150 -

ACGTGAGGCTCGGATATGTCGACTTCTGAAACATCCAAACATCGTGCGCCTCCATGACAG  
TATTTCTGAAGAAGGGTTTCACTACCTCGTGTTTGACCTTGTTACCGGCGGGGAGCTGTT  
TGAAGACATTGTGGCCAGAGAGTACTACAGTGAAGCAGATGCCAGCCACTGTATACATCA  
GATTCTGGAGAGTGTAAACCACATCCACCAGCATGACATCGTCCACAGGGACCTGAAGCC  
TGAGAACCTGCTGCTGGCGAGTAAATGCAAGGGTGCCGCCGTCAAGCTGGCTGATTTTGG  
CCTAGCCATCGAAGTACAGGGAGAGCAGCAGGCTTGGTTTGGTTTTGCTGGCACCCAGG  
TTACTTGTCCCCTGAGGTCTTGAGGAAAGATCCCTATGGAAAACCTGTGGATATCTGGGC  
CTGCGGGGTCATCCTGTATATCCTCCTGGTGGGCTATCCTCCCTTCTGGGATGAGGATCA  
GCACAAGCTGTATCAGCAGATCAAGGCTGGAGCCTATGATTTCCCATCACCAAGATGGGA  
CACGGTAACTCCTGAAGCCAAGAAGTTGATCAACCAGATGCTGACCATAAACCCAGCAAA  
GCGCATCACGGCTGACCAGGCTCTCAAGCACCCGTGGGTCTGTCAACGATCCACGGTGGC  
ATCCATGATGCATCGTCAGGAGACTGTGGAGTGTGTGCGCAAGTTCAATGCCCGGAGAAA  
ACTGAAGGGTGCCATCCTCACGACCATGCTTGTCTCCAGGAACTTCTCAGCTGCCAAAAG  
CCTATTGAACAAGAAGTCGGATGGCGGTGTCAAGCCACAGAGCAACAACAAAAACAGTCT  
CGTAAGCCCAGCCCAAGAGCCCGCGCCCTTGACAGACGGCCATGGAGCCACAAACCACTGT  
GGTACACAACGCTACAGATGGGATCAAGGGCTCCACAGAGAGCTGCAACACCACCACAGA  
AGATGAGGACCTCAAAGTGCGAAAACAGGAGATCATTAGATTACAGAACAGCTGATTGA  
AGCCATCAACAATGGGGACTTTGAGGCCTACACGAAGATTTGTGATCCAGGCCTCACTTC  
CTTTGAGCCTGAGGCCCTTGGTAACCTCGTGGAGGGGATGGATTTCCATAAGTTTTACTT  
TGAGAATCTCCTGTCCAAGAACAGCAAGCCTATCCATAACCACCATCTAAACCCACACGT  
CCACGTGATTGGGGAGGACGCAGCGTGCATCGCCTACATCCGCCTCACCCAGTACATCGA  
CGGGCAGGGTCGGCCTCGCACCAGCCAGTCAGAAGAGACCCGGGTCTGGCACCGCTCGGGA  
TGGCAAGTGGCTCAATGTCCACTATCACTGGTCAGGGGCCCTGCCGCACCGCTGCAGTG  
AGCTCAGCCACAGGGGCTTTAGGAGATTCCAGCCGGAGGTCCAACCTTCGCAGCCAGTGG  
CTCTGGAGGGCCTGAGTGACAGCGGCAGTCCTGTTTGTGTTGAGGTTTAAACAATTCAAT  
TACAAAAGCGGCAGCAGCCAATGCACGCCCTGCATGCAGCCCTCCCGCCCGCCCTTCGT  
GTCTGTCTCTGCTGTACCGAGGTGTTTTTTACATTT.

>gi|27499035|gb|XP\_044349.7|CAMK2G 518aa linear similar to  
calcium/calmodulin -dependent protein kinase II gamma [Mus  
musculus] [Homo sapiens].

MATTATCTRFTDDYQLFEELGKGAFSVVRRCVKKTSTQEYAAKIINTKKLSARDHQKLER  
EARICRLCLKHPNIVRLHDSISEEGFHYLVFDLVTGGELFEDIVAREYYSEADASHCIHQI  
LESVNHIIHQHDIVHRDLKPENLLLASKCKGA AVKLADFLAIEVQGEQQAWFGFAGTPGY  
LSPEVLRKDPYGKPVDIWACGVILYILLVGYPFFWDEDQHKLYQQIKAGAYDFPSPEWDT  
VTPEAKNLINQMLTINPAKRITADQALKHPWVCQRSTVASMMHRQETVECLRKFNNARRKL  
KGAILTTMLVSRNFSAAKSLLNKSDGGVVKPQSNKNLSLVSPAQEPAPLQTAMEPQTTVV  
HNATDGIKGSTESCNNTTTEDEDLKVRKQEI IKITEQLIEAINNGDFEAYTKICDPGLTSF  
EPEALGNLVEGMDFHKFYFENLLSKNSKPIHTTILNPHVHVIGEDAACIAYIRLTQYIDG  
QGRPRTSQSEETRVWHRRDGKWLNVHYHCSGAPAAPLQ

>gi|5453881|gb|NM\_006213.1|PHKG1 1377bp mRNA Homo sapiens  
phosphorylase kinase, gamma 1 (muscle) (PHKG1), mRNA.

GGCCTTCAGCCCTCTGTGGTCCCCTCTCCCCGGGGGGCTTTGGGATTCTTGTCAGCTCC  
TTCAAGAGCCTGCAAGCACTTAACCAGCCACCCAGAGTTCCCTCACTGAAGATCTGAGCA  
TGACCCGGGACGAGGCACTGCCGACTCTCATTCTGCACAGGACTTCTATGAGAATTATG  
AGCCCAAAGAGATCCTGGGCAGGGGCGTTAGCAGTGTGGTCAGGCGATGCATCCACAAGC  
CCACGAGCCAGGAGTACGCCGTGAAGGTCATCGACGTCACCGGTGGAGGCAGCTTCAGCC  
CGGAGGAGGTGCGGGAGCTGCGAGAAGCCACGCTGAAGGAGGTGGACATCCTGCGCAAGG

- 151 -

TCTCAGGGCACCCCAACATCATACAGCTGAAGGACACTTATGAGACCAACACTTTCTTCT  
TCTTGGTGTTTGACCTGATGAAGAGAGGGGAGCTCTTTGACTACCTCACTGAGAAGGTCA  
CCTTGAGTGAGAAGGAAACCAGAAAGATCATGCGAGCTCTGCTGGAGGTGATCTGCACCT  
TGCACAAACTCAACATCGTGACCCGGGACCTGAAGCCCGAGAACATTCTCTTGATGACA  
ACATGAACATCAAGCTCACAGACTTTGGCTTTTCTGCTGCCAGCTGGAGCCGGGAGAGAGGC  
TGCAGAGAGGTCTGCGGGACCCCCAGTTACCTGGCCCCCTGAGATTATCGAGTGCTCCATGA  
ATGAGGACCACCCGGGCTACGGGAAAGAGGTGGACATGTGGAGCACTGGCGTCATCATGT  
ACACGCTGCTGGCCGGCTCCCCGCCCTTCTGGCACCAGGAGCAGATGCTGATGCTGAGGA  
TGATCATGAGCGGCAACTACCAAGTTTGGCTCGCCCCGAGTGGGATGATTACTCGGACACCG  
TGAAGGACCTGGTCTCCCGATTCTTGGTGGTGCAACCCAGAACCGCTACACAGCGGAAG  
AGGCCTTGGCACACCCCTTCTTCCAGCAGTACTTGGTGGAGGAAGTGCGGCACCTTCAGCC  
CCCGGGGGAAGTTCAAGGTGATCGCTCTGACCGTGCTGGCTTCAGTGCGGATCTACTACC  
AGTACCGCCGGGTGAAGCCTGTGACCCGGGAGATCGTCATCCGAGACCCCTATGCCCTCC  
GGCCTCTGCGCCGGCTCATCGACGCCTACGCTTTCCGAATCTATGGCCACTGGGTGAAGA  
AGGGGCAGCAGCAGAACCGGGCAGCCCTTTTCGAGAACACACCCAAGGCCGTGCTCCTCT  
CCCTGGCCGAGGAGGACTACTGAGGGGCTGGCCAGTCAGGGAGGGCTAGGGGGCAGGTGG  
GGAGGGGAAGCCATGGAAATACAAGTCAAAGGGGTAAAAAAAAAAAAAAAAAAAAA  
>gi|5453882|gb|NP\_006204.1|PHKG1 387aa linear phosphorylase  
kinase, gamma 1 (muscle) [Homo sapiens].  
MTRDEALPDSHSAQDFYENYEPKEILGRGVSSVVRRCIHKPTSQEYAVKVIDVTGGGSFS  
PEEVRELREATLKEVDILRKVSGHPNIIQLKDTYETNTFFFLVFDLMKRGELFDYLTEKV  
TLSEKETRKIMRALLEVIC TLHKLNI VHRDLKPENILLDDNMNIKLTDGFGFSCQLEPGER  
LREVCCTPSYLAPEII ECSMNEDHPGYGKEVDMWSTGVIMYTLLAGSPFFWHRKQMLMLR  
MIMSGNYQFGSPWDDYSDTVKDLVSRFLVVQPQNRYTAEELAHPPFQOYLVEEVHRFS  
PRGKFKVIALTVLASVRIYYQYRRVKPVTREIVIRDPYALRPLRRLIDAYAFRIYGHVVK  
KGQQQNRAALFENTPKAVLLSLAEEDY  
>gi|4503412|gb|NM\_001945.1|DTR 2360bp mRNA Homo sapiens  
diphtheria toxin receptor (heparin-binding epidermal growth  
factor-like growth factor). (DTR), mRNA.  
GCTACGCGGGCCACGCTGCTGGCTGGCCTGACCTAGGCGCGCGGGGTGCGGCGGCCGCGC  
GGGCGGGCTGAGTGAGCAAGACAAGACACTCAAGAAGAGCGAGCTGCGCCTGGGTCCCGG  
CCAGGCTTGACACGAGAGGCGGGCGGCAGACGGTGCCCGCGGAATCTCCTGAGCTCCGC  
CGCCAGCTCTGGTGCCAGCGCCAGTGGCCGCGCTTCGAAAGTGACTGGTGCCCTCGCC  
GCCTCCTCTCGGTGCGGGACCATGAAGCTGCTGCCGTCGGTGGTGCTGAAGCTCTTTCTG  
GCTGCAGTTCTCTCGGCACTGGTGACTGGCGAGAGCCTGGAGCGGCTTCGGAGAGGGCTA  
GCTGCTGGAACCAGCAACCCGGACCCCTCCACTGTATCCACGGACCACTGCTACCCCTA  
GGAGGCGGCGGGACCGGAAAGTCCGTGACTTGCAAGAGGCAGATCTGGACCTTTTGAGA  
GTCACTTTATCCTCCAAGCCACAAGCACTGGCCACACCAACAAGGAGGAGCACGGGAAA  
AGAAAGAAGAAAGGCAAGGGGCTAGGGAAGAAGAGGGACCCATGTCTTCGGAAATACAAG  
GACTTCTGCATCCATGGAGAATGCAAATATGTGAAGGAGCTCCGGGCTCCCTCCTGCATC  
TGCCACCCGGGTACCATGGAGAGAGGTGTCATGGGCTGAGCCTCCAGTGGAATATCGC  
TTATATACCTATGACCACACAACCATCCTGGCCGTGGTGGCTGTGGTGCTGTCATCTGTC  
TGTCTGCTGGTCAICGTGGGGCTTCTCATGTTTAGGTACCATAGGAGAGGAGGTTATGAT  
GTGGAATAATGAAGAGAAAGTGAAGTTGGGCATGACTAATTCCCACTGAGAGAGACTTGTG  
CTCAAGGAATCGGCTGGGGACTGCTACCTCTGAGAAGACACAAGGTGATTTAGACTGCA  
GAGGGGAAGACTTCCATCTAGTCACAAAGACTCCTTCGTCCCCAGTTGCCGTCTAGGAT  
TGGGCCTCCATAATTGCTTTGCCAAATACCAGAGCCTTCAAGTGCCAAACAGAGTATG

- 152 -

TCCGATGGTATCTGGGTAAGAAGAAAGCAAAAGCAAGGGACCTTCATGCCCTTCTGATTC  
CCCTCCACCAAACCCCACTTCCCCTCATAAGTTTGTTTAAACACTTATCTTCTGGATTAG  
AATGCCGGTTAAATTCCATATGCTCCAGGATCTTTGACTGAAAAAAAAAAGAAGAAGAA  
GAAGGAGAGCAAGAAGGAAAGATTTGTGAACTGGAAGAAAGCAACAAAGATTGAGAAGCC  
ATGTACTCAAGTACCACCAAGGGATCTGCCATTGGGACCCTCCAGTGCTGGATTTGATGA  
GTTAACTGTGAAATACCACAAGCCTGAGAAGTGAATTTTGGGACTTCTACCCAGATGGAA  
AAATAACAACACTATTTTTGTTGTTGTTGTTTGTAAATGCCTCTTAAATTATATATTTATTT  
TATTCTATGTATGTTAATTTATTTAGTTTTTAACAATCTAACAATAATATTTCAAGTGCC  
TAGACTGTTACTTTGGCAATTTCTGGCCCTCCACTCCTCATCCCCACAATCTGGCTTAG  
TGCCACCCACCTTTGCCACAAAGCTAGGATGGTTCTGTGACCCATCTGTAGTAATTTATT  
GTCTGTCTACATTTCTGCAGATCTTCCGTGGTCAGAGTGCCACTGCGGGAGCTCTGTATG  
GTCAGGATGTAGGGGTTAACTTGGTCAGAGCCACTCTATGAGTTGGACTTCAGTCTTGCC  
TAGGCGATTTTGTCTACCATTTGTGTTTTGAAAGCCCAAGGTGCTGATGTCAAAGTGTA  
CAGATATCAGTGCTCTCCCGTGTCTCTCCCTGCCAAGTCTCAGAAGAGGTTGGGCTTCC  
ATGCCTGTAGCTTTCTGGTCCCTCACCCCATGGCCCCAGGCCACAGCGTGGGAACCTCA  
CTTTCCTTGTGTCAAGACATTTCTCTAACTCCTGCCATTCTTCTGGTGCTACTCCATGC  
AGGGGTCAGTGCAGCAGAGGACAGTCTGGAGAAGGTATTAGCAAAGCAAAAGGCTGAGAA  
GGAACAGGGAACATTGGAGCTGACTGTTCTTGGTAACTGATTACCTGCCAATTGCTACCG  
AGAAGGTTGGAGGTGGGGAAGGCTTTGTATAATCCACCCACCTCACCAAACGATGAAG  
GTATGCTGTGATGGTCCTTTCTGGAAGTTTCTGGTGCCATTCTGAACTGTTACAACCTTG  
TATTTCCAAACCTGGTTCATATTTATACTTTGCAATCCAAATAAAGATAACCCTTATTC  
ATAAAAAAAAAAAAAAAAAA

>gi|4503413|gb|NP\_001936.1|DTR 208aa linear diphtheria toxin  
receptor (heparin-binding epidermal growth factor-like growth  
factor); Diphtheria toxin receptor (heparin-binding EGF-like  
growth factor) [Homo sapiens].

MKLLPSVVLKFLAAVLSALVTGESLERLRRLAAGTSNPDPTVSTDQLPLGGGRDRK  
VRDLQEADLDLLRVTLSSKPQALATPNKEEHGKRKKKGKGLGKKRDPCLRKYKDFCIHGE  
CKYVKELRAPSCIHPGYHGERCHGLSLPVENRLTYDHTTILAVVAVVLSSVCLLVIVG  
LLMFRYHRRGGYDVENEKVKLGMTNSH

>gi|4507460|gb|NM\_003236.1|TGFA 4119bp mRNA Homo sapiens  
transforming growth factor, alpha (TGFA), mRNA.

CTGGAGAGCCTGCTGCCCCGCCCGCCCGTAAATGGTCCCCTCGGCTGGACAGCTCGCCCT  
GTTGCTCTGGGTATTGTGTTGGCTGCGTGCCAGGCCTTGGAGAACAGCACGTCCCCGCT  
GAGTGCAGACCCGCCCGTGGCTGCAGCAGTGGTGTCCCATTTTAATGACTGCCAGATTC  
CCACACTCAGTTCTGCTTCCATGGAACCTGCAGGTTTTTGGTGCAGGAGGACAAGCCAGC  
ATGTGTCTGCCATTCTGGGTACGTTGGTGCACGCTGTGAGCATGCGGACCTCCTGGCCGT  
GGTGGCTGCCAGCCAGAAGAAGCAGGCCATCACCGCCTTGGTGGTGGTCTCCATCGTGGC  
CCTGGCTGTCTTATCATCACATGTGTGCTGATACTGCTGCCAGGTCCGAAACACTG  
TGAGTGGTGGCGGGCCCTCATCTGCCGGCACGAGAAGCCCAGCGCCCTCCTGAAGGGAAG  
AACCGCTTGCTGCCACTCAGAAACAGTGGTCTGAAGAGCCCAGAGGAGGAGTTTGGCCAG  
GTGGACTGTGGCAGATCAATAAAGAAAGGCTTCTTCAGGACAGCACTGCCAGAGATGCCT  
GGGTGTGCCACAGACCTTCTACTTGGCCTGTAATCACCTGTGCAGCCTTTTGTGGGCCT  
TCAAAACTCTGTCAAGAACTCCGTCTGCTTGGGGTTATTAGTGTGACCTAGAGAAGAAA  
TCAGCGGACCACGATTTCAAGACTTGTTAAAAAAGAACTGCAAAGAGACGGACTCCTGTT  
CACCTAGGTGAGGTGTGTGCAGCAGTTGGTGTCTGAGTCCACATGTGTGCAGTTGTCTTC  
TGCCAGCCATGGATTCCAGGCTATATATTTCTTTTAAATGGGCCACCTCCCCACAACAGA

- 153 -

ATTCTGCCCAACACAGGAGATTTCTATAGTTATTGTTTTCTGTCATTTGCCTACTGGGGA  
AGAAAGTGAAGGAGGGGAAACTGTTTAATATCACATGAAGACCCTAGCTTTAAGAGAAGC  
TGTATCCTCTAACCACGAGACTCTCAACCAGCCCAACATCTTCCATGGACACATGACATT  
GAAGACCATCCCAAGCTATCGCCACCCTTGGAGATGATGTCTTATTTATTAGATGGATAA  
TGGTTTTATTTTTTAATCTCTTAAGTCAATGTAAAAAGTATAAAACCCCTTCAGACTTCTA  
CATTAAATGATGTATGTGTTGCTGACTGAAAAGCTATACTGATTAGAAATGTCTGGCCTCT  
TCAAGACAGCTAAGGCTTGGGAAAAGTCTTCCAGGGTGCGGAGATGGAACCAGAGGCTGG  
GTTACTGGTAGGAATAAAGGTAGGGGTTTCCAGAAATGGTGCCATTGAAGCCACAAAGCCGG  
TAAATGCCTCAATACGTTCTGGGAGAAAACCTTAGCAAATCCATCAGCAGGGATCTGTCCC  
CTCTGTTGGGGAGAGAGGAAGAGTGTGTGTGTCTACACAGGATAAACCCAATACATATTG  
TACTGCTCAGTGATTAAATGGGTTTCACTTCCTCGTGAGCCCTCGGTAAGTATGTTTAGAA  
ATAGAACATTAGCCACGAGCCATAGGCATTTTCAGGCCAAATCCATGAAAGGGGGACCACT  
CATTTATTTTCCATTTTGTGCTTGGTTGGTTTGTGCTTTATTTTTTAAAGGAGAAGTT  
TAACTTTGCTATTTATTTTCGAGCACTAGGAAAACCTATTCAGTAATTTTTTTTTTCTCA  
TTTCCATTCCAGGATGCCGGCTTTATTAACAAAACTCTAACAAGTCACCTCCACTATGTG  
GGTCTTCCTTTCCCCTCAAGAGAAGGAGCAATTGTTCCCCTGACATCTGGGTCCATCTGA  
CCCATGGGGCCTGCCTGTGAGAAACAGTGGGTCCCTTCAAATACATAGTGGATAGCTCAT  
CCCTAGGAATTTTCATTAAAATTTTGAAACAGAGTAATGAAGAAATAATATATAAACTCC  
TTATGTGAGGAAATGCTACTAATATCTGAAAAGTGAAAGATTTCTATGTATTAACCTCTTA  
AGTGCACCTAGCTTATTACATCGTGAAAGGTACATTTAAAATATGTTAAATTGGCTTGAA  
ATTTTCAGAGAATTTTGTCTTCCCCTAATTCTTCTTCCCTTGGTCTGGAAGAACAATTTCT  
ATGAATTTTCTCTTTATTTTTTTTTTATAATTTCAGACAATTCTATGACCCGTGTCTTCAT  
TTTTGGCACTCTTATTTAACAATGCCACACCTGAAGCACTTGGATCTGTTCCAGAGCTGAC  
CCCCTAGCAACGTAGTTGACACAGCTCCAGGTTTTTAAATTACTAAAATAAGTTCAAGTT  
TACATCCCTTGGGCCAGATATGTGGGTTGAGGCTTGACTGTAGCATCCTGCTTAGAGACC  
AATCAATGGACACTGGTTTTTTAGACCTCTATCAATCAGTAGTTAGCATCCAAGAGACTTT  
GCAGAGGCGTAGGAATGAGGCTGGACAGATGGCGGAACGAGAGGTTCCCTGCGAAGACTT  
GAGATTTAGTGTCTGTGAATGTTCTAGTTTCTAGGTCCAGCAAGTCACACCTGCCAGTGC  
CCTCATCCTTATGCCTGTAACACACATGCAGTGAGAGGCCTCACATATACGCCTCCCTAG  
AAGTGCCTTCCAAGTCAGTCCTTTGGAACACAGCAGGTCTGAAAAAGAGGCTGCATCAAT  
GCAAGCCTGGTTGGACCATTGTCCATGCCTCAGGATAGAACAGCCTGGCTTATTTGGGGA  
TTTTTCTTCTAGAAATCAAATGACTGATAAGCATTGGCTCCCTCTGCCATTTAATGGCAA  
TGGTAGTCTTTGGTTAGCTGCAAAAATACTCCATTTCAAGTTAAAAATGCATCTTCTAAT  
CCATCTCTGCAAGCTCCCTGTGTTTTCTTGCCCTTTAGAAAATGAATTGTTCACTACAAT  
TAGAGAATCATTTAACATCCTGACCTGGTAAGCTGCCACACACCTGGCAGTGGGGAGCAT  
CGCTGTTTCCAATGGCTCAGGAGACAATGAAAAGCCCCCATTTAAAAAATAACAAACAT  
TTTTTAAAGGCCTCCAATACTCTTATGGAGCCTGGATTTTCCCCTGCTCTACAGGCT  
GTGACTTTTTTTAAGCATCCTGACAGGAAATGTTTTCTTCTACATGGAAAGATAGACAGC  
AGCCAACCCTGATCTGGAAGACAGGGCCCCGGCTGGACACACGTGGAACCAAGCCAGGGA  
TGGGCTGGCCATTGTGTCCCCGCAGGAGAGATGGGCAGAATGGCCCTAGAGTTCTTTTCC  
CTGAGAAAGGAGAAAAAGATGGGATTGCCACTACCCACCCACACTGGTAAGGGAGGAGA  
ATTTGTGCTTCTGGAGCTTCTCAAGGGATTGTGTTTTGCAGGTACAGAAAACCTGCCTGTT  
ATCTTCAAGCCAGGTTTTTCGAGGGCACATGGGTCAACAGTTGCTTTTTTCAGTCAATTTGG  
CCGGGATGGACTAATGAGGCTCTAACACTGCTCAGGAGACCCCTGCCCTCTAGTTGGTTT  
TGGGCTTTGATCTCTTCCAACCTGCCCAGTCACAGAAGGAGGAATGACTCAAATGCCCAA  
AACCAAGAACACATTGCAGAAGTAAGACAAACATGTATATTTTTTAAATGTTCTAACATAA  
GACCTGTTCTCTTAGCCATTGATTTACCAGGCTTTCTGAAAGATCTAGTGGTTACACA

- 154 -

GAGAGAGAGAGAGTACTGAAAAAGCAACTCCTCTTCTTAGTCTTAATAATTTACTAAAAAT  
GGTCAACTTTTTCATTATCTTTATTATAATAAACCTGATGCTTTTTTTTAGAACTCCTTAC  
TCTGATGTCTGTATATGTTGCACTGAAAAGGTTAATATTTAATGTTTTAATTTATTTTGT  
GTGGTAAGTTAATTTTGTATTTCTGTAATGTGTTAATGTGATTAGCAGTTATTTTCCTTAA  
TATCTGAATTATACTTAAAGAGTAGTGAGCAATATAAGACGCAATTGTGTTTTTCAGTAA  
TGTGCATTGTTATTGAGTTGTACTGTACCTTATTTGGAAGGATGAAGGAATGAACCTTTT  
TTTCCTAAAAA

>gi|4507461|gb|NP\_003227.1|TGFA 160aa linear transforming  
growth factor, alpha [Homo sapiens].

MVPSAGQLALFALGIVLAACQALENSTSPLSADPPVAAVVSHFNDPDSHTQFCFHHGTC  
RFLVQEDKPACVCHSGYVGARCEHADLLAVVAASQKKQAITALVVVSIVALAVLIITCVL  
IHCCQVRKHCEWCRALICRHEKPSALLKGRACCHSETVV

>gi|6912653|gb|NM\_012433.1|SF3B1 4259bp mRNA Homo sapiens  
splicing factor 3b, subunit 1, 155kDa (SF3B1), mRNA.

ATGGCGAAGATCGCCAAGACTCACGAAGATATTGAAGCACAGATTCGAGAAATTC AAGGC  
AAGAAGGCAGCTCTTGATGAAGCTCAAGGAGTGGGCCTCGATTCTACAGGTTATTATGAC  
CAGGAAATTTATGGTGGAAGTGACAGCAGATTTGCTGGATACGTGACATCAATTGCTGCA  
ACTGAACTTGAAGATGATGACGATGACTATTCATCATCTACGAGTTTGCTTGCTCAGAAG  
AAGCCAGGATATCATGCCCTGTGGCATTGCTTAATGATATACCACAGTCAACAGAACAG  
TATGATCCATTGCTGAGCACAGACCTCCAAAGATTGCAGACCGGGAAGATGAATACAAA  
AAGCATAGGCGGACCATGATAATTTCCCAGAGCGTCTTGATCCTTTTGCAGATGGAGGG  
AAGACCCCTGATCCTAAATGAATGTTAGGACTTACATGGATGTAATGCGAGAACAACAC  
TTGACTAAAGAAGAACGAGAAATTAGGCAACAGCTAGCAGAAAAAGCTAAAGCTGGAGAA  
CTAAAGTCGTCAATGGAGCAGCAGCGTCCCAGCCTCCATCAAAACGAAAACGGCGTTGG  
GATCAAAACAGCTGATCAGACTCCTGGTGCCACTCCCAAAAACTATCAAGTTGGGATCAG  
GCAGAGACCCCTGGGCATACTCCTTCCTTAAGATGGGATGAGACACCAGGTCTGTCAAAG  
GGAAGCGAGACTCCTGGAGCAACCCAGGCTCAAAAATATGGGATCCTACACCTAGCCAC  
ACACCAGCGGGAGCTGCTACTCCTGGACGAGGTGATACACCAGGCCATGCGACACCAGGC  
CATGGAGGCGCAACTTCCAGTGCTCGTAAAAACAGATGGGATGAAACCCCCAAAACAGAG  
AGAGATACTCCTGGGCATGGAAGTGGATGGGCTGAGACTCCTCGAACAGATCGAGGTGGA  
GATTCTATTGGTGAAACACCGACTCCTGGAGCCAGTAAAGAAAAATCACGGTGGGATGAA  
ACACCAGCTAGTCAGATGGGTGGAAGCACTCCAGTTCTGACCCCTGGAAAGACACCAATT  
GGCACACCAGCCATGAACATGGCTACCCCTACTCCAGGTCACATAATGAGTATGACTCCT  
GAACAGCTTCAGGCTTGCGGTGGGAAAGAGAAATTGATGAGAGAAATCGCCCACTTTCT  
GATGAGGAATTAGATGCTATGTTCCCGAAGGATATAAGGTACTTCCTCCTCCAGCTGGT  
TATGTTCTTATTCGAACTCCAGCTCGAAAGCTGACAGCTACTCCAACACCTTTGGGTGGT  
ATGACTGGTTTCCACATGCAAACCTGAAGATCGAACTATGAAAAGTGTTAATGACCAGCCA  
TCTGGAAATCTTCCATTTTAAAACCTGATGATATTCAATACTTTGATAAACTATTGGTT  
GATGTTGATGAATCAACACTTAGTCCAGAAGAGCAAAAAGAGAGAAAAATAATGAAGTTG  
CTTTTAAAAATTAAGAATGGAACACCACCAATGAGAAAGGCTGCATTGCGTCAGATTACT  
GATAAAGCTCGTGAATTTGGAGCTGGTCCTTTGTTTAAATCAGATTCTTCCTCTGCTGATG  
TCTCCTACACTTGAGGATCAAGAGCGTCATTTACTTGTGAAAGTTATTGATAGGATACTG  
TACAAACTTGATGACTTAGTTCGTCCATATGTGCATAAGATCCTCGTGGTCATTGAACCG  
CTATTGATTGATGAAGATTACTATGCTAGAGTGGAAGGCCTAGAGATCATTTCTAATTTG  
GCAAAGGCTGCTGGTCTGGCTACTATGATCTCTACCATGAGACCTGATATAGATAACATG  
GATGAGTATGTCCGTAAACACAACAGCTAGAGCTTTTGCTGTTGTAGCCTCTGCCCTGGGC  
ATTCCTTCTTTATTGCCCTTCTTAAAGCTGTGTGCAAAAGCAAGAAGTCCTGGCAAGCG



- 155 -

AGACACACTGGTATTAAGATTGTACAACAGATAGCTATTCTTATGGGCTGTGCCATCTTG  
CCACATCTTAGAAGTTTAGTTGAAATCATTGAACATGGTCTTGTGGATGAGCAGCAGAAA  
GTTCCGACCATCAGTGCTTTGGCCATTGCTGCCTTGGCTGAAGCAGCAACTCCTTATGGT  
ATCGAATCTTTTGATTCTGTGTTAAAGCCTTTATGGAAGGGTATCCGCCAACACAGAGGA  
AAGGGTTTGGCTGCTTTCTTGAAGGCTATTGGGTATCTTATTCTCTTATGGATGCAGAA  
TATGCCAACTACTATACTAGAGAAGTGATGTTAATCCTTATTCGAGAATTCCAGTCTCCT  
GATGAGGAAATGAAAAAATTGTGCTGAAGGTGGTAAAAAGTGTGTTGTGGGACAGATGGT  
GTAGAAGCAAACACTACATTAAAAACAGAGATTCTTCCTCCCTTTTTTAAACACTTCTGGCAG  
CACAGGATGGCTTTGGATAGAAGAAATTACCGACAGTTAGTTGATACTACTGTGGAGTTG  
GCAAACAAAGTAGGTGCAGCAGAAATTATATCCAGGATTGTGGATGATCTGAAAGATGAA  
GCCGAACAGTACAGAAAAATGGTGATGGAGACAATTGAGAAAAATTATGGGCAATTTGGGA  
GCAGCAGATATTGATCATAAACTTGAAGAACAACCTGATTGATGGTATTCTTTATGCTTTT  
CAAGAACAGACTACAGAGGACTCAGTAATGTTGAACGGCTTTGGCACAGTGGTTAATGCT  
CTTGGCAAACGAGTCAAACCATACTTGCCTCAGATCTGTGGTACAGTTTTGTGGCGTTTA  
AATAACAAATCTGCTAAAGTTAGGCAACAGGCAGCTGACTTGATTTCTCGAACTGCTGTT  
GTCATGAAGACTTGTCAAGAGGAAAAATTGATGGGACACTTGGGTGTTGTATTGTATGAG  
TATTTGGGTGAAGAGTACCCTGAAGTATTGGGCAGCATTCTTGGAGCACTGAAGGCCATT  
GTAAATGTCATAGGTATGCATAAGATGACTCCACCAATTAAAGATCTGCTGCCTAGACTC  
ACCCCATCTTAAAGAACAGACATGAAAAAGTACAAGAGAATTGTATTGATCTTGTGGT  
CGTATTGCTGACAGGGGAGCTGAATATGTATCTGCAAGAGAGTGGATGAGGATTTGCTTT  
GAGCTTTTAGAGCTCTTAAAGCCCAAAAAAGGCTATTTCGTAGAGCCACAGTCAACACA  
TTTGGTTATATTGCAAAGGCCATTGGCCCTCATGATGTATTGGCTACACTTCTGAACAAC  
CTCAAAGTTCAAGAAAGGCAGAACAGAGTTTGTACCACTGTAGCAATAGCTATTGTTGCA  
GAAACATGTTCAACCTTTACAGTACTCCCTGCCTTAATGAATGAATACAGAGTTCCTGAA  
CTGAATGTTCAAAATGGAGTGTTAAATCGCTTTCTTCTTGTGTTGAATATATTGGTGAA  
ATGGGAAAAGACTACATTTATGCCGTAACACCGTTACTTGAAGATGCTTTAATGGATAGA  
GACCTTGTACACAGACAGACGGCTAGTGCAGTGGTACAGCACATGTCACTTGGGGTTTAT  
GGATTTGGTTGTGAAGATTGCTGAATCACTTGTGTAAGTATGTATGGCCCAATGTATTT  
GAGACATCTCCTCATGTAATTCAGGCAGTTATGGGAGCCCTAGAGGGCCTGAGAGTTGCT  
ATTGGACCATGTAGAATGTTGCAATATTGTTTACAGGGTCTGTTTCACCCAGCCCGGAAA  
GTCAGAGATGTATATTGGAAAAATTTACAACCTCATCTACATTGGTTCCAGGACGCTCTC  
ATAGCACATTACCAAGAATCTACAACGATGATAAGAACACCTATATTGCTTATGAACTT  
GACTATATCTTATAATTTTATTGTTTATTTTGTGTTTAAATGCACAGCTACTTCACACCTT  
AACTTGCTTTGATTTGGTGATGTAACTTTTAAACATTGCAGTTCAGTGTAGAACTGGT  
CATAGAGGAAGAGCTAGAAATCCAGTAGCATGATTTTTTAAATAACCTGTCTTTGTTTTG  
ATGTTAAACAGTAAATGCCAGTAGTGACCAAGAACACAGTGATTATATACACTATACTGG  
AGGGATTTTATTTTAAATTCATCTTTATGAAGATTTAGAACTCATTCTTGTGTTTAAAG  
GGAATGTTTAAATTGAGAAATAAACATTTGTGTACAAAATGCTAAAAAAAAAAAAAAAAA  
>gi|6912654|gb|NP\_036565.1|SF3B1 1304aa linear splicing factor  
3b, subunit 1, 155kDa; spliceosome-associated factor 155;  
splicing factor 3b, subunit 1, 155kD [Homo sapiens].  
MAKIAKTHEDIEAQIREIQGKKAALDEAQGVGLDSTGYDQEIYGGSDSRFAGYVTSIAA  
TELEDDDDDDYSSSTSLLGQKKPGYHAPVALLNDIPQSTEQYDPFAEHRPPKIIDREDEYK  
KHRTMIISPERLDPFADGGKTPDPKMNVRTYMDVMREQHLTKEEREIRQQLAEKAKAGE  
LKVVNGAAASQPPSKRKRRWDQTADQTPGATPKKLSSWDQAETPGHTPSLRWDETPGRAK  
GSETPGATPGSKIWDPTPSHTPAGAATPGRGDTPGHATPGHGGATSSARKNRWDETPKTE  
RDTPGHSGSWAETPRTRDGGDSIGETPTPGASKRKSRWDETPASQMGGSTPVLTPGKTPI

- 156 -

GTPAMNMATPTPGHIMSMTPEQLQAWRWEREIDERNRPLSDEELDAMFPEGYKVLPPAG  
YVPIRTPARKLTATPTPLGGMTGFHMQTEDRTMKSVNDQPSGNLPFLKPDDIQYFDKLLV  
DVDESTLSPEEQKERKIMKLLLLKIKNGTPPMRKAALRQITDKAREFGAGPLFNQILPLLM  
SPTLEDQERHLLVKVIDRILYKLLDDLVRPYVHKILVVEPLLIDEDYYARVEGLEIISNL  
AKAAGLATMISTMRPDIDNMDEYVRNTTARAFVVASALGIPSLLPFLKAVCKSKKSWQA  
RHTGIKIVQQAIALMGCAILPHLRSLVEIIEHGLVDEQQKVRTISALAI AALAEATPYG  
IESFDSVLKPLWKGIHQHRGKGLAAFLKAIGYLIPLMDAEYANYYTREVMLILIREFQSP  
DEEMKKIVLKVVKQCCGTDGVEANYIKTEILPPFFKHFWQHRMALDRRNYRQLVDTTVEL  
ANKVGAAEIIISRIVDDLKDEAEQYRKMVMETIEKIMGNLGAADIDHKL EEQLIDGILYAF  
QEQTTEDSVMLNGFGTVVNALGKRVKPYLPQICGTVLWRLNNKSAKVRQQAADLISRTAV  
VMKTCQEEKLMGHLGVVLYEYLGE EYPEVLGSILGALKAIVNVIGMHKMT PPIKDLLPRL  
TPILKNRHEKVQENCIDLVGRIADRGAEYVSAREWMRICFELLELLKAHKKAIRRATVNT  
FGYIAKAIGPHDVLATLLNNLKVQERQNRVCTTVAIAIVAETCSPFTVLPALMNEYRVPE  
LNVQNGVLKSLSFLFEYIGEMGKDYIYAVTPLLEDALMDRDLVHRQTASAVVQHMSLGVY  
GFGCEDSLNHLNLYVWPNVFETSPHVIQAVMGALEGLRVAIGPCRMLQYCLQGLFHPARK  
VRDVYWKIYNSIYIGSQDALIAHYPRIYNDKNTYIRYELDYIL

>gi|21707321|gb|BC033864.1|BC033864 2321bp mRNA Homo. sapiens,  
Similar to branched chain aminotransferase 1, cytosolic, clone  
MGC:45234 IMAGE:5186262, mRNA, complete cds.

GGTGGATGCTGCGGCATCGGAGGACCCTGCTGGTGGAGGAAATGGTTCACGCCCGTCCCC  
GTTCCCTTTG CAGGCTTGCTATTGTGCGTCTGTGATTGACAAGACCACGAGGCTGAGCGC  
GCCCTGGAGATTTTTCTATAAATGGCTTAACACCCCACTCTAGACTATTTGCTCGGATAT  
AAGGGAGACAATTGTTTTTTTGTCTTTTGCCGGCGAACCCTGGCTCTGTAGGGCTGACCT  
GGAATTTAACCAGTCTTCCCTGAGCCGGCGGAGGAGACAAAACCGCCGCGACCCCGGC  
AGGGTGGGAAGTGCAGGGCAGCGCTCCCAAGACACGCTTGTGAGGTTTCGGGCCTGGGT  
GCTTGGTTGTCTGAGCCTCCTTTTTTTGTGTTTGCTGGGTCTGAGAGGAGCGCACGGT  
ATCATGGATTGCAGTAACGGATGCTCCGCAGAGTGTACCGGAGAAGGAGGATCAAAAGAG  
GTGGTGGGGACTTTTAAGGCTAAAGACCTAATAGTCACACCAGCTACCATTTTAAAGGAA  
AAACCAGACCCCAATAATCTGGTTTTTGGAACTGTGTTACGGATCATATGCTGACGGTG  
GAGTGGTCCTCAGAGTTTGGATGGGAGAAACCTCATATCAAGCCTCTTCAGAACCTGTCA  
TTGCACCCTGGCTCATCAGCTTTGCACTATGCAGTGGAAATTATTTGAAGGATTGAAGGCA  
TTTCGAGGAGTAGATAATAAAATTCGACTGTTTCAGCCAAACCTCAACATGGATAGAATG  
TATCGCTCTGCTGTGAGGGCAACTCTGCCGGTATTTGACAAAGAAGAGCTCTTAGAGTGT  
ATTCAACAGCTTGTGAAATTGGATCAAGAATGGGTCCCATATTCAACATCTGCTAGTCTG  
TATATTCGTCTTACATTCATTGGAACCTGAGCCTTCTCTTGGAGTCAAGAAGCCTACCAA  
GCCCTGCTCTTTGTACTCTTGAGCCCACTGGGACCTTATTTTTCAAGTGGAACTTTAAT  
CCAGTGTCCCTGTGGGCCAATCCCAAGTATGTAAGAGCCTGGAAAGGTGGAACTGGGGAC  
TGCAAGATGGGAGGGAATTACGGCTCATCTCTTTTTGCCCCAATGTGAAGCAGTAGATAAT  
GGGTGTCAGCAGGTCCTGTGGCTCTATGGAGAGGACCATCAGATCACTGAAGTGGGAACT  
ATGAATCTTTTTCTTTACTGGATAAATGAAGATGGAGAAGAAGAACTGGCAACTCCTCCA  
CTAGATGGCATCATTCTTCCAGGAGTGACAAGGCGGTGCATTCTGGACCTGGCACATCAG  
TGGGACACAGA ACTCAGCTTGTTTTCAATTAATTTGCCTGATTTTCTGCAGTTCATTTAC  
TTTTGAACAACATAATTGCAATTGTAGACTGAGAGAAATTGAACTTTCAAAGAGCCATA  
TTTCTATTGCAGATATATTTTCTGCTCTTCCAAATCTACTTACAGCATGAGTTCTTCTT  
TTAAATATTCAAATATTTTGAATATTGCCAAGAGCTTTGATTTCCATTTTTATCTCTTGT  
GGGTTTATAAATTAAGAAAAATACTCATCTTATTTTTTTTAAACCTCTCTATTTTTTATTG  
CCCTTTATTCAAATAACTTGTTGACAACTTTGAACTTGAACCACTGAGGTAAAAGAACA



- 157 -

AGAATTAAACAGATAGTTTAAACACATAGCTTAAAAGGATCTTTTTCCCATTTTCCTATCC  
TTGAGCAAAGAATATATTCAAACACTTTGGCAGAAGTCAATGAGGTTATACCACTAATTC  
CATGATGAAAATCAACTGAATGTGATACTGAAAGAGAAGGAAGAGAATTGTCACTGTAAA  
GTCAACTGTTAGTCATATTAGGAAAAAAATACATACAATACAATTTCTCAAATAAAGTC  
CAAATATACATTCAATGTTTAAAAATAATGAGTATTTTCAAGATATTTGAACTCAGTCTGTT  
CTTTATTCCATAAAAGATATAGGTAAGCCGTGCACGGTGGCTCACAACCTATAATCCCAGC  
ACTTTGGCACTTTGGGAGGCTGAGGTGGGAGGATCACATGAGCCCAGCCTGGGCAACATA  
GGGAGACCGCTATCTTTACAAAATAAAATATAAAATATAAAACCTAGTTGGGCATGGCAG  
CATAACCTGTAGTCCCAGGTGCTCGGGAGACTGAGACAGGAGGATCGCTTGGGCCTGGG  
AGGTCGAGGCTGCAGTGAGCCAAGATTATGCCACTGCATTCCAGCCTGGGTGACAGGGCA  
AGACCCTGTCTTAAAAA

>gi|21707322|gb|AAH33864.1|AAH33864 320aa linear Similar to  
branched chain aminotransferase 1, cytosolic [Homo sapiens].  
MDCSNGCSAECTGEGGSKEVVGTFKAKDLIVTPATILKEKPDPNNLVFGTVFTDHMLTVE  
WSSEFGWEKPHIKPLQNLSLHPGSSALHYAVELFEGLKAFRGVDNKIRLFPQNLNMDRMY  
RSAVRATLPVFDKEELLECIQQLVKLDQEWVPYSTASLYIRPTFIGTEPSLGVKKPTKA  
LLFVLLSPVGPYFSSGTFNPVSLWANPKYVRAWKGGTGDCMKMGNYGSSLFAQCEAVDNG  
CQQVLWLYGEDHQITEVGTMNLFYWINEDGEEELATPPLDGIILPGVTRRCILDLAHQW  
DTELSLFSINLPDFLQFIYF

>gi|29570794|gb|NM\_001895.2|CSNK2A1 2323bp mRNA Homo sapiens  
casein kinase 2, alpha 1 polypeptide (CSNK2A1), transcript  
variant 2, mRNA.

CCCGCCTCCTGGTAGGAGGGGGTTTCCGCTTCCGGCAGCAGCGGCTGCAGCCTCGCTCTG  
GTCCCTGCGGCTGGCGGCCGAGCCGTGTGTCTCCTCCTCCATCGCCGCCATATTGTCTGT  
GTGAGCAGAGGGGAGAGCGGCCCGCCGCTGCCGCTTCCACCACAGTTTGAAGAAAACA  
GGTCTGAAACAAGGTCTTACCCCCAGCTGCTTCTGAACACAGTGACTGCCAGATCTCCAA  
ACATCAAGTCCAGCTTTGTCCGCCAACCTGTCTGACATGTCCGGACCCGTGCCAAGCAGG  
GCCAGAGTTTACACAGATGTTAATACACACAGACCTCGAGAATACTGGGATTACGAGTCA  
CATGTGGTGGAATGGGGAAATCAAGATGACTACCAGCTGGTTTCGAAAATTAGGCCGAGGT  
AAATACAGTGAAATTTTGAAGCCATCAACATCAAAATAATGAAAAAGTTGTTGTTAAA  
ATTCTCAAGCCAGTAAAAAAGAAGAAAATTAAGCGTGAAATAAAGATTTTGGAGAATTTG  
AGAGGAGGTCCCAACATCATCACTGGCAGACATTGTAAAAGACCCTGTGTACGAACC  
CCCGCCTTGGTTTTTTGAACACGTAAACAACACAGACTTCAAGCAATTGTACCAGACGTTA  
ACAGACTATGATATTCGATTTTACATGTATGAGATTCTGAAGGCCCTGGATTATTGTACAC  
AGCATGGGAATTATGCACAGAGATGTCAAGCCCCATAATGTCATGATTGATCATGAGCAC  
AGAAAGCTACGACTAATAGACTGGGGTTTGGCTGAGTTTATCATCCTGGCCAAGAATAT  
AATGTCCGAGTTGCTTCCCGATACTTCAAAGGTCTGAGCTACTTGTAGACTATCAGATG  
TACGATTATAGTTTGGATATGTGGAGTTTGGGTTGTATGCTGGCAAGTATGATCTTTCGG  
AAGGAGCCATTTTTCCATGGACATGACAATTATGATCAGTTGGTGAGGATAGCCAAGGTT  
CTGGGGACAGAAGATTTATATGACTATATTGACAAATAACAACATTGAATTAGATCCACGT  
TTCAATGATATCTTGGGCAGACACTCTCGAAAGCGATGGGAACGCTTTGTCCACAGTGAA  
AATCAGCACCTTGTGACGCCCTGAGGCCTTGGATTTCTTGACAAACTGCTGCGATATGAC  
CACCAGTCACGGCTTACTGCAAGAGAGGCAATGGAGCACCCCTATTTCTACACTGTTGTG  
AAGGACCAGGCTCGAATGGGTTTCTAGCATGCCAGGGGGCAGTACGCCCCGTGAGCAGC  
GCCAATATGATGTGAGGGATTTCTTCAAGTCCAACCCCTTACCCCTTGGACCTCTGGCA  
GGCTCACCAGTGATTGCTGCTGCCAACCCCTTGGGATGCCTGTTCCAGCTGCCGCTGGC  
GCTCAGCAGTAACGGCCCTATCTGTCTCCTGATGCCTGAGCAGAGGTGGGGGAGTCCACC

- 158 -

CTCTCCTTGATGCAGCTTGCGCCTGGCGGGGAGGGGTGAAACACTTCAGAAGCACCGTGT  
CTGAACCGTTGCTTGTGGATTTATAGTAGTTCAGTCATAAAAAAAAAAATTATAATAGGCT  
GATTTTCTTTTTTCTTTTTTTTTTTAACTCGAACTTTTCATAACTCAGGGGATTCCCTGA  
AAAATTACCTGCAGGTGGAATATTTTCATGGACAAATTTTTTTTTTCTCCCCTCCCAAATTT  
AGTTCCTCATCACAAAAGAACAAGATAAACCAGCCTCAATCCCGGCTGCTGCATTTAGG  
TGGAGACTTCTTCCCATTCCCACCATTGTTCTCCACCGTCCCACACTTTAGGGGGTGG  
TATCTCGTGCTCTTCTCCAGAGATTACAAAATGTAGCTTCTCAGGGGAGGCAGGAAGAA  
AGGAAGGAAGGAAAGAAGGAAGGGAGGACCCAATCTATAGGAGCAGTGGACTGCTTGCTG  
GTCGCTTACATCACTTTACTCCATAAGCGCTTCAGTGGGGTTATCCTAGTGGCTCTTGCTG  
GAAGTGTGTCTTAGTTACATCAAGATGTTGAAAATCTACCCAAAATGCAGACAGATACTA  
AAAACCTTCTGTTTCAGTAAGAATCATGTCTTACTGATCTAACCCTAAATCCAACCTCATTTA  
TACTTTTATTTTATAGTTCAGTTTAAAATGTTGATACCTTCCCTCCCAGGCTCCTTACCTT  
GGTCTTTTCCCTGTTTCATCTCCCAACATGCTGTGCTCCATAGCTGGTAGGAGAGGGAAGG  
CAAAATCTTTCTTAGTTTTCTTTGTCTTGGCCATTTTGAATTC

>gi|4503095|gb|NP\_001886.1|CSNK2A1 391aa linear casein kinase  
II alpha 1 subunit isoform a; CK2 catalytic subunit alpha  
[Homo sapiens].

MSGPVPSPRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGKRGKYSEVFEAINIT  
NNEKVVVKILKPKVKKKKIKREIKILENLRGGPNIIITLADIVKDPVSRTPALVFEHVNTD  
FKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAE  
FYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMI FRKEPFFHGHNDNYD  
QLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDF  
LDKLLRYDHQSRLTAREAMEHPYFYTVVKDQARMGSSSSMPGGSTPVSSANMMSGISSVPT  
PSPLGLPLAGSPVIAAANPLGMPVPAAAGAQQ

>gi|13375963|gb|NM\_024689.1|FLJ14103.2502bp mRNA Homo sapiens  
hypothetical protein FLJ14103 (FLJ14103); mRNA.

CTCTTTGGCCAAGCCCTGCCTCTGTACAGCCTCGAGTGGACAGCCAGAGGCTGCAGCTGG  
AGCCCAGAGCCCAAGATGGAGCCCCAGCTGGGGCCTGAGGCTGCCGCCCTCCGCCCTGGC  
TGGCTGGCCCTGCTGCTGTGGGTCTCAGCCCTGAGCTGTTCTTTCTCCTTGCCAGCTTCT  
TCCCTTTCTTCTCTGGTGCCCCAAGTCAGAACCAGCTACAATTTTGAAGGACTTTCCCTC  
GGTCTTGATAAATGCAATGCCTGCATCGGGACATCTATTTGCAAGAAGTTCTTTAAAGAA  
GAAATAAGATCTGACAACCTGGCTGGCTTCCCACCTTGGACTGCCTCCCGATTCTTCTGCTT  
TCTTATCCTGCAAATTACTCAGATGATTCCAAAATCTGGCGCCCTGTGGAGATCTTTAGA  
CTGGTCAGCAAATATCAAAACGAGATCTCAGACAGGAAAATCTGTGCCTCTGCATCAGCC  
CCAAAGACCTGCAGCATTGAGCGTGTCTGCGGAAAACAGAGAGGTTCCAGAAATGGCTG  
CAGGCCAAGCGCCTCACGCCGACCTGGTGCAGGACTGTCAACAGGGCCAGAGAGAACTA  
AAGTTCCTGTGTATGCTGAGATAACACCAGTGAAAAAGCCTGGCATGGAGCCCAGCACTG  
AGAACTTCCAGAAAGTGTTAGCCTTCTCCCAACTGTGTTATACCAACCACATTTTCAAAT  
AGTAATCATTAAGAGGCTTCTGCATCAAACCTTCACATGCAGCTCCCATGCCACCCTCC  
AGAATTCACCAACACACAGGCCACAGCAACAGGCTACCTTTGCACAATATTCTCTGAT  
GACAACCTCAAAGCCCCGGCTCTTTCCACCACACTGTGGTCCCCTAGATGGGGCTGTTGC  
TGAGCCCACCCCAATCCAGATGTGATCCCCCTGTGATCTACTTCTGGCAAGATTCTCAGT  
CTGGACAGGTCTTCCCTATGAGATAGAACCCTGATAAGGAGCTAGGGCAATTCTGACAACA  
TTACCAAAGGCCACATAACTTCTAAATTTTGGTCTGGTCTGAAGGAAAACCTGTTCTCG  
CCCTAGTGATGGATGAACTCTCTTATCTCTGGCTTCTAGAGGGAAAAAAAAGCATACCT  
CTTTTACTTTTTTAAGTACCTCCATCAGAGTCATGAAATCACCTGTCAAGACTATCTATCT  
TTTATGTTTCCATTCTGGTAAGAACTCTTTAAATGAGGACACTGCTGATTGCTGGTGATG

- 159 -

TTTTTTGAGCAAACACTCGGGGGTATGGATGAAAGCCAATCGCAGGTCAAATGACTCCTT  
GGGGAAGCTACTTCTCCTCTATTTCAGATTTTCTAAATCTTCCAAGATGAAAGCAAATC  
TAGATTTTCGGTCTTCATTGCTGTCCATTTTTGTAATGAACGAGTGTTTTTCTTTAGCTA  
GTGTATCAGGCAGGGTCTACCCAGAGAAACAGAACCAGTAGGAGATACATATACATGTCC  
AGATTTATTTCAAAGAATTGATTTACATGATTGTGGGGATTGGCAAGTCCAAAATCCATA  
TGGTAGGCCTGCAATCTGTAAACCTTTGGGCAGGAGCTGATGCTGTAGTTTGCAGATAGA  
ATTCTTGTTCCTTAAAAAATCTGTTTTTGTCTTAAGGGCTTTGAATGATTGGATCAG  
GCCCACCCAGATTACCTAGATAATCTCTTTTACTTTAAAGTAAACTGATTGTAGGTGCTAA  
TCACATCTATGAAATGCCTTCACAGCAACACCTAGATTAGCATTCGAATTGAATAACTGGG  
GAATACAGCCTAGCCAAGTTGACACATAAAATTAACCATCACAGCAACATGCCTGCTAAA  
TTTTATCGACCGTCTTCAGACTGTTAAGGATTGTGGTAGAGAACTGTGACAGCCACTCTC  
AGCATCACCTGAACCAAAGGCCCTATCAAGTAACAATATAGCCAAGCAAATTCAGT  
CAATAGAGACATTGACTGGTTGGCTGGCTTCCCAAGGGATAGCACCAGACAAGAAATGCA  
AGGATGAGGAAACCAGGCACGGGAGAGGGAGGGCAACAGAGGTCCAGGGTTTGGTTATC  
TTTTTATTTTTTCACTGGGAGGTGGTAAGTTAGCCCTGTTGCCCATGTATGCAGATGGGAG  
AAGTGATTTAGAACTCCAAAGCAATTGGTAATCCCCAAAATGGGTGTATCTGGTTTGAA  
ATGAAACCTTATTTTATTGGAAATGGTTGGTTTCCCAATTCTGTTTGCCATTGGCCAATA  
TAATTGTGGGTTTGCACATGGCCAGCACATGCCAAACAGAAGTAGACAAAGGTCTCACTC  
TGTAAGTGGGACCTTGGGGAGGAGCTGCCTCCATCATAAAGGGAGGGGTTAGTAAAAATG  
GTCTCTTAAGCCTGTTCTTGCTACAGTTATAGAGGTTGCTCAGAACCTTCTCAGCAAATA  
TAGCAGTTATCTATTGTTGTGTATTAAACCATTTC AACACAT

>gi|13375964|gb|NP\_078965.1|FLJ14103 182aa linear hypothetical  
protein FLJ14103 [Homo sapiens].

MEPQLGPEAAALRPGWLALLLWVSALSCSFSLPASSLSSLVLPQVRTSYNFGRTFLGLDKC  
NACIGTSICKKFFKEEIRSDNWLASHLGLPPDSLLSYPANYSDDSKIWRPVEIFRLVSKY  
QNEISDRKICASASAPKTCSEIRVLRKTERFQKWLQAKRLTPDLVQDCHQGQRELKFLCM  
LR

>gi|7658290|gb|AF221842.1|AF221842 3057bp mRNA Homo sapiens U5  
snRNP-associated 102 kDa protein mRNA, complete cds.

ACTTTGCTACGGAGTGCATCGGACGTCGAAGCCTAGAGTCTCTGCGTCTTTCCCTCTTCC  
GCTGCCTCATTCCTTTTCTTCTAGCCTTGGTTCGTCGCCGCCACCATGAACAAGAAGAAG  
AAACCGTTTCTAGGGATGCCCCGCGCCCTCGGCTACGTGCCGGGGCTGGGCCGGGGCGCC  
ACTGGCTTCACCACGCGGTACAGACATTGGGCCCGCCCGTGATGCAAATGACCCTGTGGAT  
GATCGCCATGCACCCCCAGGCAAGAGAACCCTTGGGGACCAGATGAAGAAAAATCAGGCT  
GCTGACGATGACGACGAGGATCTAAATGACACCAATTACGATGAGTTTAATGGCTATGCT  
GGGAGCCTCTTCTCAAGTGGACCCTACGAGAAAGATGATGAGGAAGCAGATGCTATCTAT  
GCAGCCCTGGATAAAAAGGATGGATGAAAGAAGAAAAGAACGGGAGCAAAGGGAGAAA  
GAAGAAATAGAGAAATATCGTATGGAACGCCCCAAAATCCAACAGCAGTTCTCAGACCTC  
AAGAGGAAGTTGGCAGAAAGTCACAGAAGAAGAGTGGCTGAGCATCCCCGAGGTTGGCGAT  
GCCAGAAATAAACGTACAGCGGAACCCACGCTATGAGAAGCTGACCCCTGTTCTTGACAGT  
TTCTTTGCCAAACATTTACAGACCGGAGAGAACCATACTCAGTGGATCCCCGACAACT  
CAATTTGGAGGTCTTAACACACCCTATCCAGGTGGACTAAACACTCCATACCCAGGTGGA  
ATGACGCCAGGACTGATGACACCTGGCACAGGTGAGCTGGACATGAGGAAGATTGGCCAA  
GCGAGGAACACTCTGATGGACATGAGGCTGAGCCAGGTGTCTGACTCCGTGAGTGGACAG  
ACCGTCGTTGACCCCAAAGGCTACCTGACGGATTTAAATTCCATGATCCCGACACACGGA  
GGAGACATCAATGATATCAAGAAGGCGCGACTGCTCCTCAAGTCTGTTCCGGGAGACGAAC  
CCTCATCACCCGCCAGCCTGGATTGCATCAGCCCGCCTGGAAGAAGTCACTGGGAAGCTA

- 160 -

CAAGTAGCTCGGAACCTTATCATGAAGGGGACGGAGATGTGCCCCAAGAGTGAAGATGTC  
TGGCTGGAAGCAGCCAGGTTGCAGCCTGGGGACACAGCCAAGGCCGTGGTAGCCCAAGCT  
GTCCGTCATCTCCACAGTCTGTCAAGATTACATCAGAGCCGCAGAGCTGGAACGGAC  
ATTCGTGCAAAGAAGCGGGTTCTTCGAAAGCCCTCGAGCATGTTCCAACTCGGTTTCGC  
TTGTGGAAGCAGCCGTTGAGCTGGAAGAACCTGAAGATGCTAGAATCATGCTGAGCCGA  
GCTGTGGAGTGCTGCCCCACCAGCGTGAGCTCTGGCTTGCTCTGGCAAGGCTGGAGACC  
TATGAAAATGCCCGCAAGGTCTTGAACAAGGCGCGGGAGAACAATTCCTACAGACCGACAT  
ATCTGGATCACGGCTGCTAAGCTGGAGGAAGCCAATGGGAACACGCAGATGGTGGAGAAG  
ATCATCGACCGAGCCATCACCTCGCTGCGGGCCAACGGTGTGGAGATCAACCGTGAGCAG  
TGGATCCAGGATGCCGAGGAATGTGACAGGGCTGGGAGTGTGGCCACCTGCCAGGCCGTC  
ATGCGTGCCGTGATTGGGATTGGGATTGAGGAGGAAGATCGGAAGCATACTGGATGGAG  
GATGCTGACAGTTGTGTAGCCCACAATGCCCTGGAGTGTGCACGAGCCATCTACGCCTAC  
GCCCTGCAGGTGTTCCCCAGCAAGAAGAGTGTGTGGCTGCGCGCCGCGTACTTCGAGAAG  
AACCATGGCACTCGGGAGTCCCTGGAAGCACTCCTGCAGAGGGCTGTGGCCCACTGCCCC  
AAAGCAGAGGTGCTGTGGCTCATGGGCGCCAAGTCCAAGTGGCTGGCAGGGGATGTGCCT  
GCAGCAAGGAGCATCCTGGCCCTGGCCTTCCAGGCCAACCCCAACAGTGAGGAGATCTGG  
CTGGCAGCCGTGAAGCTGGAGTCCGAGAATGATGAGTACGAGCGGGCCCGGAGGCTGCTG  
GCCAAGGCGCGGAGCAGTGCCCCACCGCCCGGGTGTTCATGAAGTCTGTGAAGCTGGAG  
TGGGTGCAAGACAACATCAGGGCAGCCCAAGATCTGTGCGAGGAGGCCCTGCGGCACTAT  
GAGGACTTCCCCAAGCTGTGGATGATGAAGGGGCAGATCGAGGAGCAGAAGGAGATGATG  
GAGAAGGCGCGGAAGCCTATAACCAGGGGTGGAAGAAGTGTCCCACTCCACACCCCTG  
TGGCTTTTGCTCTCTCGGCTGGAGGAGAAGATTGGGCAGCTTACTCGAGCACGGGCCATT  
TTGGAAGAAGTCTCGTCTGAAGAACCCAAAGAACCCTGGGCTGTGGTTGGAGTCCGTGCGG  
CTGGAGTACCGTGCGGGGCTGAAGAACATCGCAAATACACTCATGGCCAAGGCGCTGCAG  
GAGTGCCCCAACTCCGGTATCCTGTGGTCTGAGGCCATCTTCCTCGAGGCAAGGCCCCAG  
AGGAGGACCAAGAGCGTGATGCCCTGAAGAAGTGTGAGCATGACCCCATGTGCTCCTG  
GCCGTGGCCAAGCTGTTTTTGGAGTCAGCGGAAGATCACCAAGGCCAGGGAGTGGTTCCAC  
CGCACTGTGAAGATTGACTCGGACCTGGGGGATGCCTGGGCCTTCTTCTACAAGTTTGAG  
CTGCAGCATGGCACTGAGGAGCAGCAGGAGGAGGTGAGGAAGCGCTGTGAGAGTGCAGAG  
CCTCGGCATGGGGAGCTGTGGTGCGCCGTGTCCAAGGACATCGCCAACTGGCAGAAGAAG  
ATCGGGGACATCCTTAGGCTGGTGGCCGGCCGCATCAAGAACACCTTCTGATTGAGCGGT  
TGCCATGGCCGGTCTCCGTGGGGCAGGGTTGGGCCGCATGTGGAAGGGCTCTGAGCTGTG  
TCCTCCTTCATTAAAGTTTTTATGTCTCGTGTGAGAAAAA

>gi|7658291|gb|AAF66128.1|AAF66128 941aa linear U5 snRNP-  
associated 102 kDa protein [Homo sapiens].

MNKKKKPFLGMPAPLGYVPGLGRGATGFTTRSDIGPARDANDPVDDRHAPPKGRTVGDQM  
KKNQAADDDDEDLNDTNYDEFNGYAGSLFSSGPYEKDDEEADAIYAALDKRMDERRKERR  
EQREKEEIEKYRMERPKIQQQFSDLKRKLAEVTEEEWLSIPEVGDARNKRQRNPRYEKLT  
PVPDSFFAKHLQTGENHTSVDPQQTQFGGLNTPYPGGLNTPYPGGMTPGLMTPGTGELDM  
RKIGQARNTLMDMRLSQQVSDSVSGQTVVDPKGYLTDLNSMIPTHGGDINDIKKARLLLS  
VRETNPHHPPAWIASARLEEVTKLQVARNLIMKGTEMCPKSEDEVWLEAARLQPGDTAKA  
VVAQAVRHLPQSVRIYIRAAELETDIRAKKRVLRLKALEHVPNSVRLWKAAVELEEPEDAR  
IMLSRAVECCPTSVELWLALARLETYENARKVLNKARENIPDRHIWITAAKLEEANGNT  
QMVEKIIDRAITSLRANGVEINREQWIQDAEECDRAGSVATCQAVMRAVIGIGIEEEDRK  
HTWMEDADSCVAHNALECARAIYAYALQVFPSKKS VWLRAAYFEKNHGTRESLEALLQRA  
VAHCPKAEVLWLMGAKSKWLAGDVPAARSILALAFQANPNSEEIWLAAVKLESENDEYER  
ARRLLAKARSSAPTARVFMKSVKLEWVQDNIRAAQDLCEEALRHYEDFPKLWMMKGQIEE

- 161 -

QKEMMEKAREAYNQGLKKCPHSTPLWLLLSRLEEKIGQLTRARAILEKSRLKNPKNPGLW  
LESVRLEYRAGLKNIANITLMAKALQECPSGILWSEAFLEARPQRRTKSVDALKKCEHD  
PHVLLAVAKLFWSQRKITKAREWFHRTVKIDSDLGDAWAFFYKFELQHGTEEQQEEVRKR  
CESAEPRHGELWCAVSKDIANWQKKIGDILRLVAGRIKNTF

>gi|5454165|gb|NM\_006370.1|VTI1B 1287bp mRNA Homo sapiens  
vesicle transport through interaction with t-SNAREs homolog 1B  
(yeast) (VTI1B), mRNA.

CCCTTTTCGCTGCGGCCTTTCCCCAACCCGGACCCGGCACTTCTCGGGTTCCGCGACTGCC  
GATCGCCCCGGCGCGGCACCGCTCCCTCAGGAGTGCCTAGGCCGCGCAGTCTCCCGACT  
TCTCGTCAGGCTTTTCGCGCCGGCGCTCCAGCAATCACTGGCTGGAGAAGGTGGGCGTTCC  
GGCTCGAGAGGACCCTGCCGCGGCTCCGGAAGAGCCTCGTCCTGGGCGGCGGTGGTGC GG  
CGGTCGCCGTTATGGCCACTGGGCTGGGCGGCTGACCGCGGGCTAGGAAAGGGCCCAGGG  
CCCGAATCTCGGTGGCCGCTGCTCCAGCGCGGCCTGCGCCATGGCCTCCTCCGCCGCCTC  
CTCGGAGCATTTTCGAGAAGCTGCACGAGATCTTCCGCGGCCTCCATGAAGACCTACAAGG  
GGTGCCCGAGCGGCTGCTGGGGACGGCGGGGACCGAAGAAAAGAAGAAATTGATCAGGGA  
TTTTGATGAAAAGCAACAGGAAGCAAATGAAACGCTGGCAGAGATGGAGGAGGAGCTACG  
TTATGCACCCCTGTCTTTCCGAAACCCCATGATGTCTAAGCTTCGAAACTACCGGAAGGA  
CCTTGCTAAACTCCATCGGGAGGTGAGAAGCACACCTTTGACAGCCACACCTGGAGGCCG  
AGGAGACATGAAATATGGCATATATGCTGTAGAGAATGAGCATATGAATCGGCTACAGTC  
TCAAAGGGCAATGCTTCTGCAGGGCACTGAAAGCCTGAACCGGGCCACCCAAAGTATTGA  
ACGTTCTCATCGGATTGCCACAGAGACTGACCAGATTGGCTCAGAAATCATAGAAGAGCT  
GGGGGAACAACGAGACCAGTTAGAACGTACCAAGAGTAGACTGGTAAACACAAGTGAAAA  
CTTGAGCAAAAGTCGGAAGATTCTCCGTTCAATGTCCAGAAAAGTGACAACCAACAAGCT  
GCTGCTTTCCATTATCATCTTACTGGAGCTCGCCATCCTGGGAGGCCTGGTTTACTACAA  
ATTCTTTTCGAGCCATTGAACTTCTATAGGGAAGGGTTTGTGGACCAGAACTTTGACCTT  
GTGAATGCATGATGTTAGGGATGTGGATAGAATAAGCATATTGCTGCTGTGGGCTGACAG  
TTCAAGGATGCACTGTATAGCCAGGCTGTGGGAGGAGGGAGGAAAGATGAAAAACCACTT  
AAATGTGAAGGAACAACAGCAACAAGACCAGTATGATATACCAAGGTAATAAATGCTGTT  
TATGACTTCTTTAAAAA

>gi|5454166|gb|NP\_006361.1|VTI1B 232aa linear vesicle-  
associated soluble NSF attachment protein receptor (v-SN;  
vesicle-associated soluble NSF attachment protein receptor (v-  
SNARE; homolog of S. cerevisiae VTI1) [Homo sapiens].

MASSAASSEHFEKLHEIFRGLHEDLQGVPERLLGTAGTEEEKKLIRDFDEKQQEANETLA  
EMEEELRYAPLSFRNPMSKLRNYRKDLAKLHREVRSTPLTATPGGRGDMKYGIYAVENE  
HMNRLQSQRAMLLQGTESLNRATQSIERSHRIATETDQIGSEIIIEELGEQRDQLERTKSR  
LVNTSENLSKSRKILRSMRKVTTNKLILLSIIILLELAILGGLVYYKFFRSH

>gi|7705992|gb|NM\_016440.1|LOC51231 1869bp mRNA Homo sapiens  
VRK3 for vaccinia related kinase 3 (LOC51231), mRNA.

CCGAGGGTTCAGGCTGCAGAAGCCCAGAATCCCACCCAGTCCCCAAGTACAGAGGTGCT  
GTCAAGATGGAGTTTCCAACCCAGTAAATCCAAGGGCCAGACCGTGACCTCATAAAGCAT  
GATCTCCTTCTGTCCAGACTGTGGCAAAAGTATCCAAGCGGCATTCAAATTCTGCCCTA  
CTGTGGAAATTCTTTGCCTGTAGAGGAGCATGTAGGGTCCAGACCTTTGTCAATCCACA  
TGTGTCATCCTTCCAAGGCTCAAAGAGAGGGCTGAACTCCAGTTTGTAAACCTCTCCTAA  
GAAAGTGAAATGGTCCAGCACCGTCACCTCTCCCCGATTATCCCTCTTCTCAGATGGTGA  
CAGTTCTGAGTCTGAAGATACTCTGAGTTCCTCTGAGAGATCCAAAGGCTCCGGGAGCAG  
ACCCCCAACCCCAAAGCAGCCCTCAGAAGACCAGGAAGAGCCCTCAGGTGACCAGGGG

- 162 -

TAGCCCTCAGAAGACCAGCTGTAGCCCTCAGAAGACCAGGCAGAGCCCTCAGACGCTGAA  
GCGGAGCCGAGTGACCACCTCACTTGAAGCTTTGCCCACAGGGACAGTGCTGACAGACAA  
GAGTGGGCGACAGTGGAAGCTGAAGTCCTTCCAGACCAGGGACAACCAGGGCATTCTCTA  
TGAAGCTGCACCCACCTCCACCCTCACCTGTGACTCAGGACCACAGAAGCAAAAGTTCTC  
ACTCAAACCTGGATGCCAAGGATGGGCGCTTGTTCAATGAGCAGAACTTCTTCCAGCGGGC  
CGCCAAGCCTCTGCAAGTCAACAAGTGGAAGAAGCTGTACTCGACCCCACTGCTGGCCAT  
CCCTACCTGCATGGGTTTTCGGTGTTCACCAGGACAAATACAGGTTCTTGGTGTACCCAG  
CCTGGGGAGGAGCCTTCAGTCGGCCCTGGATGTCAGCCCAAAGCATGTGCTGTCAGAGAG  
GTCTGTGCTGCAGGTGGCCTGCCGGCTGCTGGATGCCCTGGAGTTCCTCCATGAGAATGA  
GTATGTTTCATGGAAATGTGACAGCTGAAAATATCTTTGTGGATCCAGAGGACCAGAGTCA  
GGTGACTTTTGGCAGGCTATGGCTTCGCCTTCCGCTATTGCCCAAGTGGCAAACACGTGGC  
CTACGTGGAAGGCAGCAGGAGCCCTCACGAGGGGGACCTTGAGTTCATTAGCATGGACCT  
GCACAAGGGATGCGGGCCCTCCCGCCGAGCGACCTCCAGAGCCTGGGCTACTGCATGCT  
GAAGTGGCTCTACGGGTTTCTGCCATGGACAAATTGCCTTCCCAACACTGAGGACATCAT  
GAAGCAAAAACAGAAGTTTGTGTGATAAGCCGGGGCCCTTCGTGGGACCCTGCGGTCACTG  
GATCAGGCCCTCAGAGACCCTGCAGAAGTACCTGAAGGTGGTGTGATGGCCCTCACGTATGA  
GGAGAAGCCGCCCTACGCCATGCTGAGGAACAACCTAGAAGCTTTGCTGCAGGATCTGCG  
TGTGTCTCCATATGACCCCATTTGGCCTCCCGATGGTGCCCTAGGTGGAATCCAGAACTTT  
CCATTTGCAGTGTGCAACAGAAAAAAAATGAAGCAATGTGACTCAAGGCCTGCTGTTTA  
ATCACAGATAAGCTTCTAGAACAAGCCCTGGAATGTGCATTCTGCCACTGGTTTCAGGA  
TACTCATCAGTCCTGATTAGCCTCCGGAGGGCCCCAGTTTCCCTCCCGTGAATGTGAAGT  
TCCCCATCTTGGTGGCCTGCCCTTCAGCCAGTGTCTTAGCAAAGCTGGATGGGGTTGGGC  
CGGCCACAGGGGGGACCCCTCCTACCCTTGACTCCTCTGTGCTTTGGTAATAAATTGTT  
TTACCAGAG

>gi|7705993|gb|NP\_057524.1|LOC51231 474aa linear VRK3 for  
vaccinia related kinase 3 [Homo sapiens].

MISFCPCGKSIQAAFKFCPYCGNSLPVEEHVGSQTFVNPVHVSFQGSKRGLNSSFETSP  
KKVKWSSTVTSPLSLFSDGDSSEEDTLSSSERSKSGSRPPTPKSSPQKTRKSPQVTR  
GSPQKTSCSPQKTRQSPQTLKRSRVTTSLALPTGTVLTDKSGRQWKLKSFQTRDNQGIL  
YEAAPTSTLTCDSPQKQKFSCLKDAKDGRLEFNEQNFQRAAKPLQVNWKKLYSTPLLA  
IPTCMGFGVHQDKYRFLVLP SLGRSLQ SALDVSPKHVLSERSVLQVACRLLDALFLHEN  
EYVHGNVTAENIFVDPEDQSQVTLAGYGFAFRYCPSGKHVAYVEGSRSPHEGDLEFI SMD  
LHKGCGPSRRSDLQSLGYCMLKWLYGFLPWTNCLPNTEDIMKQKQKFVDKPGPFVGPCH  
WIRPSETLQKYLKVVMALTYEEKPPYAMLRNNLEALLQDLRVSPYDPIGLPMVP

>gi|27479296|gb|XM\_114075.2|TCEA3 1543bp mRNA Homo sapiens  
transcription elongation factor A (SII), 3 (TCEA3), mRNA.

CGCCCCCGCCGGGCGTGTGTGTGTCGTGTGTTGGGGCCCCGCGGGGTGCGCGCCCTCC  
GCCTTCGCGCCTCCTGCCCCCGAGGCCCTACTGCTGCCCTGTGCCCTCGCCCCGCCGG  
GCGTCGCGGGCCAACATGGGCCAGGAAGAGGAGCTGCTGAGGATCGCCAAAAGCTGGAG  
AAGATGGTGGCCAGGAAGAACACGGAAGGGGCCCTGGACCTTCTGAAGAAGCTGCACAGC  
TGCCAGATGTCCATCCAGCTACTACAGACAACCAGGATTGGAGTTGCTGTTAATGGGGTC  
CGCAAGCACTGCTCAGACAAGGAGGTGGTGTCTTGGCCAAAGTCCTTATCAAAAAGTGG  
AAGCGGCTGCTAGACTCCCCTGGACCCCCAAAAGGAGAAAAAGGAGAGGAAAGAGAAAAG  
GCAAAGAAGAAGGAAAAAGGGCTTGAGTGTTTCACTGGAAGCCAGAAGCAGGCCTTTCT  
CCACCAAGGAAAAAACGAGAAGACCCCAAAACCAGGAGAGACTCTGTGGACTCCAAGTCT  
TCTGCCTCCTCCTCTCAAAAAGACCATCGGTGGAAAGATCAAACAGCAGCAAATCAAAA  
GCGGAGAGCCCCAAAACACCTAGCAGCCCCTTGACCCCCACGTTTGCCTCTTCCATGTGT



- 163 -

CTCCTGGCCCCCTGCTATCTCACAGGGGACTCTGTCCGGGACAAGTGTGTGGAGATGCTG  
TCAGCAGCCCTGAAGGCGGACGATGATTACAAGGACTATGGAGTCAACTGTGACAAGATG  
GCATCAGAAATCGAAGATCATATCTACCAAGAGCTCAAGAGCACGGACATGAAGTACCGG  
AACCGCGTGCGCAGCCGCATAAGCAACCTCAAGGACCCCAGGAACCCCGGCCTGCGGCGG  
AACGTGCTCAGTGGGGCCATCTCCGCAGGGCTTATAGCCAAGATGACGGCAGAGGAAATG  
GCCAGTGATGAACTGAGGGAGTTGAGGAATGCCATGACCCAGGAGGCCATCCGTGAGCAC  
CAGATGGCCAAGACTGGCGGCACCACCACTGACCTCTTCCAGTGACAGCAAATGCAAGAAG  
AAGAACTGCACCTATAACCAGGTGCAGACACGCAGTGCTGATGAGCCCATGACTACCTTT  
GTCTTATGCAATGAATGTGGCAATCGCTGGAAGTTCTGCTGATGGAACAGCCAGCCATGA  
ACAAGGTGAGGAAGAAGAAAGAGGAAGCGCTGAATTATCTGAACTGGAGAAGCAATAAAA  
ATTAAAGTGAAAGGAAAATACTGAACTCTGTCTGAGTGGGATGGTATGAGTTAGAGGAAGA  
ATTCTCTTGCAAATTAATAATCGGTCATTAGAAACAATTGGTTAATGGGGGAGCCTAATT  
GGAGAATGATGCTGAGAATTTGTATTGATGAACCTCTTTTAGAACTGCAGAGGGCTGGG  
CACGGTGGTTTTATGGCTGTAATCTGCAAACCTCTGGGAGGCTGAGGTGGGAGAATCGCTTA  
ACCCAGAAAGTTTGAGTCCAGCCCAGGCAACACAGCAAGACCC

>gi|20473950|gb|XP\_114075.1|TCEA3 348aa linear similar to  
Transcription elongation factor A protein 3 (Transcription  
elongation factor S-II protein 3) (Transcription elongation  
factor TFIIS.h) [Homo sapiens].

MGQEEELLRIAKKLEKMVARKNTEGALDLLKKLHSCQMSIQLLQTTRIGVAVNGVRKHCS  
DKEVVSIAKVLIKNWKRLLDSPGPPKGEKGEEREKAKKKEKGLECSDWKPEAGLSPPRKK  
REDPKTRRDSVDSKSSASSSPKRPSVERSNSSKSKAESPKTPSSPLTPTFASSMCLLAPC  
YLTGDSVRDKCVEMLSAALKADDDYKDYGVNCDKMASEIEDHIYQELKSTD MKYRNRVRS  
RISNLKDPRNPGLRRNVLSGAI SAGLIAKMTAEEMASDELRELRNAMTQEAIREHQMAKT  
GGTTTDLFQCSKCKKKNCTYNQVQTRSADPMTTFVLCNECGNRWKFC

>gi|21314607|gb|NM\_003342.2|UBE2G1 2430bp mRNA Homo sapiens  
ubiquitin-conjugating enzyme E2G 1 (UBC7 homolog, C. elegans)  
(UBE2G1), mRNA.

ACCGGCAGCGAGGCGCCGCTCCCGCCGCCTCAGCCCGGCCTTCCTCGGCTCCGGCGCTCC  
GGTCGCGGGGCCCCGGGTTCCTCGGCACACCCCGCTCCAGCCGCCCCCAGAGCCTGTCCCC  
AGCCCTTCGGAAGCCCCGGCGCCAGCCCGGGCCCTCGGCAGGGAGGATGACGGAGCTGCA  
GTCGGCACTGCTACTGCGAAGACAGCTGGCAGA ACTCAACAAAAATCCAGTGGAAGGCTT  
TTCTGCAGGTTTAAATAGATGACAATGATCTCTACCGATGGGAAGTCCTTATTATTGGCCC  
TCCAGATACACTTTATGAAGGTGGTGTTTTAAAGGCTCATCTTACTTTCCCAAAAGATTA  
TCCCCCTCCGACCTCCTAAAATGAAATTCATTACAGAAATCTGGCACCCAAATGTTGATAA  
AAATGGTGATGTGTGCATTTCTATTCTTCATGAGCCTGGGGAAGATAAGTATGGTTATGA  
AAAGCCAGAGGAACGCTGGCTCCCTATCCACACTGTGGAAACCATCATGATTAGTGT CAT  
TTCTATGCTGGCAGACCCTAATGGAGACTCACCTGCTAATGTTGATGCTGCGAAAGAATG  
GAGGGAAGATAGAAATGGAGAATTTAAAAGAAAAGTTGCCCGCTGTGTAAGAAAAAGCCA  
AGAGACTGCTTTTGTAGTGACATTTATTTAGCAGCTAGTAACTTCACTTATTTTCAGGGTCT  
CCAATTGAGAAACATGGCACTGTTTTTCTGCACTCTACCCACCTATTGCTGGACTTCTG  
TTGTACAAGTTGGCAAACACTGGCTGGAACTGGGCTGCAATAAAACATGCCAGTTATCAA  
TGCTGACAAGAGCCTAACAAGTGCCAACTTACAGATGATTACGCATTTTGAATTCTAATG  
AACTGTTTTTAACCTTCAGGAAGAATTGTAAAGACCTGTACATAGCACAAACATGATCCGGA  
TAATATATATACTGTTTCATGTACATCCACAAATACACCTTGTACCAAATAATGCTTTCTT  
GTAGTAGAATAAGAATCGTGTAATTTCTAAGAGATTTT TAGCAGGTTTTCTTTCTTATTCA  
TTGTTTCTTATCAGTTTAAAAGGATTCCTTTAAGCATGTCAGATGAAAAGCAATTAGGAT

- 164 -

TAAAAGTTTCCATTTAATTTCCCTTAAACCCTTGAGGCTTCATTAAACTCTTTTCACTTA  
CTAAACTTTTGTATCTTCTTTGTTTTGACACACTCCCCTTTGCTTTTATCTCTTACCTGC  
CAGAATGTTCTCAAATGATTTAGTTCAAATACTGAAATACTTAATGAGCAATTACTTGAT  
TTTTAATGATGACTTCGAAGGAGTCATCACTAGGTGCTTTGTCCTTTTTTGTATTCTAGTT  
GCACCCACCTCTTGGATTGGATATAGCAATAACATTTATTGGCCGTTGTGAGCTCTTGAT  
CCCAGTCATTACCCCTGAGAACTAAAAATAGATGGTTCTTAATTCAACTTACTGAAAATT  
TCCCCAAACAATAGCAAATCTGACTTTTCCCTCTTCAGTTGCCTGGTATTAAGGTTGGAT  
AAATGAAGCATGCACAGCTACAGGCTTTCTACTTAACTTCTGGGTTTGCTATTACAAATC  
CTATTTACTCTCATAACCCTTCTCCTTAGTCCTTCATATTTCTCTGCCTCTATTCTTCTAT  
ACTGCAGATTTTTCTCACCTATTGTACAAAGAAATTGCGATGTATATTTTCATGTAATTT  
GATTTTGGAAATTCTGTACCTTATGTAGTGAGTTCCTCCAAAATATAATTTTTTTTCAAT  
AATTGTCAAGTTGTTGGCTTTTATTGTATTGAATGAAGGCTATAATACTGAGTGCCAGAG  
AAGTGGTTTAGGAAAATCTCAGGTTGATTCCCTTATGCAAATGAACTTTTAATACTTGAAA  
ATCATATGGCCATGGCAGTATATGTATTTGGTTCTATCTAGATTCTTCTGTGAATCTAAA  
AGCATTACAGGGGTAAATGCTTTGCTATTTGACGTATAGATCCCGTCACTAACAATAGTA  
CACTTGGATGTGATTAATGTTTGAGCTTCAATATATTTTCATATCATAAGTTTCTAAAA  
CAACTTCAGCAAATGGTAAAATGAACATGTGCAGTGTTAAAGGCAGGCCTTAGGCTCCTT  
CATGTTTGTGTGAGGTTGTGTGTGGGAAGTAGTCTTTGGCTTATAAGGGATAGAACTTG  
AGACAGTAGCAGATGGGACATGGTGTGTGATTGTGAGAATCAGTGAGAATTCGTGCATCT  
CTGCTCTGTGGGGTTTGGAGAAATGCTTTGGCAGAAGAGTGAAAGAACTCCTGCCAAGAG  
CCCAGACCTCTACAAACGTTGTATGTCTTTTTTTAAGCAGAAATAAAATGGTTGAGGACG  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAA

>gi|13489085|gb|NP\_003333.1|UBE2G1 170aa linear ubiquitin-  
conjugating enzyme E2G 1 (UBC7 homolog, *C. elegans*);  
Ubiquitin-conjugating enzyme E2G (UBC7, *C. elegans*, human  
homolog of); ubiquitin-conjugating enzyme E2G (homologous to  
*C. elegans* UBC7); ubiquitin-conjugating enzyme E2G 1  
(homologous to *C. elegans* UBC7) [*Homo sapiens*].

MTELQSALLLRRQLAELNKNPVEGFSAGLIDDNDLYRWEVLIIGPPDTLYEGGVFKAHLT  
FPKDYPLRPPKMKFITEIWHPNVDKNGDVCISILHEPGEDKYGYEKPEERWLPPIHTVETI  
MISVISMLADPNGDSPANVDAAKEWREDRNGEFKRKVARCVRSQETAFAE

>gi|21361498|gb|NM\_015670.2|SEN3 2258bp mRNA *Homo sapiens*  
sen3/SUMO-specific protease 3 (SEN3), mRNA.

GAAGCTTGAGGCCGAGACGCCCGCTTCGGGCCCCGTCGCCCGGCTTCCCCGCTCCCCGG  
GTACTGGAAGATGAAAGAGACTATACAAGGGACCGGGTCTTGGGGGCTGAGCCTCCTGG  
ACCCGGCATACCCCCAGCTTACTCAAGTCCCAGGCGGGAGCGTCTTCGTTGGCCCCCACC  
TCCCAAACCCCGACTCAAGTCAGGTGGAGGTTTGGGCCAGATCCTGGGTGAGGACCAC  
AGTGCCAGCCAGACGCCTCCCTGTCCCCGACCTCTTTTGATGCCTCAGCAAGTGAAGA  
GGAGGAAGAAGAGGAGGAGGAGGATGAAGATGAAGAGGAGGAAGTGGCAGCTTGGAG  
GCTGCCCCCAAGATGGAGTCAGCTGGGAACCTCCAGCGGCCCGCCCTTCCCGCCCCAC  
TCATCGAAAAACCTGCTCACAGCGCCGCCGAGCCATGAGAGCCTTCCGGATGCTGCT  
CTACTCAAAAAGCACCTCGCTGACATTCCACTGGAAGCTTTGGGGGCGCCACCGGGGCCG  
GCGGCGGGGCTCGCACACCCCAAGAACCATCTTTCACCCAGCAAGGGGGTGGACGCC  
ACAGGTGCCATCCCCCTGTTGTCTGTTTTGACTCCCCCGGGGGCCACCTCCACCCCGGCT  
GGGTCTGCTAGGTGCTCTCATGGCTGAGGATGGGGTGAGAGGGTCTCCACCAGTGCCTC  
TGGGCCCCCATGGAGGAAGATGGACTCAGGTGGACTCCAAAGTCTCCTCTGGACCCTGA  
CTCGGGCCTCTTTCATGTACTCTGCCCAACGGTTTTGGGGGACAATCTGGGCCAGAAGG



- 165 -

GGAGCGCAGCTTGGCACCCCTGATGCCAGCATCCTCATCAGCAATGTGTGCAGCATCGG  
GGACCATGTGGCCAGGAGCTTTTTTCAGGGCTCAGATTTGGGCATGGCAGAAGAGGCAGA  
GAGGCCTGGGGAGAAAGCCGGCCAGCACAGCCCCCTGCGAGAGGAGCATGTGACCTGCGT  
ACAGAGCATCTTGGACGAATTCCTTCAAACGTATGGCAGCCTCATACCCCCTCAGCACTGA  
TGAGGTAGTAGAGAAGCTGGAGGACATTTTCCAGCAGGAGTTTCCACCCCTTCCAGGAA  
GGCCTGGTGTTCAGCTGATCCAGTCTTACCAGCGGATGCCAGGCAATGCCATGGTGAG  
GGGCTTCCGAGTGGCTTATAAGCGGCACGTGCTGACCATGGATGACTTGGGGACCTTGTA  
TGGACAGAACTGGCTCAATGACCAGGTGATGAACATGTATGGAGACCTGGTTCATGGACAC  
AGTCCCTGAAAAGGTGCATTTCTTCAATAGTTTCTTCTATGATAAACTCCGTACCAAGGG  
TTATGATGGGGTGAAAAGGTGGACCAAAAACGTGGACATCTTCAATAAGGAGCTACTGCT  
AATCCCCATCCACCTGGAGGTGCATTGGTCCCTCATCTCTGTTGATGTGAGGCGACGCAC  
CATCACCTATTTTGA CTGCGAGCGTACCCTAAACCGCCGCTGCCCTAAGCATATTGCCAA  
GTATCTACAGGCAGAGGCGGTAAAGAAAGACCGACTGGATTTCCACCAGGGCTGGAAAGG  
TTACTTCAAATGAATGTGGCCAGGCAGAATAATGACAGTGACTGTGGTGCTTTTGTGTT  
GCAGTACTGCAAGCATCTGGCCCTGTCTCAGCCATTGAGCTTCACCCAGCAGGACATGCC  
CAAACCTTCGTGCGGCAGATCTACAAGGAGCTGTGTCACTGCAAACCTCACTGTGTGAGCCTC  
GTACCCAGACCCCAAGCCCATAAATGGGAAGGGAGACATGGGAGTCCCTTCCCAAGAAA  
CTCCAGTTCCCTTCTCTCTTGCCTCTTCCCACTCACTTCCCTTTGGTTTTTTCATATTTA  
AATGTTTCAATTTCTGTATTTTTTTTTTCTTTGAGAGAATACTTGTGATTTCTGATGTGC  
AGGGGGTGGCTACAGAAAAGCCCTTTCTTCTCTGTTTGCAGGGGAGTGTGGCCCTGTG  
GCCTGGGTGGAGCAGTCATCCTCCCCCTTCCCCGTGCAGGGAGCAGGAAATCAGTGCTGG  
GGGTGGTGGGCGGACAATAGGATCACTGCCTGCCAGATCTTCAAACTTTTATATATATAT  
ATATATATATATATATATATATAAAATATATAAATGCCACGGTCCTGCTCTGGTCAATA  
AAGGATCCTTTGTTGATACGTAAAAA

>gi|21361499|gb|NP\_056485.2|SEN3 574aa linear sentrin/SUMO-  
specific protease 3 [Homo sapiens].

MKETIQGTGSWGPEPPPGIIPPAYSSPRRERLRWPPPPKPRLKSGGGFGPDGSGTTVPA  
RRLPVPRPSFDASASEEEEEEEEEDEDEEEVAAWRLPPRWSQLGTSQRPRPSRPTHK  
TCSQRRRRAMRAFRMLLYSKSTSLTFHWKLWGRHRGRRLGLAHPKNHLSPOQGGATPQVP  
SPCCRFDSPRGPPPPRLGLLGALMAEDGVRGSPVPSGPPMEEDGLRWTPKSPLDPSGL  
LSCTLPNGFGGQSGPEGERSLAPPDASILISNVCSIGDHVAQELFQGSDDLGMEEAERPG  
EKAGQHSPLREEHVTCVQSILDEFLQTYGSLIPLSTDEVVEKLEDIFQQEFSTPSRKGLV  
LQLIQSYQRMPPGNAMVRGFRVAYKRHLVLTMDLGLTYGQNLNDQVMNMYGDLVMDTVPE  
KVHFFNSFFYDKLRTKGYDGVKRWTKNVDIFNKELLIPIHLEVHWSLISVDVRRRTITY  
FDSQRTLNRRCPKHIAKYLAQAEAVKKDRDLDFHQGWKGYFKMNVARQNNDSDCGAFVLQYC  
KHLALSQPFSTQQDMPKLRRQIYKELCHCKLTV

>gi|5803166|gb|NM\_006802.1|SF3A3 2733bp mRNA Homo sapiens  
splicing factor 3a, subunit 3, 60kDa (SF3A3), mRNA.

AAGGGAAGATGGAGACAATACTGGAGCAGCAGCGGCGCTATCATGAGGAGAAGGAACGGC  
TCATGGACGTCATGGCTAAAGAGATGCTCACCAAGAAGTCCACGCTCCGGGACCAGATCA  
ATTCTGATCACCGCACTCGGGCCATGCAAGATAGGTATATGGAGGTGAGTGGGAACCTGA  
GGGATTTGTATGATGATAAGGATGGATTACGAAAGGAGGAGCTCAATGCCATTTCCAGGAC  
CCAATGAGTTTGCTGAATTCTATAATAGACTCAAGCAAATAAAGGAATTCACCCGGAAGC  
ACCCAAATGAGATCTGTGTGCCAATGTGAGTGGAAATTTGAGGAACTCCTGAAGGCTCGAG  
AGAATCCAAGTGAAGAGGCACAAAACCTTGGTGGAGTTCACAGATGAGGAGGGATATGGTC  
GTTATCTCGATCTCCATGACTGTTACCTCAAGTACATTAACCTGAAGGCATCTGAGAAGC  
TGGATTATATCACATACCTGTCCATCTTTGACCAATTATTTGACATTCCTAAAGAAAGGA

- 166 -

AGAATGCAGAGTATAAGAGATACCTAGAGATGCTGCTTGAGTACCTTCAGGATTACACAG  
ATAGAGTGAAGCCTCTCCAAGATCAGAATGAACTTTTTGGGAAGATTTCAGGCTGAGTTTG  
AGAAGAAATGGGAGAATGGGACCTTTCCTGGATGGCCGAAAGAGACAAGCAGTGCCCTGA  
CCCATGCTGGAGCCCATCTTGACCTCTCTGCATTCTCCTCCTGGGAGGAGTTGGCTTCTC  
TGGGTTTGGACAGATTGAAATCTGCTCTCTTAGCTTTAGGCTTGAAATGTGGCGGGACCC  
TAGAAGAGCGAGCCAGAGACTATTCAGTACCAAAGGAAAGTCCCTGGAGTCACTTGATA  
CCTCTTTGTTTGCCAAAAATCCCAAGTCAAAGGGCACCAAGCGAGACACTGAAAGGAACA  
AAGACATTGCTTTTCTAGAAGCCCAGATCTATGAATATGTAGAGATTCTCGGGGAACAGC  
GACATCTCACTCATGAAAATGTACAGCGCAAGCAAGCCAGGACAGGAGAAGAGCGAGAAG  
AAGAGGAAGAAGAGCAGATCAGTGAGAGTGAGAGTGAAGATGAAGAGAACGAGATCATT  
ACAACCCCAAAAACCTGCCACTTGGCTGGGATGGCAAACCTATTCCTACTGGCTGTATA  
AGCTTCATGGCCTAAATATCAACTACAACCTGTGAGATTTGTGGAACTACACCTACCGAG  
GGCCCAAAGCCTTCCAGCGACACTTTGCTGAATGGCGTCATGCTCATGGCATGAGGTGTT  
TGGGCATCCCAAATACTGCTCACTTTGCTAATGTGACACAGATTGAAGATGCTGTCTCCT  
TGTGGGCCAAACTGAAATTGCAGAAGGCTTCAGAACGATGGCAGCCTGACACTGAGGAAG  
AATATGAAGACTCAAGTGGGAATGTTGTGAATAAGAAGACATACGAGGATCTGAAAAGAC  
AAGGACTGCTCTAGTGTTGAGGGATGTAGCTCAGCTTTTGGGCTAGCCCAGGCTTCCCTA  
AGATCTGCTTTTTTCTATTTCTCCCAACCAAATCCTCTTAAAGACCCTTTGCTATGTAGTC  
TCATGGTCTAGCATGCATCTTGTAGAAACAAGGCATGCTGGCAGATTGCAGGGTTGAGAT  
GTGTTTTATCTGTTTTATATTTTAAAAGATTCTGCCAGAAAATAAAACCAGACCTTGTT  
TAAAGCCCAGGGTTATGGACCAACTCAGTGCTTCAGGTCTTAATGCCTCCATACCTCTTC  
CTCACCAACTTTACTAGTAGCTGAGATTTAATGGGCACCTATTATGCTACATATCATGTT  
AGGTAAATCTGACCTGACCTCTTTCCCCACCCTCCTTTGTTGCTGCTTCCCTGAATGAGT  
ATTACCCCAAGGATGAGGTCTGCCATCAGCTTAGTTAGCCATTGATGCAAATACTAGGGAA  
AGACTAGGAGGATGAGCCAGGGTTGCTACTAAGGACTAAGTGTCGCACCAAGGTTTGCCT  
TTTGTATTTGCATAAAGAAAGGAGTTGGAGCTGGGTGCAGTGGCTTGTGCCTGTAGTCCC  
AGCTACTTGGGAGGCTGAGGCAGGAGGGTTGCTTGAGACTAGCCTAGGTAACATAGTGAG  
ACCCTGTCTCATTAAAAAAGGCATGGTGGCACGCACTGTAGTCCCAGCTA  
CTCAGGAGACTGAGGCTAGAAGATCCTTTGAACCTAGGAGTTTGAGACCAGCCTGGGCGA  
TATAGTGAGGCCCCATCTCAAAAAAAGCGGGGGGGGAGTTGGGCTGTGTTG  
GAATGGGCCTGCAGCCCAACAAACAAGGGAAGTAGGACCGACAGTGACTTCACCAGCTTG  
CTAGGTGAGAATGAGAGACTGGTGGGTCTGTCTACCTGTTTCTTCTACAAGATCCCTATT  
TGACTGTAAAAGTAGCTAATACTCACATGTTCTCCAATCCCAGGTAGCCATGGTAGAGTT  
GGGTAGAGTTGAGCAGCCGCCCCAGGATCCAAATGTGGTGTCTGAAATGGAAAGAACTAA  
GGCAACCAGGAAGGCACTGATCTGCCTTATAAGCACAGTCATCTGAAAGTCAGGCCTGCT  
GCAGGACAGGATCCCCCAGAGACCCCATTTGCCTCTCAACACTCAGACCTTCAACTGTTT  
TTAATAAATCTACTTTTTAAAAAATA

>gi|5803167|gb|NP\_006793.1|SF3A3 501aa linear splicing factor  
3a, subunit 3, 60kDa; pre-mRNA splicing factor SF3a (60kD)  
[Homo sapiens].

METILEQQRRYHEEKERLMDVMKEMLTKKSTLRDQINSDHRTRAMQDRYMEVSGNLRDL  
YDDKDGLRKEELNAISGPNEFAEFYNRLKQIKEFHRKHPNEICVPMSEVEFEELLKAREN  
SEEAQNLVEFTDEEGYGRYLDLHDCYLKYINLKASEKLDYITYLSIFDQLFDIPKERKNA  
EYKRYLEMLLEYLQDYTDTRVKPLQDQNELFGKIQAEEFEKKWENGTFPGWPKETSSALTHA  
GAHLDSLAFSSWEELASLGLDRLKSALLALGLKCGGTLEERAQRLFSTKGKSLESLDTS  
FAKNPKSKGTRDTERNKDIAFLEAQIYEYVEILGEQRHLTHENVQRKQARTGEEREEEE  
EEQISESESEDEENEI IYNPKNLPLGWDGKPIPYWLYKLHGLNINYNCEICGNYTYRGP

- 167 -

AFQRHFAEWRHAHGMRC LGIPNTAHFANVTQIEDAVSLWAKLKLQKASERWQPDTEEEYE  
DSSGNVNVNKKTYEDLKRQGLL

>gi|28882054|gb|NM\_005011.2|NRF1 2514bp mRNA Homo sapiens  
nuclear respiratory factor 1 (NRF1), mRNA.

GAGGCTGCGAGGAGCCGGCGCGGTTCGCAGTCTCCACGGCGCAGGCCACGGTAGCGCAGC  
CGCTCTGAGTAGAACTTCATGGAGGAACACGGAGTGACCCAAACCGAACATATGGCTACC  
ATAGAAGCACATGCAGTGGCCCAGCAAGTGCAGCAGGTCCATGTGGCTACTTACACCGAG  
CATAGTATGCTGAGTGCTGATGAAGACTCGCCTTCTTCTCCCGAGGACACCTCTTACGAT  
GACTCAGATATACTCAACTCCACAGCAGCTGATGAGGTGACAGCTCATCTGGCAGCTGCA  
GGTCCTGTGGGAATGGCCGCTGCTGCTGCTGTGGCAACAGGAAAGAAACGGAAACGGCCT  
CATGTATTTGAGTCTAATCCATCTATCCGGAAGAGGCAACAAACACGTTTGCTTCGGAAA  
CTTCGAGCCACGTTAGATGAATATACTACTCGTGTGGGACAGCAAGCTATTGTCCTCTGT  
ATCTCACCCCTCCAAACCTAACCCCTGTCTTTAAAGTGTTTGGTGACAGCACCTTTGGAGAAT  
GTGGTGCGTAAGTACAAGAGCATGATCCTGGAAGACCTGGAGTCTGCTCTGGCAGAACAC  
GCCCCCTGCGCCACAGGAGGTTAACTCAGAACTGCCGCTCTCACCATCGACGGAATTCCA  
GTCTCTGTGGACAAAATGACCCAGGCCAGCTTCGGGCATTTATCCCAGAGATGCTCAAG  
TACTCTACAGGTGCGGGGAAAACAGGCTGGGGGAAAGAAAGCTGCAAGCCCATCTGGTGG  
CCTGAAGATATCCCCTGGGCAAATGTCCGGAGTGATGTCCGCACAGAAGAGCAAAAGCAG  
AGGGTTTCATGGACCCAGGCACTACGGACCATAGTTAAAAACTGTTATAAACAGCATGGG  
CGGGAAGACCTTTTGTATGCCCTTTGAAGATCAGCAAACGCAAACACAGGCCACAGCCACA  
CATAGTATAGCTCATCTTGTACCATCACAGACTGTAGTCCAGACTTTTAGTAACCCTGAT  
GGCACTGTCTCACTTATCCAGGTTGGTACGGGGGCAACAGTAGCCACATTGGCTGATGCT  
TCAGAAATTGCCAACCACGGTCAACGTTGCCAAGTGAATTATTCTGCCGTGGCTGATGGA  
GAGGTGGAACAAAATTGGGCCACGTTACAGGGAGGTGAGATGACCATCCAGACGACGCAA  
GCATCAGAGGCCACCCAGGCGGTGGCATCGTTGGCAGAGGCCGCGAGTGGCAGCTTCTCAG  
GAGATGCAGCAGGGAGCTACAGTCACTATGGCGCTTAACAGCGAAGCTGCCGCCCATGCT  
GTCGCCACCCTGGCTGAGGCCACCTTACAAGGTGGGGGACAGATCGTCTTGTCTGGGGAA  
ACCGCAGCAGCCGTCGGAGCACTTACTGGAGTCCAAGATGCTAATGGCCTCTTTATGGCA  
GATCGTGCAGGTGCGAAGTGATCCTGACTGACAAAGCCACAGGCCTGGTCCAGATCCCT  
GTGAGCATGTACCAGACTGTGGTGACCAGCCTCGCCCAGGGCAACGGACCAGTGCAGGTG  
GCCATGGCCCCCTGTGACCACCAGGATATCAGACAGCGCAGTCACCATGGACGGCCAAGCT  
GTGGAGGTGGTGACATTGGAACAGTGACATACAGCCATATTATGGCATCGTTTTCTAGTC  
TACTTCAAATTTTTTTACACGTTTGCAGAGGTGCAATCAAATGGAATTAAGTCTCTCGAC  
TTTGGAAGGAAAGTTTTGTAAACCTTTTTTTTTTTTAAAGGAAGAAAGCGGATTTTGGA  
TTGCATTTTTTTAAAGCACCACTCTTGATTTTCTGGGATTGGTGAAGAACTGCATTGTCA  
ATTTCACTGTCCCAAAAAGCCAAATTTGTGGCAGGACTTCTTTCTGCGGAAATGTGTGTG  
TATACTTATGTGTGTGTATGTGTGAGTGTGAATATATGTATATGTGTACATATGGACATA  
CACATTTACATATATATAAAGTATATATATACATATATATATATATATATATGTATGAAACCCG  
CATGGAATTATCTGTATGAAATCAAGGTGCGCTGTGGAAACAATAATTACCCAGTTTAG  
TGGGTGGTAGGGTACGTGGCCAGACACAGTCACCCAGTTTTTTGTTTCATACCAGGGTCATG  
CGTTGAGCTACTGACAAACTCAGGCGGAGGTGACCATGCCCTTCACCAAAGCTGCCTCCC  
AGTGGCCACACAGA ACTCTCCCTGCTGGACTCACCTGAGGAAAGAGGCTCCAGCATGGGG  
TGGGTGAGAGATGTGCTTGCAAGGTCCAGGGACTGCGTGGTCTGCCAGCTGAGATGCTCC  
TCGGGCTGGCCCAGGTGCTGACCTTGCCACAGGCAGATGAATGTCTTGAAAGCTCCCGGG  
CCTCAGCCTCCCATCTCCTCTCCTTCCCAGGAATCCTTGATCTCATGACTATTAAAATGT  
TGCTCTGGTTTTTAAGGTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

- 168 -

>gi|28882055|gb|NP\_005002.2|NRF1 522aa linear nuclear  
respiratory factor 1 [Homo sapiens].

MEEHGVQTQTEHMAIEAHAVAQQVQVHVATYTEHSMLSADEDSPPSSPEDTSYDDSDILN  
STAADEVTAHLAAAGPVGMAAAAATGKKRKRPHVFESNPSIRKRQQTRLLRKLRLATLD  
EYTTTRVGQQAIVLCISPSKPNPVFKVFGAAPLENVVRKYKSMILEDLESALAEHAPAPQE  
VNSELPLTIDGIPVSVDKMTQAQLRAFIPEMLKYSTGRGKPGWGKESCKPIWWPEDIPW  
ANVRSDVRTEEQKQRVSWTQALRTIVKNCKYQHGREDLLYAFEDQQTQTQATATHSIAHL  
VPSQTVVQTFSPDGTSLIQVGTGATVATLADASELPTTVTVAQVNYSADGEVEQNW  
ATLQGGEMTIQTTQASEATQAVASLAEAAVAASQEMQQGATVTMALNSEAAAHAVATLAE  
ATLQGGGQIVLSGETAAAVGALTGVQDANGLFMADRAGRKWILTDKATGLVQIPVSMYQT  
VVTSLAQNGPQVQVAMAPVTTTRISDSAVTMDGQAVEVVTLAQ

>gi|6996000|gb|NM\_001663.2|ARF6 1806bp mRNA Homo sapiens ADP-  
ribosylation factor 6 (ARF6), mRNA.

GGCCGGAGGGAGCCCGCGCTCGGGGCGGCGGCTGGAGGCAGCGCACCGAGTTCCCGCGAG  
GATCCATGACCTGACGGGGCCCCGGAGCCCGCGCTGCCTCTCGGGTGTCTCGGGTCGGTGG  
GGAGCCCACTGCTCGCAGGCCCGGCGGGCGGGCCGGAGGGCTGCAGTCTCCCTCGCGGTGA  
GAGGAAGGCGGAGGAGCGGGAACCGCGGCGGCGCTCGCGCGGCGCCTGCGGGGGGAAGGG  
CAGTTCCGGGGCCGGGCCGCGCCTCAGCAGGGCGGCGGCTCCCAGCGCAGTCTCAGGGCCC  
GGGTGGCGGCGGCGACTGGAGAAATCAAGTTGTGCGGTGCGGTGATGCCCCAGTGAGCGGG  
GGGCCTGGGCCTCTGCCCTTAGGAGGCAACTCCACGCGAGCCGCAAAGGGCTCTCGCGG  
CCGAGAGGCTTCGTTTCGGTTTCGCGGCGGCGGCGGCGTGTGTTGGCTGAGGGGACCCGGG  
ACACCTGAATGCCCCCGGCCCGGCTCCTCCGACGCGATGGGGAAGGTGCTATCCAAAAT  
CTTCGGGAACAAGGAAATGCGGATCCTCATGTTGGGCCTGGACGCGGCGCGCAAGACAAC  
AATCCTGTACAAGTTGAAGCTGGGCCAGTCGGTGACCACCATTCCTACTGTGGGTTTCAA  
CGTGGAGACGGTGACTTACAAAATGTCAAGTTCAACGTATGGGATGTGGGCGGCCAGGA  
CAAGATCCGGCCGCTCTGGCGGCATTACTACACTGGGACCCAAGGTCTCATCTTCGTAGT  
GGACTGCGCCGACCGCGACCGCATCGATGAGGCTCGCCAGGAGCTGCACCGCATATTATCAA  
TGACCGGGAGATGAGGGACGCCATAATCCTCATCTTCGCCAACAAGCAGGACCTGCCCGA  
TGCCATGAAACCCACGAGATCCAGGAGAACTGGGCCTGACCCGGATTTCGGGACAGGAA  
CTGGTATGTGCAGCCCTCCTGTGCCACCTCAGGGGACGGACTCTATGAGGGGCTCACATG  
GTTAACCTCTAACTACAAATCTTAATGAGCATTCTCCACCCATCCCCTGGAAGGAGAGAA  
ATCAAAAACCCATTCATAGGATTATCGCCACCATCACCTCTTTCAATTGCCACTTTCTCT  
TCTTTTGAATTTGAACTCTGGAGTTACTGTTCTACAGTTTGGCGGGGACGGGGCTTGGGG  
GTTTTCTCTTTGTTTGTTCCTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT  
TTGCGTTAGGATGGCTCTGATCTGACATTTGACATGAACACAAAGTTGCCAAGATGCTCC  
TTGTTGACTTCCAGCAGAATGGGAATGGGGGAAACACAGCAGTTCTTGGGTAAAAGTCCC  
TTTGTAATAATAGGTTTGGGATTTTTTTATTTTCGAGAGAATCTTTCATTTTCTATGTAT  
GCTTTTTTCTTTTGTGCCCAGTTTCCTTATCACTTGCTGTAGATGGCTTATTTTGCATT  
CATGCAGACTATGTTGCAAGTCTGTTTCATCTAGTAACTGAAAATTATTGCTTAATCAA  
ACTGCCGTTTGTCTTTTATATTTAAGGCCTTCCCCCCCCCTTCTTATGAGTTCTAACTTA  
GTAATTTCAAATGTGACCTTTTATATCTAAGACCAGTATAGTAACTTAGCCACAGTGG  
CAAATAATGAGTAATATTGTAATATGTTCCAGTTGCACCTCAGTATGTTAAACAGGTAAT  
GTAAGAAGTTCTCTGAAATGTCAGCAAGTAAGTTCTGAAACACATCATGCATGAGTAGGA  
ATAAAC

>gi|4502211|gb|NP\_001654.1|ARF6 175aa linear ADP-ribosylation  
factor 6 [Homo sapiens].

MGKVLISKIFGNKEMRILMLGLDAAGKTTILYKLKLGQSVTTIPTVGFNVETVITYKNVKFN

- 169 -

VWDVGGQDKIRPLWRHYTGTQGLIFVVDCAADRDRIDEARQELHRIINDREMRDAIILIF  
ANKQDLDPAMKPHEIQEKLGLTRIRDRNWYVQPSCATSGDGLYEGLTWLTSNYKS

>gi|23510442|gb|NM\_003809.2|TNFSF12 1407bp mRNA Homo sapiens  
tumor necrosis factor (ligand) superfamily, member 12  
(TNFSF12), transcript variant 1, mRNA.

CTCTCCCCGGCCCGATCCGCCCCGCGGCTCCCCCTCCCCCGATCCCTCGGGTCCCCGGGAT  
GGGGGGGCGGTGAGGCAGGCACAGCCCCCGCCCCCATGGCCGCCGTCGGAGCCAGAGG  
CGGAGGGGGCGCCGGGGGGAGCCGGGCACCGCCCTGCTGGTCCCGCTCGCGCTGGGCCTG  
GGCCTGGCGCTGGCCTGCCTCGGCCTCCTGCTGGCCGTGGTCAGTTTGGGGAGCCGGGCA  
TCGCTGTCCGCCCAGGAGCCTGCCAGGAGGAGCTGGTGGCAGAGGAGGACCAGGACCCG  
TCGGAAGTGAATCCCCAGACAGAAGAAAGCCAGGATCCTGCGCCTTTCCTGAACCGACTA  
GTTTCGGCCTCGCAGAAGTGCACCTAAAGGCCGGAACACGGGCTCGAAGAGCGATCGCA  
GCCCATTATGAAGTTCATCCACGACCTGGACAGGACGGAGCGCAGGCAGGTGTGGACGGG  
ACAGTGAGTGGCTGGGAGGAAGCCAGAATCAACAGCTCCAGCCCTCTGCGCTACAACCGC  
CAGATCGGGGAGTTTATAGTCACCCGGGCTGGGCTCTACTACCTGTACTGTACAGGTGCAC  
TTTGATGAGGGGAAGGCTGTCTACCTGAAGCTGGACTTGCTGGTGGATGGTGTGCTGGCC  
CTGCGCTGCCTGGAGGAATTCTCAGCCACTGCGGCGAGTTCCTCGGGCCCCAGCTCCGC  
CTCTGCCAGGTGTCTGGGCTGTTGGCCCTGCGGCCAGGGTCCCTCCCTGCGGATCCGCACC  
CTCCCCTGGGCCCCTCTCAAGGCTGCCCCCTTCTCACCTACTTCGGACTCTTCCAGGTT  
CACTGAGGGGCCCTGGTCTCCCCGCAGTCGTCCAGGCTGCCGGCTCCCCCTCGACAGCTC  
TCTGGGCACCCGGTCCCCCTCTGCCCCACCCTCAGCCGCTCTTTGCTCCAGACCTGCCCT  
CCCTCTAGAGGCTGCCTGGGCCTGTTACAGTGTTTTCCATCCACATAAATACAGTATTC  
CCACTCTTATCTTACAACCTCCCCACCGCCCACTCTCCACCTCACTAGCTCCCCAATCCC  
TGACCCTTTGAGGCCCCCAGTGATCTCGACTCCCCCCTGGCCACAGACCCCCAGGGCATT  
GTGTTCACTGTACTCTGTGGGCAAGGATGGGTCCAGAAGACCCCACTTCAGGCACTAAGA  
GGGGCTGGACCTGGCGGCAGGAAGCCAAAGAGACTGGGCCTAGGCCAGGAGTTCCCAAAT  
GTGAGGGGCGAGAAACAAGACAAGCTCCTCCCTTGAGAATTCCCTGTGGATTTTAAAC  
AGATATTATTTTATTATTATTGTGACAAAATGTTGATAAATGGATATTAAATAGAATAA  
GTCATAAAAAAAAAAAAAAAAAAAAAA

>gi|4507597|gb|NP\_003800.1|TNFSF12 249aa linear tumor necrosis  
factor (ligand) superfamily, member 12 isoform 1 precursor;  
APO3/DR3 ligand; TNF-related WEAK inducer of apoptosis [Homo  
sapiens].

MAARRSQRRRGRRGEPGTALLVPLALGLGLALACLGLLLAVVSLGSRASLSAQEPAQEEL  
VAEEDQDPSELNPQTEESQDPAPFLNRLVPRRSAPKGRKTRARRAIAAHYEVHPRPGQD  
GAQAGVDGTVSGWEEARINSSSPLRYNRQIGEFIVTRAGLYLYLCQVHFDEGKAVYLLKD  
LLVDGVLALRCLEEFSAATAASSLGPQLRLCQVSGLLALRPGSSLRIRTLPPWAHLKAAPFL  
TYFGLFQVH

>gi|11496238|gb|NM\_021975.1|RELA 2444bp mRNA Homo sapiens v-  
rel reticuloendotheliosis viral oncogene homolog A, nuclear  
factor of kappa light polypeptide gene enhancer in B-cells 3,  
p65 (avian) (RELA), mRNA.

GGCACGAGGCGGGGCGGGTTCGAGCTGGGCCCCGCGGCATGGACGAACTGTTCCCCCTCA  
TCTTCCCGGCAGAGCAGCCCAAGCAGCGGGGCATGCGCTTCCGCTACAAGTGCGAGGGGC  
GCTCCGCGGGCAGCATCCCAGGCGAGAGGAGCACAGATACCACCAAGACCCACCCACCA  
TCAAGATCAATGGCTACACAGGACCAGGGACAGTGCGCATCTCCCTGGTCACCAAGGACC  
CTCCTCACCGGCCTCACCCCCACGAGCTTGTAGGAAAGGACTGCCGGGATGGCTTCTATG

- 170 -

AGGCTGAGCTCTGCCCCGACCGCTGCATCCACAGTTTCCAGAACCTGGGAATCCAGTGTG  
TGAAGAAGCGGGACCTGGAGCAGGCTATCAGTCAGCGCATCCAGACCAACAACAACCCCT  
TCCAAGTTCTTATAGAAGAGCAGCGTGGGGACTACGACCTGAATGCTGTGCGGCTCTGCT  
TCCAGGTGACAGTGCGGGACCCATCAGGCAGGCCCCCTCCGCCTGCCGCCTGTCCTTTCTC  
ATCCCATCTTTGACAATCGTGCCCCCAACACTGCCGAGCTCAAGATCTGCCGAGTGAACC  
GAAACTCTGGCAGCTGCCTCGGTGGGGATGAGATCTTCTACTGTGTGACAAGGTGCAGA  
AAGAGGACATTGAGGTGTATTTACGGGACCAGGCTGGGAGGCCCGAGGCTCCTTTTCGC  
AAGCTGATGTGCACCGACAAGTGGCCATTGTGTTCCGGACCCCTCCCTACGCAGACCCCA  
GCCTGCAGGCTCCTGTGCGTGTCTCCATGCAGCTGCGGCGGCCTTCCGACCGGGAGCTCA  
GTGAGCCCATGGAATTCCAGTACCTGCCAGATACAGACGATCGTCACCGGATTGAGGAGA  
AACGTAAAAGGACATATGAGACCTTCAAGAGCATCATGAAGAAGAGTCCTTTCAGCGGAC  
CCACCGACCCCCGGCCTCCACCTCGACGCATTGCTGTGCCTTCCCGCAGCTCAGCTTCTG  
TCCCCAAGCCAGCACCCAGCCCTATCCCTTTACGTCATCCCTGAGCACCATCAACTATG  
ATGAGTTTCCCACCATGGTGTTCCTTCTGGGCAGATCAGCCAGGCCTCGGCCTTGGCCC  
CGGCCCCCTCCCCAAGTCCTGCCCCAGGCTCCAGCCCCTGCCCCCTGCTCCAGCCATGGTAT  
CAGCTCTGGCCCAGGCCCCAGCCCCTGTCCAGTCCCTAGCCCCAGGCCCTCCTCAGGCTG  
TGGCCCCACCTGCCCCCAAGCCACCCAGGCTGGGGAAGGAACGCTGTCAGAGGCCCTGC  
TGCAGCTGCAGTTTGATGATGAAGACCTGGGGGCCTTGCTTGGCAACAGCACAGACCCAG  
CTGTGTTTCAAGACCTGGCATCCGTCGACAACCTCCGAGTTTCAGCAGCTGCTGAACCAGG  
GCATACCTGTGGCCCCCACACAACCTGAGCCCATGCTGATGGAGTACCCTGAGGCTATAA  
CTCGCCTAGTGACAGCCAGAGGCCCCCGACCCAGCTCCTGCTCCACTGGGGGCCCCGG  
GGCTCCCCAATGGCCTCCTTTCAGGAGATGAAGACTTCTCCTCCATTGCGGACATGGACT  
TCTCAGCCCTGCTGAGTCAGATCAGCTCCTAAGGGGGTGACGCCTGCCCTCCCCAGAGCA  
CTGGTTGCAGGGGATTGAAGCCCTCCAAAAGCACTTACGGATTCTGGTGGGGTGTGTTCC  
AACTGCCCCCAACTTTGTGGATGTCTTCTCTCTTTTGGAGGTGCTTAAGCAGAAGCATTAACCTTCT  
CTGGAAAGGGGGGAGCTGGGGAAACTCAAACCTTTTCCCCTGTCCTGATGGTCAGCTCCCT  
TCTCTGTAGGGAACCTGTGGGGTCCCCCATCCCCATCCTCCAGCTTCTGGTACTCTCCTAG  
AGACAGAAGCAGGCTGGAGGTAAGGCCTTTGAGCCACAAAGCCTTATCAAGTGTCTTCC  
ATCATGGATTCAATTACAGCTTAATCAAAATAACGCCCCAGATACCAGCCCCTGTATGGCA  
CTGGCATTGTCCCTGTGCCTAACACCAGCGTTTGAGGGGCTGCCTTCTGCCCCTACAGAG  
GTCTCTGCCGGCTCTTTCTTGTCTCAACCATGGCTGAAGGAAACAGTGCAACAGCACTGG  
CTCTCTCCAGGATCCAGAAGGGGTTTGGTCTGGACTTCTTGTCTCTCCCTCTTCTCAAG  
TGCCTTAATAGTAGGGTAAGTTGTTAAGAGTGGGGGAGAGCAGGCTGGCAGCTCTCCAGT  
CAGGAGGCATAGTTTTTGTAGTGAACAATCAAAGCACTTGGACTCTTGCTCTTTCTACTCTG  
AACTAATAAAGCTGTTGCCAAGCTGGACGGCACGAGCTCGTGCC

>gi|11496239|gb|NP\_068810.1|RELA 537aa linear v-rel  
reticuloendotheliosis viral oncogene homolog A, nuclear factor  
of kappa light polypeptide gene enhancer in B-cells 3, p65; v-  
rel avian reticuloendotheliosis viral oncogene homolog A  
(nuclear factor of kappa light polypeptide gene enhancer in B-  
cells 3 (p65)) [Homo sapiens].

MDELFLIFPAEQPKQRGMRFRYKCEGRSAGSIPGERSTDTTKTHPTIKINGYTGPQTVR  
ISLVTKDPPHRPHPHLVGKDCRDGFYEALCPDRCIHSFQNLGIQCVKKRDLEQAIQSR  
IQTNNNPFQVPIEEQRGDYDLNAVRLCFQVTVRDPGRPLRLPPVLSHPIFDNRAPNTAE  
LKICRVNRNSGSLGGDEIFLLCDKVQKEDI EYVFTGPGWEARGSFQADVHRQVAIVFR  
TPPYADPSLQAPVRVSMQLRRPSDRELSEPMFQYLPDTPDRHRIEEKRKRTYETFKSIM



- 171 -

KKSPFSGPTDPRPPRRRIAVPSRSSASVPKPAPQYPFTSSLSTINYDEFPTMVFPSSGOI  
SQASALAPAPPQVLPQAPAPAPAPAMVSALAQAAPVPVLAPGPPQAVAPPAPKPTQAGE  
GTLSEALLQLQFDDDLGALLGNSTDPVFTDLASVDNSEFQQLLNQGIPVAPHTTEPML  
MEYPEAITRLVTAQRPPDPAPAPPLGAPGLPNGLLSGDEDFSSIADMDFSALLSQISS  
>gi|23312372|gb|NM\_001065.2|TNFRSF1A 2236bp mRNA Homo sapiens  
tumor necrosis factor receptor superfamily, member 1A  
(TNFRSF1A), mRNA.

GCTGTTGCAACACTGCCTCACTCTTCCCCCTCCACCTTCTCTCCCCCTCCTCTCTGCTTTA  
ATTTTCTCAGAATTCTCTGGACTGAGGCTCCAGTTCTGGCCTTTGGGGTTCAAGATCACT  
GGGACCAGGCCGTGATCTCTATGCCCGAGTCTCAACCCTCAACTGTCACCCCAAGGCACT  
TGGGACGTCCTGGACAGACCGAGTCCCGGGAAGCCCCAGCACTGCCGCTGCCACACTGCC  
CTGAGCCCAAATGGGGGAGTGAGAGGCCATAGCTGTCTGGCATGGGCCTCTCCACCGTGC  
CTGACCTGCTGCTGCCACTGGTGCTCCTGGAGCTGTTGGTGGGAATATACCCCTCAGGGG  
TTATTGGACTGGTCCCTCACCTAGGGGACAGGGAGAAGAGAGATAGTGTGTGTCCCCAAG  
GAAAATATATCCACCCTCAAAATAATTTCGATTTGCTGTACCAAGTGCCACAAAGGAACCT  
ACTTGTAACAATGACTGTCCAGGCCCGGGGAGGATACGGACTGCAGGGAGTGTGAGAGCG  
GCTCCTTCACCGCTTCAGAAAACCACCTCAGACACTGCCTCAGCTGCTCCAAATGCCGAA  
AGGAAATGGGTGAGGTGGAGATCTCTTCTTGACAGTGGACCGGGACACCGTGTGTGGCT  
GCAGGAAGAACCAGTACCGGCATTATTGGAGTGAAAACCTTTTCCAGTGCTTCAATTGCA  
GCCTCTGCCTCAATGGGACCGTGCACCTCTCCTGCCAGGAGAAACAGAACACCGTGTGCA  
CCTGCCATGCAGGTTTCTTTCTAAGAGAAAACGAGTGTGTCTCCTGTAGTAAGTGTAAAG  
AAAGCCTGGAGTGCACGAAGTTGTGCCTACCCAGATTGAGAATGTTAAGGGCACTGAGG  
ACTCAGGCACCACAGTGCTGTTGCCCTGGTCATTTTCTTTGGTCTTTGCCTTTTATCCC  
TCCTCTTCATTGGTTTAATGTATCGCTACCAACGGTGGAAAGTCCAAGCTCTACTCCATTG  
TTTGTGGGAAATCGACACCTGAAAAAGAGGGGGGAGCTTGAAGGAAGTACTACTAAGCCCC  
TGGCCCCAAACCAAGCTTCAGTCCCACTCCAGGCTTCACCCCCACCCTGGGCTTCAGTC  
CCGTGCCCAGTTCACCTTCACCTCCAGCTCCACCTATACCCCCGGTGAAGTGTCCCAACT  
TTGCGGCTCCCCCGCAGAGAGGTGGCACCACCCCTATCAGGGGGGCTGACCCCATCCTTGCGA  
CAGCCCTCGCCTCCGACCCCATCCCCAACCCCTTCAGAAAGTGGGAGGACAGCGCCCA  
AGCCACAGAGCCTAGACACTGATGACCCCGCGACGCTGTACGCCGTGGTGGAGAACGTGC  
CCCCGTTGCGCTGGAAGGAATTTCGTGCGGCGCCTAGGGCTGAGCGACACGAGATCGATC  
GGCTGGAGCTGCAGAACGGGCGCTGCCTGCGCGAGGCGCAATACAGCATGCTGGCGACCT  
GGAGGCGGCGCACGCCGCGGCGGAGGCCACGCTGGAGCTGCTGGGACGCGTGTCTCCGCG  
ACATGGACCTGCTGGGCTGCCTGGAGGACATCGAGGAGGCGCTTTGCGGCCCCGCGGCC  
TCCCGCCCCGCGCCAGTCTTCTCAGATGAGGCTGCGCCCCCTGCGGGCAGCTCTAAGGACC  
GTCCTGCGAGATCGCCTTCCAACCCCACTTTTTTCTGGAAAGGAGGGGTCTGAGGGGC  
AAGCAGGAGCTAGCAGCCGCTACTTGGTGCTAACCCCTCGATGTACATAGCTTTTCTCA  
GCTGCCTGCGCGCCGCGACAGTCAGCGCTGTGCGCGCGGAGAGAGGTGCGCCGTGGGCT  
CAAGAGCCTGAGTGGGTGGTTTTCGAGGATGAGGGACGCTATGCCTCATGCCGTTTTCG  
GTGTCTCACCAGCAAGGCTGCTCGGGGGCCCCCTGGTTTCGTCCCTGAGCCTTTTTCACAG  
TGCATAAGCAGTTTTTTTTGTTTTGTTTTGTTTTGTTTTGTTTTTAAATCAATCATGTT  
ACACTAATAGAACTTGGCACTCCTGTGCCCTCTGCCTGGACAAGCACATAGCAAGCTGA  
ACTGTCCTAAGGCAGGGGCGAGCACGGAACAATGGGGCCTTCAGCTGGAGCTGTGGACTT  
TTGTACATACACTAAAATTCTGAAGTTAAAGCTCTGCTCTTGGAACAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAAAAAAA

>gi|4507575|gb|NP\_001056.1|TNFRSF1A 455aa linear tumor  
necrosis factor receptor 1 precursor; tumor necrosis factor

- 172 -

receptor type 1; tumor necrosis factor-alpha receptor; tumor necrosis factor binding protein 1 [Homo sapiens].

MGLSTVPDLLLPLVLLELLVGIYPSGVIGLVPHLGDREKRDSVCPQGKYIHPQNNNSICCT  
KCHKGTYLYNDCPGPGQDTCRECESGSFTASENHLRHCLSCSKCRKEMGQVEISSCTVD  
RDTVCGCRKNQYRHYWSENLFQCFNCSLCLNGTVHLSCQEKQNTVCTCHAGFFLRENECV  
SCSNCKKSLECTKLCLPQIENVKGTEDSGTTVLLPLVIFFGLCLLSLLFIGLMYRYQRWK  
SKLYSIVCGKSTPEKEGELEGTTTKPLAPNPSFSPTPGFTPTLGFSPVPSSTFTSSSTYT  
PGDCPNFAAPRREVAPPYQGADPILATALASDPIPNPLQKWEDSAHKPQSLDTPATLY  
AVVENVPPLRWKEFVRRRLGLSDHEIDRLELQNGRCLREAQYSMLATWRRRTPRREATLEL  
LGRVLRDMDLLGCLEDIEEALCGPAALPPAPSLLR

>gi|4506738|gb|NM\_003952.1|RPS6KB2 1735bp mRNA Homo sapiens  
ribosomal protein S6 kinase, 70kDa, polypeptide 2 (RPS6KB2),  
mRNA.

AGAGACTCGTGCCGAATGGCACGAGGCCGACGGGCCCCGCGGGCCGCGCCGATGGCG  
GCCGTGTTTGGATTGGATTGGAGACGGAGGAAGGCAGCGAGGGCGAGGGCGAGCCAGAG  
CTCAGCCCCGCGGACGCATGTCCCCTTGCCGAGTTGAGGGCAGCTGGCCTAGAGCCTGTG  
GGACACTATGAAGAGGTGGAGCTGACTGAGACCAGCGTGAACGTTGGCCCAGAGCGCATC  
GGGCCCCACTGCTTTGAGCTGCTGCGTGTGCTGGGCAAGGGGGGCTATGGCAAGGTGTTT  
CAGGTGCGAAAGGTGCAAGGCACCAACTTGGGCAAAATATATGCCATGAAAGTCCTAAGG  
AAGGCCAAAATTGTGCGCAATGCCAAGGACACAGCACACACACGGGCTGAGCGGAACATT  
CTAGAGTCAGTGAAGCACCCCTTTATTTGTGGAAGTGGCCTATGCCTTCCAGACTGGTGGC  
AAACTCTACCTCATCCTTGAGTGCCTCAGTGGTGGCGAGCTCTTCACGCATCTGGAGCGA  
GAGGGCATCTTCTGGAAGATACGGCCTGCTTCTACCTGGCTGAGATCACGCTGGCCCTG  
GGCCATCTCCACTCCCAGGGCATCATCTACCGGGACCTCAAGCCCGAGAACATCATGCTC  
AGCAGCCAGGGCCACATCAAACTGACCGACTTTGGACTCTGCAAGGAGTCTATCCATGAG  
GGCGCCGTCACTCACACCTTCTGCGGCACCATTGAGTACATGGCCCCTGAGATTCTGGTG  
CGCAGTGGCCACAACCGGGCTGTGGACTGGTGGAGCCTGGGGGCCCTGATGTACGACATG  
CTCACTGGATCGCCGCCCTTTACCGCAGAGAACCAGGAAGAAAACCATGGATAAGATCATC  
AGGGGCAAGCTGGCACTGCCCCCTACCTCACCCAGATGCCCGGGACCTTGTCAAAAAG  
TTTCTGAAACGGAATCCCAGCCAGCGGATTGGGGGTGGCCAGGGGATGCTGCTGATGTG  
CAGAGACATCCCTTTTTCCGGCACATGAATTGGGACGACCTTCTGGCCTGGCGTGTGGAC  
CCCCCTTTCAGGCCCTGTCTGCAGTCAGAGGAGGACGTGAGCCAGTTTGATACCCGCTTC  
ACACGGCAGACGCCGGTGGACAGTCCTGATGACACAGCCCTCAGCGAGAGTGCCAACCAG  
GCCTTCCTGGGCTTCACATACGTGGCGCCGTCTGTCTGGACAGCATCAAGGAGGGCTTC  
TCCTTCCAGCCCAAGCTGCGCTCACCCAGGCGCTCAACAGTAGCCCCCGGGTCCCCGTC  
AGCCCCCTCAAGTTCTCCCTTTTGAGGGGTTTCGGCCCAGCCCCAGCCTGCCGGAGCCC  
ACGGAGCTACCTCTACCTCCACTCCTGCCACCGCCGCCGCCCTCGACCACCGCCCCTCTC  
CCCATCCGTCCCCCTCAGGGACCAAGAAAGTCCAAGAGGGGGCCGTGGGCGTCCAGGGCGC  
TAGGAAGCCGGGTGGGGGTGAGGGTAGCCCTTGAGCCCTGTCCCTGCGGCTGTGAGAGCA  
GCAGGACCCTGGGCCAGTTCCAGAGACCTGGGGGTGTGTCTGGGGGTGGGGTGTGAGTGC  
GTATGAAAGTGTGTGTCTGCTGGGGCAGCTGTGCCCTGAATCATGGGCACGGAGGGCCG  
CCCGCCACACCCCGCGCTCAACTGCTCCCGTGGAAGATTAAAGGGCTGAATCATG

>gi|4506739|gb|NP\_003943.1|RPS6KB2 495aa linear ribosomal  
protein S6 kinase, 70kDa, polypeptide 2; ribosomal protein S6  
kinase, 70kD, polypeptide 2; p70 ribosomal S6 kinase beta  
[Homo sapiens].

MARGRRARGAGAAAMAVFDLDLETEEGSEGEPELSPADACPLAELRAAGLEPVGHYEE



- 173 -

VELTETSVNVGPERIGPHCFELLRLVLGKGGYGKVFQVRKVQGTNLGKIYAMKVLRKAKIV  
RNAKDTAHTRAERNILES VKHPFIVELAYAFQTGGKLYLILECLSGGELFTHLEREGIFL  
EDTACFYLAIEITLALGHLHSQGI IYRDLKPENIMLSSQGHIKLTDFGLCKESIHEGAVTH  
TFCGTIEYMAPEILVRSGHNRAVDWWSLGALMYDMLTGSPPFTAENRKKTMDKIIRGKLA  
LPPYLTPDARDLVKKFLKRNPSQRIGGGPGDAADVQRHPFFRHMNWDDLAWRVDP PFRP  
CLQSEEDVSQFDTRFTRQTPVDSPDDTALSESANQAF LGFTYVAPSVLDSIKEGFSFQPK  
LRSPRRLNSSPRVPVSPLKFS PFEGFRPSPSLPEPTELPLPPLLPPPPPPSTTAPLP IRPP  
SGTKKSKRGRGRPGR

>gi|11995473|gb|NM\_019884.1|GSK3A 2169bp mRNA Homo sapiens  
glycogen synthase kinase 3 alpha (GSK3A), mRNA.

GCCAGAGCGGCGCGGCCTGGAAGAGGCCAGGGCCCGGGGGAGGCGACGGCAGCGGCGGGCG  
GCTGGGGCAGCCCGGGCAGCCCGAGCCCCGAGCCTGGGCCTGTGCTCGGCGCCATGAGC  
GGCGGCGGGCCTTCGGGAGGCGGCCCTGGGGGCTCGGGCAGGGCGCGGACTAGCTCGTTC  
GCGGAGCCCCGGCGGGCAGGCGGAGGAGGCGGCGGCGGCCCCGGAGGCTCGGCCTCCGGC  
CCAGGCGGCACCGGCGGGCGGAAAGGCATCTGTGGGGCCATGGGTGGGGGCGTGGGGGCC  
TCGAGCTCCGGGGGTGGACCCGGCGGCAGCGGCGGAGGAGGCGGAGGCCCCGGCGCA  
GGCACTAGCTTCCCGCCGCCCGGGGTGAAGCTGGGCCGTGACAGCGGGAAGGTGACCACA  
GTCGTAGCCACTCTAGGCCAAGGCCCAGAGCGCTCCCAAGAAGTGGCTTACACGGACATC  
AAAGTGATTGGCAATGGCTCATTTGGGGTCTGTGTACCAGGCACGGCTGGCAGAGACCAGG  
GAACTAGTCGCCATCAAGAAGGTTCTCCAGGACAAGAGGTTCAAGAACCGAGAGCTGCAG  
ATCATGCGTAAGCTGGACCACTGCAATATTGTGAGGCTGAGATACTTTTTCTACTCCAGT  
GGCGAGAAGAAAGACGAGCTTTACCTAAATCTGGTGCTGGAATATGTGCCCGAGACAGTG  
TACCGGGTGGCCCCGCCACTTCACCAAGGCCAAGTTGACCATCCCTATCCTCTATGTCAAG  
GTGTACATGTACCAGCTCTTCCGCAGCTTGGCCTACATCCACTCCCAGGGCGTGTGTAC  
CGCGACATCAAGCCCCAGAACCTGCTGGTGGACCCTGACACTGCTGTCTCTCAAGCTCTGC  
GATTTTGGCAGTGCAAAGCAGTTGGTCCGAGGGGAGCCCAATGTCTCCTACATCTGTTCT  
CGCTACTACCGGGCCCCAGAGCTCATCTTTGGAGCCACTGATTACACCTCATCCATCGAT  
GTTTGGTCAGCTGGCTGTGTACTGGCAGAGCTCCTCTTGGGCCAGCCCATCTTCCCTGGG  
GACAGTGGGGTGGACCAGCTGGTGGAGATCATCAAGGTGCTGGGAACACCAACCCGGGAA  
CAAATCCGAGAGATGAACCCCAACTACACGGAGTTCAAGTTCCTCAGATTAAAGCTCAC  
CCCTGGACAAAGGTGTTCAAATCTCGAACGCCGCCAGAGGCCATCGCGCTCTGCTCTAGC  
CTGCTGGAGTACACCCCATCCTCAAGGCTCTCCCCACTAGAGGCCTGTGCGCACAGCTTC  
TTTGATGAACTGCGATGTCTGGGAACCCAGCTGCCTAACAACCGCCCACTTCCCCCTCTC  
TTCAACTTCAGTGCTGGTGAACCTCTCCATCCAACCGTCTCTCAACGCCATTCTCATCCCT  
CCTCACTTGAGGTCCCCCAGCGGCACTACCACCCTCACCCCGTCCTCACAAGCTTTAACT  
GAGACTCCGACCAGCTCAGACTGGCAGTCGACCGATGCCACACCTACCCTCACTAACTCC  
TCCTGAGGGCCCCACCAAGCACCCCTTCCACTTCCATCTGGGAGCCCCAAGAGGGCGTGGG  
AAGGGGGGCCATAGCCCATCAAGCTCCTGCCCTGGCTGGGCCCCCTAGACTAGAGGGCAGA  
GGTAAATGAGTCCCTGTCCCCACCTCCAGTCCCTCCCTCACCAGCCTCACCCCTGTGGTG  
GGCTTTTTTAAGAGGATTTTAACTGGTTGTGGGGAGGGAAGAGAAGGACAGGGTGTGGGG  
GGATGAGGACCTCCTACCCCCCTTGGCCCCCTCCCTCCCCCAGACCTCCACCTCCTCCAG  
ACCCCTCCCCCTCCTGTGTCCCTTGTAATAGAACCCAGCCAGCCCGTCTCCTCTTCCCT  
TCCCTGGCCCCCGGGTGTAATAGATTGTTATAATTTTTTTCTTAAAGAAAACGTCGATT  
CGCACCGTCCAACCTGCCCCGCCCTCCTACAGCTGTAACCTCCCTCCTGTCTCTGCCC  
CCAAGGTCTACTCCCTCCTCACCCACCCCTGGAGGGCCAGGGGAGTGAGAGAGCTCCTG  
ATGTCTTAGTTTCCACAGTAAGGTTTGCCTGTGTACAGACCTCCGTTCAATAAATTATTG  
GCATGAAAA.

- 174 -

>gi|11995474|gb|NP\_063937.1|GSK3A 483aa linear glycogen synthase kinase 3 alpha [Homo sapiens].

MSGGGPSGGGPGGSGRARTSSFAEPGGGGGGGGGGPGGSASGPGGTGGGKASVGAMGGGV  
GASSSGGGPGGSGGGSGGPGAGTSFPPPGVKLGRDSGKVTTVVATLGQGPERSQEVAYT  
DIKVIENGSGFGVVYQARLAETRELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFY  
SSGEKKDELYLNLVLEYVPETVYRVARHFTKAKLTIPILYVKVYMYQLFRSLAYIHSQGV  
CHRDIKPQNLLVDPDTAVLKLCDFGSAKQLVRGEPNVSYICSRYRAPELIFGATDYTSS  
IDVWSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTPTREQUIREMNPNTYEFKFPQIK  
AHPWTKVFKSRTPEAIALCSSLLEYTPSSRLSPLEACAHSFFDELRLCLGTQLPNNRPLP  
PLFNFSAGELSIQPSLNAILIPPHLRSPSGTTTTLTPSSQALTETPTSSDWQSTDATPTLT  
NSS

>gi|7019350|gb|NM\_013246.1|CLC 1689bp mRNA Homo sapiens  
cardiotrophin-like cytokine (CLC), mRNA.

GCCTCCGGGAGAGGAGCCGCACCCGGCCGGCCCGCCCCAGCCCCATGGACCTCCGAGCA  
GGGGACTCGTGGGGGATGTTAGCGTGCCTGTGCACGGTGTCTTGGCACCTCCCTGCAGTG  
CCAGCTCTCAATCGCACAGGGGACCCAGGGCCTGGCCCCCTCCATCCAGAAAACCTATGAC  
CTCACCCGCTACCTGGAGCACCAACTCCGCAGCTTGGCTGGGACCTATCTGAACTACCTG  
GGCCCCCTTTCAACGAGCCAGACTTCAACCCTCCCCGCTGGGGGCAGAGACTCTGCCC  
AGGGCCACTGTTGACTTGGAGGTGTGGCGAAGCCTCAATGACAACTGCGGCTGACCCAG  
AACTACGAGGCCTACAGCCACCTTCTGTGTTACTTGCCTGGCCTCAACCGTCAGGCTGCC  
ACTGCTGAGCTGCGCCGAGCCTGGCCCACTTCTGCACCAGCCTCCAGGGCCTGCTGGGC  
AGCATTGCGGGCGTCATGGCAGCTCTGGGCTACCCACTGCCCCAGCCGCTGCCTGGGACT  
GAACCCACTTGGACTCCTGGCCCTGCCACAGTGACTTCCTCCAGAAGATGGACGACTTC  
TGGCTGCTGAAGGAGCTGCAGACCTGGCTGTGGCGCTCGGCCAAGGACTTCAACCGGCTC  
AAGAAGAAGATGCAGCCTCCAGCAGCTGCAGTCACCCTGCACCTGGGGGCTCATGGCTTC  
TGACTTCTGACCTTCTCCTCTTCGCTCCCCCTTCAAACCCTGCTCCCACTTTGTGAGAGC  
CAGCCCTGTATGCCAACACCTGTTGAGCCAGGAGACAGAAGCTGTGAGCCTCTGGCCCTT  
TCCTGGACCGGCTGGGCGTGTGATGCGATCAGCCCTGTCTCCTCCCCACCTCCCAAAGGT  
CTACCGAGCTGGGGAGGAGGTACAGTAGGCCCTGTCTGTCTGTTTCTACAGGAAGTCA  
TGCTCGAGGGAGTGTGAAGTGGTTAGGTTGGTGCAGAGGCGCTCATGGCCTCCTGCTTC  
TTGCCTACCACTTGGCCAGTGCCCAACCAGCCCCCTCAGGTGGCACATCTGGAGGGCAGGG  
GTTGAGGGGGCCACCACCACACATGCCTTTCTGGGGTGAAGCCCTTTGGCTGCCCCACTCT  
CCTTGGATGGGTGTTGCTCCCTTATCCCCAAATCACTCTATACATCCAATTCAGGAAACA  
AACATGGTGGCAATTCTACACAAAAAGAGATGAGATTAACAGTGCAGGGTTGGGGTCTGC  
ATTGGAGGTGCCCTATAAACCAGAAGAGAAAATACTGAAAGCACAGGGGCAGGGACAGAC  
CAGACCAGACCCAGGAGTCTCAAAGCACAGAGTGGCAAACAAAACCCGAGCTGAGCATC  
AGGACCTTGCCCTCGAATTGTCTTCCAGTATTACGGTGCCTCTTCTCTGCCCCCTTTCCCA  
GGGTATCTGTGGGTTGCCAGGCTGGGGAGGGCAACCATAGCCACACCACAGGATTTCTTG  
AAAGTTTACAATGCAGTAGCATTTTGGGGTGTAGGGTGGCAGCTCCCCAAGGCCCTGCCC  
CCCAGCCCCACCCACTCATGACTCTAAGTGTGTTGTATTAATATTTATTTATTTGGAGAT  
GTTATTTATTAGATGATATTTATTGCAGAATTTCTATTCTTGTTATTAACAAATAAAATGC  
TTGCCCCAG

>gi|7019351|gb|NP\_037378.1|CLC 225aa linear cardiotrophin-like  
cytokine; neurotrophin-1/B-cell stimulating factor-3 [Homo  
sapiens].

MDLRAGDSWGMCLCLCTVLWHLPAVPALNRTGDPGPGPSIQKTYDLTRYLEHQLRSLAGT  
YLNLYLGPFFNEPDFNPPRLGAETLPRATVDLEVWRSNDKRLRLTQNYEAYSHLLCYLRGL

- 175 -

NRQAATAELRRSLAHFCTSLQGLLGSIAGVMAALGYPLPQPLPGTEPTWTFGPAHSDFLQ  
KMDDFWLLKELQTLWLSAKDFNRLKKKMOPPAAAVTLHLGAHGF

.>gi|22068574|gb|XM\_036493.3|ZNF213 3073bp mRNA Homo sapiens  
zinc finger protein 213 (ZNF213), mRNA.

GGCCTCTGGCCGCTGGCTCCAACATCAAGCACCGGGCTCCGAGTGGCCGGGATCAGCGC  
CCCGAGGCAGAGGCCGGAGGGCGCGCGCACTGCTAGGAAGTGCTGGTCCCCCGCGCCGCT  
CTGCCAGCTTGGTCCCCCGGCAGACGCCCCCTGTACGATCGCCGCTCGCCCCGCGGGCGAG  
GCTGCGGTGGACAGCGCGGGGCTCCGGCTGGCTCGCCTTCCCGCCTGCCGTGTCTGTCTG  
AGCGACCCTGGAGTACACATCCAGATGCCAGCCAGCTACCACAGGGGATCCCTCTGGGA  
GACTGAAAGTACAGGTTCTGGGGCCAGGTTGAAGCCGACCAACCCTGAGCCTCAGGCCA  
GGGGAATGGCAGCCCCCTTGGAGGCCAGGACCAGGCCCTGGGGAGGGAGAAGGGCTTC  
TGATTGTGAAAGTGGAAGATTCTCTCTGGGAACAGGAATCTGCCCAGCATGAGGATGGCA  
GGGATTCCGAAGCCTGCCGCCAGCGCTTCCGGCAATTCTGCTACGGGGATGTGCATGGGC  
CTCATGAGGCCTTCAGCCAGCTCTGGGAGCTCTGCTGCCGCTGGCTGCGGCCCGAGCTGC  
GTACCAAGGAGCAGATCCTGGAGCTGCTGGTGCTGGAGCAGTTCCTGACAGTGCTGCCAG  
GGGAGATCCAGGGCTGGGTGCGTGAGCAGCACCCGGGAAGCGGTGAGGAGGCTGTGCGCT  
TGGTGGAGGACCTACAGAAGCAGCCAGTGAAAGCCTGGCGACAGGATGTGCCCTCGGAGG  
AGGCGGAACCCGAGGCTGCAGGCCGGGGATCCAGGCCACGGGGCCTCCCCGACGGTGG  
GGGCACGGAGGCGGCCGTCTGTTCCCCAGGAGCAGCACAGCCATAGCGCCCAGCCTCCTG  
CTCTTCTTAAAGAGGGTCGTCCCGGAGAGACGACGGACACCTGCTTTGTCTCTGGGGTCC  
ATGGACCTGTGGCATTGGGAGACATCCCATTTCTATTTCTCCCGGAAGAATGGGGCACCC  
TGGACCCTGCTCAGCGGGATCTCTTCTGGGACATAAAGCGGGAGAACTCCCGGAACACCA  
CCCTGGGTTTTTGGGCTCAAAGGCCAAAGTGAGAAGTCCCTGCTGCAGGAGATGGTGCCGG  
TGGTGCCAGGCCAGACAGGCAGCGACGTGACTGTGTCCTGGAGCCCCGAGGAGGCTGAGG  
CCTGGGAGAGCGAGAACCGGCCGAGGGCGGCCCTGGGCCCAGTGGTGGGCGCGCGACGGG  
GGCGGCCACCCACTCGCCGGCGCCAGTTCGGGGACCTGGCAGCCGAGAAGCCGCACAGCT  
GCGGGCAGTGTGGAAAGCGCTTCCGCTGGGGCTCGGACCTGGCGCGGCACCAGCGCACGC  
ACACGGGCGAGAAGCCACACAAGTGCCCTGAGTGCGACAAGAGCTTCCGCAGCTCCTCGG  
ACCTGGTGCGCCACCAAGGCGTGACACGGGCGAGAAGCCCTTCTCCTGTTCCGAGTGCG  
GCAAGAGCTTCAGCCGCAGCGCCTACCTGGCCGACCACCAGCGCATAACACGGGCGAGA  
AGCCTTTCGGCTGCAGCGACTGCGGCAAGAGCTTCTCGCTGCGCTCCTACCTGCTGGACC  
ATCGGCGTGTGCACACCGGTGAGCGGCCCTTCGGCTGCGGAGAGTGCGACAAGAGCTTCA  
AGCAGCGCGCGCACCTCATCGCGCATCAGAGCCTGCACGCCAAGATGGCCCAGCCCCGTGG  
GGTGAGCAGCTGGCTTGGCCGGAAACCCGGGGGAGGCCAGCCACGGCACATCCTGCTTT  
GTTACCACTGGGACTCTCCTTCCATCTGTGGCCACCTCCCGGGCTGTCCGAGGGACCCC  
AGGGTACCTCACACTCGGAGCTCGCCTGCCCTGCTTGGCTCTGAGGACCTGCCAGCGCT  
CAAAGGGAACGGAAGCCTTCCCCTCCCCGCCCCCGATCTTGTCCTCTTTCCCCCTTCTGCG  
CCTAGCGTTCTCTTCCCCTCTAGTTTCTTGAGCCCCAACACATTCTTGGCAGGGACAG  
CAGGGTGGCAAGGACTCAGGTCTAGGTCCCTTCCCAGAAGCCCCGAGCCTCATTTGACT  
GTGTGGCTCTTTGGCCCCCACCCTGTGGGGTGGGTCCATGGGTGAGGCTCTGCCCTACC  
AACCTGTGCCTTTCAGTGGGCGTGGAGGACTGGCCTTGGCCCCCAGGGGGCTGCTGGAC  
TTTGGGAGAGACAGCCACACCTGTGGGACCGCGGGTCTTAGTCACGGCGGCAGGGGCTT  
TCTGGCCCCCTCCCACTCCCGTTTCCAGGCCATGACCACTCTGCCCTGTCTGGCCATAC  
GGACTCGGCCTGCCTTTGCCCTCGGCCTACTTGCCCTAGCATGAGGCTCTGAGAGCCACC  
TGCCCAACCAATCTGGTGAGGATAATGGTGGCTCCAGCGACAGGAGGCCAACCCTGGAGAC  
CAAGAACAGGGCGCCTGGCTGCCATCTTTTCTCCTCCAGAGGTGGGGCTGCACCAGACTCAG  
CACTAGCACTCCATCAGCACTAGCACCTCACTCCATCAGCACTAGCACCTCACTCCATCG

- 176 -

GCCCCGGCACCCCTGCTCCATCGGCACTGGCGCCCTGCTCCATCGGCACTAATGCTCCACT  
CGGCGCCCCACTCCATCGGCCCCGCTCCATCGGCACTAATGCCCACTCGGCGCCCCACT  
CCATCAGCACTAATGCTCCACTCCATTGGCACTAACGCCCCAACTCCAGCGGCACTAATG  
ACCCGCTCCTTTGACATTGGTGCCCCACTCCATCAGCACTAACGCCCTGCTCCATCGGCA  
CTGGTGTCCCACTCCATTGTCTACTAACGTCCGGCTCCATCGGCACTACCACCCGCTCCA  
TCATCACTATGTCCAGCTCCGTCCGCACTACCACCTGCTCCATCATCACTACGTCCAGC  
TCCAACGGCACTGGTGCCCCATTCCATCGGCACTAACGCCCCGCTCCACCGGCACCAGTG  
CCTCGCTCCATTGGCACCAACGCCAGCTCCACCGGTACTGGCTCCCTGCTCCATCGGCA  
CTAACGCCCTGCT

>gi|14777854|gb|XP\_036493.1|ZNF213 459aa linear similar to  
Zinc finger protein 213 (Putative transcription factor CR53)  
[Homo sapiens].

MAAPLEAQDQAPGEGEGLLIVKVEDSSWEQESAQHEDGRDSEACRQRFRQFCYGDVHGPH  
EAFSQLWELCCRWLRLPELRTKEQILELLVLEQFLTVLPGEIQGWVREQHPGSGEEAVALV  
EDLQKQPVKAWRQDVPSEEAPEAAGRGSQATGPPPTVGARRRPSVPQEQHSHSAQPPAL  
LKEGRPGETTDTCTFVSGVHGPPVALGDI PFYFSREEWGTLDPAQRDLFWDIKRENSRNTTL  
GFGGLKGQSEKSLLOEMVPVVPVGQTGSDVTVSWSPEEAEEAWESNRPRALGPVVGARRGR  
PPTRRRRQFRDLAAEKPHSCGQCGRFRWGSDLARHQRTHTGEKPHKCPECDKSFSSSDL  
VRHQGVHTGEKPFSCSECGKSF SRSAYLADHQRIHTGEKPFSGSDCGKSFSLRSYLLDHR  
RVHTGERPFGCGECDKSFQRAHLIAHQSLHAKMAQPVG

>gi|21536281|gb|NM\_003656.3|CAMK1 1501bp mRNA Homo sapiens  
calcium/calmodulin-dependent protein kinase I (CAMK1), mRNA.  
GGAGAGAGCCCGCCGAGCCGAGCCGAGCCCCAGCTCCAGCAAGAGCGCGGGCGGGTGGCCC  
AGGCACGCAGCGGTGAGGACCGCGGCCACAGCTCGGCGCCAACCACCGCGGGCCTCCCAG  
CCAGCCCCGCGCGGGGCAGCCGCAGGAGCCCTGGCTGTGGTTCGGGGGGCAGTGGGCCAT  
GCTGGGGGGCAGTGGAAGGCCCCAGGTGGAAGCAGGCGGAGGACATTAGAGACATCTACGA  
CTTCCGAGATGTTCTGGGCACGGGGGCCTTCTCGGAGGTGATCCTGGCAGAAGATAAGAG  
GACGCAGAAGCTGGTGGCCATCAAATGCATTGCCAAGGAGGCCCTGGAGGGCAAGGAAGG  
CAGCATGGAGAATGAGATTGCTGTCTGCACAAGATCAAGCACCCCAACATTGTAGCCCT  
GGATGACATCTATGAGAGTGGGGGCCACCTCTACCTCATCATGCAGCTGGTGTCTGGGTGG  
GGAGCTCTTTGACCGTATTGTGGAAAAAGGCTTCTACACGGAGCGGGACGCCAGCCGCCT  
CATCTTCCAGGTGCTGGATGCTGTGAAATACCTGCATGACCTGGGCATTGTACACCGGGA  
TCTCAAGCCAGAGAATCTGCTGTACTACAGCCTGGATGAAGACTCCAAAATCATGATCTC  
CGACTTTGGCCTCTCCAAGATGGAGGACCCGGGCAGTGTGCTCTCCACCGCCTGTGGAAC  
TCCGGGATACGTGGCCCCCTGAAGTCTGGCCCAGAAGCCCTACAGCAAGGCTGTGGATTG  
CTGGTCCATAGGTGTCATCGCCTACATCTTGCTCTGCGGTTACCCTCCCTTCTATGACGA  
GAATGATGCCAAACTCTTTGAACAGATTTTGAAGGCCGAGTACGAGTTTGACTCTCCTTA  
CTGGGACGACATCTCTGACTCTGCCAAAGATTTTCATCCGGCACTTGATGGAGAAGGACCC  
AGAGAAAAGATTACCTGTGAGCAGGCCTTGCAGCACCCATGGATTGCAGGAGATACAGC  
TCTAGATAAGAATATCCACCAGTCGGTGAGTGAGCAGATCAAGAAGAAGTTTGCCAAGAG  
CAAGTGGAAGCAAGCCTTCAATGCCACGGCTGTGGTGCAGGCACATGAGGAACTGCAGCT  
GGGCACCAGCAGGAGGGGCAGGGGCAGACGGCGAGCCATGGGGAGCTGCTGACACCAGT  
GGCTGGGGGGGCCGGCAGCTGGCTGTTGCTGTGCGAGACTGCTGCGTGGAGCCGGGCACAGA  
ACTGTCCCCCACACTGCCCCACCAGCTCTAGGGCCCTGGACCTCGGGTCATGATCCTCTG  
CGTGGGAGGGCTTGGGGGCAGCCTGCTCCCTTCCCTCCCTGAACCGGGAGTTTCTCTGC  
CCTGTCCCTCCTCACCTGCTTCCCTACCACTCCTCACTGCATTTTCCATACAAATGTTT  
CTATTTTATTGTTCTTCTTGTAAATAAAGGGAAGATAAAACCAAAAAAAAAAAAAAAAAA

- 177 -

A

>gi|4502553|gb|NP\_003647.1|CAMK1 370aa linear  
calcium/calmodulin-dependent protein kinase I [Homo sapiens].  
MLGAVEGPRWKQAEDIRDIYDFRDVLGTGAFSEVILAEDKRTQKLVAIKCIAKEALEGKE  
GSMENEIAVLHKIKHPNIVALDDIYESGGHLYLIMQLVSGGELEFDRIVEKGFYTERDASR  
LIFQVLDAVKYLHDLGIVHRDLKPENLLYSLDEDSKIMISDFGLSKMEDPGSVLSTACG  
TPGYVAPEVLAQKPYSKAVDCWSIGVIAIILLCGYPFFYDENDAKLFEQILKAIEYEFDSP  
YWDDISDSAKDFIRHLMKEDPEKRFTCEQALQHPWIAGDTALDKNIHQSVSEQIKKNFAK  
SKWKQAFNATAVVRHMRKLQLGTSQEGQGQTASHGELLTPVAGGPAAGCCCRDCCVEPGT  
ELSPTLPHQL

>gi|13186237|gb|NM\_023107.1|FGFR1 2590bp mRNA Homo sapiens  
fibroblast growth factor receptor 1 (fms-related tyrosine  
kinase 2, Pfeiffer syndrome) (FGFR1), transcript variant 5,  
mRNA.

CCTCTTGC GGCCACAGGCGCGGCGTCTCTCGGCGGCGGGCGGCAGCTAGCGGGAGCCGGGA  
CGCCGGTGCAGCCGCAGCGCGCGGAGGAACCCGGGTGTGCCGGGAGCTGGGCGGCCACGT  
CCGGACGGGACCGAGACCCCTCGTAGCGCATTGCGGCGACCTCGCCTTCCCCGGCCGCGA  
GCGCGCCGCTGCTTGAAAAGCCGCGGAACCCAAGGACTTTTCTCCGGTCCGAGCTCGGGG  
CGCCCCGCAGGCGCACGGTACCCGTGCTGCAGTCGGGCACGCCGCGGCGCCGGGGGCTC  
CGCAGGGCGATGGAGCCGGTCTGCAAGGAAAGTGAGGCGCCGCGCTGCGTTCTGGAGGA  
GGGGGGCACAAAGTCTGGAGACCCCGGGTGGCGGACGGGAGCCCTCCCCCGCCCCGCT  
CCGGGGCACCAGCTCCGGCTCCATTGTTCCCGCCCCGGGCTGGAGGCGCCGAGCACCCGAGC  
GCCGCCGGGAGTCGAGCGCCGGCCGCGGAGCTCTTGCGACCCCGCCAGGACCCGAACAGA  
GCCCCGGGGGCGGCGGGGCCGGAGCCGGGGACGCGGGCACACGCCCGCTCGCACAAAGCCACG  
GCGGACTCTCCCGAGGCGGAACCTCCACGCCGAGCGAGGGTCAGTTTGAAAAGGAGGATC  
GAGCTCACTGTGGAGTATCCATGGAGATGTGGAGCCTTGTACCAACCTCTAACTGCAGA  
ACTGGGATGTGGAGCTGGAAGTGCCTCCTCTTCTGGGCTGTGCTGGTCACAGCCACACTC  
TGCACCGCTAGGCCGTCCCCGACCTTGCTGAACAAGATGCTCTCCCTCCTCGGAGGAT  
GATGATGATGATGATGACTCCTCTTCAGAGGAGAAAGAAACAGATAACACCAAACCAAAC  
CGTATGCCCGTAGCTCCATATTGGACATCCCCAGAAAAGATGGAAAAGAAATTGCATGCA  
GTGCCGGCTGCCAAGACAGTGAAGTTCAAATGCCCTTCCAGTGGGACCCCCAAACCCACA  
CTGCGCTGGTTGAAAAATGGCAAAGAATTCAAACCTGACCACAGAATTGGAGGCTACAAG  
GTCCGTTATGCCACCTGGAGCATCATAATGGACTCTGTGGTGCCCTCTGACAAGGGCAAC  
TACACCTGCATTGTGGAGAATGAGTACGGCAGCATCAACCACACATACCAGCTGGATGTC  
GTGGAGCGGTCCCCTCACCGGCCCATCCTGCAAGCAGGGTTGCCCGCCAACAAAACAGTG  
GCCCTGGGTAGCAACGTGGAGTTCATGTGTAAGGTGTACAGTGACCCGAGCCGCACATC  
CAGTGGCTAAAGCACATCGAGGTGAATGGGAGCAAGATTGGCCAGACAACCTGCCTTAT  
GTCCAGATCTTGAAGGTAATCATGGCACCAGTCTTCGTGGGCCAGTCTACTGGGAAGGAG  
ACCACTGTCTCGGGGGCTCAAGTTCCTGTGGGCAGGCTCAGTTGCCCCGAATGGGATCA  
TTCCTCACGCTTCAGGCACACACACTCCATCTCAGTAGGGATCTAGCCACATCCCCCAGG  
ACTAGTAACAGAGGTCACAAAGTGGAGGTGAGCTGGGAACAGAGGGCTGCAGGGATGGGT  
GGTGCTGGTCTGTAATAAGCTTTGAGAGCAACGTCACTGGGGCTTTGGGGTCAGCTACAC  
AAGGAAGGCATTTGGACCCCTGCCTTTTCATTGCCCGAAACCAGAGCCTTTCCACCAAGC  
GTTTCCAGTCTTAGCCCTGTGTTCTGAGTTACGTACGATCTTTCTGGCAAATGGGGTGC  
ATGATAAGAGCATCTCTTACGAAGAGTTGGAAAAACAAATGCCATATATAAATTCTAAGC  
CATATGAGGACGAGGAGTAATGGCATTTTCTTCCTTTTTCCTCTCACTCCCAGACATTCA  
TTGTCCCTGAATGCTCCATTAATCCAGGGAAGGTAATTGCCTAAATCTCCAGTGGATCTC

- 178 -

GCAACAGGAAGGAACCAGAAGCTGGGAAAGTTGTTTACCTCTTTGTCCCAGAGTTAGACC  
TCATCCTCCCCTAGCTTAGCTGTCTCAGAGATATACTGGCCCTCCCTTCTCTTCTCTTTG  
CTGCTGGTGCTAAAACTGCTCTGTAGGTCATTGGCCACTGTCTCCACTCACAACCCCTGC  
TCCAGTCCTGGAGGGAGTGGGTAAACACAAATAGAACATTCCATTGAAGCAGTGATTC  
TTTTTTTTTTTTTTTTTTTTTTAATCAAATGCTTTGGACTTTTGAAGTCCACTTGTTCTGT  
ACTTGTAAGGGAAGGAAGGCCGGGCGCAGTCGTCACGCCTGTAATCCCAGCACTTTAG  
ATCACTTGAGGTCAGGAGTTTGAGACCAGCCCGGCCAACATGGTGAAACCCCATCTCTAC  
TAAAAATACAAAATTAGCTGTGCATAGTGGTTGGCACCTGTAGTCCCAGCTACTCAGGA  
GGCTGAGGCAAGCTAACTGCTTGAACCCAGAAGGCAGAGGTTGCAGTGAGCTGAGATCAC  
GCCACTGCACTCCAGCCTGGGTGACAGAGTGAGTGAGACTCTGCGTTAAAAA

>gi|13186238|gb|NP\_075595.1|FGFR1 302aa linear fibroblast  
growth factor receptor 1 isoform 5 precursor; fms-related  
tyrosine kinase-2; heparin-binding growth factor receptor;  
FMS-like tyrosine kinase 2; basic fibroblast growth factor  
receptor 1; N-sam tyrosine kinase; FLG protein; protein-  
tyrosine kinase; tyrosylprotein kinase; hydroxyaryl-protein  
kinase [Homo sapiens].

MWSWKCLLFWAVLVTATLCTARPSPTLPEQDALPSSSEDDDDDDSSSEEKETDNTKPNRM  
PVAPYWTSPEKMEKHLHAVPAAKTVKFKCPSSGTPNPTRLWLKNGKEFKPDHRIGGYKVR  
YATWSIIMDSVVP SDKGN YTCI VENEYGSINHTYQLDVVERS PHRPILQAGLPANKTVAL  
GSNVEFMCKVYSDPQPHIQWLKHIEVNGSKIGPDNLPYVQILKVIMAPVFVGQSTGKETT  
VSGAQVPVGR LSCPRMG SFLTLQAHTLHL SRDLATSPRTSNRGHKVEVSWEQRAAGMGA  
GL

>gi|4758007|gb|NM\_004071.1|CLK1 1834bp mRNA Homo sapiens CDC-  
like kinase 1 (CLK1), mRNA.

ATTTTATAGATAATCATTAAAGACCACAGAAAATGTAACAGATCCTACTCTTCAAAATAAT  
TGCTATTCAGTATTAAACGAGCAGTCAGCTGCGTGATTCCCGTGATTGCGTTACAAGCT  
TTGTCTCCTTCGACTTGGAGTCTTTGTCCAGGACGATGAGACACTCAAAGAGAACTTACT  
GTCCTGATTGGGATGACAAGGATTGGGATTATGGAAAATGGAGGAGCAGCAGCAGTCATA  
AAAGAAGGAAGAGATCACATAGCAGTGCCCGAGGAGAACAGCGCTGCAAATACAATCACT  
CTAAATGTGTGATAGCCATTATTTGGAAAGCAGGTCCTATAAATGAGAAAGATTATCATA  
GTCGACGCTACATTGATGAGTACAGAAATGACTACACTCAAGGATGTGAACCTGGACATC  
GCCAAAGAGACCATGAAAGCCGGTATCAGAACCATAGTAGCAAGTCTTCTGGTAGAAGTG  
GAAGAAGTAGTTATAAAAGCAAACACAGGATTCACCACAGTACTTCACATCGTCGTTTAC  
ATGGGAAGAGTCACCGAAGGAAAAGAACAGGAGTGTAGAGGATGATGAGGAGGGTCACC  
TGATCTGTCAGAGTGGAGACGTACTAAGTGCAAGATATGAAATTGTTGATACTTTAGGTG  
AAGGAGCTTTTGGAAAAGTTGTGGAGTGCATCGATCATAAAGCGGGAGGTAGACATGTAG  
CAGTAAAAATAGTTAAAAATGTGGATAGATACTGTGAAGCTGCTCGCTCAGAAATACAAG  
TTCTGGAACATCTGAATACAACAGACCCCAACAGTACTTCCGCTGTGTCCAGATGTTGG  
AATGGTTTGGAGCATCATGGTCACATTTGCATTGTTTTTGAAGTATTGGGACTTAGTACTT  
ACGACTTCATTAAAGAAAATGGTTTTCTACCATTTGCGACTGGATCATATCAGAAAGATGG  
CATATCAGATATGCAAGTCTGTGAATTTTTTGCACAGTAATAAGTTGACTCACACAGACT  
TAAAGCCTGAAAACATCTTATTTGTGCAGTCTGACTACACAGAGGCGTATAATCCCAAAA  
TAAACGTGATGAACGCACCTTAATAAATCCAGATATTAAAGTTGTAGACTTTGGTAGTG  
CAACATATGATGACGAACATCACAGTACATTGGTATCTACAAGACATTATAGAGCACCTG  
AAGTTATTTTAGCCCTAGGGTGGTCCCAACCATGTGATGTCTGGAGCATAGGATGCATTC

- 179 -

TTATTGAATACTATCTTGGGTTTACCGTATTTCCAACACACGATAGTAAGGAGCATTTAG  
CAATGATGGAAAGGATTCTTGGACCTCTACCAAAACATATGATACAGAAAACCAGGAAAC  
GTAAATATTTTACCACGATCGATTAGACTGGGATGAACACAGTTCTGCCGGCAGATATG  
TTTCAAGAGCCTGTAAACCTCTGAAGGAATTTATGCTTTCTCAAGATGTTGAACATGAGC  
GTCTCTTTGACCTCATTCAGAAAATGTTGGAGTATGATCCAGCCAAAAGAATTACTCTCA  
GAGAAGCCTTAAAGCATCCTTTCTTTGACCTTCTGAAGAAAAGTATATAGATCTGTAATT  
GGACAGCTCTCTCGAAGAGATCTTACAGACTGTATCAGTCTAATTTTTTAAATTTTAAGTT  
ATTTTGTACAGCTTTGTAAATTCTTAACATTTTTTATATTGCCATGTTTATTTTGTGGG  
TAATTTGGTTCATTAAGTACATAGCTAAGGTAATGAACATCTTTTTTCAGTAATTGTAAAG  
TGATTTATTTCAGAATAAATTTTTTGTGCTTATGA

>gi|4758008|gb|NP\_004062.1|CLK1 484aa linear CDC-like kinase  
1; protein tyrosine kinase STY [Homo sapiens].

MRHSKRITYCPDWDDKDWDYDGKWRSSSSHKRRKRSHSSAQENKRCKYNHSMCDSHYLESR  
SINEKDYHSRRYIDEYRNDYTQGCPEGHRQRDHESRYQNHSSKSSGRSGRSSYKSKHRIH  
HSTSHRRSHGKSHRRKRTRSVEDDEEGLICQSGDVLRSARYEIVDTLGEGAFGKVVECID  
HKAGGRHVAVKIVKNVDRYCEARSEIQVLEHLNNTDPNSTFRVCQMLEWFEHHGHICIV  
FELLGLSTYDFIKENGFLPFRLDHIRKMAYQICKSVNLFHSNKLTHTDLPENILFVQSD  
YTEAYNPKIKRDERTLINPDIKVVDFGSATYDDEHHSTLVSTRHYRAPEVILALGWSQPC  
DVWSIGCILIEYYLGFTVFPTHDSKEHLAMMERILGPLPKHMIQKTRKRKYFHHDRLDWD  
EHSSAGRYVSRACKPLKEFMLSQDVEHERLFDLIQKMLEYDPAKRITLREALKHPFFDLL  
KKSI

>gi|20127640|gb|NM\_025128.2|MUS81 2352bp mRNA Homo sapiens  
MUS81 endonuclease (MUS81), mRNA.

GGCACGAGGGTCTCAAAGGCTGGCTGGAGTGGAGCCAAAGGAAAAGATCGTTAGAGACAG  
CGCCCCTGACCAACCACTTAGAGCAGCGCAGGGGTGGGAGGGCGGCCGCAGGCTCTCCTC  
TCGTTAGTGCCCCCTGTGTTTGGGGCCCCGTGATCTCAACGGTCCTGCCCTCGGTCTCCC  
TCTTCCCCCGCCCCGCCCTGGGCCAGGTGTTTGAATCCCGACTCCAGAACTGGCGGCGTC  
CCAGTCCCGCGGGCGTGGAGCGCCGGAGGACCCGCCCTCGGGCTCATGGCGGCCCCGGTC  
CGCCTGGGGCCGGAAGCGCCCGCTGCCTGCCTGTCCCAACCCGCTCTTCGTTCTGCTGGCTG  
ACCGAGTGGCGGGACGAGGCGACCCGCAGCAGGCACCGCACGCGCTTCGTATTTTCAAGAG  
GCGCTGCGTTCCCTCCGACGGTACCCACTGCCGCTGCGCAGCGGGAAGGAAGCTAAGATC  
CTACAGCACTTCGGAGACGGGCTCTGCCGGATGCTGGACGAGCGGCTGCAGCGGCACCGA  
ACATCGGGCGGTGACCATGCCCCGGACTCACCATCTGGAGAGAACAGTCCAGCCCCGCAG  
GGGCGACTTGCGGAAGTCCAGGACTCTTCCATGCCAGTTCCTGCCCGAGCCCAAGCGGGA  
GGCTCTGGCAGCTACTGGCCAGCTCGGCACTCAGGAGCCCGAGTGATACTGCTGGTGCTC  
TACCGGGAGCACCTGAATCCTAATGGTCACCACTTCTTAACCAAGGAGGAGCTGCTGCAG  
AGGTGTGCTCAGAAGTCCCCAGGGTAGCCCTGGGAGTGCCCCACCCTGGCCAGCCCTC  
CGTCCCTCCTTCACAGGAACCTGGTCCTCAGGACACACCAGCCAGCCAGGTACTCATTG  
ACCCAGAGGGCCTGGAGCTGGCCCAGAAGTTGGCCGAGTCAGAAGGCCTGAGCTTGCTG  
AATGTGGGCATCGGGCCCAAGGAGCCCCCTGGGGAGGAGACAGCAGTGCCAGGAGCAGCT  
TCAGCAGAGCTTGCCAGTGAAGCAGGGGTCCAGCAGCAGCCACTGGAGCTGAGGCCTGGA  
GAGTACAGGGTGCTGTTGTGTGTGGACATTGGCGAGACCCGGGGGGCGGGCACAGGCCG  
GAGCTGCTCCGAGAGCTACAGCGGCTGCACGTGACCCACACGGTGCGCAAGCTGCACGTT  
GGAGATTTTGTGTGGGTGGCTCAGGAGACCAATCCTAGAGACCCAGCAAACCCTGGGGAG  
TTGGTACTGGATCACATTGTGGAGCGCAAGCGACTGGATGACCTTTGCAGCAGCATCATC  
GACGGCCGCTTCCGGGAGCAGAAGTTCCGACTGAAGCGCTGTGGTCTGGAGCGCCGGGTA  
TACCTGGTGGAAGAGCATGGTTCCGTCCACAACCTCAGCCTTCCTGAGAGCACACTGCTG



- 180 -

CAGGCTGTCACCAACACTCAGGTCATTGATGGCTTTTTTGTGAAGCGCACAGCAGACATT  
AAGGAGTCAGCCGCCTACCTGGCCCTCTTGACTCGGGGCCTGCAGAGACTCTACCAGGGC  
CACACCCTACGCAGCCGCCCTGGGGAACCCCTGGGAACCCCTGAATCAGGGGCCATGACC  
TCTCCAAACCCTCTCTGCTCACTCCTCACCTTCAGTGACTTCAACGCAGGAGCCATCAAG  
AATAAGGCCCAGTCGGTGCGAGAAGTGTGTGCCCCGGCAGCTGATGCAGGTGCGCGGAGTG  
AGTGGGGAGAAGGCAGCAGCCCTGGTGGATCGATACAGCACCCCTGCCAGCCTCCTGGCC  
GCCTATGATGCCTGTGCCACCCCCAAGGAACAAGAGACTGCTGAGCACCATTAAGTGT  
GGGCGTCTACAGAGGAATCTGGGGCCTGCTCTGAGCAGGACCTTATCCCAGCTCTACTGC  
AGCTACGGCCCCCTTGACCTGAGCTTATGCCGTGAAACAGCCCCCAGCCCCCGTCTGTCCC  
CCAACCCAGGCTAGCCAGCCTTTTAACAACATCTTTTGGGGTACAATTAGAATCTAAGTG  
TTTGACGCCATATGTGTGTCATGTAGAAGATGCCTAGCCCTGGGGACCTTGTGAAATACGCA  
GGAACCAGGGATACCATCTGGTCCAGTGTTTAAACAAAGCTGCTTAGCACCTGGAAT  
TCCCTGGTCAGGGAGATGGAGTCAGTGGGGCATTGCAGCTTGAATCTATTTTATGTCAC  
CAGTTGGTCCTCATCAAATAAAATTTCTTAGGAGTGCAGAGGGCTCATTGGGAAAATAA  
AAATAATAAAAAATAAAATAAACTTCCTAAAAGAAAAGATTGAAACCCAAAAA  
AAAAA

>gi|13376707|gb|NP\_079404.1|MUS81 476aa linear MUS81  
endonuclease [Homo sapiens].

MLDERLQRHRTSGGDHAPDSPGENSPAPQGRLEVDSSMPVPAQPKAGGSGSYWPARH  
SGARVILLVLYREHLNPNNGHHFLTKEELLQRCQKSPRVAPGSAPPWPALRSLHRNLVL  
RTHQPARYSLTPEGLELAQKLAESEGLSLLNVGIGPKEPPGEETA VPGAASAELASEAGV  
QQQPLELRPGEYRVLLCVDIGETRGGGHRPELLELRLHVTHTVRKLHVGD FVWVAQET  
NPRDPANPGELVLDHIVERKRLDDLCSSIIDGRFREQKFRLKRCGLERRVYLVEEHGSVH  
NLSLPESTLLQAVTNTQVIDGFFVKRTADIKESAAYLALLTRGLQRLYQGH TLRSPWGT  
PGNPESGAMTSPNPLCSLLTFSDFNAGAIKKAQSVREVFARQLMQVRGVSGEKAALVD  
RYSTPASLLAAYDACATPKETLLSTIKCGR LQRLNLPALSR TLSQLYCSYGPLT

>gi|19923239|gb|NM\_003376.2|VEGF 3166bp mRNA Homo sapiens  
vascular endothelial growth factor (VEGF), mRNA.

AAGAGCTCAGAGAGAAGTCGAGGAAGAGAGACGGGGTCAGAGAGAGCGCGCGGGCGT  
GCGAGCAGCGAAAGCGACAGGGGCAAAGTGAGTGACCTGCTTTTGGGGGTGACCGCCGGA  
GCGCGGCGTGAGCCCTCCCCCTTGGGATCCCGCAGCTGACCAGTCGCGCTGACGGACAGA  
CAGACAGACACCGCCCCCAGCCCCAGTTACCACCTCCTCCCCGGCCGGCGGGCAGAGTG  
GACGCGGCGGGCAGCCGCGGGCAGGGGCCGAGCCCGCCCCCGAGGCGGGGTGGAGGGG  
GTCGGAGCTCGCGGCGTCGCACTGAACTTTTCGTCCAACTTCTGGGCTGTTCTCGCTTC  
GGAGGAGCCGTGGTCCGCGCGGGGGAAGCCGAGCCGAGCGGAGCCGCGAGAAGTGCTAGC  
TCGGGCGGGGAGGAGCCGAGCCGAGGAGGGGGAGGAGGAAGAAGAGAAGGAAGAGGAG  
AGGGGGCCGCACTGGCGACTCGGCGCTCGGAAGCCGGGCTCATGGACGGGTGAGGCGGCG  
GTGTGCGCAGACAGTGCTCCAGCGCGCGCTCCCCAGCCCTGGCCCCGGCCTCGGGCCGG  
GAGGAAGAGTAGCTCGCCGAGGCGCCGAGGAGAGCGGGCCGCCACAGCCCGAGCCGGA  
GAGGGACGCGAGCCGCGCGCCCCGGTTCGGGCCTCCGAAACCATGAACTTTCTGCTGTCTT  
GGGTGCATTGGAGCCTTGCTTGCTGCTCTACCTCCACCATGCCAAGTGGTCCCAGGCTG  
CACCCATGGCAGAAGGAGGAGGGCAGAATCATCACGAAGTGGTGAAGTTCATGGATGTCT  
ATCAGCGCAGCTACTGCCATCCAATCGAGACCCTGGTGGACATCTTCCAGGAGTACCCTG  
ATGAGATCGAGTACATCTTCAAGCCATCCTGTGTGCCCTGATGCGATGCGGGGGCTGCT  
CCAATGACGAGGGCCTGGAGTGTGTGCCCACTGAGGAGTCCAACATCACCATGCAGATTA  
TGCGGATCAAACCTACCAAGGCCAGCACATAGGAGAGATGAGCTTCTACAGCACAACA  
AATGTGAATGCAGACCAAAGAAAGATAGAGCAAGACAAGAAAATCCCTGTGGGCCTTGCT



- 181 -

CAGAGCGGAGAAAGCATTTGTTTGTACAAGATCCGCAGACGTGTAAATGTTCTTGCAAAA  
ACACACACTCGCGTTGCAAGGCGAGGCAGCTTGAGTTAAACGAACGTACTTGAGATGTG  
ACAAGCCGAGGCGGTGAGCCGGGCGAGGAGGAAGGAGCCTCCCTCAGGGTTTCGGGAACCA  
GATCTCTCTCCAGGAAAGACTGATACAGAACGATCGATACAGAAACCACGCTGCCGCCAC  
CACACCATCACCATCGACAGAACAGTCCTTAATCCAGAAACCTGAAATGAAGGAAGAGGA  
GACTCTGCGCAGAGCACTTTGGGTCCGGAGGGCGAGACTCCGGCGGAAGCATTCCCGGGC  
GGGTGACCCAGCACGGTCCCTCTTGAATTGGATTCCGCCATTTTATTTTCTTGCTGCTA  
AATCACCAGAGCCCGGAAGATTAGAGAGTTTTATTTCTGGGATTCCTGTAGACACACCCAC  
CCACATACATACATTTATATATATATATATTATATATATAAAAAATAAATATCTCTATT  
TTATATATATAAAATATATATATTCTTTTTTTTAAATTAACAGTGCTAATGTTATTGGTGT  
CTTCACTGGATGTATTTGACTGCTGTGGACTTGAGTTGGGAGGGGAATGTTCCCACTCAG  
ATCCTGACAGGGAAGAGGAGGAGATGAGAGACTCTGGCATGATCTTTTTTTTGTCCCACT  
TGGTGGGGCCAGGGTCCTCTCCCCTGCCCAAGAATGTGCAAGGCCAGGGCATGGGGGCAA  
ATATGACCCAGTTTTGGGAACACCGACAAACCCAGCCCTGGCGCTGAGCCTCTCTACCCC  
AGGTCAGACGGACAGAAAGACAAATCACAGGTTCCGGGATGAGGACACCGGCTCTGACCA  
GGAGTTTGGGGAGCTTCAGGACATTGCTGTGCTTTGGGGATTCCCTCCACATGCTGCACG  
CGCATCTCGCCCCCAGGGGCACTGCCTGGAAGATTGAGGAGCCTGGGCGGCCTTCGCTTA  
CTCTCACCTGCTTCTGAGTTGCCCGAGGAGGCCACTGGCAGATGTCCCGGCGAAGAGAAGA  
GACACATTGTTGGAAGAAGCAGCCCATGACAGCGCCCCCTTCCTGGGACTCGCCCTCATCC  
TCTTCCTGCTCCCCCTTCCTGGGGTGAGCCTAAAAGGACCTATGTCCTCACACCATTGAA  
ACCACTAGTTCTGTCCCCCAGGAAACCTGGTTGTGTGTGTGTGAGTGGTTGACCTTCCT  
CCATCCCCTGGTCCTTCCCTTCCCTTCCCGAGGCACAGAGAGACAGGGCAGGATCCACGT  
GCCCATTTGTGGAGGCAGAGAAAAGAGAAAGTGTTTTATATACGGTACTTATTTAATATCC  
CTTTTAAATTAGAAATTAGAACAGTTAATTTAATTAAAGAGTAGGGTTTTTTTTTCAGTAT  
TCTTGGTTAATATTTAATTTCAACTATTTATGAGATGTATCTTTTGCTCTCTCTTGCTCT  
CTTATTTGTACCGGTTTTTGTATATAAAATTCATGTTTCCAATCTCTCTCTCCCTGATCG  
GTGACAGTCACTAGCTTATCTTGAACAGATATTTAATTTTGCTAACACTCAGCTCTGCCC  
TCCCCGATCCCCTGGCTCCCCAGCACACATTCCCTTTGAAAGAGGGTTTCAATATACATCT  
ACATACTATATATATATTGGGCAACTTGTATTTGTGTGTATATATATATATATATGTTTA  
TGTATATATGTGATCCTGAAAAAATAAACATCGCTATTCTGTTTTTTTATATGTTCAAACC  
AAACAAGAAAAAATAGAGAATTCTACATACTAAATCTCTCTCCTTTTTTAAATTTAATAT  
TTGTTATCATTTATTTATTGGTGCTACTGTTTATCCGTAATAATTGTGGGGAAAAGATAT  
TAACATCACGTCTTTGTCTCTAGTGAGTTTTTTCGAGATATTCCGTAGTACATATTTATT  
TTTAAACAACGACAAAGAAATACAGATATATCTTAAAAA

>gi|19923240|gb|NP\_003367.2|VEGF 191aa linear vascular  
endothelial growth factor [Homo sapiens].

MNFLLSVHWSLALLLYLHHAKWSQAAPMAEGGQNHHEVVKFMDVYQRSYCHPIETLVD  
IFQEYPDEIEYIFKPSCVPLMRCGGCSNDEGLECVPTESNITMQIMRIKPHQGHIGEM  
SFLQHNKCECRPKKDRARQENPCGPCSERRKHLFVQDPQTCKCCKNTHSRCKARQLELN  
ERTCRCDKPRR

>gi|16306545|gb|NM\_033649.1|FGF18 1466bp mRNA Homo sapiens  
fibroblast growth factor 18 (FGF18), transcript variant 2,  
mRNA.

CACGGCCGGAGAGACGCGGAGGAGGAGACATGAGCCGGCGGGCGCCAGACGGAGCGGCC  
GTGACGCTTTCGCGCTGCAGCCGCGCGCCCCGACCCCGGAGCGCTGACCCCTGGCCCCAC  
GCAGCTCCGCGCCCGGGCCGGAGAGCGCAACTCGGCTTCCAGACCCGCGCGCATGCTGT  
CCCCGACTGAGCCGGGCGAGCCAGCCTCCACGGACGCCCCGGACGGCCGGCCGGCCAGCA

- 182 -

GTGAGCGAGCTTCCCCGCACCGGCCAGGCGCCTCCTGCACAGCGGCTGCCGCCCCGCAGC  
CCCTGCGCCAGCCCGGAGGGCGCAGCGCTCGGGAGGAGCCGCGCGGGGCGCTGATGCCGC  
AGGGCGCGCCGCGGAGCGCCCCGGAGCAGCAGAGTCTGCAGCAGCAGCAGCCGGCGAGGA  
GGGAGCAGCAGCAGCGGCGGCGGCGGCGGCGGCGGCGGAGGCGCCCGGTCCCGGCCG  
CGCGGAGCGGACATGTGCAGGCTGGGCTAGGAGCCGCCGCTCCCTCCCGCCCAGCGATG  
TATTCAGCGCCCTCCGCTGCACTTGCTGTGTTTACACTTCCTGCTGCTGTGCTTCCAG  
GTACAGGTGCTGGTTGCCGAGGAGAACGTGGACTTCCGCATCCACGTGGAGAACCAGACG  
CGGGCTCGGGACGATGTGAGCCGTAAGCAGCTGCGGCTGTACCAGCTCTACAGCCGGACC  
AGTGGGAAACACATCCAGGTCTTGGGCCGCGAGGATCAGTGCCCGCGGCGAGGATGGGGAC  
AAGTATGCCCAGCTCCTAGTGGAGACAGACACCTTCGGTAGTCAAGTCCGGATCAAGGGC  
AAGGAGACGGAATTCTACCTGTGCATGAACCGCAAAGGCAAGCTCGTGGGGAAGCCCGAT  
GGCACCAGCAAGGAGTGTGTGTTTCATCGAGAAGGTTCTGGAGAACAACCTACACGGCCCTG  
ATGTCGGCTAAGTACTCCGGCTGGTACGTGGGCTTCACCAAGAAGGGGCGGCCGCGGAAG  
GGCCCCAAGACCCGGGAGAACCAGCAGGACGTGCATTTTCATGAAGCGCTACCCCAAGGGG  
CAGCCGGAGCTTCAGAAGCCCTTCAAGTACACGACGGTGACCAAGAGGTCCCGTCGGATC  
CGGCCACACACCCTGCCTAGGCCACCCCGCGCGGCCCTCAGGTGCGCCCTGGCCACACT  
CACACTCCAGAAAACCTGCATCAGAGGAATATTTTTTACATGAAAAATAAGGATTTTATTG  
TTGACTTGAAACCCCCGATGACAAAAGACTCACGCAAAGGGACTGTAGTCAACCCACAGG  
TGCTTGTCTCTCTCTAGGAACAGACAACCTCTAAACTCGTCCCCAGAGGAGGACTTGAATG  
AGGAAACCAACACTTTGAGAAACCAAAGTCCTTTTTTCCCAAAGGTTCTGAAAGGAAAAAA  
AAAAAAAAAACAAAAA

>gi|16306546|gb|NP\_387498.1|FGF18. 207aa linear fibroblast  
growth factor 18 precursor [Homo sapiens].

MYSAPSACTCLCLHFLLLCFQVQVLVAEENVDFRIHVENQTRARDDVSRKQLRLYQLYSR  
TSGKHIQVLGRRISARGEDGDKYAQLLVETDTFGSQVRIKKGKTEFYLCMNRKGLVGP  
DGTSKECVFIEKVLENNYTALMSAKYSGWYVGFTTKGRPRKGPKTRENQQDVHFMKRYPK  
GQPELQKPFKYTTVTKRSRIRPHTPA

>gi|24496766|gb|NM\_004712.3|HGS 2926bp mRNA Homo sapiens  
hepatocyte growth factor-regulated tyrosine kinase substrate  
(HGS), mRNA.

CGGAAGCGGAAGTCGGGGGCGCGCCAGCTCGTAGCAGGGGAGCGCCCGCGGCGTCGGGT  
TTGGGCTGGAGGTCGCCATGGGGCGAGGCAGCGGCACCTTCGAGCGTCTCCTAGACAAGG  
CGACCAGCCAGCTCCTGTTGGAGACAGATTGGGAGTCCATTTTGCAGATCTGCGACCTGA  
TCCGCCAAGGGGACACACAAGCAAAATATGCTGTGAATTCCATCAAGAAGAAAGTCAACG  
ACAAGAACCCACACGTCGCCTTGTATGCCCTGGAGGTCATGGAATCTGTGGTAAAGAACT  
GTGGCCAGACAGTTCATGATGAGGTGGCCAACAAGCAGACCATGGAGGAGCTGAAGGACC  
TGCTGAAGAGACAAGTGGAGGTAAACGTCCGTAACAAGATCCTGTACCTGATCCAGGCCT  
GGGCGCATGCCTTCCGGAACGAGCCCAAGTACAAGGTGGTCCAGGACACCTACCAGATCA  
TGAAGGTGGAGGGGCACGTCTTTCCAGAATTCAAAGAGAGCGATGCCATGTTTGCTGCCG  
AGAGAGCCCCAGACTGGGTGGACGCTGAGGAATGCCACCGCTGCAGGGTGCAGTTCCGGG  
TGATGACCCGTAAGCACCACTGCCGGGCGTGTGGGCAGATATTCTGTGGAAAGTGTTCTT  
CCAAGTACTCCACCATCCCCAAGTTTGGCATCGAGAAGGAGGTGCGCGTGTGTGAGCCCT  
GCTACGAGCAGCTGAACAGGAAAGCGGAGGGAAAGGCCACTTCCACCACTGAGCTGCCCC  
CCGAGTACCTGACCAGCCCCCTGTCTCAGCAGTCCCAGCTGCCCCCAAGAGGGACGAGA  
CGGCCCTGCAGGAGGAGGAGGAGCTGCAGCTGGCCCTGGCGCTGTCACAGTCAGAGGCGG  
AGGAGAAGGAGAGGCTGAGACAGAAGTCCACGTACACTTCGTACCCCAAGGCGGAGCCCA  
TGCCCTCGGCCTCCTCAGCGCCCCCGCCAGCAGCCTGTACTCTTACCTGTGAACTCGT

- 183 -

CGGCGCCTCTGGCTGAGGACATCGACCCTGAGCTCGCACGGTATCTCAACCGGAACTACT  
 GGGAGAAGAAGCAGGAGGAGGCTCGCAAGAGCCCCACGCCATCTGCGCCCGTGCCCTGA  
 CGGAGCCGGCTGCACAGCCTGGGGAAGGGCACGCAGCCCCACCAACGTGGTGGAGAACC  
 CCTCCCGGAGACAGACTCTCAGCCCATTCCTCCCTCTGGTGGCCCTTTAGTGAGCCAC  
 AGTTCCACAATGGCGAGTCTGAGGAGAGCCACGAGCAGTTCCTGAAGGCGCTGCAGAACG  
 CCGTCACCACCTTCGTGAACCGCATGAAGAGTAACCACATGCGGGGCGCAGCATCACCA  
 ATGACTCGGCCGTGCTCTCACTCTTCCAGTCCATCAACGGCATGCACCCGCAGCTGCTGG  
 AGCTGCTCAACCAGCTGGACGAGCGCAGGCTGTACTATGAGGGGCTGCAGGACAAGCTGG  
 CACAGATCCGCGATGCCCCGGGGGGCGCTGAGTGCCCTGCGCGAAGAGCACCGGGAGAAGC  
 TTCGCCGGGCAGCCGAGGAGGCAGAGCGCCAGCGCCAGATCCAGCTGGCCAGAAAGCTGG  
 AGATAATGCGGCAGAAGAAGCAGGAGTACCTGGAGGTGCAGAGGCAGCTGGCCATCCAGC  
 GCCTGCAGGAGCAGGAGAAGGAGCGGCAGATGCGGCTGGAGCAGCAGAAGCAGACGGTCC  
 AGATGCGCGCGCAGATGCCCCGCTTCCCCCTGCCCTACGCCAGCTCCAGGCCATGCCCG  
 CAGCCGGAGGTGTGCTCTACCAGCCCTCGGGACCAGCCAGCTTCCCCAGCACCTTCAGCC  
 CTGCCGGCTCGGTGGAGGGCTCCCCAATGCACGGCGTGTACATGAGCCAGCCGGCCCCCTG  
 CCGCTGGCCCCCTACCCAGCATGCCAGCACTGCGGCTGATCCAGCATGGTGAGTGCCCT  
 ACATGTACCCAGCAGGGGGCCACTGGGGCGCAGGCGGCCCCCAGGCCAGGCCGGAACCA  
 CCGCCAGCCCCGCTTACTCATCCTACCAGCCTACTCCACAGCGGGCTACCAGAACGTGG  
 CCTCCCAGGCCCCACAGAGCCTCCCGGCCATCTCTCAGCCTCCGCAGTCCAGCACCATGG  
 GCTACATGGGGAGCCAGTCAGTCTCCATGGGCTACCAGCCTTACAACATGCAGAACTCTCA  
 TGACCACCCTCCCAAGCCAGGATGCGTCTCTGCCACCCAGCAGCCCTACATCGCGGGGC  
 AGCAGCCCATGTACCAGCAGATGGCACCCCTCTGGCGGTCCCCCCCAGCAGCAGCCCCCG  
 TGGCCAGCAACCGCAGGCACAGGGGCGCGCCGGCACAGGGCAGCGAGGCCAGCTCATTT  
 CATTGACTGACCCAGGCCATGCTCACGTCCGGAGTAACACTACATACAGTTCACCTGAA  
 ACGCCTCGTCTCTAACTGCCGTGCTCCTGCCTCCCTGTCTCTACTGCCGGTAGTGTCCC  
 TTCTCTGCGAGTGAGGGGGGGCCTTCACCCCAAGCCCACCTCCCTTGTCTCTCAGCCTACT  
 GCAGTCCCTGAGTTAGTCTCTGCTTTCTTTCCCAGGGCTGGGCCATGGGGAGGGAAGGA  
 CTTTCTCCAGGGGAAGCCCCAGCCCTGTGGGTGATGGTCTGTGAGAGGTGGCAGGAAT  
 GGGGACCCTCACCCCCCAAGCAGCCTGTGCCCTCTGGCCGCACTGTGAGCTGGCTGTGGT  
 GTCTGGGTGTGGCCTGGGGCTCCCTCTGCAGGGGCTCTCTCGGCAGCCACAGCCAAGGG  
 TGGAGGCTTCAGGTCTCCAGCTTCTCTGCTTCTCAGCTGCCATCTCCAGTGCCCCAGAAT  
 GGTACAGCGATAATAAAATGTATTTAGAAAAA

>gi|4758528|gb|NP\_004703.1|HGS 777aa linear hepatocyte growth  
 factor-regulated tyrosine kinase substrate; human growth  
 factor-regulated tyrosine kinase substrate [Homo sapiens].  
 MGRGSGTFERLLDKATSQLLLETDWESILQICDLIRQGDTQAKYAVNSIKKKVNDKNPHV  
 ALYALEVMESVVKNCGQTVHDEVANKQTMELKDLLKROVEVNRNKILYLIQAWAHAFR  
 NEPKYKVVQDTYQIMKVEGHVFPFVKESDAMFAAERAPDWVDAEECHRCRVQFGVMTRKH  
 HCRACGQIFCGKCSSKYSTIPKFGIEKEVRVCEPCYEQLNRKAEGKATSTTELPPEYLTS  
 PLSQQSQLPPKRDETAHQEEEEELQLALALSQSEAEKERLRQKSTYTSYPKAEPMPSSASS  
 APPASSLYSSPVNSSAPLAEDIDPELARYLNRNYWEKKQEEARKSPTPSAPVPLTEPAAQ  
 PGEHHAAPTENVENPLPETDSQPIPPSGGPFSEPOFHNGESEESHEQFLKALQNAVTTFV  
 NRMKSNHMRGRSITNDSAVLSLFQSSINGMHPQLLELLNQLDERRLYEGLQDKLAQIRDA  
 RGALSALREEHREKLRRAAEEAERQRQIQLAQKLEIMRQKKQEYLEVQRQLAIQRLQEQE  
 KERQMRLEQQKQTVQMRAQMPAFPLPYAQLQAMPAAGGVLYQPSGPASFPSTFSPAGSVE  
 GSPMHGVYMSQPAAPAGPYPSMPSTAADPSMVSAAYMYPAGATGAQAAPQAQAGPTASPAY  
 SSYQPTPTAGYQNVASQAPQSLPAISQPPQSSMTMGYMGSSVSMGYQPYNMQLMTTLPS

- 184 -

QDASLPPQQPYIAGQQPMYQQMAPSGGPPQQQPPVAQQPQAQGPPAQGSEAQLISFD  
>gi|20127435|gb|NM\_003821.2|RIPK2 1898bp mRNA Homo sapiens  
receptor-interacting serine-threonine kinase 2 (RIPK2), mRNA.  
GGCACGAGGGTCAGCTCTGGTTCGGAGAAGCAGCGGCTGGCGTGGGCCATCCGGGGAATG  
GGCGCCCTCGTGACCTAGTGTTCGGGGGCAAAAAGGGTCTTGCCGGCCTCGCTCGTGACG  
GGCGGTATCTGGGCGCCTGAGCGCGGCGTGGGAGCCTTGGGAGCCGCCGCAGCAGGGGGC  
ACACCCGGAACCGGCCTGAGCGCCCGGGACCATGAACGGGGAGGCCATCTGCAGCGCCCT  
GCCCACCATTCCCTACCACAACTCGCCGACCTGCGCTACCTGAGCCGCGGCGCCTCTGG  
CACTGTGTCTGTCGCGCCCGCCACGCAGACTGGCGCGTCCAGGTGGCCGTGAAGCACCTGCA  
CATCCACACTCCGCTGCTCGACAGTGAAAGAAAGGATGTCTTAAGAGAAGCTGAAATTTT  
ACACAAAGCTAGATTTAGTTACATTCTTCCAATTTTGGGAATTTGCAATGAGCCTGAATT  
TTTGGGAATAGTTACTGAATACATGCCAAATGGATCATTAAATGAACTCCTACATAGGAA  
AACTGAATATCCTGATGTTGCTTGGCCATTGAGATTTTCGCATCCTGCATGAAATTGCCCT  
TGGTGTAATTAACCTGCACAATATGACTCCTCCTTTACTTCATCATGACTTGAAGACTCA  
GAATATCTTATTGACAATGAATTTTCATGTTAAGATTGCAGATTTTGGTTTATCAAAGTG  
GCGCATGATGTCCCTCTCACAGTCACGAAGTAGCAAATCTGCACCAGAAGGAGGGACAAT  
TATCTATATGCCACCTGAAAACCTATGAACCTGGACAAAAATCAAGGGCCAGTATCAAGCA  
CGATATATATAGCTATGCAGTTATCACATGGGAAGTGTTATCCAGAAAACAGCCTTTTGA  
AGATGTCACCAATCCTTTGCAGATAATGTATAGTGTGTCACAAGGACATCGACCTGTTAT  
TAATGAAGAAAGTTTGGCATATGATATACCTCACCGAGCACGTATGATCTCTCTAATAGA  
AAGTGGATGGGCACAAAATCCAGATGAAAGACCATCTTCTTAAATGTTTAATAGAACT  
TGAACCAGTTTGTGAGAACATTTGAAGAGATAACTTTTCTTGAAGCTGTTATTCAGCTAAA  
GAAAACAAAGTTACAGAGTGTTTCAAGTGCCATTACCTATGTGACAAGAAGAAAATGGA  
ATTATCTCTGAACATACCTGTAAATCATGGTCCACAAGAGGAATCATGTGGATCCTCTCA  
GCTCCATGAAAATAGTGGTTCTCCTGAACTTCAAGGTCCCTGCCAGCTCCTCAAGACAA  
TGATTTTTTATCTAGAAAAGCTCAAGACTGTTATTTTATGAAGCTGCATCACTGTCCTGG  
AAATCACAGTTGGGATAGCACCATTTCTGGATCTCAAAGGGCTGCATTCTGTGATCACAA  
GACCACTCCATGCTCTTCAGCAATAATAAATCCACTCTCAACTGCAGGAACTCAGAACG  
TCTGCAGCCTGGTATAGCCCAGCAGTGGATCCAGAGCAAAAGGGAAGACATTGTGAACCA  
AATGACAGAAGCCTGCCTTAACCAAGTCGCTAGATGCCCTTCTGTCCAGGGACTTGATCAT  
GAAAGAGGACTATGAACTTGTTAGTACCAAGCCTACAAGGACCTCAAAGTCAGACAATT  
ACTAGACACTACTGACATCCAAGGAGAAGAATTTGCCAAAGTTATAGTACAAAAATTGAA  
AGATAACAAACAAATGGGTCTTCAGCCTTACCCGGAATACTTGTGGTTTCTAGATCACC  
ATCTTTAAATTTACTTCAAAAATAAAGCATGTAAGTGACTGTTTTTCAAGAAGAAATGTG  
TTTCATAAAAGGATATTTATAAAAAAAAAAAAAAAAAAAAAA  
>gi|4506537|gb|NP\_003812.1|RIPK2 540aa linear receptor-  
interacting serine-threonine kinase 2; receptor interacting  
protein 2 [Homo sapiens].  
MNGEAICSAIPTIPYHKLADRLYLRSRGASGTVSSARHADWRVQVAVKHLHIHTPLLDSE  
KDVLREAEILHKARFSYILPILGICNEPEFLGIVTEYMPNGSLNELLRKTEYPDVAWPL  
RFRILHEIALGVNYLHNMTPLHDLKTQNILLDNEFHVKIADFGLSKWRMMSLSQSRS  
SKSAPEGGTIIYMPENYEPGQKSRAIKHDIYSYAVITWEVLSRKQPFEDVTNPLQIMY  
SVSQGHRPVINEESLPYDIPHRARMISLIESGWAQNPDERPSFLKCLIELEPVLRTFEEI  
TFLEAVIQKKTKLQSVSSAIHLCDKKKMELSLNIPVNHGPQEESCGSSQLHENS GSPET  
SRSLPAPQDNDFLSRKAQDCYFMKLHHC PGNHSWDSTISGSQRAAFCDHKTTPCSSAIIN  
PLSTAGNSERLQPGIAQQWIIQSKREDIVNQMTACLNQSLDALLSRDLIMKEDYELVSTK  
PTRTSKVRQLLDTTDIQGEEFAKVIQVQKLKDNKQMGLOPYPEILVVSRSPLNLLQNKSM

- 185 -

>gi|26051238|gb|NM\_021137.3|TNFAIP1 3571bp mRNA Homo sapiens tumor necrosis factor, alpha-induced protein 1 (endothelial) (TNFAIP1), mRNA.

CACAGCTTGGGACTGCTGAGGGGCGAGGCGGCTGCAGGCTAGGGGCGGCTCGGAGTCCGCT  
GGCCACCCAGCTGAGAGGAGAGGCGCCCCCGGGGACGCACTGAGATTATGAGGCTCTGGC  
CTCCACTGGCCACTCACTCGTGACCCTTTCCACCACGGCGGAGCCTTCCAAGCCTACCTC  
CTGCCGTGTGGTGATCTACCTGCAGCGGGAGATGTCGGGGGACACCTGCCTGTGCCCAGC  
CTCAGGGGCCAAGCCCAAGCTCAGTGGCTTCAAGGGAGGAGGGTTGGGCAACAAGTATGT  
CCAGCTCAACGTGGGCGGCTCTCTGTACTACCCACTGTGCGGGCCCTGACCCGCCACGA  
CACCATGCTCAAGGCCATGTTTCAGTGGGCGCATGGAGGTGCTGACCGACAAAGAAGGCTG  
GATCCTCATAGACCGTTGTGGAAAGCACTTTTGGCACCATTGTTGAATTACCTCCGAGATGA  
CACCATCACCTCCCTCAGAACC GGCAAGAAATCAAGGAATTGATGGCTGAAGCAAAGTA  
TTACCTCATCCAGGGGCTGGTGAATATGTGCCAGAGTGCCCTGCAGGACAAGAAGGACTC  
CTACCAGCCTGTGTGCAACATCCCCATCATCACATCCCTAAAGGAGGAGGAGCGGCTCAT  
CGAATCCTCCACCAAGCCCGTGGTGAAGCTGCTGTACAACAGAAGCAACAACAAGTATTC  
CTACACCAGCAACTCTGACGACCACCTGCTGAAAAACATCGAGCTGTTTGACAAGCTCTC  
CCTGCGCTTCAACGGCCGCGTGCTCTTCATCAAGGATGTCATTGGTGACGAGATCTGCTG  
CTGGTCCTTTTATGGCCAGGGCCGTAAGCTGGCAGAGGTGTGCTGTACCTCCATCGTGTA  
TGCCACGGAGAAGAAGCAGACCAAGGTGGAATTCCAGAGGCCCGAATCTATGAGGAGAC  
ACTCAACGTCTACTCTATGAGACTCCCCGCGTCCCCGACAACCTCCTTGTTGGAGGCCAC  
AAGCCGTAGCCGCAGCCAGGCTTCCCCCAGTGAAGATGAGGAGACCTTTGAACTGCGGGA  
CCGTGTCCGCCGCATCCACGTCAAGCGCTACAGCACTTACGATGACCGGCAGCTCGGCCA  
CCAGTCTACCCATCGCGACTGACCAGACCCTCAGGGAGTCAGGGCACGGGAGGCCCTATC  
TCCCATCCTGTGGAACCCGCCCCATTTGGCCACCCCATGCTGCTGCTGCCTGGGTCTCTGC  
TCTAGCACCCAGAGGCATGACAGGCCCTGCTCAGAGGTGAGAGGGTCTGGGCAGAGGAGG  
GACCACATTCCCCTGCCTTGCCCCCTGAGCACTTCTGGAGACTGCGTCCTGTCTATCTGC  
TCACCATCACCTTCCCTGCCCGACGGAGCTGCTTCTGCTCCCTGGGGCATATGGACTGAC  
CCACCTCCTGCTGAGAACCTTCCCCTAGGCCCTGTGCAGAAAGGGCTACTGCCCCTTAGGC  
CTCAGCTGGGGGAAAGGCAGTTCTGGTGCTGTAGAGGCCCTGGTGCAGAAAGTGGGACGT  
CTTTTTTCTTAAGGTGTTTAAAGCACAGGCTTGATAAGTTTGGTTTTTAAAAAATAATCTA  
GGAAATGAATAATTCTAAATCTAGTAATGAGGAACTGAGCATTCTTTTGCCCTCCAGG  
GTGCCAAGACCCTACATATGACAGAACCCTTGGCCCTTCTCCATGCCTGTGGGATCTGTT  
TCTTTAAAGCACTTTGTACTGTTATTTCAGGAGGTTGATAATCTCCTTGACCCATGTCTTT  
CTACCCTAATCCCCACTTCCCTGCAGAATCAATCTGAGGGAGGGGATAAAGAGGAAGCAA  
TAAAAAATAACATCCGACAGAGCAGCTCTGGCTTTGCCAGCCTGGCCAGCAGCTCAGAG  
TGCACCGAGGAGGGAAGGATGGCTAAGCTGGGACCGGCAGTCCTCACAGGGTGCCCTGTGA  
GAAAGGACATTTTACCCCCACATCATAGTCACATCACTGACTCCTAGGTCTAGCACGACT  
GCTCTTTGTGATTCTCTTGAGTACCCTTGGCTTCCAGCCATGCTGTCTCTCACATACGGTA  
AAGCCAAAGAGCTGTACATGGGCCAGAAACATGAGCCACGGCAGGAAGACCGTGGAGCC  
CGTGGGCACATGCATGGTGTGGCTGGCATGCCCATCAGCTGAGGACAGCAAACCTCCCAGC  
AGCCCCCTACAGAGGTGGCACATGCTTGGCCACACATCTACTCCCTGCCACACCATCTAT  
GCTCTTGGTTGGTGCTGGCTGGGATGGCGGTTCTGCCAGTGGTGTCTCTGAGCGCGGGA  
TGACAGGAGCAACCGAAGCACCCTGAAGGCCTTCACTCCTTGTGGGTAACCTCAGCCATG  
GAGATGCCAAGCACTAGCCAGGAGGTGAGTTCTCTTTAGGGCTTTGGTTTTTCATTCTT  
TTTGTGGCTTGGCCAAACCAGAAATTCAGCTTATCTGAATTATTTTCCAAAGGAATGCT  
GTCAGGGAGGGACTGTTCTGCCAGCCTAACAAAGCAACGTAGCCACGTATAGTACCCACT  
TTCTGCTCTTTGGAGAGAACACAGGTTATCAAGTTCATCTCTCTTGACTACTCTTATGAT

- 186 -

AGCTGATGCCACAGAGCCTATGGGCAAATGCCAGACCCAGGGTTAGACACAAGGACCTGA  
AGTGACATGACGGCGGGACAGGGGAAATGTGACTTTCTAATTAGGCATTTTATGTTAGTC  
ACAGTCTTGAATGTATAAACAGCACTAAGACTCTCAGGTCAGGTACCTTGGTGATCAGCT  
ACTAGTTCTTCCAGCCCTCATTGAGGTAACAAGATAAAGACAAATCCACTTCTTTGGCCA  
AATTCAGGCTTTTGGCTTTATGACTTTCCACAGAGACTGGAATGCGTCAGCCTGAGACCA  
CTGGCCTATTTTCTCAGCTGCCCTCTTGAGGTCCTTTAACTCAAATTCAGCTCCCC  
ACTGAGGTGTTGTGATGCTTGCCCTTTTGACCTCCCCATCCCCCTTAGTCCCTGCTTACTA  
CTTTGACATTCACATCCTCAGTGTCTCAGTCTTTTTTGGCCGAGAAAGCACAGTAGTCTGG  
GACTGGGCATTTATCTTCTCTGACTGAAAATCTCTCCTTGGTCTTAAGGAAAACTAAC  
ATTGAACTCACTGACATGATCTTAGCTTCTTTAATCAGACTTTGTGACTTAAAAGTTTGG  
GGGTTTTCTTTGAAAGTTTCCAGCCCTATTCAGAAAGCAACTCTTGGCTGTGTGCATTTT  
TCAACTCCAAGCAGCCAGGGGTAAGTAAACAAAGTATGGATGAAGGTCAGATTTTCTTG  
TCAGTTTCTGAGAAACCTGGCAGCCTGCTGTTAACAACACAGGCCAGTATTGGGTTTTAT  
TGAATTTGGTATGTGACCAAGGTCGGCCTAAAGGATGGCGCAGGTCCTGGGCAGGAAAGA  
ATTTTCTCTTTATCACATAACTGTAATATTTGGTTGCTCAGCATAAGTGATGGAAGCAAA  
CACTAATTTCTAATAAAATTGTGTAAACTC

>gi|10863937|gb|NP\_066960.1|TNFAIP1 316aa linear tumor  
necrosis factor, alpha-induced protein 1 [Homo sapiens].

MSGDTCLCPASGAKPKLSGFKGGGLGNKYVQLNVGGSlyYTTVRALTRHDTMLKAMFSGR  
MEVLTDKEGWILIDRCGKHFGTILNYLRDDTITLPQNRQEI KELMAEAKYYLIQGLVNMC  
QSALQDKKDSYQPV CNIP IITSLKEERLIESSTKPVVKLLYNRSNNKYSYTSNSDDHLL  
KNIELFDKLSLRFNGRVLF IKDVI GDEICWSFYGQGRKLA EVCCTSIVYATEKKQTKVE  
FPEARIEETLNVLLYETPRVPD NSLLEATSRSR SQASPEDEETFELRDRVRRIHV KRY  
STYDDRQLGHQSTHRD

>gi|27597077|gb|NM\_006293.2|TYRO3 3949bp mRNA Homo sapiens  
TYRO3 protein tyrosine kinase (TYRO3), mRNA.

GCGGTGGCGCGGGAGCGGCCCCGGGACCCCGCGCTGCTGACGGCGGCGACCGCGGCCGG  
AGGCGGGCGCGGGTCTCGGAGGCGGTGCGCTCAGCACCGCCCCACGGGCGGCCCCAGCCC  
CTCCCGCAGCCCTCCTCCCTCCCGCTCCCTTCCCGCCGCTCCTCCCCGCCCTCCTCCCT  
CCTCGCTCGCGGGCCGGGCCCCGCATGGTGCGGCGTCCGCGCCGATGGCGCTGAGGCGGA  
GCATGGGGCGGCGGGGCTCCCGCCGCTGCCGCTGCCGCGCCACCGCGGCTCGGGCTGC  
TGCTGGCGGCTCTGGCTTCTCTGCTGCTCCCGGAGTCCGCGCCGCGCAGGTCTGAAGCTCA  
TGGGAGCCCCGGTGAAGCTGACAGTGTCTCAGGGGCAGCCGGTGAAGCTCAACTGCAGTG  
TGGAGGGGATGGAGGAGCCTGACATCCAGTGGGTGAAGGATGGGGCTGTGGTCCAGAACT  
TGGACCAGTTGTACATCCAGTCAGCGAGCAGCACTGGATCGGCTTCTCAGCCTGAAGT  
CAGTGGAGCGCTCTGACGCCGGCCGGTACTGGTGCCAGGTGGAGGATGGGGGTGAAACCG  
AGATCTCCAGCCAGTGTGGCTCACGGTAGAAGGTGTGCCATTTTTCAGAGTGAGCCAA  
AAGATCTGGCAGTGCCACCCAATGCCCTTTTCCAAGTGTCTTGTGAGGCTGTGGGTCCCC  
CTGAACCTGTTACCATTGTCTGGTGGAGAGGAACTACGAAGATCGGGGGACCCGCTCCCT  
CTCCATCTGTTTTAAATGTAACAGGGGTGACCCAGAGCACCATGTTTTCTGTGAAGCTC  
ACAACCTAAAAGGCCTGGCCTCTTCTCGCACAGCCACTGTTTCACTTCAAGCACTGCCTG  
CAGCCCCCTTCAACATCACCGTGACAAAGCTTTCAGCAGCAACGCTAGTGTGGCCTGGA  
TGCCAGGTGCTGATGGCCGAGCTCTGCTACAGTCTGTACAGTTCAGGTGACACAGGCCC  
CAGGAGGCTGGGAAGTCCTGGCTGTTGTGGTCCCTGTGCCCCCTTTACCTGCCTGCTCC  
GGGACCTGGTGCCTGCCACCAACTACAGCCTCAGGGTGCCTGTGCCAATGCCTTGGGGC  
CCTCTCCCTATGCTGACTGGGTGCCCTTTCAGACCAAGGGTCTAGCCCCAGCCAGCGCTC  
CCCAAACCTCCATGCCATCCGCACAGATTCAGGCCTCATCTTGGAGTGGGAAGAAGTGA



- 187 -

TCCCCGAGGCCCTTTTGAAGGCCCTGGGACCCTACAACTGTCCTGGGTTCAGACA  
ATGGAACCCAGGATGAGCTGACAGTGGAGGGGACCAGGGCCAATTTGACAGGCTGGGATC  
CCCCAAAGGACCTGATCGTACGTGTGTGCGTCTCCAATGCAGTTGGCTGTGGACCCTGGA  
GTCAGCCACTGGTGGTCTCTTCTCATGACCGTGCAGGCCAGCAGGGCCCTCCTCACAGCC  
GCACATCCTGGGTACCTGTGGTCCTTGGTGTGCTAACGGCCCTGGTGACGGCTGCTGCCC  
TGGCCCTCATCCTGCTTCGAAAGAGACGGAAAGAGACGCGGTTTGGGCAAGCCTTTGACA  
GTGTCATGGCCCGGGGAGAGCCAGCCGTTCACTTCCGGGCAGCCCGGTCTTCAATCGAG  
AAAGGCCCGAGCGCATCGAGGCCACATTGGACAGCTTGGGCATCAGCGATGAACTAAAGG  
AAAACTGGAGGATGTGCTCATCCAGAGCAGCAGTTACCCCTGGGCCGGATGTTGGGCA  
AAGGAGAGTTTGGTTCAGTGCGGGAGGCCAGCTGAAGCAAGAGGATGGCTCCTTTGTGA  
AAGTGGCTGTGAAGATGCTGAAAGCTGACATCATTGCCTCAAGCGACATTGAAGAGTTCC  
TCAGGGAAGCAGCTTGCATGAAGGAGTTTGACCATCCACACGTGGCCAACTTGTGGGG  
TAAGCCTCCGGAGCAGGGCTAAAGGCCGTCTCCCATCCCATGGTCATCTTGCCCTTCA  
TGAAGCATGGGGACCTGCATGCCTTCCTGCTCGCCTCCCGGATTGGGGAGAACCCCTTTA  
ACCTACCCCTCCAGACCCCTGATCCGGTTCATGGTGGACATTGCCTGCGGCATGGAGTACC  
TGAGCTCTCGGAACTTCATCCACCGAGACCTGGCTGCTCGGAATTGCATGCTGGCAGAGG  
ACATGACAGTGTGTGTGGCTGACTTCGGACTCTCCCGGAAGATCTACAGTGGGGACTACT  
ATCGTCAAGGCTGTGCCTCCAACTGCCTGTCAAGTGGCTGGCCCTGGAGAGCCTGGCCG  
ACAACCTGTATACTGTGCAGAGTGACGTGTGGGCGTTTCGGGGTGACCATGTGGGAGATCA  
TGACACGTGGGCAGACGCCATATGCTGGCATCGAAAACGCTGAGATTTACAACCTACCTCA  
TTGGCGGGAACCGCCTGAAACAGCCTCCGGAGTGTATGGAGGACGTGTATGATCTCATGT  
ACCAGTGTGGAGTGTGACCCCAAGCAGCGCCCGAGCTTTACTTGTCTGCGAATGGAAC  
TGGAGAACATCTTGGGCCAGCTGTCTGTGCTATCTGCCAGCCAGGACCCCTTATACATCA  
ACATCGAGAGAGCTGAGGAGCCCACTGCGGGAGGCAGCCTGGAGCTACCTGGCAGGGATC  
AGCCCTACAGTGGGGCTGGGGATGGCAGTGGCATGGGGGCAGTGGGTGGCACTCCAGTG  
ACTGTGCGGTACATACTCACCCCGGAGGGCTGGCTGAGCAGCCAGGGCAGGCAGAGCACC  
AGCCAGAGAGTCCCCTCAATGAGACACAGAGGCTTTTGTGCTGCTGCAGCAAGGGCTACTGC  
CACACAGTAGCTGTTAGCCACAGGCAGAGGGCATCGGGGCCATTTGGCCGGCTCTGGTG  
GCCACTGAGCTGGCTGACTAAGCCCCGTCTGACCCAGCCAGACAGCAAGGTGTGGAGG  
CTCCTGTGGTAGTCTTCCCAAGCTGTGCTGGGAAGCCCGGACTGACCAAATCACCCAATC  
CCAGTTCTTCTGCAACCACTCTGTGGCCAGCCTGGCATCAGTTTAGGCCTTGGCTTGAT  
GGAAGTGGGCCAGTCTTGGTTGTCTGAACCCAGGCAGCTGGCAGGAGTGGGGTGGTTATG  
TTTCCATGGTTACCATGGGTGTGGATGGCAGTGTGGGGAGGGCAGGTCCAGCTCTGTGGG  
CCCTACCCCTCTGCTGAGCTGCCCCCTGCTGCTTAAGTGCATGCATTGAGCTGCCTCCAGC  
CTGGTGGCCAGCTATTACCACACTTGGGGTTTAAATATCCAGGTGTGCCCTCCAAGTC  
ACAAAGAGATGTCCTTGTAATATTCCTTTTAGGTGAGGGTTGGTAAGGGGTGGTATCT  
CAGGTCTGAATCTTACCATCTTCTGATTCCGCACCCTGCCTACGCCAGGAGAAGTTGA  
GGGGAGCATGCTTCCCTGCAGCTGACCGGGTCACACAAAGGCATGCTGGAGTACCCAGCC  
TATCAGGTGCCCCCTTCCAAAGGCAGCGTGCCGAGCCAGCAAGAGGAAGGGGTGCTGTG  
AGGCTTGCCAGGAGCAAGTGAGGCCGGAGAGGAGTTTCAGGAACCCTTCTCCATACCCAC  
AATCTGAGCACGCTACCAAATCTCAAAATATCCTAAGACTAACAAAGGCAGCTGTGTCTG  
AGCCCAACCCTTCTAAACGGTGACCTTTAGTGCCAACTTCCCCTCTAACTGGACAGCCTC  
TTCTGTCCCAAGTCTCCAGAGAGAAATCAGGCCTGATGAGGGGGAATTCCTGGAACCTGG  
ACCCAGCCTTGGTGGGGGAGCCTCTGGAATGCATGGGGCGGGTCTAGCTGTTAGGGAC  
ATTTCCAAGCTGTTAGTTGCTGTTTAAATAGAAATAAAATTGAAGACT

>gi|27597078|gb|NP\_006284.2|TYRO3 890aa linear TYRO3 protein  
tyrosine kinase; Brt; Dtk; Sky; Tif; Tyro3 protein tyrosine

- 188 -

kinase (sea-related receptor tyrosine kinase); tyrosine-protein kinase receptor TYRO3 precursor [Homo sapiens].

MALRRSMGRPGLPPLPLPPPPRLGLLLLAALASLLLLPESAAAGLKLIMGAPVKLTVSQGPV  
 KLNCSVEGMEEPDIQWVKDGAUVQNLQDQLYIPVSEQHWIGFLSLKSVERS DAGRYWCQVE  
 DGGETEISQPVWLTVEGVPPFFFTVEPKDLAVPPNAPFQLSCEAVGPPEPVTIVWWRGTTKI  
 GGPAPSPSVLNVTVGTQSTMFSC EAHNLKGLASSRTATVHLQALPAAPFNITVTKLSSSN  
 ASVAWMPGADGRALLQSC TVQVTQAPGGWEVLAVVVPVPPFTCLLRDLVPATNYS LRVC  
 ANALGPS PYADWVPFQTKGLAPASAPQNLHAIRTD SGLILEWEEVIPEAPLEGPLGPYKL  
 SWVQDNGTQDELTVEGTRANLTGWDPQKDLIVRVCVSNVAVGCGPWSQPLVVSSHDRAGQQ  
 GPPHSRTSWVPVVLGVLTALVTAAALALILLRKRKETRFGQAFDSVMARGEPAVHFRAA  
 RSFNRERPERIEATLDSLGI SDELKEKLEDVLIPEQQFTLGRMLGKGEFGSVREAQLKQE  
 DGSFVKVAVKMLKADI IASSDIEEFLREAACMKEFDH PHVAKLVGVSLRSRAKGRLPIM  
 VILPFMKHGD LHAFL LASRIGENPFNLPLQTLIRFMVDIACGMEYLSSRNFIHRDLAARN  
 CMLAEDMTVCVADFGLSRKIYSGDYRQGCASKLPVKWLALES LADNLYTVQSDVWAFGV  
 TMWEIMTRGQTPYAGIENAEIYNYLIGGNRLKQPPECMEDVYDLMYQCWSADPKQRPST  
 CLRMEL ENILGQLSVLSASQDPLYINIERAE EPTAGGSLELPGRDQPYSGAGD GSGMGAV  
 GGTPSDCRYILTPGGLAEQPGQAEHQPE SPLNETQRLLLLLQQGLLPHSSC

>gi|4502884|gb|NM\_003992.1|CLK3 1762bp mRNA Homo sapiens CDC-like kinase 3 (CLK3), transcript variant phclk3, mRNA.

TGGGGCACTGGTACCTCCAGGACCTGGAGTGTACTGGAAGAAATGGTGCAGTCCAGATGC  
 ATCACTGTAAGCGATACCGCTCCCCTGAACCAGACCCGTACCTGAGCTACCGATGGAAGA  
 GGAGGAGGTCCTACAGTCGGGAACATGAAGGGAGACTGCGATACCCGTCCCGAAGGGAGC  
 CTCCCCACGAAGATCTCGGTCCAGAAGCCATGACCGCCTGCCCTACCAGAGGAGGTACC  
 GGGAGCGCCGTGACAGCGATACATACCGGTGTGAAGAGCGGAGCCCATCCTTTGGAGAGG  
 ACTACTATGGACCTTCACGTTCTCGTCATCGTCGGCGATCGCGGGAGAGGGGGCCATACC  
 GGACCCGCAAGCATGCCCACCACTGCCACAAACGCCGCACCAGGTCTTG TAGCAGCGCCT  
 CCTCGAGAAGCCAACAGAGCAGTAAGCGCACAGGCGGAGTGTGGAAGATGACAAGGAGG  
 GTCACCTGGTGTGCCGGATCGGCGATTGGCTCCAAGAGCGATATGAGATTGTGGGGAACC  
 TGGGTGAAGGCACCTTTGGCAAGGTGGTGGAGTGCTTGGACCATGCCAGAGGGAAGTCTC  
 AGGTTGCCCTGAAGATCATCCGCAACGTGGGCAAGTACCGGGAGGCTGCCCGGCTAGAAA  
 TCAACGTGCTCAAAAAAATCAAGGAGAAGGACAAAGAAAACAAGTTCCTGTGTGTCTTGA  
 TGTCTGACTGGTTCAACTTCCACGGTCACATGTGCATCGCCTTTGAGCTCCTGGGCAAGA  
 ACACCTTTGAGTTCCTGAAGGAGAATAACTTCCAGCCTTACCCCTACCACATGTCCGGC  
 ACATGGCCTACCAGCTCTGCCACGCCCTTAGATTTCTGCATGAGAATCAGCTGACCCATA  
 CAGACTTGAAACCTGAGAACATCCTGTTTGTGAATTCTGAGTTTGAAACCCTCTACAATG  
 AGCACAAGAGCTGTGAGGAGAAGTCAGTGAAGAACACCAGCATCCGAGTGGCTGACTTTG  
 GCAGTGCCACATTTGACCATGAGCACCACACCACCATTTGTGGCCACCCGTCACTATCGCC  
 CGCCTGAGGTGATCCTTGAGCTGGGCTGGGCACAGCCCTGTGACGTCTGGAGCATTTGGCT  
 GCATTCTCTTTGAGTACTACCGGGGCTTCACTCTTCCAGACCCACGAAAACCGAGAGC  
 ACCTGGTGATGATGGAGAAGATCCTAGGGCCCATCCCATCACACATGATCCACCGTACCA  
 GGAAGCAGAAATATTTCTACAAAGGGGGCCTAGTTTGGGATGAGAACAGCTCTGACGGCC  
 GGTATGTGAAGGAGAAGTGC AAACCTCTGAAGAGTTACATGCTCCAAGACTCCCTGGAGC  
 ACGTGCAGCTGTTTGACCTGATGAGGAGGATGTTAGAATTTGACCCTGCCAGCGCATCA  
 CACTGGCCGAGGCCCTGCTGCACCCCTTCTTTGCTGGCCTGACCCCTGAGGAGCGGTCTCT  
 TCCACACCAGCCGCAACCCAAGCAGATGACAGGCACAGGCCACCGCATGAGGAGATGGAG  
 GGCGGGACTGGGCCGCCAGCCCTTGACTCCAGCCTCGACCGCCAGCCCCAGGCCAGAG  
 CCACCCAATGAACAGTGCAATGTGAAGGAAGGCAGGAGCCTGCAGGGGAGCAGACTTGGT



- 189 -

GCCCAGCTGCCAGAAAGCACAGATTTGACCCAAGCTATTTATATGTTATAAAGTTATAAT  
AAAGTGTTTCTTACTGTTTGTA

>gi|4502885|gb|NP\_003983.1|CLK3 490aa linear CDC-like kinase 3  
isoform hclk3 [Homo sapiens].

MHHCKRYRSPEPDPYLSYRWKRRRSYSREHEGRLRYPSSRREPPRRRSRSRSHDRLPYQRR  
YRERRDSITYRCEERSPSFGEDYYGPSRSRHRRRSRERGPYRTRKHAHHCHKRRTRSCSS  
ASSRSQQSSKRTGRSVEDDKEGHLVCRIGDWLQERYEIVGNLGEFTFGKVVECLDHARGK  
SQVALKIIRNVGKYREAAARLEINVLLKKIKEKDKENKFLCVLMSDWFNFHGHMCIAFELLG  
KNTFEFLKENNFQPYPLPHVRHMAVQLCHALRFLHENQLTHTDLKPENILFVNSEFETLY  
NEHKSCEEKSVKNTSIRVADFGSATFDHEHHTTIVATRHYRPPEVILELQWAPCDVWSI  
GCILFEYYRGFTLFQTHENREHLVMMEKILGPIPSHMIHRTRKQKYFYKGGGLVWDENSSD  
GRYVKENCKPLKSYMLQDSLEHVQLFDLMRRMLEFDPAQRITLAEALLHPFFAGLTPEER  
SFHTSRNPSR

>gi|9910121|gb|NM\_020249.1|ADAMTS9 3674bp mRNA Homo sapiens a  
disintegrin-like and metalloprotease (reprolysin type) with  
thrombospondin type 1 motif, 9 (ADAMTS9), mRNA.

GCGGGAAGCACCATGCAGTTTGTATCCTGGGCCACACTGCTAACGCTCCTGGTGCGGGAC  
CTGGCCGAGATGGGGAGCCCAGACGCCGCGCGGCCGTACGCAAGGACAGGCTGCACCCG  
AGGCAAGTGAAATTATTAGAGACCCTGGGCGAATACGAAATCGTGTCTCCCATCCGAGTG  
AACGCTCTCGGAGAACCCTTTCCACGAACGTCCACTTCAAAGAACGCGACGGAGCATT  
AACTCTGCCACTGACCCCTGGCCTGCCTTCGCCTCCTCCTCTTCTCCTCTACCTCCTCC  
CAGGCGCATTACCGCCTCTCTGCCTTCGGCCAGCAGTTTCTATTTAATCTCACCGCCAAT  
GCCGGATTTATCGCTCCACTGTTCACTGTCACCCTCCTCGGGACGCCCGGGGTGAATCAG  
ACCAAGTTTTATTCCGAAGAGGAAGCGGAACCTCAAGCACTGTTTCTACAAAGGCTATGTC  
AATACCAACTCCGAGCACACGGCCGTCATCAGCCTCTGCTCAGGAATGCTGGGCACATTC  
CGGTCTCATGATGGGGATTATTTTATTGAACCACTACAGTCTATGGATGAACAAGAAGAT  
GAAGAGGAACAAAACAAACCCACATCATTTATAGGCGCAGCGCCCCCAGAGAGAGCCC  
TCAACAGGAAGGCATGCATGTGACACCTCAGAACAACAAAATAGGCACAGTAAAGACAAG  
AAGAAAACCAGAGCAAGAAAATGGGGAGAAAGGATTAACCTGGCTGGTGACGTAGCAGCA  
TTAAACAGCGGCTTAGCAACAGAGGCATTTTCTGCTTATGGTAATAAGACGGACAACACA  
AGAGAAAAGAGGACCCACAGAAGGACAAAACGTTTTTTATCCTATCCACGGTTTGTAGAA  
GTCTTGGTGGTGGCAGACAACAGAATGGTTTCATACCATGGAGAAAACCTTCAACACTAT  
ATTTTAACCTTTAATGTCAATTGTAGCCTCTATCTATAAAGACCCAAGTATTGGAAATTTA  
ATTAATATTGTTATTGTGAACCTTAATTTGTGATTCATAATGAACAGGATGGGCCTTCCATA  
TCTTTTAATGCTCAGACAACATTAACAAAACCTTTGCCAGTGGCAGCATTCGAAGAACAGT  
CCAGGTGGAATCCATCATGATACTGCTGTTCTCTTAACAAGACAGGATATCTGCAGAGCT  
CACGACAAATGTGATACCTTAGGCCTGGCTGAACTGGGAACCATTTGTGATCCCTATAGA  
AGCTGTTCTATTAGTGAAGATAGTGGATTGAGTACAGCTTTTACGATCGCCCATGAGCTG  
GGCCATGTGTTTAACATGCCTCATGATGACAACAACAAATGTAAAGAAGAAGGAGTTAAG  
AGTCCCCAGCATGTGATGGCTCCAACACTGAACTTCTACACCAACCCCTGGATGTGGTCA  
AAGTGTAGTCGAAAATATATCACTGAGTTTTTATAGACTGGTTATGGCGAGTGTGTTGCTT  
AACGAACCTGAATCCAGACCCTACCCTTTGCCTGTCCAACCTGCCAGGCATCCTTTACAAC  
GTGAATAACAATGTGAATTGATTTTTTGACCAGGTTCTCAGGTGTGCCCATATATGATG  
CAGTGACAGACGGCTCTGGTGCAATAACGTCAATGGAGTACACAAAGGCTGCCGGACTCAG  
CACACACCCTGGGCCGATGGGACGGAGTGCAGACCTGGAAAGCACTGCAAGTATGGATTT  
TGTGTTCCCAAAGAAATGGATGTCCCGTGACAGATGGATCCTGGGGAAGTTGGAGTCCC  
TTTGGAACCTGCTCCAGAACATGTGGAGGGGGCATCAAAACAGCCATTTCGAGAGTGCAAC

- 190 -

AGACCAGAACCAAAAAATGGTGGAAAATACTGTGTAGGACGTAGAATGAAATTTAAGTCC  
TGCAACACGGAGCCATGTCTCAAGCAGAAGCGAGACTTCCGAGATGAACAGTGTGCTCAC  
TTTGACGGGAAGCATTTTAACATCAACGGTCTGCTTCCCAATGTGCGCTGGGTCCCTAAA  
TACAGTGGAATTCTGATGAAGGACCGGTGCAAGTTGTTCTGCAGAGTGGCAGGGAACACA  
GCCTACTATCAGCTTCGAGACAGAGTGATAGATGGAACCTCTTGTGGCCAGGACACAAAT  
GATATCTGTGTCCAGGGCCTTTGCCGGCAAGCTGGATGCGATCATGTTTTAACTCAAAA  
GCCCCGAGAGATAAATGTGGGGTTTGTGGTGGCGATAATTCTTCATGCAAAACAGTGGCA  
GGAACATTTAATACAGTACATTATGGTTACAATACTGTGGTCCGAATTCCAGCTGGTGCT  
ACCAATATTGATGTGCGGCAGCACAGTTTCTCAGGGGAAACAGACGATGACAACTACTTA  
GCTTTATCAAGCAGTAAAGGTGAATTCCTTGCTAAATGGAACTTTGTTGTCACAATGGCC  
AAAAGGGAAATTTCGATTGGGAATGCTGTGGTAGAGTACAGTGGGTCCGAGACTGCCGTA  
GAAAGAATTAACCAACAGATCGCATTGAGCAAGAACTTTTGCTTCAGGTTTTGTGCGGTG  
GGAAAGTTGTACAACCCCGATGTACGCTATTCTTTCAATATTCGAATTGAAGATAAACCT  
CAGCAGTTTTTACTGGAACAGTCATGGGCCATGGCAAGCATGCAGTAAACCTGCCAAGGG  
GAACGGAAACGAAAACCTTGTTCACCAGGGAATCTGATCAGCTTACTGTTTCTGATCAA  
AGATGCGATCGGCTGCCCCAGCCTGGACACATTACTGAACCCTGTGGTACAGACTGTGAC  
CTGAGGTGGCATGTTGCCAGCAGGAGTGAATGTAGTGCCCACTGTGGCTTGGGTTACCGC  
ACATTGGACATCTACTGTGCCAAATATAGCAGGCTGGATGGGAAGACTGAGAAGGTTGAT  
GATGGTTTTTGCAGCAGCCATCCCAAACCAAGCAACCGTGAAAAATGCTCAGGGGAATGT  
AACACGGGTGGCTGGCGCTATTCTGCCTGGACTGAATGTTCAAAAAGCTGTGACGGTGGG  
ACCCAGAGGAGAAGGGCTATTTGTGTCAATACCCGAAATGATGTACTGGATGACAGCAAA  
TGCACACATCAAGAGAAAGTTACCATTAGAGGTGCAGTGAGTTCCCTTGTCACAGTGG  
AAATCTGGAGACTGGTCAGAGGTAAGATGGGAGGGCTGTTATTTCCCTAGGTCATCTCT  
TACATTCTAGTTCTGGTGCTCTCTATCTGTTTAAAGACAAACCTTGTCACCTTTCTCCC  
ACCTCTCCCTTTCTCCCTTGCTCTCCCTTGAGAAAACAACTCCAGTTCTCTGCCTGCACCA  
TGACTGTCGTACTGGATGTAAC TAGTCTACCAGTGACCTCAGGGCACTTTGGGCTTGGCT  
AGATCACTCACTGTTGTAGCTTCTGTTGTGATTTTGAAGTTGCAGTCCATCACCTTCCCT  
CCTCTTTGAGCCCTAGCTAAGTCACTGAAAGGAAATCATGGATTTATTAATCATAAAGCT  
ATACTAGCTCACATCTGAAGTCAACATGAAGTTTCTACTTCCTTGTCTTTGAAATAAGA  
GAATTAGACCCCAGGGAGTGACCTCTCTGACTTACCCATCCAACCTGCCCAAAAAAAAAA  
AAAAAAAAAAAAAAAA

>gi|9910122|gb|NP\_064634.1|ADAMTS9 1072aa linear a disintegrin  
and metalloproteinase with thrombospondin motifs-9  
preproprotein [Homo sapiens].

MQFVSWATLLTLLVRDLAEMGSPDAAA VRKDRLHPRQVKLLLETLGEYEIVSPIRVNALG  
EPFPTNVHFKRTRRSINSATDPWPAFASSSSSTSSQAHYRLSAFGQQFLFNLTANAGFI  
APLFTVTLLGTPGVNQTKFYSEEEAELKHC FYKGYVNTNSEHTAVISLCSGMLGTFRSHD  
GDYFIEPLQSMDEQEDEEEQNKP HIIYRRSAPQREPSTGRHACDTSEHKNRHSDKKKTR  
ARKWGERINLAGDVAALNSGLATEAFSAYGNKTDNTREKRTHRRTKRFLSYPRFVEVLV  
ADNRMVSYHGENLQHYILTLMSIVASIYKDPSIGNLINIVIVNLIIVIHNEQDGPSISFNA  
QTTLKNLCQWQHSKNSPGGIHHDTAVLLTRQD ICRAHDKCDTLGLAELGTICDPYRSCSI  
SEDSGLSTAFTIAHELGHVFNMPHDDNNKCKEEGVKSPQHVMAPTLNFYTNPWMWSKCSR  
KYITEFLDTGYGECLLNEPESRPYPLPVQLPGILYNVNKQCELI FGPGSQVCPYMMQCRR  
LWCNNVNGVHKGCRTQHTPWADGTECEPGKHCKYGFVCPKEMDVPVTDGSGWSWSPFGTC  
SRTC GGGIKTAIRECNRPEPKNGGKYCVGRRMKFKSCNTEPCLKQKRDFRDEQCAHFDGK  
HFNINGLLPNVRWVPKYSGILMKDRCKLFCRVAGNTAYYQLRDRVIDGTPCGQDNDICV  
QGLCRQAGCDHVLNSKARRDKCGVCGGDNSSCKTVAGTFNTVHYGYNTVVRI PAGATNID

- 191 -

VRQHSFSGETDDDNYLALSSSKGEFLNGNFVVTMAKREIRIGNAVVEYSGSETAVERIN  
STDRIEQELLLQVLSVGKLYNPDRVYSFNIPIEDKPQQFYWNSHGPWQACSKPCQGERKR  
KLVCTRESQDLTVSDQRCDRLPQPGHITEPCGTDCDLRWHVASRSECSAQCGLGVRTLDI  
YCAKYSRLDGKTEKVDGFCSSHPKPSNREKCSGECNTGGWRYSAWTECSKSCDGGTQRR  
RAICVNTRNDVLDDSKCTHQEKVTIQRCSEFPCPQWKSGDWSEVRWEGCYFP

>gi|17981697|gb|NM\_001262.2|CDKN2C 2104bp mRNA Homo sapiens  
cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)  
(CDKN2C), transcript variant 1, mRNA.

CTCTGCCGAGCCTCCTTAAACTCTGCCGTTAAATGGGGGCGGGTTTTTCAACTCAAAA  
AGCGCTCAATTTTTTTCTTTTCAAAAAAGCTGATGAGGTCGGAAGGAGAGAGAAA  
CCGGCACCCCTCTCTGAGAGGCAACAGAAGCAGCAATTGTTTCAGCGAAAAAGCAGCAAG  
GGAGGGAGTGAAGGAAAAAGCAAAAAAGGGGGCGACACGCAAGTGCCTGTAGGGGTGAA  
AGGAGCAGGGACCGCGATCTAGGGGGGATCAGCTACAAAAGAACTGTCACTGGGAGC  
GGTGCGGCCAAGGAGGAAGCAGTGCTGCCAGGCTCTGCTCCAGGGCACAGCTGGCTGGCG  
GCTGCCCTGTCCGCAGCAAAGGGGGCACAGGCCGGGGACCGCGAGAGGTGGCAAAGTGGCA  
CCGGGCGCCGAGGCTGCTGAGCGCTCGCCGAGACGGCGACCGGACTGGCTGCCCCGGAAC  
TGCGGCGACTCTCCCTACTCAGAACTTGCCCTACGTTTCCCAGGACTCTCCCCATCTCCA  
GAGGCCCCACAAAACCGGGAAAGGAAGGAAGGACAGCGGCGGCAGCAGCTCAATGAGT  
GCCTACAGCAGAAAGCCTGAACGAGCTCGGTCTGAGGCGGGAAGTTCCCGGGGGGGCTGC  
CCAGTGACAGCCGCAATGCTGCCGCGAGCTGCCCCAGCAGTCCGGGCTCCGTAGACGCTTT  
CCGCATCACTCTCCTTCCTCGGGCTGCCGGGAGTCCCGGGACCTGGCGGGGCCGGCATGA  
CGGGCTTCTCGGGGGCCCGCCGCACGCCCGGCAGCCTCCGGAGACGCGCGCCGAGCCCGG  
CTCCACAGGCCTCTGAGGCTCGGCGGGGCTGCGGCTGCCTGGCGGGCGGGCTCCGGAGCT  
TTCCTGAGCGGCATTAGCCACGGCTTGCCCCGACGCGACCAAAGGCTCTTCTGGAGAA  
GCCCAGAGCACTGGGCAATCGTTACGACCTGTAACCTTGAGGGCCACCGAACTGCTACTCC  
CGTTCGCCTTTGGCGATCATCTTTTAACCCTCCGGAGCACGTCAGCATCCAGCCACCGCG  
GCGCTCTCCAGCAGCGGAGGACCCAGGACTATCCCTTCGGCGAGACGGATGGAAACCGA  
GCCCCCTGGAGGACCTGCCCCCTGCAGTTCTGCCTCACACGGCTCAAGTCACCACCGTGAA  
CAAGGGACCCTAAAGAATGGCCGAGCCTTGGGGGAACGAGTTGGCGTCCGCAGCTGCCAG  
GGGGGACCTAGAGCAACTTACTAGTTTGTGCAAAATAATGTAAACGTCAATGCACAAAA  
TGGATTGGAAGGACTGCGCTGCAGGTTATGAACTTGGAATCCCGAGATTGCCAGGAG  
ACTGCTACTTAGAGGTGCTAATCCCGATTTGAAAGACCGAACTGGTTTCGCTGTCAATTCA  
TGATGCGGCCAGAGCAGGTTTCCTGGACACTTTACAGACTTTGCTGGAGTTTCAAGCTGA  
TGTTAACATCGAGGATAATGAAGGGAACCTGCCCTTGCACTTGGCTGCCAAAGAAGGCCA  
CCTCCGGGTGGTGGAGTTCTTGGTGAAGCACACGGCCAGCAATGTGGGGCATCGGAACCA  
TAAGGGGGACACCGCCTGTGATTTGGCCAGGCTCTATGGGAGGAATGAGGTTGTTAGCCT  
GATGCAGGCAAACGGGGCTGGGGGAGCCACAAATCTTCAATAAACGTGGGGAGGGCTCCC  
CCACGTTGCCTCTACTTTATCAATTAAGTACTGAGTAGCTCTCCTGACTTTTAATGTCATTTG  
TTAAATAACAGTTCTGTTCATATGTTAAGCAGCTAAATTTTCTGAACTGCATAAGTGAAA  
ATCTTACAACAGGCTTATGAATATATTTAAGCAACATCTTTTAACTGCAAAATCTGTT  
CTAACATGTAATTGCAGATAACTTTGACTTTCTTCTGAATATTTTATCTTTCCTTGGCTT  
TTCCTTGCTTCCCCTTTTGCCAACTCTCAACACCCAAGTTGAAGACTTTGTTTTTAAAT  
GGTTTGTCTGATGCTTTTGTCTAATTAAACACTTTCAAAACAGGAAAAA

>gi|4502751|gb|NP\_001253.1|CDKN2C 168aa linear cyclin-  
dependent kinase inhibitor 2C; cyclin-dependent kinase 6

- 192 -

inhibitor p18; cyclin-dependent kinase 4 inhibitor C; cyclin-dependent inhibitor; CDK6 inhibitor p18 [Homo sapiens].

MAEPWGNELASAAARGDLEQLTSLQNNVNVNAQNGFGR TALQVMKLG NPEIARRLLLRG  
ANPDLKDR TGFAVIHDAARAGFLDTLQTLLEFQADVNI EDNEGNLPLHLAAKEGHLRVVE  
FLVKHTASNVGHRNHKGD TACDLARLYGRNEVVSLMQANGAGGATNLQ

>gi|23510344|gb|NM\_002037.3|FYN 2650bp mRNA Homo sapiens FYN  
oncogene related to SRC, FGR, YES (FYN), transcript variant 1,  
mRNA.

GCCGCGCTGGTGGCGGCGGCGCGTCGTTGCAGTTGCGCCATCTGTCAGGAGCGGAGCCGG  
CGAGGAGGGGGCTGCCGCGGGCGAGGAGGAGGGGTGCGCCGCGAGCCGAAGGCCTTCGAGA  
CCCCCCCCGCGCCCGGCGGCGAGAGTAGAGGCGAGGTTGTTGTGCGAGCGGCGCGTCTCTC  
TCCCGCCCCGGGCGCGCCGCGCTTCTCCAGCGCACCGAGGACCGCCCCGGGCGCACACAAA  
GCCGCGCGCCGCGCCGCGACCGCCCGGCGGCGCCGCGCCCGCGCCAGGGAGGGATTTCGGCCG  
CCGGGCGCGGGGACACCCCCGGCGCGCCCGCCCTCGGTGCTCTCGGAAGGCCACCGGCTCCC  
GGGCCCCGCGGGGACCCCCCGGAGCCGCTCGGCCGCGCCGAGGAGGGCGGGGAGAGGA  
CCATGTGAGTGGGCTCCGGAGCCTCAGCGCCGCGCAGTTTTTTTTGAAGAAGCAGGATGCT  
GATCTAAACGTGGA AAAAGACCAGTCCTGCCTCTGTTGTAGAAGACATGTGGTGTATATA  
AAGTTTGTGATCGTTGGCGGACATTTTGG AATTTAGATAATGGGCTGTGTGCAATGTAAG  
GATAAAGAAGCAACAAA ACTGACGGAGGAGAGGGACGGCAGCCTGAACCAGAGCTCTGGG  
TACCGCTATGGCACAGACCCCCACCCCTCAGCACTACCCAGCTTCGGTGTGACCTCCATC  
CCCAACTACAACA ACTTCCACGCAGCCGGGGGCCAAGGACTCACCGTCTTTGGAGGTGTG  
AACTCTTCGTCTCATA CGGGGACCTTGCGTACGAGAGGAGGAACAGGAGTGACACTCTTT  
GTGGCCCTTTATGACTATGAAGCACGGACAGAAGATGACCTGAGTTTTTCACAAAGGAGAA  
AAATTTCAAATATTGAACAGCTCGGAAGGAGATTGGTGGGAAGCCCGCTCCTTGACA ACT  
GGAGAGACAGGTTACATTCCCAGCAATTATGTGGCTCCAGTTGACTCTATCCAGGCAGAA  
GAGTGGTACTTTGGAAA ACTTGGCCGAAAAGATGCTGAGCGACAGCTATTGTCCTTTGGA  
AACCCAAGAGGTACCTTTCTTATCCGCGAGAGTGAAACCACCAAAGGTGCCTATTCACTT  
TCTATCCGTGATTGGGATGATATGAAAGGAGACCATGTCAAACATTATAAAATTCGCAAA  
CTTGACAATGGTGGATACTACATTACCACCCGGGCCCAGTTTGAAACACTTCAGCAGCTT  
GTACAACATTACTCAGAGAGAGCTGCAGGTCTCTGCTGCCGCCTAGTAGTTCCCTGTCAC  
AAAGGGATGCCAAGGCTTACCGATCTGTCTGTCAA AACCAAAGATGTCTGGGAAATCCCT  
CGAGAATCCCTGCAGTTGATCAAGAGACTGGGAAATGGGCAGTTTGGGGAAGTATGGATG  
GGTACCTGGAATGGAAACACAAAAGTAGCCATAAAGACTCTTAAACCAGGCACAATGTCC  
CCCGAATCATTCCTTGAGGAAGCGCAGATCATGAAGAAGCTGAAGCACGACAAGCTGGTC  
CAGCTCTATGCAGTGGTGTCTGAGGAGCCCATCTACATCGTCACCGAGTATATGAACAAA  
GGAAGTTTACTGGATTTCTTAAAGATGGAGAAGGAAGAGCTCTGAAATTACCAATCTT  
GTGGACATGGCAGCACAGGTGGCTGCAGGAATGGCTTACATCGAGCGCATGAATTATATC  
CATAGAGATCTGCGATCAGCAAACATTCTAGTGGGGAATGGACTCATATGCAAGATTGCT  
GACTTCGGATTGGCCCGATTGATAGAAGACAATGAGTACACAGCAAGACAAGGTGCAAAG  
TTCCCATCAAGTGGACGGCCCCCGAGGCAGCCCTGTACGGGAGGTTCA CAATCAAGTCT  
GACGTGTGGTCTTTTGG AATCTTACTCACAGAGCTGGTCAACAAAGGAAGAGTGCCATAC  
CCAGGCATGAACAACCGGGAGGTGCTGGAGCAGGTGGAGCGAGGCTACAGGATGCCCTGC  
CCGCAGGACTGCCCCATCTCTCTGCATGAGCTCATGATCCACTGCTGGAAAAAGGACCCT  
GAAGAACGCCCCACTTTT GAGTACTTG CAGAGCTTCCTGGAAGACTACTTTACCGCGACA  
GAGCCCCAGTACCAACCTGGTGAAAACCTGTAAGGCCCGGTCTGCGGAGAGAGGCCTTG  
TCCCAGAGGCTGCCCCACCCCTCCCCATTAGCTTTCAATTCCGTAGCCAGCTGCTCCCCA  
GCAGCGGAACCGCCAGGATCAGATTGCATGTGACTCTGAAGCTGACGAACTTCCATGGC

- 193 -

CCTCATTAATGACACTTGTCCCCAAATCCGAACCTCCTCTGTGAAGCATTTCGAGACAGAA  
CCTTGTTATTTCTCAGACTTTTGAAAATGCATTGTATCGATGTTATGTAAAAGGCCAAAC  
CTCTGTTTCAAGTGTAATAGTTACTCCAGTGCCAAACATCCTAGTGCTTTTCTTTTAA  
AATGCAAATCCTATGTGATTTTAACTCTGTCTTCACCTGATTCAACTAAAAAAG  
TATTATTTTCCAAAAGTGGCCTCTTTGTCTAAAACAATAAAATTTTTTTCATGTTTTAA  
CAAAAACCAA

>gi|4503823|gb|NP\_002028.1|FYN 537aa linear protein-tyrosine  
kinase fyn isoform a; proto-oncogene tyrosine-protein kinase  
fyn; src/yes-related novel gene; src-like kinase; c-syn  
protooncogene; tyrosine kinase p59fyn(T); OKT3-induced calcium  
influx regulator [Homo sapiens].

MGCVQCKDKEATKLTEERDGS LNQSSGYRYGTDPTPQHYPSPFGVTSIPNYNNFHAAGGQG  
LTVFGGVNSSSHTGTLRTRGGTGVTFLFVALYDYEARTEDDL SFHKGEKFQILNSSEGDWW  
EARS LTTGETGYIPSNYVAPVDSIQAE EWYFGKLGRKDAERQLLSFGNPRGTF LIRESET  
TKGAYSL SIRDWDDMKGDHVKHYKIRKLDNGGYYITTRAQFETLQQLVQHYSERAA GLCC  
RLVVPCHKGMPRLTDL SVKTKDVWEIPRESLQLIKRLGNGQFGEVWMGTWNGNTKVAIKT  
LKPGTMSPE SFLEEAQIMKKLKHDKLVQLYAVVSEPIYIVTEYMNKGSLLD FLKDGEGR  
ALKLPNLVDMAAQVAAGMAYIERMNYIHRDLRSANILVGNGLICKIADFGLARLI EDNEY  
TARQGA KFPIKWTAP EAALYGRFTIKSDVWSFGILLTELVT KGRVPYPGMN NREVLEQVE  
RGYRMPCPQDCPISLHELMHCWKKDPEERPTFEYLQSFLEDYFTATEPQYQPGENL

>gi|15055546|gb|NM\_000800.2|FGF1 2357bp mRNA Homo sapiens  
fibroblast growth factor 1 (acidic) (FGF1), transcript variant  
1, mRNA.

GAGCCGGGCTACTCTGAGAAGAAGACACCAAGTGGATTCTGCTTCCCCTGGGACAGCACT  
GAGCGAGTGTGGAGAGAGGTACAGCCCTCGGCCTACAAGCTCTTTAGTCTTGAAAGCGCC  
ACAAGCAGCAGCTGCTGAGCCATGGCTGAAGGGGAAATCACCACCTTCACAGCCCTGACC  
GAGAAGTTTAATCTGCCTCCAGGGAATTACAAGAAGCCCAAACCTCCTCTACTGTAGCAAC  
GGGGGCCACTTCTGAGGATCCTTCCGGATGGCACAGTGGATGGGACAAGGGACAGGAGC  
GACCAGCACATT CAGCTGCAGCTCAGTGCGGAAAGCGTGGGGGAGGTGTATATAAAGAGT  
ACCGAGACTGGCCAGTACTTGCCATGGACACCGACGGGCTTTTATACGGCTCACAGACA  
CCAAATGAGGAATGTTTGTTCCTGGAAAGGCTGGAGGAGAACCATTACAACACCTATATA  
TCCAAGAAGCATGCAGAGAAGAATTGGTTTGTGGCCTCAAGAAGAATGGGAGCTGCAAA  
CGCGGTCCTCGGACTCACTATGGCCAGAAAGCAATCTTGTTTCTCCCCCTGCCAGTCTCT  
TCTGATTAAAGAGATCTGTTCTGGGTGTTGACCACTCCAGAGAAGTTTCGAGGGGTCTCT  
ACCTGGTTGACCCAAAAATGTTCCCTTGACCATTGGCTGCGCTAACCCCCAGCCACAGA  
GCCTGAATTTGTAAGCAACTTGCTTCTAAATGCCAGTTCACTTCTTTGCAGAGCCTTTT  
ACCCCTGCACAGTTTAGAACAGAGGGACCAAATTGCTTCTAGGAGTCAACTGGCTGGCCA  
GTCTGGGTCTGGGTTTGGATCTCCAATTGCCTCTTGCCAGGCTGAGTCCCTCCATGCAAAA  
GTGGGGCTAAATGAAGTGTGTTAAGGGGTCGGCTAAGTGGGACATTAGTAACTGCACACT  
ATTTCCCTCTACTGAGTAAACCTATCTGTGATTCCCCCAAACATCTGGCATGGCTCCCT  
TTTGTCTTCTCTGTGCCCTGCAAATATTAGCAAAGAAGCTTCATGCCAGGTTAGGAAGGC  
AGCATTCATGACCAGAAACAGGGACAAAGAAATCCCCCTTCAGAACAGAGGCATTTAA  
AATGGAAAAGAGAGATTGGATTTTGGTGGGTAACTTAGAAGGATGGCATCTCCATGTAGA  
ATAAATGAAGAAAGGGAGGCCAGCCGAGGAAGGCAGAAATAAATCCTTGGGAGTCATTA  
CCACGCCTTGACCTTCCCAAGGTTACTCAGCAGCAGAGAGCCCTGGGTGACTTCAGGTGG  
AGAGCACTAGAAGTGGTTTCTGATAACAAGCAAGGATATCAGAGCTGGGAAATTCATGT  
GGATCTGGGGACTGAGTGTGGGAGTGCAGAGAAAGAAAGGGAAACTGGCTGAGGGGATAC

- 194 -

CATAAAAAGAGGATGATTTTCAGAAGGAGAAGGAAAAAGAAAGTAATGCCACACATTGTGC  
TTGGCCCCTGGTAAGCAGAGGCTTTGGGGTCCTAGCCCAGTGCTTCTCCAACACTGAAGT  
GCTTGCAGATCATCTGGGGACCTGGTTTGAATGGAGATTCTGATTCAGTGGGTTGGGGGC  
AGAGTTTCTGCAGTTCCATCAGGTCCCCCCCAGGTGCAGGTGCTGACAATACTGCTGCCT  
TACCCGCCATACATTAAGGAGCAGGGTCTGGTCTCTAAAGAGTTATTCAAATGAAGGTGG  
TTCGACGCCCCGAACCTCACCTGACCTCAACTAACCCTTAAAAATGCACACCTCATGAGT  
CTACCTGAGCATTTCAGGCAGCACTGACAATAGTTATGCCTGTACTAAGGAGCATGATTTT  
AAGAGGCTTTGGCCAATGCCTATAAAATGCCCATTTTGAAGATATACAAAAACATACTTC  
AAAAATGTTAAACCCTTACCAACAGCTTTTCCCAGGAGACCATTGTATTACCATTACTT  
GTATAAATACACTTCTGCTTAAACTTGACCCAGGTGGCTAGCAAATTAGAAACACCATT  
CATCTCTAACATATGATACTGATGCCATGTAAAGGCCTTTAATAAGTCATTGAAATTTAC  
TGTGAGACTGTATGTTTTAATTGCATTTAAAAATATATAGCTTGAAAGCAGTTAAACTGA  
TTAGTATTCAGGCAGTGAAGATGATAGTAATAGGATACAATGTATAAGCTACTCACTTAT  
CTGATACTTATTTACCTATAAAATGAGATTTTTGTTTTCCACTGTGCTATTACAAATTTT  
CTTTTGAAAGTAGGAAGCTTTAAGCAATGGTAATTGTGAATAAAAATTGATGAGAGTGTT  
AAAAAAAAAAAAAAAAAAAA

>gi|4503697|gb|NP\_000791.1|FGF1 155aa linear fibroblast growth  
factor 1 (acidic) isoform 1 precursor; heparin-binding growth  
factor 1 precursor; endothelial cell growth factor, alpha;  
endothelial cell growth factor, beta [Homo sapiens].

MAEGEITTF TALTEKFNLPPGNYKKPKLLYCSNGGHFLRILPDGTV DGRSDQHIQLQ  
LSAESVGEVYIKSTETGQY LAMDTDGLLYGSQTPNEECLFLERLEENHYNTYISKKHAEK  
NWFVGLKKN GSCKRGP RTHYGQKAILFLPLPVSSD

>gi|27552761|gb|NM\_002825.3|PTN 1029bp mRNA Homo sapiens  
pleiotrophin (heparin binding growth factor 8, neurite growth-  
promoting factor 1) (PTN), mRNA.

TCTGCTTTTAATAAGCTTCCCAATCAGCTCTCGAGTGCAAAGCGCTCTCCCTCCCTCGCC  
CAGCCTTCGTCCCTCCTGGCCCCGCTCCTCTCATCCCTCCCATTTCTCCATTTCCCTTCCGTT  
CCCTCCCTGTCAGGGCGTAATTGAGTCAAAGGCAGGATCAGGTTCCCCGCCTTCCAGTCC  
AAAAATCCCGCCAAGAGAGCCCCAGAGCAGAGGAAAATCCAAAGTGAGAGAGGGGAAGA  
AAGAGACCAGTGAGTCATCCGTCCAGAAGGCGGGGAGAGCAGCAGCGGCCCAAGCAGGAG  
CTGCAGCGAGCCGGGTACCTGGACTCAGCGGTAGCAACCTCGCCCCCTTGCAACAAAGGCA  
GACTGAGCGCCAGAGAGGACGTTTCCAACCTCAAAAATGCAGGCTCAACAGTACCAGCAGC  
AGCGTCGAAAATTTGCAGCTGCCTTCTTGGCATTCAATTTTCATACTGGCAGCTGTGGATA  
CTGCTGAAGCAGGGAAGAAAGAGAAAACAGAAAAAAAAGTGAAGAAGTCTGACTGTGGAG  
AATGGCAGTGGAGTGTGTGTGTGCCACCAGTGGAGACTGTGGGCTGGGCACACGGGAGG  
GCACTCGGACTGGAGCTGAGTGCAAGCAAACCATGAAGACCCAGAGATGTAAGATCCCT  
GCAACTGGAAGAAGCAATTTGGCGCGGAGTGCAAATACCAGTTCCAGGCCTGGGGAGAAT  
GTGACCTGAACACAGCCCTGAAGACCAGAACTGGAAGTCTGAAGCGAGCCCTGCACAATG  
CCGAATGCCAGAAGACTGTCACCATCTCCAAGCCCTGTGGCAAACCTGACCAAGCCCAAAC  
CTCAAGCAGAATCTAAGAAGAAGAAAAAGGAAGGCAAGAAACAGGAGAAGATGCTGGATT  
AAAAGATGTCACCTGTGGAACATAAAAAGGACATCAGCAAACAGGATCAGTTAACTATTG  
CATTTATATGTACCGTAGGCTTTGTATTCAAAAATTATCTATAGCTAAGTACACAATAAG  
CAAAAACAA

>gi|4506281|gb|NP\_002816.1|PTN 168aa linear pleiotrophin  
(heparin binding growth factor 8, neurite growth-promoting

- 195 -

factor 1); heparin affin regulatory protein; heparin-binding growth-associated molecule [Homo sapiens].

MQAQQYQQQRRKFAAAFLAFIFILAAVDTAEAGKKEKPEKKVKKSDCGEWQWSVCVPTSG  
DCGLGTREGTRTGAECKQTMKTQRCIKPCNWKKQFGAECKYQFQAWGECDLNTALKTRTG  
SLKRALHNAECQKTVTISKPCGKLTKPKPQAESKKKKKEGKKQEKMLD

>gi|4504008|gb|NM\_000169.1|GLA 1350bp mRNA Homo sapiens  
galactosidase, alpha (GLA), mRNA.

AGGTTAATCTTAAAAGCCCAGGTTACCCGCGGAAATTTATGCTGTCCGGTCACCGTGACA  
ATGCAGCTGAGGAACCCAGAACTACATCTGGGCTGCGCGCTTGCCTTCCTGGCC  
CTCGTTTCCTGGGACATCCCTGGGGCTAGAGCACTGGACAATGGATTGGCAAGGACGCCT  
ACCATGGGCTGGCTGCACTGGGAGCGCTTCATGTGCAACCTTGACTGCCAGGAAGAGCCA  
GATTCCTGCATCAGTGAGAAGCTCTTCATGGAGATGGCAGAGCTCATGGTCTCAGAAGGC  
TGGAAGGATGCAGGTTATGAGTACCTCTGCATTGATGACTGTTGGATGGCTCCCCAAAGA  
GATTCAGAAGGCAGACTTCAGGCAGACCCTCAGCGCTTTCCTCATGGGATTGCCAGCTA  
GCTAATTATGTTTACAGCAAAGGACTGAAGCTAGGGATTTATGCAGATGTTGGAAATAAA  
ACCTGCGCAGGCTTCCCTGGGAGTTTTGGATACTACGACATTGATGCCAGACCTTTGCT  
GACTGGGGAGTAGATCTGCTAAAATTTGATGGTTGTTACTGTGACAGTTTGGAAAATTTG  
GCAGATGGTTATAAGCACATGTCCTTGGCCCTGAATAGGACTGGCAGAAGCATTTGTGTAC  
TCCTGTGAGTGGCCTCTTTATATGTGGCCCTTTCAAAGCCCAATTATACAGAAATCCGA  
CAGTACTGCAATCACTGGCGAAATTTTGCTGACATTGATGATTCCTGGAAAAGTATAAAG  
AGTATCTTGGACTGGACATCTTTTAAACCAGGAGAGAATTGTTGATGTTGCTGGACCAGGG  
GGTTGGAATGACCCAGATATGTTAGTGATTGGCAACTTTGGCCTCAGCTGGAATCAGCAA  
GTAATCAGATGGCCCTCTGGGCTATCATGGCTGCTCCTTTATTCATGTCTAATGACCTC  
CGACACATCAGCCCTCAAGCCAAAGCTCTCCTTCAGGATAAGGACGTAATTGCCATCAAT  
CAGGACCCCTTGGGCAAGCAAGGGTACCAGCTTAGACAGGGAGACAACTTTGAAGTGTGG  
GAACGACCTCTCTCAGGCTTAGCCTGGGCTGTAGCTATGATAAACCGGCAGGAGATTGGT  
GGACCTCGCTCTTATAACCATCGCAGTTGCTTCCCTGGGTAAAGGAGTGGCCTGTAATCCT  
GCCTGCTTCATCACACAGCTCCTCCCTGTGAAAAGGAAGCTAGGGTTCTATGAATGGACT  
TCAAGGTTAAGAAGTCACATAAATCCACAGGCACCTGTTTTGCTTCAGCTAGAAAATACA  
ATGCAGATGTCATTAAAAGACTTACTTTAA

>gi|4504009|gb|NP\_000160.1|GLA 429aa linear galactosidase,  
alpha [Homo sapiens].

MQLRNPFLHLGCALALRFLALVSWDIPGARALDNGLARTPTMGWLHWERFMCNLDQEEP  
DSCISEKLFMEMAELMVSEGWKDAGYEYLCIDDCWMAPOQDSEGRLOADPQRFPHGIRQL  
ANYVHSGKGLKLGITYADVGNKTCAGFPGSFGYYDIDAQTFADWGVDLLKFDGICYDSLENL  
ADGYKHMSLALNRTGRSIVYSCWPLYMWPFOKPNYTEIRQYCNHWRNFADIDDSWKSILK  
SILDWTSFNQERIVDVAGPGGWNDPDMLVIGNFGLSWNQVQTQMALWAIMAAPLFMSNDL  
RHISPAKALLQDKDVIAINQDPLGKQGYQLRQGDNFVWERPLSGLAWAVAMINRQEIG  
GPRSYTIAVASLGKGVACNPACFITQLLPVKRKLGFYEWTSLRLRSHINPTGTVLLQLENT  
MQMSLKDLL

>gi|18587778|gb|XM\_091624.1|LOC162542 287bp mRNA Homo sapiens  
similar to ADP-ribosylation factor 1 (LOC162542), mRNA.

GTCTGATTTTTATGGTTGACAGTAATGACAGAGAGCAGATTGATGAGGCCTGGGAAGTGC  
TAACTTACTTGTAGAGGACGATGAGCTCAGAAATGCAGTTTTATTGGTATTTGCCAATA  
AACAAGATCTCCCTAATACTATGAACGCGGCAGAGATAACGGACAAGCTCGGCCTCCATT  
CCCTCCGCTACAGAACTGGCACATTCAGGCTACTTGTGCCACTACTGGACATGGGCTTT  
ACGAAGGCCTGAACTGGCTCGCCAACCAGTTCCAGAACCAGAACTGA



- 196 -

>gi|18587779|gb|XP\_091624.1|LOC162542 91aa linear similar to ADP-ribosylation factor 1 [Homo sapiens].

MVDSNDREQIDEAWEVLTYLLEDELRLNAVLLVFANKQDLPNTMNAAEITDKLGLHSLRY RNWHIQATCATTGHGLYEGLNWLANQFQNNQ

>gi|4557572|gb|NM\_000401.1|EXT2 3781bp mRNA Homo sapiens exostoses (multiple) 2 (EXT2), mRNA.

CTGTCTGAGCATTTCCTGAGCGGAGCCTGAGCGCGCCTGCCTGGGAAAACACTGCAGCGGT  
GCTCGGACTCCTCCTGTCCAGCAGGAGGCGCGGCCCGGAGCTCCCGCATGCGCAGTGCG  
CTCGGTGTCAGACGGCCCGGATCCCGGTTACCGGCCCTCGCTCGCTGCTCGCCAGCCCA  
GACTCGGCCCTGGCAGTGGCGGCTGGCGATTCCGACCGATCCGACCTGGGCGGAGGTGGC  
CCGCGCCCCGCGGCATGAGCCGGTGACCAAGCTCGGGGCCGAGCGGGAGGCAGCCGTGGC  
CGAGCCACAGGGATCTGATTCTCCAGGGGGATGTCTGCGCCTCAGGGTCCGGTGGTG  
GCCTGCGGCATCCCTTGCGGTGCCAGAAGCCGTGGGACGAGTGTCTTTAATGTTATAGAG  
CTACTCAGAGTTGCTGTTTCTCCTTGAGATGCTTTTGGAGTGTGAGGAAGAGGCTGTCTG  
TGTCATTATGTGTGCGTCGGTCAAGTATAATATCCGGGGTCCCTGCCCTCATCCCAAGAAT  
GAAGACCAAGCACCGAATCTACTATATCACCTCTTCTCCATTGTCTCCTGGGCTCAT  
TGCCACTGGCATGTTTCAGTTTTGGCCCCATTCTATCGAGTCCTCAAATGACTGGAATGT  
AGAGAAGCGCAGCATCCGTGATGTGCCGGTTGTTAGGCTGCCAGCCGACAGTCCCATCCC  
AGAGCGGGGGGATCTCAGTTGCAGAATGCACACGTGTTTTGATGTCTATCGCTGTGGCTT  
CAACCCAAAGAACAAAATCAAGGTGTATATCTATGCTCTGAAAAAGTACGTGGATGACTT  
TGGCGTCTCTGTGAGCAACACCATCTCCCGGGAGTATAATGAACTGCTCATGGCCATCTC  
AGACAGTGAATACTACACTGATGACATCAACCGGGCCTGTCTGTTTGTTCCTCCATCGA  
TGTGCTTAACCAGAACACACTGCGCATCAAGGAGACAGCACAAAGCGATGGCCAGCTCTC  
TAGGTGGGATCGAGGTACGAATCACCTGTTGTTCAACATGTTGCCTGGAGGTCCCCAGA  
TTATAACACAGCCCTGGATGTCCCAGAGACAGGGCCCTGTTGGCTGGTGGCGGCTTTTC  
TACGTGGACTTACCGGCAAGGCTACGATGTCAGCATTCTGTCTATAGTCCACTGTCAGC  
TGAGGTGGATCTTCAGAGAAAGGACCAGGTCCACGGCAATACTTCCTCCTGTCATCTCA  
GGTGGGTCTCCATCCTGAGTACAGAGAGGACCTAGAAGCCCTCCAGGTCAAACATGGAGA  
GTCAGTGTAGTACTCGATAAATGCACCAACCTCTCAGAGGGTGTCTTTCTGTCCGTAA  
GCGCTGCCACAAGCACCGGTCTTCGATTACCCACAGGTGCTACAGGAGGCTACTTTCTG  
TGTGGTTCTTCGTGGAGCTCGGCTGGGCCAGGCAGTATTGAGCGATGTGTTACAAGCTGG  
CTGTGTCCCGGTTGTCAATTGCAGACTCCTATATTTTGCCTTTCTCTGAAGTTCTTGACTG  
GAAGAGAGCATCTGTGGTTGTACCAGAAGAAAAGATGTGAGATGTGTACAGTATTTTGCA  
GAGCATCCCCCAAAGACAGATTGAAGAAATGCAGAGACAGGCCCGGTGGTTCTGGGAAGC  
GTACTTCCAGTCAATTAAAGCCATTGCCCTGGCCACCCTGCAGATTATCAATGACCGGAT  
CTATCCATATGCTGCCATCTCCTATGAAGAATGGAATGACCCTCCTGCTGTGAAGTGGGG  
CAGCGTGAGCAATCCACTCTTCCTCCCGCTGATCCCACCACAGTCTCAAGGGTTCACCGC  
CATAGTCCTCACCTACGACCGAGTAGAGAGCCTCTTCGGGTCATCACTGAAGTGTCCAA  
GGTGCCCACTCTATCCAACTACTTGTGCTCTGGAATAATCAGAATAAAAACCTCCAGA  
AGATTCTCTCTGGCCCAAATCCGGGTTCCATTAAAAGTTGTGAGGACTGCTGAAAACAA  
GTTAAGTAACCGTTTCTTCCCTTATGATGAAATCGAGACAGAAGCTGTTCTGGCCATTGA  
TGATGATATCATTATGCTGACCTCTGACGAGCTGCAATTTGGTTATGAGGTCTGGCGGGA  
ATTCCTGACCGGTTGGTGGGTTACCCGGGTCGTCTGCATCTCTGGGACCATGAGATGAA  
TAAGTGGAAGTATGAGTCTGAGTGGACGAATGAAGTGTCCATGGTGCTCACTGGGGCAGC  
TTTTTATCACAAGTATTTTAAATTACCTGTATACCTACAAAATGCCTGGGGATATCAAGAA  
CTGGGTAGATGCTCATATGAACTGTGAAGATATTGCCATGAACTTCCTGGTGGCCAACGT  
CACGGGAAAAGCAGTTATCAAGGTAACCCACGAAAGAAATTCAGTGTCCTGAGTGCAC



- 197 -

AGCCATAGATGGGCTTTCACTAGACCAAACACACATGGTGGAGAGGTCAGAGTGCATCAA  
 CAAGTTTGCTTCAGTCTTCGGGACCATGCCTCTCAAGGTGGTGGAACACCGAGCTGACCC  
 TGTCTGTACAAAGATGACTTTCTGAGAAGCTGAAGAGCTTCCCCAACATTGGCAGCTT  
 ATGAAACGTGTCATTGGTGGAGGTCTGAATGTGAGGCTGGGACAGAGGGAGAGAACAAGG  
 CCTCCCAGCACTCTGATGTCAGAGTAGTAGGTTAAGGGTGGAAGGTTGACCTACTTGGAT  
 CTTGGCATGCACCCACCTAACCCTTTCTCAAGAACAAAGAACCTAGAATGAATATCCAA  
 GCACCTCGAGCTATGCAACCTCTGTTCTTGTAATTTCTTATGATCTCTGATGGGTTCTTCT  
 CGAAAATGCCAAGTGGAAGACTTTGTGGCATGCTCCAGATTTAAATCCAGCTGAGGCTCC  
 CTTTGTTCCTCAGTTCCATGTAACAATCTGGAAGGAACTTCACGGACAGGAAGACTGCTG  
 GAGAAGAGAAGCGTGTTAGCCCATTTGAGGTCTGGGGAATCATGTAAAGGGTACCCAGAC  
 CTCACCTTTTAGTTATTTACATCAATGAGTTCTTTCAGGGAACCAAACCCAGAATTCGGTG  
 CAAAAGCCAAACATCTTGGTGGGATTGTGATAAATGCCTTGGGACCTGGAGTGCTGGGCTT  
 GTGCACAGGAAGAGCACCAGCCGCTGAGTCAGGATCCTGTCAGTTCCATGAGCTATTCCT  
 CTTTGGTTTGGCTTTTGTGATATGATTAATAATTATTTTTTATTCTTTTCTACTGTGTCT  
 TAAACACCAATTCCTGATAGTCCAAGGAACCACCTTTCTCCCTTGATATATTTAACTCCG  
 TCTTTGGCCTGACAACAGTCTTCTGCCCATGTCTGGGAACACACGCCAGGAGGAATGTCT  
 GATACCCTCTGCATCAAGCGTAAGAAGGTCCCAAATCATAACCATTTTAAGAACAGATGA  
 CTCAGAAACCTCCAGAGGAATCTGTTTGCTTCTGATTAGATCCAGTCAATGTTTTAAAG  
 GTATTGTCAGAGAAAAACAGAGGGTCTGTACTAGCCATGCAAGGAGTCGCTCTAGCTGGT  
 ACCCGTAAAAGTTGTGGGATTGTGACCCCCCATCCCAAGGGGATGCCAAAATTTCTCTCA  
 TTCTTTTGGTATAAACTTAACATTAGCCAGGGAGGTTCTGGCTAACGTTAAATGCTGCTA  
 TACAACCTGCTTTGCAACAGTTGCTGGTATATTTAAATCATTAATTTTCAGCATTACTAA  
 T

>gi|4557573|gb|NP\_000392.1|EXT2 718aa linear exostoses  
 (multiple) 2 [Homo sapiens].

MCASVKYNIRGPALIPRMKTKHRIYYITLFSIVLLGLIATGMFQFWPHSIESSNDWNVEK  
 RSIRDVPVVRLPADSPIPERGDLSCRMHTCFDVYRCGFNPKNKIKVYIYALKKYVDDFGV  
 SVSNTISREYNELLMAISDSDYTTDDINRACLFVPSIDVLNQNTLRKETQAQAMAQLSRW  
 DRGTHNLLFNMLPGPPDYNTALDVPDRDRALLAGGGFSTWYRQGYDVSIPVYSPLSAEV  
 DLPEKGPGRQYFLLSSQVGLHPEYREDLEALQVKHGESVLVLDKCTNLSEGVLSVRKRC  
 HKHQVFDYPQVLQEATFCVVLRGARLGQAVLSDVLQAGCVPVVIADSYILPFSEVLWDWR  
 ASVVVPEEKMSDVYSILQSI PQRIEEMQRQARWFWEAYFQSIKAIALATLQIINDRIYP  
 YAAISYEEWNPAPVKGWSVSNPLFLPLIPPQSOGFTAIVLTYDRVESLFRVITEVSKVP  
 SLSKLLVVWNNQNKNPEDSLWPKIRVPLKVVRTAENKLSNRFFPYDEIETEAVLAIDDD  
 IIMLTSDQLQFGYEVWREFPDRLVGYPGRLLHLDHEMNKWKEYEWTNEVSMVLTGAIFY  
 HKYFNYLYTYKMPGDIKNWVDAHMNCEDIAMNFLVANVTGKAVIKVTPRKFKCPECTAI  
 DGLSLDQTHMVERSEKINKFASVFGTMPLKVVEHRADPVLYKDDFPEKLKSFPNIGSL

>gi|27597083|gb|NM\_006838.2|METAP2 1908bp mRNA Homo sapiens  
 methionyl aminopeptidase 2 (METAP2), mRNA.

CTCTGTCTCATTCCCTCGCGCTCTCTCGGGCAACATGGCGGGTGTGGAGGAGGTAGCGGC  
 CTCCGGGAGCCACCTGAATGGCGACCTGGATCCAGACGACAGGGAAGAAGGAGCTGCCTC  
 TACGGCTGAGGAAGCAGCCAAGAAAAAAGACGAAAGAAGAAGAAGAGCAAAGGGCCTTC  
 TGCAGCAGGGGAACAGGAACCTGATAAAGAATCAGGAGCCTCAGTGGATGAAGTAGCAAG  
 ACAGTTGGAAAGATCAGCATTGGAAGATAAAGAAAGAGATGAAGATGATGAAGATGGAGA  
 TGGCGATGGAGATGGAGCAACTGGAAAGAAGAAGAAAAAGAAGAAGAAGAGAGGACC  
 AAAAGTTCAAACAGACCCTCCCTCAGTTCCAATATGTGACCTGTATCCTAATGGTGTATT  
 TCCCAAAGGACAAGAATGCGAATACCCACCCACACAAGATGGGCGAACAGCTGCTTGAG

- 198 -

AACTACAAGTGAAGAAAAGAAAGCATTAGATCAGGCAAGTGAAGAGATTTGGAATGATTT  
TCGAGAAGCTGCAGAAGCACATCGACAAGTTAGAAAATACGTAATGAGCTGGATCAAGCC  
TGGGATGACAATGATAGAAATCTGTGAAAAGTTGGAAGACTGTTACGCAAGTTAATAAA  
AGAGAATGGATTAAATGCAGGCCTGGCATTTCCTACTGGATGTTCTCTCAATAATTGTGC  
TGCCCATTTATACTCCCAATGCCGGTGACACAACAGTATTACAGTATGATGACATCTGTAA  
AATAGACTTTTGGAACACATATAAGTGGTAGGATTATTGACTGTGCTTTTACTGTCACTTT  
TAATCCCAAATATGATACGTTATTAAAAGCTGTAAAAGATGCTACTAACAACCTGGAATAAA  
GTGTGCTGGAATTGATGTTCTGTCTGTGTGATGTTGGTGAGGCCATCCAAGAAGTTATGGA  
GTCCTATGAAGTTGAAATAGATGGGAAGACATATCAAGTGAAACCAATCCGTAATCTAAA  
TGGACATTCAATTGGGCAATATAGAATACATGCTGGAAAAACAGTGCCGATTGTGAAAGG  
AGGGGAGGCAACAAGAATGGAGGAAGGAGAAGTATATGCAATTGAAACCTTTGGTAGTAC  
AGGAAAAGGTGTTGTTTCATGATGATATGGAATGTTTACATTACATGAAAAATTTTGATGT  
TGGACATGTGCCAATAAGGCTTCCAAGAACAACAACTTGTAAATGTCATCAATGAAAA  
CTTTGGAACCCTTGCCCTTCTGCCGCAGATGGCTGGATCGCTTGGGAGAAAGTAAATACTT  
GATGGCTCTGAAGAATCTGTGTGACTTGGGCATTGTAGATCCATATCCACCATTATGTGA  
CATTAAAGGATCATATACAGCGCAATTTGAACATAACCATCCTGTTGCGTCCAACATGTAA  
AGAAGTTGTCAGCAGAGGAGATGACTATTAACTTAGTCCAAAGCCACCTCAACACCTTT  
ATTTTCTGAGCTTTGTTGGAAAACATGATACCAGAATTAATTTGCCACATGTTGTCTGTT  
TTAACAGTGGACCCATGTAATACTTTTATCCATGTTTAAAAAGAAGGAATTTGGACAAAG  
GCAAACCGTCTAATGTAATTAACCAACGAAAAAGCTTTCCGGACTTTTAAATGCTAACTG  
TTTTTCCCCTTCCTGTCTAGGAAAATGCTATAAAGCTCAAATTAGTTAGGAATGACTTAT  
ACGTTTTGTTTTGAATACCTAAGAGATACTTTTTGGATATTTATATTGCCATATTCTTAC  
TTGAATGCTTTGAATGACTACATCCAGTTCTGCACCTATACCCTCTGGTGTTGCTTTTTA  
ACCTTCCTGGAATCCATTTCTAAAAATAAAGACATTTTCAGATCTGA

>gi|5803092|gb|NP\_006829.1|METAP2 478aa linear methionyl  
aminopeptidase 2; methionine aminopeptidase; eIF-2-associated  
p67 [Homo sapiens].

MAGVEEVAASGSHLNGDLDPDDREEGAASTAEFAAKKKRRKKKSKGPSAAGEQEPDKES  
GASVDEVARQLERSALEDKERDEDEDGDGDGDGATGKKKKKKKKRGPVKVQTDPPSPVI  
CDLYPNGVFPKGQCEYPPPTQDGRTAAWRTTSEEKKALDQASEEIWNDFREAAEAHRQVR  
KYVMSWIKPGMTMIEICEKLEDCSRKLKENGLNAGLAFPTGCSLNNCAAHYTPNAGDTT  
VLQYDDICKIDFGTHISGRIIDCAFTVTFNPKYDTLLKAVKDATNTGIKCAGIDVRLCDV  
GEAIQEVMESEYEIDGKTYQVKPIRNLNGHSIGQYRIHAGKTVPIVKGGEATRMEEGEV  
YAIETFGSTGKGVVHDDMECSHYMKNFDVGHVPIRLPRTKHLNINENFGTLAFCRRWL  
DRLGESKYLMAKLNLCDLGIIDPYPPLCDIKGSYTAQFEHTILLRPTCKEVVSRGDDY

>gi|10864040|gb|NM\_021230.1|MLL3 12689bp mRNA Homo sapiens  
myeloid/lymphoid or mixed-lineage leukemia3 (MLL3), mRNA.

AAAATTCCTTAGTTGCTGGCTTTGACCTTTTATGTTGCTGAGTTTTACACATCTATTTTC  
TCAACTGCCATATCCTAGGGGGCTTGGAGTACCCATAATACAGTGAGCCCACCTTCCTGG  
TCCCCAGACATTTTCAAGGTGGGCGGTGGGTCTGGATTTCAGGAAAGCGGAGACCTCGAGGT  
ATTTGGAGCATCAAAGTGGGCGGTGGGTCTGGATTTCAGGAAAGCGGAGACCTCGAGGT  
GCAGGACTGTCGGGGCGAGGTGGCCGAGGCAGGTCAAAGCTGAAAAGTGGAAATCGGAGCT  
GTTGTATTACCTGGGGTGTCTACTGCAGATATTTTCATCAAATAAGGATGATGAAGAAAAC  
TCTATGCACAATAACAGTTGTGTTGTTTTCTAGCAGTGACAAGTTCACCTTTGAATCAGGAT  
ATGTGTGTAGTTTGTGGCAGTTTGGCCAAGGAGCAGAAGGAAGATTACTTGCCTGTTCT  
CAGTGTGGTCAGTGTTACCATCCATACTGTGTGAGTATTAAGATCACTAAAGTGGTTCTT  
AGCAAAGGTTGGAGGTGTCTTGAGTGCAGTGTGTGTGAGGCCTGTGGGAAGGCAACTGAC

- 199 -

CCAGGAAGACTCCTGCTGTGTGATGACTGTGACATAAGTTATCACACCTACTGCCTAGAC  
CCTCCATTGCAGACAGTTCCCAAAGGAGGCTGGAAGTGCAAATGGTGTGTTTGGTGCAGA  
CACTGTGGAGCAACATCTGCAGGTCTAAGATGTGAATGGCAGAACAAATTACACACAGTGC  
GCTCCTTGTGCAAGCTTATCTTCCTGTCCAGTCTGCTATCGAACTATAGAGAAGAAGAT  
CTTATTCTGCAATGTAGACAATGTGATAGATGGATGCATGCAGTTTGTGAGAACTTAAAT  
ACTGAGGAAGAAGTGGAATAATGTAGCAGACATTGGTTTTGTATTGTAGCATGTGCAGACCC  
TATATGCCTGCGTCTAATGTGCCTTCCTCAGACTGCTGTGAATCTTCACTTGTAGCACAA  
ATTGTACAAAAGTAAAAGAGCTAGACCCACCCAAGACTTATACCCAGGATGGTGTGTGT  
TTGACTGAATCAGGGATGACTCAGTTACAGAGCCTCACAGTTACAGTTCCAAGAAGAAAA  
CGGTCAAAACCAAATTTGAAATTGAAGATTATAAATCAGAATAGCGTGGCCGTCCTTCAG  
ACCCCTCCAGACATCCAATCAGAGCATTCAAGGGATGGTGAAATGGATGATAGTCGAGAA  
GGAGAACTTATGGATTGTGATGGAAAATCAGAATCTAGTCCTGAGCGGGAAGCTGTGGAT  
GATGAACTAAGGGAGTGGAAGGAACAGATGGTGTCAAAAAGAGAAAAAGGAAACCATAC  
AGACCAGGTATTGGTGGATTTATGGTGCGGCAAAGAAGTCGAACTGGGCAAGGGAAAACC  
AAAAGATCTGTGATCAGAAAAGATTCTCAGGCTCTATTTCCGAGCAGTTACCTTGCAGA  
GATGATGGCTGGAGTGAGCAGTTACCAGATACTTTAGTTGATGAATCTGTTTCTGTTACT  
GAAAGCACTGAAAAAATAAAGAAGAGATACCGAAAAGGAAAAATAAGCTTGAAGAACT  
TTCCCTGCCTATTTACAAGAAGCTTTCTTTGGAAAAGATCTTCTAGATACAAGTAGACAA  
AGCAAGATAAGTTTAGATAATCTGTCAGAAGATGGAGCTCAGCTTTTATATAAAACAAAC  
ATGAACACAGGTTTCTTGGATCCTTCCTTAGATCCACTACTTAGTTTCATCCTCGGCTCCA  
ACAAAATCTGGAATCACGGTCCTGCTGATGACCCATTAGCTGATATTTCTGAAGTTTTA  
AACACAGATGATGACATTCTTGGAAATAATTTAGATGATCTAGCAAAATCAGTTGATCAT  
TCAGATATTGGTCCTGTCACTGATGATCCTTCCTCTTTGCCTCAGCCAAATGTCAATCAG  
AGTTCACGACCATTAAAGTGAAGAACAGCTAGATGGGATCCTCAGTCCTGAACTAGACAAA  
ATGGTCACAGATGGAGCAATTCTTGGAAAATTATATAAAATTCAGAGCTTGGCGGAAAA  
GATGTTGAAGACTTATTTACAGCTGTACTTAGTCCTGCGAACACTCAGCCAACTCCATTG  
CCACAGCCTCCCCACCAACACAGCTGTTGCCAATACACAATCAGGATGCTTTTTTCACGG  
ATGCCTCTCATGAATGGCCTTATTGGATCCAGTCCTCATCTCCACATAATTCTTTGCCA  
CCTGGAAGCGGACTGGGAACTTTCTCTGCAATTGCACAATCCTCTTATCCTGATGCCAGG  
GATAAAAATTAGCCTTTAATCCAATGGCAAGTGATCCTAACAACCTTTGGACATCATCA  
GCTCCCACTGTGGAAGGAGAAAATGACACAATGTGGAATGCCAGAGAAGCACGCTTAAG  
TGGGAGAAAGAGGAGGCTCTGGGTGAAATGGCAACTGTTGCCCCAGTTCTCTACACCAAT  
ATTAATTTCCCCAACTTAAAGGAAGAATTCCCTGATTGGACTACTAGAGTGAAGCAAATT  
GCCAAATTGTGGAGAAAAGCAAGCTCACAAGAAAGAGCACCATATGTGCAAAAAGCCAGA  
GATAACAGAGCTGCTTTACGCATTAATAAAGTACAGATGTCAAATGATTCCATGAAAAGG  
CAGCAACAGCAAGATAGCATTTGATCCCAGCTCTCGTATTGATTTCGGAGCTTTTTAAAGAT  
CCTTTAAAGCAAAGAGAATCAGAACATGAACAGGAATGGAAATTTAGACAGCAAATGCGT  
CAGAAAAGTAAGCAGCAAGCTAAAATTGAAGCCACACAGAACTTGAACAGGTGAAAAAT  
GAGCAGCAGCAGCAGCAACAACAGCAATTTGGTTCTCAGCATCTTCTGGTGCAGTCTGGT  
TCAGATACACCAAGTAGTGGGATACAGAGTCCCTTGACACCTCAGCCTGGCAATGGAAAT  
ATGTCTCCTGCACAGTCATTCCATAAAGAACTGTTTACAAAACAGCCACCCAGTACCCCT  
ACGTCTACATCTTCAGATGATGTGTTTGTAAAGCCACAAGCTCCACCTCCTCCTCCAGCC  
CCATCCCGGATTCCTATCCAGGATAGTCTTTCTCAGGCTCAGACTTCTCAGCCACCCTCA  
CCGCAAGTGTTTTACCTGGGTCTCTAACTCACGACCACCATCTCCAATGGATCCATAT  
GCAAAAATGGTTGGTACCCCTCGACCACCTCCTGTGGGCCATAGTTTTTCCAGAAGAAAT  
TCTGCTGCACCAGTGGAATACTGTACACCTTTATCATCGGTATCTAGGCCCTTCAAATG  
AATGAGACAACAGCAAATAGGCCATCCCCTGTCAGAGATTTATGTTCTTCTTCCACGACA

- 200 -

AATAATGACCCCTATGCAAAACCTCCAGACACACCTAGGCCTGTGATGACAGATCAATTT  
CCCAAATCCTTGGGCCCTATCCCGGTCTCCTGTAGTTTCAGAACAAACTGCAAAAGGCCCT  
ATAGCAGCTGGAACCACTGATCACTTTACTAAACCATCTCCTAGGGCAGATGTGTTTCAA  
AGACAAAGGATACCTGACTCATATGCACGACCCTTGTTGACACCTGCACCTCTTGATAGT  
GGTCCTGGACCTTTTAAGACTCCAATGCAACCTCCTCCATCCTCTCAGGATCCTTATGGA  
TCAGTGTACAGGCATCAAGGCGATTGTCTGTTGACCCTTATGAAAGGCCTGCTTTGACA  
CCAAGACCTATAGATAATTTTCTCATAATCAGTCAAATGATCCATATAGTCAGCCTCCC  
CTTACCCACATCCAGCAGTGAATGAATCTTTTGCCCATCCTTCAAGGGCTTTTCCCAG  
CCTGGAACCATATCAAGGCCAATCTCAGGACCCTACTCCCAACCCCCAGGAACCTCCA  
CGACCTGTTGTAGATTCTTATTCCTCAATCTTCAGGAACAGCTAGGTCCAATACAGACCCT  
TACTCTCAACCTCCTGGAACCTCCCGGCCCTACTACTGTTGACCCATATAGTCAGCAGCCC  
CAAACCCCAAGACCATCTACACAACTGACTTGTTTGTTACACCTGTAACAAATCAGAGG  
CATTCTGATCCATATGCTCATCCTCCTGGAACACCAAGACCTGGAATTTCTGTCCCTTAC  
TCTCAGCCACCAGCAACACCAAGGCCAAGGATTTTCAAGAGGGTTTTACTAGGTCCTCAATG  
ACAAGACCAGTCCTCATGCCAAATCAGGATCCTTTCTGCAAGCAGCACAAAACCGAGGA  
CCAGCTTTACCTGGCCCCGTTGGTAAGGCCACCTGATACATGTTCCCAGACACCTAGGCC  
CCTGGACCTGGTCTTTTCAAGACACATTTAGCCGTGTTTCCCCATCTGCTGCCCGTGATCCC  
TATGATCAGTCTCCAATGACTCCAAGATCTCAGTCTGACTCTTTTGGAACAAGTCAAACCT  
GCCCATGATGTTGCTGATCAGCCAAGGCCTGGATCAGAGGGGAGCTTCTGTGCATCTTCA  
AACTCTCCAATGCACTCCCAAGGCCAGCAGTTCTCTGGTGTCTCCCAACTTCCTGGACCT  
GTGCCAACTTCAGGAGTAAGTATACACAGAATACTGTAAATATGGCCCAAGCAGATACA  
GAGAAATTGAGACAGCGGCAGAAAGTTACGTGAAATCATTCTCCAGCAGCAACAGCAGAAG  
AAGATTGCAGGTCGACAGGAGAAGGGGTACAGGACTCACCCGCAGTGCCTCATCCAGGG  
CCTCTTCAACACTGGCAACCAGAGAATGTTAACCAGGCTTTCACCAGACCCCCACCTCCC  
TATCCTGGGAACATTAGGTCTCCTGTTGCCCTCCTTTAGGACCTAGATATGCTGTTTTT  
CCAAAAGATCAGCGTGGACCCTATCCTCCTGATGTTGCTAGTATGGGGATGAGACCTCAT  
GGATTTAGATTTGGATTTCCAGGAGGTAGTCATGGTACCATGCCGAGTCAAGAGCGCTTC  
CTTGTCCTCCTCAGCAAATACAGGGATCTGGAGTTTCTCCACAGCTAAGAAGATCAGTA  
TCTGTAGATATGCCTAGGCCTTTAAATAACTCACAAATGAATAATCCAGTTGGACTTCCT  
CAGCATTTTTTACCACAGAGCTTGCCAGTTCAGCAGCACAACTACTGGGCCAAGCATAT  
ATTGAACTGAGACATAGGGCTCCTGACGGAAGGCAACGGCTGCCTTTCAGTGCTCCACCT  
GGCAGCGTTGTAGAGGCATCTTCTAATCTGAGACATGGAACTTCATTCCCCGGCCAGAC  
TTTCCGGGGCCCTAGACACACAGACCCCATGCGACGACCTCCCAGGGTCTACCTAATCAG  
CTACCTGTGCACCCAGATTTGGAACAAGTGCCACCATCTCAACAAGAGCAAGGTCATTCT  
GTCCATTCATCTTCTATGGTCATGAGGACTCTGAACCATCCACTAGGTGGTGAATTTTCA  
GAAGCTCCTTTGTCAACATCTGTACCGTCTGAAACAACGTCTGATAATTTACAGATAACC  
ACCCAGCCTTCTGATGGTCTAGAGGAAAACTTGATTCTGATGACCCTTCTGTGAAGGAA  
CTGGATGTTAAAGACCTTGAGGGGGTTGAAGTCAAAGACTTAGATGATGAAGATCTTGAA  
AACTTAAATTTAGATACAGAGGATGGCAAGGTAGTTGAATTGGATACTTTAGATAATTTG  
GAACTAATGATCCCAACCTGGATGACCTCTTAAGGTGAGGAGAGTTTGATATCATTTGCA  
TATACAGATCCAGAACTTGACATGGGAGATAAGAAAAGCATGTTTAAATGAGGAACTAGAC  
CTTCCAATTGATGATAAGTTAGATAATCAGTGTGTATCTGTTGAACCAAAAAAAGGAA  
CAAGAAAACAAAACCTCTGGTTCTCTCTGATAAACATTCAACACAGAAAAAATCCACTGTT  
ACCAATGAGGTAAAAACGGAAGTACTGTCTCAAATTTCTAAGGTGGAATCCAAATGTGAA  
ACTGAAAAAATGATGAGAATAAAGATAATGTTGACACTCCTTGCTCACAGGCTTCTGCT  
CACTCAGACCTAAATGATGGAGAAAAGACTTCTTTGCATCCTTGTGATCCAGATCTATTT  
GAGAAAAGAACCAATCGAGAACTGCTGGCCCCAGTGCAATGTCATTTCAGGCATCCACT

- 201 -

CAACTACCTGCTCAAGATGTAATAAACTCTTGTGGCATAACTGGATCAACTCCAGTTCTC  
TCAAGTTTACTTGTCTAATGAGAAATCTGATAATTCAGACATTAGGCCATCGGGGTCTCCA  
CCACCACCAACTCTGCCGGCCTCCCCATCCAATCATGTGTCAAGTTTGCCTCCTTTCTATA  
GCACCGCCTGGCCGTGTTTTTGGATAATGCCATGAATTCTAATGTGACAGTAGTCTCTAGG  
GTAAACCATGTTTTTTCTCAGGGTGTGCAGGTAAACCCAGGGCTCATTCCAGGTCAATCA  
ACAGTTAACCACAGTCTGGGGACAGGAAAACCTGCAACTCAAACCTGGGCCTCAAACAAGT  
CAGTCTGGTACCAGTAGCATGTCTGGACCCCAACAGCTAATGATTCTCAAACATTAGCA  
CAGCAGAATAGAGAGAGGGCCCTTCTTCTAGAGAACAGCCTCTACTTCTACAGGATCTT  
TTGGATCAAGAAAGGCAAGAACAGCAGCAGCAAAGACAGATGCAAGCCATGATTTCGTGAG  
CGATCAGAACCCTTCTCCCTAATATTGATTTTGATGCAATTACAGATCCTATAATGAAA  
GCCAAAATGGTGGCCCTTAAAGGTATAAATAAAGTGTGTCACAAAACAATCTGGGCATG  
CCACCAATGGTGTGATGAGCAGGTTCCCTTTTATGGGCCAGGTGGTAACTGGAACACAGAAC  
AGTGAAGGACAGAACCTTGGACCACAGGCCATTCTCAGGATGGCAGTATAACACATCAG  
ATTTCTAGGCCTAATCTCCAAATTTTGGTCCAGGCTTTGTCAATGATTACAGCGTAAG  
CAGTATGAAGAGTGGCTCCAGGAGACCCAACAGCTGCTTCAAATGCAGCAGAAGTATCTT  
GAAGAACAAATTGGTGTCTCACAGAAAATCTAAGAAGGCCCTTTTCAGCTAAACAACGTACT  
GCCAAGAAAGCTGGGCGTGAATTTCCAGAGGAAGATGCAGAACAACCTCAAGCATGTTACT  
GAACAGCAAAGCATGGTTCAGAAACAGCTAGAACAGATTCTGTAAACAACAGAAAGAACAT  
GCTGAATTGATTGAAGATTATCGGATCAAACAGCAGCAGCAATGTGCAATGGCCCCACCT  
ACCATGATGCCCAGTGTCCAGCCCCAGCCACCCCTAATTCAGGTGCCACTCCACCCACC  
ATGAGCCAACCCACCTTTCCCATGGTGCCACAGCAGCTTCAGCACCAGCAGCACACAACA  
GTTATTTCTGGCCATACTAGCCCTGTTAGAATGCCCAGTTTACCTGGATGGCAACCCAAC  
AGTGCTCCTGCCACCTGCCCTCAATCCTCCTAGAATTCAGCCCCCAATTGCCCAGTTA  
CCAATAAAAACCTTGTACACCAGCCCCAGGGACAGTCTCAAATGCAAATCCACAGAGTGGA  
CCACCACCTCGGGTAGAATTTGATGACAACAATCCCTTTAGTGAAAGTTTTCAAGAACGG  
GAACGTAAGGAACGTTTACGAGAACAGCAAGAGAGACAACGGATCCAACTCATGCAGGAG  
GTAGATAGACAAAGAGCTTTGCAGCAGAGGATGGAAATGGAGCAGCATGGTATGGTGGGC  
TCTGAGATAAGTAGTAGTAGGACATCTGTGTCCAGATTCCCTTCTACAGTTCCGACTTA  
CCTTGTGATTTTATGCAACCTCTAGGACCCCTTCAGCAGTCTCCACAACACCAACAGCAA  
ATGGGGCAGGTTTTACAGCAGCAGAATATACAACAAGGATCAATTAATTACCCCTCCACC  
CAAACCTTTCATGCAGACTAATGAGCGAAGGCAGGTAGGCCCTCCTTCATTTGTTCTGAT  
TCACCATCAATCCCTGTTGGAAGCCCAAATTTTTCTTCTGTGAAGCAGGGACATGGAAAT  
CTTTCTGGGACCAGCTTCCAGCAGTCCCAGTGAGGCCTTCTTTTACACCTGCTTTACCA  
GCAGCACCTCCAGTAGCTAATAGCAGTCTCCCATGTGGCCAAGATTCTACTATAACCCAT  
GGACACAGTTATCCGGGATCAACCCAATCGCTCATTGAGTTGTATTCTGATATAATCCCA  
GAGGAAAAAGGGAAAAAGAAAAGAACAAAGAAAGAAAGAGATGATGATGCAGAATCC  
ACCAAGGCTCCATCAACTCCCCATTAGATATAACTGCCCCACCGACTCCAGGCATCTCA  
GAACTACCTCTACTCCTGCAGTGAGCACACCCAGTGAGCTTCCTCAACAAGCCGACCAA  
GAGTCGGTGGAACCAAGTCGGCCCATCCACTCCCAATATGGCAGCAGGCCAGCTATGTACA  
GAATTAGAGAACAACTGCCCAATAGTGATTTCTCACAAGCAACTCCAAATCAACAGACG  
TATGCAAATTCAGAAGTAGACAAGCTCTCCATGGAAACCCCTGCCAAAACAGAAGAGATA  
AACTGGAAAAGGCTGAGACAGAGTCTTGGCCAGGCCAAGAGGAGCCTAAATTGGAGGAA  
CAGAATGGTAGTAAGGTAGAAGGAAACGCTGTAGCCTGTCTCTCTCCTCAGCACAGAGT  
CCTCCCCATTCTGCTGGGGCCCCCTGCTGCCAAAGGAGACTCAGGGAATGAACTTCTGAAA  
CACTTGTGTAATAAATAAAGTCACTCTTCTTTTGAATCAAAAACCTGAGGGCAGTATT  
TGTTCAGAAGATGACTGTACAAAGGATAATAAAGTAGTTGAGAAGCAGAACCAGCTGAA  
GACTGCAAACTTTGGGGGCTCAAATGCAAGGTGGTTTTGGATGTGGCAACCAGTTGCCA

- 202 -

AAAACAGATGGAGGAAGTGAAACCAAGAAACAGCGAAGCAAACGGACTCAGAGGACGGGT  
GAGAAAGCAGCACCTCGCTCAAAGAAAAGGAAAAGGACGAAGAGGAGAAACAAGCTATG  
TACTCTAGCACTGACACGTTTACCCACTTGAAACAGGTGAGGCAGCTCTCTCTGCTCCCT  
CTAATGGAACCAATCATTGGAGTGAACTTTGCACACTTTCTTCCTTATGGCAGTGGCCAA  
TTTAATAGTGGGAATCGACTTCTAGGAACCTTTTGGCAGTGCTACCCTGGAAGGGGTTCG  
GACTACTATTCTCAGTTGATCTACAAGCAGAATAATTTAAGTAATCCTCCAACACCCCT  
GCCTCTCTTCCTCTACACCACCTCCTATGGCTTGTCAGAAGATGGCCAATGGTTTTGCA  
ACAACCTGAAGAACCTTGCTGGAAAAGCCGGAGTGTTAGTGAGCCATGAAGTTACCAAACCT  
CTAGGACCTAAACCATTTTCAGCTGCCCTTCAGACCCAGGACGACTTGTTGGCCCGAGCT  
CTTGCTCAGGGCCCCAAGACAGTTGATGTGCCAGCCTCCCTCCCAACACCACCTCATAAC  
AATCAGGAAGAATTAAGGATACAGGATCACTGTGGTGATCGAGATACTCCTGACAGTTTT  
GTTCCCTCATCCTCTCCTGAGAGTGTGGTTGGGGTAGAAGTGAGCAGGTATCCAGATCTG  
TCATTGGTCAAGGAGGAGCCTCCAGAACCGGTGCCGTCCCCCATCATTCCAATTCTTCCT  
AGCACTGCTGGGAAAAGTTCAAGATCAAGAAGGAATGACATCAAACTGAGCCAGGCACT  
TTATATTTTTGCGTCACCTTTTTGGTGCTTCCCCAAATGGTCCCAGATCAGGTCTTATATCT  
GTAGCAATTACTCTGCATCCTACAGCTGCTGAGAACATTAGCAGTGTTGTGGCTGCATTT  
TCCGACCTTCTTCACGTCCGAATCCCTAACAGCTATGAGGTTAGCAGTGCTCCAGATGTC  
CCATCCATGGGTTTGGTCAGTAGCCACAGAATCAACCCGGGTTTGGAGTATCGACAGCAT  
TTACTTCTCCGTGGGCCTCCGCCAGGATCTGCAAACCTCCAGATTAGTGAGCTCTTAC  
CGGCTGAAGCAGCCTAATGTACCATTTCTTCCAACAAGCAATGGTCTTTCTGGATATAAG  
GATTCTAGTCATGGTATTGCAGAAAGCGCAGCACTCAGACCACAGTGGTGTTGTCAATTGT  
AAAGTGGTTATTCTTGGAAGTGGTGTCGGAAATCTTTCAAAGATCTGACCCTTTTGAAC  
AAGGATTCCCGAGAAAGCACCAAGAGGGTAGAGAAGGACATTGTCTTCTGTAGTAATAAC  
TGCTTTATTCTTTATTTCATCAACTGCACAAGCGAAAACTCAGAAAACAAGGAATCCATT  
CCTTCATTGCCACAATCACCTATGAGAGAAACGCCCTTCCAAAGCATTTTCATCAGTACAGC  
AACAACATCTCCACTTTGGATGTGCACTGTCTCCCCAGCTCCAGAGAAAGCTTCTCCC  
CCTGCCTCACCAACCATCGCCTTCCCTCCTGCTTTTGAAGCAGCCCAAGTCGAGGCCAAG  
CCAGATGAGCTGAAGGTGACAGTCAAGCTGAAGCCTCGGCTAAGAGCTGTCCATGGTGGG  
TTTGAAGATTGCAGGCCGCTCAATAAAAAATGGAGAGGAATGAAATGGAAGAAAGTGGAGC  
ATTCATATTGTAATCCCTAAGGGGACATTTAAACCACCTTGTGAGGATGAAATAGATGAA  
TTTCTAAAGAAATTGGGCACTTCCCTTAAACCTGATCCTGTGCCCAAAGACTATCGGAAA  
TGTTGCTTTTGTATGAAGAAGGTGATGGATTGACAGATGGACCAGCAAGGCTACTCAAC  
CTTGACTTGGATCTGTGGGTCCACTTGAAGTGCCTCTGTGGTCCACGGAGGTCTATGAG  
ACTCAGGCTGGTGCCTTAATAAATGTGGAGCTAGCTCTGAGGAGAGGCCCTACAAATGAAA  
TGTGTCTTCTGTACAAAGACGGGTGCCACTAGTGGATGCCACAGATTTTCGATGCACCAAC  
ATTTATCACTTCACTTGCGCCATTAAAGCACAATGCATGTTTTTTAAGGACAAAACCTATG  
CTTTGCCCCATGCACAAACCAAAGGGAATTCATGAGCAAGAATTAAGTTACTTTGCAGTC  
TTCAGGAGGGTCTATGTTTCAGCGTGATGAGGTGCGACAGATTGCTAGCATCGTGCAACGA  
GGAGAACGGGACCATAACCTTTCGCGTGGGTAGCCTCATCTTCCACACAATTGGTCAGCTG  
CTTCCACAGCAGATGCAAGCATTCATTCTCCTAAAGCACTCTTCCCTGTGGGCTATGAA  
GCCAGCCGGCTGTACTGGAGCACTCGCTATGCCAATAGGCGCTGCCGCTACCTGTGCTCC  
ATTGAGGAGAAGGATGGGCGCCAGTGTTTGTTCATCAGGATTGTGGAACAAGGCCATGAA  
GACCTGGTTCTAAGTGACATCTCACCTAAAGGTGTCTGGGATAAGATTTTGGAGCCTGTG  
GCATGTGTGAGAAAAAAGTCTGAAATGCTCCAGCTTTTCCCAGCGTATTTAAAGGAGAG  
GATCTGTTTGGCCTGACCGTCTCTGCAGTGGCACGCATAGCGGAATCACTTCCTGGGGTT  
GAGGCATGTGAAAATTATACCTTCCGATACGGCCGAAATCCTCTCATGGAACCTTCCTCTT  
GCCGTTAACCCACAGGTTGTGCCCGTTCTGAACCTAAATGAGTGCCCATGTCAAGAGG



- 203 -

CCTCACACCTTAAACAGCACCAGCACCTCAAAGTCATTTTCAGAGCACAGTCACTGGAGAA  
CTGAACGCACCTTATAGTAAACAGTTTGTTCCTCAAGTCATCGCAGTACCGGAAGATG  
AAAACCTGAATGGAAATCCAATGTGTATCTGGCACGGTCTCGGATTCAGGGGCTGGGCCTG  
TATGCTGCTCGAGACATTGAGAAACACACCATGGTCATTGAGTACATCGGGACTATCATT  
CGAAACGAAGTAGCCAACAGGAAAGAGAAGCTTTATGAGTCTCAGAACCGTGGTGTGTAC  
ATGTTCCGCATGGATAACGACCATGTGATTGACGCGACGCTCACAGGAGGGCCCGCAAGG  
TATATCAACCATTTCGTGTGCACCTAATTGTGTGGCTGAAGTGGTGACTTTTGAGAGAGGA  
CACAAAATTATCATCAGCTCCAGTCCGAGAATCCAGAAAGGAGAAGAGCTCTGCTATGAC  
TATAAGTTTGACTTTGAAGATGACCAGCACAAAGATTCGGTGTCCTGTGGAGCTGTGAAC  
TGCCGGAAGTGGATGAACTGAAATGCATTTCCTTGCTAGCTCAGCGGGCGGCTTGTCCCTA  
GGAAGAGGCGATTCAACACACCATTTGGAATTTTGCAGACAGAAAGAGATTTTGTCTTCT  
GTTTTATGACTTTTGAAGAAAGCTTCTGGGAGTTCTGATTTCTCAGTCCTTTAGGTTAA  
AGCAGCGCCAGGAGGAAGCTGACAGAAGCAGCGTTCCTGAAGTGGCCGAGGTTAAACGGA  
ATCACAGAATGGTCCAGCACTTTTGCTTT

>gi|10864041|gb|NP\_067053.1|MLL3 4025aa linear  
myeloid/lymphoid or mixed-lineage leukemia 3; ALR-like protein  
[Homo sapiens].

MHNTVVLFFSSDKFTLNQDMCVVCGSFGQGAEGRLACSQCGQCYHPYCVSIKITKVVLS  
KGWRLECTVCEACGKATDPGRLLLCDDCDISYHTYCLDPPLQTVPKGGWKCKWCVWCRH  
CGATSAGLRCEWQNNYTQCAPCASLSSCPVCYRNYREEDLILQCRQCDRWMHAVCQNLNT  
EEVENVADIGFDCSMCRPYMPASNVPSSDCESSLVAQIVTKVKELDPPKTYTQDGVCL  
TESGMTQLQSLTVTVPRRKRSPKPKLKLKIINQNSVAVLQTPPDIQSEHSRDGEMDDSREG  
ELMDCDGKSESSPEREAVDDETKGVEGTDGVKKRKRKPYRPGIGGFMRQRSTGQGKTK  
RSVIRKDSSGSISEQLPCRDDGWSEQLPDTLVDESVSVTESTEKIKKRYRKRKNKLEETF  
PAYLQEAFFGKDLLDTSRQSKISLDNLSEDGAQLLYKTNMNTGFLDPSLDPLSSSSAPT  
KSGTHGPADDPLADISEVLNTDDDILGIISDDLAKSVSDHSDIGPVTDDPSSLPQPNVNS  
SRPLSEEQLDGILSPELDKMVTDGAILGKLYKIPELGGKDVEDLFTAVLSPANTQPTPLP  
QPPPTQLLPPIHNQDAFSRMPLMNLIGSSPHLPHNSLPPGSGLGTFSAIAQSSYPDARD  
KNSAFNPMASDPNNSWTSSAPTVEGENDTMSNAQRSTLKEKEEALGEMATVAPVLYTNI  
NFPNLKEEFPDWTTTRVKQIAKLWRKASSQERAPYVQKARDNRAALRINKVQMSNDSMKRQ  
QQQDSIDPSSRIDSELFKDPLKQRESEHEQEWFQMRQKSKQQAIEATQKLEQVKNE  
QQQQQQQQFGSQHLLVQSGSDTPSSGIQSPLTPQPGNGNMSPAQSFHKEFTKQPPSTPT  
STSSDDVFVKPQAPPPPPAPSRIPIDSLSQAQTSQPPSPQVFSFGSSNSRPPSPMDPYA  
KMVGTPRPPPVGHFSRNSAAPVENCTPLSSVSRPLQMNETTANRPSVPRDLCSSSTTN  
NDPYAKPPDTPRPVMTDQFPKSLGLSRSPVSEQTAKGPAAAGTSDHFTKPSPRADVFOR  
QRIPDSYARPLLTPAPLDSGPGPFKTPMQPPSSQDPYGSVSQASRRLSVDPYERPALT  
RPIDNFSHNQSNDPYSQPPLTPHPAVNESFAHPSRAFSQPGTISRPTSQDPYSQPPGTPR  
PVVDSYSQSSGTARSNTDPYSQPPGTPRPPTTVDPYSQQPQTPRPSTQTDLFVTPVTNQRH  
SDPYAHPPGTPRPGISVPYSQPPATPRPRISEGFTRSSMTRPVLMPNQDPFLQAAQNRRGP  
ALPGPLVRPPDTCSTQTPRPPGGLSDTFSRVSPSAARDPYDQSPMTPRSQSDSFGTSQTA  
HDVADQPRPGSEGSFCASSNSPMHSQGGQFSGVSQPLPGPVPTSGVTDTONTVNMAQADTE  
KLRQRQKLREIILQQQQQKKIAGRQEKGSQDSPAVPHPGPLQHWQPENVNQAFTRP PPPY  
PGNIRSPVAPPLGPRYAVFPKDQRGYPYPPDVASMGMRPHGFRFGFPGGSHGTMPQSQRFL  
VPPQQIQGSGVSPQLRRSVSVDMPRPLNNSQMNNPVGLPQHFSPOSLPVQQHNIILQAYI  
ELRHRAPDGRQRLPFSAPPGSVVEASSNLRHGNFI PRPDFPGPRHTDPMRRPPQGLPNQL  
PVHPDLEQVPPSQQEQQHSHVSSSMVMRTLNLHPLGGEFSEAPLSTSVPSSETTSDNLQITT  
QPSDGLEEKLDSDDPSVKELDVKDLEGEVVKDLDDLEDLENLNLDTEDGKVVELDTLDNLE

- 204 -

TNDPNLDDLLRSGEFDIIAYTDPPELMDGDKKSMFNEELDLPIDDKLDNQCVSVEPKKKEQ  
 ENKTLVLSDKHSPQKKSTVTNEVKTEVLSPNSKVESKCEKTEKNDENKDNVDTPCSQASAH  
 SDLNDGEKTSLHPCDPLDFEKRTNRETAGPSANVIOASTQLPAQDVINSCGITGSTPVLS  
 SLLANEKSDNSDIRPSGSPPPPTLPASPSNHVSSLPPFIAPPGRVLDNAMNSNVTVVSRV  
 NHVFSQGVQVNPGLIPGQSTVNHSLGTGKPATQTGPQTSQSGTSSMSGPQQLMIPQTLAQ  
 QNRERPLLLLEEQLLLQDLDDQERQEQQQQRQMAMIRQRSEPPFPNIDFDAITDPIMKA  
 KMVALKGINKVMAQNNLGMPPMVMSRFPFMGQVVTGTQNSEGQNLGPQAIPODGSITHQI  
 SRPNPPNFGPGFVNDSSQRKQYEEWLQETOQQLLQMQQKYLEEQIGAHRKSKKALSAKQRTA  
 KKAGREFPEEDAEQLKHVTEQQSMVQKQLEQIRKQQKEHAELIEDYRIKQQQQCAMAPPT  
 MMPSVQPPPLIPGATPPTMSQPTFPMVPQQLQHQQHTTVISGHTSPVRMPSLPGWQPN  
 APAHLPLNPPRIQPPIAQLPIKTCTPAPGTVSNANPQSGPPRVEFDDNNPFSESFQERE  
 RKERLREQQERQRIQLMQEVDQRALQQRMEMEQHGMVGSEISSSRTSVSQIPFYSSDLP  
 CDFMQPLGPLQQSPQHQQMGQVLQQQNIQQGSINSPSTQTFMQTNERRQVGPSPFVPS  
 PSIPVGSPNFSSVKQGHGNLSGTSFQQSPVRPSFTPALPAAPPVANSSSLPCGQDSTITHG  
 HSYPGSTQSLIQLYSDIIPEEKGKKRTRKKKRDDDAESTKAPSTPHSDITAPPTPGISE  
 TTSTPAVSTPSELPPQADQESVEPVGPSTPNMAAGQLCTELENKLPNSDFSQATPNQQTY  
 ANSEVDKLSMETPAKTEEIKLEKAETESCPGQEEPKEEQNGSKVEGNAVACPVSSAQSP  
 PHSAGAPAAKGDGSGNELLKHLKKNKSSSLNQNKPEGSCSEDDCTKDNKLVEKQNPAG  
 LQTLGAQMGGFGCGNQLPKTDGGSETKKQRSKRTQRTGEKAAPRSKKRKKDEEEKQAMY  
 SSTDTFTHLKQVRQLSLLPLMEPIIGVNFHFPLPYGSGQFNSGNRLLGTFGSATLEGVSD  
 YYSQLIYQNNLSNPPTPPASLPPTPPPMACQKMANGFATTEELAGKAGVLVSHEVTKTL  
 GPKPFQLPFRPQDDLLARALAQQGPKTVDPASLPPTPHNNQEELRIQDHCGRDTPDSFV  
 PSSSPESVVGVEVSRYPDLSLVKEEPPEPVPSPIIPILPSTAGKSSESRRNDIKTEPGTL  
 YFASPFGPSPNGPRSGLISVAITLHPTAAENISSVVAAFSDLLHVRI PNSYEVSSAPDVP  
 SMGLVSSHRIINPGLEYRQHLLLRGPPPGSANPPRLVSSYRLKQPNVPFPPTSNGLSGYKD  
 SSHGIAESAALRPQWCCHCKVVIILGSGVRKSFKDLTLLNKDSRESTKRVEKDIVFCNNC  
 FILYSSTAQAKNSENKESIPSLPQSPMRETSPKAFHQYSNNISTLDVHCLPQLPEKASPP  
 ASPPIAFPPAFEAQVEAKPDELKVTVKLPRLRAVHGGFEDCRPLNKKWRGMKWKWSI  
 HIVIPKGTFFKPPCEDEIDEFLKKLGTSLKPDPVPKDYRKCCFCHEEGDGLTDGPARLLNL  
 DLDLWVHLNCAWSTEVYETQAGALINVELALRRGLQMKCVFCHKTGATSGCHRFRCTNI  
 YHFTCAIKAQCMFFKDKTMLCPMHKPKGIHEQELSYFAVFRVYVQRDEVQRQIASIVQRG  
 ERDHTFRVGLIFHTIGQLLPQQMQAFHSPKALFPVGYEASRLYWSTRYANRRCRYLCSI  
 EEKDGPRPVFVIRIVEQGHEDLVLSDISPKGVDKILEPVACVRKKSEMLQLFPAYLKGED  
 LFGLTVSAVARIAESLPGEACENYTFRYGRNPLMELPLAVNPTGCARSEPKMSAHVKRP  
 HTLNSTSTSKSFQSTVTGELNAPYSKQFVHSKSSQYRKMKTEWKSNNVYLARSRIQGLGLY  
 AARDIEKHTMVIEWYIGTIIIRNEVANRKEKLYESQNRGVYMFMDNDHVIDATLTGGPARY  
 INHSCAPNCVAEVVTFERGHKIIISSSRRIQKGEELCYDYKFDDEDQHKIPCHCGAVNC  
 RKWMN

>gi|21359851|gb|NM\_000966.2|RARG 2663bp mRNA Homo sapiens  
 retinoic acid receptor, gamma (RARG), mRNA.

GGCACGAGGCAGTGGGCAGGCCAGGCAGGGCGGGTACGGAGCCTCCCAGGCTGGGGCAGT  
 GGGCATGGGCAGGGGCTGTGGCTGAAGACCTCGCCCGCCACTGCAGACTCCAGGGGACT  
 CTCACACCGCAGCTGCCATGGCCACCAATAAGGAGCGACTCTTTGCGGCTGGTGCCCTGG  
 GGCCTGGATCTGGCTACCCAGGGGCGAGTTTCCCTTTCGCCTTCCCAGGGGCACTCAGGG  
 GGTCTCCGCCTTTTCGAGATGCTGAGCCCTAGCTTCCGGGGCCTGGGCCAGCCTGACCTCC  
 CCAAGGAGATGGCCTCTCTGTCGGTGGAGACACAGAGCACCAGCTCAGAGGAGATGGTGC  
 CCAGCTCGCCCTCGCCCCCTCCGCCTCCTCGGGTCTACAAGCCATGCTTCGTGTGCAATG



- 205 -

ACAAGTCCTCTGGCTACCACTATGGGGTCAGCTCTTGTGAAGGCTGCAAGGGCTTCTTTC  
GCCGAAGCATCCAGAAGAACATGGTGTACACGTGTCACCGCGACAAAACTGTATCATCA  
ACAAGGTGACCAGGAATCGCTGCCAGTACTGCCGGCTACAGAAGTGCTTCGAAGTGGGCA  
TGTCCAAGGAAGCTGTGCGAAATGACCGGAACAAGAAGAAGAAAGAGGTGAAGGAAGAAG  
GGTCACCTGACAGCTATGAGCTGAGCCCTCAGTTAGAAGAGCTCATCACCAAGGTCAGCA  
AAGCCCATCAGGAGACTTTCCCTCGCTCTGCCAGCTGGGCAAGTATACCACGAACTCCA  
GTGCAGACCACCGCGTGCAGCTGGATCTGGGGCTGTGGGACAAGTTCAGTGAGCTGGCTA  
CCAAGTGATCATCAAGATCGTGGAGTTTGCCAAGCGGTTGCCTGGCTTTACAGGGCTCA  
GCATTGCTGACCAGATCACTCTGCTCAAAGCTGCCTGCCTAGATATCCTGATGCTGCGTA  
TCTGCACAAGGTACACCCAGAGCAGGACACCATGACCTTCTCCGACGGGCTGACCCTGA  
ACCGGACCCAGATGCACAATGCCGGCTTCGGGGCCCTCACAGACCTTGTCTTTGCCTTTG  
CTGGGCAGCTCCTGCCCCCTGGAGATGGATGACACCGAGACAGGGCTGCTCAGCGCCATCT  
GCCTCATCTGCGGAGACCGCATGGACCTGGAGGAGCCCGAAAAAGTGGACAAGCTGCAGG  
AGCCACTGCTGGAAGCCCTGAGGCTGTACGCCCCGGCGCCGGCGGCCAGCCAGCCCTACA  
TGTTCCCAAGGATGCTAATGAAAATCACCGACCTCCGGGGCATCAGCACTAAGGGAGCTG  
AAAGGGCCATTACTCTGAAGATGGAGATTCCAGGCCCCGATGCCTCCCTTAATCCGAGAGA  
TGCTGGAGAACCCTGAAATGTTTGAGGATGACTCCTCGCAGCCTGGTCCCCACCCCAATG  
CCTCTAGCGAGGATGAGGTTCTTGGGGGCCAGGGCAAAGGGGGCCTGAAGTCCCCAGCCT  
GACCAGGGCCCCCTGACCTCCCCGCTGTGGGGGTTGGGGCTTCAGGCAGCAGACTGACCAT  
CTCCCAGACCGCCAGTGACTGGGGGAGGACCTGCTCTGCCCTCTCCCCACCCCTTCCAAT  
GAGCTCCTTGTTTTTTGCCAAAGTTTCTAGGGGTGCCTCTGTGTTTCATCCCTTCTCTGATC  
TAACCGGCTCCCTCGCCAGTCCCGGGGGCCTGCCCTGCTCCCACCAGGAGAGAGGGCAAA  
GGGATGAGCCTGGGTTTGGAATCTAAAATCTCAGCACTGCCCCATGGGTCTTAGACTTCC  
CAGGGCAAGAGGAAGACCCTGCCATTCCACAGCCCCCTTCTCTGCCAGGTGCTTGGCTCT  
CTGAGAGCAAACAGGAACACTAGAGACCAAAAAGGGGACAAAGGAGAAGGGCTGAGCCCA  
CCTTCTTGCTCCTACCCTTGGTGCCTAATGCTGTGTGATGCACCTGCAGGGTGTGTGCTA  
GCCTCTGTGCCCCGTCCTTGTGCCAGGTCAAGGTGGGGGCAGGCTGGGGCCCTGCATTTCT  
GGGGCAGGAACAGAGGGTGAAGGGGACAGATAGATGCAGGTCCATTCTGCACCTCTTGGC  
TCGGGTGCAGAGTTCACCTGTGCCCTCCGTTATAAGTCCCTCCCCAGCCCTGTCTATGT  
GCCTTGGGCTCCTCCTGCCCTCCATCTCAGCCATTGGGGCAGGGACCCTCCTACACTACA  
GAGGGGCCAGGGGATCCCTCTCTCCCTAGTGCTTCCACCCTTTACTCCCCAGAGCAGCT  
TGGCCCAGGGAGGGGGGATGCTGCTTAGCTGATCCCGCCCTGACCCAGAGGAAGCCTCTA  
TTTATTTATTAGCTTTTGTTTTACACCGTGGAATTGACCCCTTCTCTCCAGGGGTCTTGGGT  
GGGGGAGCCCAGGGCCCCCTGTGACCCCTCCTTTCTTCTTCCAATCCCCAGTTTGTATTTA  
GCTGCCAAATAAGATTCCCATTTGGCTCCCTGTGTTCTCTTGGGGGGTCAAGGTGCTGTCC  
CCTCCCCCTCTGTTTACATCTCCCCCTTACCCCGCTGTATCGCATATTGCTGAGTTTCTA  
TTTTTGCAAAATAAAGTGATGGAACTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAAAAAAAAAAAAAAA

>gi|4506423|gb|NP\_000957.1|RARG 454aa linear retinoic acid  
receptor, gamma; Retinoic acid receptor, gamma polypeptide  
[Homo sapiens].

MATNKERLFAAGALGPGSGYPGAGFPFAFPALRGSPPFEMLSPSFRGLGQPDLPKEMAS  
LSVETQSTSSEEMVSSSPSPPPPPRVYKPCFVCNDKSSGYHYGVSSCEGCKGFFRRSIQK  
NMVYTCHRDKNCIINKVTRNRCQYCRLOKCFEVMGSKEAVRNDRNKKKKEVKEEGSPDSY  
ELSPQLEELITKVSKAHQETFPQLCQLGKYTTNSSADHRVQLDLGLWDKFSELATKCI IK  
IVEFAKRLPGFTGLSIADQITLLKAACLDILMLRICTRYTPEQDTMTFSDGLTLNRTQMH  
NAGFGPLTDLVFAFAGQLLPLEMDDTETGLLSAICLICGDRMDLEEPEKVVDKLEPLLEA

- 206 -

LRLYARRRRPSQPYMFPRMLMKITDLRGISTKGAERAITLKMEIPGPMPLIREMLENPE  
MFEDDSSQPGPHPNASSEDEVPGGQGGKGLKSPA

>gi|14670376|gb|NM\_015318.1|P114-RHO-GEF 5113bp mRNA Homo  
sapiens Rho-specific guanine nucleotide exchange factor p114  
(P114-RHO-GEF), mRNA.

GCTGGCGGAGAGCGGCCTGCGGGCGATCGGGCCGAGCCTCGCTCAAGGAGCACCCCCGGG  
GCACCCCTCCTGTCCGATGGCAGCCCGGCCCTGTCCAGGAATGTCGGTATGACGGTCTCTC  
AGAAAGGGGGTCCCCAGCCAACACCGAGCCCGGCTGGCCCTGGGACGCAACTCGGACCAA  
TCACAGGAGAGATGGATGAAGCCGATTCTGCGTTTTTTAAAATTTAAGCAGACAGCTGATG  
ACTCTCTGTCCCTTACATCTCCAAACACCGAGTCCATTTTTGTAGAAGATCCCTACACCG  
CCTCGCTGAGGAGTGAGATTGAGTCAGACGGCCACGAGTTTGAAGCTGAGTCCTGGAGCC  
TCGCCGTGGATGCAGCCTACGCCAAGAAGCAAAAGAGGGAGGTGGTGAAGAAGACAAGATG  
TCCTTTATGAGCTGATGCAGACAGAGGTGCACCACGTGCGGACGCTCAAGATCATGCTGA  
AGGTGTACTCCAGGGCCCTGCAGGAGGAGCTGCAGTTCAGCAGCAAGGCCATTGGCCGCC  
TCTTCCCATGCGCTGACGACCTGCTGGAGACGCACAGCCACTTCCTCGCTCGGCTCAAGG  
AGCGCCGCCAGGAGTCCCTGGAGGAGGGCAGTGACCGGAATTATGTCATCCAGAAAATCG  
GCGACCTCCTGGTTCAGCAGTTTTTCAGGTGAAAATGGGGAGAGAATGAAAGAAAAGTACG  
GTGTGTTTTGTAGTGGCCACAATGAAGCTGTTAGTCATTACAAGTTGCTGCTTCAGCAAA  
ACAAGAAATTTCAAAACTTGATCAAGAAAAATTGGCAACTTCTCCATCGTGCGGCGGCTTG  
GCGTGCAGGAGTGCAATTCTCCTGGTTACACAACGCATAACCAAATACCCAGTGCTGGTGG  
AGCGCATCATCCAGAACACGGAAGCTGGCACTGAGGACTATGAAGACCTGACCCAGGCCT  
TGAACCTCATCAAAGATATCATCTCACAAGTGGACGCCAAGGTCAGTGAGTGTGAGAAGG  
GCCAGCGCCTCAGGGAGATCGCAGGGAAGATGGACCTGAAGTCTTCCAGCAAACCTCAAGA  
ACGGGCTCACCTTCGCAAGGAAGACATGCTTCAGCGGCAGCTCCACCTGGAGGGCATGC  
TATGCTGGAAGACCACATCAGGGCGCTTGAAAGATATCCTGGCTATCCTGCTGACCGACG  
TACTTTTGCTGCTACAAGAAAAGATCAGAAATACGTCTTTGCTTCTGTGGACTCAAAGC  
CACCCGTCTATCTCGTTACAAAAGCTCATCGTGAGGGGAAGTGGCCAACGAGGAGAAAGCGA  
TGTTTCTGATCAGCGCCTCCTTGCAAGGGCCGGAGATGTATGAAATCTACACGAGCTCCA  
AAGAGGACAGGAACGCCTGGATGGCCCAATCCAAAGGGCTGTGGAGAGCTGCCCTGACG  
AGGAGGAGGGGGCCCTTCAGCCTGCCCCGAAGAGGAAAGGAAGGTGGTCGAGGCCCCGCGCCA  
CGAGACTCCGGGACTTTCAAGAGCGGTTGAGCATGAAAGACCAGCTGATCGCACAGAGCC  
TCCTAGAGAAACAGCAGATCTACCTGGAGATGGCCGAGATGGGCGGCCTCGAAGACCTGC  
CCCAGCCCCGAGGCCTATTCCGTGGAGGGGACCCATCCGAGACCCTGCAGGGGGAGCTAA  
TTCTCAAGTCGGCCATGAGCGAGATCGAGGGCATCCAGAGCCTGATCTGCAGGCGGCTGG  
GCAGCGCCAACGGCCAGGCGGAAGACGGAGGCAGCTCCACAGGCCCCGCCAGGAGGGCTG  
AGACCTTCGCGGGCTACGACTGCACAAACAGCCCCACCAAGAATGGCAGTTTCAAGAAGA  
AAGTCAGCAGCACTGACCCAGGCCCCGAGACTGGCGAGGCCCCCAACAGCCGGACT  
TGAAGCTCAGTGACAGTGACATTCTGAGGAGCTCTGAGGAATCGCCGCAGGTGGTGGAGG  
CGCCAGGCACGGAATCCGATCCCCGTCTGCCACCGTCTGGAGTCGGAGCTTGTCCAGC  
GGATCCAGACACTGTCCCAGCTGCTCCTGAACCTTCAGGCGGTAATCGCCCACCAGGACA  
GCTATGTGGAGACGCAGCGGGCTGCCATCCAGGAGCGGGAGAAGCAGTTCGGGCTGCAGT  
CGACGCGTGGGAACCTGCTGCTGGAGCAGGAGCGGCAACGCAACTTCGAGAAGCAGCGGG  
AGGAGCGCGCGGCCCTGGAGAAGCTGCAGAGCCAGCTGCGGCACGAGCAGCAGCGCTGGG  
AGCGCGAGCGCCAGTGGCAGCACAGGAGCTGGAGCGTGCGGGCGCGCGGCTGCAGGAGC  
GCGAGGGCGAGGCGCGGCAGCTACGCGAGCGGCTGGAGCAGGAGCGGGCCGAGCTGGAGC  
GCCAGCGCCAGGCCTACCAGCACGACCTGGAGCGGCTGCGCGAGGCCCAGCGTGCCGTGG  
AGCGCGAGCGGGAGCGCCTGGAGCTGCTGCGCCGCCTCAAGAAGCAGAACACCGCGCCAG

- 207 -

GCGCGCTGCCGCCCCGACACACTGGCCGAGGCCAGCCCCCAAGCCACCCTCCCAGCTTCA  
ACGGGGAAGGGCTGGAGGGCCCTCGGGTGAGCATGCTGCCATCCGGCGTGGGGCCAGAGT  
ACGCAGAGCGCCCCGAGGTGGCTCGCCGGGACAGCGCCCCCACCAGAGCCGGCTGGCCA  
AGAGCGATGTGCCCATCCAGCTGCTCAGCGCCACCAACCAGTTCCAGAGGCAGGCGGCCG  
TGCAGCAGCAGATCCCCACCAAGCTGGCGGCCTCCACCAAGGGTGGCAAGGACAAGGGCG  
GCAAGAGCAGGGGCTCTCAGCGCTGGGAGAGCTCAGCGTCCTTCGACCTGAAGCAGCAGC  
TGCTGCTCAACAAGCTCATGGGGAAAGATGAGAGCACCTCACGGAACCGCCGCTCGCTGA  
GCCCTATCCTGCCCGGCAGACACAGTCCTGCGCCCCCACCAGACCCTGGCTTCCCCGCCC  
CGAGCCCACCGCCAGCTGACAGCCCCCTCGAGGGCTTCTCTCTCAAGGCCGGGGGCACAG  
CCCTCCTGCCCGGCCCCCAGCTCCCTCGCCACTGCCGGCCACACCACTCAGCGCCAAGG  
AGGACGCCAGCAAAGAAGACGTCATCTTCTTCTAAAAGGGCCGTGACTCAAGGAAAGTTT  
TTAATGGAAAGTTGAGCCAGAACTAAACCAGGGAGCTGTCTGAAATCATAGCACCCCATC  
CGGGTGGCGGGGAGATCAACTCCGAGCTGTTTTTCCGAGGCAGTGAGGAACGGTGCCGGC  
TCTGCACGGAGCTGAGGACAGGACAGACCTTGCTTTGAGAAGGAGCTGCCGGCCGGGGCC  
ACGCTCCACAGCCGCCGCGCGACAGTGGAGCCAAGGGTTAGGGCACCAGGAGGGGCCAGG  
TGGCGTCCGCAGCATCTGTCCCCAGAATCAGGCAGAATCCACTTCCCAAACAGAGCCCCA  
CGCAGGTTTACCATGAACCTCAGGGTCAGGGAATGAGCCAGGCACGGGGGCATGGGCAGA  
GAGGGCCACGGGGCAGGGCCCACTGAGGGAACATCAGTGGCCCTCCAGTCAGGTTCTGTG  
GGTTTGAAGCCCATCGTGAAAGGGGCTGACCTTTGCCCTTTTTTACTTGGCATTTGGTTT  
TGAAACCAGCTGTTTTCCCAAACCTCTGCTTCCCAAGGGCAACCGTTGCTGTTACACGCTC  
AGCCTGTCTGGGGGAGCGGGCCTCTAGCTTCAGCCAGGGCGGGTACACACCCTGGGCACA  
GGGTCCTCAGCCCCCGGGAAATGAGCTCCAGGGCTGGCGTCCCACCTTCCAGGTGGGGG  
CTGGCACATCACAGACTGTGAGAGCGCCATGTCCCAGGGCATGCAGAGGTTGCACCTAG  
AGACGTTGCAGCAAGTGGACAAGTGGCCGCTGTGCGGGCCCCCTCGCTTGTAAGTGAAGTGT  
TGCAGCTTACGGTCCGTTCCCTGGAGGGGTGGAGGAAGGAGGTGTTGGGCAGCATCAAAG  
GTGCTGGGACATCCAGGGTGGTGAGATCCATCCACGATCCAGCTCCGGTGGAGAAAGGG  
CCCATGTCAAGCCTTGTTCTGCACCCCAAGCATTTGGTGGTAGGACTGGGTCTGGCTGAT  
CGTCCTTGTTCCAGTGGGGTACATGTGAGCCCCTGCCAGGGCCAAGTCCTTCTCCCGAA  
CCCAGGGTCTGGGAACTGCAGATCCCGGGGGGATTACAGCCCTTCTCCCACTGTGCTGGC  
AGAGGCACTCCTGTGACGCTGAATACAGTGAACAGGGACATTCCCGCCACTCGGGGACAG  
ATGGGCACAAGGGAGGGGAACTCCATCAGGAAGTGCTCCCCTGGGCAGAGGCGCCCACT  
GGGTGCTGTGGGCTCAGGAGGGGGCGGGCAGGAGCTGGTGCCAACCGGGAACCAGAGCC  
CCACAGCCATACAGCCCATTGGTGACAAGGTCTTGAGAACACAGTGGCCAGGTGTCCCA  
GGCTCCTGGCCCCCTCCGACGACCTCAACTCTGCCCAGCCCGGTCCCTGGCCATCAGCGAC  
GCTGTCCGCCCCCGTCAGATCCCATGTGTGCCATGTTTATCATCAGTGTTTTGTATTTT  
TGTAAGTATCGGAGCACTTTACAGAAGCTGACTGTACATTCTGTTCTGTTGTGAAG  
AGAACATTCCAGACCCTGGCACCCCTCCTGAGCCGGCGTGTGCCGGTCCAGCCCTCCGAG  
ATGCCACAATTCTTGATGGGGGAGAAGTTCAAGGAATTTCTGCTCGGCCACGCGGTGG  
GAACCCCGCGTCCCCGCCATGTGGCAGAGGGGTCTCAGTCGTGCTAGGCATCGGGCGGCA  
GCGCCGACAGCCCTTCCCTCGCCAGTGCCCCCTCGGCCACTCCTGGGTTGGAGCCCGATTT  
TATTTGTAAAGTTGACAGTCGAGCAAATGTTCTTATTTTCGTGGGATCTGCACACGTCTT  
TGTCAGTTGTGGTCATGATCTTAGTCACCTGCTAATTATTTTACAATGATTACAACATT  
TCCTCACTGCGGGATATTTCTGACCCGCTTTAGAACTTAAGACCTGATTCTAGCAATAAA  
CGTGTCCGAGATG

>gi|14670377|gb|NP\_056133.1|P114-RHO-GEF 1015aa linear Rho-  
specific guanine nucleotide exchange factor p114 [Homo  
sapiens].

- 208 -

MTVSQKGGPQPTSPAGPGTQLGPITGEMDEADSAFLKFKQTADDSLSLTSPNTESIFVE  
DPYTASLRSEIESDGHFEAESWSLAVDAAYAKKQKREVVKRQDVLYELMQTEVHHVRTL  
KIMLKVYSRALQEELQFSSKAIGRLFPCADDLLETHSHFLARLKERRQESLEEGSDRNYV  
IQKIGDLLVQQFSGENGERMKEKYGVFCSGHNEAVSHYKLLLQONKKFQNLIKKIGNFSI  
VRRLGVQECILLVTQRITKYPVLVERIIQNTTEAGTEDYEDLTQALNLIKDIISQVDAKVS  
ECEKGQRLREIAGKMDLKSSSKLKNGLTFRKEDMLQRLHLEGMLCWKTTSGRLKDILAI  
LLTDVLLLLQEKDQKYVFASVDSKPPVISLQKLI VREVANEEKAMFLISASLQGPMEYEI  
YTSSKEDRNAWMAHIQRAVESCPDEEEGPFSLPEEERKVVEARATRLRDFQERLSMKDQL  
IAQSLLEKQQIYLEMAEMGGLEDLPQPRGLFRGGDPSETLQGELILKSAMSEIEGIQSLI  
CRRLLGSANGQAEDGGSSTGPPRRAETFAGYDCTNSPTKNGSFKKKVSSTDPRPDRWRGPP  
NSPDLKLSDSIDPGSSEESPOVVEAPGTESDPRLPVLESELVQRIQTLSQLLLLNLQAVI  
AHQDSYVETQRAAIQEREKQFRLQSTRGNLLLEQERQRFKQREERAALKQSQLRHE  
QQRWERERQWQHQLERAGARLQEREGEARQLRERLEQERAELERQRQAYQHDLERLREA  
QRAVERERERLELLRLKKQNTAPGALPPDTLAEAAQPPSHPPSFNGEGLEGPRVSMPLPSG  
VGPEYAERPEVARRDSAPTESRLAKSDVPIQLLSATNQFORQAAVQQQIPTKLAASKGG  
KDKGGKSRGSQRWESSASFDLKQQLLLNKLGMKDESTSRNRRSLSPILPGRHSPAPPPDP  
GFPAPSPPPADSPSEGFSLKAGGTALLPGPPAPSPPLPATPLSAKEDASKEDVIF

>gi|23238259|gb|NM\_005198.3|CHKL 1595bp mRNA Homo sapiens  
choline kinase-like (CHKL), transcript variant 1, mRNA.

CCCGGGCCGGGGCACGGAGAGAGCCGAGCGCCGAGCCGTGAGCCGAATAGAGCCGGAGA  
GACCCGAGTATGACCGGAGAAGCCCAGGCCGCGCGGAAGAGGAGCCGAGCGCGGCCGGAA  
GGAACCGAGCCCGTCCGAAGGGAGCGGAGCGCAGCCTGGCCTGGGGCCCGGTCGAGCCCG  
CGCCATGGCGGCCGAGGCGACAGCTGTGGCCGGAAGCGGGGCTGTTGGCGGCTGCCTGGC  
CAAAGACGGCTTGCAGCAGTCTAAGTGCCCGGACACTACCCCAAACGGCGGCGCGCCTC  
GTCGCTGTGCGGTGACGCGGAGCGCCGAGCCTACCAATGGTGCCGGGAGTACTTGGGCGG  
GGCCTGGCGCCGAGTGCAGCCCGAGGAGCTGAGGGTTTACCCCGTGAGCGGAGGCCTCAG  
CAACCTGCTCTTCCGCTGCTCGCTCCCGGACCACCTGCCAGCGTTGGCGAGGAGCCCG  
GGAGGTGCTTCTGCGGCTGTACGGAGCCATCTTGACGGGCGTGGAATCCCTGGTGCTAGA  
AAGCGTGATGTTTCGCCATACTTGCGGAGCGGTGCTGGGGCCCCAGCTGTACGGAGTCTT  
CCCAGAGGGCCGGCTGGAACAGTACATCCCAAGTCGGCCATTGAAAACCTCAAGAGCTTCG  
AGAGCCAGTGTTGTCAGCAGCCATTGCCACGAAGATGGCGCAATTTTCATGGCATGGAGAT  
GCCTTTTACCAAGGAGCCCCACTGGCTGTTTGGGACCATGGAGCGGTACCTAAACAGAT  
CCAGGACCTGCCCCCACTGGCCTCCCTGAGATGAACCTGCTGGAGATGTACAGCCTGAA  
GGATGAGATGGGCAACCTCAGGAAGTTACTAGAGTCTACCCCATCGCCAGTCGTCTTCTG  
CCACAATGACATCCAGGAAGGGAACATCTTGCTGCTCTCAGAGCCAGAAAATGCTGACAG  
CCTCATGCTGGTGGACTTCGAGTACAGCAGTTATACTATAGGGGCTTTGACATTGGGAA  
CCATTTTGTGAGTGGGTTTATGATTATACTCACGAGGAATGGCCTTTCTACAAAGCAAG  
GCCACAGACTACCCCACTCAAGAACAGCAGTTGCATTTTATTTCGTCATTACCTGGCAGA  
GGCAAAGAAAGGTGAGACCCTCTCCCAAGAGGAGCAGAGAAAACCTGGAAGAAGATTGTCT  
GGTAGAAGTCAGTCGGTATGCTCTGGCATCCCATTTCTTCTGGGGTCTGTGGTCCATCCT  
CCAGGCATCCATGTCCACCATAGAATTTGGTTACTTGGACTATGCCAGTCTCGGTTCCA  
GTTCTACTTCCAGCAGAAGGGGCAGCTGACCAGTGTCACCTCCTCATCCTGACTCCACCC  
TCCCACTCCTTGGATTTCTCCTGGAGCCTCCAGGGCAGGACCTTGGAGGGAGGAACAACG  
AGCAGAAGGCCCTGGCGACTGGGCTGAGCCCCCAAGTGAAACTGAGGTTTCAGGAGACCGG  
CCTGTTCTGAGTTTGTAGTAGGTCCCATGGCTGGCAGGCCAGAGCCCCGTGCTGTGTAT  
GTAACACAATAAACAAGCTTCTTCTTCCACCCCTG

- 209 -

>gi|6978649|gb|NP\_005189.2|CHKL 395aa linear  
choline/ethanolamine kinase isoform a [Homo sapiens].

MAAEATAVAGSGAVGGCLAKDGLQQSKCPDTPKRRRASSLSRDAERRAYQWCREYLGGA  
WRRVQPEELRVYPVSGGLSNLLFRCSLPDHLPSVGEEPREVLLRLYGAILQGVDSLVL  
VMFAILAERSLGPQLYGVFPEGRLEQYIPSRPLKTQELREPVLSAAIATKMAQFHGMEMP  
FTKEPHWLFGTMERYLKQIQDLPPPTGLPEMNLLMYSKDEMGNLRKLLSTPSPVVFCH  
NDIQEGNILLSEPENADSLMLVDFEYSSYNYRGFDIGNHFCEWVYDYTHEEWPFYKARP  
TDYPTQEQQLHFIRHYLAEAKKGETLSQEEQRKLEEDLLVEVSRYALASHFFWGLWSILQ  
ASMSTIEFGYLDYAQSRFQFYFQQKGQLTSVHSSS

>gi|4757755|gb|NM\_004039.1|ANXA2 1362bp mRNA Homo sapiens  
annexin A2 (ANXA2), mRNA.

CATTTGGGGACGCTCTCAGCTCTCGGCGCACGGCCCAGCTTCCTTCAAATGTCTACTGT  
TCACGAAATCCTGTGCAAGCTCAGCTTGGAGGGTGATCACTCTACACCCCCAAGTGCATA  
TGGGTCTGTCAAAGCCTATACTAACTTTGATGCTGAGCGGGATGCTTTGAACATTGAAAC  
AGCCATCAAGACCAAAGGTGTGGATGAGGTCACCATTGTCAACATTTTGACCAACCGCAG  
CAATGCACAGAGACAGGATATTGCCTTCGCCTACCAGAGAAGGACCAAAAAGGAACTTGC  
ATCAGCACTGAAGTCAGCCTTATCTGGCCACCTGGAGACGGTGATTTTGGGCCTATTGAA  
GACACCTGCTCAGTATGACGCTTCTGAGCTAAAAGCTTCCATGAAGGGGCTGGGAACCGA  
CGAGGACTCTCTCATTGAGATCATCTGCTCCAGAACCAACCAGGAGCTGCAGGAAATTA  
CAGAGTCTACAAGGAAATGTACAAGACTGATCTGGAGAAGGACATTATTTCCGACACATC  
TGGTGACTTCCGCAAGCTGATGGTTGCCCTGGCAAAGGGTAGAAGAGCAGAGGATGGCTC  
TGTCATTGATTATGAACTGATTGACCAAGATGCTCGGGATCTCTATGACGCTGGAGTGAA  
GAGGAAAGGAACTGATGTTCCCAAGTGGATCAGCATCATGACCGAGCGGAGCGTGCCCCA  
CCTCCAGAAAGTATTTGATAGGTACAAGAGTTACAGCCCTTATGACATGTTGGAAAGCAT  
CAGGAAAGAGGTTAAAGGAGACCTGGAAAATGCTTTCCTGAACCTGGTTCAGTGCATTCA  
GAACAAGCCCCTGTATTTTGCTGATCGGCTGTATGACTCCATGAAGGGCAAGGGGACGCG  
AGATAAGGTCCTGATCAGAATCATGGTCTCCCGCAGTGAAGTGGACATGTTGAAAATTAG  
GTCTGAATTCAAGAGAAAGTACGGCAAGTCCCTGTACTATTATATCCAGCAAGACACTAA  
GGGCGACTACCAGAAAGCGCTGCTGTACCTGTGTGGTGGAGATGACTGAAGCCCGACACG  
GCCTGAGCGTCCAGAAATGGTGTCTACCATGCTTCCAGCTAACAGGTCTAGAAAACCAGC  
TTGCGAATAACAGTCCCCGTGGCCATCCCTGTGAGGGTGACGTTAGCATTACCCCCAACC  
TCATTTTAGTTGCCTAAGCATTGCCTGGCCTTCCTGTCTAGTCTCTCCTGTAAGCCAAAG  
AAATGAACATTCCAAGGAGTTGGAAGTGAAGTCTATGATGTGAAACACTTTGCCTCCTGT  
GTACTGTGTCATAAACAGATGAATAAACTGAATTTGTACTTT

>gi|4757756|gb|NP\_004030.1|ANXA2 339aa linear annexin A2;  
annexin II; annexin II (lipocortin II); calpactin I, heavy  
polypeptide (p36); lipocortin II; Annexin II (lipocortin I);  
annexin II (lipocortin II; calpactin I, heavy polypeptide)  
[Homo sapiens].

MSTVHEILCKLSLEGDHSTPPSAYGSVKAYTNFDAERDALNIETAIKTKGVDEVTIVNIL  
TNRSNAQRQDIAFAYQRRTKKELASALKSALSGHLETIVILGLLKTTPAQYDASELKASMKG  
LGTDEDSLIEIICSRTNQELQEINRVYKEMYKTDLEKDIISDTSGDFRKLKLMVALAKGRRA  
EDGSVIDYELIDQDARDLYDAGVKRKGTDVPSKWISIMTERSVPFLQKVFDTRYKSYSPYDM  
LESIRKEVKGDLENFLNLVQCIQNKPLYFADRLYDSMKGKGTRDKVLIRIMVSRSEVDM  
LKIRSEFKRKYGKSLYYYIQQDTKGDYQKALLYLCGGDD

- 210 -

>gi|27484939|gb|XM\_084635.3|LOC143785 1982bp mRNA Homo sapiens similar to hypothetical protein XP\_084635 [Homo sapiens] (LOC143785), mRNA.

TACTATCAGGGGGCAAGAGCCTTTCTCTCCAGCTACACACTCCATCTCCCGGGAGCAAGG  
GGAAACTCCGAGAGGAGGGGCAACAGAGCCAGCATCTTGCCAGGGCCCCGGAGGAGGGGTT  
CCCCGCTACGCCTGTGCCGGAGGAGTTCCAGTCACCGAGCGAGGGGCGCAAGGGTGGGTG  
CATCCTGCGCTGCCGGCGGGCGCTACCCAGACGCTGGTGTGCAGAGCCACATGAAGCCT  
GCTGGGGACTGGGGGCCAGGGAGCAGCAAGCCAGCTGGGACTGAGGCGGACGCTGTCTCA  
GGGAGACGCTGACTCGCAAAGACACTCCCTTCCTTGTGCCTGGGTAAAAAGTCTCCTCCT  
GGGGTCCCTGGCCATCCTGAATATCCAGAATGGTGTCTTCTGAAGTTCTTCTGCATGAGTT  
TCTTCTGCCACCTGTGTCAAGGCTACTTCGATGGCCCCCTCTACCCAGAGATGTCCAATG  
GGACTCTGCACCACTACTTCGTGCCCGATGGGGACTATGAGGAGAACGATGACCCCGAGA  
AGTGCCAGCTGCTCTTCAGGGTGAGTGACCACAGGCGCTGCTCCCAGGGGGAGGGGAGCC  
AGGTTGGCAGCCTGCTGAGCCTCACCCCTGCGGGAGGAGTTACCCGTGCTGGGCCGCCAGG  
TGGAGGATGCTGGGCGCGTGCTGGAGGGCATCAGCAAAAGCATCTCCTACGACCTAGACG  
GGGAAGAGAGCTATGGCAAGTACCTGCGGCGGGAGTCCCACCAGATCGGGGATGCCTACT  
CCAACCTCGGACAAATCCCTCACTGAGCTGGAGAGCAAGTTCAAGCAGGGCCAGGAACAGG  
ACAGCCGGCAGGAGAGCAGGCTCAACGAGGACTTTCTGGGAATGCTGGTCCACACCAGGT  
CCCTGCTGAAGGAGACACTGGACATCTCTGTGGGGCTCAGGGACAAATACGAGCTGCTGG  
CCCTCACCATTAGGAGCCATGGGACCCGACTAGGTGCGCTGAAAAATGATTATCTTAAAG  
TATAGGTGGAAGGATACAAATGCTAGAAAGAGGGAATCAAATCAGCCCCGTTTTTGGAGGG  
TGGGGGACAGAAGATGGGGCTACATTTCCCCCATACTACTATTTTTTTTATATCCCGATT  
TGCACTTTGAGAATACATCTAAGGTCATCTTTCAAAGAGAGAAAAATTGGACACTTGAGTG  
ACTTTGTTTTTTAGTTTTTGTGTGTACATTATTTATGTGATTGTTATGGAATTGTCACCT  
GGAAGAACAATTTTAAGCAATGTCATTTCTAGATGGGTTTCTAATTCTGCAGAGACACC  
CGTTTCAGCCACATCTAAAGAGCACAGTTTATGTGGTGCGGAATTAACTTCCCCATCC  
TGCAGATTATGTGGAATAACCCAAAGATAATAGTGCATAGCTCCTTTCAGCCTCTAGCCT  
TCACTCCTGGGCTCCAAAAGCTATCCCAGTTGCCTGTTTTTCAAATGAGGTTCAAGGTGC  
TGCTTTGCATGCCTGCCAACCCATGGAAGTTGTTTCTTACTTCTTTTCTCTCTTATTTAT  
TAACCATGGTCTGAGAGTTGTTTTTGTTCATGTAACAGTATTGCCACAAAACCTATAGGC  
AAATCGTGTTTGCAGGGAGATTTCTGATGCCTCTGTGGGTGTGTGTAAGTTAAAGTGGCC  
ACATTTAAGAAGGCCAAGCTTTGTAGTGGTTGCACAGTCACACTGATATGCTGATTTGCT  
CTTTCTCATTTGTATGTCTATGCTTTGTCTCATCAGTGCTATAGTAAATTACAAAGAAATAGG  
TAGATTGTATGAACATACCCACAAATGCCTATGATTTAGGTTACCAATGTATTCTTTCTC  
ATTTGGGGTTTTGCTTCTGTCTGTCTGTTTATTGGAACTTGTACTTCAAGTAGGGGGAA  
TCCTAATTCTAATAACTCCTTAGCTAAGTTTTATTATTTCAGGCAATAAACATGTTTTTCAT  
GT

>gi|18578340|gb|XP\_084635.1|LOC143785 211aa linear similar to hypothetical protein XP\_084635 [Homo sapiens].

MVFLKFFCMSFFCHLCQGYFDGPLYPEMSNGTLHHYFVPDGDYEENDDPEKCQLLFRVSD  
HRRCSQGEQSQVGSLLSLTLREEFTVLGRQVEDAGRVLEGISKSISYDLGDGEESYGKYLR  
RESHQIGDAYSNSDKSLTELESKFQGGQEQDSRQESRLNEDFLGMLVHTRSLKETLDIS  
VGLRDKYELLALTIRSHGTRLGRLKNDYLKV

>gi|4507464|gb|NM\_003239.1|TGFB3 2574bp mRNA Homo sapiens transforming growth factor, beta 3 (TGFB3), mRNA.

CCTGTTTtagacacatggacaacaatcccagcgctacaaggcacacagtcgcgcttcttcgt  
cctcaggggtgccagcgcttcctggaagtcctgaagctctcgcagtgccagtgagttcatg

- 211 -

CACCTTCTTGCCAAGCCTCAGTCTTTGGGATCTGGGGAGGCCGCTGGTTTTCTCCCTC  
CTTCTGCACGTCTGCTGGGGTCTCTTCTCTCCAGGCCTTGCCGTCCCCCTGGCCTCTCT  
TCCCAGCTCACACATGAAGATGCACCTTGCAAAGGGCTCTGGTGGTCCTGGCCCTGCTGAA  
CTTTGCCACGGTCAGCCTCTCTCTGTCCACTTGACCACCTTGGACTTCGGCCACATCAA  
GAAGAAGAGGGTGGAAGCCATTAGGGGACAGATCTTGAGCAAGCTCAGGCTCACCAGCCC  
CCCTGAGCCAACGGTGATGACCCACGTCCCCTATCAGGTCCTGGCCCTTTACAACAGCAC  
CCGGGAGCTGCTGGAGGAGATGCATGGGGAGAGGGAGGAAGGCTGCACCCAGGAAAACAC  
CGAGTCGGAATACTATGCCAAAGAAATCCATAAATTCGACATGATCCAGGGGCTGGCGGA  
GCACAACGAACTGGCTGTCTGCCCTAAAGGAATTACCTCCAAGGTTTTCCGCTTCAATGT  
GTCCTCAGTGGAGAAAAATAGAACCAACCTATTCCGAGCAGAATTCCGGGTCTTGCGGGT  
GCCCAACCCAGCTCTAAGCGGAATGAGCAGAGGATCGAGCTCTTCCAGATCCTTCGGCC  
AGATGAGCACATTGCCAAACAGCGCTATATCGGTGGCAAGAATCTGCCACACGGGGCAC  
TGCCGAGTGGCTGTCTTTGATGTCACTGACACTGTGCGTGAGTGGCTGTTGAGAAGAGA  
GTCCAACCTTAGGTCTAGAAATCAGCATTCACTGTCCATGTACACCTTTCAGCCCAATGG  
AGATATCCTGGAAAACATTCACGAGGTGATGGAAATCAAATTCAAAGGCGTGGACAATGA  
GGATGACCATGGCCGTGGAGATCTGGGGCGCCTCAAGAAGCAGAAGGATCACCACAACCC  
TCATCTAATCCTCATGATGATTCCCCCACACCGGCTCGACAACCCGGGCCAGGGGGGTCA  
GAGGAAGAAGCGGGCTTTGGACACCAATTACTGCTTCCGCAACTTGAGAGGAGAACTGCTG  
TGTGCGCCCCCTCTACATTGACTTCCGACAGGATCTGGGCTGGAAGTGGGTCCATGAACC  
TAAGGGCTACTATGCCAACTTCTGCTCAGGCCCTTGCCCATACCTCCGCAGTGCAGACAC  
AACCACAGCACGGTGCTGGGACTGTACAACACTCTGAACCCTGAAGCATCTGCCTCGCC  
TTGCTGCGTGCCCCAGGACCTGGAGCCCCTGACCATCCTGTACTATGTTGGGAGGACCCC  
CAAAGTGGAGCAGCTCTCCAACATGGTGGTGAAGTCTTGTAATGTAGCTGAGACCCAC  
GTGCGACAGAGAGAGGGGAGAGAGAACCACCCTGCCTGACTGCCCGCTCCTCGGGAAAC  
ACACAAGCAACAAACCTCACTGAGAGGCCTGGAGCCCACAACCTTCGGCTCCGGGCAAAT  
GGCTGAGATGGAGGTTTCCTTTTGGAACATTTCTTTCTTGCTGGCTCTGAGAATCACGGT  
GGTAAAGAAAGTGTGGGTTTGGTTAGAGGAAGGCTGAACTCTTCAGAACACACAGACTTT  
CTGTGACGCAGACAGAGGGGATGGGGATAGAGGAAAGGGATGGTAAGTTGAGATGTTGTG  
TGGCAATGGGATTTGGGCTACCCTAAAGGGAGAAAGGAAGGGCAGAGAATGGCTGGGTCAG  
GGCCAGACTGGAAGACACTTCAGATCTGAGGTTGGATTTGCTCATTGCTGTACCACATCT  
GCTCTAGGGAATCTGGATTATGTTATACAAGGCAAGCATTTTTTTTTTTTAAAGACAGGTT  
ACGAAGACAAAGTCCCAGAATTGTATCTCATACTGTCTGGGATTAAGGGCAAATCTATTA  
CTTTTGCAAACCTGTCTCTACATCAATTAACATCGTGGGTCACTACAGGGAGAAAATCCA  
GGTCATGCAGTTCCTGGCCCATCAACTGTATTGGGCCTTTTGATATGCTGAACGCAGAA  
GAAAGGGTGGAAATCAACCCTCTCCTGTCTGCCCTCTGGGTCCCTCCTCTCACCTCTCCC  
TCGATCATATTTCCCTTGGACACTTGGTTAGACGCCTTCCAGGTCAGGATGCACATTTCT  
TGGATTGTGGTTCCATGCAGCCTTGGGGCATTATGGGTCTTCCCCCACTTCCCCTCCAAG  
ACCCTGTGTTTCAATTTGGTGTTCCTGGAAGCAGGTGCTACAACATGTGAGGCATTTCGGGGA  
AGCTGCACATGTGCCACACAGTGACTTGGCCCCAGACGCATAGACTGAGGTATAAAGACA  
AGTATGAATATTACTCTCAAAATCTTTGTATAAATAAATATTTTTTGGGGCATCCTGGATG  
ATTTCACTTCTGGAATATTGTTTCTAGAACAGTAAAAGCCTTATTCTAAGGTG  
>gi|4507465|gb|NP\_003230.1|TGFB3 412aa linear transforming  
growth factor, beta 3 [Homo sapiens].  
MKMHLQRALVVLALLNFATVLSLSTCTTLDFGHIKKRVEAIRGQILSKLRLTSPPEPT  
VMTHVPYQVLALYNSTRELLEEMHGEREEGCTQENTESEYYAKEIHKFDMIQGLAEHNEL  
AVCPKGITSKVFRFNVSSVEKNRNTLNFRAEFRVLRVPNPSSKRNEQRIELFQILRPDEHI  
AKQRYIGGKNLPTRGTAEWLSFDVTDTVREWLLRRESNLGLEISIHCPCHTFQPNGDILE



- 212 -

NIHEVMEIKFKGVDNEDDHGRGDLGRLKKQKDHHPHLIILMMIPPHRLDNPQGQGGQRKKR  
ALDTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKGYIANFCSGPCPYLRSADTTHTST  
VLGLYNTLNPEASASPPCCVPQDLEPLTILYYVGRTPKVEQLSNMVVKSCKS

>gi|21735553|gb|NM\_002419.2|MAP3K11 3603bp mRNA Homo sapiens  
mitogen-activated protein kinase kinase kinase 11 (MAP3K11),  
mRNA.

ACAAAGGGAGGAGGAAGAAGGGAGCGGGGTCGGAGCCGTCGGGGCCAAAGGAGACGGGGC  
CAGGAACAGGCAGTCTCGGCCCAACTGCGGACGCTCCCTCCACCCCCTGCGCAAAAAGAC  
CCAACCGGAGTTGAGGCGCTGCCCTGAAGGCCCCACCTTACACTTGGCGGGGGCCGGAG  
CCAGGCTCCCAGGACTGCTCCAGAACCGAGGGAAGCTCGGGTCCCTCCAAGCTAGCCATG  
GTGAGGCGCCGGAGGCCCCGGGGCCCCACCCCCCGGCCTGACCACACTGCCCTGGGTGC  
CCTCCTCCAGAAGCCCGAGATGCGGGGGGCGGGGAGACAACACTCCTGGCTCCCCAGAGA  
GGCGTGGGTCTGGGGCTGAGGGCCAGGGCCCGGATGCCCAGGTTCCGGGACTAGGGCCTT  
GGCAGCCAGCGGGGTGGGGACCACGGGCACCCAGAGAAGGTCCTCCACACATCCCAGCG  
CCGGCTCCCGGCCATGGAGCCCTTGAAGAGCCTCTTCTCAAGAGCCCTCTAGGGTCATG  
GAATGGCAGTGGCAGCGGGGGTGGTGGGGGCGGTGGAGGAGGCCGGCCTGAGGGGTCTCC  
AAAGGCAGCGGGTTATGCCAACCCTGGTGTGGACAGCCCTGTTCTGACTACGAGCCAGTGG  
GCAGGATGAGCTGGCCCTGAGGAAGGGTGACCGTGTGGAGGTGCTGTCCCGGGACGCAGC  
CATCTCAGGAGACGAGGGCTGGTGGGCGGGCCAGGTGGGTGGCCAGGTGGGCATCTTCCC  
GTCCAACATATGTGTCTCGGGGTGGTGGCCCGCCCCCTGCGAGGTGGCCAGCTTCCAGGA  
GCTGCGGCTGGAGGAGGTGATCGGCATTGGAGGCTTTGGCAAGGTGTACAGGGGCAGCTG  
GCGAGGTGAGCTGGTGGCTGTGAAGGCAGCTCGCCAGGACCCCGATGAGGACATCAGTGT  
GACAGCCGAGAGCGTTTCGCCAGGAGGCCCGGCTCTTCGCCATGCTGGCACACCCCAACAT  
CATTGCCCTCAAGGCTGTGTGCCTGGAGGAGCCCAACCTGTGCCTGGTGATGGAGTATGC  
AGCCGGTGGGCCCTCAGCCGAGCTCTGGCCGGGCGGCGCGTGCCTCCCATGTGCTGGT  
CAACTGGGCTGTGCAGATTGCCCGTGGGATGCACTACCTGCACTGCGAGGCCCTGGTGCC  
CGTCATCCACCGTGATCTCAAGTCCAACAACATTTTGCTGCTGCAGCCCATTGAGAGTGA  
CGACATGGAGCACAAGACCCTGAAGATCACCGACTTTGGCCTGGCCCGAGAGTGGCACA  
AACCACACAAATGAGTGCCGCGGGCACCTACGCCTGGATGGCTCCTGAGGTTATCAAGGC  
CTCCACCTTCTCTAAGGGCAGTGACGTCTGGAGTTTGGGGTGCTGCTGTGGGAACTGCT  
GACCGGGGAGGTGCCATACCGTGGCATTGACTGCCTTGCTGTGGCCTATGGCGTAGCTGT  
TAACAAGCTCACACTGCCCATCCCATCCACCTGCCCGAGCCCTTCGCACAGCTTATGGC  
CGACTGCTGGGCGCAGGACCCCCACCGCAGGCCCGACTTCGCCTCCATCCTGCAGCAGTT  
GGAGGCGCTGGAGGCACAGGTCCTACGGGAAATGCCGCGGACTCCTTCCATTCCATGCA  
GGAAGGCTGGAAGCGCGAGATCCAGGGTCTCTTCGACGAGCTGCGAGCCAAGGAAAAGGA  
ACTACTGAGCCGCGAGGAGGAGCTGACGCGAGCGGCGCGGAGCAGCGGTACAGGCGGA  
GCAGCTGCGGCGGCGGAGCACCTGCTGGCCAGTGGGAGCTAGAGGTGTTTCGAGCGCGA  
GCTGACGCTGCTGCTGCAGCAGGTGGACCGCGAGCGACCGCACGTGCGCCGCGCGCGG  
GACATTCAAGCGCAGCAAGCTCCGGGCGCGGACGGCGGCGAGCGTATCAGCATGCCACT  
CGACTTCAAGCACCGCATCACCGTGCAGGCCTCACCCGGCCTTGACCGGAGGAGAAACGT  
CTTCGAGGTGCGGCCTGGGGATTGCCCCACCTTTCCCCGGTTCCGAGCCATCCAGTTGGA  
GCCTGCAGAGCCAGGCCAGGCATGGGGCCGCCAGTCCCCCGACGTCTGGAGGACTCAAG  
CAATGGAGAGCGGCGAGCATGCTGGGCTTGGGGTCCAGTTCCCCCAAGCCTGGGGAAGC  
CCAGAAATGGGAGGAGAAGGTCCCGCATGGACGAAGCCACATGGTACCTGGATTGAGATGA  
CTCATCCCCCTTAGGATCTCCTTCCACACCCCCAGCACTCAATGGTAACCCCCCGCGGCC  
TAGCCTGGAGCCCGAGGAGCCCAAGAGGCCTGTCCCCGCGAGAGCGCGGTAGCAGCTCTGG  
GACGCCCAAGCTGATCCAGCGGGCGCTGCTGCGCGGCACCGCCCTGCTCGCCTCGCTGGG



- 213 -

CCTTGGCCGCGACCTGCAGCCGCCGGGAGGCCAGGACGCGAGCGCGGGGAGTCCCCGAC  
AACACCCCCACGCCAACGCCCGCGCCCTGCCCGACCGAGCCGCCCCCTTCCCCGCTCAT  
CTGCTTCTCGCTCAAGACGCCCCGACTCCCCGCCACTCCTGCACCCCTGTTGCTGGACCT  
GGGTATCCCTGTGGGCCAGCGGTGAGCCAAGAGCCCCGACGTGAGGAGGAGCCCCGCGG  
AGGCACTGTCTACCCCCACCGGGGACATCACGCTCTGCTCCTGGCACCCAGGCACCCC  
ACGTTACACACCCCTGGGCCTCATCAGCCGACCTCGGCCCTCGCCCCCTTCGCAGCCGCAT  
TGATCCCTGGAGCTTTGTGTGTCAGCTGGGCCACGGCCTTCTCCCCTGCCATCACCACAGCC  
TGACCCCGCCGAGCACCTTGACCTTGTTCCCGGACTCAGACCCCTTCTGGGACTCCCC  
ACCTGCCAACCCCTTCCAGGGGGGGCCCCAGGACTGCAGGGCACAGACCAAAGACATGGG  
TGCCAGGCCCCGTGGGTGCCGGAAGCGGGGCTTGAGTGGGCCAGGCCACTCCCCGAG  
CTCCAGCTGCCTTAGGAGGAGTCACAGCATACTGGAACAGGAGCTGGGTGAGCCTCTG  
CAGCTGCCTCAGTTTCCCCAGGGACCCACCCCCCTTTGGGGGTGAGGAACACTACACTG  
CACAGGAAGCCTTCACTGGAAGGGGGACCTGCGCCCCACATCTGAAACCTGTAGGTC  
CCCCAGCTCACCTGCCCTACTGGGGCCCAACTGTACCCAGCTGGTTGGGAGGACCAG  
AGCCTGTCTCAGGGAATTGCCTGCTGGGGTGATGCAGGGAGGAGGGGAGGTGCAGGGAAG  
AGGGGCCGGCCTCAGCTGTCACCAGCACTTTTGACCAAGTCCTGCTACTGCGGCCCTGC  
CCTAGGGCTTAGAGCATGGACCTCCTGCCCTGGGGGTGATCTGGGGCCAGGGCTCTCTGG  
ATGCCTTCTGCTGCCCCAGCCAGGGTTGAGTCTTAGCCTCGGGATCCAGTGAAGCCAG  
AAGCCAAATAAACTCAAAAGCTGTCTCCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAA

>gi|4505195|gb|NP\_002410.1|MAP3K11 847aa linear mitogen-  
activated protein kinase kinase kinase 11; mixed lineage  
kinase 3; SH3 domain-containing proline-rich kinase; protein-  
tyrosine kinase PTK1 [Homo sapiens].

MEPLKSLFLKSPLGSWNGSGSGGGGGGGGRPEGSPKAAGYANPVWTALFDYEPSGQDEL  
ALRKGDREVLRSDAISGDEGWAGQVGGQVGIFPSNYVSRGGPPPPCEVASFQELRLE  
EVIGIGGFVKVYRGSWRGELVAVKAARQDPDEDISVTAESVRQEARLFAMLAHPNIIALK  
AVCLEEPNLCLVMEYAAGGPLSRALAGRRVPPHVLVNWAVQIARGMHYHLHCEALVPVIHR  
DLKSNNILLLOPIESDDMEHKTLLKIDTDFGLAREWHKTTQMSAAGTYAWMAPEVIKASTFS  
KGSVDWSFGVLLWELLTGEVVPYRGIDCLAVAYGVAVNKLTLPI PSTCPEPFQAQLMADCWA  
QDPHRRPDFASILQOLEALEAQVLRMPRDSFHSMQEGWKREIQGLFDELRAKEKELLSR  
EEELTRAAREQRSQAEQLRRREHLLAQWELEVFEREITLLLQQVDRERPHVRRRRGTFRK  
SKLRARDGGERISMPIDFKHRI TVQASPLDRRRNVFEVGP GDSPTTFPRFRAIQLEPAEP  
GQAWGRQSPRRLEDSSNGERRACWAWGPSSPKPGEAQNGRRRSRMDEATWYLDSSDSSPL  
GSPSTPPALNGNPPRPSLEPEEPKRPVPAERGSSSGTPKLIQRALLRGTALLASLGLGRD  
LQPPGGPGRERGESPTTPPTPTPAPCPTPEPPSPPLICFSLKTPDSPPTPAPLLLLDLGIPV  
GQRSAKSPREEEPRGTVSPPPGTSRSAPGTPGTSPPLGLISRPRPSPLRSRIDPWS  
FVSAGPRPSPLPSPQAPRRAPWTLFPDSDPFWDSPANPFQGGPQDCRAQTKDMGAQAP  
WVPEAGP

>gi|4505784|gb|NM\_000294.1|PHKG2 1571bp mRNA Homo sapiens  
phosphorylase kinase, gamma 2 (testis) (PHKG2), mRNA.

AAGGTGAGCGACTGCAGGCAAACCCGGCGACAGCGCAGCTCGCGTCGACCCTGGCTCCTC  
TGCCTGCCCCCTCAGGCCCCCGCCTCCTTCAGGATGACGCTGGACGTGGGGCCGGAGGAT  
GAGCTGCCCCGACTGGGCCCGCCGCAAGAGTTTTACCAGAAGTACGACCCTAAGGACGTC  
ATCGGCAGAGGAGTGAGCTCTGTGGTCCGCCGTTGTGTTTCATCGAGCTACTGGCCACGAG  
TTTGCGGTGAAGATTATGGAAGTGACAGCTGAGCGGCTGAGTCTGAGCAGCTGGAGGAG  
GTGCGGGAAGCCACACGGCGAGAGACACACATCCTTCGCCAGGTGCGCGGCCACCCCCAC

- 214 -

ATCATCACCTCATCGATTCTTACGAGTCTTCTAGCTTCATGTTCTCTGGTGTGTTGACCTG  
ATGCGGAAGGGAGAGCTGTTTGACTATCTCACAGAGAAGGTGGCCCTCTCTGAAAAGGAA  
ACCAGGTCCATCATGCGGTCTCTGCTGGAAGCAGTGAGCTTTCTCCATGCCAACAACATT  
GTGCATCGAGATCTGAAGCCCGAGAATATTCTCCTAGATGACAATATGCAGATCCGACTT  
TCAGATTTTCGGGTTCTCCTGCCACTTGGAACCTGGCGAGAAGCTTCGAGAGTTGTGTGGG  
ACCCAGGGTATCTAGCGCCAGAGATCCTTAAATGCTCCATGGATGAAACCCACCCAGGC  
TATGGCAAGGAGGTGCACCTCTGGGCCTGTGGGGTGATCTTGTTCACTCCTGGCTGGC  
TCGCCACCCTTCTGGCACCCGGCGGCAGATCCTGATGTTACGCATGATCATGGAGGGCCAG  
TACCAGTTCAGTTCCTCCCGAGTGGGATGACCGTTCCAGCACTGTCAAAGACCTGATCTCC  
AGGCTGCTGCAGGTGGATCCTGAGGCACGCCTGACAGCTGAGCAGGCCCTACAGCACCCC  
TTCTTTGAGCGTTGTGAAGGCAGCAACCCTGGAACCTCACCCCCCGCCAGCGGTTCCGG  
GTGGCAGTGTGGACAGTGTGGCTGCTGGACGAGTGGCCCTAAGCACCCATCGTGTACGG  
CCACTGACCAAGAATGCACTGTTGAGGGACCCCTTATGCGCTGCGGTCAGTGCGGCACCTC  
ATCGACAACTGTGCCTTCCGGCTCTACGGGCACTGGGTAAAGAAAGGGGAGCAGCAGAAC  
CGGGCGGCTCTCTTTCAGCACCCGGCCCCCTGGGCCTTTTCCCATCATGGGCCCTGAAGAG  
GAGGGAGACTCTGCTGCTATAACTGAGGATGAGGCCGTGCTTGCTGCTGGGCTAGGACCTC  
AACCCAGGGATTCCAGGAAGCAGAACTCTCCAGAAGAAGGTTTTGATCATTCCAGCT  
CCTCTGGGCTCTGGCCTCAGGCCACTAATGATCCTGCTACCTCTTGAAGACCAGCCCG  
GTACCTCTCTCCCCACTGGCCAGGACTCTGAGATCAGAGCTGGGGTGAAGGGAGCCATT  
CTGAACGCCACGCTGGCCCGGTCAGTGCTGCATGCACTGCATATGAAATAAAATCTGCT  
ACACGCCAGGG

>gi|4505785|gb|NP\_000285.1|PHKG2 406aa linear phosphorylase  
kinase, gamma 2 (testis); Phosphorylase kinase, gamma 2  
(testis/liver) [Homo sapiens].

MTLDVGPEDLPDWAAAKEFYQKYDPKDVIGRGVSSVVRRCVHRATGHEFAVKIMEVTAE  
RLSPEQLEEVREATRRETHILRQVAGHPHIITLIDSYESSFMFLVFDLMRKGELEFDYLT  
EKValseKETRSIMRSLLEAVSFLHANNIVHRDLKPENILLDDNMQIRLSDFGFSCHLEP  
GEKLRELCTPGYLAPAILKCSMDETHPGYGKEVDLWACGVILFTLLAGSPFFWHRRQIL  
MLRMIMEGQYQFSSPEWDDRSSTVKDLISRLQLQVDPEARLTAEQALQHPFFERCEGSQPW  
NLTPRQRFRAVAVWTVLAAGRVALSTHRVRPLTKNALLRDPYALRSVRHLIDNCAFRLYGH  
WVKKGEQQNRAALFQHRPPGPFPIMGPEEEGDSAAITEDEAVLVLG

>gi|5453789|gb|NM\_006169.1|NNMT 952bp mRNA Homo sapiens  
nicotinamide N-methyltransferase (NNMT), mRNA.

TGAACTCTGGATGCTGTTAGCCTGAGACTCAGGAAGACAACTTCTGCAGGGTCACTCCCT  
GGCTTCTGGAGGAAAGAGAAGGAGGGCAGTGCTCCAGTGGTACAGAAGTGAGACATAATG  
GAATCAGGCTTCACCTCCAAGGACACCTATCTAAGCCATTTTAACCCCTCGGGATTACCTA  
GAAAAATATTACAAGTTTGGTTCTAGGCACTCTGCAGAAAGCCAGATTCTTAAGCACCTT  
CTGAAAAATCTTTTCAAGATATTCTGCCTAGACGGTGTGAAGGGAGACCTGCTGATTGAC  
ATCGGCTCTGGCCCCACTATCTATCAGCTCCTCTCTGCTTGTAATCCTTTAAGGAGATC  
GTCGTCACTGACTACTCAGACCAGAACCTGCAGGAGCTGGAGAAGTGGCTGAAGAAAGAG  
CCAGAGGCCTTTGACTGGTCCCCAGTGGTGACCTATGTGTGTGATCTTGAAGGGAACAGA  
GTCAAGGGTCCAGAGAAGGAGGAGAAGTTGAGACAGGCGGTCAAGCAGGTGCTGAAGTGT  
GATGTGACTCAGAGCCAGCCACTGGGGGCCGTCCCCTTACCCCCGGCTGACTGCGTGCTC  
AGCACACTGTGTCTGGATGCCGCCTGCCAGACCTCCCCACCTACTGCAGGGGCGCTCAGG  
AACCTCGGCAGCCTACTGAAGCCAGGGGGCTTCCTGGTGATCATGGATGCGCTCAAGAGC  
AGCTACTACATGATTGGTGAGCAGAAGTTCTCCAGCCTCCCCCTGGGCCGGGAGGCAGTA  
GAGGCTGCTGTGAAAGAGGCTGGCTACACAATCGAATGGTTTGAGGTGATCTCGCAAAGT

- 215 -

TATTCTTCCACCATGGCCAACAACGAAGGACTTTTCTCCCTGGTGGCGAGGAAGCTGAGC  
AGACCCCTGTGATGCCTGTGACCTCAATTAAAGCAATTCCTTTGACCTGTCA

>gi|5453790|gb|NP\_006160.1|NNMT 264aa linear nicotinamide N-methyltransferase [Homo sapiens].

MESGFTSKDITYLSHFNPRDYLEKYYKFGSRHSAESQILKHLKLNLFKIFCLDGVKGDLLI  
DIGSGPTIYQLLSACESFKEIVVTDYSDQNLQELEKWLKKEPEAFDWSPVVTYVCDLEGN  
RVKGPEKEEKLQAVKQVLKCDVTQSQPLGAVPLPPADCVLSTLCLDAACPDLPYCRAL  
RNLGSLKPKGGFLVIMDALKSSYYMIGEQQKFSSLPLGREAVEAAVKEAGYTIEWFEVISQ  
SYSSTMANNEGLFSLVARKLSRPL

>gi|4507668|gb|NM\_003295.1|TPT1 830bp mRNA Homo sapiens tumor protein, translationally-controlled 1 (TPT1), mRNA.

CCCCCGAGCGCCGCTCCGGCTGCACCGCGCTCGCTCCGAGTTTCAGGCTCGTGCTAAG  
CTAGCGCCGTCGTCGTCTCCCTTCAGTCGCCATCATGATTATCTACCGGGACCTCATCAG  
CCACGATGAGATGTTCTCCGACATCTACAAGATCCGGGAGATCGCGGACGGGTTGTGCCT  
GGAGGTGGAGGGGAAGATGGTCAGTAGGACAGAAGGTAACATTGATGACTCGCTCATTGG  
TGGAAATGCCTCCGCTGAAGGCCCGAGGGCGAAGGTACCGAAAGCACAGTAATCACTGG  
TGTCGATATTGTCATGAACCATCACCTGCAGGAAACAAGTTTCACAAAAGAAGCCTACAA  
GAAGTACATCAAAGATTACATGAAATCAATCAAAGGGAAACTTGAAGAACAGAGACCAGA  
AAGAGTAAACCTTTTATGACAGGGGCTGCAGAACAAATCAAGCACATCCTTGCTAATTT  
CAAAAACCTACCAGTTCTTTATTTGGTGAAAACATGAATCCAGATGGCATGGTTGCTCTATT  
GGACTACCGTGAGGATGGTGTGACCCCATATATGATTTTCTTTAAGGATGGTTTAGAAAT  
GGAAAAATGTTAACAAATGTGGCAATTATTTTGGATCTATCACCTGTCATCATAACTGGC  
TTCTGCTTGTCATCCACACAACACCAGGACTTAAGACAAATGGGACTGATGTCATCTTGA  
GCTCTTCATTTATTTTACTGTGATTTATTTGGAGTGGAGGCATTGTTTTTAAGAAAAAC  
ATGTCATGTAGGTTGTCTAAAAATAAAATGCATTTAAACTCATTGAGAG

>gi|4507669|gb|NP\_003286.1|TPT1 172aa linear tumor protein, translationally-controlled 1; fortilin; histamine-releasing factor [Homo sapiens].

MIIYRDLISHDEMFSDIYKIREIADGLCLEVEGKMVSRTEGNIDDSLIGGNASAEGPGE  
GTESTVITGVDIVMNHHLQETSFTKEAYKKYIKDYMKSIKGLKEEQRPVVKPFMTGAAE  
QIKHILANFKNYQFFIGENMNPDGMVALLDYREDGVTPYMIFFKDGLEMEKC

>gi|27477073|gb|NM\_018725.2|IL17BR 2077bp mRNA Homo sapiens interleukin 17B receptor (IL17BR), transcript variant 1, mRNA.

AGCGCAGCGTGCGGGTGGCCTGGATCCCGCGCAGTGCGCCGCGCATGTCGCTCGTGCTGC  
TAAGCCTGGCCGCGCTGTGCAGGAGCGCCGTACCCCGAGAGCCGACCGTTCAATGTGGCT  
CTGAAACTGGGCCATCTCCAGAGTGGATGCTACAACATGATCTAATCCCGGAGACTTGA  
GGGACCTCCGAGTAGAACCTGTTACAACCTAGTGTTGCAACAGGGGACTATTCAATTTTGA  
TGAATGTAAGCTGGGTACTCCGGGCAGATGCCAGCATCCGCTTGTTGAAGGCCACCAAGA  
TTTGTGTGACGGGCAAAAGCAACTTCCAGTCTTACAGCTGTGTGAGGTGCAATTACACAG  
AGGCCTTCCAGACTCAGACCAGACCCTCTGGTGGTAAATGGACATTTTCTTACATCGGCT  
TCCCTGTAGAGCTGAACACAGTCTATTTTCATTGGGGCCCATATATTCTAATGCAAATA  
TGAATGAAGATGGCCCTTCCATGTCTGTGAATTTACCTCACCAGGCTGCCTAGACCACA  
TAATGAAATATAAAAAAAGTGTGTCAAGGCCGGAAGCCTGTGGGATCCGAACATCACTG  
CTTGTAAGAAGAATGAGGAGACAGTAGAAGTGAACCTTCAACCACTCCCCTGGGAAACA  
GATACATGGCTCTTATCCAACACAGCACTATCATCGGGTTTTCTCAGGTGTTTGAGCCAC  
ACCAGAAGAAACAAACGCGAGCTTCAGTGGTGATTCCAGTGACTGGGGATAGTGAAGGTG  
CTACGGTGCAGCTGACTCCATATTTTCTTACTTGTGGCAGCGACTGCATCCGACATAAAG

- 216 -

GAACAGTTGTGCTCTGCCCACAAACAGGCGTCCCTTTCCCTCTGGATAACAACAAAAGCA  
AGCCGGGAGGCTGGCTGCCTCTCCTCCTGCTGTCTCTGCTGGTGGCCACATGGGTGCTGG  
TGGCAGGGATCTATCTAATGTGGAGGCACGAAAGGATCAAGAAGACTTCCTTTTCTACCA  
CCACACTACTGCCCCCATTAAGGTTCTTGTGGTTTACCCATCTGAAATATGTTTCCATC  
ACACAATTTGTTACTTCACTGAATTTCTTCAAACCATTCAGAGAAGTGAGGTCATCCTTG  
AAAAGTGGCAGAAAAAGAAAATAGCAGAGATGGGTCCAGTGCAGTGGCTTGCCACTCAA  
AGAAGGCAGCAGACAAAGTCGTCTTCTTCTTCCAATGACGTCAACAGTGTGTGCGATG  
GTACCTGTGGCAAGAGCGAGGGCAGTCCAGTGAGAACTCTCAAGACCTCTTCCCCCTTG  
CCTTTAACCTTTTCTGCAGTGATCTAAGAAGCCAGATTTCATCTGCACAAATACGTGGTGG  
TCTACTTTAGAGAGATTGATACAAAAGACGATTACAATGCTCTCAGTGTCTGCCCCAAGT  
ACCACCTCATGAAGGATGCCACTGCTTTCTGTGCAGAACTTCTCCATGTCAAGCAGCAGG  
TGTCAGCAGGAAAAAGATCACAAGCCTGCCACGATGGCTGCTGCTCCTTGTAGCCCACCC  
ATGAGAAGCAAGAGACCTTAAAGGCTTCCATATCCACCAATTACAGGGAAAAAACGTGTG  
ATGATCCTGAAGCTTACTATGCAGCCTACAAACAGCCTTAGTAATTAAAACATTTTATAC  
CAATAAAATTTTCAAATATTGCTAACTAATGTAGCATTAACTAACGATTGGAAACTACAT  
TTACAACTTCAAAGCTGTTTTATACATAGAAATCAATTACAGTTTTAATTGAAAACTATA  
ACCATTTTGATAATGCAACAATAAAGCATCTTCAGCCAAACATCTAGTCTTCCATAGACC  
ATGCATTGCAGTGTACCCAGAACTGTTTAGCTAATATTCTATGTTTAATTAATGAATACT  
AACTCTAAGAACCCCTCACTGATTCCTCAATAGCATCTTAAGTGAAAAACCTTCTATTA  
CATGCAAAAAATCATTGTTTTTAAGATAACAAAAGTAGGGAATAAACAAGCTGAACCCAC  
TTTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

>gi|27477074|gb|NP\_061195.2|IL17BR 502aa linear IL-17B  
receptor isoform 1 precursor; IL-17B receptor; interleukin 17  
receptor homolog 1; interleukin 17 receptor homolog; cytokine  
receptor CRL4 [Homo sapiens].

MSLVLLSLAALCRSAVPREPTVQCGSETGPSPEWMLQHDLI PGDLRLDLRVEPVTTTSVATG  
DYSILMNVS WVLRADASIRLLKATKICVTGKSNFQSYSCVRCNYTEAFQTQTRPSGGKWT  
FSYIGFPVELNTVYFIGAHNIPNANMNEDGPSMSVNFTSPGCLDHIMKYKKKCVKAGSLW  
DPNITACKKNEETVEVNFTTTPLGNRYMALIQHSTIIIGFSQVFEHPQKKQTRASVVI PVT  
GDSEGATVQLTPYFPTCGSDCIRHKGTVVLC PQTGVFPFLDNNKSKPGGWLP LLLLLSLLV  
ATWVLVAGIYLMWRHERIKKTSFSTTTLLPPIKVLVVYPSEICFHHTICYFTEFLQNHCR  
SEVILEKWQKKKIAEMGPVQWLATQKKAADKVVFLLSNDVNSVCDGTGCGKSEGSPSENSQ  
DLFPLAFNLFCSDLRSQIHLHKYVVVYFREIDTKDDYNALSVC PKYHLMKDATAFCAELL  
HVKQQVSAGKRSQACHDGCCSL

>gi|14165275|gb|NM\_032411.1|ECRG4 772bp mRNA Homo sapiens  
esophageal cancer related gene 4 protein (ECRG4), mRNA.

GGATAACCCGCGGCCGCGCCTGCCCGCTCGCACCCCTCTCCCGCGCCCGGTTCTCCCTCG  
CAGCACCTCGAAGTGCGCCCTCGCCCTCCTGCTCGCGCCCCGCGCCATGGCTGCCTCC  
CCCGCGCGCCTGCTGTCTGGCCCTGACCGGGCTGGCGCTGCTCCTGCTCCTGTGCTGG  
GGCCCAGGTGGCATAAGTGGAATAAACTCAAGCTGATGCTTCAAAAACGAGAAGCACCT  
GTTCCAATAAGACTAAAGTGGCCGTTGATGAGAATAAAGCCAAAGAATTCCTTGGCAGC  
CTGAAGCGCCAGAAGCGGCAGCTGTGGGACCGGACTCGGCCCGAGGTGCAGCAGTGGTAC  
CAGCAGTTTCTCTACATGGGCTTTGACGAAGCGAAATTTGAAGATGACATCACCTATTGG  
CTTAACAGAGATCGAAATGGACATGAATACTATGGCGATTACTACCAACGTCACTATGAT  
GAAGACTCTGCAATTGGTCCCCGGAGCCCCTACGGCTTTAGGCATGGAGCCAGCGTCAAC  
TACGATGACTACTAACCATGACTTGCCACACGCTGTACAAGAAGCAAATAGCGATTCTCT  
TCATGTATCTCCTAATGCCTTACACTACTTGGTTTCTGATTTGCTCTATTTTCAGCAGATC

- 217 -

TTTCTACCTACTTTGGTGATCAAAAAAGAAGAGTTAAAACAACACATGTAAATGCCTTTT  
GATATTTTCATGGGAATGTTTAAAAATAGAAATAAAGCATTTTGTTAAAACGA  
>gi|14165276|gb|NP\_115787.1|ECRG4 148aa linear esophageal  
cancer related gene 4 protein [Homo sapiens].  
MAASPARPAVLALTGLALLLLLCWGPGGISGNKLLMLQKREAPVPTKTKVAVDENKAKE  
FLGSLKRQKRQLWDRTRPEVQQWYQQFLYMGFDEAKFEDDITYWLNDRNGHEYGYDYQ  
RHYDEDSAIGPRSPYGFRHGASVNYDDY